

In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register.

The following guiding principles have been applied to the disclosure:

- Information will be excluded in order to protect the privacy of patients and all named persons associated with the study*
- Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the **GSK Clinical Study Register**.*
- Aggregate data will be included; with any direct reference to individual patients excluded*

**Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered*

TITLE PAGE**Division:** Worldwide Development**Information Type:** Worldwide Epidemiology Final Study Report**Control:** Non-Interventional.

Title:	Post-marketing study of ropinirole prolonged release tablets in Parkinson's disease: Evaluation outcomes associated with long-term use of Ropinirole-PR using the clinical practice research datalink (CPRD)
---------------	--

Phase: IV**Compound Number:** SKF101468**Effective Date:** 23-APR-2018**Description:** A post marketing observational study to evaluate outcomes in Parkinson's disease patients prescribed ropinirole-PR compared to immediate release dopamine agonists as part of a commitment to the MHRA.**Subject:** Pharmacoepidemiology post marketing study, Parkinson's disease**Author(s):**PPD
**Indication Studied:** Parkinson's Disease

This study was performed in compliance with Good Clinical Practices and GlaxoSmithKline Standard Operating Procedures for all processes involved, including the archiving of essential documents.

Copyright 2018 the GlaxoSmithKline group of companies. All rights reserved.
Unauthorised copying or use of this information is prohibited.

PASS INFORMATION

Title	Post-marketing study of ropinirole prolonged release tablets: Evaluation of the short-term drug utilisation patterns and long term use of Ropinirole-PR using the clinical practice research database (CPRD)
Version identifier of the final study report	1.0
Date of last version of the final study report.	23-APR-2018
EU PAS register number	EUPAS12518
Active substance	Ropinirole
Medicinal product	Trade names Adartrel; Requip; Requip XL; Spiroco XL; Ralnea XL
Product reference	Ropinirole [2mg] Prolonged-release tablet (PL 10592/0293) Ropinirole [3mg] Prolonged-release tablet (10592/0294) Ropinirole [4mg] Prolonged-release tablet (PL 10592/0295) Ropinirole [8mg] Prolonged-release tablet (PL 10592/0296)
Procedure number	MHRA Ref No: PL 10592/0293 – 0001
Marketing authorisation holder(s)	Adartrel: GlaxoWellcome UK Ltd. Requip and Requip XL – SmithKline Beecham Ltd
Joint PASS	No
Research question and objectives	The primary objective of this study is to estimate the risk of dyskinesias and impulse control disorders amongst individuals prescribed the prolonged release ropinirole as monotherapy, compared to individuals initiating immediate release dopamine agonist monotherapy. Additional outcomes of interest include time to levodopa initiation, evaluating adherence to medication, average daily dose in the subset of patients who switched ropinirole formulations, and the extent of off-label use of ropinirole-PR.

Country(-ies) of study	England and Wales.
Author	<p>PPD Director Epidemiology</p> <p>Real World Evidence and Epidemiology R&D Projects, Clinical Platforms & Sciences GSK Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex, UB11 1BT, United Kingdom Email PPD</p>

MARKETING AUTHORISATION HOLDER(S)


Marketing authorisation holder(s)	<p>SmithKline Beecham Limited Great West Road, Brentford, Middlesex TW8 9GS</p> <p>Trading as: GlaxoSmithKline UK Stockley Park West, Uxbridge, Middlesex UB11 1BT</p>
MAH contact person	<p>PPD Regulatory Project Manager</p> <p>UK Pharma Regulatory Direct Tel: PPD e-mail: PPD</p>

SPONSOR SIGNATORY SIGNATURE PAGE

I have read this report and confirm that to the best of my knowledge this report accurately describes the conduct and results of the study WEUKSTV2488.


Name of Project Officer: Usha Gungabissoon

Title of Project Officer: Director, Epidemiology

Signature:  _____
Date: 23/04/2018

Name of Therapy Area Head: Monika Stender

Title of Therapy Area Head: Senior Director, Epidemiology

Signature:  _____
Date: 23 April 2018

PPD 

8.5.2	Resourcing	29
8.6	Data analyses	29
8.6.1	Essential analyses	29
8.6.1.1	Descriptive and univariate analyses	29
8.6.1.2	Incidence estimation	29
8.6.1.3	Multiple regression analyses - Cox proportional hazards regression	30
8.6.1.4	Censoring	30
8.6.2	Exploratory analyses	30
8.6.3	General considerations for data analyses	30
8.6.4	Amendments to the statistical analysis plan	31
8.7	Quality control and quality assurance	32
8.8	Other aspects	32
8.8.1	Validity of using READ codes to identify individuals with Parkinson's disease	32
8.8.2	Capture of PD medication use in the primary care setting	33
8.8.3	Validity and justification for choice of outcomes of interest	33
9	PROTECTION OF HUMAN SUBJECTS	34
9.1	Ethical approval and subject consent	34
9.2	Subject confidentiality	34
10	RESULTS	35
10.1	Study population	35
10.2	Baseline characteristics before and after propensity score matching	37
10.3	Results of essential analyses	41
10.3.1	Dyskinesia	41
10.3.2	Impulse control disorders	42
10.3.3	Time to levodopa initiation	42
10.3.4	Adherence and persistence	42
10.3.5	Average daily dose amongst ropinirole-IR to ropinirole-PR switchers	44
10.3.6	Off-label use of ropinirole-PR	45
10.4	Other analyses	46
10.5	Adverse events/adverse reactions	46
11	DISCUSSION	47
11.1	Interpretations of Results	47
11.2	Limitations	50
12	CONCLUSIONS	52
13	REFERENCES	53
	APPENDICES	55
	ANNEX 1: LIST OF STAND-ALONE DOCUMENTS	55
	ANNEX 2: READ AND BNF CODES	55

1 LIST OF ABBREVIATIONS

AE	Adverse Event
BNF	British National Formulary
COMT	Catechol O-methyltransferase inhibitor
CPRD	Clinical Practice Research Database (UK)
GP	General Practitioner
GSK	GlaxoSmithKline
ICD	Impulse control disorder
IR-DA	Immediate release dopamine agonist
MAO-Bi	Monoamine oxidase type B inhibitor
MHRA	UK Medicines and Healthcare Products Regulatory Agency
MPR	Medication possession ratio
NHS	National Health Service
PD	Parkinson's disease
QC	Quality Control
Ropinirole-IR	Ropinirole, immediate release formulation
Ropinirole-PR	Ropinirole, prolonged release formulation
UTS	up to standard' date

Trademark Information

Trademarks of the GlaxoSmithKline group of companies
Adartrel
Ralnea XL
Requip
Requip XL
Spiroco

Trademarks not owned by the GlaxoSmithKline group of companies
SAS

2 RESPONSIBLE PARTIES

PPD

Director Epidemiology

Real World Evidence & Epidemiology
R&D Projects, Clinical Platforms & Sciences
GSK
Stockley Park West,
1-3 Ironbridge Road,
Uxbridge,
Middlesex,
UB11 1BT, United Kingdom
Email PPD

PPD

Regulatory Project Manager
UK Pharma Regulatory
GlaxoSmithKline UK Limited
Stockley Park West,
1-3 Ironbridge Road,
Uxbridge,
Middlesex,
UB11 1BT, United Kingdom
Email PPD

3 ABSTRACT

Title

Post-marketing study of ropinirole prolonged release tablets: Evaluation of the short-term drug utilisation patterns and long term use of Ropinirole-PR using the clinical practice research database (CPRD)

Keywords

Pharmacoepidemiology, Parkinson's disease, dopamine agonist, post-marketing.

Rationale and background

GSK committed to conducting a post-marketing observational study to address questions posed by the MHRA about the risk of potential long term consequences associated with continuous dopamine agonism in Parkinson's disease patients prescribed ropinirole-PR including off-label use. Consequently, GSK proposed to use data from the Clinical Practice Research Datalink (CPRD), a UK primary care database, to address the questions posed by the MHRA.

Research questions and objectives

The primary objective of this observational study was to estimate the risk of dyskinesias and impulse control disorders amongst individuals prescribed the prolonged release ropinirole as monotherapy, compared to individuals initiating immediate release dopamine agonist monotherapy for treatment of Parkinson's disease (PD). Additional outcomes of interest included time to levodopa initiation, evaluating adherence to medication and average daily dose in the subset of PD patients who switched from the immediate release formulation of ropinirole (ropinirole-IR) to the prolonged release formulation of ropinirole (ropinirole-PR).

Study design

This study utilised a propensity score matched cohort design using observational data from a UK primary care database.

Setting

The study was conducted using data recorded on the Clinical Practice Research Datalink (CPRD). The CPRD is a UK primary care based observational electronic health record database. Within the United Kingdom, ongoing Parkinson's disease treatment is managed in the primary care setting by general practitioners.

Subjects and study size, including dropouts

Parkinson's disease patients initiating an oral dopamine agonist as monotherapy between 2008 and 2013 were eligible for inclusion in the study. A total of 534 PD patients

initiating ropinirole PR monotherapy and 472 PD patients initiating an immediate release dopamine agonist (IR-DA) monotherapy that met the inclusion criteria were identified. After propensity score matching, the final study population consisted of 341 PD patients initiating ropinirole-PR monotherapy and 341 PD patients initiating immediate release dopamine agonist monotherapy.

Variables and data sources

All data were obtained directly from the CPRD.

Results

The propensity matched groups were generally similar with regards to demographics and other baseline characteristics, however, differences in the prevalence of diabetes and prior dopamine agonist use existed; 3.8% of the IR-DA and 7.3% of the ropinirole-PR group had a history of diabetes at baseline and 6.5% of the IR-DA initiators and 62.2% of the ropinirole-PR initiators had switched from another dopamine agonist at baseline.

Dyskinesia: 5 cases of probable or possible dyskinesia were identified in the cohort. All patients with probable dyskinesia had initiated levodopa during the observation period, prior to the dyskinesia diagnosis.

The unadjusted incidence of probable dyskinesia in the IR-DA initiator group was 3.95 per 1,000 person-years (PY) and 3 per 1,000 PY in the ropinirole-PR initiator group.

The Poisson model yielded a rate of dyskinesia in the IR-DA initiator group of 3.93 per 1,000 PY (95% CI 0.98, 15.7) compared to 2.98 per 1,000 PY (95% CI 0.74, 11.9) amongst the ropinirole-PR initiator group. The incident rate ratio was 1.32 (95% CI 0.19, 9.37) (IR-DA compared to ropinirole-PR).

Impulse control disorders: <5 cases of ICD were identified and occurred in the IR-DA group. The median time to ICD was 23 months from treatment initiation, and levodopa had been initiated prior to the ICD diagnosis. In order to preserve confidentiality, as per CPRD policy, further descriptive characteristics are not provided.

Time to levodopa initiation: Overall, 40.7% (n=138) of the IR-DA group and 46.6% (n=159) of the ropinirole-PR cohort initiated levodopa during the observation period. The median time to initiation of levodopa was 297 days (interquartile range (IQR) 111, 552) and 417 days (IQR 205, 736) for the IR-DA and ropinirole-PR groups respectively.

In an underpowered study, the adjusted hazard ratio of initiating levodopa was non-significantly reduced at 0.7 (95% CI 0.37 - 1.31, p=0.257) comparing ropinirole-PR to IR-DA.

Adherence and Persistence:

Individuals in the ropinirole-PR group remained on treatment for longer and had a higher medication possession ratio than the IR-DA group; these were statistically significant

differences. Median treatment duration for IR-DA was 444 days (IQR 147, 848) and 682 days (IQR 309, 1099) for ropinirole-PR ($p < 0.0001$). Amongst the IR-DA, 45.7% had a medication possession ratio (MPR) of at least 80% compared to 68.6% in the ropinirole-PR group ($p < 0.0001$).

Average daily dose amongst ropinirole-IR to ropinirole-PR switchers

The average daily dose amongst the subset of the ropinirole-PR initiators that switched from ropinirole-IR and who had available dose information was estimated (N=71). The average daily dose was 6.9mg (95% CI 6, 7.9) amongst those prescribed ropinirole-IR prior to switching formulation, and was 8.6mg (95% CI 7.5, 9.6) following the switch to ropinirole PR; this was not statistically significant.

Off-label use of ropinirole-PR

A total of 2,388 individuals with at least one prescription for ropinirole-PR and at least 12 months of prior GP registration were identified on the CPRD. The majority (n=1844, 77.2%) had a Parkinson's disease diagnosis, but 544 individuals (22.8%) did not have a history of PD and were considered off-label users. The off-label population comprised of the following: history of restless leg syndrome (RLS) 45.4%, history of sexual dysfunction 11.8%, history of fibromyalgia or history of limb movement (without mention of RLS) 2.2% and other 40.6%. There was no evidence of paediatric use of ropinirole-PR (aged <18 years).

Discussion

Compared to immediate release dopamine agonist monotherapy, individuals prescribed ropinirole-PR for treatment of Parkinson's disease remained on treatment longer and had greater medication adherence. A non-significant trend relating to time to initiation of levodopa was observed, however the study was not adequately powered to explore this further. The low numbers of dyskinesia and ICD events identified do not permit comparisons to be made between treatment groups.

4 AMENDMENTS AND UPDATES

Amendment or update no	Date	Section of study protocol	Amendment or update	Reason
1.	April 5th 2016	7. Rationale	Additional context	ISAC review
2.	April 5th 2016	9.2.3 Matching criteria	Additional context	ISAC review
3.	April 5th 2016	New section: handling of missing data	New section created outlining handling of missing data	ISAC review
4.	April 5th 2016	9.10 Limitations of research methods	Further detail about how to progress study if a lower than expected GP response rate is achieved	ISAC review
5	April 5th 2016	10.2 Subject confidentiality	Inclusion of a statement agreeing to adhere to CPRD policy.	ISAC review
6.	April 6th 2016	9.7.2	Inclusion of evaluation of the off-label population with an unspecified indication	
7.	December 8th 2016 (endorsed by ISAC in June 2017)	Section 9: Research methods	GP questionnaire no longer deemed feasible due to loss of contributing practices and loss to follow-up of patients. Any wording relating to use of a GP questionnaire removed. Endorsed by MHRA	Impact on sample size

Amendment or update no	Date	Section of study protocol	Amendment or update	Reason
8.	May 2017	Methods	Although the plan was to initially match at least 2 IR-DA patients per ropinirole-PR patient, a decision was made to limit this to 1:1 matching due to the dissimilarities' of the patients remaining after the first round of matching.	

5 MILESTONES

Milestone	Initial planned date	Revised planned dates	Date achieved
Submission to ISAC for approval	October-November 2015	March 2016	March 2016 Further amendment granted in May 2017
Registration in the EU PAS register	<i>Following ISAC approval</i>	September 2016	September 2016
Identification of study populations	November 2015		July 2016
Start of data collection (GP questionnaire)	January 2016	Not applicable	-
Interim review of response rate	March 2016	Not applicable	-
End of data collection	May 2016	Not applicable	
Review of achieved response rate	May 2016	Not applicable	
Analysis of data	June 2016	May 2017	May 2017
Final report of study results	September 2016	April 2018	April 2018

6 RATIONALE AND BACKGROUND

6.1 Background

6.1.1 Parkinson's Disease

Parkinson's disease (PD) is an age-related progressive neurodegenerative condition, involving the progressive loss of nigrostriatal neurones which results in deficiency of the neurotransmitter dopamine. The average age of onset is between 60-65 years and the prevalence amongst those aged >60 years is around 1%. Similar frequencies are observed in males and females, although some studies report a slight male preponderance. (Samii et al, 2004)

Currently available therapies aim to replace or compensate for the lost dopamine in order to improve motor function. Choice of initial therapy depends on a patient's age and specific symptoms. Dopamine agonists, levodopa or monoamine oxidase B (MAO-B) inhibitors are recommended first line therapy options for people in the early stages of Parkinson's disease whose motor symptoms do not impact on their quality of life. (NICE, 2017) Due to the higher risk of motor fluctuations and dyskinesia in younger-onset PD, dopamine agonists may be favoured as initial treatment for patients less than 60-65 years of age. (Connolly & Lang, 2014) (Brooks, 2000)

Levodopa may be used as first line treatment in patients in the early stages of Parkinson's disease whose motor symptoms impact on their quality of life or older patients. (Connolly & Lang, 2014) (NICE, 2017) Dopamine agonists are often avoided in older PD patients as they are more likely to induce confusion than levodopa. (Schapira, 2007)

6.1.2 Parkinson's disease treatment

Dopamine agonists

Dopamine agonists exert their anti-parkinsonian effects by acting directly on dopamine receptors and mimicking the endogenous neurotransmitter. (Brooks, 2000) (Bonuccelli & Ceravolo, 2008) Two subclasses of dopamine agonist exist: ergot (bromocriptine, pergolide, lisuride, α -dihydroergocryptine and cabergoline) and non-ergot (apomorphine, rotigotine, pramipexole, piribedil, pramipexole and ropinirole).

Dopamine agonists can be used as monotherapy or as an adjunct to levodopa. When used as monotherapy, the intention is to delay the need to initiate levodopa therapy and hence deferring the onset of levodopa associated complications. Most patients that initiate dopamine agonist therapy will eventually need the addition of levodopa to their treatment regimen. (Connolly & Lang, 2014).

Conversely, individuals initiating their treatment as levodopa monotherapy may be prescribed a dopamine agonist as adjunctive therapy in patients exhibiting fluctuating motor responses and dyskinesias associated with its chronic use. (Connolly & Lang, 2014;

Giroux, 2007) Addition of dopamine agonists allows a reduction in dose of levodopa and leads to improvement in the disabling complications.

Known side effects of dopamine agonists include hallucinations, excessive daytime sleepiness, hypotension and nausea. (Bonuccelli & Ceravolo, 2008) Other potential complications include impulse control behaviours. (Bonuccelli & Ceravolo, 2008) (British National Formulary, 2015) Ergot derived dopamine agonists are also associated with an increased risk of cardiac valve regurgitation and as a result are not generally prescribed. (Schade et al, 2007)

Ropinirole (prolonged and immediate release formulations)

Ropinirole is a potent and highly selective non-ergot dopamine receptor agonist that is active both peripherally and centrally. It is indicated for Parkinson's disease and the symptomatic treatment of moderate to severe idiopathic restless legs syndrome (RLS). Ropinirole is available in two formulations, an immediate release (ropinirole-IR) and a prolonged release (ropinirole-PR). Ropinirole-IR (REQUIP™) has been approved and marketed in the UK for over fifteen years and has been shown to be well tolerated and effective. (Adler et al, 1997; Pahwa et al, 2004) Ropinirole-IR is administered three times daily for the treatment of PD. The initial daily dose is 0.75mg titrating upwards to a maximum dose of 24mg daily.

Ropinirole-PR, licensed in 2008 for the treatment of PD, is taken once a day providing a simplified dosing regimen and reduced pill-burden. The initial dose of treatment is 2mg once daily, to a maximum daily dose of 24mg based on the patient's response. For patients switching from ropinirole-IR, patients should be switched to the equivalent daily dose of ropinirole-PR. The once daily dosing has the potential to improve compliance, which may lead to improved efficacy. The prolonged release formulation reduces plasma-level fluctuations in the concentration of ropinirole over a 24-hour period, producing a smoother pharmacokinetic profile which may result in a reduced potential to cause side-effects. (Pahwa R et al, 2007)

Levodopa

Levodopa is the amino acid precursor of dopamine and remains the most potent and widely used antiparkinson drug throughout much of the disease course. The aim of levodopa treatment is to replace dopamine; levodopa enters dopaminergic neurons where it is metabolised to dopamine, replacing the depleted endogenous neurotransmitter. In combination with a peripheral decarboxylase inhibitor, it is the most effective symptomatic treatment.

Known side-effects of levodopa include dyskinesias and on-off fluctuations. (British National Formulary, 2015)

Decarboxylase inhibitors, Catechol O-methyltransferase (COMT) inhibitors Monoamine oxidase type B (MAO-B) are often prescribed together with levodopa to prolong its action. MAO-B inhibitors prevent the breakdown dopamine in the brain. Whereas decarboxylase and COMT inhibitors are generally only prescribed with levodopa,

MAOB-I's can be used on their own in the early stages of the condition or in conjunction with levodopa.

6.1.3 Outcomes associated with long-term PD treatment

Motor complications

Development of motor fluctuations (such as end-of-dose wearing-off, on-off phenomena and dyskinesias) are known complications of long-term dopaminergic treatment. (Samii et al, 2004). Motor complications can impair quality of life and cause significant disability for patients. (Connolly & Lang, 2014)

Drug induced dyskinesias are abnormal involuntary movements which can present as a wide variety of phenomenologies, including stereotypy, chorea, ballism, myoclonus, dystonia, and a combination of any of these hyperkinesias. (Vijayakumar, 2016) They are a central side effect of dopaminergic therapy and represent a major clinical problem in the management of patients with PD. Dopaminergic reduction strategies will reduce dyskinesias but worsen PD symptoms. Amantadine may be used to reduce dyskinesia severity. (Connolly & Lang, 2014) Dyskinesias are reported to occur in up to 45% of patients after 5 years of therapy with levodopa and 20% amongst those prescribed a dopamine agonist. (Gomez et al, 1997; Rascol et al, 2000; Samii et al, 2004)

Amongst patients prescribed levodopa, motor complications may begin as early as 2 years into therapy, although it is generally assumed that motor fluctuations occur in about 50 percent of patients after 5 years of levodopa treatment, increasing to 70 percent among patients treated for 15 years or more. (Giroux, 2007) (Santens & de Noordhout, 2006)

Dopamine agonists are less likely than levodopa to cause dopaminergic motor complications, particularly dyskinesia. The reason for this is not known, however it may be related to the longer half-life of dopamine agonists and differences in receptor selectivity. (Brooks, 2000) Abnormal pulsatile stimulation of dopamine receptors by the intermittent administration of agents with short half-lives such as levodopa is considered by some an important factor in the development of motor fluctuations. (Olanow & Obeso, 2000; Santens, et al, 2003; Brooks, 2000; Samii et al, 2004)

Impulse control disorders

Impulse control disorders (ICDs) are defined as behaviours that are performed repetitively, excessively, and compulsively to an extent that interferes in major areas of life functioning. In recent years, there has been increasing evidence and awareness that PD patients are at increased risk of developing one or more of four major ICDs, which are compulsive or pathological gambling, buying, sexual, and eating behaviours. (Weintraub et al, 2014)

6.2 Rationale

GSK committed to conducting a post-marketing observational study to address questions posed by the MHRA about the risk of potential long term consequences associated with continuous dopamine agonism in patients prescribed ropinirole-PR. GSK proposed to use data from the Clinical Practice Research Datalink (CPRD), a UK primary care database, to estimate the incidence of dyskinesias and impulse control disorders in patients initiating ropinirole PR monotherapy (**ropinirole-PR**) compared to those initiating an immediate release dopamine (**IR-DA**) agonist as monotherapy for the treatment of PD. In addition, GSK proposed to evaluate whether differences in treatment persistence exist which may be attributable to short term tolerability or improved compliance due to the simpler dosing regimen as well as comparing time to levodopa initiation between treatment groups. Lastly, the MHRA requested that the extent of off-label use of ropinirole-PR also be assessed.

7 RESEARCH QUESTION AND OBJECTIVES

7.1 Primary objective:

1: To estimate the incidence of dyskinesia and impulse control disorders in individuals initiating ropinirole-PR monotherapy compared to those initiating IR-DA agonist monotherapy for the treatment of Parkinson's disease.

7.2 Secondary objectives:

2: To estimate time to levodopa use amongst PD patients initiating ropinirole-PR monotherapy and those initiating IR-DA monotherapy.

3: To describe treatment persistence and adherence amongst PD patients initiating ropinirole-PR monotherapy and those initiating IR-DA monotherapy.

4: To estimate the average daily dose of ropinirole amongst the subset of PD patients switching from ropinirole-IR to ropinirole-PR before and after switching formulation.

5: To describe the extent of off-label use amongst ropinirole-PR initiators.

8 RESEARCH METHODS

8.1 Study design

This observational study used a cohort design with propensity score matching.

Parkinson's disease patients initiating an oral dopamine agonist as monotherapy between 2008 and 2013 were eligible for inclusion in the study.

The exposure groups of interest were PD patients initiating ropinirole-PR monotherapy (**ropinirole-PR**) and PD patients initiating an oral immediate release dopamine agonist


monotherapy (**IR-DA**). The two groups were propensity score matched. Refer to Section 8.2.4 for detail about matching criteria.

8.1.1 Observation period

The start of the observation period (index date) commenced 30 days after date of initiation of the dopamine agonist therapy. Patients were followed-up until a censoring event occurred which was defined as the earliest of discontinuation of therapy +30 days, development of an outcome of interest (dyskinesia or impulse control disorder), or end of follow-up on the CPRD up to a maximum of 5 years of treatment.

The observation period started 30 days after initiating therapy to ensure that instances where a patient might be switching from another therapy (for example because of developing an outcome of interest) be attributed to the correct exposure period. Similarly, this was the justification for censoring patients 30 days after treatment discontinuation. See Figure 1 for a schematic of the study design.

Figure 1 Schematic of study design: Longitudinal evaluation of dopamine agonist monotherapy (ropinirole-PR vs. IR-DA matched cohort)



8.2 Study Population and Setting

8.2.1 Clinical Practice Research Datalink

The study was conducted using data recorded on the Clinical Practice Research Datalink (CPRD). The CPRD is an observational UK primary care electronic health record database. Within the United Kingdom, ongoing Parkinson's disease treatment is managed in the primary care setting by general practitioners.

The CPRD contains anonymised longitudinal records collected from computerised primary care practices throughout the UK and includes all records deemed relevant to patient care. Details of demographics, primary care diagnoses and prescription treatment are routinely recorded by date in individual patient records. Due to the structure of the UK National Health Service (NHS), details of referrals, secondary care diagnoses and deaths are also captured. Major events from before computerisation are added retrospectively so that the GP has complete patient records. Data on preventive medicine can also be recorded with laboratory results electronically transferred to many practices. Medical events are automatically coded at entry using the READ coding system ([NHS Digital](#), 2018). Prescriptions issued by the GP are coded using British National Formulary (BNF) coding. Each patient within the CPRD is assigned an 'up to standard' date (UTS) when the recording of their details is considered to be of research standard.

Data quality of the CPRD is monitored continuously by MHRA and practices that fail to maintain the required standards are removed from the database. The data is collected from over 400 contributing clinical practices throughout the UK and currently contains around 4 million active patients. The CPRD has been found to be highly representative of the UK general population. Several studies have demonstrated nearly identical age and sex distributions when stratified by geographic region between the CPRD population and the entire UK population. ([Walley & Mantgani, 1997](#)) On average, individual patients are followed for more than 6 years.

Version 2017 Q3 of the CRPD was used.

8.2.2 Populations of interest

The populations of interest comprised of individuals on the CPRD with a recorded Parkinson's disease diagnosis that had initiated either ropinirole-PR monotherapy (**ropinirole-PR**) or an oral immediate release dopamine agonist (**IR-DA**) as monotherapy between 2008 and 2013.

Parkinson's disease

Parkinson's disease was defined based on the presence of a READ code for primary or idiopathic PD and aged at least 40 years at the date of PD diagnosis. PD diagnosis date was derived using an algorithm based approach using the earliest of the date of PD READ code, prescription for a dopaminergic therapy or PD symptomatology recorded using READ codes (refer to [Annex 2](#) for detail and for codes used). This method of assigning PD diagnosis date was found to be more accurate than using date of first PD

READ code alone based on findings from an initial pilot study conducted in 2010 (refer to [Annex 1](#) for details of the pilot study)

Individuals with evidence of secondary or drug induced Parkinsonism were excluded. (refer to [Annex 2](#) for detail and for codes used).

8.2.2.1 Exposure groups: Ropinirole-PR and Immediate release dopamine agonist monotherapy

BNF codes were used to identify dopamine agonist therapies of interest (ropinirole and immediate release dopamine agonists). Individuals were required to have least two prescriptions for a medication of interest.

As previously mentioned, follow-up commenced from date of initiation of therapy + 30days. In addition, individuals initially in the IR-DA cohort that subsequently switched to ropinirole-PR entered the ropinirole-PR cohort at the time of switch + 30 days.

(refer to [Annex 2](#) for detail and for codes used).

8.2.3 Inclusion and Exclusion criteria

Inclusion criteria:

Individuals were required to

- Meet the case definition of Parkinson's disease
- Have initiated a dopamine agonist therapy between 2008-2013 and received at least two prescriptions for the therapy of interest.
- Have a minimum of 12 months of registration prior the date of initiation of the dopamine agonist therapy +30 days in order to collect information on disease, comorbidity, medical and prescription history.
- Belong to practices that are considered up to research standard at initiation of therapy.

Exclusion criteria

- Individuals in the immediate release dopamine agonist cohort that had previously been prescribed any prolonged release dopamine agonist (ropinirole-PR or pramipexole-PR) were excluded.
- Individuals with evidence of adjunctive or prior history of levodopa use at time of initiating the dopamine agonist therapy were excluded, as were individuals with a history of dyskinesia or impulse control disorders prior to index date.
- Individuals with evidence of secondary or drug induced PD
- Aged <40 years at the time of PD diagnosis

All codes underwent review by a clinician at GSK (refer to [Annex 2](#) for codes used).

8.2.4 Matching Criteria and Restriction

8.2.4.1 Propensity score matching

The propensity score is defined as the conditional probability of being treated given the baseline covariates and aims to improve comparability between the exposure groups at baseline. Propensity scores are used to simultaneously control for the presence of several covariate factors. (D'Agostino, 1998)

Individuals from the comparator cohort (**IR-DA cohort**) were matched on a 1:1 basis to individuals in the **ropinirole-PR cohort** using greedy matching.

Propensity scores were calculated given the factors recorded up to the time of initiation of the therapy of interest. The following covariates were used to generate the propensity score: age at initiation, gender, history of hypercholesterolemia, history of hypertension, history of diabetes, use of MAO-B prior to initiation, PD duration at initiation, number of GP visits in the 12 months prior to initiation and the Charlson comorbidity score.

Standardised differences were calculated between the baseline covariates for the ropinirole-PR and IR-DA cohorts before and after matching to determine whether the matching was successful in balancing the groups. A standardized difference of an absolute value greater than 0.20 (small effect size) was used as a threshold to identify imbalance. (Cohen, 1988)


Of the 534 individuals initiating ropinirole-PR monotherapy, 341 were matched to an equivalent number of individuals initiating IR-DA monotherapy.

Propensity score matching improved comparability between groups as shown in [Table 1](#) and [Figure 1](#) with the exception of whether the treatment was a first line therapy, where differences remained.

Table 1 Comparison of standardised differences before and after propensity score matching

Variable	Standardised Difference	
	Before Match	After Match
Age at PD diagnosis	-0.2774	0.0732
Disease duration at treatment initiation	0.6398	0.0436
Charlson comorbidity score	-0.0695	0.0457
Number of GP consultations in 12m prior to initiation	-0.0811	-0.0263
Propensity score	0.7596	0.0006
Gender	0.0296	0.006
History of Hypercholesterolemia	-0.0716	-0.0264
History of Hypertension	-0.0766	0.0294
History of Diabetes	-0.1514	0.1539
MAOB ever used prior to treatment initiation	0.1594	-0.0453
First DA therapy used following PD diagnosis	1.6559	1.4334
History of Asthma	0.0296	0.006

Figure 2 Propensity score distributions before and after propensity score matching



All analyses were conducted amongst the matched ropinirole-PR monotherapy (N=341) and immediate release monotherapy (N=341) groups.

8.2.5 Outcome definitions

8.2.5.1 Dyskinesia

Dyskinesia was identified using READ codes recorded on the CPRD. Dyskinesia was coded as probable or possible depending on the specific READ codes (refer to [Annex 2](#) for codes used).

Individuals were classified as having dyskinesia if:

CPRD algorithm = [probable]

or

CPRD algorithm = [possible] + initiation of amantadine + clinical review*

* Review of the patient's electronic medical record by two physicians at GSK; a physician in the real world evidence group and independently by the ropinirole safety physician to determine outcome status.

Date of earliest dyskinesia READ code was used to determine date of dyskinesia diagnosis.

8.2.5.2 Impulse control disorders

Impulse control disorders (ICD) were identified using READ codes on the CPRD. The following categories of impulse control disorder were evaluated.

- i. Compulsive eating
- ii. Pathological gambling
- iii. Hypersexuality
- iv. Other impulse control disorder

The earliest date that the ICD was recorded on the CPRD was deemed to be the date of diagnosis.

(refer to [Annex 2](#) for codes used).

8.2.5.3 Time to levodopa initiation

Time to levodopa use was evaluated in both cohorts. Since levodopa is associated with dyskinesias, delay in its use may further reduce the risk of the development of motor complications, or reflect better control of PD symptoms by current therapy.

BNF codes were used to identify levodopa containing medications. (refer to [Annex 2](#) for codes used).

8.2.5.4 Duration of treatment persistence

Duration of the treatment was defined as the number of days between the last dose date (last prescription date at censoring plus days' supply) and the first prescription date.

8.2.5.5 Adherence

The medication possession ratio (MPR) was used to describe adherence to medication. This was calculated by summing the days' supply from the first to the last prescription (inclusive) divided by time between the last prescription date plus days' supply and the first prescription date.

MPR was categorised into the following: <30%, 30-50%, 51-80% and \geq 80%.

8.2.5.6 Ropinirole daily dose amongst switchers from ropinirole-IR to ropinirole-PR

The average daily dose of ropinirole was calculated for individuals who switched from the immediate release ropinirole to the prolonged release formulation to assess whether individuals switch to an equivalent dose. Switchers were defined as the subset of the ropinirole-PR population with least one script for ropinirole-IR formulation in the one month period prior to ropinirole-PR index date. The difference between the average daily dose of the last ropinirole-IR script and first ropinirole-PR was calculated. Details about how average daily dose was estimated can be seen in [Annex 2](#).

8.2.5.7 Ropinirole-PR off-label use

All individuals on the CPRD with at least one ropinirole-PR prescription (irrespective of age) and at least 12 months of medical history prior to index date (initiation + 30 days) were identified on the CPRD. The requirement of 12 month GP registration was required in order to allow sufficient time to determine likely indication for prescription for the off-label evaluation.

The off-label population comprised of individuals prescribed ropinirole-PR without PD. The likely indication for treatment was identified using READ codes recorded prior to initiation of therapy. The proportion of the off-label population with restless leg syndrome (RLS), fibromyalgia, sexual dysfunction, periodic limb movement disorder (without mention of RLS) (PLMD) was calculated. In addition, the proportion of the off-label population aged <18years at index date (paediatric population) was calculated. Individuals initiating therapy without any history of the above-mentioned conditions were coded as “other”.

READ codes were reviewed by a clinician at GSK ([Annex 2](#)).

8.2.6 Confounders and effect modifiers

Potential confounders and covariates of interest are listed below in [Table 2](#). These included age, gender and comorbidity burden. Since the risk of motor fluctuations such as dyskinesias increases with advancing disease state, PD duration at treatment initiation was considered as a potential confounder. The number of distinct dopamine agonists used up to the index date may be important to consider since frequent switchers may reflect individuals with uncontrolled PD or those with emerging motor fluctuations. The mean number of GP consultations in the year up to initiation of therapy was also deemed of potential interest.

Table 2 Potential confounders and covariates of interest

Covariate	Comments
<u>Demographics and baseline health state</u>	
Age at initiation of therapy	
Age at PD diagnosis	
Gender	
Mean number of GP consultations in 12 months up to index date	
Charlson comorbidity score at index date	
Use of anti-hypertensive treatments \leq index date	
Type 2 diabetes	
Use of medications to treat hypercholesteraemia	
Respiratory illness (COPD, asthma)	
History of psychiatric disease	
Index year	
Duration of PD at initiation of therapy	
<u>PD medication history up to and including index date</u>	
Duration of PD treatment	Time from first ever dopaminergic therapy to initiation of therapy of interest.
MAOB-I use	
Number of distinct dopamine agonist therapies used	Based on generic name. To identify prior DA use at baseline and frequent switchers of DA treatment up to baseline.
Amantadine use	Amantadine can be prescribed as a monotherapy to provide relief of symptoms of mild, early-stage PD. It may also be prescribed concomitantly with dopaminergic therapies during the later stages of Parkinson's disease to control involuntary movements (dyskinesias).
Apomorphine use	

8.3 Data Sources

This study was conducted using data recorded on the CPRD.

8.4 Study size

The desired sample size for the initial study was 1000 patients (500 of whom in the ropinirole-PR group); this was based on a Cox regression of the log hazard ratio on a covariate with a standard deviation of 0.50 assuming independent sampling of the

exposure groups (i.e. no matching). This achieved 82% power at a 0.05 significance level to detect a regression coefficient equal to 0.4055. The sample size assumed an anticipated event rate of 0.20 of dyskinesia. In addition, the use of matching was expected to provide some additional power.

However, the sample size achieved was lower than expected, as were the numbers of individuals with a dyskinesia. In total 534 ropinirole-PR initiators and 472 immediate release dopamine agonist initiators were identified. After propensity score matching, the final study population comprised of 341 PD patients in the ropinirole-PR monotherapy group and an equivalent number initiating immediate release dopamine agonist monotherapy. Instead, we estimated the power of the study based on the achieved sample size and on the levodopa event rate observed for a Cox regression based on the following assumptions.

- Sample size: total of exposed (Ropinirole-PR) and unexposed (IR-DA) subjects N= 682
- Regression coefficient (B): from the hazard ratio that the study has power to detect: 0.7, $\ln(0.7) = -0.357$
- SD of X1 = 0.5.
- Event rate: proportion of subjects who initiate L-dopa during the observation period. P = 0.3.
- R-squared X1 vs other Xs: R2 = 0
- Significance threshold: Two-sided alpha = 0.05

Based on the sample size, the highest power that the study could achieve was 72%; (for levodopa initiation); this is not considered sufficiently powered for the endpoint under consideration. This is a top level of power that could be achieved; the estimate based on the assumption that zero correlation between exposure and other covariates (R2=0) has been achieved by matching.

8.5 Data Management

8.5.1 Data transformation (Data handling conventions)

The data handling, analysis and quality control was conducted in-house by a named programmer and QC analyst that were dedicated to this study using in-house full-featured CPRD data.

The data derived from the CPRD database was held in-house and maintained as a SAS dataset in the WWEpi UNIX project area on a secure network server with restricted access.

8.5.2 Resourcing

The study was managed by the neurosciences epidemiology team and conducted by the Real World Data & Analytics team within the Real World Evidence and Epidemiology department at GlaxoSmithKline.

The following functions were involved in the study

- Epidemiologist
- Principal programmer
- QC analyst
- Named statistical consultant
- Clinical coding consultant
- Safety scientist
- Safety physician
- Clinical epidemiologist (physician)

8.6 Data analyses

8.6.1 Essential analyses

8.6.1.1 Descriptive and univariate analyses

Normally distributed continuous variables were presented as mean \pm standard deviation (SD) and skewed data as median (inter quartile range). Comparisons of continuous variables between the exposure groups were evaluated using the Student's t-test and categorical data evaluated using a chi-squared test with Yate's correction or by Fisher's exact test depending on the sample sizes. For the univariable analyses a two-sided p-value of 0.05 was considered to be statistically significant. For outcomes comparing median durations (i.e. median duration of treatment) between groups, a Wilcoxon test was performed to assess significance.

A paired sample t-test was used to assess whether patients prescribed ropinirole-IR who switch to ropinirole-PR, switch to an equivalent daily dose.

8.6.1.2 Incidence estimation

The incidence of dyskinesia was expressed as the number of events per 1,000 person-years (PY) of follow-up and was calculated for the matched ropinirole-PR and immediate release dopamine agonist cohorts. Follow-up commenced at index date and (initiation + 30 days) and censored as outlined in Section 8.1.1. Crude incident rates per 1,000 PY with exact Poisson 95% CI for each type of outcome was calculated.

Due to the small numbers of cases of dyskinesia identified adjusted estimates of incidence for these outcomes were not produced and stratification estimates (i.e. by age group or by line of therapy) were not calculated.

The incidence of impulse control disorders was not calculated due to too few events.

8.6.1.3 Multiple regression analyses - Cox proportional hazards regression

A Cox proportional hazards regression model was used to evaluate time to levodopa initiation in individuals in the matched cohorts. A diagnostic test was performed in order to check whether the proportional hazards assumption was satisfied, by adding an exposure x time interaction term to the model.

Crude hazard ratios and 95% CI were estimated using the **ropinirole PR** and the **IR-DA** cohorts. Adjusted hazards ratios were estimated, accounting for potential confounders (count of prior DA therapies, year of treatment initiation, gender, age at PD diagnosis and duration of the disease at the time of treatment initiation) as well as the matched group id variable.

Follow-up commenced at index date and (initiation + 30 days) and censored as outlined in Section 8.1.1.

8.6.1.4 Censoring

Follow-up continued up to the earliest of: the recording of the outcome of interest (ICD or dyskinesia), discontinuation of therapy+30days, end of a patient record or end of CPRD follow-up up to a maximum of 5 years of treatment.

8.6.2 Exploratory analyses

Not applicable

8.6.3 General considerations for data analyses

Sample size:

Sample size was lower than expected, as were the number of events of dyskinesia. The power to detect a statistically significant difference based on the achieved sample size and on time to levodopa initiation as an endpoint was not optimal. Refer to Section 8.4 for detail.

Confounding:

Two approaches were used to adjust for potential confounders: matching (propensity score matching with inclusion of forced match variables) and covariate adjustment.

Multiplicity:

No adjustment for multiplicity was performed. As such, due to the multiple comparisons involved for example in the comparison of demographic and baseline characteristics, it is possible that a statistically significant may be observed by chance.

Missing data:

It is acknowledged that data that are missing not at random (MNAR) may bias any observed results. In this study, outcome data, may be susceptible to missingness not at random. There are a number of factors that may influence this which include:

- Time period - better reporting of outcomes in more recent years due to improved reporting and recording of information by GPs. In order to minimise this, the study population was restricted to those initiating therapy between 2008 and 2013 i.e. the time from ropinirole-PR launch.
- Heightened reporting of specific outcomes due to new knowledge of adverse events (for example media reporting of ICDs associated with dopamine agonist use). As above, the population was restricted to those initiating therapy from 2008.

Other:

- Differential reporting based on exposure status
 - This study involves reuse of existing data, therefore not deemed to be a problem.
 - Exposure data (treatment) and other covariates of interest are well captured in the database.

Under reporting of outcomes:

- It is acknowledged that dyskinesias and impulse control disorders may be under-reported on the CPRD.

8.6.4 Amendments to the statistical analysis plan

- It was no longer deemed feasible to collect additional outcome data via GP questionnaire as this would have resulted in the potential loss of around half of the individuals in the study population. Outcome data was obtained from data recorded only on the CPRD. ISAC and the MHRA were consulted about this amendment.
- Individuals were matched using propensity score on a 1:1 basis due to insufficient numbers of patients and due to the poor quality of matches remaining after the first round of matching.
- The population was restricted to those initiating therapy within the same time period (i.e. 2008-2013) in order to reduce effects of changes in reporting with regards to impulse control disorders and to ensure similar potential for long-term follow-up.
- Duration of the treatment was crudely defined as the number of days between the last dose date (last prescription date at censoring plus days' supply) and the first prescription date.

- Due to the small numbers of individuals with an impulse control disorder or dyskinesia, the following analyses were not conducted as initially planned.
 - Calculation of incidence for impulse control disorders due to too few events identified.
 - Estimation of incidence of dyskinesia or impulse control disorders restricted to those without a prior history of DA at baseline (i.e. first line dopamine agonist therapy users).
 - Adjusted estimates of incidence of dyskinesia or ICD due to insufficient numbers of individuals with an outcome of interest.
 - Incident rate ratios for dyskinesia or ICD for those continuing treatment for up to 1, 3 and 5 years.
 - A Cox proportional hazards regression model estimating time to dyskinesia or impulse control disorders.
 - Time varying confounders (levodopa and use of medications known to prolong the action of levodopa) in the above.
 - Evaluation of dose of treatment (due to low numbers with outcome of interest and due to missing dose data on the CPRD).

8.7 Quality control and quality assurance

The study protocol underwent internal GSK review by epidemiology, statistics, clinical and observational database experts at the epidemiology Protocol Review Forum (PRF) in addition to ISAC approval. All analyses were conducted according to internal quality control procedures.

8.8 Other aspects

8.8.1 Validity of using READ codes to identify individuals with Parkinson's disease

In the UK, patients with suspected Parkinson's disease are referred by their GP to a specialist (neurologist or a geriatrician with a special interest in Parkinson's disease) where a diagnosis is made and treatment initiated. Patients usually have follow-up visits with the specialist every 6-12 months, however ongoing patient management (including repeat prescriptions) occurs in the primary care setting in coordination with a PD nurse specialist.

The pilot study conducted by GSK found that use of READ codes to identify PD patients was good; 40 out of the 41 cases included in the pilot study were correctly identified as PD using READ codes. It also found that the earliest of PD READ code, PD medication or PD symptomatology provided a more accurate estimate of PD diagnosis date than using PD READ code alone. Please refer to [Annex 1](#) for further details of the pilot study.

8.8.2 Capture of PD medication use in the primary care setting

Although PD treatment is initiated by a specialist, ongoing treatment (including repeat prescriptions) is managed in the primary care setting, meaning that it is believed that the CPRD adequately captures ongoing treatment of PD patients.

However, it is important to note that although prescriptions may have been issued by a GP, this does not mean that a patient filled their prescription or took their medications as instructed.

8.8.3 Validity and justification for choice of outcomes of interest

The pilot study mentioned above, aimed to compare outcomes identified on the CPRD with those reported via a GP questionnaire. The pilot study included individuals with Parkinson's disease, some of whom had an outcome of interest as defined by the presence of READ codes. Questions were included on the GP questionnaire that required the GP to note the presence or absence of the outcome and the date of onset of the outcome. The outcomes of interest that were evaluated as part of the pilot study were dyskinesia, end of dose wearing off, on-off phenomena, sudden onset of sleep and impulse control disorders. Comparisons were made between data captured on the CPRD with GP responses.

Based on findings from the pilot study, it was deemed that it would not be feasible to include end of dose wearing off or sudden onset of sleep as outcomes in the study due to a poor response to the question by GPs, a lack of appropriate medical codes available on the CPRD or substantial conflicting results between CPRD and GP questionnaire meaning that the validity of the outcome would be questionable.

Good agreement was observed between the CPRD and GP questionnaire for impulse control disorders; all cases of impulse control disorders (ICD) identified from the GP questionnaire had a corresponding READ code recorded on the CPRD.

Dyskinesias were classified as possible or probable dyskinesia based on READ codes recorded on the CPRD. There was less agreement observed between CPRD and GP responses for dyskinesia, however slightly better agreement was observed for the subset classified as probable dyskinesia.

Refer to [Annex 1](#) for further detail about the findings from the pilot study, including the level of agreement between the data sources for each outcome of interest.

9 PROTECTION OF HUMAN SUBJECTS

9.1 Ethical approval and subject consent

Independent Scientific Advisory Committee (ISAC) approval was obtained prior to initiating the study and for any major amendments.

9.2 Subject confidentiality


GSK did not have access to potentially patient identifiable information. In addition, as per CPRD policy, in order to preserve confidentiality, cells containing fewer than 5 events are not disclosed due to the possibility of unintentional (deductive) disclosure.

10 RESULTS

10.1 Study population

A total of 534 PD patients initiating ropinirole PR monotherapy and 472 PD patients initiating an immediate release dopamine agonist monotherapy between 2008 and 2013 that also met the inclusion criteria were identified. After propensity score matching, the final study population consisted of 341 PD patients initiating ropinirole-PR monotherapy and 341 PD patients initiating immediate release dopamine agonist monotherapy. [Figure 2](#) below shows the attrition due to application of inclusion and exclusion criteria in order to obtain the final study population.

Figure 3 Derivation of the study population



* includes 324 switched to ropinirole PR from the immediate release DA initiator cohort

10.2 Baseline characteristics before and after propensity score matching

Baseline Characteristics before propensity score matching

Table 3 compares baseline characteristics between the unmatched IR-DA (N=472) and ropinirole-PR (N=534) monotherapy initiators.

Ropinirole-PR initiators were slightly younger at diagnosis of Parkinson's disease as compared to IR-DA initiators, (62.8 years vs. 65.3 years p value = 0.003). The gender distribution was comparable between treatment groups (63.3% male ropinirole-PR cohort vs. 61.9% in the IR-DA cohort p=0.6). Although the Charlson comorbidity score was similar between treatment groups, individuals in the IR-DA group had a higher prevalence of diabetes compared to the Ropinirole-PR group (10.8% vs. 6.6% p 0.02). The proportions of patients with a history of asthma or hypertension or hypercholesterolaemia were similar between groups.

The disease duration at the time of treatment initiation differed between groups; the median time from PD diagnosis to treatment initiation was 9 months in the ropinirole-PR group compared to 1 month in the IR-DA group (p <.0001). The number of general practice (GP) consultations in 12 months prior to initiation of therapy were similar across both groups.

Differences in regards to the number of other dopamine agonist therapies prescribed prior to treatment initiation were observed; individuals in the IR-DA group were more likely to have initiated their therapy as first line dopamine agonist treatment following PD diagnosis, whereas the ropinirole-PR group were more likely to have initiated therapy after switching from another dopamine agonist. 5.5% of the IR-DA initiators and 69.5% of the ropinirole-PR initiators had switched from another dopamine agonist at baseline. The mean number of prior dopamine agonists amongst IR-DA was 0.1 vs. 0.7 amongst ropinirole-PR.

Table 3 Demographics and baseline characteristics of immediate release dopamine agonist and ropinirole-PR monotherapy initiators (before propensity score matching)

	Immediate Release Dopamine Agonist initiators n=472		Ropinirole-PR Initiators n=534		p value
	Mean	95% CI	Mean	95% CI	
Age at Parkinson's diagnosis	65.3	64.5, 66.1	62.8	62, 63.5	<.0001
Age at initiation of therapy	65.8	65, 66.7	64.1	63.4, 64.9	0.0027
Average duration from diagnosis to treatment initiation (months)	6.2 (median 1)	5.2, 7.3	15.9 (median 9)	14.4, 17.5	<.0001
Charlson comorbidity score	0.8	0.7, 0.9	0.7	0.6, 0.8	0.2715
Average number of GP consultations in 12m prior to initiation	10.9	10.2, 11.7	10.3	9.5, 11	0.1982
Count of other dopamine agonists prior to initiation	0.1	0, 0.1	0.7	0.7, 0.8	<.0001
Count of other anti-Parkinson's drugs prior to initiation	0.2	0.1, 0.2	0.2	0.2, 0.3	0.0064
Propensity Score	0.5	0.5, 0.5	0.6	0.6, 0.6	<.0001
	N	%	N	%	p value
Gender					0.63954
Female	180	38.1	196	36.7	
Male	292	61.9	338	63.3	
History of Asthma					0.84622
No	426	90.3	480	89.9	
Yes	46	9.7	54	10.1	

	Immediate Release Dopamine Agonist initiators n=472		Ropinirole-PR Initiators n=534		p value
	Mean	95% CI	Mean	95% CI	
History of Hypercholesterol emia					0.256 23
No	404	85.6	470	88	
Yes	68	14.4	64	12	
History of Hypertension					0.225 94
No	196	41.5	242	45.3	
Yes	276	58.5	292	54.7	
History of Diabetes					0.016 11
No	421	89.2	499	93.4	
Yes	51	10.8	35	6.6	
MAOB ever used prior to Rx					0.012 24
No	401	85	421	78.8	
Yes	71	15	113	21.2	
Amantadine ever used prior to Rx					0.189 24
No	>=467	>=98.9	526	98.5	
Yes	<=5	<1.1	8	1.5	
First DA used following PD diagnosis					<.000 1
Yes	446	94.5	163	30.5	
No	26	5.5	371	69.5	

Baseline Characteristics after Propensity Score Matching

Matching resulted in improved comparability between groups in regards to age and average disease duration. However, differences in the history of diabetes and whether the treatment was first line therapy or not remained. 3.8% of the IR-DA and 7.3% of the ropinirole-PR group had a history of diabetes at baseline. 6.5% of the IR-DA initiators and 62.2% of the ropinirole-PR initiators had switched from another dopamine agonist at baseline. [Table 4](#) compares baseline characteristics between IR-DA (N=341) and ropinirole-PR (N=341) monotherapy initiators after propensity score matching. Please also refer to [Section 8.2.4.1](#) which provides standardised differences for key variables before and after propensity score matching.

Table 4 Demographics and baseline characteristics of immediate release dopamine agonist and ropinirole-PR monotherapy initiators (after propensity score matching)

	Immediate Release Dopamine Agonist initiator n=341		Ropinirole-PR Initiator n=341		p value
	Mean	95% CI	Mean	95% CI	
Age at Parkinson's diagnosis	63.5	(62.5, 64.5)	64.1	(63.2, 65.1)	0.3397
Age at initiation of therapy	64.2	(63.2, 65.2)	64.9	(64, 65.8)	0.3097
Average duration from diagnosis to treatment initiation (months)	8.1 (median 2)	(6.8, 9.5)	8.7 (median 4)	(7.4, 10)	0.5696
Charlson comorbidity score	0.7	(0.6, 0.8)	0.7	(0.6, 0.9)	0.5509
Average number of GP consultations in 12m prior to initiation	11.1	(10.3, 12)	10.9	(9.9, 11.9)	0.7318
Count of other dopamine agonists prior to initiation	0.1	(0, 0.1)	0.6	(0.6, 0.7)	<.0001
Count of other anti-Parkinson's drugs prior to initiation	0.2	(0.2, 0.2)	0.2	(0.1, 0.2)	0.7090
Propensity Score	0.5	(0.5, 0.5)	0.5	(0.5, 0.5)	0.9385
	N	%	N	%	p value
Gender					0.9371
Female	130	38.1	129	37.8	
Male	211	61.9	212	62.2	
History of Asthma					0.2469
No	303	88.9	312	91.5	
Yes	38	11.1	29	8.5	
History of Hypercholesterolemia					0.7306
No	296	86.8	299	87.7	
Yes	45	13.2	42	12.3	

	Immediate Release Dopamine Agonist initiator n=341		Ropinirole-PR Initiator n=341		
	Mean	95% CI	Mean	95% CI	p value
History of Hypertension					0.700 8
No	159	46.6	154	45.2	
Yes	182	53.4	187	54.8	
History of Diabetes					0.045 1
No	328	96.2	316	92.7	
Yes	13	3.8	25	7.3	
MAOB ever used prior to Rx					0.553 9
No	275	80.6	281	82.4	
Yes	66	19.4	60	17.6	
Amantadine ever used prior to Rx					0.412 2
No	>=336	98.5	>=336	98.5	
Yes	<=5	1.5	<=5	1.5	
First DA used following PD diagnosis					<.000 1
Yes	319	93.5	129	37.8	
No	22	6.5	212	62.2	

10.3 Results of essential analyses

10.3.1 Dyskinesia

In total 5 individuals had a possible or probable dyskinesia related code during the observation period. All patients with probable dyskinesia had initiated levodopa during the observation period, prior to the dyskinesia diagnosis. The median time to dyskinesia was similar between groups (28 months in the IR-DA group and 33.5 months in the ropinirole-PR group, not a statistically significant difference). Further descriptive characteristics for these individuals are not provided in order to preserve confidentiality as per CPRD policy.

The corresponding unadjusted incidence of probable dyskinesia in the IR-DA initiator group was 3.95 per 1,000 PY and 3 per 1,000 PY in the ropinirole-PR initiator group.

The Poisson model yielded a rate of dyskinesia in the IR-DA initiator group of 3.93 per 1,000 PY (95% CI 0.98, 15.7) compared to 2.98 per 1,000 PY (95% CI 0.74, 11.9)

amongst the ropinirole-PR initiator group. The incident rate ratio was 1.32 (95% CI 0.19, 9.37) (IR-DA compared to ropinirole-PR).

10.3.2 Impulse control disorders

<5 cases of ICD were identified and occurred in the IR-DA group. The median time to ICD was 23 months from treatment initiation and levodopa had been initiated prior to the ICD diagnosis. In order to preserve confidentiality as per CPRD policy, further descriptive characteristics are not provided.

10.3.3 Time to levodopa initiation

Overall, 40.7% (n=138) of the IR-DA group and 46.6% (n=159) of the ropinirole-PR cohort initiated levodopa during the observation period. However, it is important to note that the median duration of treatment for ropinirole-PR was 682 days, which is significantly longer than 444 days for the immediate release dopamine agonist group which may in part explain this difference.

The median time to initiation of levodopa in the IR-DA group was 297 days (IQR 111, 552) compared to 417 days (IQR 205, 736) in the ropinirole-PR group.

The mean time to levodopa initiation was 399.6 days (95% CI 336, 463.1) in the IR-DA group and 500.6 days (95% CI 444.3, 556.8) in the ropinirole-PR group.

The Cox proportional hazards model evaluating the relative hazard of initiation of levodopa was adjusted on the count of prior DA therapies, calendar year of treatment initiation, gender, age at PD diagnosis and disease duration. The matching group ID was defined as a stratum variable. The adjusted hazard ratio of initiating levodopa was 0.7 (95% CI 0.37 - 1.31, p=0.257) comparing ropinirole-PR to IR-DA. The lower hazard of levodopa initiation in the ropinirole-PR group was not significantly different than the IR-DA group.

10.3.4 Adherence and persistence

Table 5 , Table 6, Figure 3 and Figure 4 and summarise time to discontinuation of therapy and the medication possession ratio between the treatment groups. In summary, individuals in the ropinirole-PR group remained on treatment for longer and had a higher medication possession ratio than the IR-DA group; these were statistically significant differences.

Table 5 Time to discontinuation

	Duration of treatment, days	
	Mean (CI)	Median (IQR)*
IR-DA	605.9 (548.7, 663)	444 (147, 848)
Ropinirole-PR	748.4 (693.9, 802.9)	682 (309, 1099)
* p <0.0001 (Wilcoxon test two sample test between two medians)		

Figure 4 Mean duration of treatment (days) and 95% CI





Table 6 Medication possession ratio for ropinirole-PR and IR-DA initiators

MPR	IR-DA		Ropinirole-PR	
	N	%	N	%
<30%	68	19.9	56	16.4
30-50%	39	11.4	10	2.9
51-80%	78	22.9	41	12.0
>=80%	156	45.7	234	68.6
Mean MPR (95% CI)	64.4 (60.6, 68.1)		76.9 (73.2, 80.6)	
P value	P<0.0001			

Figure 5 Medication possession ratio IR-DA and ropinirole-PR groups




10.3.5 Average daily dose amongst ropinirole-IR to ropinirole-PR switchers

The average daily dose amongst the subset of the ropinirole-PR initiators that switched from ropinirole-IR with available dose information was estimated (N=71). The average daily dose was 6.9mg (95% 6, 7.9) amongst those prescribed ropinirole-IR prior to switching formulation, and was 8.6mg (95% CI 7.5, 9.6) following the switch to ropinirole PR; this was not statistically significant.

Table 7 Average daily dose of ropinirole amongst the subset of patients switching from ropinirole-IR to ropinirole-PR before and after switching formulation (N=71)

	Average daily dose (mg)	95% CI	min	max
Ropinirole-IR	6.9	(6, 7.9)	1.5	18
Ropinirole-PR	8.6	(7.5, 9.6)	2	20

Figure 6 Average daily dose (mg) and 95% CI of ropinirole before and after switching formulations



10.3.6 Off-label use of ropinirole-PR

A total of 2,388 individuals with at least one prescription for ropinirole-PR and at least 12 months of GP registration at the time of initiation were identified on the CPRD. Of these, the majority (n=1844, 77.2%) had a Parkinson’s disease diagnosis and 544 individuals (22.8%) did not have a history of PD; these comprise the off-label population. There was no evidence of use of ropinirole-PR in the paediatric age group (<18 years).

A summary of the diagnosis history of the off-label population (N=544) is shown below in [Table 8](#).

Table 8 Potential off label use of ropinirole PR

	n	%
History of restless leg syndrome (RLS)	247	45.40
History of sexual dysfunction	64	11.76
History of Fibromyalgia or History of limb movement (without mention of RLS)	12	2.21
No history of any of the conditions specified above.	221	40.63
Total	544	

10.4 Other analyses

Not applicable

10.5 Adverse events/adverse reactions

It is not feasible to make a causality assessments at the individual case level using data from retrospective observational database studies.

11 DISCUSSION

This observational study evaluated outcomes amongst individuals prescribed ropinirole-PR monotherapy for the treatment of Parkinson's disease compared to a propensity matched cohort of individuals initiating an immediate release dopamine agonist.

11.1 Interpretations of Results

Although a smaller than desired study size was evaluated, some interesting trends were observed.

Firstly, in the unmatched populations ropinirole-PR initiators were slightly younger at diagnosis of Parkinson's disease compared to IR-DA initiators, (62.8 years vs. 65.3 years), had a longer disease duration at the time of treatment initiation (median disease duration at treatment initiation 9 months vs. 1 month ($p < .0001$) and were more likely to have switched from another dopamine agonist. A younger age at diagnosis and longer disease duration are known risk factors for development of dyskinesias. (Sharma, 2010) (Espay, 2010)

Matching resulted in improved comparability between groups, however some differences remained, notably that the majority of the ropinirole-PR group had switched from another dopamine agonist whereas for the IR-DA group, the majority initiated treatment as the first dopamine agonist following PD diagnosis, however, the mean disease duration between groups were similar. It is not clear what factors would be influencing the difference in prior dopamine agonist use based on the available data.

Dyskinesia:

Less than one percent of the study population met the definition for dyskinesia; this is lower than has been reported elsewhere (Rascol, 2000). This may be because the evaluated population could reflect a less advanced PD population, be due to the length of follow-up, or due to underreporting or coding in the primary care setting. For example, dyskinesias may be diagnosed by a PD specialist and therefore be captured in discharge letters or free text rather than reflected in structured data on the primary care record or else a GP may modify a patient's treatment rather than recording a formal diagnosis of a dyskinesia. All patients with probable dyskinesia had initiated levodopa during the observation period, prior to the dyskinesia diagnosis. Neither dose of levodopa or concurrent use of medications that prolong the effects of levodopa such as COMT inhibitors, decarboxylase inhibitors or MAOB were accounted for in this analysis. The median time to dyskinesia was 28 months in the IR-DA group and 33.5 months in the ropinirole-PR group but these were not statistically significant differences. The low numbers of individuals identified with a dyskinesia prevent these findings being interpreted.

The incidence of dyskinesia in the IR-DA initiator group was 3.93 per 1,000 PY (95% CI 0.98, 15.7) compared to 2.98 per 1,000 PY (95% CI 0.74, 11.9) amongst the ropinirole-PR initiator group; the incident rate ratio was 1.32 (95% CI 0.19, 9.37) (IR-DA compared to ropinirole-PR) which was not statistically significant. Other known risk factors for development of dyskinesia include female gender, severity of PD, weight and levodopa

dose (Sharma, 2010); with the exception of gender none of these could be accounted for in the analysis.

Early use of longer acting non-levodopa (i.e. dopamine agonists) medications is reported to delay the onset of dyskinesia (Sharma, 2010). However, whether there is a difference in dyskinesia incidence or time to onset of dyskinesia when immediate-release and prolonged release dopamine agonist formulations are compared as early monotherapy has yet to be studied.

Impulse control disorders:

Too few cases of ICD were identified to permit meaningful analysis.

Time to levodopa initiation:

Overall, 46.6% of the ropinirole-PR cohort and 40.7% of the IR-DA group initiated levodopa during the observation period. However, the median duration of treatment for ropinirole-PR was significantly longer than the immediate release dopamine agonist group (682 days vs. 444 days) which may in part explain this difference

The analysis of time to levodopa initiation showed a trend, albeit non-significant, towards delayed initiation of levodopa in those treated with ropinirole-PR than those in the immediate release dopamine agonist group. The median time to initiation of levodopa in the ropinirole-PR group was 417 days (IQR 205, 736) vs. 297 days (IQR 111, 552) in the IR-DA group.

Similarly, the adjusted hazard ratio of initiating levodopa was 0.7 (95% CI 0.37 - 1.31, p.=0.257) comparing ropinirole-PR to IR-DA. However, as noted earlier, the power of this study was sub-optimal and although a trend was observed, it is not appropriate to draw further conclusions from this.

Adherence and persistence:

Individuals in the ropinirole-PR group remained on treatment for longer compared to IR-DA (median time to discontinuation 682 days (IQR 309, 1099) vs. 444 days (IQR 147, 848) and had a higher medication possession ratio than the IR-DA group (68.6% of the ropinirole-PR group and 45.7% of the IR-DA group had an MPR of at least 80%); these were statistically significant differences.

In more recent years, patients have been able to automatically have prescriptions sent electronically to their local pharmacy via the NHS' Electronic Prescription Service (EPS). Since patients in the ropinirole-PR group were more likely to have initiated their therapy in more recent years than the IR-DA group, it is possible that the higher MPR may be an artefact of automatic prescription refills via the EPS. The development and subsequent deployment of EPS occurred between 2003 and 2015. (Hibberd, 2017) As of early 2016 deployment of the EPS was still ongoing, therefore the extent to which automatic refills would impact the estimation of MPR is not expected to be substantive in the time period evaluated. The simpler dosing regimen of ropinirole-PR could account for the higher MPR observed in this study.

Average daily dose amongst ropinirole-IR to ropinirole-PR switchers:

The usual daily dose as stated in the British National Formulary (BNF), is 9-16mg daily (maximum 24mg per day). The recommended starting dose of ropinirole-IR is 0.25mg taken three times daily (total daily dose 0.75mg) titrated to a maximum daily dose of 24 mg. For ropinirole-PR, the initial dose is 2 mg once daily, increased by 2 mg intervals of at least 1 week up to 8 mg once daily and increased if still no response to a maximum of 24 mg per day. The BNF recommends that patients switching from the IR to PR ropinirole formulation, should be switched to an equivalent total daily dose and that if control is not maintained after switching, to titrate the dose.

In this study, the average daily dose amongst switchers with available dose information (N=71) was 6.9mg (95% CI 6, 7.9) amongst those prescribed ropinirole-IR prior to switching formulation, and was 8.6mg (95% CI 7.5, 9.6) following the switch to ropinirole PR. This difference was not statistically significant, however could be explained by the different available strengths for both formulations meaning that patients may not be able to switch to an equivalent daily dose. Ropinirole-IR is available in 0.25 mg, 0.5 mg, 1 mg, 2mg, and 5mg tablets, whereas ropinirole-PR is available in 2mg, 4mg, and 8mg tablets. Because ropinirole-IR is available in doses less than 1 mg (0.25 and 0.50 mg), conversion to prolonged release doses may approximate but may not always equal 1:1 dosing. The ropinirole global datasheet recommends the following doses for patients switching formulations ([Table 9](#)).

Table 9 Recommended dose of ropinirole PR tablets for patients switching from ropinirole IR tablets

Ropinirole immediate release total daily dose (mg)	Ropinirole prolonged release daily dose (mg)
0.75–2.25	2
3–4.5	4
6	6
7.5–9	8
12	12
15–18	16
21	20
24	24

Off-label use of ropinirole-PR:

Almost one quarter of all individuals with at least one script of ropinirole-PR did not have a PD diagnosis code recorded and were considered as possibly off-label use in this study. Almost one half of the off-label population met the criteria for RLS and forty percent were classified as “other” i.e. did not have a history of RLS, sexual dysfunction, fibromyalgia or periodic limb movement.

11.2 Limitations

- It is not appropriate to draw conclusions from any treatment comparisons due to the small sample size and lower than expected numbers of events of dyskinesia or ICD. Furthermore, the study was not optimally powered to detect significant differences with regards to time to levodopa initiation between treatment groups.
- The use of administrative data of this type carries some limitations. A primary limitation is our limited ability to control for confounding. Matching by use of propensity scores helped to ensure that the exposure groups were similar at baseline, however, it is only possible to control for potential confounders that are contained within the CPRD data. GP’s choice of therapy may be influenced by a number of factors such as Parkinson’s disease severity, and nature of the PD symptoms which is not measurable using data from the CPRD.
- As mentioned, although propensity score matching improved comparability between groups, a difference with regards to the line of therapy remained; individuals in the ropinirole-PR group were more likely to have switched from another dopamine agonist, whereas the IR-DA initiators were more likely to have initiated therapy as a first line dopamine agonist treatment. The reasons for switching are not known, however may reflect a subset of patients who were not optimally controlled for their PD symptoms, have not tolerated or have experienced an adverse event on their previous dopamine agonist medication. The impact of this difference on the outcomes under study are not known.
- We found that once patients initiated ropinirole-PR treatment, they remained on therapy longer than IR-DA. As such, higher rates of outcomes seen in ropinirole-PR may occur as a consequence of longer follow-up in any crude analyses that do not take into account person time at risk. It is important to note that it is possible that patients remained on therapy longer for reasons including improved tolerability, a simpler dosing regimen or effectiveness.
- In more recent years, patients have been able to automatically have prescriptions sent electronically to their local pharmacy via the NHS’ Electronic Prescription Service (EPS) negating the need to contact their GP directly. Since patients in the ropinirole-PR group were more likely to have initiated their therapy in more recent years than the IR-DA group, it is possible that the higher MPR observed may be an artefact of automatic prescription refills via the EPS. Based on the time period evaluated and uptake, it is not believed that this would substantively impact the MPR between groups. Refer to Section 11.1 for more detail.
- The CPRD is representative of patient care as provided by GPs in the primary care setting. In the UK, PD patients are initially assessed and prescribed therapy

by Neurologists or PD Nurse Specialists, however, it is believed that ongoing therapy is managed in primary care. The CPRD will not therefore capture prescriptions issued by specialists, however subsequent prescriptions will be.

- As described earlier there may be under-recording of outcomes of interest in structured primary care data such as information recorded as free text or in discharge letters from specialists. This could account for the small numbers of individuals with dyskinesia or ICD.
- Duration of the treatment was defined as the number of days between the last dose date (last prescription date at censoring plus days' supply) and the first prescription date. This is crude measurement because switching in between the first and last prescription was not taken into account.
- The following dyskinesia risk factors were not accounted for in the analysis due to lack of available data: severity of PD, weight and levodopa dose.
- There is the possibility of enhanced GP ascertainment/patient reporting of compulsive behaviours among dopamine agonist users because of media attention related to this class of drug. However, this should not affect our ropinirole-PR vs. other dopamine agonists comparison because they are in the same class and the study period was the same between groups.
- This study only evaluated patients as far back as they were registered with an up-to-standard CPRD practice to obtain information on prior dopamine agonist prescriptions and medical diagnoses. Some events occurring prior to this may be missing however their effect on the baseline risk of dyskinesias or other adverse outcomes is likely to be minimal.
- Dose of treatment has not been accounted for in the analyses, nor has use of COMT, decarboxylase inhibitors or MAOB during the observation period; these are known to prolong the effects of levodopa and hence may modify the risk of some of the outcomes of interest.
- Finally, we used prescriptions issued as a proxy for treatment compliance. This merely represents prescriptions given to the patient and does not represent dispensed prescriptions. It is therefore possible that some patients are not taking their medications, but are still receiving prescriptions. Again, this occurrence should be non-differential across our treatment groups, however may vary by age of patient.

12 CONCLUSIONS

Compared to immediate release dopamine agonist monotherapy, individuals prescribed ropinirole-PR for treatment of Parkinson's disease remained on treatment longer and had greater medication adherence. A non-significant trend relating to time to initiation of levodopa was observed, however the study was not adequately powered to explore this further. The low number of dyskinesia and ICD events identified do not permit comparisons to be made between treatment groups.

13 REFERENCES

- Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J. et al. (1997). Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. *Neurology*, *49*, 393-399.
- Bonuccelli, U. & Ceravolo, R. (2008). The safety of dopamine agonists in the treatment of Parkinson's disease. *Expert.Opin.Drug Saf*, *7*, 111-127.
- British National Formulary. (2015). Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Ref Type: Online Source <https://bnf.nice.org.uk/> accessed March 1st 2018
- Brooks, D. J. (2000). Dopamine agonists: their role in the treatment of Parkinson's disease. *J Neurol Neurosurg.Psychiatry*, *68*, 685-689.
- Cohen, J. (1988). Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd ed). Lawrence Erlbaum Associates Publishers: Hillsdale, NJ.
- Connolly, B. S. & Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: a review. *JAMA*, *311*, 1670-1683.
- D'Agostino, R. B. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Statistics in Medicine*, *17*, 2265-2281.
- Espay, A.J. (2010) Management of Motor Complications in Parkinson Disease: Current and emerging Therapies *Neurol Clin* *28* 913–925
- Giroux, M. L. (2007). Parkinson disease: managing a complex, progressive disease at all stages. *Cleve.Clin.J Med.*, *74*, 313-8, 320.
- Gomez, A. G., Jorge, R., Garcia, S., Scipioni, O., & Gershanik, O. (1997). Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. *Mov Disord.*, *12*, 277-284.
- Hibberd, R., Cornford, T., Lichtner, V. England's electronic prescription service. (2017) Book chapter in Aanestad, Margunn, Grisot, Miria, Hanseth, Ole and Vassilakopoulou, Polyxeni, (eds.) Information Infrastructure Within European Health Care: Working with the Installed Base. Health Informatics. Venters, W., BarberSpringer, N. , New York, USA. 109-128.
- NHS Digital (2018). READ codes. Online Source: <https://digital.nhs.uk/services/terminology-and-classifications/read-codes> Date accessed April 23rd 2018
- NICE guideline [NG71] Parkinson's disease in adults: July 2017 Online Source: <https://www.nice.org.uk/guidance/ng71> Date accessed March 1st 2018

- Olanow, C. W. & Obeso, J. A. (2000). Preventing levodopa-induced dyskinesias. *Ann.Neurol*, 47, S167-S176.
- Pahwa R, Stacy M A, Factor S A, Lyonsa K E, Stocchi F, Hersh B P et al. (2007). Ropinirole 24-hour prolonged release. *Neurology*, 68, 1108-1115.
- Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H. et al. (2006). Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, 66, 983-995.
- Pahwa, R., Lyons, K. E., & Hauser, R. A. (2004). Ropinirole therapy for Parkinson's disease. *Expert.Rev.Neurother.*, 4, 581-588.
- Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. *N.Engl.J.Med.*, 342, 1484-1491.
- Samii, A., Nutt, J. G., & Ransom, B. R. (2004). Parkinson's disease. *Lancet*, 363, 1783-1793.
- Santens, P. & de Noordhout, A. M. (2006). Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey. *Acta Neurol Belg.*, 106, 137-141.
- Santens, P., Boon, P., Van, R. D., & Caemaert, J. (2003). The pathophysiology of motor symptoms in Parkinson's disease. *Acta Neurol.Belg.*, 103, 129-134.
- Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. *N.Engl.J.Med.*, 356, 29-38.
- Schapira, A. (2007) Treatment Options in the Modern Management of Parkinson Disease. *Arch Neurol*. 64 (8), 1083-8
- Sharma, J.C., Bachmann, C.G., Linazasoro, G. (2010) Classifying risk factors for dyskinesia in Parkinson's disease. *Parkinsonism and Related Disorders* 16 490-497
- Thomas, A., Bonanni, L., Di, I. A., Varanese, S., Anzellotti, F., D'Andreagiovanni, A. et al. (2006). End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. *J Neurol*, 253, 1633-1639.
- Vijayakumar, D., Jankovic, J. (2016) Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. *Drugs*, 76, 759-777
- Walley, T. & Mantgani, A. (1997). The UK General Practice Research Database. *Lancet*, 350, 1097-1099.
- Weintraub, D., David, A. S., Evans, A. H., Grant, J. E., & Stacy, M. (2014). Clinical spectrum of impulse control disorders in Parkinson's disease. *Mov Disord*.

APPENDICES**Annex 1: LIST OF STAND-ALONE DOCUMENTS**

No	Title
1.	Summary of findings from Pilot study
2	Charlson Score
3	Diabetes (prescriptions)
4	Diabetes (diagnosis)
5	Hypertension
6	PD medications
7	Psychiatric disease

Annex 2: READ and BNF codes**Parkinson's disease READ codes**

medcode	read_code	desc
9509	Eu02300	[X]Dementia in Parkinson's disease
96860	F11x900	Cerebral degeneration in Parkinson's disease
4321	F12..00	Parkinson's disease
1691	F120.00	Paralysis agitans
14912	F12z.00	Parkinson's disease NOS

Parkinson's disease symptoms READ codes

To be used together with PD READ codes and dopaminergic therapies to derive PD diagnosis date

medcode	read_code	desc
10718	297A.00	O/E - Parkinsonian tremor
20242	2944.00	O/E - muscle rigid - cogwheel
18660	2944.11	O/E - cog wheel rigidity
53655	2987.00	O/E -Parkinson flexion posture
17004	2987.11	O/E - Parkinson posture
59824	2994.00	O/E-festination-Parkinson gait
16860	2994.11	O/E - Parkinson gait
10795	2994.12	O/E - festination
7572	F116.00	Lewy body disease

Secondary or drug induced Parkinson's disease

Either a code for drug induced PD or exposure to any prescription for drugs known to induce Parkinsonism in the 3month period before the Parkinson's disease diagnosis date.

review	comments	medcode	read_code	desc
Y	secondary PD	52589	A94y100	Syphilitic parkinsonism
Y	secondary PD	51105	F123.00	Postencephalitic parkinsonism
Y	secondary PD	100128	F124.00	Vascular parkinsonism
Y	secondary PD	24001	F12W.00	Secondary parkinsonism due to other external agents
Y	secondary PD	26181	F12X.00	Secondary parkinsonism, unspecified
Y	secondary PD	97170	Fyu2100	[X]Other secondary parkinsonism
Y	secondary PD	86062	Fyu2200	[X]Parkinsonism in diseases classified elsewhere
Y	secondary PD	72879	Fyu2900	[X]Secondary parkinsonism, unspecified
Y	drug-induced PD	33544	F121.00	Parkinsonism secondary to drugs
Y	drug-induced PD	19478	F121.11	Drug induced parkinsonism
Y	drug-induced PD	5443	F122.00	Malignant neuroleptic syndrome
Y	drug-induced PD	105947	Fyu2000	[X]Other drug-induced secondary parkinsonism

Use of any of the following in the 3 month period prior to PD diagnosis date

bnfcode	prod code	drugs substance	productname
00000000	3490	Amitriptyline hydrochloride/Perphenazine	Amitriptyline 10mg / Perphenazine 2mg tablets
04030100	595	Amitriptyline hydrochloride/Perphenazine	Amitriptyline 25mg / Perphenazine 2mg tablets
04020100	21744	Benperidol	Anquil 250microgram Tablet (Concord Pharmaceuticals Ltd)
04020101	47365	Benperidol	Anquil 250microgram tablets (Archimedes Pharma UK Ltd)
04065400	35442	Cinnarizine/Dimenhydrinate	Arlevert tablets (Hampton Pharmaceuticals Ltd)
04070100	12976	Metoclopramide hydrochloride/Lysine acetylsalicylate	Aspirin 900mg / Metoclopramide 10mg oral powder sachets sugar free

bnfcode	prod code	drugs substance	productname
04020101	2540	Benperidol	Benperidol 250microgram tablets
04020100	31796	Benperidol	Benquil 250microgram tablets (Concord Pharmaceuticals Ltd)
04020100/ 40120000	500	Prochlorperazine maleate	Buccastem 3mg Tablet (Reckitt Benckiser Healthcare (UK) Ltd)
04065400	42882	Prochlorperazine maleate	Buccastem 3mg tablets (Alliance Pharmaceuticals Ltd)
04065400	5971	Prochlorperazine maleate	Buccastem M 3mg tablets (Alliance Pharmaceuticals Ltd)
04020100/ 40120000	28862	Chlorpromazine hydrochloride	Chloractil 100mg Tablet (DDSA Pharmaceuticals Ltd)
04020100/ 40120000	17227	Chlorpromazine hydrochloride	Chloractil 25mg Tablet (DDSA Pharmaceuticals Ltd)
04020100/ 40120000	25653	Chlorpromazine hydrochloride	Chloractil 50mg Tablet (DDSA Pharmaceuticals Ltd)
04020100/ 40120000	8506	Chlorpromazine Hydrochloride	Chlorpromazine 100mg suppository
04020100	2154	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets
04020100	46960	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets (IVAX Pharmaceuticals UK Ltd)
04020100	34736	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets (Teva UK Ltd)
04020100	58492	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets (Waymade Healthcare Plc)
04020100	8519	Chlorpromazine hydrochloride	Chlorpromazine 100mg/5ml oral solution
04020100	45281	Chlorpromazine hydrochloride	Chlorpromazine 100mg/5ml oral solution (Rosemont Pharmaceuticals Ltd)
00000000	9965	Chlorpromazine embonate	Chlorpromazine 100mg/5ml oral suspension sugar free
04020100/ 40120000	37705	Chlorpromazine Hydrochloride	Chlorpromazine 100mg/5ml suspension
00000000	2474	Chlorpromazine hydrochloride	Chlorpromazine 10mg tablets
00000000	8045		CHLORPROMAZINE 200 MG TAB
00000000	13479		CHLORPROMAZINE 25 MG SUP
04020100	588	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets
04020100	31175	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (A A H Pharmaceuticals Ltd)
04020100	34693	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (Genus Pharmaceuticals Ltd)
04020100	31184	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (IVAX Pharmaceuticals UK Ltd)
04020100	34668	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (Teva UK Ltd)
04020100	22606	Chlorpromazine hydrochloride	Chlorpromazine 25mg/1ml solution for injection ampoules
04020100	3952	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml oral solution
04020100	44186	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml oral solution (A A H Pharmaceuticals Ltd)
04020100/ 40120000	37871	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml Oral solution (Rosemont Pharmaceuticals Ltd)
04020100	9190	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml oral solution sugar free
04020100	56862	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml syrup (Rosemont Pharmaceuticals Ltd)
04020100/ 40120000	8311	Chlorpromazine Hydrochloride	Chlorpromazine 25mg/ml injection
04020100/ 40120000	41645	Chlorpromazine Hydrochloride	Chlorpromazine 25mg/ml Injection (Antigen Pharmaceuticals)
00000000	247		CHLORPROMAZINE 50 MG INJ

bnfcode	prod code	drugs substance	productname
04020100	3348	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets
04020100	31171	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets (A A H Pharmaceuticals Ltd)
04020100	34630	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets (Genus Pharmaceuticals Ltd)
04020100	31172	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets (Teva UK Ltd)
04020100	35929	Chlorpromazine hydrochloride	Chlorpromazine 50mg/2ml solution for injection ampoules
04020100	4434	Chlorpromazine hydrochloride	Chlorpromazine 50mg/5ml oral solution
00000000	17221		CHLORPROMAZINE HCl 10 MG INJ
00000000	12544		CHLORPROMAZINE HCl 100 MG MIX
00000000	30346		CHLORPROMAZINE HCl 100 MG TAB
00000000	12137		CHLORPROMAZINE HCl 25 MG TAB
00000000	19033		CHLORPROMAZINE HCl 50 MG INJ
00000000	10446		CHLORPROMAZINE HCl 50 MG TAB
00000000	31747		CHLORPROMAZINE HYDROCHLORIDE
04020100	30111	Chlorprothixene	Chlorprothixene 50mg tablets
04065400	7768	Cinnarizine	Cinaziere 15mg tablets (Ashbourne Pharmaceuticals Ltd)
00000000	2937		CINNARIZINE 10 MG TAB
04065400	845	Cinnarizine	Cinnarizine 15mg tablets
04065400	34484	Cinnarizine	Cinnarizine 15mg tablets (A A H Pharmaceuticals Ltd)
04065400	34839	Cinnarizine	Cinnarizine 15mg tablets (Actavis UK Ltd)
04065400	48215	Cinnarizine	Cinnarizine 15mg tablets (Generics (UK) Ltd)
04065400	23974	Cinnarizine	Cinnarizine 15mg tablets (IVAX Pharmaceuticals UK Ltd)
04065400	35351	Cinnarizine/Dimenhydrinate	Cinnarizine 20mg / Dimenhydrinate 40mg tablets
02060400/ 03040103	55657	Cinnarizine	Cinnarizine 25mg tablets
00000000	2098	Cinnarizine	Cinnarizine 75mg capsules
04020100	1319	Zuclopenthixol dihydrochloride	Clopixol 10mg tablets (Lundbeck Ltd)
04020100	22049	Zuclopenthixol decanoate	Clopixol 200mg/1ml solution for injection ampoules (Lundbeck Ltd)
04020100/ 04020200	3774	Zuclopenthixol Decanoate	Clopixol 200mg/ml Oily injection (Lundbeck Ltd)
04020100	9347	Zuclopenthixol dihydrochloride	Clopixol 25mg tablets (Lundbeck Ltd)
04020100	13368	Zuclopenthixol dihydrochloride	Clopixol 2mg tablets (Lundbeck Ltd)
04020100	31538	Zuclopenthixol acetate	Clopixol Acuphase 100mg/2ml solution for injection ampoules (Lundbeck Ltd)
04020100	36101	Zuclopenthixol acetate	Clopixol Acuphase 50mg/1ml solution for injection ampoules (Lundbeck Ltd)
04020100	5762	Zuclopenthixol Acetate	Clopixol acuphase 50mg/ml Oily injection (Lundbeck Ltd)
04020100	12073	Zuclopenthixol decanoate	Clopixol Conc 500mg/1ml solution for injection ampoules (Lundbeck Ltd)
00000000	19752		DEPIXOL (10ML VIAL)
04020200	19283	Flupentixol decanoate	Depixel 20mg/1ml solution for injection ampoules (Lundbeck Ltd)
04020200	2136	Flupentixol Decanoate	Depixel 20mg/ml Injection (Lundbeck Ltd)

bnfcode	prod code	drugs substance	productname
04020100	5712	Flupentixol dihydrochloride	Depixol 3mg tablets (Lundbeck Ltd)
04020200	2156	Flupentixol decanoate	Depixol 40mg/2ml solution for injection ampoules (Lundbeck Ltd)
04020200	14889	Flupentixol decanoate	Depixol Conc 100mg/1ml solution for injection ampoules (Lundbeck Ltd)
04020200	2155	Flupentixol Decanoate	Depixol -conc 100mg/ml Injection (Lundbeck Ltd)
04020200	18197	Flupentixol decanoate	Depixol Conc 50mg/0.5ml solution for injection ampoules (Lundbeck Ltd)
04020200	14130	Flupentixol decanoate	Depixol Low Volume 200mg/1ml solution for injection ampoules (Lundbeck Ltd)
00000000	25015		DEPIXOL-CONC (1ML AMP)
02060400/ 03040103	40326	Dimenhydrinate	Dimenhydrinate with cinnarizine 40mg+20mg tablets
04020100/ 40120000	28679	Haloperidol	Dozic 2mg/ml Oral solution (Rosemont Pharmaceuticals Ltd)
04020100	6134	Haloperidol	Dozic 5mg/5ml oral solution (Rosemont Pharmaceuticals Ltd)
04020100/ 15010401	15171	Droperidol	Droleptan 10mg Tablet (Janssen-Cilag Ltd)
04020100/ 15010401	13369	Droperidol	Droleptan 1mg/ml Oral solution (Janssen-Cilag Ltd)
04020100/ 15010401	21125	Droperidol	Droleptan 5mg/ml Injection (Janssen-Cilag Ltd)
00000000	25759		DROPERIDOL
04020100/ 15010401	3773	Droperidol	Droperidol 10mg tablets
04020100/ 15010401	15128	Droperidol	Droperidol 1mg/ml liquid
04065400	40928	Droperidol	Droperidol 2.5mg/1ml solution for injection ampoules
00000000	13341		DROPERIDOL 5 MG/5ML ELI
04065400	57571		Droperidol 5mg/5ml oral solution
04020100/ 15010401	22609	Droperidol	Droperidol 5mg/ml injection
04020100/ 5010401	53634	Droperidol	Droperidol capsules
04020100/ 15010401	42229	Droperidol	Droperidol oral liquid
15010401	24457	Fentanyl Citrate	Fentanyl with droperidol 500microgramwith2.5mg/ml Injection
04020100	840	Perphenazine	Fentazin 2mg tablets (Mercury Pharma Group Ltd)
04020100	7919	Perphenazine	Fentazin 4mg tablets (Mercury Pharma Group Ltd)
04020100/ 40120000	228	Perphenazine	Fentazin 5mg/ml Injection (Goldshield Pharmaceuticals Ltd)
00000000	24282		FENTAZIN 8 MG TAB
00000000	27565		FLUANXOL
04030400	3951	Flupentixol dihydrochloride	Fluanxol 1mg tablets (Lundbeck Ltd)
04030400	50592	Flupentixol dihydrochloride	Fluanxol 1mg tablets (Sigma Pharmaceuticals Plc)
04030400	3953	Flupentixol dihydrochloride	Fluanxol 500microgram tablets (Lundbeck Ltd)
04020200	18175	Flupentixol decanoate	Flupentixol 100mg/1ml solution for injection ampoules
04030400	600	Flupentixol dihydrochloride	Flupentixol 1mg tablets
04020200	14839	Flupentixol decanoate	Flupentixol 200mg/1ml solution for injection ampoules
04020200	14966	Flupentixol decanoate	Flupentixol 20mg/1ml solution for injection ampoules

bnfcode	prod code	drugs substance	productname
04020100	5707	Flupentixol dihydrochloride	Flupentixol 3mg tablets
04020200	2276	Flupentixol decanoate	Flupentixol 40mg/2ml solution for injection ampoules
04030400	2275	Flupentixol dihydrochloride	Flupentixol 500microgram tablets
04020200	18155	Flupentixol decanoate	Flupentixol 50mg/0.5ml solution for injection ampoules
04020200	8712	Flupentixol Decanoate	Flupentixol decanoate 100mg/ml Injection
04020200	1733	Flupentixol Decanoate	Flupentixol decanoate 20mg/ml Injection
04020100/ 04030400	55620	Flupentixol Dihydrochloride	Flupentixol Liquid
04020100	5212	Fluphenazine hydrochloride	Fluphenazine 1mg tablets
00000000	8377	Fluphenazine hydrochloride	Fluphenazine 2.5mg tablets
00000000	5298	Fluphenazine hydrochloride	Fluphenazine 5mg tablets
04020200	35176	Fluphenazine decanoate	Fluphenazine decanoate 100mg/1ml solution for injection ampoules
04020200	10514	Fluphenazine Decanoate	Fluphenazine decanoate 100mg/ml Injection
00000000	16229		FLUPHENAZINE DECANOATE 12.5 MG INJ
04020200	35530	Fluphenazine decanoate	Fluphenazine decanoate 12.5mg/0.5ml solution for injection ampoules
04020200	35065	Fluphenazine decanoate	Fluphenazine decanoate 25mg/1ml solution for injection ampoules
04020200	41970	Fluphenazine decanoate	Fluphenazine decanoate 25mg/1ml solution for injection ampoules (Hospira UK Ltd)
04020200	9022	Fluphenazine Decanoate	Fluphenazine decanoate 25mg/ml Injection
04020200	41971	Fluphenazine decanoate	Fluphenazine decanoate 25mg/ml Injection (Antigen Pharmaceuticals)
04020200	35391	Fluphenazine decanoate	Fluphenazine decanoate 50mg/0.5ml solution for injection ampoules
04020200	35723	Fluphenazine decanoate	Fluphenazine decanoate 50mg/2ml solution for injection ampoules
04020200	17190	Fluphenazine Enantate	Fluphenazine enanthate 25mg/ml Injection
00000000	24107		FLUPHENAZINE HCl ELI
04030100	20571	Nortriptyline Hydrochloride	Fluphenazine with nortriptyline 500microgramswith10mg Tablet
00000000	26526		FLUSPIRILENE 2.00mg/ml
04020200	10827	Fluspirilene	Fluspirilene 2mg/ml Injection
01020300/ 04065500	21863	Metoclopramide hydrochloride	Gastrese la 15mg Modified-release tablet (Manufacturer unknown)
00000000	23379		GASTROBID CONTINUS
00000000	8273	Metoclopramide hydrochloride	Gastrobid Continus 15mg tablets (Napp Pharmaceuticals Ltd)
04065500	17496	Metoclopramide hydrochloride	Gastroflux 10mg tablets (Ashbourne Pharmaceuticals Ltd)
01020300/ 04065500	17946	Metoclopramide Hydrochloride	Gastromax 30mg Modified-release capsule (Pfizer Ltd)
00000000	30351		HALDOL 1.5 MG TAB
04020100	23678	Haloperidol	Haldol 10mg tablets (Janssen-Cilag Ltd)
04020100/ 40120000	24494	Haloperidol	Haldol 10mg/ml Liquid (Janssen-Cilag Ltd)
00000000	15645		HALDOL 20 MG TAB
04020100	12921	Haloperidol	Haldol 2mg/ml oral solution (Janssen-Cilag Ltd)
04020100	22660	Haloperidol	Haldol 5mg tablets (Janssen-Cilag Ltd)

bnfcode	prod code	drugs substance	productname
04020100	38540	Haloperidol	Haldol 5mg/1ml solution for injection ampoules (Janssen-Cilag Ltd)
04020100/ 40120000	6523	Haloperidol	Haldol 5mg/ml Injection (Janssen-Cilag Ltd)
04020100	12386	Haloperidol decanoate	Haldol decanoate 100mg/1ml solution for injection ampoules (Janssen-Cilag Ltd)
04020100	2094	Haloperidol decanoate	Haldol decanoate 50mg/1ml solution for injection ampoules (Janssen-Cilag Ltd)
04020100	329	Haloperidol	Haloperidol 1.5mg tablets
04020100	34339	Haloperidol	Haloperidol 1.5mg tablets (A A H Pharmaceuticals Ltd)
04020100	32838	Haloperidol	Haloperidol 1.5mg tablets (IVAX Pharmaceuticals UK Ltd)
04020100	43520	Haloperidol	Haloperidol 1.5mg tablets (Teva UK Ltd)
04020100	52050		Haloperidol 1.5mg/5ml oral suspension
04020100/ 40120000	17379	Haloperidol	Haloperidol 1.5mg/5ml sugar free Oral solution
00000000	25063		HALOPERIDOL 100mg/ml
00000000	12050		HALOPERIDOL 100MG/ML 100 MG INJ
04020100	475	Haloperidol	Haloperidol 10mg tablets
04020100	45810	Haloperidol	Haloperidol 10mg/5ml oral solution sugar free
04020100	47808	Haloperidol	Haloperidol 10mg/5ml oral solution sugar free (A A H Pharmaceuticals Ltd)
04020100/ 40120000	10435	Haloperidol	Haloperidol 10mg/ml Oral solution
04020100	47149	Haloperidol	Haloperidol 1mg/5ml oral solution
04020100	47013	Haloperidol	Haloperidol 1mg/5ml oral suspension
04020100/ 40120000	5192	Haloperidol	Haloperidol 1mg/5ml sugar free Oral solution
04020100/ 40120000	41546	Haloperidol	Haloperidol 1mg/ml Liquid (Hillcross Pharmaceuticals Ltd)
04020100/ 40120000	34039	Haloperidol	Haloperidol 1mg/ml Liquid (Rosemont Pharmaceuticals Ltd)
04020100/ 40120000	2620	Haloperidol	Haloperidol 1mg/ml Oral solution
04020100/ 40120000	9975	Haloperidol	Haloperidol 1mg/ml sugar free Oral solution
04020100	12387	Haloperidol	Haloperidol 20mg tablets
00000000	8129	Haloperidol	Haloperidol 20mg/2ml solution for injection ampoules
04020100	36771	Haloperidol	Haloperidol 250micrograms/5ml oral suspension
04020100	49207	Haloperidol	Haloperidol 2mg/5ml oral solution
04020100	53649	Haloperidol	Haloperidol 2mg/5ml oral suspension
04020100/ 40120000	11213	Haloperidol	Haloperidol 2mg/5ml sugar free Oral solution
04020100/ 40120000	55871	Haloperidol	Haloperidol 2mg/ml Liquid (Hillcross Pharmaceuticals Ltd)
04020100/ 40120000	42000	Haloperidol	Haloperidol 2mg/ml Liquid (Rosemont Pharmaceuticals Ltd)
04020100/ 40120000	13105	Haloperidol	Haloperidol 2mg/ml Oral solution
04020100/ 40120000	3233	Haloperidol	Haloperidol 2mg/ml sugar free Liquid
00000000	8136		HALOPERIDOL 5 MG LIQ

bnfcode	prod code	drugs substance	productname
04020100	2419	Haloperidol	Haloperidol 500microgram capsules
04020100/ 40120000	42807	Haloperidol	Haloperidol 500microgram Tablet (Lagap)
00000000	3671	Haloperidol	Haloperidol 500microgram tablets
00000000	43431	Haloperidol	Haloperidol 500microgram tablets (A A H Pharmaceuticals Ltd)
00000000	41420	Haloperidol	Haloperidol 500microgram tablets (Sandoz Ltd)
04020100/ 40120000	32051	Haloperidol	Haloperidol 5mg Tablet (Generics (UK) Ltd)
04020100	2621	Haloperidol	Haloperidol 5mg tablets
04020100	34903	Haloperidol	Haloperidol 5mg tablets (IVAX Pharmaceuticals UK Ltd)
04020100	42895	Haloperidol	Haloperidol 5mg tablets (Teva UK Ltd)
04020100	38262	Haloperidol	Haloperidol 5mg/1ml solution for injection ampoules
04020100	55848	Haloperidol	Haloperidol 5mg/1ml solution for injection ampoules (Mercury Pharma Group Ltd)
04020100	45880	Haloperidol	Haloperidol 5mg/5ml oral solution sugar free
04020100/ 40120000	4234	Haloperidol	Haloperidol 5mg/ml Injection
04020100/ 40120000	34272	Haloperidol	Haloperidol 5mg/ml Injection (Antigen Pharmaceuticals)
04020100	15814	Haloperidol decanoate	Haloperidol decanoate 100mg/1ml solution for injection ampoules
04020100	10565	Haloperidol decanoate	Haloperidol decanoate 50mg/1ml solution for injection ampoules
04020100/ 40120000	43020	Haloperidol	Haloperidol Oral solution
04020100/ 40120000	19002	Chlorpromazine Hydrochloride	Largactil 100mg Suppository (Rhone-Poulenc Rorer Ltd)
04020100/ 40120000	7493	Chlorpromazine hydrochloride	Largactil 100mg Tablet (Hawgreen Ltd)
04020100	58702	Chlorpromazine hydrochloride	Largactil 100mg tablets (Sanofi)
04020100/ 40120000	8771	Chlorpromazine hydrochloride	Largactil 10mg Tablet (Hawgreen Ltd)
00000000	55012	Chlorpromazine hydrochloride	Largactil 10mg tablets (Sanofi)
04020100/ 40120000	2814	Chlorpromazine hydrochloride	Largactil 25mg Tablet (Hawgreen Ltd)
04020100	55011	Chlorpromazine hydrochloride	Largactil 25mg tablets (Sanofi)
04020100/ 40120000	10434	Chlorpromazine hydrochloride	Largactil 25mg/5ml Oral solution (Hawgreen Ltd)
04020100	57550	Chlorpromazine hydrochloride	Largactil 25mg/5ml syrup (Sanofi)
00000000	12356		LARGACTIL 50 MG INJ
04020100/ 40120000	3772	Chlorpromazine hydrochloride	Largactil 50mg Tablet (Hawgreen Ltd)
04020100	58703	Chlorpromazine hydrochloride	Largactil 50mg tablets (Sanofi)
04020100	7514	Chlorpromazine hydrochloride	Largactil 50mg/2ml solution for injection ampoules (Sanofi)
04020100/ 40120000	15418	Chlorpromazine embonate	Largactil forte 100mg/5ml Oral suspension (Hawgreen Ltd)
00000000	10689		LARGACTIL FORTE SYR
04020100	28231	Levomepromazine maleate	Levinan 6mg Tablet (Link Pharmaceuticals Ltd)
04020100	49606	Levomepromazine maleate	Levinan 6mg tablets (Archimedes Pharma UK Ltd)

bnfcode	prod code	drugs substance	productname
04020100	5014	Levomepromazine maleate	Levomepromazine 25mg tablets
04020100	6064	Levomepromazine hydrochloride	Levomepromazine 25mg/1ml solution for injection ampoules
04020100	53951	Levomepromazine maleate	Levomepromazine 6.25mg/5ml oral solution
04020100	40782	Levomepromazine Maleate	Levomepromazine 6mg Tablet
04020100	7390	Levomepromazine maleate	Levomepromazine 6mg tablets
00000000	20174	Loxapine succinate	Loxapac 10mg capsules (Wyeth Pharmaceuticals)
00000000	12619	Loxapine succinate	Loxapac 25mg capsules (Wyeth Pharmaceuticals)
00000000	26800	Loxapine succinate	Loxapac 50mg capsules (Wyeth Pharmaceuticals)
00000000	12616	Loxapine succinate	Loxapine 10mg capsules
00000000	12615	Loxapine succinate	Loxapine 25mg capsules
00000000	12630	Loxapine succinate	Loxapine 50mg capsules
00000000	27581		MAXOLON
01020300/ 04065500	511	Metoclopramide hydrochloride	Maxolon 10mg Tablet (Shire Pharmaceuticals Ltd)
04065500	39621	Metoclopramide hydrochloride	Maxolon 10mg tablets (Amdipharm Plc)
01020300/ 04065500	179	Metoclopramide hydrochloride	Maxolon 10mg/2ml Injection (Shire Pharmaceuticals Ltd)
04065500	39653	Metoclopramide hydrochloride	Maxolon 10mg/2ml solution for injection ampoules (Amdipharm Plc)
00000000	15093		MAXOLON 500 MG INJ
00000000	304	Metoclopramide hydrochloride	Maxolon 5mg tablets (Shire Pharmaceuticals Ltd)
01020300/ 04065500	1724	Metoclopramide hydrochloride	Maxolon 5mg/5ml Oral solution (Shire Pharmaceuticals Ltd)
04065500	39710	Metoclopramide hydrochloride	Maxolon 5mg/5ml syrup (Amdipharm Plc)
04065500	14844	Metoclopramide hydrochloride	Maxolon High Dose 100mg/20ml solution for injection ampoules (Amdipharm Plc)
04065500	8386	Metoclopramide hydrochloride	Maxolon Paediatric 5mg/5ml liquid (Amdipharm Plc)
04065500	15601	Metoclopramide hydrochloride	Maxolon SR 15mg capsules (Amdipharm Plc)
00000000	8774	Thioridazine hydrochloride	Melleril 100mg tablets (Novartis Pharmaceuticals UK Ltd)
00000000	26661		MELLERIL 100mg/5ml
00000000	15157	Thioridazine	Melleril 100mg/5ml oral suspension (Novartis Pharmaceuticals UK Ltd)
00000000	284	Thioridazine hydrochloride	Melleril 10mg tablets (Novartis Pharmaceuticals UK Ltd)
00000000	1162	Thioridazine hydrochloride	Melleril 25mg tablets (Novartis Pharmaceuticals UK Ltd)
00000000	19606		MELLERIL 25mg/5ml
00000000	23201		MELLERIL 25mg/5ml
00000000	3579	Thioridazine	Melleril 25mg/5ml oral suspension (Novartis Pharmaceuticals UK Ltd)
00000000	4673	Thioridazine hydrochloride	Melleril 25mg/5ml syrup (Novartis Pharmaceuticals UK Ltd)
00000000	2502	Thioridazine hydrochloride	Melleril 50mg tablets (Novartis Pharmaceuticals UK Ltd)
04065500	11576	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Actavis UK Ltd)
04065500	16567	Metoclopramide hydrochloride	Metoclopramide 100mg/20ml solution for injection ampoules
01020300/ 04065500	34887	Metoclopramide hydrochloride	Metoclopramide 10mg Tablet (C P Pharmaceuticals Ltd)

bnfcode	prod code	drugsubstance	productname
04065500	455	Metoclopramide hydrochloride	Metoclopramide 10mg tablets
04065500	34325	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (A A H Pharmaceuticals Ltd)
04065500	26363	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Actavis UK Ltd)
04065500	53162	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Alliance Healthcare (Distribution) Ltd)
04065500	33229	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Teva UK Ltd)
01020300/ 04065500	299	Metoclopramide Hydrochloride	Metoclopramide 10mg/2ml Injection
04065500	35046	Metoclopramide hydrochloride	Metoclopramide 10mg/2ml solution for injection ampoules
04065500	48445	Metoclopramide hydrochloride	Metoclopramide 10mg/2ml solution for injection ampoules (A A H Pharmaceuticals Ltd)
04065500	34084	Metoclopramide hydrochloride	Metoclopramide 10mg/2ml solution for injection ampoules (Mercury Pharma Group Ltd)
04065500	43448	Metoclopramide hydrochloride	Metoclopramide 12.5mg/5ml oral solution
04065500	405	Metoclopramide hydrochloride	Metoclopramide 15mg modified-release capsules
00000000	3716	Metoclopramide hydrochloride	Metoclopramide 15mg modified-release tablets
01020300/0 4065500	6521	Metoclopramide Hydrochloride	Metoclopramide 1mg/ml sugar free Oral solution
01020300/ 04065500	17832	Metoclopramide Hydrochloride	Metoclopramide 30mg Modified-release capsule
00000000	1759		METOCLOPRAMIDE 5 MG TAB
00000000	4892	Metoclopramide hydrochloride	Metoclopramide 5mg tablets
01020300/ 04065500	4142	Metoclopramide Hydrochloride	Metoclopramide 5mg/5ml Oral solution
04065500	5081	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free
04065500	47547	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (A A H Pharmaceuticals Ltd)
04065500	52677	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (Alliance Healthcare (Distribution) Ltd)
04065500	25994	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (Rosemont Pharmaceuticals Ltd)
04065500	25992	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (Sandoz Ltd)
01020300/ 04065500	13034	Metoclopramide Hydrochloride	Metoclopramide 5mg/ml Injection (Phoenix Healthcare Distribution Ltd)
00000000	3323		METOCLOPRAMIDE HCl 10 MG TAB
00000000	20806		METOCLOPRAMIDE SR
04065500/ 04070401	3726	Metoclopramide Hydrochloride	Metoclopramide with aspirin 5mg + 325mg Effervescent tablet
04065500/ 04070401	17180	Metoclopramide Hydrochloride	Metoclopramide with aspirin 5mg + 450mg Effervescent tablet
04065500/ 04070401	17456	Metoclopramide Hydrochloride	Metoclopramide with lysine acetylsalicylate 10mg + 900mg Oral solution
04065500/ 04070401	12869	Metoclopramide Hydrochloride	Metoclopramide with paracetamol 5mg + 500mg Sachets
04065500/ 04070401	12778	Metoclopramide Hydrochloride	Metoclopramide with paracetamol 5mg + 500mg Tablet
01020300/ 04065500	8784	Metoclopramide hydrochloride	Metox 10mg Tablet (M A Steinhard Ltd)
04070100	5288	Metoclopramide hydrochloride/Lysine acetylsalicylate	MigraMax oral powder sachets (Zentiva)
04065500/ 04070100	3155	Metoclopramide Hydrochloride	Migravess 5mg+325mg Effervescent tablet (Bayer Plc)

bnfcode	prod code	drugs substance	productname
04070401			
04065500/ 04070401	3386	Metoclopramide Hydrochloride	Migravess forte 5mg+450mg Effervescent tablet (Bayer Plc)
00000000	22174		MODECATE
00000000	8043		MODECATE 12.5 MG INJ
04020200	35122	Fluphenazine decanoate	Modecate 12.5mg/0.5ml solution for injection ampoules (Sanofi)
04020200	33780	Fluphenazine decanoate	Modecate 25mg/1ml solution for injection ampoules (Sanofi)
04020200	3926	Fluphenazine Decanoate	Modecate 25mg/ml Injection (Sanofi-Synthelabo Ltd)
04020200	35445	Fluphenazine decanoate	Modecate 50mg/2ml solution for injection ampoules (Sanofi)
00000000	23340		MODECATE CONC
04020200	35455	Fluphenazine decanoate	Modecate Concentrate 100mg/1ml solution for injection ampoules (Sanofi)
04020200	12128	Fluphenazine Decanoate	Modecate concentrate 100mg/ml Injection (Sanofi-Synthelabo Ltd)
04020200	35487	Fluphenazine decanoate	Modecate Concentrate 50mg/0.5ml solution for injection ampoules (Sanofi)
00000000	26684		MODECATE DISPOSABLE SYRINGE
00000000	26692		MODECATE DISPOSABLE SYRINGE
04020100	5597	Fluphenazine hydrochloride	Moditen 1mg tablets (Sanofi)
00000000	7918	Fluphenazine hydrochloride	Moditen 2.5mg tablets (Sanofi)
00000000	20703	Fluphenazine hydrochloride	Moditen 5mg tablets (Sanofi-Synthelabo Ltd)
04020200	25835	Fluphenazine Enantate	Moditen enanthate 25mg/ml Injection (Sanofi-Synthelabo Ltd)
00000000	19738		MORPHINE,COCAINE & CHLORPROMAZINE MIX
00000000	8493	Nortriptyline hydrochloride/Fluphenazine hydrochloride	Motipress tablets (Sanofi-Synthelabo Ltd)
00000000	2936	Fluphenazine hydrochloride/Nortriptyline hydrochloride	Motival 10mg/500microgram tablets (Sanofi)
04020100	8031	Pericyazine	Neulactil 10mg Tablet (JHC Healthcare Ltd)
04020100	40881	Pericyazine	Neulactil 10mg tablets (Sanofi)
04020100	7833	Pericyazine	Neulactil 2.5mg Tablet (JHC Healthcare Ltd)
04020100	39830	Pericyazine	Neulactil 2.5mg tablets (Sanofi)
04020100	21064	Pericyazine	Neulactil 25mg Tablet (JHC Healthcare Ltd)
00000000	29967		NEULACTIL FORTE
04020100	13902	Pericyazine	Neulactil Forte syrup (Sanofi)
00000000	7780	Fluphenazine hydrochloride/Nortriptyline hydrochloride	Nortriptyline 10mg / Fluphenazine 500microgram tablets
00000000	14578	Nortriptyline hydrochloride/Fluphenazine hydrochloride	Nortriptyline 30mg / Fluphenazine 1.5mg tablets
04020100	4232	Levomepromazine maleate	Nozinan 25mg tablets (Sanofi)
04020100	52846	Levomepromazine hydrochloride	Nozinan 25mg/1ml solution for injection ampoules (Lexon (UK) Ltd)
04020100	4442	Levomepromazine hydrochloride	Nozinan 25mg/1ml solution for injection ampoules (Sanofi)

bnfcode	prod code	drugs substance	productname
04020100	27148	Pimozide	Orap 10mg Tablet (Janssen-Cilag Ltd)
00000000	4524	Pimozide	Orap 2mg tablets (Janssen-Cilag Ltd)
04020100	15047	Pimozide	Orap 4mg tablets (Janssen-Cilag Ltd)
04070401	3514	Paracetamol/Metoclopramide hydrochloride	Paracetamol 500mg / Metoclopramide 5mg effervescent powder sachets sugar free
04070401	2306	Paracetamol/Metoclopramide hydrochloride	Paracetamol 500mg / Metoclopramide 5mg tablets
04070401	890	Paracetamol/Metoclopramide hydrochloride	Paramax sachets (Zentiva)
04070401	892	Paracetamol/Metoclopramide hydrochloride	Paramax tablets (Zentiva)
04020100/ 04030200	3356	Trifluoperazine Hydrochloride	Parstelin Tablet (GlaxoSmithKline Consumer Healthcare)
00000000	29972		PERICYAZINE
04020100	8032	Pericyazine	Pericyazine 10mg tablets
04020100	12195	Pericyazine	Pericyazine 10mg/5ml oral solution
00000000	22655		PERICYAZINE 2.5 MG ELI
04020100	7834	Pericyazine	Pericyazine 2.5mg tablets
04020100	15472	Pericyazine	Pericyazine 25mg tablet
04020100	609	Perphenazine	Perphenazine 2mg tablets
04020100/ 04030100	16323	Amitriptyline Hydrochloride	Perphenazine 2mg with Amitriptyline 10mg tablet
04020100/ 04030100	6894	Amitriptyline Hydrochloride	Perphenazine 2mg with Amitriptyline 25mg tablet
04020100/ 40120000	14987	Perphenazine	Perphenazine 2mg/5ml oral solution sugar free
04020100	2157	Perphenazine	Perphenazine 4mg tablets
04020100/ 40120000	25909	Perphenazine	Perphenazine 4mg/5ml Oral solution sugar free
04020100/ 40120000	17087	Perphenazine	Perphenazine 5mg/ml injection
00000000	20061		PERPHENAZINE 8 MG TAB
04020100	8637	Pimozide	Pimozide 10mg tablet
00000000	2489	Pimozide	Pimozide 2mg tablets
04020100	5821	Pimozide	Pimozide 4mg tablets
04020200	12340	Pipotiazine Palmitate	Piportil 50mg/ml Depot injection (JHC Healthcare Ltd)
04020200	35488	Pipotiazine palmitate	Piportil Depot 100mg/2ml solution for injection ampoules (Sanofi)
04020200	35235	Pipotiazine palmitate	Piportil Depot 50mg/1ml solution for injection ampoules (Sanofi)
04020200	36394	Pipotiazine palmitate	Pipotiazine 100mg/2ml solution for injection ampoules
04020200	35684	Pipotiazine palmitate	Pipotiazine 50mg/1ml solution for injection ampoules
04020200	10944	Pipotiazine Palmitate	Pipotiazine palmitate 50mg/ml depot injection
01020300/ 04065500	8525	Metoclopramide hydrochloride	Primperan 10mg Tablet (Berk Pharmaceuticals Ltd)
01020300/ 04065500	9118	Metoclopramide hydrochloride	Primperan 5mg/5ml Oral solution sugar free (Berk Pharmaceuticals Ltd)
01020300/ 04065500	23753	Metoclopramide Hydrochloride	Primperan 5mg/ml Injection (Berk Pharmaceuticals Ltd)
04020100/ 04065400	14364	Prochlorperazine mesilate	Prochlorperazine 12.5mg/1ml solution for injection ampoules

bnfcode	prod code	drugs substance	productname
04020100/ 04065400	32122	Prochlorperazine mesilate	Prochlorperazine 12.5mg/1ml solution for injection ampoules (Mercury Pharma Group Ltd)
04020100/ 04065400	1990	Prochlorperazine maleate	Prochlorperazine 25mg suppositories
00000000	3932	Prochlorperazine maleate	Prochlorperazine 25mg tablets
04065400	4769	Prochlorperazine maleate	Prochlorperazine 3mg buccal tablets
00000000	237		PROCHLORPERAZINE 5 MG ELI
00000000	9590	Prochlorperazine mesilate	Prochlorperazine 5mg effervescent granules sachets sugar free
04020100/ 04065400	1434	Prochlorperazine maleate	Prochlorperazine 5mg suppositories
04020100/ 40120000	54458	Prochlorperazine maleate	Prochlorperazine 5mg Tablet (Teva UK Ltd)
04020100/ 04065400	85	Prochlorperazine maleate	Prochlorperazine 5mg tablets
04020100/ 04065400	34344	Prochlorperazine maleate	Prochlorperazine 5mg tablets (A A H Pharmaceuticals Ltd)
04020100/ 04065400	32064	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Actavis UK Ltd)
04020100/ 04065400	43420	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Dr Reddy's Laboratories (UK) Ltd)
04020100/ 04065400	32772	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Generics (UK) Ltd)
04020100/ 04065400	32551	Prochlorperazine maleate	Prochlorperazine 5mg tablets (IVAX Pharmaceuticals UK Ltd)
04020100/ 04065400	55038	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Sigma Pharmaceuticals Plc)
04020100/ 04065400	32876	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Teva UK Ltd)
04020100/ 04065400	6036	Prochlorperazine mesilate	Prochlorperazine 5mg/5ml oral solution
04020100/ 40120000	4401	Prochlorperazine Maleate	Prochlorperazine maleate 10mg modified release capsule
04020100/ 40120000	15438	Prochlorperazine Maleate	Prochlorperazine maleate 15mg modified release capsul
00000000	3024		PROCHLORPERAZINE MALEATE 3 MG TAB
04020100/ 40120000	5510	Prochlorperazine Mesilate	Prochlorperazine mesilate 12.5mg/ml injection
04020100	3197	Promazine Hydrochloride	Promazine 100mg tablet
04020100	15395	Promazine Hydrochloride	Promazine 12.5mg/5ml oral solution
04020100	46945	Promazine hydrochloride	Promazine 25mg Tablet (Biorex Laboratories Ltd)
04020100	2972	Promazine hydrochloride	Promazine 25mg tablets
04020100	6443	Promazine hydrochloride	Promazine 25mg/5ml oral solution
04020100	40390	Promazine hydrochloride	Promazine 25mg/5ml syrup (Rosemont Pharmaceuticals Ltd)
04020100	3228	Promazine hydrochloride	Promazine 50mg tablets
04020100	41732	Promazine hydrochloride	Promazine 50mg tablets (Teva UK Ltd)
04020100	55890	Promazine Hydrochloride	Promazine 50mg/5ml Liquid (Rosemont Pharmaceuticals Ltd)
04020100	10780	Promazine Hydrochloride	Promazine 50mg/5ml oral solution
04020100	17634	Promazine hydrochloride	Promazine 50mg/5ml oral solution
04020100	14610	Promazine Hydrochloride	Promazine 50mg/5ml oral solution sugar free
04020100	38089	Promazine hydrochloride	Promazine 50mg/5ml syrup (Rosemont Pharmaceuticals Ltd)

bnfcode	prod code	drugs substance	productname
04020100	15161	Promazine Hydrochloride	Promazine 50mg/ml injection
04020100	43654	Promazine Hydrochloride	Promazine 50mg/ml injection
04020100	41995	Promazine Hydrochloride	Promazine 50mg/ml Injection (Genus Pharmaceuticals Ltd)
00000000	8988		PROMAZINE HCl 25 MG TAB
00000000	26660		PROMAZINE HYDROCHLORIDE
04020100/ 04065400	13607	Prochlorperazine maleate	Proziere 5mg tablets (Ashbourne Pharmaceuticals Ltd)
04020200	57170	Flupentixol decanoate	Psytixol 100mg/1ml solution for injection ampoules (Generics (UK) Ltd)
04020200	57762	Flupentixol decanoate	Psytixol 40mg/2ml solution for injection ampoules (Generics (UK) Ltd)
04020200	8044	Fluspirilene	Redeptin 2mg/ml Injection (Janssen-Cilag Ltd)
04020100	8979	Haloperidol	Serenace 1.5mg tablets (Teva UK Ltd)
04020100	13484	Haloperidol	Serenace 10mg tablets (Teva UK Ltd)
00000000	13391		SERENACE 20 MG INJ
04020100	13483	Haloperidol	Serenace 20mg tablets (Teva UK Ltd)
00000000	28968	Haloperidol	Serenace 20mg/2ml solution for injection ampoules (IVAX Pharmaceuticals UK Ltd)
04020100	8153	Haloperidol	Serenace 2mg/ml liquid (Teva UK Ltd)
04020100	5545	Haloperidol	Serenace 500microgram capsules (Teva UK Ltd)
04020100	13338	Haloperidol	Serenace 5mg tablets (Teva UK Ltd)
04020100	7436	Haloperidol	Serenace 5mg/1ml solution for injection ampoules (IVAX Pharmaceuticals UK Ltd)
04020100	33493	Promazine Hydrochloride	Sparine 100mg Tablet (Wyeth Pharmaceuticals)
04020100	12193	Promazine hydrochloride	Sparine 25mg Tablet (Wyeth Pharmaceuticals)
04020100	3226	Promazine hydrochloride	Sparine 50mg Tablet (Wyeth Pharmaceuticals)
04020100	3227	Promazine Hydrochloride	Sparine 50mg/5ml Liquid (Wyeth Pharmaceuticals)
04020100	13311	Promazine Hydrochloride	Sparine 50mg/ml Injection (Wyeth Pharmaceuticals)
01020100/ 04020100	8445	Isopropamide Iodide	Stelabid Tablet (GlaxoSmithKline Consumer Healthcare)
00000000	27582		STELAZINE
00000000	1735	Trifluoperazine hydrochloride	Stelazine 10mg Spansules (Mercury Pharma Group Ltd)
04020100/ 40120000	18289	Trifluoperazine Hydrochloride	Stelazine 10mg/ml Concentrate (Goldshield Pharmaceuticals Ltd)
00000000	8042	Trifluoperazine hydrochloride	Stelazine 15mg Spansules (Mercury Pharma Group Ltd)
04020100/ 04065400	57605	Trifluoperazine hydrochloride	Stelazine 1mg tablets (Lexon (UK) Ltd)
04020100/ 04065400	1318	Trifluoperazine hydrochloride	Stelazine 1mg tablets (Mercury Pharma Group Ltd)
04020100/ 04065400	8985	Trifluoperazine hydrochloride	Stelazine 1mg/5ml syrup (Mercury Pharma Group Ltd)
04020100/ 40120000	7479	Trifluoperazine Hydrochloride	Stelazine 1mg/ml Injection (Goldshield Pharmaceuticals Ltd)
00000000	2713	Trifluoperazine hydrochloride	Stelazine 2mg Spansules (Mercury Pharma Group Ltd)
04020100/ 04065400	1316	Trifluoperazine hydrochloride	Stelazine 5mg tablets (Mercury Pharma Group Ltd)
00000000	29838		STELAZINE CONCENTRATE 10mg/ml
04020100/ 04065400	29948	Trifluoperazine hydrochloride	Stelazine Forte 1mg/ml oral solution (Mercury Pharma

bnfcode	prod code	drugs substance	productname
04065400			Group Ltd)
00000000	8775		STELAZINE TAB
00000000	24243		STEMETIL
00000000	19824		STEMETIL (1ML)
04020100/ 04065400	14356	Prochlorperazine mesilate	Stemetil 12.5mg/1ml solution for injection ampoules (Sanofi)
04020100/ 40120000	3246	Prochlorperazine Mesilate	Stemetil 12.5mg/ml Injection (Castlemead Healthcare Ltd)
00000000	7985		STEMETIL 2.5 MG SUP
04020100/ 04065400	1234	Prochlorperazine maleate	Stemetil 25mg suppositories (Sanofi)
00000000	5497	Prochlorperazine maleate	Stemetil 25mg tablets (Sanofi)
04020100/ 04065400	227	Prochlorperazine maleate	Stemetil 5mg suppositories (Sanofi)
04020100/ 40120000	512	Prochlorperazine maleate	Stemetil 5mg Tablet (Castlemead Healthcare Ltd)
04020100/ 04065400	50462	Prochlorperazine maleate	Stemetil 5mg tablets (Doncaster Pharmaceuticals Ltd)
04020100/ 04065400	49170	Prochlorperazine maleate	Stemetil 5mg tablets (Lexon (UK) Ltd)
04020100/ 04065400	51551	Prochlorperazine maleate	Stemetil 5mg tablets (Mawdsley-Brooks & Company Ltd)
04020100/ 04065400	39887	Prochlorperazine maleate	Stemetil 5mg tablets (Sanofi)
04020100/ 04065400	51579	Prochlorperazine maleate	Stemetil 5mg tablets (Sigma Pharmaceuticals Plc)
04020100/ 04065400	54429	Prochlorperazine maleate	Stemetil 5mg tablets (Waymade Healthcare Plc)
04020100/ 40120000	7593	Prochlorperazine mesilate	Stemetil 5mg/5ml Oral solution (Castlemead Healthcare Ltd)
04020100/ 04065400	40001	Prochlorperazine mesilate	Stemetil 5mg/5ml syrup (Sanofi)
00000000	3738	Prochlorperazine mesilate	Stemetil Eff 5mg sachets (Sanofi)
04065400	9215	Cinnarizine	Stugeron 15mg tablets (Janssen-Cilag Ltd)
04065400	1355	Cinnarizine	Stugeron 15mg tablets (McNeil Products Ltd)
00000000	9304	Cinnarizine	Stugeron Forte 75mg capsules (Janssen-Cilag Ltd)
04020100	28147	Chlorprothixene	Taractan 15mg Tablet (Roche Products Ltd)
03040103	16667	Thiethylperazine	Thiethylperazine 10mg Tablet
03040103	15343	Thiethylperazine	Thiethylperazine 6.5mg/ml injection
03040103	7969	Thiethylperazine	Thiethylperazine suppository
00000000	23517		THIOPROPAZATE HCl 10 MG TAB
00000000	29445		THIOPROPERAZINE MESYLATE 10 MG TAB
00000000	21675		THIOPROPERAZINE MESYLATE 25 MG TAB
00000000	28979		THIORIDAZINE 100mg/5ml
04020100	45860	Thioridazine hydrochloride	Thioridazine 100mg Tablet (IVAX Pharmaceuticals UK Ltd)
04020100	3021	Thioridazine hydrochloride	Thioridazine 100mg tablets
00000000	10675	Thioridazine	Thioridazine 100mg/5ml oral suspension
04020100	15598	Thioridazine Hydrochloride	Thioridazine 100mg/5ml sugar free Oral solution
04020100	1192	Thioridazine hydrochloride	Thioridazine 10mg tablets

bnfcode	prod code	drugsubstance	productname
04020100	2801	Thioridazine Hydrochloride	Thioridazine 10mg/5ml Oral solution
04020100	47361	Thioridazine Hydrochloride	Thioridazine 10mg/5ml Oral solution (Rosemont Pharmaceuticals Ltd)
04020100	34905	Thioridazine hydrochloride	Thioridazine 25mg Tablet (IVAX Pharmaceuticals UK Ltd)
04020100	1218	Thioridazine hydrochloride	Thioridazine 25mg tablets
00000000	43424	Thioridazine hydrochloride	Thioridazine 25mg tablets (A A H Pharmaceuticals Ltd)
00000000	20668		THIORIDAZINE 25mg/5ml
00000000	26082		THIORIDAZINE 25mg/5ml
04020100	3605	Thioridazine hydrochloride	Thioridazine 25mg/5ml oral solution
00000000	47881	Thioridazine hydrochloride	Thioridazine 25mg/5ml oral solution (Rosemont Pharmaceuticals Ltd)
00000000	9387	Thioridazine	Thioridazine 25mg/5ml oral suspension
04020100	10405	Thioridazine Hydrochloride	Thioridazine 25mg/5ml sugar free Oral solution
04020100	35787	Thioridazine hydrochloride	Thioridazine 50mg Tablet (IVAX Pharmaceuticals UK Ltd)
04020100	1314	Thioridazine hydrochloride	Thioridazine 50mg tablets
00000000	34902	Thioridazine hydrochloride	Thioridazine 50mg tablets (A A H Pharmaceuticals Ltd)
04020100	17399	Thioridazine Hydrochloride	Thioridazine 50mg/5ml Oral solution
04020100	42816	Thioridazine Hydrochloride	Thioridazine 50mg/5ml Oral solution (Rosemont Pharmaceuticals Ltd)
00000000	52143		THIORIDAZINE CONCENTRATE 750MG/5ML 750 MG ELI
00000000	10870		THIORIDAZINE S/F 50 MG/5ML SYR
03040103	16668	Thiethylperazine	Torecan 10mg Tablet (Novartis Pharmaceuticals UK Ltd)
03040103	22053	Thiethylperazine	Torecan 6.5mg/ml Injection (Novartis Pharmaceuticals UK Ltd)
03040103	7970	Thiethylperazine	Torecan Suppository (Novartis Pharmaceuticals UK Ltd)
04020100/ 04030200	3955	Trifluoperazine Hydrochloride	Tranlycypromine with trifluoperazine Tablet
00000000	2714	Trifluoperazine hydrochloride	Trifluoperazine 10mg modified-release capsules
00000000	22245		TRIFLUOPERAZINE 10mg/ml
04020100/ 40120000	18668	Trifluoperazine Hydrochloride	Trifluoperazine 10mg/ml concentrate
00000000	3937	Trifluoperazine hydrochloride	Trifluoperazine 15mg modified-release capsules
04020100/ 04065400	1857	Trifluoperazine hydrochloride	Trifluoperazine 1mg tablets
04020100/ 04065400	40162	Trifluoperazine hydrochloride	Trifluoperazine 1mg tablets (A A H Pharmaceuticals Ltd)
04020100/ 04065400	13145	Trifluoperazine hydrochloride	Trifluoperazine 1mg/5ml oral solution sugar free
04020100/ 04065400	55382	Trifluoperazine hydrochloride	Trifluoperazine 1mg/5ml oral solution sugar free (Mercury Pharma Group Ltd)
04020100/ 40120000	8537	Trifluoperazine Hydrochloride	Trifluoperazine 1mg/ml Injection
00000000	1159	Trifluoperazine hydrochloride	Trifluoperazine 2mg modified-release capsules
00000000	19645		TRIFLUOPERAZINE 5.00mg/ml
00000000	10535		TRIFLUOPERAZINE 5.00MG/ML 5 MG SYR

bnfcode	prod code	drugs substance	productname
04020100/ 04065400	1245	Trifluoperazine hydrochloride	Trifluoperazine 5mg tablets
04020100/ 04065400	41663	Trifluoperazine hydrochloride	Trifluoperazine 5mg tablets (A A H Pharmaceuticals Ltd)
04020100/ 04065400	11531	Trifluoperazine hydrochloride	Trifluoperazine 5mg/5ml oral solution sugar free
00000000	28965		TRIFLUOPERAZINE HCL/ISOPROP.IODIDE FORTE TAB
00000000	10356		TRIFLUOPERAZINE TAB
04020100/ 04030200	24890	Trifluoperazine Hydrochloride	Trifluoperazine with tranlycypromine 1mg + 10mg Tablet
04020100	23659	Trifluperidol	Trifluperidol 0.5mg Tablet
04020100	22814	Trifluperidol	Trifluperidol 1mg Tablet
00000000	17877		TRIFLUPERIDOL 2 MG TAB
04020100	21047	Trifluperidol	Triperidol 0.5mg Tablet (Lagap)
04020100	21027	Trifluperidol	Triperidol 1mg Tablet (Lagap)
04020100/ 04030100	1453	Amitriptyline hydrochloride/Perphenazine	Triptafen m 2mg+10mg Tablet (Goldshield Pharmaceuticals Ltd)
04030100	1208	Amitriptyline hydrochloride/Perphenazine	Triptafen tablets (Mercury Pharma Group Ltd)
00000000	38827	Amitriptyline hydrochloride/Perphenazine	Triptafen-M tablets (Mercury Pharma Group Ltd)
04020100	21339	Levomepromazine maleate	Veractil 25mg Tablet (Rhone-Poulenc Rorer Ltd)
04020100/ 40120000	8689	Prochlorperazine Maleate	Vertigon spansule 10 10mg Spansule (GlaxoSmithKline Consumer Healthcare)
04020100/ 40120000	17849	Prochlorperazine Maleate	Vertigon spansule 15 15mg Spansule (GlaxoSmithKline Consumer Healthcare)
04020100	9686	Zuclopenthixol dihydrochloride	Zuclopenthixol 10mg tablets
04020100	13600	Zuclopenthixol dihydrochloride	Zuclopenthixol 25mg tablets
04020100	12707	Zuclopenthixol dihydrochloride	Zuclopenthixol 2mg tablets
04020100	31537	Zuclopenthixol acetate	Zuclopenthixol acetate 100mg/2ml solution for injection ampoules
04020100	24270	Zuclopenthixol acetate	Zuclopenthixol acetate 50mg/1ml solution for injection ampoules
04020100	14576	Zuclopenthixol Acetate	Zuclopenthixol acetate 50mg/ml oily injection
04020100	28355	Zuclopenthixol decanoate	Zuclopenthixol decanoate 200mg/1ml solution for injection ampoules
04020100/ 04020200	3775	Zuclopenthixol Decanoate	Zuclopenthixol decanoate 200mg/ml oily injection
04020100	12224	Zuclopenthixol decanoate	Zuclopenthixol decanoate 500mg/1ml solution for injection ampoules
00000000	25635		ZUCLOPENTHIXOL DIHYDROCHLORIDE

Parkinson's disease treatments

Refer to [Annex 1](#) for codes used to identify dopamine agonists (immediate release dopamine agonists, ropinirole-PR, pramipexole-PR (exclusion)), as well as levodopa containing medications, amantadine and MAO-B-i.

Dyskinesia (probable and possible)

review	medcode	read_code	desc
Probable	16179	2972.00	O/E - choreiform movement
Probable	6889	F135.00	Other choreas
Probable	4108	F135000	Hemiballismus
Probable	34327	F135200	Drug-induced chorea
Probable	27450	F135z00	Other choreas NOS
Probable	27655	F137200	Drug-induced dystonia
Probable	50078	F138.00	Fragments of torsion dystonia
Probable	23356	F138100	Orofacial dyskinesia
Probable	5094	F138111	Tardive dyskinesia
Probable	2005	F138200	Spasmodic torticollis
Probable	71249	F138z00	Fragments of torsion dystonia NOS
Probable	63182	F139.00	Paroxysmal dyskinesia
Probable	107057	F139000	Paroxysmal non-kinesigenic dyskinesia
Probable	67242	F139100	Paroxysmal kinesigenic dyskinesia
Probable	51777	F13A.00	Paroxysmal dystonia
Probable	94690	F13B.00	Myoclonic dystonia
Probable	2006	F13X.00	Dystonia, unspecified
Probable	65734	Fyu2400	[X]Other dystonia
Probable	94540	Fyu2600	[X]Other chorea
Probable	52917	Fyu2A00	[X]Dystonia, unspecified
Probable	2003	R013.11	[D]Dyskinesia
Possible	36027	1B2..00	Involuntary movement symptom
Possible	31658	1B2Z.00	Involuntary movemt.symptom NOS
Possible	17533	297..00	O/E - involuntary movements
Possible	39341	2973.00	O/E - athetosis
Possible	43079	297Z.00	O/E - involuntary movement NOS
Possible	19491	E273.00	Stereotyped repetitive movements
Possible	64158	E273z00	Stereotyped repetitive movements NOS
Possible	19740	Eu9y400	[X]Stereotyped movement disorders
Possible	35006	F13..00	Other extrapyramidal disease and abnormal movement disorders
Possible	5545	F132.00	Myoclonus
Possible	19015	F132300	Myoclonic jerks
Possible	28281	F132y00	Other specified myoclonus
Possible	97376	F132y11	Paramyoclonus multiplex
Possible	37897	F132z00	Myoclonus NOS
Possible	27967	F137.00	Symptomatic torsion dystonia
Possible	92598	F137100	Double athetosis
Possible	25777	F137y00	Other specified symptomatic torsion dystonia
Possible	62081	F137z00	Symptomatic torsion dystonia NOS

review	medcode	read_code	desc
Possible	2829	F138000	Blepharospasm
Possible	21268	F138300	Organic writers' cramp
Possible	6787	F13z.00	Other/unspecified extrapyramidal/abnormal movement disorders
Possible	36319	F13zz00	Extrapyramidal disease and abnormal movement disorder NOS
Possible	100790	Fyu2.00	[X]Extrapyramidal and movement disorders
Possible	100612	Fyu2700	[X]Other specified extrapyramidal and movement disorders
Possible	5412	R010.00	[D]Abnormal involuntary movements
Possible	18925	R010000	[D]Head movements abnormal
Possible	20323	R010400	[D]Athetosis, acquired, NOS
Possible	15845	R010z00	[D]Abnormal involuntary movement NOS
Possible	67936	Ryu3000	[X]Other and unspecified abnormal involuntary movements
Possible	34864	2979.00	O/E - myoclonus

Impulse control disorders

Classify	medcode	read_code	desc
compulsive eating	35490	1614.00	Excessive eating - polyphagia
compulsive eating	60373	1614.11	Hyperalimentation - symptom
compulsive eating	31227	1614.12	Polyphagia symptom
compulsive eating	3477	C38y.00	Other hyperalimentation
compulsive eating	4377	E275100	Bulimia (non-organic overeating)
compulsive eating	11608	E275111	Compulsive eating disorder
compulsive eating	9581	Eu50200	[X]Bulimia nervosa
compulsive eating	6583	Eu50211	[X]Bulimia NOS
compulsive eating	96475	Eu50212	[X]Hyperorexia nervosa
compulsive eating	33863	Eu50300	[X]Atypical bulimia nervosa
compulsive eating	39383	Eu50400	[X]Overeating associated with other psychological disturbncs
compulsive eating	17439	Eu50411	[X]Psychogenic overeating
compulsive eating	15235	R036.00	[D]Polyphagia
compulsive eating	17642	R036000	[D]Excessive eating
compulsive eating	605	R036011	[D]Bulimia NOS
compulsive eating	98900	R036100	[D]Hyperalimentation
compulsive eating	72870	R036z00	[D]Polyphagia NOS
Compulsive pulling out hair	20286	E27z000	Hair plucking
Compulsive pulling out hair	3165	Eu63300	[X]Trichotillomania
Compulsive water drinking	26395	E275700	Psychogenic polydipsia
Compulsive water drinking	45362	E275711	Compulsive water drinking
hypersexuality	52941	E22y500	Nymphomania
hypersexuality	68750	E22y600	Satyriasis

Classify	medcode	read_code	desc
hypersexuality	20882	E27z300	Masturbation
hypersexuality	29001	E2C1.11	Promiscuity
hypersexuality	26411	Eu52700	[X]Excessive sexual drive
hypersexuality	50326	Eu52800	[X]Erotomania
other impulse control disorders	22654	1P3..00	Compulsive behaviour
other impulse control disorders	51769	1P30.00	Compulsive uncontrollable drug taking
other impulse control disorders	66615	1P31.00	Compulsive drug taking
other impulse control disorders	26155	28L..00	O/E - impulsive behaviour
other impulse control disorders	23597	E213.00	Explosive personality disorder
other impulse control disorders	25468	E2C3.00	Impulse control disorder NEC
other impulse control disorders	22539	E2C3000	Impulse control disorder, unspecified
other impulse control disorders	53590	E2C3400	Intermittent explosive disorder
other impulse control disorders	94096	E2C3500	Isolated explosive disorder
other impulse control disorders	58054	E2C3z00	Impulse control disorder NOS
other impulse control disorders	58693	Eu60313	[X]Explosive personality disorder
other impulse control disorders	20973	Eu63.00	[X]Habit and impulse disorders
other impulse control disorders	25152	Eu63y00	[X]Other habit and impulse disorders
other impulse control disorders	58897	Eu63z00	[X]Habit and impulse disorder, unspecified
Pathological fire-setting	20473	E2C3300	Pyromania
Pathological fire-setting	32142	Eu63100	[X]Pathological fire-setting
pathological gambling	20255	E2C3100	Pathological gambling
pathological gambling	45543	Eu63000	[X]Pathological gambling
pathological gambling	8863	Eu63011	[X]Compulsive gambling
pathological gambling	25367	ZV4K500	[V]Gambling and betting
Pathological stealing	16631	13HN000	Theft
Pathological stealing	22911	13HN100	Shoplifting
Pathological stealing	9769	E2C1100	Solitary stealing
Pathological stealing	31719	E2C1111	Shop lifting
Pathological stealing	20032	E2C3200	Kleptomania
Pathological stealing	11731	Eu63200	[X]Pathological stealing

Off-label indications

classify	medcode	read_code
Fibromyalgia	4657	N239.00
Fibromyalgia	717	N248.00
Periodic limb movement disorder	5545	F132.00
Periodic limb movement disorder	19015	F132300
Periodic limb movement disorder	28281	F132y00
Periodic limb movement disorder	37897	F132z00
Restless legs syndrome	6275	F13z200
Sexual dysfunction	94821	1ABB.00
Sexual dysfunction	94343	1ABC.00
Sexual dysfunction	94316	1ABG.00
Sexual dysfunction	102274	1D1B.00
Sexual dysfunction	15649	E227.00
Sexual dysfunction	6362	E227.11
Sexual dysfunction	23534	E227000
Sexual dysfunction	2259	E227100
Sexual dysfunction	809	E227200
Sexual dysfunction	710	E227300
Sexual dysfunction	3838	E227311
Sexual dysfunction	19082	E227400
Sexual dysfunction	27816	E227500
Sexual dysfunction	20133	E227z00
Sexual dysfunction	9485	Eu52.00
Sexual dysfunction	28283	Eu52000
Sexual dysfunction	48175	Eu52011
Sexual dysfunction	56603	Eu52012
Sexual dysfunction	21122	Eu52013
Sexual dysfunction	42056	Eu52100
Sexual dysfunction	24483	Eu52111
Sexual dysfunction	33494	Eu52200
Sexual dysfunction	60716	Eu52211
Sexual dysfunction	12066	Eu52212
Sexual dysfunction	17639	Eu52213
Sexual dysfunction	18332	Eu52300
Sexual dysfunction	34336	Eu52311
Sexual dysfunction	10550	Eu52312
Sexual dysfunction	44683	Eu52y00
Sexual dysfunction	48953	Eu52z00
Sexual dysfunction	17894	K27y100
Sexual dysfunction	16060	ZV41700

Charlson comorbidity score

Refer to [Annex 1](#) for codes used to derive the Charlson score. Codes used where review = “Y” and where =‘N’ but in the comments as ‘COPD’ or ‘COPD - High Sensitivity’ or ‘COPD Exac - High Specif’ were included

Hypertension

Refer to [Annex 1](#)

Hypercholesteraemia

medcode	read_code	desc
2493	44P3.00	Serum cholesterol raised
35720	44P4.00	Serum cholesterol very high
339	C320.00	Pure hypercholesterolaemia
3484	C320.11	Familial hypercholesterolaemia
55855	C320.12	Fredrickson type IIa lipidaemia
59095	C320.13	Low density lipoproteinaemia
3386	C320000	Familial hypercholesterolaemia
34825	C320100	Hyperbetalipoproteinaemia
26019	C320200	Hyperlipidaemia, group A
34224	C320300	Low-density-lipoprotein-type (LDL) hyperlipoproteinaemia
37273	C320400	Fredrickson's hyperlipoproteinaemia, type IIa
97989	C320500	Familial defective apolipoprotein B-100
102958	C320600	Polygenic hypercholesterolaemia
53091	C320y00	Other specified pure hypercholesterolaemia
7447	C320z00	Pure hypercholesterolaemia NOS
5791	C322.00	Mixed hyperlipidaemia
52992	C322.11	Fredrickson type IIb lipidaemia
59564	C322.12	Fredrickson type III lipidaemia
4833	C322.13	Xanthoma tuberosum
102390	C322000	Familial combined hyperlipidaemia
107252	C329.00	Hypercholesterolaemia
637	C324.00	Hyperlipidaemia NOS

Type 2 diabetesRefer to [Annex 1](#)**Psychiatric disease**Refer to [Annex 1](#)**Respiratory disease (asthma)**

medcode	read_code	description
5867	173A.00	Exercise induced asthma
22752	173c.00	Occupational asthma
73522	173d.00	Work aggravated asthma
11022	178..00	Asthma trigger
41017	1780	Aspirin induced asthma
102341	1781	Asthma trigger - pollen
103955	1782	Asthma trigger - tobacco smoke
102952	1783	Asthma trigger - warm air
103952	1784	Asthma trigger - emotion
103945	1785	Asthma trigger - damp
103321	1786	Asthma trigger - animals
102301	1787	Asthma trigger - seasonal
103813	1788	Asthma trigger - cold air
102449	1789	Asthma trigger - respiratory infection
103944	178A.00	Asthma trigger - airborne dust
102871	178B.00	Asthma trigger - exercise
11370	102..00	Asthma confirmed
24479	663d.00	Emergency asthma admission since last appointment
25181	663e.00	Asthma restricts exercise
26861	6.63E+02	Asthma sometimes restricts exercise
26506	#####	Asthma severely restricts exercise
26504	663f.00	Asthma never restricts exercise
13066	663h.00	Asthma - currently dormant
10487	663j.00	Asthma - currently active
47337	663m.00	Asthma accident and emergency attendance since last visit
19520	663n.00	Asthma treatment compliance satisfactory
7416	663N.00	Asthma disturbing sleep
30815	663N000	Asthma causing night waking
38146	663N100	Asthma disturbs sleep weekly
13175	663N200	Asthma disturbs sleep frequently
13173	663O.00	Asthma not disturbing sleep
38143	663O000	Asthma never disturbs sleep

medcode	read_code	description
19519	663p.00	Asthma treatment compliance unsatisfactory
7191	663P.00	Asthma limiting activities
102713	663P000	Asthma limits activities 1 to 2 times per month
102888	663P100	Asthma limits activities 1 to 2 times per week
103998	663P200	Asthma limits activities most days
13174	663Q.00	Asthma not limiting activities
42824	663q.00	Asthma daytime symptoms
39570	663r.00	Asthma causes night symptoms 1 to 2 times per month
26501	663s.00	Asthma never causes daytime symptoms
31225	663t.00	Asthma causes daytime symptoms 1 to 2 times per month
24884	663u.00	Asthma causes daytime symptoms 1 to 2 times per week
7378	663U.00	Asthma management plan given
13064	663V.00	Asthma severity
26503	663v.00	Asthma causes daytime symptoms most days
3458	663V000	Occasional asthma
3018	663V100	Mild asthma
13065	663V200	Moderate asthma
3366	663V300	Severe asthma
38144	663w.00	Asthma limits walking up hills or stairs
7229	663W.00	Asthma prophylactic medication used
38145	663x.00	Asthma limits walking on the flat
9018	663y.00	Number of asthma exacerbations in past year
9552	66Y5.00	Change in asthma management plan
9663	66Y9.00	Step up change in asthma management plan
18223	66YA.00	Step down change in asthma management plan
41020	66YC.00	Absent from work or school due to asthma
10043	66YJ.00	Asthma annual review
13176	66YK.00	Asthma follow-up
102170	66Yp.00	Asthma review using Roy Colleg of Physicians three questions
31167	66YP.00	Asthma night-time symptoms
102400	66Yq.00	Asthma causes night time symptoms 1 to 2 times per week
102395	66Yr.00	Asthma causes symptoms most nights
103612	66Ys.00	Asthma never causes night symptoms
107167	66Yu.00	Number days absent from school due to asthma in past 6 month
24506	8791	Further asthma - drug prevent.
29645	8793	Asthma control step 0
16785	8794	Asthma control step 1
16667	8795	Asthma control step 2
18224	8796	Asthma control step 3
20886	8797	Asthma control step 4
20860	8798	Asthma control step 5

medcode	read_code	description
10274	8B3j.00	Asthma medication review
5515	9N1d.00	Seen in asthma clinic
5798	H312000	Chronic asthmatic bronchitis
5909	H312011	Chronic wheezy bronchitis
78	H33..00	Asthma
1555	H33..11	Bronchial asthma
7146	H330.00	Extrinsic (atopic) asthma
2290	H330.11	Allergic asthma
1208	H330.12	Childhood asthma
15248	H330.13	Hay fever with asthma
7731	H330.14	Pollen asthma
14777	H330000	Extrinsic asthma without status asthmaticus
5627	H330011	Hay fever with asthma
27926	H330100	Extrinsic asthma with status asthmaticus
6707	H330111	Extrinsic asthma with asthma attack
45782	H330z00	Extrinsic asthma NOS
5267	H331.00	Intrinsic asthma
3665	H331.11	Late onset asthma
29325	H331000	Intrinsic asthma without status asthmaticus
58196	H331100	Intrinsic asthma with status asthmaticus
18323	H331111	Intrinsic asthma with asthma attack
45073	H331z00	Intrinsic asthma NOS
25796	H332.00	Mixed asthma
40823	H334.00	Brittle asthma
106805	H335.00	Chronic asthma with fixed airflow obstruction
4442	H33z.00	Asthma unspecified
32727	H33z.11	Hyperreactive airways disease
4892	H33z000	Status asthmaticus NOS
233	H33z011	Severe asthma attack
232	H33z100	Asthma attack
8335	H33z111	Asthma attack NOS
12987	H33z200	Late-onset asthma
16070	H33zz00	Asthma NOS
4606	H33zz11	Exercise induced asthma
21232	H33zz12	Allergic asthma NEC
18207	H33zz13	Allergic bronchitis NEC
93353	H35y600	Sequoiosis (red-cedar asthma)
39478	H35y700	Wood asthma
47684	H47y000	Detergent asthma

Average daily dose estimation

The average prescribed daily dose was calculated based on tablet strength, prescription duration and number of daily tablets per prescription in switchers from ropinirole IR to ropinirole PR.

- Days' supply: if not stated, then divide total quantity by the quantity prescribed per day.
- Daily dose: multiply the quantity prescribed per day by the dose of the tablets
- Where two scripts are given on the same day (different strengths), assume that the doses are additive (i.e. 2mg and 4mg on same day = 6mg).
- Paired t-test used to compare daily dose of the first PR prescription with the dose of the most recent ropinirole IR prescribed within 30 days before switching.

review	comments	medcode	read_code	clinical_pat	description	matching_t
Y	Schizophrenia	854	E10..00	56442	Schizophrenic disorders	% E1%
Y	Schizophrenia	32222	E100.00	764	Simple schizophrenia	% E1%
Y	Schizophrenia	73295	E100.11	4	Schizophrenia simplex	% E1%
Y	Schizophrenia	15733	E100000	1841	Unspecified schizophrenia	% E1%
Y	Schizophrenia	23616	E100100	7	Subchronic schizophrenia	% E1%
Y	Schizophrenia	3984	E100200	3643	Chronic schizophrenic	% E1%
Y	Schizophrenia	57666	E100300	10	Acute exacerbation of subchronic sc	% E1%
Y	Schizophrenia	44498	E100400	46	Acute exacerbation of chronic schiz	% E1%
Y	Schizophrenia	53625	E100z00	60	Simple schizophrenia NOS	% E1%
Y	Schizophrenia	30619	E101.00	306	Hebephrenic schizophrenia	% E1%
Y	Schizophrenia	66506	E101000	1	Unspecified hebephrenic schizophre	% E1%
Y	Schizophrenia	97919	E101400	1	Acute exacerbation of chronic hebe	% E1%
Y	Schizophrenia	48054	E101z00	6	Hebephrenic schizophrenia NOS	% E1%
Y	Schizophrenia	25546	E102.00	248	Catatonic schizophrenia	% E1%
Y	Schizophrenia	58716	E102000	2	Unspecified catatonic schizophrenia	% E1%
Y	Schizophrenia	99199	E102100	2	Subchronic catatonic schizophrenia	% E1%
Y	Schizophrenia	107222	E102400	1	Acute exacerbation of chronic catat	% E1%
Y	Schizophrenia	63867	E102z00	6	Catatonic schizophrenia NOS	% E1%
Y	Schizophrenia	1494	E103.00	24728	Paranoid schizophrenia	% E1%
Y	Schizophrenia	33383	E103000	93	Unspecified paranoid schizophrenia	% E1%
Y	Schizophrenia	104760	E103100	3	Subchronic paranoid schizophrenia	% E1%
Y	Schizophrenia	31362	E103200	198	Chronic paranoid schizophrenia	% E1%
Y	Schizophrenia	51322	E103300	14	Acute exacerbation of subchronic p	% E1%
Y	Schizophrenia	53032	E103400	72	Acute exacerbation of chronic par	% E1%
Y	Schizophrenia	9281	E103z00	300	Paranoid schizophrenia NOS	% E1%
Y	Schizophrenia	576	E104.00	902	Acute schizophrenic episode	% E1%
Y	Schizophrenia	93167	E104.11	1	Oneirophrenia	% E1%
Y	Schizophrenia	66410	E105.00	12	Latent schizophrenia	% E1%
Y	Schizophrenia	102311	E105000	3	Unspecified latent schizophrenia	% E1%
Y	Schizophrenia	94299	E105200	3	Chronic latent schizophrenia	% E1%
Y	Schizophrenia	102446	E105z00	1	Latent schizophrenia NOS	% E1%
Y	Schizophrenia	38063	E106.00	228	Residual schizophrenia	% E1%
Y	Schizophrenia	2117	E107.00	7107	Schizo-affective schizophrenia	% E1%
Y	Schizophrenia	99000	E107.11	1	Cyclic schizophrenia	% E1%
Y	Schizophrenia	58862	E107000	71	Unspecified schizo-affective schizop	% E1%
Y	Schizophrenia	61098	E107100	5	Subchronic schizo-affective schizopt	% E1%
Y	Schizophrenia	43800	E107200	58	Chronic schizo-affective schizophrer	% E1%
Y	Schizophrenia	58866	E107300	4	Acute exacerbation subchronic schiz	% E1%
Y	Schizophrenia	63478	E107400	13	Acute exacerbation of chronic schiz	% E1%
Y	Schizophrenia	10575	E107z00	170	Schizo-affective schizophrenia NOS	% E1%
Y	Schizophrenia	39062	E10y.00	69	Other schizophrenia	% E1%
Y	Schizophrenia	92994	E10y.11	3	Cenesthopathic schizophrenia	% E1%
Y	Schizophrenia	33338	E10y000	85	Atypical schizophrenia	% E1%
Y	Schizophrenia	99070	E10y100	1	Coenesthopathic schizophrenia	% E1%
Y	Schizophrenia	49761	E10yz00	44	Other schizophrenia NOS	% E1%
Y	Schizophrenia	8407	E10z.00	9989	Schizophrenia NOS	% E1%
Y	Schizophrenia	37395	E14z.11	40	Childhood schizophrenia NOS	% E1%
Y	Schizophrenia	34236	Eu20.00	3856	[X]Schizophrenia	% Eu2%
Y	Schizophrenia	16764	Eu20000	1771	[X]Paranoid schizophrenia	% Eu2%
Y	Schizophrenia	50060	Eu20011	10	[X]Paraphrenic schizophrenia	% Eu2%
Y	Schizophrenia	43405	Eu20100	26	[X]Hebephrenic schizophrenia	% Eu2%
Y	Schizophrenia	53985	Eu20111	8	[X]Disorganised schizophrenia	% Eu2%
Y	Schizophrenia	61501	Eu20200	14	[X]Catatonic schizophrenia	% Eu2%
Y	Schizophrenia	20572	Eu20211	73	[X]Catatonic stupor	% Eu2%

Y	Schizophrenia	64533	Eu20212	4	[X]Schizophrenic catalepsy	% Eu2%
Y	Schizophrenia	35877	Eu20213	49	[X]Schizophrenic catatonia	% Eu2%
Y	Schizophrenia	31493	Eu20214	2	[X]Schizophrenic flexibilatis cerea	% Eu2%
Y	Schizophrenia	60013	Eu20300	48	[X]Undifferentiated schizophrenia	% Eu2%
Y	Schizophrenia	91547	Eu20311	4	[X]Atypical schizophrenia	% Eu2%
Y	Schizophrenia	64264	Eu20500	20	[X]Residual schizophrenia	% Eu2%
Y	Schizophrenia	24107	Eu20511	524	[X]Chronic undifferentiated schizopl	% Eu2%
Y	Schizophrenia	35848	Eu20600	141	[X]Simple schizophrenia	% Eu2%
Y	Schizophrenia	49420	Eu20y00	29	[X]Other schizophrenia	% Eu2%
Y	Schizophrenia	34966	Eu20z00	126	[X]Schizophrenia, unspecified	% Eu2%
Y	Schizophrenia	54387	Eu21.12	8	[X]Borderline schizophrenia	% Eu2%
Y	Schizophrenia	64993	Eu21.13	2	[X]Latent schizophrenia	% Eu2%
Y	Schizophrenia	62449	Eu21.14	4	[X]Prepsychotic schizophrenia	% Eu2%
Y	Schizophrenia	40386	Eu21.15	24	[X]Prodromal schizophrenia	% Eu2%
Y	Schizophrenia	49852	Eu21.16	7	[X]Pseudoneurotic schizophrenia	% Eu2%
Y	Schizophrenia	71250	Eu21.17	1	[X]Pseudopsychopathic schizophren	% Eu2%
Y	Schizophrenia	21595	Eu23100	108	[X]Acute polymorphic psychot disor	% Eu2%
Y	Schizophrenia	26143	Eu23112	10	[X]Cycloid psychosis with symptoms	% Eu2%
Y	Schizophrenia	104763	Eu25211	1	[X]Cyclic schizophrenia	% Eu2%
Y	Schizophrenia	37580	Eu25212	121	[X]Mixed schizophrenic and affectiv	% Eu2%
Y	Other psychosis	1915	1BH..00	10314	Delusions	% 1BH%
Y	Other psychosis	17982	1BH..11	1907	Delusion	% 1BH%
Y	Other psychosis	43462	1BH0.00	199	Delusion of persecution	% 1BH%
Y	Other psychosis	32875	1BH1.00	106	Grandiose delusions	% 1BH%
Y	Other psychosis	55479	1BH2.00	110	Ideas of reference	% 1BH%
Y	Other psychosis	22643	1BH3.00	5135	Paranoid ideation	% 1BH%
Y	Other psychosis	12472	225E.00	798	O/E - paranoid delusions	% 225E%
Y	Other psychosis	52523	225F.00	29	O/E - delusion of persecution	% 225F%
Y	Other psychosis	15249	E00y.00	2086	Other senile and presenile organic p	% E0%
Y	Other psychosis	51494	E00y.11	2	Presbyophrenic psychosis	% E0%
Y	Other psychosis	2882	E00z.00	12881	Senile or presenile psychoses NOS	% E0%
Y	Other psychosis	16237	E01..00	572	Alcoholic psychoses	% E0%
Y	Other psychosis	4500	E011000	1390	Korsakov's alcoholic psychosis	% E0%
Y	Other psychosis	11106	E011100	82	Korsakov's alcoholic psychosis with	% E0%
Y	Other psychosis	30404	E015.00	148	Alcoholic paranoia	% E0%
Y	Other psychosis	33670	E01y.00	191	Other alcoholic psychosis	% E0%
Y	Other psychosis	68111	E01yz00	9	Other alcoholic psychosis NOS	% E0%
Y	Other psychosis	67651	E01z.00	65	Alcoholic psychosis NOS	% E0%
Y	Other psychosis	16256	E02..00	1805	Drug psychoses	% E0%
Y	Other psychosis	45997	E021.00	103	Drug-induced paranoia or hallucinat	% E0%
Y	Other psychosis	12628	E021000	623	Drug-induced paranoid state	% E0%
Y	Other psychosis	20026	E021100	362	Drug-induced hallucinosis	% E0%
Y	Other psychosis	26481	E021z00	52	Drug-induced paranoia or hallucinat	% E0%
Y	Other psychosis	51135	E02y.00	78	Other drug psychoses	% E0%
Y	Other psychosis	28767	E02yz00	31	Other drug psychoses NOS	% E0%
Y	Other psychosis	26002	E02z.00	1469	Drug psychosis NOS	% E0%
Y	Other psychosis	55150	E03..00	847	Transient organic psychoses	% E0%
Y	Other psychosis	10543	E03y000	566	Organic delusional syndrome	% E0%
Y	Other psychosis	47109	E03y100	89	Organic hallucinosis syndrome	% E0%
Y	Other psychosis	2114	E03y300	1754	Unspecified puerperal psychosis	% E0%
Y	Other psychosis	59197	E03yz00	5	Other transient organic psychoses N	% E0%
Y	Other psychosis	57637	E03z.00	30	Transient organic psychoses NOS	% E0%
Y	Other psychosis	62087	E04..00	78	Other chronic organic psychoses	% E0%
Y	Other psychosis	23835	E040.11	238	Korsakoff's non-alcoholic psychosis	% E0%
Y	Other psychosis	23677	E04y.00	3	Other specified chronic organic psyc	% E0%

Y	Other psychosis	39625 E04z.00	94 Chronic organic psychosis NOS	% E0%
Y	Other psychosis	66545 E0y..00	17 Other specified organic psychoses	% E0%
Y	Other psychosis	36861 E0z..00	373 Organic psychoses NOS	% E0%
Y	Other psychosis	15958 E1...00	1432 Non-organic psychoses	% E1%
Y	Other psychosis	14656 E11..00	4309 Affective psychoses	% E1%
Y	Other psychosis	2560 E11..12	5379 Depressive psychoses	% E1%
Y	Other psychosis	26161 E11..13	601 Manic psychoses	% E1%
Y	Other psychosis	41992 E11z.00	126 Other and unspecified affective psychoses	% E1%
Y	Other psychosis	54607 E11z000	69 Unspecified affective psychoses NOS	% E1%
Y	Other psychosis	33425 E11zz00	201 Other affective psychosis NOS	% E1%
Y	Other psychosis	4261 E12..00	9975 Paranoid states	% E1%
Y	Other psychosis	14743 E120.00	2530 Simple paranoid state	% E1%
Y	Other psychosis	3890 E121.00	1994 Chronic paranoid psychosis	% E1%
Y	Other psychosis	14971 E122.00	2283 Paraphrenia	% E1%
Y	Other psychosis	62680 E123.00	5 Shared paranoid disorder	% E1%
Y	Other psychosis	50868 E123.11	20 Folie a deux	% E1%
Y	Other psychosis	31589 E12y.00	84 Other paranoid states	% E1%
Y	Other psychosis	66766 E12y000	5 Paranoia querulans	% E1%
Y	Other psychosis	31455 E12yz00	93 Other paranoid states NOS	% E1%
Y	Other psychosis	12771 E12z.00	4984 Paranoid psychosis NOS	% E1%
Y	Other psychosis	31984 E13..00	395 Other nonorganic psychoses	% E1%
Y	Other psychosis	20228 E13..11	286 Reactive psychoses	% E1%
Y	Other psychosis	8478 E130.00	1060 Reactive depressive psychosis	% E1%
Y	Other psychosis	17770 E130.11	1792 Psychotic reactive depression	% E1%
Y	Other psychosis	29937 E131.00	136 Acute hysterical psychosis	% E1%
Y	Other psychosis	15053 E133.00	675 Acute paranoid reaction	% E1%
Y	Other psychosis	68058 E133.11	Bouffee delirante	% E1%
Y	Other psychosis	24345 E134.00	59 Psychogenic paranoid psychosis	% E1%
Y	Other psychosis	16333 E13y.00	196 Other reactive psychoses	% E1%
Y	Other psychosis	22117 E13y000	21 Psychogenic stupor	% E1%
Y	Other psychosis	23538 E13y100	70 Brief reactive psychosis	% E1%
Y	Other psychosis	26119 E13yz00	51 Other reactive psychoses NOS	% E1%
Y	Other psychosis	14965 E13z.00	9969 Nonorganic psychosis NOS	% E1%
Y	Other psychosis	3636 E13z.11	12569 Psychotic episode NOS	% E1%
Y	Other psychosis	43225 E14..00	13 Psychoses with origin in childhood	% E1%
Y	Other psychosis	56143 E141.00	9 Disintegrative psychosis	% E1%
Y	Other psychosis	41207 E141100	1 Residual disintegrative psychoses	% E1%
Y	Other psychosis	71819 E14y.00	1 Other childhood psychoses	% E1%
Y	Other psychosis	24244 E14y000	4 Atypical childhood psychoses	% E1%
Y	Other psychosis	69155 E14y100	7 Borderline psychosis of childhood	% E1%
Y	Other psychosis	66757 E14yz00	4 Other childhood psychoses NOS	% E1%
Y	Other psychosis	52849 E14z.00	19 Child psychosis NOS	% E1%
Y	Other psychosis	16537 E1y..00	37 Other specified non-organic psychoses	% E1%
Y	Other psychosis	22188 E1z..00	357 Non-organic psychosis NOS	% E1%
Y	Other psychosis	61969 E212200	111 Schizotypal personality	% E2122%
Y	Other psychosis	47619 Eu02z12	45 [X] Presenile psychosis NOS	% Eu0%
Y	Other psychosis	27935 Eu02z15	283 [X] Senile psychosis NOS	% Eu0%
Y	Other psychosis	57993 Eu03.11	17 [X]Korsakov's psychosis, nonalcohol	% Eu0%
Y	Other psychosis	24387 Eu04.13	141 [X]Acute / subacute infective psychosis	% Eu0%
Y	Other psychosis	25338 Eu05000	61 [X]Organic hallucinosis	% Eu0%
Y	Other psychosis	46808 Eu05100	25 [X]Organic catatonic disorder	% Eu0%
Y	Other psychosis	21986 Eu05200	832 [X]Organic delusional [schizophrenia]	% Eu0%
Y	Other psychosis	24009 Eu05211	18 [X]Paranoid organic state	% Eu0%
Y	Other psychosis	31877 Eu05212	60 [X]Schizophrenia-like psychosis in episode	% Eu0%
Y	Other psychosis	6709 Eu05y11	271 [X]Epileptic psychosis NOS	% Eu0%

Y	Other psychosis	67434	Eu06z11	4	[X]Organic psychosyndrome	% Eu0%
Y	Other psychosis	21985	Eu0z.11	533	[X]Organic psychosis NOS	% Eu0%
Y	Other psychosis	8766	Eu0z.12	1212	[X]Symptomatic psychosis NOS	% Eu0%
Y	Other psychosis	12353	Eu10500	174	[X]Mental & behav dis due to use al	% Eu1%
Y	Other psychosis	6467	Eu10511	358	[X]Alcoholic hallucinosis	% Eu1%
Y	Other psychosis	30162	Eu10513	111	[X]Alcoholic paranoia	% Eu1%
Y	Other psychosis	17607	Eu10514	432	[X]Alcoholic psychosis NOS	% Eu1%
Y	Other psychosis	11670	Eu10611	285	[X]Korsakov's psychosis, alcohol indi	% Eu1%
Y	Other psychosis	62000	Eu10700	12	[X]Men & behav dis due alcoh: resid	% Eu1%
Y	Other psychosis	50964	Eu11500	35	[X]Mental & behav dis due to use of	% Eu1%
Y	Other psychosis	27652	Eu11700	5	[X]Men & beh dis due opioids: resid	% Eu1%
Y	Other psychosis	38429	Eu12500	144	[X]Mental & behav dis due to canna	% Eu1%
Y	Other psychosis	57574	Eu12700	8	[X]Mnt/bh dis due cannabinds: resic	% Eu1%
Y	Other psychosis	69138	Eu13500	6	[X]Mental & behav dis due to seds/t	% Eu1%
Y	Other psychosis	49565	Eu14500	29	[X]Mental & behav dis due to use cc	% Eu1%
Y	Other psychosis	102591	Eu14700	1	[X]Men & beh dis due cocaine: resid	% Eu1%
Y	Other psychosis	49879	Eu15500	9	[X]Mental/behav dis oth stims inc c	% Eu1%
Y	Other psychosis	59163	Eu15700	6	[X]Mnt/bh dis oth stm inc caffne res	% Eu1%
Y	Other psychosis	54983	Eu16500	9	[X]Mental & behav dis due to halluc	% Eu1%
Y	Other psychosis	105346	Eu16700	2	[X]Mnt/bh dis due hallucngns: resid	% Eu1%
Y	Other psychosis	98618	Eu18500	1	[X]Mental & behav dis due to vol sol	% Eu1%
Y	Other psychosis	24637	Eu19500	75	[X]Ment/behav dis mlti drug use/otl	% Eu1%
Y	Other psychosis	56948	Eu19700	10	[X]Men/beh dis mlt drg use/oth sub	% Eu1%
Y	Other psychosis	102475	Eu1A500		[X]Mental behav disord due crack cc	% Eu1%
Y	Other psychosis	17281	Eu2..00	1376	[X]Schizophrenia, schizotypal and de	% Eu2%
Y	Other psychosis	94001	Eu20y12	13	[X]Schizophreniform disord NOS	% Eu2%
Y	Other psychosis	18053	Eu20y13	158	[X]Schizophrenifrm psychos NOS	% Eu2%
Y	Other psychosis	39316	Eu21.00	186	[X]Schizotypal disorder	% Eu2%
Y	Other psychosis	91511	Eu21.11	3	[X]Latent schizophrenic reaction	% Eu2%
Y	Other psychosis	26859	Eu21.18	95	[X]Schizotypal personality disorder	% Eu2%
Y	Other psychosis	28562	Eu22.00	535	[X]Persistent delusional disorders	% Eu2%
Y	Other psychosis	34389	Eu22000	1050	[X]Delusional disorder	% Eu2%
Y	Other psychosis	2113	Eu22011	9105	[X]Paranoid psychosis	% Eu2%
Y	Other psychosis	11172	Eu22012	1744	[X]Paranoid state	% Eu2%
Y	Other psychosis	47947	Eu22013	47	[X]Paraphrenia - late	% Eu2%
Y	Other psychosis	65127	Eu22014	1	[X]Sensitiver Beziehungswahn	% Eu2%
Y	Other psychosis	4843	Eu22015	10926	[X]Paranoia	% Eu2%
Y	Other psychosis	62405	Eu22100	6	[X]Delusional misidentification synd	% Eu2%
Y	Other psychosis	55221	Eu22111	33	[X]Capgras syndrome	% Eu2%
Y	Other psychosis	98821	Eu22200	3	[X]Cotard syndrome	% Eu2%
Y	Other psychosis	66077	Eu22y00	13	[X]Other persistent delusional disor	% Eu2%
Y	Other psychosis	40981	Eu22y11	120	[X]Delusional dysmorphophobia	% Eu2%
Y	Other psychosis	50248	Eu22y12	10	[X]Involutional paranoid state	% Eu2%
Y	Other psychosis	55236	Eu22y13	6	[X]Paranoia querulans	% Eu2%
Y	Other psychosis	49223	Eu22z00	89	[X]Persistent delusional disorder, un	% Eu2%
Y	Other psychosis	25019	Eu23.00	1310	[X]Acute and transient psychotic dis	% Eu2%
Y	Other psychosis	36720	Eu23000	189	[X]Acute polymorphic psychot disor	% Eu2%
Y	Other psychosis	50023	Eu23011	1	[X]Bouffee delirante	% Eu2%
Y	Other psychosis	21455	Eu23012	39	[X]Cycloid psychosis	% Eu2%
Y	Other psychosis	11778	Eu23200	104	[X]Acute schizophrenia-like psychoti	% Eu2%
Y	Other psychosis	59096	Eu23211	4	[X]Brief schizophreniform disorder	% Eu2%
Y	Other psychosis	70884	Eu23212	2	[X]Brief schizophrenifrm psych	% Eu2%
Y	Other psychosis	94604	Eu23214	7	[X]Schizophrenic reaction	% Eu2%
Y	Other psychosis	44307	Eu23300	51	[X]Other acute predominantly delus	% Eu2%
Y	Other psychosis	27770	Eu23312	146	[X]Psychogenic paranoid psychosis	% Eu2%

Y	Other psychosis	44503	Eu23y00	53	[X]Other acute and transient psychc	% Eu2%
Y	Other psychosis	34168	Eu23z00	196	[X]Acute and transient psychotic dis	% Eu2%
Y	Other psychosis	31707	Eu23z11	108	[X]Brief reactive psychosis NOS	% Eu2%
Y	Other psychosis	29651	Eu23z12	320	[X]Reactive psychosis	% Eu2%
Y	Other psychosis	51302	Eu24.00	57	[X]Induced delusional disorder	% Eu2%
Y	Other psychosis	105606	Eu24.11	1	[X]Folie a deux	% Eu2%
Y	Other psychosis	47230	Eu24.12	25	[X]Induced paranoid disorder	% Eu2%
Y	Other psychosis	11973	Eu24.13	176	[X]Induced psychotic disorder	% Eu2%
Y	Other psychosis	9422	Eu25.00	8456	[X]Schizoaffective disorders	% Eu2%
Y	Other psychosis	33847	Eu25000	119	[X]Schizoaffective disorder, manic t	% Eu2%
Y	Other psychosis	16905	Eu25011	48	[X]Schizoaffective psychosis, manic	% Eu2%
Y	Other psychosis	51903	Eu25012	32	[X]Schizophreniform psychosis, man	% Eu2%
Y	Other psychosis	11055	Eu25100	444	[X]Schizoaffective disorder, depress	% Eu2%
Y	Other psychosis	35274	Eu25111	119	[X]Schizoaffective psychosis, depres	% Eu2%
Y	Other psychosis	41022	Eu25112	39	[X]Schizophreniform psychosis, dep	% Eu2%
Y	Other psychosis	33693	Eu25200	133	[X]Schizoaffective disorder, mixed t	% Eu2%
Y	Other psychosis	58532	Eu25y00	28	[X]Other schizoaffective disorders	% Eu2%
Y	Other psychosis	37681	Eu25z00	441	[X]Schizoaffective disorder, unspeci	% Eu2%
Y	Other psychosis	33410	Eu25z11	202	[X]Schizoaffective psychosis NOS	% Eu2%
Y	Other psychosis	30985	Eu2y.00	284	[X]Other nonorganic psychotic disor	% Eu2%
Y	Other psychosis	31738	Eu2y.11	107	[X]Chronic hallucinatory psychosis	% Eu2%
Y	Other psychosis	11244	Eu2z.00	711	[X]Unspecified nonorganic psychosi	% Eu2%
Y	Other psychosis	694	Eu2z.11	17993	[X]Psychosis NOS	% Eu2%
Y	Other psychosis	21338	Eu60000	158	[X]Paranoid personality disorder	% Eu600%
Y	Other psychosis	69000	Eu60013	1	[X]Querulant personality disorder	% Eu600%
Y	Other psychosis	48687	Eu60014	48	[X]Sensitive paranoid personality dis	% Eu600%
Y	Other psychosis	38371	Eu60100	156	[X]Schizoid personality disorder	% Eu601%
Y	Depression	12399	9H90.00	12865	Depression annual review	% 9H9%
Y	Depression	12122	9H91.00	26371	Depression medication review	% 9H9%
Y	Depression	30405	9H92.00	365984	Depression interim review	% 9H9%
Y	Depression	42931	9HA0.00	8397	On depression register	% 9HA%
Y	Depression	51258	9Ov..00	19063	Depression monitoring administrati	% 9Ov%
Y	Depression	71009	9Ov0.00	19186	Depression monitoring first letter	% 9Ov%
Y	Depression	72966	9Ov1.00	7348	Depression monitoring second lette	% 9Ov%
Y	Depression	91105	9Ov2.00	4595	Depression monitoring third letter	% 9Ov%
Y	Depression	88644	9Ov3.00	1230	Depression monitoring verbal invite	% 9Ov%
Y	Depression	85852	9Ov4.00	517	Depression monitoring telephone in	% 9Ov%
Y	Depression	46244	E02y300	83	Drug-induced depressive state	% E0%
Y	Depression	10610	E112.00	43723	Single major depressive episode	% E1%
Y	Depression	5879	E112.11	44298	Agitated depression	% E1%
Y	Depression	6546	E112.12	12353	Endogenous depression first episod	% E1%
Y	Depression	6950	E112.13	62684	Endogenous depression first episod	% E1%
Y	Depression	595	E112.14	53762	Endogenous depression	% E1%
Y	Depression	34390	E112000	1028	Single major depressive episode, un	% E1%
Y	Depression	16506	E112100	5800	Single major depressive episode, mi	% E1%
Y	Depression	15155	E112200	6382	Single major depressive episode, mc	% E1%
Y	Depression	15219	E112300	1660	Single major depressive episode, sev	% E1%
Y	Depression	32159	E112400	298	Single major depressive episode, sev	% E1%
Y	Depression	43324	E112500	293	Single major depressive episode, pa	% E1%
Y	Depression	7011	E112z00	2418	Single major depressive episode NO	% E1%
Y	Depression	15099	E113.00	15814	Recurrent major depressive episode	% E1%
Y	Depression	6932	E113.11	82069	Endogenous depression - recurrent	% E1%
Y	Depression	35671	E113000	338	Recurrent major depressive episode	% E1%
Y	Depression	29342	E113100	1483	Recurrent major depressive episode	% E1%
Y	Depression	14709	E113200	7982	Recurrent major depressive episode	% E1%

Y	Depression	25697 E113300	1107 Recurrent major depressive episode % E1%
Y	Depression	24171 E113400	464 Recurrent major depressive episode % E1%
Y	Depression	56273 E113500	196 Recurrent major depressive episode % E1%
Y	Depression	6482 E113700	39505 Recurrent depression % E1%
Y	Depression	25563 E113z00	1875 Recurrent major depressive episode % E1%
Y	Depression	27491 E11y200	181 Atypical depressive disorder % E1%
Y	Depression	9183 E11z200	2899 Masked depression % E1%
Y	Depression	1055 E135.00	42149 Agitated depression % E1%
Y	Depression	1131 E204.00	225909 Neurotic depression reactive type % E204%
Y	Depression	2639 E204.11	124766 Postnatal depression % E204%
Y	Depression	16632 E291.00	2256 Prolonged depressive reaction % E291%
Y	Depression	324 E2B..00	1808376 Depressive disorder NEC % E2B%
Y	Depression	2972 E2B0.00	1291 Postviral depression % E2B%
Y	Depression	4323 E2B1.00	45764 Chronic depression % E2B%
Y	Depression	20785 Eu20400	48 [X]Post-schizophrenic depression % Eu2%
Y	Depression	4639 Eu32.00	281891 [X]Depressive episode % Eu32%
Y	Depression	9055 Eu32.11	8487 [X]Single episode of depressive reac % Eu32%
Y	Depression	18510 Eu32.12	442 [X]Single episode of psychogenic de % Eu32%
Y	Depression	7604 Eu32.13	6066 [X]Single episode of reactive depres % Eu32%
Y	Depression	11717 Eu32000	36955 [X]Mild depressive episode % Eu32%
Y	Depression	9211 Eu32100	84867 [X]Moderate depressive episode % Eu32%
Y	Depression	9667 Eu32200	22167 [X]Severe depressive episode witho % Eu32%
Y	Depression	41989 Eu32211	135 [X]Single episode agitated depressn % Eu32%
Y	Depression	22806 Eu32212	1360 [X]Single episode major depression % Eu32%
Y	Depression	59386 Eu32213	37 [X]Single episode vital depression w % Eu32%
Y	Depression	12099 Eu32300	3940 [X]Severe depressive episode with p % Eu32%
Y	Depression	24117 Eu32311	185 [X]Single episode of major depressic % Eu32%
Y	Depression	52678 Eu32312	41 [X]Single episode of psychogenic de % Eu32%
Y	Depression	24112 Eu32313	528 [X]Single episode of psychotic depre % Eu32%
Y	Depression	28863 Eu32314	128 [X]Single episode of reactive depres % Eu32%
Y	Depression	10667 Eu32400	12063 [X]Mild depression % Eu32%
Y	Depression	98346 Eu32500	384 [X]Major depression, mild % Eu32%
Y	Depression	98252 Eu32600	1084 [X]Major depression, moderately se % Eu32%
Y	Depression	98414 Eu32700	1405 [X]Major depression, severe withou % Eu32%
Y	Depression	98417 Eu32800	232 [X]Major depression, severe with ps % Eu32%
Y	Depression	103677 Eu32B00	24 [X]Antenatal depression % Eu32%
Y	Depression	6854 Eu32y00	1955 [X]Other depressive episodes % Eu32%
Y	Depression	10720 Eu32y11	311 [X]Atypical depression % Eu32%
Y	Depression	56609 Eu32y12	71 [X]Single episode of masked depres % Eu32%
Y	Depression	2970 Eu32z00	81072 [X]Depressive episode, unspecified % Eu32%
Y	Depression	543 Eu32z11	665407 [X]Depression NOS % Eu32%
Y	Depression	3291 Eu32z12	15284 [X]Depressive disorder NOS % Eu32%
Y	Depression	28248 Eu32z13	421 [X]Prolonged single episode of react % Eu32%
Y	Depression	5987 Eu32z14	73783 [X] Reactive depression NOS % Eu32%
Y	Depression	3292 Eu33.00	34344 [X]Recurrent depressive disorder % Eu33%
Y	Depression	8851 Eu33.11	2658 [X]Recurrent episodes of depressive % Eu33%
Y	Depression	19696 Eu33.12	578 [X]Recurrent episodes of psychogen % Eu33%
Y	Depression	8902 Eu33.13	3042 [X]Recurrent episodes of reactive de % Eu33%
Y	Depression	28756 Eu33.14	105 [X]Seasonal depressive disorder % Eu33%
Y	Depression	8826 Eu33.15	3722 [X]SAD - Seasonal affective disorder % Eu33%
Y	Depression	29784 Eu33000	1564 [X]Recurrent depressive disorder, ct % Eu33%
Y	Depression	29520 Eu33100	5878 [X]Recurrent depressive disorder, ct % Eu33%
Y	Depression	33469 Eu33200	1560 [X]Recurr depress disorder cur epi s % Eu33%
Y	Depression	11329 Eu33211	870 [X]Endogenous depression without % Eu33%
Y	Depression	11252 Eu33212	302 [X]Major depression, recurrent with % Eu33%

Y	Depression	73991	Eu33214	10	[X]Vital depression, recurrent witho	% Eu33%
Y	Depression	47009	Eu33300	815	[X]Recurrent depress disorder cur e	% Eu33%
Y	Depression	23731	Eu33311	402	[X]Endogenous depression with psy	% Eu33%
Y	Depression	32941	Eu33313	256	[X]Recurr severe episodes/major de	% Eu33%
Y	Depression	31757	Eu33314	41	[X]Recurr severe episodes/psychoge	% Eu33%
Y	Depression	16861	Eu33315	337	[X]Recurrent severe episodes of psy	% Eu33%
Y	Depression	37764	Eu33316	62	[X]Recurrent severe episodes/reacti	% Eu33%
Y	Depression	47731	Eu33y00	180	[X]Other recurrent depressive disor	% Eu33%
Y	Depression	44300	Eu33z00	2894	[X]Recurrent depressive disorder, ur	% Eu33%
Y	Depression	36616	Eu33z11	29	[X]Monopolar depression NOS	% Eu33%
Y	Depression	7953	Eu34100	8173	[X]Dysthymia	% Eu341%
Y	Depression	8584	Eu34111	1142	[X]Depressive neurosis	% Eu341%
Y	Depression	10290	Eu34112	423	[X]Depressive personality disorder	% Eu341%
Y	Depression	7737	Eu34113	2799	[X]Neurotic depression	% Eu341%
Y	Depression	15220	Eu34114	5258	[X]Persistant anxiety depression	% Eu341%
Y	Depression	19054	Eu3y111	180	[X]Recurrent brief depressive episod	% Eu3y111%
Y	Depression	11913	Eu41200	32323	[X]Mixed anxiety and depressive dis	% Eu41%, %
Y	Depression	7749	Eu41211	4357	[X]Mild anxiety depression	% Eu41%, %
Y	Depression	13307	Eu53011	3511	[X]Postnatal depression NOS	% Eu530%
Y	Depression	4979	Eu53012	270	[X]Postpartum depression NOS	% Eu530%
Y	Depression	32845	Eu92000	75	[X]Depressive conduct disorder	% Eu920%
Y	Dementia	55023	66h..00	8006	Dementia monitoring	% 66h..%
Y	Dementia	12710	6AB..00	190800	Dementia annual review	% 6AB%
Y	Dementia	85853	9Ou..00	818	Dementia monitoring administrator	% 9Ou%
Y	Dementia	49674	9Ou1.00	11037	Dementia monitoring first letter	% 9Ou%
Y	Dementia	83576	9Ou2.00	2260	Dementia monitoring second letter	% 9Ou%
Y	Dementia	89036	9Ou3.00	900	Dementia monitoring third letter	% 9Ou%
Y	Dementia	89037	9Ou4.00	277	Dementia monitoring verbal invite	% 9Ou%
Y	Dementia	65235	9Ou5.00	388	Dementia monitoring telephone inv	% 9Ou%
Y	Dementia	1916	E00..11	24179	Senile dementia	% E0%
Y	Dementia	1350	E00..12	64141	Senile/presenile dementia	% E0%
Y	Dementia	7323	E000.00	15351	Uncomplicated senile dementia	% E0%
Y	Dementia	15165	E001.00	1537	Presenile dementia	% E0%
Y	Dementia	42602	E001000	31	Uncomplicated presenile dementia	% E0%
Y	Dementia	49513	E001100	50	Presenile dementia with delirium	% E0%
Y	Dementia	30032	E001200	143	Presenile dementia with paranoia	% E0%
Y	Dementia	27677	E001300	85	Presenile dementia with depression	% E0%
Y	Dementia	38438	E001z00	210	Presenile dementia NOS	% E0%
Y	Dementia	44674	E002.00	231	Senile dementia with depressive or	% E0%
Y	Dementia	18386	E002000	513	Senile dementia with paranoia	% E0%
Y	Dementia	21887	E002100	612	Senile dementia with depression	% E0%
Y	Dementia	41089	E002z00	31	Senile dementia with depressive or	% E0%
Y	Dementia	37015	E003.00	306	Senile dementia with delirium	% E0%
Y	Dementia	19477	E004.00	2530	Arteriosclerotic dementia	% E0%
Y	Dementia	8634	E004.11	4087	Multi infarct dementia	% E0%
Y	Dementia	43089	E004000	86	Uncomplicated arteriosclerotic dem	% E0%
Y	Dementia	56912	E004100	16	Arteriosclerotic dementia with deliri	% E0%
Y	Dementia	55467	E004200	34	Arteriosclerotic dementia with para	% E0%
Y	Dementia	43292	E004300	71	Arteriosclerotic dementia with depr	% E0%
Y	Dementia	42279	E004z00	304	Arteriosclerotic dementia NOS	% E0%
Y	Dementia	54505	E012.00	99	Other alcoholic dementia	% E0%
Y	Dementia	27342	E012.11	652	Alcoholic dementia NOS	% E0%
Y	Dementia	62132	E02y100	23	Drug-induced dementia	% E0%
Y	Dementia	25386	E041.00	1294	Dementia in conditions EC	% E0%
Y	Dementia	7664	Eu00.00	16671	[X]Dementia in Alzheimer's disease	% Eu0%

Y	Dementia	49263	Eu00000	263	[X]Dementia in Alzheimer's disease	% Eu0%
Y	Dementia	25704	Eu00011	45	[X]Presenile dementia,Alzheimer's t	% Eu0%
Y	Dementia	60059	Eu00012	13	[X]Primary degen dementia, Alzheim	% Eu0%
Y	Dementia	61528	Eu00013	9	[X]Alzheimer's disease type 2	% Eu0%
Y	Dementia	38678	Eu00100	596	[X]Dementia in Alzheimer's disease	% Eu0%
Y	Dementia	46762	Eu00111	38	[X]Alzheimer's disease type 1	% Eu0%
Y	Dementia	11379	Eu00112	1152	[X]Senile dementia,Alzheimer's type	% Eu0%
Y	Dementia	43346	Eu00113	57	[X]Primary degen dementia of Alzhe	% Eu0%
Y	Dementia	30706	Eu00200	1241	[X]Dementia in Alzheimer's dis, atyp	% Eu0%
Y	Dementia	29386	Eu00z00	777	[X]Dementia in Alzheimer's disease,	% Eu0%
Y	Dementia	8195	Eu00z11	6497	[X]Alzheimer's dementia unspec	% Eu0%
Y	Dementia	6578	Eu01.00	38479	[X]Vascular dementia	% Eu0%
Y	Dementia	9565	Eu01.11	942	[X]Arteriosclerotic dementia	% Eu0%
Y	Dementia	46488	Eu01000	41	[X]Vascular dementia of acute onset	% Eu0%
Y	Dementia	11175	Eu01100	1057	[X]Multi-infarct dementia	% Eu0%
Y	Dementia	55838	Eu01111	31	[X]Predominantly cortical dementia	% Eu0%
Y	Dementia	8934	Eu01200	179	[X]Subcortical vascular dementia	% Eu0%
Y	Dementia	31016	Eu01300	635	[X]Mixed cortical and subcortical va	% Eu0%
Y	Dementia	55313	Eu01y00	153	[X]Other vascular dementia	% Eu0%
Y	Dementia	19393	Eu01z00	704	[X]Vascular dementia, unspecified	% Eu0%
Y	Dementia	12621	Eu02.00	651	[X]Dementia in other diseases classi	% Eu0%
Y	Dementia	28402	Eu02000	146	[X]Dementia in Pick's disease	% Eu0%
Y	Dementia	54106	Eu02100	44	[X]Dementia in Creutzfeldt-Jakob di	% Eu0%
Y	Dementia	37014	Eu02200	167	[X]Dementia in Huntington's disease	% Eu0%
Y	Dementia	9509	Eu02300	1464	[X]Dementia in Parkinson's disease	% Eu0%
Y	Dementia	41185	Eu02400	16	[X]Dementia in human immunodef	% Eu0%
Y	Dementia	26270	Eu02500	2383	[X]Lewy body dementia	% Eu0%
Y	Dementia	64267	Eu02y00	51	[X]Dementia in other specified dise	% Eu0%
Y	Dementia	4693	Eu02z00	31042	[X] Unspecified dementia	% Eu0%
Y	Dementia	48501	Eu02z11	50	[X] Presenile dementia NOS	% Eu0%
Y	Dementia	34944	Eu02z13	82	[X] Primary degenerative dementia	% Eu0%
Y	Dementia	4357	Eu02z14	11289	[X] Senile dementia NOS	% Eu0%
Y	Dementia	27759	Eu02z16	183	[X] Senile dementia, depressed or p	% Eu0%
Y	Dementia	68125	Eu04000	13	[X]Delirium not superimposed on de	% Eu0%
Y	Dementia	53446	Eu04100	53	[X]Delirium superimposed on deme	% Eu0%
Y	Dementia	26323	Eu10711	496	[X]Alcoholic dementia NOS	% Eu1%
Y	Dementia	1917	F110.00	49331	Alzheimer's disease	% F110%
Y	Dementia	16797	F110000	630	Alzheimer's disease with early onset	% F110%
Y	Dementia	32057	F110100	689	Alzheimer's disease with late onset	% F110%
Y	Dementia	11136	F111.00	289	Pick's disease	% F111%
Y	Dementia	29512	F112.00	551	Senile degeneration of brain	% F112%
Y	Dementia	7572	F116.00	1481	Lewy body disease	% F116%
Y	Dementia	59122	Fyu3000	4	[X]Other Alzheimer's disease	% Fyu30%
Y	Dementia	55222	ZS7C500	10	Language disorder of dementia	% ZS7C5%
Y	Bipolar	8567	E11..11	5843	Bipolar psychoses	% E1%
Y	Bipolar	37070	E110.00	1120	Manic disorder, single episode	% E1%
Y	Bipolar	18909	E110.11	997	Hypomanic psychoses	% E1%
Y	Bipolar	20110	E110000	1047	Single manic episode, unspecified	% E1%
Y	Bipolar	14728	E110100	3924	Single manic episode, mild	% E1%
Y	Bipolar	24640	E110200	16	Single manic episode, moderate	% E1%
Y	Bipolar	43093	E110300	6	Single manic episode, severe witho	% E1%
Y	Bipolar	50218	E110400	29	Single manic episode, severe, with p	% E1%
Y	Bipolar	36611	E110z00	42	Manic disorder, single episode NOS	% E1%
Y	Bipolar	26227	E111.00	203	Recurrent manic episodes	% E1%
Y	Bipolar	19967	E111000	277	Recurrent manic episodes, unspecifi	% E1%

Y	Bipolar	46425 E111100	18 Recurrent manic episodes, mild	% E1%
Y	Bipolar	27739 E111200	24 Recurrent manic episodes, moderat	% E1%
Y	Bipolar	65811 E111300	13 Recurrent manic episodes, severe w	% E1%
Y	Bipolar	32295 E111400	25 Recurrent manic episodes, severe, v	% E1%
Y	Bipolar	58863 E111500	2 Recurrent manic episodes, partial or	% E1%
Y	Bipolar	46415 E111z00	93 Recurrent manic episode NOS	% E1%
Y	Bipolar	3702 E114.00	452 Bipolar affective disorder, currently	% E1%
Y	Bipolar	17385 E114.11	540 Manic-depressive - now manic	% E1%
Y	Bipolar	35738 E114000	62 Bipolar affective disorder, currently	% E1%
Y	Bipolar	36126 E114100	42 Bipolar affective disorder, currently	% E1%
Y	Bipolar	46434 E114200	35 Bipolar affective disorder, currently	% E1%
Y	Bipolar	16347 E114300	17 Bipolar affect disord, currently mani	% E1%
Y	Bipolar	55829 E114400	33 Bipolar affect disord, currently mani	% E1%
Y	Bipolar	59011 E114500	5 Bipolar affect disord,currentlly manic	% E1%
Y	Bipolar	57605 E114z00	46 Bipolar affective disorder, currently	% E1%
Y	Bipolar	4677 E115.00	470 Bipolar affective disorder, currently	% E1%
Y	Bipolar	12831 E115.11	883 Manic-depressive - now depressed	% E1%
Y	Bipolar	15923 E115000	46 Bipolar affective disorder, currently	% E1%
Y	Bipolar	35734 E115100	58 Bipolar affective disorder, currently	% E1%
Y	Bipolar	27890 E115200	47 Bipolar affective disorder, currently	% E1%
Y	Bipolar	35607 E115300	20 Bipolar affect disord, now depresser	% E1%
Y	Bipolar	63701 E115400	14 Bipolar affect disord, now depresser	% E1%
Y	Bipolar	72026 E115500	6 Bipolar affect disord, now depresser	% E1%
Y	Bipolar	37296 E115z00	73 Bipolar affective disorder, currently	% E1%
Y	Bipolar	31316 E116.00	1331 Mixed bipolar affective disorder	% E1%
Y	Bipolar	31535 E116000	219 Mixed bipolar affective disorder, un:	% E1%
Y	Bipolar	24689 E116100	21 Mixed bipolar affective disorder, mil	% E1%
Y	Bipolar	63150 E116200	20 Mixed bipolar affective disorder, mc	% E1%
Y	Bipolar	63284 E116300	8 Mixed bipolar affective disorder, sev	% E1%
Y	Bipolar	54195 E116400	42 Mixed bipolar affective disorder, sev	% E1%
Y	Bipolar	63651 E116500	7 Mixed bipolar affective disorder, pa	% E1%
Y	Bipolar	63583 E116z00	131 Mixed bipolar affective disorder, NC	% E1%
Y	Bipolar	14784 E117.00	6206 Unspecified bipolar affective disord	% E1%
Y	Bipolar	49763 E117000	66 Unspecified bipolar affective disord	% E1%
Y	Bipolar	63698 E117100	10 Unspecified bipolar affective disord	% E1%
Y	Bipolar	68647 E117200	13 Unspecified bipolar affective disord	% E1%
Y	Bipolar	73423 E117300	1 Unspecified bipolar affective disord	% E1%
Y	Bipolar	68326 E117400	13 Unspecified bipolar affective disord	% E1%
Y	Bipolar	70721 E117500	6 Unspecified bipolar affect disord, pa	% E1%
Y	Bipolar	27986 E117z00	279 Unspecified bipolar affective disord	% E1%
Y	Bipolar	60178 E11y.00	214 Other and unspecified manic-depre	% E1%
Y	Bipolar	11596 E11y000	836 Unspecified manic-depressive psych	% E1%
Y	Bipolar	70925 E11y100	2 Atypical manic disorder	% E1%
Y	Bipolar	70399 E11y300	5 Other mixed manic-depressive psych	% E1%
Y	Bipolar	33426 E11yz00	26 Other and unspecified manic-depre	% E1%
Y	Bipolar	12707 E211300	1264 Cyclothymic personality disorder	% E2113%
Y	Bipolar	12173 Eu30.00	1892 [X]Manic episode	% Eu30%
Y	Bipolar	9521 Eu30.11	723 [X]Bipolar disorder, single manic epi	% Eu30%
Y	Bipolar	2741 Eu30000	13480 [X]Hypomania	% Eu30%
Y	Bipolar	13024 Eu30100	915 [X]Mania without psychotic sympto	% Eu30%
Y	Bipolar	21065 Eu30200	737 [X]Mania with psychotic symptoms	% Eu30%
Y	Bipolar	37102 Eu30211	30 [X]Mania with mood-congruent psyc	% Eu30%
Y	Bipolar	48632 Eu30212	13 [X]Mania with mood-incongruent ps	% Eu30%
Y	Bipolar	32088 Eu30y00	29 [X]Other manic episodes	% Eu30%
Y	Bipolar	44513 Eu30z00	138 [X]Manic episode, unspecified	% Eu30%

Y	Bipolar	4678	Eu30z11	1781	[X]Mania NOS	% Eu30%
Y	Bipolar	6874	Eu31.00	38495	[X]Bipolar affective disorder	% Eu31%
Y	Bipolar	1531	Eu31.11	7757	[X]Manic-depressive illness	% Eu31%
Y	Bipolar	6710	Eu31.12	1292	[X]Manic-depressive psychosis	% Eu31%
Y	Bipolar	66153	Eu31.13	15	[X]Manic-depressive reaction	% Eu31%
Y	Bipolar	16808	Eu31000	887	[X]Bipolar affective disorder, curren	% Eu31%
Y	Bipolar	26299	Eu31100	53	[X]Bipolar affect disorder cur epi ma	% Eu31%
Y	Bipolar	28277	Eu31200	124	[X]Bipolar affect disorder cur epi ma	% Eu31%
Y	Bipolar	16562	Eu31300	373	[X]Bipolar affect disorder cur epi mil	% Eu31%
Y	Bipolar	23713	Eu31400	100	[X]Bipol aff disord, curr epis sev dep	% Eu31%
Y	Bipolar	4732	Eu31500	97	[X]Bipolar affect dis cur epi severe d	% Eu31%
Y	Bipolar	44693	Eu31600	105	[X]Bipolar affective disorder, curren	% Eu31%
Y	Bipolar	104065	Eu31800	10	[X]Bipolar affective disorder type I	% Eu31%
Y	Bipolar	103915	Eu31900	170	[X]Bipolar affective disorder type II	% Eu31%
Y	Bipolar	104051	Eu31911	9	[X]Bipolar II disorder	% Eu31%
Y	Bipolar	53840	Eu31y00	82	[X]Other bipolar affective disorders	% Eu31%
Y	Bipolar	73924	Eu31y11	45	[X]Bipolar II disorder	% Eu31%
Y	Bipolar	51032	Eu31y12	102	[X]Recurrent manic episodes	% Eu31%
Y	Bipolar	33751	Eu31z00	518	[X]Bipolar affective disorder, unspec	% Eu31%
Y	Bipolar	29451	Eu33213	123	[X]Manic-depress psychosis,depress	% Eu33%
Y	Bipolar	28677	Eu33312	119	[X]Manic-depress psychosis,depress	% Eu33%
Y	Bipolar	21540	Eu34000	1350	[X]Cyclothymia	% Eu340%
Y	Bipolar	54848	Eu34012	10	[X]Cycloid personality	% Eu340%
Y	Bipolar	23854	Eu34013	188	[X]Cyclothymic personality	% Eu340%
Y	Anxiety	636	E200.00	1029358	Anxiety states	% E200%
Y	Anxiety	6939	E200000	20762	Anxiety state unspecified	% E200%
Y	Anxiety	4069	E200100	127604	Panic disorder	% E200%
Y	Anxiety	462	E200111	235436	Panic attack	% E200%
Y	Anxiety	4659	E200200	39807	Generalised anxiety disorder	% E200%
Y	Anxiety	655	E200300	682008	Anxiety with depression	% E200%, %
Y	Anxiety	1758	E200400	41414	Chronic anxiety	% E200%
Y	Anxiety	4634	E200500	6814	Recurrent anxiety	% E200%
Y	Anxiety	4534	E200z00	101170	Anxiety state NOS	% E200%
Y	Anxiety	1907	E202.00	8297	Phobic disorders	% E202%
Y	Anxiety	16638	E202.11	3250	Social phobic disorders	% E202%
Y	Anxiety	9944	E202.12	4432	Phobic anxiety	% E202%
Y	Anxiety	2300	E202000	16940	Phobia unspecified	% E202%
Y	Anxiety	3076	E202100	20224	Agoraphobia with panic attacks	% E202%
Y	Anxiety	12838	E202200	6193	Agoraphobia without mention of pa	% E202%
Y	Anxiety	16199	E202300	313	Social phobia, fear of eating in publi	% E202%
Y	Anxiety	31957	E202400	134	Social phobia, fear of public speakin	% E202%
Y	Anxiety	18603	E202500	98	Social phobia, fear of public washing	% E202%
Y	Anxiety	14729	E202z00	4284	Phobic disorder NOS	% E202%
Y	Anxiety	20773	Eu05400	308	[X]Organic anxiety disorder	% Eu0%
Y	Anxiety	9386	Eu40.00	11688	[X]Phobic anxiety disorders	% Eu40%
Y	Anxiety	2571	Eu40000	15675	[X]Agoraphobia	% Eu40%
Y	Anxiety	16729	Eu40011	283	[X]Agoraphobia without history of p	% Eu40%
Y	Anxiety	14890	Eu40012	1078	[X]Panic disorder with agoraphobia	% Eu40%
Y	Anxiety	11602	Eu40100	4318	[X]Social phobias	% Eu40%
Y	Anxiety	42788	Eu40112	51	[X]Social neurosis	% Eu40%
Y	Anxiety	9785	Eu40200	2766	[X]Specific (isolated) phobias	% Eu40%
Y	Anxiety	12635	Eu40214	2073	[X]Simple phobia	% Eu40%
Y	Anxiety	27685	Eu40y00	96	[X]Other phobic anxiety disorders	% Eu40%
Y	Anxiety	34064	Eu40z00	579	[X]Phobic anxiety disorder, unspecif	% Eu40%
Y	Anxiety	7222	Eu40z11	5253	[X]Phobia NOS	% Eu40%

Y	Anxiety	67898	Eu40z12	23	[X]Phobic state NOS	% Eu40%
Y	Anxiety	5385	Eu41.00	8918	[X]Other anxiety disorders	% Eu41%
Y	Anxiety	8205	Eu41000	5614	[X]Panic disorder [episodic paroxysn	% Eu41%
Y	Anxiety	6408	Eu41011	5939	[X]Panic attack	% Eu41%
Y	Anxiety	4081	Eu41012	3572	[X]Panic state	% Eu41%
Y	Anxiety	10344	Eu41100	16476	[X]Generalized anxiety disorder	% Eu41%
Y	Anxiety	962	Eu41111	5338	[X]Anxiety neurosis	% Eu41%
Y	Anxiety	35825	Eu41112	937	[X]Anxiety reaction	% Eu41%
Y	Anxiety	50191	Eu41113	2827	[X]Anxiety state	% Eu41%
Y	Anxiety	44321	Eu41300	125	[X]Other mixed anxiety disorders	% Eu41%
Y	Anxiety	24066	Eu41y00	119	[X]Other specified anxiety disorders	% Eu41%
Y	Anxiety	23838	Eu41z00	5105	[X]Anxiety disorder, unspecified	% Eu41%
Y	Anxiety	25638	Eu41z11	9093	[X]Anxiety NOS	% Eu41%
N		131	1B13.00	400128	Anxiousness	% 1B13%
N		5902	1B13.11	490892	Anxiousness - symptom	% 1B13%
N		93401	1B13.12	10733	Anxious	% 1B13%
N		1996	1B17.00	382758	Depressed	% 1B17%
N		4824	1B17.11	282477	C/O - feeling depressed	% 1B17%
N		2930	1B17.12	15697	C/O - feeling unhappy	% 1B17%
N		9796	1B1U.00	168422	Symptoms of depression	% 1B1U%
N		10438	1B1U.11	21896	Depressive symptoms	% 1B1U%
N		10015	1BT..00	247926	Depressed mood	% 1BT%
N		8928	1BT..11	886126	Low mood	% 1BT%
N		26028	1BT..12	1682	Sad mood	% 1BT%
N		22713	1S42.00	437	Manic mood	% 1S42%
N		1908	2257	103949	O/E - depressed	% 2257%
N		13124	2258	8826	O/E - anxious	% 2258%
N		29339	66H..00	39792	Rheumatol. disorder monitoring	% 66h..%
N		8111	66H..11	14192	Arthritis monitoring	% 66h..%
N		16839	66H..12	15219	Rheumatism monitoring	% 66h..%
N		17412	66H..13	10513	Rheumatoid arthrit. monitoring	% 66h..%
N		32589	9H9..00	4887	Mental health annual physical exam	% 9H9%
N		34360	9h9..00	2220	Exception reporting: mental health c	% 9H9%
N		11774	9h91.00	43178	Except from mental health quality ir	% 9H9%
N		11750	9h92.00	21185	Except from mental health quality ir	% 9H9%
N		18692	9hA..00	5273	Exception reporting: asthma quality	% 9HA%
N		32577	9HA..00	75	Mental health registration status	% 9HA%
N		11673	9hA1.00	54548	Excepted from asthma quality indic	% 9HA%
N		44936	9HA1.00	2421	Removed from depression register	% 9HA%
N		11695	9hA2.00	207505	Excepted from asthma quality indic	% 9HA%
N		35089	9OU..00	2303	Clinic 'C' monitoring admin.	% 9Ou%
N		35099	9OU1.00	16017	Attends clinic C monitoring	% 9Ou%
N		51188	9OU2.00	49	Refuses clinic C monitoring	% 9Ou%
N		51953	9OU3.00	61	Clinic C monitoring default	% 9Ou%
N		42646	9OU4.00	17558	Clinic C monitoring 1st letter	% 9Ou%
N		42650	9OU5.00	5747	Clinic C monitoring 2nd letter	% 9Ou%
N		42651	9OU6.00	2995	Clinic C monitoring 3rd letter	% 9Ou%
N		55465	9OU7.00	32	Clinic C monitor.verbal invite	% 9Ou%
N		60443	9OU8.00	51	Clinic C monitor.phone invite	% 9Ou%
N		59248	9OU9.00	48	Clinic C monitoring deleted	% 9Ou%
N		46313	9OUA.00	1776	Clinic C monitoring check done	% 9Ou%
N		64287	9OUZ.00	4585	Clinic C monitoring admin.NOS	% 9Ou%
N		50921	9OV..00	1099	Clinic 'D' monitoring admin.	% 9Ov%
N		59235	9OV1.00	771	Attends clinic D monitoring	% 9Ov%
N		93954	9OV2.00	202	Refuses clinic D monitoring	% 9Ov%

N	72752 90V3.00	410 Clinic D monitoring default	% 90v%
N	51388 90V4.00	17197 Clinic D monitoring 1st letter	% 90v%
N	51391 90V5.00	3417 Clinic D monitoring 2nd letter	% 90v%
N	51412 90V6.00	1163 Clinic D monitoring 3rd letter	% 90v%
N	69615 90V7.00	608 Clinic D monitor.verbal invite	% 90v%
N	66591 90V8.00	231 Clinic D monitor.phone invite	% 90v%
N	91615 90V9.00	25 Clinic D monitoring deleted	% 90v%
N	67095 90VA.00	999 Clinic D monitoring check done	% 90v%
N	63433 90VZ.00	1405 Clinic D monitoring admin.NOS	% 90v%
N	38286 A411.00	68 Jakob-Creutzfeldt disease	% A411%
N	7233 E0...00	1236 Organic psychotic conditions	% E0%
N	33707 E00..00	3705 Senile and presenile organic psychosi	% E0%
N	16225 E010.00	1125 Alcohol withdrawal delirium	% E0%
N	22277 E010.11	915 DTs - delirium tremens	% E0%
N	1476 E010.12	1589 Delirium tremens	% E0%
N	20762 E011.00	54 Alcohol amnestic syndrome	% E0%
N	18636 E011200	350 Wernicke-Korsakov syndrome	% E0%
N	41920 E011z00	4 Alcohol amnestic syndrome NOS	% E0%
N	37946 E012000	34 Chronic alcoholic brain syndrome	% E0%
N	25110 E013.00	218 Alcohol withdrawal hallucinosis	% E0%
N	57939 E014.00	53 Pathological alcohol intoxication	% E0%
N	20407 E014.11	458 Drunkenness - pathological	% E0%
N	2082 E01y000	31540 Alcohol withdrawal syndrome	% E0%
N	3844 E020.00	23940 Drug withdrawal syndrome	% E0%
N	15876 E022.00	152 Pathological drug intoxication	% E0%
N	6359 E023.00	2482 Nicotine withdrawal	% E0%
N	29783 E02y000	96 Drug-induced delirium	% E0%
N	22103 E02y400	411 Drug-induced personality disorder	% E0%
N	4033 E030.00	13783 Acute confusional state	% E0%
N	22466 E030.11	780 Delirium - acute organic	% E0%
N	3486 E030.12	3462 Toxic confusional state	% E0%
N	25051 E030000	90 Acute confusional state, post traum	% E0%
N	50683 E030100	150 Acute confusional state, of infective	% E0%
N	94079 E030200	4 Acute confusional state, of endocrin	% E0%
N	70409 E030300	10 Acute confusional state, of metaboli	% E0%
N	25114 E030400	204 Acute confusional state, of cerebrov	% E0%
N	41537 E030z00	726 Acute confusional state NOS	% E0%
N	17021 E031.00	1434 Subacute confusional state	% E0%
N	24077 E031.11	90 Delirium - subacute organic	% E0%
N	61238 E031000	10 Subacute confusional state, post tra	% E0%
N	69359 E031100	7 Subacute confusional state, of infec	% E0%
N	38671 E031300	4 Subacute confusional state, of meta	% E0%
N	24035 E031400	87 Subacute confusional state, of ceret	% E0%
N	55784 E031z00	51 Subacute confusional state NOS	% E0%
N	68201 E03y.00	76 Other transient organic psychoses	% E0%
N	24510 E03y200	70 Organic affective syndrome	% E0%
N	27414 E040.00	72 Non-alcoholic amnestic syndrome	% E0%
N	4951 E042.00	2184 Chronic confusional state	% E0%
N	58687 E100500	900 Schizophrenia in remission	% E1%
N	67768 E101500	7 Hebephrenic schizophrenia in remis	% E1%
N	102427 E102500	7 Catatonic schizophrenia in remissio	% E1%
N	36172 E103500	209 Paranoid schizophrenia in remission	% E1%
N	96883 E105500	14 Latent schizophrenia in remission	% E1%
N	56438 E107500	144 Schizo-affective schizophrenia in rer	% E1%
N	70000 E110600	373 Single manic episode in full remissio	% E1%

N	37178	E111600	89	Recurrent manic episodes, in full rer	% E1%
N	57409	E112600	143	Single major depressive episode, in i	% E1%
N	55384	E113600	502	Recurrent major depressive episode	% E1%
N	63784	E114600	27	Bipolar affective disorder, currently	% E1%
N	57465	E115600	50	Bipolar affective disorder, now depr	% E1%
N	55064	E116600	76	Mixed bipolar affective disorder, in i	% E1%
N	24230	E117600	204	Unspecified bipolar affective disorder	% E1%
N	10825	E118.00	3130	Seasonal affective disorder	% E1%
N	3489	E11z100	17557	Rebound mood swings	% E1%
N	7332	E132.00	3951	Reactive confusion	% E1%
N	22098	E140.00	1219	Infantile autism	% E1%
N	43444	E140.11	11	Kanner's syndrome	% E1%
N	1276	E140.12	14184	Autism	% E1%
N	7302	E140.13	240	Childhood autism	% E1%
N	63251	E140000	16	Active infantile autism	% E1%
N	69016	E140100	6	Residual infantile autism	% E1%
N	36662	E140z00	69	Infantile autism NOS	% E1%
N	31599	E141.11	10	Heller's syndrome	% E1%
N	28106	E202600	120	Acrophobia	% E202%
N	28938	E202700	275	Animal phobia	% E202%
N	1723	E202800	8130	Claustrophobia	% E202%
N	31672	E202900	87	Fear of crowds	% E202%
N	4167	E202A00	75547	Fear of flying	% E202%
N	1510	E202B00	4826	Cancer phobia	% E202%
N	2366	E202C00	3940	Dental phobia	% E202%
N	10390	E202D00	554	Fear of death	% E202%
N	6071	E202E00	1220	Fear of pregnancy	% E202%
N	38543	E202z11	192	Weight fixation	% E202%
N	1533	E290.00	4025	Brief depressive reaction	% E290%
N	2775	E290000	60726	Grief reaction	% E290%
N	10734	E290011	21619	Bereavement reaction	% E290%
N	36246	E290z00	108	Brief depressive reaction NOS	% E290%
N	22863	Eu0..00	86	[X]Organic, including symptomatic, i	% Eu0%
N	37072	Eu03.00	43	[X]Organic amnesic synd not induce	% Eu0%
N	25066	Eu04.00	225	[X]Delirium, not induced by alcoholH	% Eu0%
N	39337	Eu04.11	44	[X]Acute / subacute brain syndrome	% Eu0%
N	7389	Eu04.12	5816	[X]Acute / subacute confusional stat	% Eu0%
N	21933	Eu04.14	52	[X]Acute / subacute organic reactor	% Eu0%
N	22065	Eu04.15	34	[X]Acute / subacute psycho-organic	% Eu0%
N	52394	Eu04y00	90	[X]Other delirium	% Eu0%
N	53924	Eu04z00	312	[X]Delirium, unspecified	% Eu0%
N	27969	Eu05.00	128	[X]Oth mental disorder brain damag	% Eu0%
N	24000	Eu05300	1135	[X]Organic mood [affective] disorder	% Eu0%
N	50125	Eu05500	93	[X]Organic dissociative disorder	% Eu0%
N	11994	Eu05600	503	[X]Organic emotionally labile [asthe	% Eu0%
N	11936	Eu05700	5190	[X]Mild cognitive disorder	% Eu0%
N	41950	Eu05y00	18	[X]Oth sp mental disord brain dama	% Eu0%
N	50069	Eu05z00	25	[X]Unspec mental disorder brain dai	% Eu0%
N	47873	Eu05z11	27	[X]Organic brain syndrome NOS	% Eu0%
N	97622	Eu05z12	3	[X]Organic mental disorder NOS	% Eu0%
N	23710	Eu06.00	69	[X]Personality and behav disorder bi	% Eu0%
N	59589	Eu06000	23	[X]Organic personality disorder	% Eu0%
N	93492	Eu06011	3	[X]Organic pseudopsychopathic per:	% Eu0%
N	51665	Eu06012	74	[X]Frontal lobe syndrome	% Eu0%
N	48462	Eu06013	15	[X]Limbic epilepsy personality	% Eu0%

N	50084	Eu06100	6 [X]Postencephalitic syndrome	% Eu0%
N	24579	Eu06200	526 [X]Postconcussional syndrome	% Eu0%
N	64416	Eu06211	4 [X]Postcontusional syndrome	% Eu0%
N	20582	Eu06212	48 [X]Post-traumatic brain syndrome	% Eu0%
N	52872	Eu06y00	4 [X]Oth organ personality behav diso	% Eu0%
N	45419	Eu06y11	14 [X]Right hemispheric organic affecti	% Eu0%
N	63902	Eu06z00	6 [X]Unspec organ personality behav	% Eu0%
N	45945	Eu0z.00	81 [X]Unspecified organic or symptom	% Eu0%
N	30034	Eu1..00	339 [X]Mental and behavioural disorder:	% Eu1%
N	5611	Eu10.00	1476 [X]Mental and behavioural disorder:	% Eu1%
N	44299	Eu10000	361 [X]Mental & behav dis due to use al	% Eu1%
N	9508	Eu10011	1790 [X]Acute alcoholic drunkenness	% Eu1%
N	21879	Eu10100	366 [X]Mental and behav dis due to use	% Eu1%
N	39327	Eu10200	637 [X]Mental and behav dis due to use	% Eu1%
N	28780	Eu10211	1969 [X]Alcohol addiction	% Eu1%
N	5758	Eu10212	1660 [X]Chronic alcoholism	% Eu1%
N	69691	Eu10213	1 [X]Dipsomania	% Eu1%
N	20514	Eu10300	133 [X]Mental and behav dis due to use	% Eu1%
N	64101	Eu10400	60 [X]Men & behav dis due alcohol: with	% Eu1%
N	17259	Eu10411	1153 [X]Delirium tremens, alcohol induce	% Eu1%
N	65932	Eu10512	12 [X]Alcoholic jealousy	% Eu1%
N	39799	Eu10600	77 [X]Mental and behav dis due to use	% Eu1%
N	37691	Eu10712	119 [X]Chronic alcoholic brain syndrome	% Eu1%
N	32927	Eu10800	3087 [X]Alcohol withdrawal-induced seizu	% Eu1%
N	45169	Eu10y00	16 [X]Men & behav dis due to use alcol	% Eu1%
N	64389	Eu10z00	16 [X]Ment & behav dis due use alcoho	% Eu1%
N	47335	Eu11.00	205 [X]Mental and behavioural disorder:	% Eu1%
N	42456	Eu11000	24 [X]Mental & behav dis due to use of	% Eu1%
N	37568	Eu11100	20 [X]Mental and behav dis due to use	% Eu1%
N	34249	Eu11200	716 [X]Mental and behav dis due to use	% Eu1%
N	10538	Eu11211	7591 [X]Drug addiction - opioids	% Eu1%
N	4564	Eu11212	20764 [X]Heroin addiction	% Eu1%
N	36241	Eu11300	79 [X]Mental and behav dis due to use	% Eu1%
N	25527	Eu11311	855 [X]Cold turkey, opiate withdrawal	% Eu1%
N	97488	Eu11400	1 [X]Men & behav dis due opioid: with	% Eu1%
N	103991	Eu11600	1 [X]Mental and behav dis due to use	% Eu1%
N	52739	Eu11y00	4 [X]Men & behav dis due to use opio	% Eu1%
N	91801	Eu11z00	13 [X]Ment & behav dis due use opioid	% Eu1%
N	10655	Eu12.00	555 [X]Mental and behavioural disorder:	% Eu1%
N	37389	Eu12000	19 [X]Mental & behav dis due cannabir	% Eu1%
N	50343	Eu12100	50 [X]Mental and behav dis due to use	% Eu1%
N	56504	Eu12200	101 [X]Mental and behav dis due to can	% Eu1%
N	21662	Eu12211	4153 [X]Drug addiction - cannabis	% Eu1%
N	65681	Eu12300	13 [X]Mental and behav dis due cannat	% Eu1%
N	97561	Eu12600	4 [X]Mental and behav dis due to use	% Eu1%
N	64308	Eu12y00	5 [X]Men/behav dis due to use cannal	% Eu1%
N	64987	Eu12z00	10 [X]Ment/behav dis due use cannabi	% Eu1%
N	41317	Eu13.00	38 [X]Mental and behavioural dis due u	% Eu1%
N	64210	Eu13000	7 [X]Mental & behav dis due seds/hyp	% Eu1%
N	93407	Eu13100	6 [X]Mental and behav dis due to use	% Eu1%
N	44330	Eu13200	77 [X]Mental and behav dis due to sed	% Eu1%
N	25757	Eu13211	1068 [X]Drug addiction- sedative / hypno	% Eu1%
N	61342	Eu13300	19 [X]Mental and behav dis due seds/h	% Eu1%
N	44131	Eu13400	9 [X]Men & beh dis due seds/hypns: v	% Eu1%
N	32052	Eu14.00	162 [X]Mental and behavioural disorder:	% Eu1%

N	49566	Eu14000	17 [X]Mental & behav dis due to use cc %	Eu1%
N	47739	Eu14100	25 [X]Mental and behav dis due to use %	Eu1%
N	50302	Eu14200	53 [X]Mental and behav dis due to use %	Eu1%
N	11746	Eu14211	1250 [X]Drug addiction - cocaine %	Eu1%
N	67535	Eu14300	7 [X]Mental and behav dis due to use %	Eu1%
N	43101	Eu15.00	63 [X]Mental & behav disorder due oth %	Eu1%
N	44742	Eu15000	15 [X]Mnt/beh dis due oth stim inc caff %	Eu1%
N	72712	Eu15100	4 [X]Ment/behav dis due to use oth st %	Eu1%
N	33493	Eu15200	22 [X]Mental and behav dis oth stim in %	Eu1%
N	10045	Eu15211	763 [X]Drug addiction-other stimul %	Eu1%
N	48760	Eu15300	7 [X]Mnt/behav dis other stimInts inc %	Eu1%
N	56650	Eu15z00	2 [X]Ment/beh dis oth stims inc caffei %	Eu1%
N	50265	Eu16.00	15 [X]Mental and behavioural disorder: %	Eu1%
N	66187	Eu16000	9 [X]Mental & behav dis due hallucinc %	Eu1%
N	67491	Eu16100	[X]Mental and behav dis due to use %	Eu1%
N	65826	Eu16200	4 [X]Mental and behav dis due to halli %	Eu1%
N	47784	Eu16211	51 [X]Drug addiction - hallucinogen %	Eu1%
N	56179	Eu16300	3 [X]Mental and behav dis due halluci %	Eu1%
N	35196	Eu16711	11 [X]Post hallucinogen perception disc %	Eu1%
N	92291	Eu16z00	4 [X]Ment/behav dis due use hallucinc %	Eu1%
N	61905	Eu17.00	7 [X]Mental and behavioural disorder %	Eu1%
N	56144	Eu17100	3 [X]Mental and behav dis due to use %	Eu1%
N	107792	Eu17200	4 [X]Mental and behav dis due to use %	Eu1%
N	101519	Eu17300	1 [X]Mental and behav dis due to use %	Eu1%
N	31736	Eu18.00	81 [X]Mental & behav disorders due to %	Eu1%
N	50136	Eu18000	9 [X]Mental & behav dis due vol solve %	Eu1%
N	59009	Eu18100	20 [X]Mental and behav dis due volatilk %	Eu1%
N	52815	Eu18200	8 [X]Mental and behav dis due to vol : %	Eu1%
N	33585	Eu18211	75 [X]Drug addiction - solvent %	Eu1%
N	62106	Eu18400	1 [X]Men & beh dis vol solvents: withc %	Eu1%
N	49068	Eu18z00	1 [X]Ment/behav dis due use vol solve %	Eu1%
N	10656	Eu19.00	272 [X]Men & behav disorder multiple d %	Eu1%
N	60676	Eu19000	24 [X]Mental/behav dis multi drg use/c %	Eu1%
N	62959	Eu19100	25 [X]Mental and behav dis mlti drg/ot %	Eu1%
N	45208	Eu19200	75 [X]Mental and behav dis mlti/oth ps %	Eu1%
N	9615	Eu19211	1679 [X]Drug addiction NOS %	Eu1%
N	51290	Eu19300	8 [X]Mental and behav dis mlti/oth ps %	Eu1%
N	65950	Eu19400	1 [X]Mnt/bh dis mlti drg use/oth psy s %	Eu1%
N	106958	Eu19600	1 [X]Mental/behav dis multi drg use/c %	Eu1%
N	93009	Eu19y00	4 [X]Men/beh dis mlt drg use/oth psy %	Eu1%
N	70961	Eu19z00	7 [X]Ment/beh dis multi drug use/oth %	Eu1%
N	32640	Eu1A.00	65 [X]Mental and behavioural disorder: %	Eu1%
N	60420	Eu1A000	6 [X]Ment behav dis due use crack coc %	Eu1%
N	86034	Eu1A100	3 [X]Mental behav disorders due use c %	Eu1%
N	102582	Eu1A200	4 [X]Mental behav disorders due use c %	Eu1%
N	101738	Eu1A300	2 [X]Mental behav disord due crack cc %	Eu1%
N	91577	Eu1Az00	2 [X]Ment behav dis due crack cocainc %	Eu1%
N	101720	Eu22300	978 [X]Paranoid state in remission %	Eu2%
N	101987	Eu26.00	772 [X]Nonorganic psychosis in remissio %	Eu2%
N	27584	Eu31700	989 [X]Bipolar affective disorder, curren %	Eu31%
N	101054	Eu32900	381 [X]Single major depr ep, severe with %	Eu32%
N	101153	Eu32A00	138 [X]Recurr major depr ep, severe wit %	Eu32%
N	22116	Eu33400	520 [X]Recurrent depressive disorder, ct %	Eu33%
N	26839	Eu34011	107 [X]Affective personality disorder %	Eu340%
N	50998	Eu3y000	75 [X]Other single mood affective disor %	Eu3y0%

N	30688 Eu3y011	176 [X]Mixed affective episode	% Eu3y0%
N	67965 Eu40211	1 [X]Acrophobia	% Eu40%
N	18248 Eu40212	595 [X]Animal phobias	% Eu40%
N	11280 Eu40213	109 [X]Claustrophobia	% Eu40%
N	12508 Eu40300	5397 [X]Needle phobia	% Eu40%
N	28167 Eu41y11	157 [X]Anxiety hysteria	% Eu41%
N	40224 Eu53000	507 [X]Mild mental/behav disorder asso	% Eu530%
N	43690 Eu60400	60 [X]Histrionic personality disorder	% Eu604%
N	27945 Eu60411	172 [X]Hysterical personality disorder	% Eu604%
N	69185 Eu60412	1 [X]Psychoinfantile personality disorc	% Eu604%
N	89580 F1110A		% F111%

Reviewed by PPD for Psychiatric diseases including schizophrenia, bipolar, dementia, depression, anx

review	comments	prodcode	drugsubsta	productnar	formulatio	bnfchapter	bnfcode	matching_terms
Y	also used f	30129	Reserpine	Abicol Tabl	Tablet	Centrally A	2050200	%ABICOL%, %reserpine%
Y	also used f	14477	Quinapril	h Accupro 1C	Tablet	Angiotensii	2050501	%ACCUPRO%, %Quinapril%
Y	also used f	14478	Quinapril	h Accupro 2C	Tablet	Angiotensii	2050501	%ACCUPRO%, %Quinapril%
Y	also used f	15096	Quinapril	h Accupro 4C	Tablet	Angiotensii	2050501	%ACCUPRO%, %Quinapril%
Y	also used f	7314	Quinapril	h Accupro 5n	Tablet	Angiotensii	2050501	%ACCUPRO%, %Quinapril%
Y		15031	Hydrochlor	Accuretic 1	Tablet	Angiotensii	2050501	%ACCURETIC%, %CHLOROTHIAZ%, %Quinapri
Y	also used f	8172	Acebutolol	Acebutolol	Capsule	Beta-adren	2040000	%Acebutolol%
Y		14126	Acebutolol	Acebutolol	Tablet	Unknown	0	%Acebutolol%, %CHLOROTHIAZ%, %thiazide%
Y	also used f	8113	Acebutolol	Acebutolol	Capsule	Beta-adren	2040000	%Acebutolol%
Y	also used f	7620	Acebutolol	Acebutolol	Tablet	Beta-adren	2040000	%Acebutolol%
Y	also used f	45309	Acebutolol	Acebutolol	Tablet	Beta-adren	2040000	%Acebutolol%
Y	also used f	18269	Captopril	Acepril 12.!	Tablet	Angiotensii	2050501	%ACEPRIL%, %Captopril%
Y	also used f	3069	Captopril	Acepril 25n	Tablet	Angiotensii	2050501	%ACEPRIL%, %Captopril%
Y	also used f	18325	Captopril	Acepril 50n	Tablet	Angiotensii	2050501	%ACEPRIL%, %Captopril%
Y		18263	Hydrochlor	Acezide 25	Tablet	Angiotensii	2050501	%ACEZIDE%, %CHLOROTHIAZ%, %Captopril%,
Y	also used f	25054		ADALAT		Unknown	0	%ADALAT%
Y	also used f	2521	Nifedipine	Adalat 10r	Capsule	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	27910		ADALAT 5		Unknown	0	%ADALAT%
Y	also used f	662	Nifedipine	Adalat 5mg	Capsule	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	541	Nifedipine	Adalat LA 2	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	58557	Nifedipine	Adalat LA 2	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	57653	Nifedipine	Adalat LA 2	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	43753	Nifedipine	Adalat LA 3	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	53500	Nifedipine	Adalat LA 3	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	52017	Nifedipine	Adalat LA 3	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	53278	Nifedipine	Adalat LA 3	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	1854	Nifedipine	Adalat la 3f	Tablet	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	43818	Nifedipine	Adalat LA 6	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	56469	Nifedipine	Adalat LA 6	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	51917	Nifedipine	Adalat LA 6	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	57531	Nifedipine	Adalat LA 6	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	4227	Nifedipine	Adalat la 6f	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	25027		ADALAT RETARD 10		Unknown	0	%ADALAT%
Y	also used f	2280	Nifedipine	Adalat reta	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	2343	Nifedipine	Adalat reta	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	53629	Nifedipine	Adalat reta	Modified-r	Calcium-ch	2060200	%ADALAT%, %nifedipine%
Y	also used f	45685	Nifedipine	Adanif XL 3	Modified-r	Calcium-ch	2060200	%ADANIF%, %nifedipine%
Y	also used f	46887	Nifedipine	Adanif XL 6	Modified-r	Calcium-ch	2060200	%ADANIF%, %nifedipine%
Y	also used f	41979	Nifedipine	Adipine la :	Modified-r	Calcium-ch	2060200	%ADIPINE%, %nifedipine%
Y	also used f	47217	Nifedipine	Adipine la f	Modified-r	Calcium-ch	2060200	%ADIPINE%, %nifedipine%
Y	also used f	4239	Nifedipine	Adipine MF	Modified-r	Calcium-ch	2060200	%ADIPINE%, %nifedipine%
Y	also used f	3711	Nifedipine	Adipine MF	Modified-r	Calcium-ch	2060200	%ADIPINE%, %nifedipine%
Y	also used f	13139	Nifedipine	Adipine XL	Modified-r	Calcium-ch	2060200	%ADIPINE%, %nifedipine%
Y	also used f	10246	Nifedipine	Adipine XL	Modified-r	Calcium-ch	2060200	%ADIPINE%, %nifedipine%
Y	also used f	9374	Diltiazem	h Adizem 60f	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	19015		ADIZEM CONTINUS 12		Unknown	0	%ADIZEM%
Y	also used f	517	Diltiazem	f Adizem sr :	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	4852	Diltiazem	h Adizem sr :	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	2811	Diltiazem	f Adizem sr :	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	3118	Diltiazem	h Adizem sr f	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	8558	Diltiazem	f Adizem xl 1	Capsule	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	9240	Diltiazem	f Adizem xl 1	Capsule	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	793	Diltiazem	h Adizem xl 2	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	6309	Diltiazem	h Adizem xl 3	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y		23505	Diltiazem	f Adizem xl f	Modified-r	Thiazides A	02020100/	%ADIZEM%, %Adizem xl plus%, %diltiazem%
Y	also used f	38818	Diltiazem	h Adizem-SR	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	38964	Diltiazem	h Adizem-SR	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	38831	Diltiazem	h Adizem-SR	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	48870	Diltiazem	h Adizem-SR	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	38632	Diltiazem	h Adizem-SR	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	38865	Diltiazem	h Adizem-XL	Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	9211		ADIZEM-XL 180 MG C		Unknown	0	%ADIZEM%

Y	also used f	52276	Diltiazem h Adizem-XL Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	38855	Diltiazem h Adizem-XL Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	10267	Diltiazem h Adizem-XL Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	38882	Diltiazem h Adizem-XL Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	60620	Diltiazem h Adizem-XL Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	38634	Diltiazem h Adizem-XL Modified-r	Calcium-ch	2060200	%ADIZEM%, %diltiazem%
Y	also used f	2001	Spironolact Aldactide 2 Tablet	Potassium-	2020400	%spironolactone%, %thiazide%
Y	also used f	1297	Spironolact Aldactide 5 Tablet	Potassium-	2020400	%spironolactone%, %thiazide%
Y	also used f	7952	Spironolact Aldactone Tablet	Potassium-	2020300	%ALDACTONE%, %spironolactone%
Y	also used f	2389	Spironolact Aldactone Tablet	Potassium-	2020300	%ALDACTONE%, %spironolactone%
Y	also used f	4960	Spironolact Aldactone Tablet	Potassium-	2020300	%ALDACTONE%, %spironolactone%
Y		8033	Methyldop Aldomet 1 Tablet	Centrally A	2050200	%ALDOMET%, %methyldopa%
Y		7626	Methyldop Aldomet 2 Tablet	Centrally A	2050200	%ALDOMET%, %methyldopa%
Y		43988	Methyldop Aldomet 2 Tablet	Centrally A	2050200	%ALDOMET%, %methyldopa%
Y		14390	Methyldop Aldomet 2 Oral suspei	Centrally A	2050200	%ALDOMET%, %methyldopa%
Y		7642	Methyldop Aldomet 5 Tablet	Centrally A	2050200	%ALDOMET%, %methyldopa%
Y		43989	Methyldop Aldomet 5 Tablet	Centrally A	2050200	%ALDOMET%, %methyldopa%
Y		7416	Methyldop Aldomet 5 Injection	Centrally A	2050200	%ALDOMET%, %methyldopa%
Y	also used f	26238	Prazosin h y Alphavase Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	13610	Prazosin h y Alphavase Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	19823	Prazosin h y Alphavase Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	26237	Prazosin h y Alphavase Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	5117	Candesarta Amias 16m Tablet	Angiotensii	2050502	%Amias%, %Candesartan%
Y	also used f	4155	Candesarta Amias 2mg Tablet	Angiotensii	2050502	%Amias%, %Candesartan%
Y	also used f	31072	Candesarta Amias 32m Tablet	Angiotensii	2050502	%Amias%, %Candesartan%
Y	also used f	4685	Candesarta Amias 4mg Tablet	Angiotensii	2050502	%Amias%, %Candesartan%
Y	also used f	5013	Candesarta Amias 8mg Tablet	Angiotensii	2050502	%Amias%, %Candesartan%
Y	also used f	31375	Amiloride f Amilamont Oral solutic	Potassium-	2020300	%AMILAMONT%, %amiloride%
Y	also used f	20066	Amiloride f Amil-Co 5n Tablet	Potassium-	2020400	%AMIL-CO%, %CHLOROTHIAZ%, %amiloride%
Y	also used f	18361	Amiloride f Amilmaxco Tablet	Potassium-	2020400	%AMILMAXCO%, %CHLOROTHIAZ%, %amilori
Y	also used f	2681	AMILORIDE 10 MG TA	Unknown	0	%amiloride%
Y	also used f	18497	Furosemid Amiloride 1 Tablets	Loop Diure	02020200/	%amiloride%, %furosemide%
Y	also used f	5727	Amiloride f Amiloride 2 Tablet	Potassium-	2020400	%amiloride%, %thiazide%
Y	also used f	15874	Furosemid Amiloride 2 Tablets	Loop Diure	02020200/	%amiloride%, %furosemide%
Y	also used f	3701	Amiloride f Amiloride 2 Tablets	Thiazides A	02020100/	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	44254	Amiloride f Amiloride 5 Tablets	Potassium-	2020300	%amiloride%
Y	also used f	14587	Bumetanid Amiloride 5 Tablet	Potassium-	2020400	%amiloride%, %bumetanide%
Y	also used f	9456	Furosemid Amiloride 5 Tablets	Loop Diure	02020200/	%amiloride%, %furosemide%
Y	also used f	2002	Amiloride f Amiloride 5 Tablets	Thiazides A	02020100/	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	4034	Amiloride f Amiloride 5 Solution	Thiazides A	02020100/	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	41630	Amiloride f Amiloride 5 Tablet	Potassium-	2020300	%amiloride%
Y	also used f	1060	Amiloride f Amiloride 5 Tablet	Potassium-	2020300	%amiloride%
Y	also used f	33837	Amiloride f Amiloride 5 Tablet	Potassium-	2020300	%amiloride%
Y	also used f	34750	Amiloride f Amiloride 5 Tablet	Potassium-	2020300	%amiloride%
Y	also used f	43523	Amiloride f Amiloride 5 Tablet	Potassium-	2020300	%amiloride%
Y	also used f	34324	Amiloride f Amiloride 5 Tablet	Potassium-	2020300	%amiloride%
Y	also used f	46930	Amiloride f Amiloride 5 Tablet	Potassium-	2020300	%amiloride%
Y	also used f	9935	Amiloride f Amiloride 5 Oral solutic	Potassium-	2020300	%amiloride%
Y	also used f	60149	Amiloride f Amiloride 5 Oral suspei	Potassium-	2020300	%amiloride%
Y	also used f	19611	AMILORIDE 5MG/HYD	Unknown	0	%amiloride%, %thiazide%
Y	also used f	19721	AMILORIDE 5MG/HYD	Unknown	0	%amiloride%, %thiazide%
Y	also used f	19695	AMILORIDE HYDROCHI	Unknown	0	%amiloride%
Y	also used f	3285	AMILORIDE S/F 5 MG/	Unknown	0	%amiloride%
Y		3526	Atenolol Amiloride v Capsules	Thiazides A	02020100/	%Atenolol%, %CHLOROTHIAZ%, %amiloride%,
Y		30519	Timolol Mæ Amiloride v Tablets	Thiazides A	02020100/	%CHLOROTHIAZ%, %Timolol% & %tab%, %am
Y	also used f	21848	AMILOSPARE 5 MG TA	Unknown	0	%AMILOSPARE%
Y	also used f	24893	Amiloride f Amilospare Tablet	Potassium-	2020300	%AMILOSPARE%, %amiloride%
Y		35189	Valsartan/ε Amlodipine Tablets	Calcium-ch	2060200	%Valsartan%, %amlodipine%
Y	also used f	6856	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	34093	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	56147	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	36202	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	54515	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%

Y	also used f	54654	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	58580	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	56334	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	49636	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	59001	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	60244	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	54696	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	59762	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	42210	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	52440	Amlodipine 10mg/5ml	Calcium-ch	2060200	%amlodipine%
Y	also used f	45070	Amlodipine Amlodipine Oral suspei	Calcium-ch	2060200	%amlodipine%
Y	also used f	47002	Amlodipine Amlodipine Oral Suspei	Calcium-ch	2060200	%amlodipine%
Y	also used f	54983	Amlodipine Amlodipine Oral suspei	Calcium-ch	2060200	%amlodipine%
Y		35343	Valsartan/; Amlodipine Tablets	Calcium-ch	2060200	%Valsartan%, %amlodipine%
Y		35329	Valsartan/; Amlodipine Tablets	Calcium-ch	2060200	%Valsartan%, %amlodipine%
Y	also used f	749	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	32595	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	53868	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	43880	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	54633	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	39804	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	32917	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	45279	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	39914	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	43470	Amlodipine Amlodipine Tablet	Calcium-ch	2060200	%amlodipine%
Y	also used f	46724	Amlodipine Amlodipine Oral solutic	Calcium-ch	2060200	%amlodipine%
Y	also used f	16162	Amlodipine Amlodipine Oral suspei	Calcium-ch	2060200	%amlodipine%
Y	also used f	71	Amlodipine Amlodipine Tablets	Calcium-ch	2060200	%amlodipine%
Y	also used f	29	Amlodipine Amlodipine Tablets	Calcium-ch	2060200	%amlodipine%
Y	also used f	6477	Amlodipine Amlodipine Tablets	Calcium-ch	2060200	%amlodipine%
Y	also used f	729	Amlodipine Amlodipine Tablets	Calcium-ch	2060200	%amlodipine%
Y	also used f	46233	Amlodipine Amlodipine Oral Solutic	Calcium-ch	2060200	%amlodipine%
Y	also used f	31761	Amlodipine Amlostin 1 Tablet	Calcium-ch	2060200	%AMLOSTIN%, %amlodipine%
Y	also used f	17640	Amlodipine Amlostin 5 Tablet	Calcium-ch	2060200	%AMLOSTIN%, %amlodipine%
Y	also used f	28048	Propranolol Angilol 10n Tablet	Supraventr 02030202/	%ANGILOL%, %Propranolol%	
Y	also used f	31833	Propranolol Angilol 80n Tablet	Supraventr 02030202/	%ANGILOL%, %Propranolol%	
Y	also used f	20878	Nifedipine Angiopine Capsule	Calcium-ch	2060200	%ANGIOPINE%, %nifedipine%
Y	also used f	21872	Nifedipine Angiopine Capsule	Calcium-ch	2060200	%ANGIOPINE%, %nifedipine%
Y	also used f	13699	Nifedipine Angiopine Modified-r	Calcium-ch	2060200	%ANGIOPINE%, %nifedipine%
Y	also used f	13672	Nifedipine Angiopine Modified-r	Calcium-ch	2060200	%ANGIOPINE%, %nifedipine%
Y	also used f	5181	Nifedipine Angiopine Modified-r	Calcium-ch	2060200	%ANGIOPINE%, %nifedipine%
Y	also used f	13410	Diltiazem h Angiozem Modified-r	Calcium-ch	2060200	%ANGIOZEM%, %diltiazem%
Y	also used f	16850	Diltiazem h Angiozem Modified-r	Calcium-ch	2060200	%ANGIOZEM%, %diltiazem%
Y	also used f	12705	Diltiazem h Angiozem Modified-r	Calcium-ch	2060200	%ANGIOZEM%, %diltiazem%
Y	also used f	9410	Diltiazem h Angitil SR 1 Modified-r	Calcium-ch	2060200	%ANGITIL%, %diltiazem%
Y	also used f	5054	Diltiazem h Angitil SR 1 Modified-r	Calcium-ch	2060200	%ANGITIL%, %diltiazem%
Y	also used f	11223	Diltiazem h Angitil SR 9 Modified-r	Calcium-ch	2060200	%ANGITIL%, %diltiazem%
Y	also used f	13033	Diltiazem h Angitil XL 2 Modified-r	Calcium-ch	2060200	%ANGITIL%, %diltiazem%
Y	also used f	15288	Diltiazem h Angitil XL 3 Modified-r	Calcium-ch	2060200	%ANGITIL%, %diltiazem%
Y	also used f	24195	Atenolol Antipressa Tablet	Beta-adren	2040000	%ANTIPRESSAN%, %Atenolol%
Y	also used f	26211	Atenolol Antipressa Tablet	Beta-adren	2040000	%ANTIPRESSAN%, %Atenolol%
Y	also used f	24191	Atenolol Antipressa Tablet	Beta-adren	2040000	%ANTIPRESSAN%, %Atenolol%
Y		13317	Hydralazine Apresoline Powder for Vasodilato		2050100	%APRESOLINE%, %hydralazine%
Y	also used f	2362	Hydralazine Apresoline Tablet	Vasodilato	2050100	%APRESOLINE%, %hydralazine%
Y	also used f	2680	Hydralazine Apresoline Tablet	Vasodilato	2050100	%APRESOLINE%, %hydralazine%
Y	also used f	8526	Bendroflun Aprinox 2.5 Tablet	Thiazides A	2020100	%APRINOX%, %thiazide%
Y	also used f	7698	Bendroflun Aprinox 5n Tablet	Thiazides A	2020100	%APRINOX%, %thiazide%
Y		9196	Irbesartan Aprovel 15 Tablet	Angiotensii	2050502	%Aprovel%, %Irbesartan%
Y		11348	Irbesartan Aprovel 30 Tablet	Angiotensii	2050502	%Aprovel%, %Irbesartan%
Y		7338	Irbesartan Aprovel 75 Tablet	Angiotensii	2050502	%Aprovel%, %Irbesartan%
Y	also used f	33836	Propranolol Apsolol 16 Tablet	Supraventr 02030202/	%APSOLOL%, %Propranolol%	
Y	also used f	27964	Propranolol Apsolol 40 Tablet	Supraventr 02030202/	%APSOLOL%, %Propranolol%	
Y		25644	Oxprenolol Apsolox 80 Tablet	Beta-adren	2040000	%Apsolox%, %Oxprenolol%

Y	also used f	7709	Piretanide	Arelix 6mg Capsule	Loop Diure	2020200	%Arelix%, %Piretanide%
Y	also used f	18332	Amiloride	Aridil 20mg Tablet	Loop Diure	02020200/	%ARIDIL%, %amiloride%, %furosemide%
Y	also used f	29398	Atenolol	Atenamin 1 Tablet	Beta-adren	2040000	%ATENAMIN%, %Atenolol%
Y	also used f	20728	Atenolol	Atenamin 2 Tablet	Beta-adren	2040000	%ATENAMIN%, %Atenolol%
Y	also used f	21133	Atenolol	Atenamin 5 Tablet	Beta-adren	2040000	%ATENAMIN%, %Atenolol%
Y	also used f	20502	Atenolol	Atenix 100 Tablet	Beta-adren	2040000	%ATENIX%, %Atenolol%
Y	also used f	17322	Atenolol	Atenix 25 t Tablet	Beta-adren	2040000	%ATENIX%, %Atenolol%
Y	also used f	10191	Atenolol	Atenix 50 t Tablet	Beta-adren	2040000	%ATENIX%, %Atenolol%
Y		13526	Atenolol/C	Atenix Co 1 Tablet	Thiazides A	02020100/	%ATENIX%, %Atenolol%, %chlortalidone%
Y		21873	Atenolol/C	Atenix Co 5 Tablet	Thiazides A	02020100/	%ATENIX%, %Atenolol%, %chlortalidone%
Y	also used f	24677		ATENOLOL	Unknown	0	%Atenolol%
Y	also used f	25037		ATENOLOL	Unknown	0	%Atenolol%
Y	also used f	24	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	33085	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	46931	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	33079	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	31934	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	46908	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34754	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	19191	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	33184	Atenolol	Atenolol 1C Tablet	Beta-adren	2040000	%Atenolol%
Y		1788	Chlortalido	Atenolol 1C Tablets	Thiazides A	02020100/	%Atenolol%, %chlortalidone%
Y		9178	Atenolol/B	Atenolol 25 Capsule	Unknown	0	%Atenolol%, %thiazide%
Y	also used f	26	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	33657	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	59982	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	44858	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	50702	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	47870	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	53826	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	49953	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	51998	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	52310	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34492	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	19172	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	31536	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34585	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	53802	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	29368	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34976	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34575	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	54542	Atenolol	Atenolol 25 Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	6066	Atenolol	Atenolol 25 Oral solutio	Beta-adren	2040000	%Atenolol%
Y	also used f	56445	Atenolol	Atenolol 25 Oral solutio	Beta-adren	2040000	%Atenolol%
Y	also used f	51643	Atenolol	Atenolol 25 Oral solutio	Beta-adren	2040000	%Atenolol%
Y		4542	Atenolol/N	Atenolol 5C Modified-r	Beta-adren	2040000	%Atenolol%, %nifedipine%
Y	also used f	34882	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	5	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	33092	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	53414	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	33850	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	53204	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	52500	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	59695	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	53215	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	54752	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	33650	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	19182	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34695	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	55778	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34265	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	34365	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	36261	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%

Y	also used f	34443	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y	also used f	57817	Atenolol	Atenolol 5C Tablet	Beta-adren	2040000	%Atenolol%
Y		581	Chlortalido	Atenolol 5C Tablets	Thiazides A	02020100/	%Atenolol%, %chlortalidone%
Y		4983	Atenolol	Atenolol w Capsules	Thiazides A	02020100/	%Atenolol%, %CHLOROTHIAZ%, %amiloride%,
Y		8765	ATENOLOL/CHLORTHA	Unknown		0	%Atenolol%, %CHLORTHALIDONE%
Y		56606	Azilsartan r	Azilsartan r Tablet	Angiotensii	2050502	%Azilsartan%
Y		51368	Azilsartan r	Azilsartan r Tablet	Angiotensii	2050502	%Azilsartan%
Y	also used f	11394	Indoramin	Baratol 25r Tablet	Alpha-adre	02050400/	%indoramin%
Y	also used f	40256	Indoramin	Baratol 25r Tablet	Alpha-adre	02050400/	%indoramin%
Y	also used f	16198	Indoramin	Baratol 50r Tablet	Alpha-adre	02050400/	%indoramin%
Y	also used f	15457	Mefruside	Baycaron 2 Tablet	Thiazides A	2020100	%Baycaron%, %Mefruside%
Y	also used f	52136	Propranolol	Bedranol s Modified-r	Beta-adren	02040000/	%BEDRANOL%, %Propranolol%
Y	also used f	47907	Propranolol	Bedranol S Modified-r	Beta-adren	02040000/	%BEDRANOL%, %Propranolol%
Y	also used f	28996	Propranolol	Bedranol S Modified-r	Beta-adren	02040000/	%BEDRANOL%, %Propranolol%
Y	also used f	19810		BEDRANOL SR 80 MG (Unknown		0	%BEDRANOL%
Y	also used f	47833	Propranolol	Bedranol S Modified-r	Unknown	0	%BEDRANOL%, %Propranolol%
Y	also used f	57063	Propranolol	Bedranol S Modified-r	Beta-adren	02040000/	%BEDRANOL%, %Propranolol%
Y	also used f	14808	Propranolol	Bedranol S Modified-r	Beta-adren	02040000/	%BEDRANOL%, %Propranolol%
Y		29443	Betanidine	Bendogen : Tablet	Adrenergic	2050300	%BENDOGEN%, %betanidine%
Y		40421	Betanidine	Bendogen ! Tablet	Adrenergic	2050300	%BENDOGEN%, %betanidine%
Y	also used f	17561	Potassium	Bendroflun Modified-r	Unknown	0	%thiazide%
Y	also used f	1211	Bendroflun	Bendroflun Modified-r	Thiazides A	2020100	%thiazide%
Y	also used f	34803	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	2	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	33651	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	34059	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	40886	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	33415	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	27689	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	47844	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	34602	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	31670	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y	also used f	27256	Bendroflun	Bendroflun Tablet	Thiazides A	02020100/	%thiazide%
Y		22912	Propranolol	Bendroflun Capsules	Thiazides A	02020100/	%Propranolol%, %thiazide%
Y		19142	Timolol Mz	Bendroflun Tablets	Thiazides A	02020100/	%Timolol% & %tab%, %thiazide%
Y	also used f	7351	Bendroflun	Bendroflun Oral suspei	Thiazides A	02020100/	%thiazide%
Y	also used f	58	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	23427	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	34124	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	40149	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	41517	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	31820	Bendroflun	Bendroflun Tablet	Thiazides A	2020100	%thiazide%
Y		11338	Nadolol	Bendroflun Tablets	Thiazides A	02020100/	%Nadolol%, %thiazide%
Y		23131	Propranolol	Bendroflun Modified R	Thiazides A	02020100/	%Propranolol%, %thiazide%
Y	also used f	53812	Bendroflun	Bendroflumethiazide c	Thiazides A	2020100	%thiazide%
Y	also used f	30272	Benzthiazic	Benthiazidc Capsules	Thiazides A	02020100/	%thiazide%, %triamterene%
Y	also used f	26217	Amiloride l	Berkamil 5i Tablet	Potassium-	2020300	%BERKAMIL%, %amiloride%
Y	also used f	28844	Verapamil	Berkatens : Tablet	Supraventr	02030202/	%BERKATENS%, %verapamil%
Y	also used f	26252	Verapamil	Berkatens : Tablet	Supraventr	02030202/	%BERKATENS%, %verapamil%
Y	also used f	23872	Verapamil	Berkatens : Tablet	Supraventr	02030202/	%BERKATENS%, %verapamil%
Y	also used f	25059	Verapamil	Berkatens i Tablet	Supraventr	02030202/	%BERKATENS%, %verapamil%
Y	also used f	12495	Propranolol	Berkolol 1C Tablet	Supraventr	02030202/	%BERKOLOL%, %Propranolol%
Y	also used f	24218	Propranolol	Berkolol 1C Tablet	Supraventr	02030202/	%BERKOLOL%, %Propranolol%
Y	also used f	21866	Propranolol	Berkolol 4C Tablet	Supraventr	02030202/	%BERKOLOL%, %Propranolol%
Y	also used f	21839	Propranolol	Berkolol 8C Tablet	Supraventr	02030202/	%BERKOLOL%, %Propranolol%
Y	also used f	21803	Bendroflun	Berkozide i Tablet	Thiazides A	2020100	%BERKOZIDE%, %thiazide%
Y	also used f	21867	Bendroflun	Berkozide ! Tablet	Thiazides A	2020100	%BERKOZIDE%, %thiazide%
Y		1684	Atenolol/N	Beta-Adala Modified-r	Beta-adren	2040000	%ADALAT%, %Atenolol%, %BETA-ADALAT%, %
Y		52728	Atenolol/N	Beta-Adala Modified-r	Beta-adren	2040000	%ADALAT%, %Atenolol%, %BETA-ADALAT%, %
Y	also used f	23326	Propranolol	Betadur cr Modified-r	Beta-adren	02040000/	%BETADUR%, %Propranolol%
Y	also used f	3344	Metoprolo	Betaloc 10i Tablet	Beta-adren	02040000/	%BETALOC%, %Metoprolo%
Y	also used f	8071	Metoprolo	Betaloc 50i Tablet	Beta-adren	02040000/	%BETALOC%, %Metoprolo%
Y	also used f	20813		BETALOC S.A.	Unknown	0	%BETALOC%

Y	also used f	24378	BETALOC S.A. (CALENC	Unknown	0	%BETALOC%
Y	also used f	3474	Metoprolo	Betaloc-SA Modified-r	Beta-adren 02040000/	%BETALOC%, %Metoprolol%
Y	also used f	54623	Propranolol	Beta-Progr Modified-r	Beta-adren 02040000/	%BETA-PROGRAME%, %Propranolol%
Y	also used f	45877	Propranolol	Beta-Progr Modified-r	Beta-adren 02040000/	%BETA-PROGRAME%, %Propranolol%
Y	also used f	26229	Propranolol	Beta-Progr Modified-r	Beta-adren 02040000/	%BETA-PROGRAME%, %Propranolol%
Y		10879	Betanidine	Bethanidin Tablets	Adrenergic 2050300	%betanidine%
Y		28676	Betanidine	Bethanidin Tablets	Adrenergic 2050300	%betanidine%
Y	also used f	12037	Timolol	ma Betim 10m Tablet	Beta-adren 02040000/	%BETIM%
Y	also used f	29610	Timolol	ma Betim 10m Tablet	Beta-adren 02040000/	%BETIM%
Y	also used f	30913	Bumetanid	Bumetanid 1m Tablet	Loop Diure 2020200	%BETINEX%, %bumetanide%
Y	also used f	41489	Diltiazem	h Bi-Carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	28949	Diltiazem	h Bi-carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	39171	Diltiazem	h Bi-Carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	20642	Diltiazem	h Bi-carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	39298	Diltiazem	h Bi-Carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	23233	Diltiazem	h Bi-carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	31489	Diltiazem	h Bi-carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	47724	Diltiazem	h Bi-Carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	44887	Diltiazem	h Bi-carzem : Modified-r	Calcium-ch 2060200	%BI-CARZEM%, %diltiazem%
Y	also used f	21905	Bisoprolol	h Bipranix 10 Tablet	Beta-adren 02040000/	%BIPRANIX%, %Bisoprolol%
Y	also used f	21966	Bisoprolol	h Bipranix 5n Tablet	Beta-adren 02040000/	%BIPRANIX%, %Bisoprolol%
Y		17462	Bisoprolol	h Bisoprolol Tablet	Unknown 0	%Bisoprolol%, %CHLOROTHIAZ%, %thiazide%
Y	also used f	1290	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	53334	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	57176	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	33839	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	34821	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	58982	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	58973	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	19178	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	55298	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	41591	Bisoprolol	h Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	52611	Bisoprolol	10mg/5ml c	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	43564	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 2040000	%Bisoprolol%
Y	also used f	472	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	59037	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	55929	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	34963	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	52635	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	59969	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	32114	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	19200	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	57934	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	24083	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	7553	Bisoprolol	h Bisoprolol ! Oral suspei	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	5713	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	38991	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	58455	Bisoprolol	h Bisoprolol ! Tablet	Beta-adren 02040000/	%Bisoprolol%
Y	also used f	7852	Timolol	ma Blocadren : Tablet	Beta-adren 02040000/	%BLOCADREN%
Y	also used f	25630	BRINALDIX	K EFFERVE Unknown	0	%Brinaldix%
Y	also used f	18983	Potassium	Brinaldix k Effervesce	Diuretics W 2020800	%Brinaldix%
Y	also used f	22619	Diltiazem	h Britiazim 6l Modified-r	Calcium-ch 2060200	%BRITIAZIM%, %diltiazem%
Y	also used f	814	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	32091	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	39602	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	55548	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	31932	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	34934	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	36767	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	45305	Bumetanid	Bumetanid Tablet	Loop Diure 2020200	%bumetanide%
Y	also used f	5218	Bumetanid	Bumetanid Oral solutic	Loop Diure 2020200	%bumetanide%
Y	also used f	19300	Bumetanid	Bumetanid Solution fo	Loop Diure 2020200	%bumetanide%
Y	also used f	6160	Bumetanid	Bumetanid Modified-r	Unknown 0	%bumetanide%

Y	also used f	7806	Bumetanid Bumetanid Tablet	Loop Diure	2020200	%bumetanide%
Y	also used f	34613	Bumetanid Bumetanid Tablet	Loop Diure	2020200	%bumetanide%
Y	also used f	2495	Bumetanid Bumetanid Tablets	Loop Diure	02020200/	%amiloride%, %bumetanide%
Y	also used f	27555	BURINEX	Unknown	0	%BURINEX%
Y	also used f	15341	Bumetanid Burinex 0.5 Solution fo	Loop Diure	2020200	%BURINEX%, %bumetanide%
Y	also used f	2788	Bumetanid Burinex 1r Tablet	Loop Diure	2020200	%BURINEX%, %bumetanide%
Y	also used f	12226	Bumetanid Burinex 1r Oral solutio	Loop Diure	2020200	%BURINEX%, %bumetanide%
Y	also used f	12294	Bumetanid Burinex 5r Tablet	Loop Diure	2020200	%BURINEX%, %bumetanide%
Y	also used f	2493	Bumetanid Burinex A 5 Tablet	Potassium-	2020400	%BURINEX%, %amiloride%, %bumetanide%
Y	also used f	19683	BURINEX K	Unknown	0	%BURINEX%
Y	also used f	1776	Bumetanid Burinex K n Modified-r	Unknown	0	%BURINEX%, %bumetanide%
Y	also used f	26337	Felodipine Cabren 10r Modified-r	Calcium-ch	2060200	%Cabren%, %felodipine%
Y	also used f	30915	Felodipine Cabren 2.5 Modified-r	Calcium-ch	2060200	%Cabren%, %felodipine%
Y	also used f	30991	Felodipine Cabren 5m Modified-r	Calcium-ch	2060200	%Cabren%, %felodipine%
Y	also used f	22019	Nifedipine Calanif 10n Capsule	Calcium-ch	2060200	%CALANIF%, %nifedipine%
Y	also used f	26265	Nifedipine Calanif 5m Capsule	Calcium-ch	2060200	%CALANIF%, %nifedipine%
Y	also used f	29676	Diltiazem h Calazem 6C Modified-r	Calcium-ch	2060200	%CALAZEM%, %diltiazem%
Y	also used f	14861	Nifedipine Calchan MI Modified-r	Calcium-ch	2060200	%CALCHAN%, %nifedipine%
Y	also used f	11769	Nifedipine Calchan MI Modified-r	Calcium-ch	2060200	%CALCHAN%, %nifedipine%
Y	also used f	18975	Diltiazem h Calcicard 6 Modified-r	Calcium-ch	2060200	%CALCICARD%, %diltiazem%
Y	also used f	11973	Diltiazem h Calcicard C Modified-r	Calcium-ch	2060200	%CALCICARD%, %diltiazem%
Y	also used f	9723	Diltiazem h Calcicard C Modified-r	Calcium-ch	2060200	%CALCICARD%, %diltiazem%
Y	also used f	22142	Nifedipine Calcilat 10r Capsule	Calcium-ch	2060200	%CALCILAT%, %nifedipine%
Y	also used f	4741	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	52208	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	57977	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	54414	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	53680	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	529	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	57266	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	59802	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	7043	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	54326	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	531	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	58646	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	51647	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	53755	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	4818	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	51519	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	57273	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	59690	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	51117	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	50185	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	57026	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	52559	Candesarta Candesarta Tablet	Angiotensii	2050502	%Candesartan%
Y	also used f	3310	Captopril Capoten 12 Tablet	Angiotensii	2050501	%CAPOTEN%, %Captopril%
Y	also used f	56509	Captopril Capoten 12 Tablet	Angiotensii	2050501	%CAPOTEN%, %Captopril%
Y	also used f	1144	Captopril Capoten 25 Tablet	Angiotensii	2050501	%CAPOTEN%, %Captopril%
Y	also used f	3839	Captopril Capoten 5C Tablet	Angiotensii	2050501	%CAPOTEN%, %Captopril%
Y		25051	CAPOZIDE	Unknown	0	%CAPOZIDE%
Y		1520	Hydrochlor Capozide 2 Tablet	Angiotensii	2050501	%CAPOZIDE%, %CHLOROTHIAZ%, %Captopril%
Y		39227	Hydrochlor Capozide L Tablet	Angiotensii	2050501	%CAPOZIDE%, %CHLOROTHIAZ%, %Captopril%
Y		3203	Hydrochlor Capozide L Tablet	Thiazides A	02020100/	%CAPOZIDE%, %CHLOROTHIAZ%, %Captopril%
Y		32166	Hydrochlor Capto-co 2 Tablet	Thiazides A	02020100/	%CAPTO-CO%, %CHLOROTHIAZ%, %Captopril%
Y	also used f	25998	Captopril Captomex Tablet	Angiotensii	2050501	%CAPTOMEX%, %Captopril%
Y	also used f	28820	Captopril Captomex Tablet	Angiotensii	2050501	%CAPTOMEX%, %Captopril%
Y	also used f	24482	Captopril Captomex Tablet	Angiotensii	2050501	%CAPTOMEX%, %Captopril%
Y	also used f	8923	CAPTOPRIL 100 MG TA	Unknown	0	%Captopril%
Y	also used f	33646	Captopril Captopril 1 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	34544	Captopril Captopril 1 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	1121	Captopril Captopril 1 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	46951	Captopril Captopril 1 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	41633	Captopril Captopril 1 Tablet	Angiotensii	2050501	%Captopril%

Y	also used f	46957	Captopril	Captopril 1 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	58195	Captopril	Captopril 1 Oral solutic	Angiotensii	2050501	%Captopril%
Y	also used f	35302	Captopril	Captopril 1 Oral suspei	Angiotensii	2050501	%Captopril%
Y	also used f	43507	Captopril	Captopril 2 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	34562	Captopril	Captopril 2 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	34936	Captopril	Captopril 2 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	1143	Captopril	Captopril 2 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	43649	Captopril	Captopril 2 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	41617	Captopril	Captopril 2 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	37655	Captopril	Captopril 2 Tablet	Angiotensii	2050501	%Captopril%
Y		11641	Captopril	Captopril 2 Tablets	Thiazides A	02020100/	%CHLOROTHIAZ%, %Captopril%, %thiazide%
Y	also used f	52499	Captopril	Captopril 2 Oral solutic	Angiotensii	2050501	%Captopril%
Y	also used f	59915	Captopril	Captopril 2 Oral solutic	Angiotensii	2050501	%Captopril%
Y	also used f	39512	Captopril	Captopril 2 Oral Suspei	Angiotensii	2050501	%Captopril%
Y	also used f	54544	Captopril	Captopril 2 Oral suspei	Angiotensii	2050501	%Captopril%
Y	also used f	52293	Captopril	Captopril 2 Capsule	Angiotensii	2050501	%Captopril%
Y	also used f	15958	Captopril	Captopril 2 Tablets	Angiotensii	2050501	%Captopril%
Y	also used f	36742	Captopril	Captopril 2 Oral Suspei	Angiotensii	2050501	%Captopril%
Y	also used f	17633	Captopril	Captopril 3 Oral Liquid	Angiotensii	2050501	%Captopril%
Y	also used f	217		CAPTOPRIL 4 MG/ML I	Unknown	0	%Captopril%
Y	also used f	34719	Captopril	Captopril 5 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	34937	Captopril	Captopril 5 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	1807	Captopril	Captopril 5 Tablet	Angiotensii	2050501	%Captopril%
Y	also used f	41743	Captopril	Captopril 5 Tablet	Angiotensii	2050501	%Captopril%
Y		10902	Captopril	Captopril 5 Tablets	Thiazides A	02020100/	%CHLOROTHIAZ%, %Captopril%, %thiazide%
Y	also used f	46851	Captopril	Captopril 5 Oral solutic	Angiotensii	2050501	%Captopril%
Y	also used f	59699		Captopril 5mg/5ml ora	Angiotensii	2050501	%Captopril%
Y	also used f	17624	Captopril	Captopril 5 Oral suspei	Angiotensii	2050501	%Captopril%
Y	also used f	33336	Captopril	Captopril 5 Oral suspei	Angiotensii	2050501	%Captopril%
Y	also used f	44527	Captopril	Captopril 5 Oral solutic	Angiotensii	2050501	%Captopril%
Y	also used f	43432	Captopril	Captopril 6 Tablets	Angiotensii	2050501	%Captopril%
Y	also used f	28486	Captopril	Captopril 6 Oral suspei	Angiotensii	2050501	%Captopril%
Y	also used f	45228	Captopril	Captopril c Capsules	Angiotensii	2050501	%Captopril%
Y		39242	Lisinopril/f	Carace 10 f Tablet	Angiotensii	2050501	%CARACE%, %CHLOROTHIAZ%, %Lisinopril%,
Y		17655	Lisinopril/f	Carace 10 f Tablet	Thiazides A	02020100/	%CARACE%, %CHLOROTHIAZ%, %Lisinopril%,
Y	also used f	16701	Lisinopril	Carace 10n Tablet	Angiotensii	2050501	%CARACE%, %Lisinopril%
Y	also used f	10882	Lisinopril	Carace 2.5f Tablet	Angiotensii	2050501	%CARACE%, %Lisinopril%
Y		39147	Lisinopril/f	Carace 20 f Tablet	Thiazides A	02020100/	%CARACE%, %CHLOROTHIAZ%, %Lisinopril%,
Y		9764	Lisinopril/f	Carace 20 f Tablet	Thiazides A	02020100/	%CARACE%, %CHLOROTHIAZ%, %Lisinopril%,
Y	also used f	12313	Lisinopril	Carace 20n Tablet	Angiotensii	2050501	%CARACE%, %Lisinopril%
Y	also used f	14387	Lisinopril	Carace 5m Tablet	Angiotensii	2050501	%CARACE%, %Lisinopril%
Y		21231	Lisinopril/f	Caralpha 2f Tablet	Angiotensii	2050501	%CARALPHA%, %CHLOROTHIAZ%, %Lisinopril%
Y	also used f	11943	Nicardipine	Cardene 2f Capsule	Calcium-ch	2060200	%CARDENE%, %nicardipine%
Y	also used f	7562	Nicardipine	Cardene 3f Capsule	Calcium-ch	2060200	%CARDENE%, %nicardipine%
Y	also used f	3302	Nicardipine	Cardene SF Modified-r	Calcium-ch	2060200	%CARDENE%, %nicardipine%
Y	also used f	12875	Nicardipine	Cardene SF Modified-r	Calcium-ch	2060200	%CARDENE%, %nicardipine%
Y	also used f	19858	Bisoprolol f	Cardicor 1f Tablet	Beta-adren	02040000/	%Bisoprolol%, %CARDICOR%
Y	also used f	17615	Bisoprolol f	Cardicor 5f Tablet	Beta-adren	02040000/	%Bisoprolol%, %CARDICOR%
Y	also used f	18185	Bisoprolol f	Cardicor 7. Tablet	Beta-adren	02040000/	%Bisoprolol%, %CARDICOR%
Y	also used f	17325	Nifedipine	Cardilate N Modified-r	Calcium-ch	2060200	%CARDILATE%, %nifedipine%
Y	also used f	20257	Nifedipine	Cardilate N Modified-r	Calcium-ch	2060200	%CARDILATE%, %nifedipine%
Y	also used f	24366	Felodipine	Cardiopen Modified-r	Calcium-ch	2060200	%CARDIOPLEN%, %felodipine%
Y	also used f	35592	Felodipine	Cardiopen Modified-r	Calcium-ch	2060200	%CARDIOPLEN%, %felodipine%
Y	also used f	24365	Felodipine	Cardiopen Modified-r	Calcium-ch	2060200	%CARDIOPLEN%, %felodipine%
Y	also used f	36023	Doxazosin	Cardozin xl Modified-r	Alpha-adre	02050400/	%CARDOZIN%, %doxazosin%
Y	also used f	37243	Doxazosin	Cardozin xl Modified-r	Alpha-adre	02050400/	%CARDOZIN%, %doxazosin%
Y	also used f	46066	Doxazosin	Cardozin XI Modified-r	Alpha-adre	02050400/	%CARDOZIN%, %doxazosin%
Y	also used f	38461	Doxazosin	Cardozin XI Modified-r	Alpha-adre	02050400/	%CARDOZIN%, %doxazosin%
Y	also used f	4449	Doxazosin	Cardura 1n Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	4802	Doxazosin	Cardura 2n Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	8086	Doxazosin	Cardura 4n Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	755	Doxazosin	Cardura XL Modified-r	Alpha-adre	02050400/	%doxazosin%
Y	also used f	5618	Doxazosin	Cardura XL Modified-r	Alpha-adre	02050400/	%doxazosin%

Y	also used f	29827	Carteolol H Carteolol H Tablets	Beta-adren	2040000	%Carteolol%
Y	also used f	28700	Carteolol H Cartrol 10n Tablet	Beta-adren	2040000	%CARTROL%, %Carteolol%
Y	also used f	18722	CARVEDILOL	Unknown	0	%carvedilol%
Y	also used f	2629	Carvedilol Carvedilol : Tablet	Beta-adren	2040000	%carvedilol%
Y	also used f	34501	Carvedilol Carvedilol : Tablet	Beta-adren	2040000	%carvedilol%
Y	also used f	33374	Carvedilol Carvedilol : Tablet	Beta-adren	2040000	%carvedilol%
Y	also used f	7049	Carvedilol Carvedilol : Tablet	Beta-adren	2040000	%carvedilol%
Y	also used f	47107	Carvedilol Carvedilol : Oral suspei	Unknown	0	%carvedilol%
Y	also used f	59549	Carvedilol Carvedilol : Oral suspei	Beta-adren	2040000	%carvedilol%
Y	also used f	4410	Carvedilol Carvedilol (Tablet	Beta-adren	2040000	%carvedilol%
Y	also used f	34740	Carvedilol Carvedilol (Tablet	Beta-adren	2040000	%carvedilol%
Y	also used f	19202	Carvedilol Carvedilol (Tablet	Beta-adren	2040000	%carvedilol%
Y	also used f	25487	Doxazosin Cascor 2m Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	25551	Doxazosin Cascor 4m Tablet	Alpha-adre	02050400/	%doxazosin%
Y		4215	Clonidine h Catapres 1(Tablet	Centrally A	2050200	%clonidine%
Y		30293	Clonidine h Catapres 1(Solution fo	Centrally A	2050200	%clonidine%
Y		23380	Clonidine h Catapres 3(Tablet	Centrally A	2050200	%clonidine%
Y		8296	Clonidine h Catapres PI Modified-r	Unknown	0	%clonidine%
Y		4265	Celiprolol f Celectol 20 Tablet	Beta-adren	2040000	%CELECTOL%, %celiprolol%
Y		57573	Celiprolol f Celectol 20 Tablet	Beta-adren	2040000	%CELECTOL%, %celiprolol%
Y		56485	Celiprolol f Celectol 20 Tablet	Beta-adren	2040000	%CELECTOL%, %celiprolol%
Y		35054	Celiprolol f Celectol 20 Tablet	Beta-adren	2040000	%CELECTOL%, %celiprolol%
Y		16776	Celiprolol f Celectol 40 Tablet	Beta-adren	2040000	%CELECTOL%, %celiprolol%
Y		35940	Celiprolol f Celectol 40 Tablet	Beta-adren	2040000	%CELECTOL%, %celiprolol%
Y		8262	Celiprolol f Celiprolol 2 Tablet	Beta-adren	2040000	%celiprolol%
Y		42795	Celiprolol f Celiprolol 2 Tablet	Beta-adren	2040000	%celiprolol%
Y		41740	Celiprolol f Celiprolol 2 Tablet	Beta-adren	2040000	%celiprolol%
Y		7974	Celiprolol f Celiprolol 4 Tablet	Beta-adren	2040000	%celiprolol%
Y	also used f	18973	Bendroflun Centyl 2.5n Tablet	Thiazides A	2020100	%CENTYL%, %thiazide%
Y	also used f	29991	Bendroflun Centyl 5mg Tablet	Thiazides A	2020100	%CENTYL%, %thiazide%
Y	also used f	20426	Potassium Centyl k 2(Modified-r	Diuretics W	2020800	%CENTYL%, %thiazide%
Y	also used f	20431	Potassium Centyl K m(Modified-r	Unknown	0	%CENTYL%, %thiazide%
Y	also used f	2979	Bendroflun Centyl k Ta Modified-r	Diuretics W	2020800	%CENTYL%, %thiazide%
Y	also used f	30592	CHLOROTHIAZIDE / SP	Unknown	0	%CHLOROTHIAZ%, %spironolactone%, %thiazi
Y	also used f	30034	CHLOROTHIAZIDE / SP	Unknown	0	%CHLOROTHIAZ%, %spironolactone%, %thiazi
Y	also used f	13246	Chlorothia: Chlorothia: Oral suspei	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	27489	CHLOROTHIAZIDE 25 N	Unknown	0	%CHLOROTHIAZ%, %thiazide%
Y	also used f	22525	CHLOROTHIAZIDE 250	Unknown	0	%CHLOROTHIAZ%, %thiazide%
Y	also used f	54679	Chlorothia: Chlorothia: Tablet	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	59834	Chlorothiazide 250mg,	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	6816	Chlorothia: Chlorothia: Oral suspei	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	56804	Chlorothia: Chlorothia: Oral suspei	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	30035	CHLOROTHIAZIDE 40N	Unknown	0	%CHLOROTHIAZ%, %spironolactone%, %thiazi
Y	also used f	26120	CHLOROTHIAZIDE 50 N	Unknown	0	%CHLOROTHIAZ%, %thiazide%
Y	also used f	8836	Chlorothia: Chlorothia: Tablets	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	60603	Chlorothia: Chlorothia: Oral suspei	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	54341	Chlorothiazide 5mg/5r	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	30367	CHLOROTHIAZIDE 60N	Unknown	0	%CHLOROTHIAZ%, %spironolactone%, %thiazi
Y	also used f	55889	Chlorothia: Chlorothiazide oral sol	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	31235	CHLOROTHIAZIDE SAC	Unknown	0	%CHLOROTHIAZ%, %thiazide%
Y	also used f	30368	CHLOROTHIAZIDE/SPIF	Unknown	0	%CHLOROTHIAZ%, %spironolactone%, %thiazi
Y	also used f	55050	CHLOROTHIAZIDE/SPIF	Unknown	0	%CHLOROTHIAZ%, %spironolactone%, %thiazi
Y	also used f	30365	CHLOROTHIAZIDE/SPIF	Unknown	0	%CHLOROTHIAZ%, %spironolactone%, %thiazi
Y	also used f	3548	Chlortalido Chlortalido Tablets	Thiazides A	02020100/	%chlortalidone%
Y		19055	Chlortalido Chlortalido Tablets	Thiazides A	02020100/	%Atenolol%, %chlortalidone%
Y		16786	Chlortalido Chlortalido Tablets	Thiazides A	02020100/	%Atenolol%, %chlortalidone%
Y	also used f	605	Chlortalido Chlortalido Tablet	Thiazides A	2020100	%chlortalidone%
Y	also used f	10796	CHLORTHALIDONE 25M	Unknown	0	%CHLORTHALIDONE%
Y	also used f	20160	CHLORTHALIDONE 50C	Unknown	0	%CHLORTHALIDONE%
Y	also used f	12574	Cilazapril n Cilazapril 1 Tablet	Angiotensii	2050501	%Cilazapril%
Y	also used f	12412	Cilazapril n Cilazapril 2 Tablet	Angiotensii	2050501	%Cilazapril%
Y	also used f	15605	Cilazapril Cilazapril 2 Tablets	Angiotensii	2050501	%Cilazapril%
Y	also used f	12411	Cilazapril n Cilazapril 5 Tablet	Angiotensii	2050501	%Cilazapril%

Y	also used f	13026	Cilazapril r	Cilazapril 5 Tablet	Angiotensii	2050501	%Cilazapril%
Y		2878	Clonidine h	Clonidine 1 Tablet	Centrally A	02050200/	%clonidine%
Y		49684	Clonidine	Clonidine 1 Transderm	Centrally A	2050200	%clonidine%
Y		60136		Clonidine 100microgra	Centrally A	02050200/	%clonidine%
Y		16248	Clonidine h	Clonidine 1 Solution fo	Centrally A	2050200	%clonidine%
Y		58529	Clonidine	Clonidine 2 Transderm	Centrally A	2050200	%clonidine%
Y		5289	Clonidine h	Clonidine 2 Modified-r	Unknown	0	%clonidine%
Y		6694	Clonidine h	Clonidine 3 Tablet	Centrally A	2050200	%clonidine%
Y		54467		Clonidine 300microgra	Centrally A	2050200	%clonidine%
Y		52555	Clonidine h	Clonidine 5 Oral solutic	Centrally A	02050200/	%clonidine%
Y		53142	Clonidine h	Clonidine 5 Oral suspei	Centrally A	02050200/	%clonidine%
Y		58090		Clonidine 75microgran	Centrally A	02050200/	%clonidine%
Y		27894		CLONIDINE HYDROCHL	Unknown	0	%clonidine%
Y		25462	Pindolol	Clopamide Tablets	Beta-adren	2040000	%Clopamide%, %Pindolol%
Y	also used f	22839	Potassium	Clopamide Effervescer	Diuretics W	2020800	%Clopamide%
Y	also used f	3793	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	34622	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	193	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	60258	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	34280	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	41533	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	25965	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	56	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	33658	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	41719	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	33527	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	57908	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	43508	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	28129	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	59412	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	31773	Amiloride f	Co-amilofr Tablet	Potassium-	2020400	%amiloride%, %furosemide%
Y	also used f	30773	Amiloride f	Co-amilofr Tablet	Loop Diure	02020200/	%amiloride%, %furosemide%
Y	also used f	47647	Furosemid	Co-amilofr Oral Liquid	Loop Diure	02020200/	%furosemide%
Y	also used f	924	Amiloride f	Co-amilozic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	60354	Amiloride f	Co-amilozic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	34367	Amiloride f	Co-amilozic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	18733	Amiloride f	Co-amilozic Oral Soluti	Thiazides A	02020100/	%amiloride%
Y	also used f	923	Amiloride f	Co-amilozic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	46916	Amiloride f	Co-amilozic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	31150	Amiloride f	Co-amilozic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	41556	Amiloride f	Co-amilozic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y		10316	Hydrochlor	CoAprovel Tablet	Thiazides A	02020100/	%Aprovel%, %CHLOROTHIAZ%, %Irbesartan%,
Y		11526	Irbesartan/	CoAprovel Tablet	Thiazides A	02020100/	%Aprovel%, %CHLOROTHIAZ%, %Irbesartan%,
Y		35196	Hydrochlor	CoAprovel Tablet	Thiazides A	02020100/	%Aprovel%, %CHLOROTHIAZ%, %Irbesartan%,
Y		41897		CO-BETALOC	Unknown	0	%BETALOC%, %CO-BETALOC%
Y		18287	Metoprolo	Co-Betaloc Modified-r	Unknown	0	%BETALOC%, %CHLOROTHIAZ%, %CO-BETALC
Y		10627	Hydrochlor	Co-Betaloc Tablet	Unknown	0	%BETALOC%, %CHLOROTHIAZ%, %CO-BETALC
Y		6877	Valsartan/	t Co-Diovan Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Diovan%, %Valsartan%, %
Y		25382	Valsartan/	t Co-Diovan Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Diovan%, %Valsartan%, %
Y		764	Hydrochlor	Co-Diovan Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Diovan%, %Valsartan%, %
Y		52858	Hydrochlor	Co-Diovan Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Diovan%, %Valsartan%, %
Y	also used f	15811	Spironolact	Co-flumact Tablet	Potassium-	2020400	%spironolactone%, %thiazide%
Y	also used f	11384	Spironolact	Co-flumact Tablet	Potassium-	2020400	%spironolactone%, %thiazide%
Y	also used f	43695	Doxazosin	Colixil XL 4 Modified-r	Alpha-adre	02050400/	%COLIXIL%, %doxazosin%
Y		13871	Oxprenolol	Co-prenozi Modified-r	Beta-adren	2040000	%Oxprenolol%, %co-prenozi%, %thiazide%
Y	also used f	2746	Nifedipine	Coracten S Modified-r	Calcium-ch	2060200	%CORACTEN%, %nifedipine%
Y	also used f	4856	Nifedipine	Coracten S Modified-r	Calcium-ch	2060200	%CORACTEN%, %nifedipine%
Y	also used f	3712	Nifedipine	Coracten X Modified-r	Calcium-ch	2060200	%CORACTEN%, %nifedipine%
Y	also used f	4939	Nifedipine	Coracten X Modified-r	Calcium-ch	2060200	%CORACTEN%, %nifedipine%
Y	also used f	21665		CORDILOX	Unknown	0	%CORDILOX%
Y	also used f	1748	Verapamil	Cordilox 12 Tablet	Calcium-ch	2060200	%CORDILOX%, %verapamil%
Y	also used f	12104	Verapamil	Cordilox 16 Tablet	Calcium-ch	2060200	%CORDILOX%, %verapamil%
Y	also used f	8884	Verapamil	Cordilox 4C Tablet	Calcium-ch	2060200	%CORDILOX%, %verapamil%

Y	also used f	16677	Verapamil Cordilox 8C Tablet	Calcium-ch	2060200	%CORDILOX%, %verapamil%
Y	also used f	13965	Verapamil Cordilox M Modified-r	Calcium-ch	2060200	%CORDILOX%, %verapamil%
Y	also used f	13415	Nadolol Corgard 40 Tablet	Unknown	0	%CORGARD%, %Nadolol%
Y	also used f	10716	Nadolol Corgard 80 Tablet	Beta-adren	2040000	%CORGARD%, %Nadolol%
Y		5330	Nadolol/Be Corgaretic Tablet	Unknown	0	%CORGARETIC%, %Nadolol%, %thiazide%
Y		14438	Nadolol/Be Corgaretic Tablet	Unknown	0	%CORGARETIC%, %Nadolol%, %thiazide%
Y	also used f	30473	Nifedipine Coroday M Modified-r	Calcium-ch	2060200	%CORODAY%, %nifedipine%
Y		5721	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		34899	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		46952	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		37725	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		34012	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		41572	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		9783	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		32094	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		31708	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		34449	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		34034	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y		34825	Atenolol/C Co-tenidon Tablet	Thiazides A	02020100/	%Atenolol%, %CO-TENIDONE%, %chlortalidon
Y	also used f	5416	Triamteren Co-triamte Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %thiazide%, %triamterene%
Y	also used f	47804	Triamteren Co-triamte Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %thiazide%, %triamterene%
Y	also used f	56506	Perindopril Coversyl 2r Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	5612	Perindopril Coversyl 2r Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	56508	Perindopril Coversyl 4r Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	5800	Perindopril Coversyl 4r Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	14960	Perindopril Coversyl 8r Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	38026	Perindopril Coversyl Ar Tablets	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	38034	Perindopril Coversyl Ar Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	51807	Perindopril Coversyl Ar Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	37965	Perindopril Coversyl Ar Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y	also used f	50347	Perindopril Coversyl Ar Tablet	Angiotensii	2050501	%COVERSYL%, %Perindopril%
Y		51258	Indapamid: Coversyl Ar Tablet	Thiazides A	02020100/	%COVERSYL%, %Perindopril%, %indapamide%
Y		37908	Indapamid: Coversyl Ar Tablet	Thiazides A	02020100/	%COVERSYL%, %Perindopril%, %indapamide%
Y		14228	Indapamid: Coversyl Pl Tablet	Unknown	0	%COVERSYL%, %Perindopril%, %indapamide%
Y	also used f	14965	Losartan pr Cozaar 100 Tablet	Angiotensii	2050502	%Cozaar%, %Losartan%
Y	also used f	52427	Losartan pr Cozaar 100 Tablet	Angiotensii	2050502	%Cozaar%, %Losartan%
Y	also used f	40571	Losartan pr Cozaar 12: Tablet	Angiotensii	2050502	%Cozaar%, %Losartan%
Y	also used f	41232	Losartan Pr Cozaar 2.5r Oral Suspe	Angiotensii	2050502	%Cozaar%, %Losartan%
Y	also used f	4226	Losartan pr Cozaar 25n Tablet	Angiotensii	2050502	%Cozaar%, %Losartan%
Y	also used f	5723	Losartan pr Cozaar 50n Tablet	Angiotensii	2050502	%Cozaar%, %Losartan%
Y		37747	Losartan pr Cozaar-Cor Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Cozaar%, %Losartan%, %
Y		21423	Losartan pr Cozaar-Cor Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Cozaar%, %Losartan%, %
Y		57796	Losartan pr Cozaar-Cor Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Cozaar%, %Losartan%, %
Y		4540	Losartan pr Cozaar-Cor Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Cozaar%, %Losartan%, %
Y		55160	Losartan pr Cozaar-Cor Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Cozaar%, %Losartan%, %
Y		11561	Hydrochlor Co-zidocap Tablet	Angiotensii	2050501	%CHLOROTHIAZ%, %Captopril%, %co-zidocap
Y		11351	Hydrochlor Co-zidocap Tablet	Angiotensii	2050501	%CHLOROTHIAZ%, %Captopril%, %co-zidocap
Y		52145	Oxprenolol Cyclopenthiazide 0.25r	Thiazides A	02020100/	%Oxprenolol%, %thiazide%
Y	also used f	23492	CYCLOPENTHIAZIDE 25	Unknown	0	%thiazide%
Y	also used f	1170	Cyclopenth Cyclopenth Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	2833	Potassium CYCLOPEN` Tablets	Thiazides A	2020100	%thiazide%
Y		4375	Debrisoqui Debrisoqui Tablet	Unknown	0	%debrisoquine%
Y		4374	Debrisoqui Debrisoqui Tablets	Adrenergic	2050300	%debrisoquine%
Y		25393	Methoserp Decaserpyl Tablet	Centrally A	2050200	%DECASERPYL%, %methoserpidine%
Y		10713	Methoserp Decaserpyl Tablet	Centrally A	2050200	%DECASERPYL%, %methoserpidine%
Y		4406	Benzthiazic Decaserpyl Tablet	Centrally A	2050200	%DECASERPYL%, %methoserpidine%, %thiazic
Y		7911	Debrisoqui Declinax 1C Tablet	Adrenergic	2050300	%DECLINAX%, %debrisoquine%
Y		8342	Debrisoqui Declinax 2C Tablet	Adrenergic	2050300	%DECLINAX%, %debrisoquine%
Y	also used f	26220	Amiloride l Delvas Tab Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %DELVAS%, %amiloride%,
Y	also used f	25494	Spirololact Diatensec ` Tablet	Potassium-	2020300	%DIATENSEC%, %spiroinolactone%
Y		25506	DIAZOXIDE 15 MG INJ	Unknown	0	%diazoxide%
Y		32267	Diazoxide : Solution fo Vasodilato	Unknown	2050100	%diazoxide%
Y	also used f	25777	Diltiazem h Dilcardia Si Modified-r	Calcium-ch	2060200	%DILCARDIA%, %diltiazem%

Y	also used f	21145	Diltiazem h Dilcardia Sl Modified-r	Calcium-ch	2060200	%DILCARDIA%, %diltiazem%
Y	also used f	18379	Diltiazem h Dilcardia Sl Modified-r	Calcium-ch	2060200	%DILCARDIA%, %diltiazem%
Y	also used f	32658	Diltiazem F Dilcardia xl Modified-r	Calcium-ch	2060200	%DILCARDIA%, %diltiazem%
Y	also used f	15221	Diltiazem F Dilcardia xl Modified-r	Calcium-ch	2060200	%DILCARDIA%, %diltiazem%
Y	also used f	26460	Diltiazem h Dilcardia xl Modified-r	Calcium-ch	2060200	%DILCARDIA%, %diltiazem%
Y	also used f	30197	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	48288	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	49289	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	57208	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	219	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	43430	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	49001	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	1995	Diltiazem F Diltiazem 1 12 Hour M	Calcium-ch	2060200	%diltiazem%
Y	also used f	3061	Diltiazem F Diltiazem 1 12 Hour M	Calcium-ch	2060200	%diltiazem%
Y	also used f	30242	Diltiazem h Diltiazem 1 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	4635	Diltiazem h Diltiazem 2 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	2663	Diltiazem F Diltiazem 2 Modified R	Calcium-ch	2060200	%diltiazem%
Y	also used f	4808	Diltiazem h Diltiazem 2 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	9708	Diltiazem F Diltiazem 2 24 Hour M	Calcium-ch	2060200	%diltiazem%
Y	also used f	4923	Diltiazem F Diltiazem 2 24 Hour M	Calcium-ch	2060200	%diltiazem%
Y	also used f	5326	Diltiazem F Diltiazem 2 24 Hour M	Calcium-ch	2060200	%diltiazem%
Y	also used f	5348	Diltiazem h Diltiazem 3 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	13926	Diltiazem h Diltiazem 3 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	2453	Diltiazem F Diltiazem 6 Modified R	Calcium-ch	2060200	%diltiazem%
Y	also used f	636	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	18404	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	48272	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	1836	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	21763	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	46937	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	41635	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	32870	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	21778	Diltiazem h Diltiazem 6 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	1538	Diltiazem F Diltiazem 6 Tablets	Calcium-ch	2060200	%diltiazem%
Y	also used f	55257	Diltiazem h Diltiazem 6 Oral soluti	Calcium-ch	2060200	%diltiazem%
Y	also used f	11922	Diltiazem h Diltiazem 6 Oral suspei	Calcium-ch	2060200	%diltiazem%
Y	also used f	1686	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	48282	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	48457	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	56758	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	4732	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	27136	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	49390	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	57859	Diltiazem h Diltiazem 9 Modified-r	Calcium-ch	2060200	%diltiazem%
Y		18606	Diltiazem F Diltiazem a Modified R	Thiazides A	02020100/	%CHLOROTHIAZ%, %diltiazem%, %thiazide%
Y	also used f	32089	Diltiazem F Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	31676	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	34824	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	42804	Diltiazem F Diltiazem F Capsule	Calcium-ch	2060200	%diltiazem%
Y	also used f	18403	Diltiazem F Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	45759	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	27685	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	34581	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	38066	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	32262	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	21773	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	34377	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	12639	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	34475	Diltiazem h Diltiazem F Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	15659	DILTIAZEM HCL S/R 18 Unknown		0	%diltiazem%
Y	also used f	9094	DILTIAZEM HCL SR 300 Unknown		0	%diltiazem%
Y	also used f	8024	DILTIAZEM HCL XL 300 Unknown		0	%diltiazem%
Y	also used f	30491	DILTIAZEM HYDROCHL Unknown		0	%diltiazem%

Y	also used f	42731	Diltiazem † Diltiazem s Capsule	Calcium-ch	2060200	%diltiazem%
Y	also used f	47415	Diltiazem h Diltiazem s Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	27135	Diltiazem h Diltiazem s Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	42819	Diltiazem h Diltiazem x Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	16038	Diltiazem h Dilzem SR † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	5194	Diltiazem † Dilzem sr 1 Capsule	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	11770	Diltiazem h Dilzem SR † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	5513	Diltiazem h Dilzem sr 6 Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	13302	Diltiazem h Dilzem SR † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	4308	Diltiazem h Dilzem sr 9 Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	13240	Diltiazem h Dilzem XL † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	59098	Diltiazem h Dilzem XL † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	60415	Diltiazem h Dilzem XL † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	13075	Diltiazem h Dilzem XL † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	59863	Diltiazem h Dilzem XL † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	13127	Diltiazem h Dilzem XL † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	3370	Diltiazem † Dilzem xl † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	3676	Diltiazem † Dilzem xl † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	2686	Diltiazem h Dilzem xl † Modified-r	Calcium-ch	2060200	%DILZEM%, %diltiazem%
Y	also used f	6518	Valsartan Diovan 16C Capsule	Angiotensii	2050502	%Diovan%, %Valsartan%
Y	also used f	45600	Valsartan Diovan 16C Tablet	Angiotensii	2050502	%Diovan%, %Valsartan%
Y	also used f	39199	Valsartan Diovan 32C Tablet	Angiotensii	2050502	%Diovan%, %Valsartan%
Y	also used f	11251	Valsartan Diovan 40n Capsule	Angiotensii	2050502	%Diovan%, %Valsartan%
Y	also used f	24359	Valsartan Diovan 40n Tablet	Angiotensii	2050502	%Diovan%, %Valsartan%
Y	also used f	11252	Valsartan Diovan 80n Capsule	Angiotensii	2050502	%Diovan%, %Valsartan%
Y	also used f	18852	Diltiazem h Disogram S Modified-r	Calcium-ch	2060200	%DISOGRAM%, %diltiazem%
Y	also used f	18874	Diltiazem h Disogram S Modified-r	Calcium-ch	2060200	%DISOGRAM%, %diltiazem%
Y	also used f	19426	Diltiazem h Disogram S Modified-r	Calcium-ch	2060200	%DISOGRAM%, %diltiazem%
Y	also used f	19440	Diltiazem h Disogram S Modified-r	Calcium-ch	2060200	%DISOGRAM%, %diltiazem%
Y	also used f	18834	Diltiazem h Disogram S Modified-r	Calcium-ch	2060200	%DISOGRAM%, %diltiazem%
Y	also used f	18830	Diltiazem h Disogram S Modified-r	Calcium-ch	2060200	%DISOGRAM%, %diltiazem%
Y	also used f	7734	Potassium Diuride-K Modified-r	Diuretics W	2020800	%DIURIDE-K%, %furosemide%
Y	also used f	26292	Furosemid Diuresal 40 Tablet	Loop Diure	2020200	%DIURESAL%, %furosemide%
Y	also used f	4044	Xipamide Diurexan 2 Tablet	Thiazides A	2020100	%Diurexan%, %Xipamide%
Y	also used f	33724	Chlorothia: Diuril 250n Oral suspei	Thiazides A	2020100	%CHLOROTHIAZ%, %DIURIL%, %thiazide%
Y		29570	Methyldop Dopamet 1 Tablet	Centrally A	2050200	%DOPAMET%, %methyldopa%
Y		24196	Methyldop Dopamet 2 Tablet	Centrally A	2050200	%DOPAMET%, %methyldopa%
Y		25289	Methyldop Dopamet 5 Tablet	Centrally A	2050200	%DOPAMET%, %methyldopa%
Y	also used f	7549	Doxazosin Doxadura 1 Tablet	Alpha-adre	02050400/	%DOXADURA%, %doxazosin%
Y	also used f	7547	Doxazosin Doxadura 2 Tablet	Alpha-adre	02050400/	%DOXADURA%, %doxazosin%
Y	also used f	10088	Doxazosin Doxadura 4 Tablet	Alpha-adre	02050400/	%DOXADURA%, %doxazosin%
Y	also used f	35272	Doxazosin Doxadura † Modified-r	Alpha-adre	02050400/	%DOXADURA%, %doxazosin%
Y	also used f	119	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	34715	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	48150	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	55916	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	60319	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	55906	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	34601	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	41543	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	59209	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	45328	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	34342	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	20369	Doxazosin Doxazosin Oral suspei	Alpha-adre	02050400/	%doxazosin%
Y	also used f	493	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	34625	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	56145	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	50467	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	45583	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	33094	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	40891	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	58276	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%
Y	also used f	57074	Doxazosin Doxazosin Tablet	Alpha-adre	02050400/	%doxazosin%

Y	also used f	19193	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	57784	Doxazosin	Doxazosin Oral suspei	Alpha-adre	02050400/ %doxazosin%
Y	also used f	582	Doxazosin	Doxazosin Modified-r	Alpha-adre	02050400/ %doxazosin%
Y	also used f	1294	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	57448	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	51685	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	53322	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	60200	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	59862	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	34553	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	19216	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	54785	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	58325	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	45342	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	40678	Doxazosin	Doxazosin Tablet	Alpha-adre	02050400/ %doxazosin%
Y	also used f	35603	Doxazosin	Doxazosin Oral suspei	Alpha-adre	02050400/ %doxazosin%
Y	also used f	5496	Doxazosin	Doxazosin Modified-r	Alpha-adre	02050400/ %doxazosin%
Y	also used f	45265	Doxazosin	Doxazosin Modified-r	Alpha-adre	02050400/ %doxazosin%
Y	also used f	47807	Doxazosin	Doxazosin Modified-r	Alpha-adre	02050400/ %doxazosin%
Y	also used f	53033	Doxazosin	Doxazosin Modified-r	Alpha-adre	02050400/ %doxazosin%
Y	also used f	18716	Furosemid	Dryptal 10r Injection	Loop Diure	2020200 %DRYPTAL%, %furosemide%
Y	also used f	21849	Furosemid	Dryptal 40r Tablet	Loop Diure	2020200 %DRYPTAL%, %furosemide%
Y	also used f	27556		DYAZIDE	Unknown	0 %DYAZIDE%
Y	also used f	1721	Triamteren	Dyazide 50 Tablet	Potassium-	2020400 %CHLOROTHIAZ%, %DYAZIDE%, %thiazide%, %
Y	also used f	4068	Triamteren	Dytac 50mJ Capsule	Potassium-	2020300 %triamterene%
Y	also used f	7136	Triamteren	Dytide cap: Capsule	Unknown	0 %DYTIDE%, %thiazide%, %triamterene%
Y	also used f	56850	Captopril	Ecopace 12 Tablet	Angiotensii	2050501 %Captopril%, %ECOPACE%
Y	also used f	32514	Captopril	Ecopace 25 Tablet	Angiotensii	2050501 %Captopril%, %ECOPACE%
Y		51897	Azilsartan r	Edarbi 20r Tablet	Angiotensii	2050502 %Azilsartan%, %Edarbi%
Y	also used f	36753	Enalapril m	Ednyt 10mJ Tablet	Angiotensii	2050501 %EDNYT%, %Enalapril%
Y	also used f	44657	Enalapril m	Ednyt 2.5mJ Tablet	Angiotensii	2050501 %EDNYT%, %Enalapril%
Y	also used f	22439	Enalapril m	Ednyt 20mJ Tablet	Angiotensii	2050501 %EDNYT%, %Enalapril%
Y	also used f	33057	Enalapril m	Ednyt 5mJ Tablet	Angiotensii	2050501 %EDNYT%, %Enalapril%
Y	also used f	10892	Bisoprolol	Emcor 10r Tablet	Beta-adren	02040000/ %Bisoprolol%, %EMCOR%
Y	also used f	4771	Bisoprolol	Emcor LS 5 Tablet	Beta-adren	02040000/ %Bisoprolol%, %EMCOR%
Y	also used f	58751	Enalapril m	Enalapril 1. Oral suspei	Angiotensii	2050501 %Enalapril%
Y	also used f	1299	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	32241	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	19208	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	52010	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	55903	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	34952	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	41746	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	42894	Enalapril m	Enalapril 1(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	13755	Enalapril M	Enalapril 1(Wafer	Angiotensii	2050501 %Enalapril%
Y	also used f	448	Enalapril m	Enalapril 2. Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	41417	Enalapril m	Enalapril 2. Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	41694	Enalapril m	Enalapril 2. Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	28127	Enalapril m	Enalapril 2. Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	43563	Enalapril m	Enalapril 2. Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	20188	Enalapril M	Enalapril 2. Wafer	Angiotensii	2050501 %Enalapril%
Y	also used f	57882	Enalapril m	Enalapril 2. Oral suspei	Angiotensii	2050501 %Enalapril%
Y		5189	Enalapril m	Enalapril 2(Tablet	Thiazides A	02020100/ %CHLOROTHIAZ%, %Enalapril%, %thiazide%
Y	also used f	1904	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	33078	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	31716	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	53719	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	34453	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	34768	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	34712	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	59996	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	34798	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%
Y	also used f	42902	Enalapril m	Enalapril 2(Tablet	Angiotensii	2050501 %Enalapril%

Y	also used f	34953	Enalapril m Enalapril 2(Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	24041	Enalapril IV Enalapril 2(Wafer	Angiotensii	2050501	%Enalapril%
Y	also used f	50780	Enalapril m Enalapril 2r Oral solutic	Angiotensii	2050501	%Enalapril%
Y	also used f	57378	Enalapril m Enalapril 2r Oral suspei	Angiotensii	2050501	%Enalapril%
Y	also used f	50334	Enalapril m Enalapril 4r Oral suspei	Angiotensii	2050501	%Enalapril%
Y	also used f	34400	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	196	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	35794	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	53915	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	46974	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	42908	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	45217	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	60143	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	43411	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	42901	Enalapril m Enalapril 5r Tablet	Angiotensii	2050501	%Enalapril%
Y	also used f	22708	Enalapril IV Enalapril 5r Wafer	Angiotensii	2050501	%Enalapril%
Y	also used f	37080	Enalapril m Enalapril 5r Oral solutic	Angiotensii	2050501	%Enalapril%
Y	also used f	50863	Enalapril m Enalapril 5r Oral solutic	Angiotensii	2050501	%Enalapril%
Y	also used f	37087	Enalapril m Enalapril 5r Oral suspei	Angiotensii	2050501	%Enalapril%
Y	also used f	52882	Enalapril m Enalapril 5r Oral suspei	Angiotensii	2050501	%Enalapril%
Y	also used f	27890	ENALAPRIL MALEATE	Unknown	0	%Enalapril%
Y	also used f	3509	ENALAPRIL MALEATE 4	Unknown	0	%Enalapril%
Y	also used f	16708	Enalapril IV Enalapril tit Titration P:	Angiotensii	2050501	%Enalapril%
Y	also used f	18267	Methyloct Enduron 5r Tablet	Thiazides A	2020100	%ENDURON%, %thiazide%
Y		18244	ENDURONYL TAB	Unknown	0	%ENDURON%
Y	also used f	10251	Eplerenone Eplerenone Tablet	Potassium-	2020300	%eplerenone%
Y	also used f	16531	Eplerenone Eplerenone Tablet	Potassium-	2020300	%eplerenone%
Y		6939	Eprosartan Eprosartan Tablet	Angiotensii	2050502	%Eprosartan%
Y		13123	Eprosartan Eprosartan Tablet	Angiotensii	2050502	%Eprosartan%
Y		12836	Eprosartan Eprosartan Tablet	Angiotensii	2050502	%Eprosartan%
Y		18247	Betanidine Esbatal 10r Tablet	Adrenergic	2050300	%ESBATAL%, %betanidine%
Y		14442	Betanidine Esbatal 50r Tablet	Adrenergic	2050300	%ESBATAL%, %betanidine%
Y	also used f	17252	Hydrochlor Esidrex 25r Tablet	Thiazides A	2020100	%CHLOROTHIAZ%, %ESIDREX%, %thiazide%
Y	also used f	13363	Hydrochlor Esidrex 50r Tablet	Thiazides A	2020100	%CHLOROTHIAZ%, %ESIDREX%, %thiazide%
Y	also used f	36519	Potassium Esidrex -k T Tablet	Diuretics W	2020800	%ESIDREX%
Y	also used f	13472	ESIDREX-K TAB	Unknown	0	%ESIDREX%
Y	also used f	41885	Indapamide Ethibide XL Modified-r:	Thiazides A	2020100	%ETHIBIDE%, %indapamide%
Y	also used f	30462	Verapamil Ethimil MR Modified-r:	Calcium-ch	2060200	%ETHIMIL%, %verapamil%
Y	also used f	18414	Carvedilol Eucardic 12 Tablet	Beta-adren	2040000	%EUCARDIC%, %carvedilol%
Y	also used f	19437	Carvedilol Eucardic 25 Tablet	Beta-adren	2040000	%EUCARDIC%, %carvedilol%
Y	also used f	14146	Carvedilol Eucardic 6. Tablet	Beta-adren	2040000	%EUCARDIC%, %carvedilol%
Y		35096	Valsartan/ Exforge 10r Tablet	Calcium-ch	2060200	%EXFORGE%, %Valsartan%, %amlodipine%
Y		35697	Valsartan/ Exforge 5m Tablets	Calcium-ch	2060200	%EXFORGE%, %Valsartan%, %amlodipine%
Y		35317	Amlodipine Exforge 5m Tablet	Calcium-ch	2060200	%EXFORGE%, %Valsartan%, %amlodipine%
Y	also used f	20459	Felodipine Felendil xl : Modified-r:	Calcium-ch	2060200	%FELENDIL%, %felodipine%
Y	also used f	29145	Felodipine Felendil xl : Modified-r:	Calcium-ch	2060200	%FELENDIL%, %felodipine%
Y	also used f	10153	Felodipine Felendil xl ! Modified-r:	Calcium-ch	2060200	%FELENDIL%, %felodipine%
Y	also used f	32922	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y	also used f	568	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y	also used f	33091	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y		21162	Felodipine/ Felodipine Modified-r:	Drugs Affec	2050500	%Ramipril%, %felodipine%
Y	also used f	491	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y	also used f	60569	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y		17474	Felodipine/ Felodipine Modified-r:	Drugs Affec	2050500	%Ramipril%, %felodipine%
Y	also used f	48009	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y	also used f	501	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y	also used f	43512	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y	also used f	44859	Felodipine Felodipine Modified-r:	Calcium-ch	2060200	%felodipine%
Y	also used f	30557	Felodipine Felogen XL Modified-r:	Calcium-ch	2060200	%FELOGEN%, %felodipine%
Y	also used f	25572	Felodipine Felogen XL Modified-r:	Calcium-ch	2060200	%FELOGEN%, %felodipine%
Y	also used f	17566	Felodipine Felotens XI Modified-r:	Calcium-ch	2060200	%FELOTENS%, %felodipine%
Y	also used f	37897	Felodipine Felotens XI Modified-r:	Calcium-ch	2060200	%FELOTENS%, %felodipine%
Y	also used f	17557	Felodipine Felotens XI Modified-r:	Calcium-ch	2060200	%FELOTENS%, %felodipine%

Y	also used f	55306 Felodipine Folpik XL 5 Modified-r	Calcium-ch	2060200	%felodipine%
Y	also used f	5277 Nifedipine Fortipine L Modified-r	Calcium-ch	2060200	%FORTIPINE%, %nifedipine%
Y	also used f	633 Fosinopril : Fosinopril : Tablet	Angiotensii	2050501	%Fosinopril%
Y	also used f	5861 Fosinopril : Fosinopril : Tablet	Angiotensii	2050501	%Fosinopril%
Y	also used f	16206 Furosemid: Froop 40m Tablet	Loop Diure	2020200	%FROOP%, %furosemide%
Y	also used f	21938 Amiloride f Froop Co 5 Tablet	Potassium-	2020400	%FROOP%, %amiloride%, %furosemide%
Y	also used f	4873 Amiloride f Fru-Co 5mg Tablet	Potassium-	2020400	%FRU-CO%, %amiloride%, %furosemide%
Y	also used f	20538 Furosemid: Frumax 40r Tablet	Loop Diure	2020200	%FRUMAX%, %furosemide%
Y	also used f	20785 FRUMIL	Unknown	0	%FRUMIL%
Y	also used f	39807 Amiloride f Frumil 40r Tablet	Potassium-	2020400	%FRUMIL%, %amiloride%, %furosemide%
Y	also used f	211 Amiloride f Frumil 40r Tablet	Loop Diure	02020200/	%FRUMIL%, %amiloride%, %furosemide%
Y	also used f	13435 Amiloride f Frumil Fort Tablet	Potassium-	2020400	%FRUMIL%, %amiloride%, %furosemide%
Y	also used f	38901 Amiloride f Frumil LS 2 Tablet	Potassium-	2020400	%FRUMIL%, %amiloride%, %furosemide%
Y	also used f	1301 Amiloride f Frumil Is 2(Tablet	Loop Diure	02020200/	%FRUMIL%, %amiloride%, %furosemide%
Y	also used f	9431 Amiloride f Frusemek 4 Tablet	Loop Diure	02020200/	%FRUSEMEK%, %amiloride%, %furosemide%
Y	also used f	3902 FRUSEMIDE 20MG/SPI	Unknown	0	%spironolactone%
Y	also used f	25075 FRUSEMIDE 40MG/AN	Unknown	0	%amiloride%
Y	also used f	2961 Triamteren Frusene 50 Tablet	Potassium-	2020400	%FRUSENE%, %furosemide%, %triamterene%
Y	also used f	14761 Furosemid: Frusid 40m Tablet	Loop Diure	2020200	%FRUSID%, %furosemide%
Y	also used f	5868 Furosemid: Frusol 20m Oral solutic	Loop Diure	2020200	%FRUSOL%, %furosemide%
Y	also used f	9680 Furosemid: Frusol 40m Oral solutic	Loop Diure	2020200	%FRUSOL%, %furosemide%
Y	also used f	14837 Furosemid: Frusol 50m Oral solutic	Loop Diure	2020200	%FRUSOL%, %furosemide%
Y	also used f	58224 Furosemid: Furosemid: Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	562 Furosemid: Furosemid: Injection	Loop Diure	2020200	%furosemide%
Y	also used f	46116 Furosemid: Furosemid: Injection	Loop Diure	2020200	%furosemide%
Y	also used f	40247 Furosemid: Furosemid: Injection	Loop Diure	2020200	%furosemide%
Y	also used f	3287 Furosemid: Furosemid: Oral Solutic	Loop Diure	2020200	%furosemide%
Y	also used f	17960 Potassium Furosemid: Modified-r	Unknown	0	%furosemide%
Y	also used f	29780 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	47815 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	55 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	30625 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	31548 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	59290 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	53967 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	27926 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	56051 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	59884 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	32918 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	54825 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	19194 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	41292 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	4705 Furosemid: Furosemid: Injection	Loop Diure	2020200	%furosemide%
Y	also used f	35162 Furosemid: Furosemid: Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	52887 Furosemid: Furosemid: Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	57600 Furosemid: Furosemid: Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	59030 Furosemid: Furosemid: Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	6118 Furosemid: Furosemid: Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	57610 Furosemid: Furosemid: Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	59939 Furosemide 20mg/5ml	Loop Diure	2020200	%furosemide%
Y	also used f	30875 Furosemid: Furosemid: Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	52045 Furosemide 250mg/5n	Loop Diure	2020200	%furosemide%
Y	also used f	8102 Potassium Furosemid: Modified-r	Diuretics V	2020800	%furosemide%
Y	also used f	19192 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	6 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	27690 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	56375 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	34006 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	59911 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	46699 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	60291 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	46948 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	25717 Furosemid: Furosemid: Tablet	Loop Diure	2020200	%furosemide%

Y	also used f	34557	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	27696	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	32896	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	34374	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	27447	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	5728	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	42488	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	42388	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	3248	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	25334	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	41828	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	41405	Furosemid; Furosemid; Tablet	Loop Diure	2020200	%furosemide%
Y	also used f	5249	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	49268	Furosemide 50mg/5ml	Loop Diure	2020200	%furosemide%
Y	also used f	19258	Furosemid; Furosemid; Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	55738	Furosemid; Furosemid; Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	19056	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	60465	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	36190	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	51983	Furosemide 5mg/5ml (Loop Diure	2020200	%furosemide%
Y	also used f	52900	Furosemid; Furosemid; Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	32277	Furosemid; Furosemid; Solution fo	Loop Diure	2020200	%furosemide%
Y	also used f	58078	Furosemid; Furosemid; Oral solutic	Loop Diure	2020200	%furosemide%
Y	also used f	4211	Furosemid; Furosemid; Tablet	Loop Diure	02020200/	%amiloride%, %furosemide%
Y	also used f	1369	Furosemid; Furosemid; Tablet	Loop Diure	02020200/	%amiloride%, %furosemide%
Y	also used f	5220	Furosemid; Furosemid; Tablet	Loop Diure	02020200/	%amiloride%, %furosemide%
Y	also used f	26529	Penbutolol Furosemid; Tablet	Loop Diure	02020200/	%furosemide%
Y	also used f	3050	Triamteren Furosemid; Tablet	Loop Diure	02020200/	%furosemide%, %triamterene%
Y	also used f	15715	Nifedipine Genalat ret Modified-r	Calcium-ch	2060200	%GENALAT%, %nifedipine%
Y		60007	Generic Sevikar HCT 4(Angiotensii	2050502	%SEVIKAR%
Y	also used f	8025	Trandolapr Gopten 1m Capsule	Angiotensii	2050501	%GOPTEN%, %Trandolapril%
Y	also used f	8026	Trandolapr Gopten 2m Capsule	Angiotensii	2050501	%GOPTEN%, %Trandolapril%
Y	also used f	29130	Trandolapr Gopten 4m Capsule	Angiotensii	2050501	%GOPTEN%, %Trandolapril%
Y	also used f	16710	Trandolapr Gopten 50(Angiotensii	2050501	%GOPTEN%, %Trandolapril%
Y		7923	Guanethidi Guanethidi Tablet	Adrenergic	2050300	%guanethidine%
Y		31080	Guanethidi Guanethidi Solution fo	Adrenergic	2050300	%guanethidine%
Y		17291	Guanethidi Guanethidi Tablet	Adrenergic	2050300	%guanethidine%
Y	also used f	47543	Propranolol Half Beta-P Modified-r	Unknown	0	%BETA-PROGRANE%, %Propranolol%
Y	also used f	56173	Propranolol Half Beta-P Modified-r	Beta-adren	02040000/	%BETA-PROGRANE%, %Propranolol%
Y	also used f	46363	Propranolol Half Beta-P Modified-r	Beta-adren	02040000/	%BETA-PROGRANE%, %Propranolol%
Y	also used f	20468	Propranolol Half Beta-P Modified-r	Beta-adren	02040000/	%BETA-PROGRANE%, %Propranolol%
Y	also used f	1006	Propranolol Half Indera Modified-r	Beta-adren	02040000/	%INDERAL%, %Propranolol%
Y	also used f	22208	Propranolol Half propar Modified-r	Beta-adren	02040000/	%PROPANIX%, %Propranolol%
Y	also used f	28788	Propranolol Half propat Modified-r	Beta-adren	02040000/	%PROPATARD%, %Propranolol%
Y	also used f	3343	Verapamil Half Securc Modified-r	Calcium-ch	2060200	%HALF SECURON%, %SECURON%, %verapami
Y	also used f	15619	Propranolol Half-betad Modified-r	Beta-adren	02040000/	%BETADUR%, %Propranolol%
Y	also used f	25052	HALF-INDERAL LA	Unknown	0	%INDERAL%
Y	also used f	47530	Diltiazem h Horizem SF Modified-r	Calcium-ch	2060200	%Horizem SR%, %diltiazem%
Y	also used f	214	HYDRALAZINE 1 MG S\	Unknown	0	%hydralazine%
Y	also used f	18861	Hydralazin; Hydralazin; Oral suspei	Vasodilato	2050100	%hydralazine%
Y	also used f	504	Hydralazin; Hydralazin; Powder for	Vasodilato	2050100	%hydralazine%
Y	also used f	573	Hydralazin; Hydralazin; Tablet	Vasodilato	2050100	%hydralazine%
Y	also used f	31220	Hydralazin; Hydralazin; Tablet	Vasodilato	2050100	%hydralazine%
Y	also used f	43500	Hydralazin; Hydralazin; Tablet	Vasodilato	2050100	%hydralazine%
Y	also used f	1296	Hydralazin; Hydralazin; Tablet	Vasodilato	2050100	%hydralazine%
Y	also used f	41639	Hydralazin; Hydralazin; Tablet	Vasodilato	2050100	%hydralazine%
Y	also used f	59512	Hydralazin; Hydralazin; Oral solutic	Vasodilato	2050100	%hydralazine%
Y	also used f	31971	HYDRALAZINE 6.25 MC	Unknown	0	%hydralazine%
Y	also used f	23746	HYDRALAZINE HCl 10 M	Unknown	0	%hydralazine%
Y	also used f	21749	HYDRALAZINE HCl 100	Unknown	0	%hydralazine%
Y	also used f	4507	HYDRALAZINE HCl 12.5	Unknown	0	%hydralazine%
Y	also used f	13525	Hydroflum; Hydrenox 5 Tablet	Thiazides A	2020100	%HYDRENOX%, %thiazide%
Y		24520	HYDROCHLOROTHIAZI	Unknown	0	%CHLOROTHIAZ%, %Metoprolol%, %thiazide%

Y	also used f	23483	HYDROCHLOROTHIAZI	Unknown	0	%CHLOROTHIAZ%, %thiazide%
Y	also used f	15577	HYDROCHLOROTHIAZI	Unknown	0	%CHLOROTHIAZ%, %thiazide%
Y	also used f	542	Hydrochlor Hydrochlor Tablet	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	3517	Hydrochlor Hydrochlor Tablet	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	48132	Hydrochlor Hydrochlor Capsule	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	57488	Hydrochlor Hydrochlor Oral Solutio	Thiazides A	2020100	%CHLOROTHIAZ%, %thiazide%
Y	also used f	19890	Amiloride l Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	22923	Amiloride l Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y		28177	Atenolol Hydrochlor Capsule	Thiazides A	02020100/	%Atenolol%, %CHLOROTHIAZ%, %amiloride%,
Y		15135	Captopril Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Captopril%, %thiazide%
Y		11133	Captopril Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Captopril%, %thiazide%
Y		38367	Losartan Pr Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		14738	Losartan Pr Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		24632	Losartan Pr Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		29427	Metoprolo Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Metoprolol%, %thiazide%
Y		33659	Metoprolo Hydrochlor Modified-r	Thiazides A	02020100/	%CHLOROTHIAZ%, %Metoprolol%, %thiazide%
Y		35380	Hydrochlor Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %thiazide%
Y		39021	Hydrochlor Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %thiazide%
Y		21182	Timolol M Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Timolol% & %tab%, %am
Y	also used f	15127	Triamteren Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %thiazide%, %triamterene%
Y		24484	Valsartan Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Valsartan%, %thiazide%
Y		24268	Valsartan Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Valsartan%, %thiazide%
Y		23456	Valsartan Hydrochlor Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Valsartan%, %thiazide%
Y	also used f	12110	Hydroflum Hydroflum Tablet	Thiazides A	2020100	%thiazide%
Y	also used f	29529	Spironolaci Hydroflum Tablet	Thiazides A	02020100/	%spironolactone%, %thiazide%
Y	also used f	45916	Spironolaci Hydroflum Tablet	Thiazides A	02020100/	%spironolactone%, %thiazide%
Y		21346	Methyldop Hydromet Tablet	Centrally A	2050200	%HYDROMET%, %methyldopa%
Y	also used f	12440	Hydrochlor Hydrosalur Tablet	Unknown	0	%CHLOROTHIAZ%, %HYDROSALURIC%, %SALL
Y	also used f	16632	Hydrochlor Hydrosalur Tablet	Unknown	0	%CHLOROTHIAZ%, %HYDROSALURIC%, %SALL
Y	also used f	3054	Chlortalido Hygroton 1 Tablet	Thiazides A	02020100/	%HYGROTON%, %chlortalidone%
Y	also used f	3997	Chlortalido Hygroton 5 Tablet	Thiazides A	2020100	%HYGROTON%, %chlortalidone%
Y	also used f	8891	Potassium Hygroton -l Tablet	Thiazides A	2020100	%HYGROTON%
Y		23345	Alseroxylo Hypercal 2l Tablet	Centrally A	2050200	%HYPERCAL%, %alseroxyton%
Y		30691	Rauwolfia l Hypercal b Tablet	Centrally A	2050200	%HYPERCAL%, %rauwolfia%
Y	also used f	25500	Amiloride l Hypertane Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %amiloride%, %thiazide%
Y	also used f	21216	Nifedipine Hypolar Re Modified-r	Calcium-ch	2060200	%HYPOLAR%, %nifedipine%
Y	also used f	9485	Nifedipine Hypolar Re Modified-r	Calcium-ch	2060200	%HYPOLAR%, %nifedipine%
Y	also used f	23736	Nifedipine Hypolar XL Modified-r	Calcium-ch	2060200	%HYPOLAR%, %nifedipine%
Y	also used f	19566	HYPOVASE	Unknown	0	%HYPOVASE%
Y	also used f	1292	Prazosin h Hypovase 1 Tablet	Alpha-adre	02050400/	%HYPOVASE%, %prazosin%
Y	also used f	5183	Prazosin h Hypovase 2 Tablet	Alpha-adre	02050400/	%HYPOVASE%, %prazosin%
Y	also used f	4111	Prazosin h Hypovase 5 Tablet	Alpha-adre	02050400/	%HYPOVASE%, %prazosin%
Y	also used f	8198	Prazosin h Hypovase 5 Tablet	Alpha-adre	02050400/	%HYPOVASE%, %prazosin%
Y	also used f	24211	HYPOVASE B.D. START	Unknown	0	%HYPOVASE%
Y	also used f	12518	Hypovase t Not applica	Unknown	0	%HYPOVASE%
Y	also used f	2347	Terazosin l Hytrin 10m Tablet	Alpha-adre	02050400/	%Hytrin%, %Terazosin%
Y	also used f	37428	Terazosin l Hytrin 10m Tablet	Alpha-bloc	7040150	%Hytrin%, %Terazosin%
Y	also used f	8077	Terazosin l Hytrin 2mg Tablet	Alpha-adre	02050400/	%Hytrin%, %Terazosin%
Y	also used f	36649	Terazosin l Hytrin 2mg Tablet	Alpha-adre	02050400/	%Hytrin%, %Terazosin%
Y	also used f	2346	Terazosin l Hytrin 5mg Tablet	Alpha-adre	02050400/	%Hytrin%, %Terazosin%
Y	also used f	36780	Terazosin l Hytrin 5mg Tablet	Alpha-adre	02050400/	%Hytrin%, %Terazosin%
Y	also used f	8076	Hytrin tabl Not applica	Alpha-bloc	7040150	%Hytrin%
Y	also used f	12858	Imidapril h Imidapril 1l Tablet	Angiotensii	2050501	%Imidapril%
Y	also used f	18219	Imidapril h Imidapril 2l Tablet	Angiotensii	2050501	%Imidapril%
Y	also used f	16924	Imidapril h Imidapril 5l Tablet	Angiotensii	2050501	%Imidapril%
Y	also used f	5112	Indapamid Indapamid Modified-r	Thiazides A	2020100	%indapamide%
Y	also used f	46675	Indapamid Indapamid Modified-r	Thiazides A	2020100	%indapamide%
Y	also used f	60020	Indapamid Indapamid Modified-r	Thiazides A	2020100	%indapamide%
Y	also used f	2612	Indapamid Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	48099	Indapamid Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	43516	Indapamid Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	54316	Indapamid Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	56296	Indapamid Indapamid Tablet	Thiazides A	2020100	%indapamide%

Y	also used f	56760	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	34551	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	40907	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	55259	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	42906	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	49529	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	33083	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	48079	Indapamid	Indapamid Tablet	Thiazides A	2020100	%indapamide%
Y	also used f	44310		INDERAL	Unknown	0	%INDERAL%
Y	also used f	2414	Propranolol	Inderal 10n Tablet	Beta-adren	02040000/	%INDERAL%, %Propranolol%
Y	also used f	8331	Propranolol	Inderal 16C Tablet	Supraventr	02030202/	%INDERAL%, %Propranolol%
Y	also used f	1050	Propranolol	Inderal 40n Tablet	Beta-adren	02040000/	%INDERAL%, %Propranolol%
Y	also used f	1048	Propranolol	Inderal 80n Tablet	Beta-adren	02040000/	%INDERAL%, %Propranolol%
Y	also used f	3005	Propranolol	Inderal LA : Modified-r	Beta-adren	02040000/	%INDERAL%, %Propranolol%
Y	also used f	52609	Propranolol	Inderal LA : Modified-r	Beta-adren	02040000/	%INDERAL%, %Propranolol%
Y		4796	Propranolol	Inderetic 8i Capsule	Unknown	0	%INDERETIC%, %Propranolol%, %thiazide%
Y		8369	Propranolol	Inderex 16i Modified-r	Unknown	0	%INDEREX%, %Propranolol%, %thiazide%
Y	also used f	44168	Indapamid	Indipam XL Modified-r	Thiazides A	2020100	%INDIPAM%, %indapamide%
Y		5815	Indoramin	Indoramin Tablet	Alpha-adre	02050400/	%indoramin%
Y		9019	Indoramin	Indoramin Tablet	Alpha-adre	02050400/	%indoramin%
Y	also used f	8830	Enalapril m	Innovace 1 Tablet	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	8106	Enalapril m	Innovace 2 Tablet	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	8105	Enalapril m	Innovace 2 Tablet	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	8800	Enalapril m	Innovace 5 Tablet	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	27871	Enalapril M	Innovace n Wafer	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	29530	Enalapril M	Innovace n Wafer	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	31587	Enalapril M	Innovace n Wafer	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	11197	Enalapril M	Innovace n Wafer	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y	also used f	15085	Enalapril M	Innovace T Titration P	Angiotensii	2050501	%Enalapril%, %INNOVACE%
Y		1021	Enalapril m	Innozide 2i Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Enalapril%, %INNOZIDE%
Y	also used f	14144	Eplerenone	Inspira 25m Tablet	Potassium-	2020300	%INSPRA%, %eplerenone%
Y	also used f	29694	Eplerenone	Inspira 50m Tablet	Potassium-	2020300	%INSPRA%, %eplerenone%
Y		31160		IRBESARTAN	Unknown	0	%Irbesartan%
Y		11448	Hydrochlor	Irbesartan Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Irbesartan%, %thiazide%
Y		1293	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		58108	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		58201	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		60597	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		11469	Irbesartan/	Irbesartan Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Irbesartan%, %thiazide%
Y		35481	Irbesartan/	Irbesartan Tablets	Thiazides A	02020100/	%CHLOROTHIAZ%, %Irbesartan%, %thiazide%
Y		2971	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		55017	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		59393	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		52972	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		36939	Irbesartan	Irbesartan Suspensior	Angiotensii	2050502	%Irbesartan%
Y		828	Irbesartan	Irbesartan Tablet	Angiotensii	2050502	%Irbesartan%
Y		7922	Guanethidi	Ismelin 10r Tablet	Adrenergic	2050300	%ISMELIN%, %guanethidine%
Y	also used f	48189	Guanethidi	Ismelin 10r Solution fo	Adrenergic	2050300	%ISMELIN%, %guanethidine%
Y	also used f	30127	Guanethidi	Ismelin 10r Solution fo	Adrenergic	2050300	%ISMELIN%, %guanethidine%
Y		13379	Guanethidi	Ismelin 25r Tablet	Adrenergic	2050300	%ISMELIN%, %guanethidine%
Y		8310	Isradipine	Isradipine 2 Tablet	Calcium-ch	2060200	%ADIPINE%, %isradipine%
Y	also used f	5914	Amlodipine	Istin 10mg Tablet	Calcium-ch	2060200	%Istin 10mg%, %amlodipine%
Y	also used f	3917	Amlodipine	Istin 5mg t: Tablet	Calcium-ch	2060200	%Istin 5mg%, %amlodipine%
Y	also used f	28157	Triamteren	Kalspare Is Tablet	Thiazides A	02020100/	%KALSPARE%, %triamterene%
Y	also used f	12546	Chlortalido	Kalspare Tz Tablet	Thiazides A	02020100/	%KALSPARE%, %chlortalidone%, %triamteren
Y	also used f	16498	Chlortalido	Kalspare ta Tablet	Potassium-	2020400	%KALSPARE%, %chlortalidone%, %triamteren
Y		7543	Atenolol/A	Kalten cap: Capsule	Beta-adren	2040100	%Atenolol%, %CHLOROTHIAZ%, %KALTEN%, 9
Y	also used f	21943	Captopril	Kaplon 12: Tablet	Angiotensii	2050501	%Captopril%, %KAPLON%
Y	also used f	26995	Captopril	Kaplon 25n Tablet	Angiotensii	2050501	%Captopril%, %KAPLON%
Y	also used f	32048	Captopril	Kaplon 50n Tablet	Angiotensii	2050501	%Captopril%, %KAPLON%
Y	also used f	38434	Felodipine	Keloc SR 1i Modified-r	Calcium-ch	2060200	%KELOC%, %felodipine%
Y	also used f	35696	Diltiazem	h Kenzem SR Modified-r	Calcium-ch	2060200	%KENZEM%, %diltiazem%
Y	also used f	37774	Diltiazem	h Kenzem SR Modified-r	Calcium-ch	2060200	%KENZEM%, %diltiazem%

Y	also used f	27401	Diltiazem h Kenzem SR Modified-r	Calcium-ch	2060200	%KENZEM%, %diltiazem%
Y	also used f	21981	KERLONE	Unknown	0	%KERLONE%
Y	also used f	12519	Betaxolol h Kerlone 20 Tablet	Unknown	0	%KERLONE%
Y		54940	Ketanserin Ketanserin Tablet	Hypertensi	2050000	%ketanserin%
Y		34171	Labetalol h Labetalol 1 Tablet	Beta-adren	2040000	%labetalol%
Y		1597	Labetalol h Labetalol 1 Tablet	Beta-adren	2040000	%labetalol%
Y		34177	Labetalol h Labetalol 1 Tablet	Beta-adren	2040000	%labetalol%
Y		41827	Labetalol h Labetalol 1 Tablet	Beta-adren	2040000	%labetalol%
Y	also used f	38370	Labetalol h Labetalol 1 Solution fo	Beta-adren	2040000	%labetalol%
Y	also used f	59222	Labetalol h Labetalol 1 Solution fo	Beta-adren	2040000	%labetalol%
Y		47674	Labetalol h Labetalol 2 Tablet	Beta-adren	2040000	%labetalol%
Y		34188	Labetalol h Labetalol 2 Tablet	Beta-adren	2040000	%labetalol%
Y		2775	Labetalol h Labetalol 2 Tablet	Beta-adren	2040000	%labetalol%
Y		30770	Labetalol h Labetalol 2 Tablet	Beta-adren	2040000	%labetalol%
Y		44083	Labetalol h Labetalol 2 Tablet	Beta-adren	2040000	%labetalol%
Y		47673	Labetalol h Labetalol 4 Tablet	Beta-adren	2040000	%labetalol%
Y		1295	Labetalol h Labetalol 4 Tablet	Beta-adren	2040000	%labetalol%
Y		40240	Labetalol h Labetalol 4 Tablet	Beta-adren	2040000	%labetalol%
Y		45250	Labetalol h Labetalol 4 Tablet	Beta-adren	2040000	%labetalol%
Y		4725	Labetalol h Labetalol 5 Tablet	Beta-adren	2040000	%labetalol%
Y	also used f	19068	Labetalol h Labetalol 5 Solution fo	Unknown	0	%labetalol%
Y		7491	LABETALOL TAB	Unknown	0	%labetalol%
Y		35778	Labetalol h Labrocol 1(Tablet	Beta-adren	2040000	%LABROCOL%, %labetalol%
Y		22793	Labetalol h Labrocol 2(Tablet	Beta-adren	2040000	%LABROCOL%, %labetalol%
Y		16645	Labetalol h Labrocol 4(Tablet	Beta-adren	2040000	%LABROCOL%, %labetalol%
Y		5158	Lacidipine Lacidipine : Tablet	Calcium-ch	2060200	%lacidipine%
Y		3221	Lacidipine Lacidipine : Tablet	Calcium-ch	2060200	%lacidipine%
Y		57680	Lacidipine Lacidipine : Tablet	Calcium-ch	2060200	%lacidipine%
Y		56994	Lacidipine Lacidipine : Tablet	Calcium-ch	2060200	%lacidipine%
Y	also used f	45040	Doxazosin Larbex XL 4 Modified-r	Alpha-adre	02050400/	%LARBEX%, %doxazosin%
Y	also used f	7582	Potassium Lasikal mor Modified-r	Unknown	0	%LASIKAL%, %furosemide%
Y	also used f	7441	Spiro nolact Lasilactone Capsule	Potassium-	2020400	%LASILACTONE%, %furosemide%, %spironola
Y		24832	Penbutolol Lasipressin Tablet	Loop Diure	02020200/	%LASIPRESSIN%, %Lasipressin%
Y	also used f	26328	LASIX (25ML)	Unknown	0	%LASIX%
Y	also used f	22539	LASIX (2ML)	Unknown	0	%LASIX%
Y	also used f	20513	LASIX 10 MG INJ	Unknown	0	%LASIX%
Y	also used f	7799	Furosemid Lasix 20mg Tablet	Loop Diure	2020200	%LASIX%, %furosemide%
Y	also used f	4258	Furosemid Lasix 20mg Solution fo	Loop Diure	2020200	%LASIX%, %furosemide%
Y	also used f	12318	Furosemid Lasix 250m Solution fo	Loop Diure	2020200	%LASIX%, %furosemide%
Y	also used f	7606	Furosemid Lasix 40mg Tablet	Loop Diure	2020200	%LASIX%, %furosemide%
Y	also used f	10392	Furosemid Lasix 500m Tablet	Loop Diure	2020200	%LASIX%, %furosemide%
Y	also used f	10422	Furosemid Lasix 50mg Solution fo	Loop Diure	2020200	%LASIX%, %furosemide%
Y	also used f	4182	Furosemid Lasix 5mg/ Oral solutic	Loop Diure	2020200	%LASIX%, %furosemide%
Y	also used f	23256	LASIX PAED	Unknown	0	%LASIX%
Y	also used f	10781	Potassium Lasix with l Modified-r	Diuretics W	2020800	%LASIX%, %furosemide%
Y	also used f	2772	Amiloride l Lasoride 5r Tablet	Potassium-	2020400	%LASORIDE%, %amiloride%, %furosemide%
Y		5593	Lercanidipi Lercanidipi Tablet	Calcium-ch	2060200	%lercanidipine%
Y		57444	Lercanidipi Lercanidipi Tablet	Calcium-ch	2060200	%lercanidipine%
Y		47331	Lercanidipi Lercanidipi Tablet	Calcium-ch	2060200	%lercanidipine%
Y		13243	Lercanidipi Lercanidipi Tablet	Calcium-ch	2060200	%lercanidipine%
Y		59233	Lercanidipi Lercanidipi Tablet	Calcium-ch	2060200	%lercanidipine%
Y		56767	Lercanidipi Lercanidipi Tablet	Calcium-ch	2060200	%lercanidipine%
Y		6786	Lisinopril/ l Lisinopril 1 Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Lisinopril%, %thiazide%
Y		37710	Lisinopril/ l Lisinopril 1 Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Lisinopril%, %thiazide%
Y	also used f	65	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	43416	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	55639	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	45300	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	53271	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	47159	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	54288	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	54928	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	33977	Lisinopril Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%

Y	also used f	60010	Lisinopril	Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	58863	Lisinopril	Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	54037	Lisinopril	Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	32597	Lisinopril	Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	19223	Lisinopril	Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	58871	Lisinopril	Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	57048	Lisinopril	Lisinopril 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	277	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	43412	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	55896	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	58451	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	58682	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	58461	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	43566	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	30921	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	60097	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	56279	Lisinopril	Lisinopril 2 Oral solutic	Angiotensii	2050501	%Lisinopril%
Y	also used f	58258	Lisinopril	Lisinopril 2 Oral suspei	Angiotensii	2050501	%Lisinopril%
Y		6468	Lisinopril/f	Lisinopril 2 Tablet	Thiazides A 02020100/	%CHLOROTHIAZ%, %Lisinopril%, %thiazide%	
Y		55399	Lisinopril/f	Lisinopril 2 Tablet	Thiazides A 02020100/	%CHLOROTHIAZ%, %Lisinopril%, %thiazide%	
Y		54201	Lisinopril/f	Lisinopril 2 Tablet	Thiazides A 02020100/	%CHLOROTHIAZ%, %Lisinopril%, %thiazide%	
Y		33353	Lisinopril/f	Lisinopril 2 Tablet	Thiazides A 02020100/	%CHLOROTHIAZ%, %Lisinopril%, %thiazide%	
Y		56244	Lisinopril/f	Lisinopril 2 Tablet	Thiazides A 02020100/	%CHLOROTHIAZ%, %Lisinopril%, %thiazide%	
Y	also used f	69	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	43413	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	55002	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	45324	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	59111	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	34696	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	53551	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	46979	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	55588	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	19198	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	51433	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	34799	Lisinopril	Lisinopril 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	78	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	43418	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	58294	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	45337	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	55456	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	45816	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	53820	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	34471	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	52088	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	60309	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	46975	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	19204	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	59109	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	60232	Lisinopril	Lisinopril 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	11987	Lisinopril	Lisinopril 5 Oral solutic	Angiotensii	2050501	%Lisinopril%
Y	also used f	37778	Lisinopril	Lisinopril 5 Oral suspei	Angiotensii	2050501	%Lisinopril%
Y	also used f	54283	Lisinopril	Lisinopril 5 Oral suspei	Angiotensii	2050501	%Lisinopril%
Y	also used f	20975	Lisinopril	Lisinopril 7 Oral suspei	Angiotensii	2050501	%Lisinopril%
Y	also used f	54512	Lisinopril	Lisinopril O Oral Solutic	Angiotensii	2050501	%Lisinopril%
Y	also used f	41573	Lisinopril	Lisopress 1 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	41538	Lisinopril	Lisopress 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	41522	Lisinopril	Lisopress 2 Tablet	Angiotensii	2050501	%Lisinopril%
Y	also used f	41532	Lisinopril	Lisopress 5 Tablet	Angiotensii	2050501	%Lisinopril%
Y		14495	Minoxidil	Loniten 10r Tablet	Vasodilato	2050100	%LONITEN%, %minoxidil%
Y		9697	Minoxidil	Loniten 2.5 Tablet	Vasodilato	2050100	%LONITEN%, %minoxidil%
Y		9463	Minoxidil	Loniten 5m Tablet	Vasodilato	2050100	%LONITEN%, %minoxidil%
Y	also used f	32934	Ramipril	Lopace 10r Capsule	Angiotensii	2050501	%LOPACE%, %Ramipril%
Y	also used f	29627	Ramipril	Lopace 2.5 Capsule	Angiotensii	2050501	%LOPACE%, %Ramipril%

Y	also used f	28586	Ramipril Lopace 5m Capsule	Angiotensii	2050501	%LOPACE%, %Ramipril%
Y	also used f	26255	Propranolol Lopranolol Modified-r	Beta-adren	02040000/	%LOPRANOL%, %Propranolol%
Y	also used f	13499	Metoprolol Lopresor 1 Tablet	Beta-adren	2040000	%LOPRESOR%, %Metoprolol%
Y	also used f	46740	Metoprolol Lopresor 1 Tablet	Beta-adren	02040000/	%LOPRESOR%, %Metoprolol%
Y	also used f	10429	Metoprolol Lopresor 5 Tablet	Beta-adren	2040000	%LOPRESOR%, %Metoprolol%
Y	also used f	46614	Metoprolol Lopresor 5 Tablet	Beta-adren	02040000/	%LOPRESOR%, %Metoprolol%
Y	also used f	16669	LOPRESOR SR 200 MG	Unknown	0	%LOPRESOR%
Y	also used f	20082	Metoprolol Lopresor SI Modified-r	Beta-adren	02040000/	%LOPRESOR%, %Metoprolol%
Y		8147	Metoprolol Lopresoret Tablet	Thiazides A	02020100/	%LOPRESOR%, %LOPRESORETIC%, %Metopro
Y		37650	Hydrochlor Losartan 1(Tablets	Angiotensii	2050504	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		48039	Losartan pr Losartan 1 Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		10323	Losartan pr Losartan 1(Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		52189	Losartan pr Losartan 1(Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y	also used f	624	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	49588	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	54404	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	55446	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	60506	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	57028	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	56970	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	47006	Losartan pr Losartan 1(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	52658	Losartan 100mg/5ml o	Angiotensii	2050502	%Losartan%
Y	also used f	39944	Losartan pr Losartan 1; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	52886	Losartan pr Losartan 1; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	58967	Losartan pr Losartan 1; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	59340	Losartan pr Losartan 1; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	40711	Losartan Pr Losartan 2. Oral Suspe	Angiotensii	2050502	%Losartan%
Y	also used f	520	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	50971	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	58274	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	54740	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	51186	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	58649	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	48398	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	49492	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	55718	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	59271	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	59086	Losartan pr Losartan 2; Tablet	Angiotensii	2050502	%Losartan%
Y		6437	Losartan pr Losartan 5(Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		56975	Losartan pr Losartan 5(Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y		56204	Losartan pr Losartan 5(Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Losartan%, %thiazide%
Y	also used f	1780	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	56104	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	54049	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	51601	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	54735	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	59750	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	54843	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	55296	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	59351	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	54057	Losartan pr Losartan 5(Tablet	Angiotensii	2050502	%Losartan%
Y	also used f	52659	Losartan pr Losartan 5(Oral solutic	Angiotensii	2050502	%Losartan%
Y	also used f	59903	Losartan 50mg/5ml or	Angiotensii	2050502	%Losartan%
Y	also used f	43184	Indapamid Mapemid Modified-r	Thiazides A	2020100	%MAPEMID%, %indapamide%
Y	also used f	17143	Mefruside Mefruside Tablet	Thiazides A	2020100	%FRUSID%, %Mefruside%
Y	also used f	30400	Metoprolol Mepranix 1 Tablet	Beta-adren	2040000	%MEPRANIX%, %Metoprolol%
Y	also used f	29762	Metoprolol Mepranix 5 Tablet	Beta-adren	2040000	%MEPRANIX%, %Metoprolol%
Y		18252	Methyldop Metalpha 2 Tablet	Centrally A	2050200	%METALPHA%, %methyldopa%
Y		25275	Methyldop Metalpha 5 Tablet	Centrally A	2050200	%METALPHA%, %methyldopa%
Y	also used f	8602	Metolazon Metenix 5r Tablet	Thiazides A	2020100	%METENIX%, %metolazone%
Y		29187	Methoserp Methoserp Tablet	Centrally A	2050200	%methoserpidine%
Y		10714	Methoserp Methoserp Tablet	Centrally A	2050200	%methoserpidine%
Y		29696	Benzthiazic Methoserp Tablet	Centrally A	2050200	%methoserpidine%, %thiazide%

Y	also used f	20057	Methyclotl Methyclotl Tablet	Thiazides A	2020100	%thiazide%
Y		3049	Methyldop Methyldop Tablet	Centrally A	2050200	%methyldopa%
Y		25836	METHYLDOPA 200 MG Unknown		0	%methyldopa%
Y		2649	METHYLDOPA 250 MG Unknown		0	%methyldopa%
Y		9225	Methyldop Methyldop Capsule	Centrally A	2050200	%methyldopa%
Y		41661	Methyldop Methyldop Tablet	Centrally A	2050200	%methyldopa%
Y		1707	Methyldop Methyldop Tablet	Centrally A	2050200	%methyldopa%
Y		32913	Methyldop Methyldop Tablet	Centrally A	2050200	%methyldopa%
Y		23761	Methyldop Methyldop Oral suspei	Centrally A	2050200	%methyldopa%
Y		3070	Methyldop Methyldop Tablet	Centrally A	2050200	%methyldopa%
Y		26919	Methyldop Methyldop Injection	Centrally A	2050200	%methyldopa%
Y		28738	Methyldop Methyldop Tablet	Centrally A	2050200	%CHLOROTHIAZ%, %methyldopa%, %thiazide'
Y	also used f	53674	Metolazon Metolazon Tablet	Thiazides A	2020100	%metolazone%
Y	also used f	49752	Metolazone 2.5mg/5r	Thiazides A	2020100	%metolazone%
Y	also used f	4334	Metolazon Metolazon Tablet	Thiazides A	2020100	%metolazone%
Y	also used f	4332	Metolazon Metolazon Tablet	Thiazides A	2020100	%metolazone%
Y	also used f	55777	Metolazone 5mg/5ml	Thiazides A	2020100	%metolazone%
Y	also used f	54329	Metolazon Metolazon Oral suspei	Thiazides A	2020100	%metolazone%
Y	also used f	54643	Metolazon Metolazon Oral Soluti	Thiazides A	2020100	%metolazone%
Y		7066	Hydrochlor Metoprolo Tablet	Unknown	0	%CHLOROTHIAZ%, %Metoprolol%, %thiazide9
Y	also used f	753	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34125	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34854	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34509	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	40167	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34092	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y		22151	METOPROLOL 100MG, Unknown		0	%CHLOROTHIAZ%, %Metoprolol%
Y		41892	METOPROLOL 100MG, Unknown		0	%CHLOROTHIAZ%, %Metoprolol%
Y	also used f	51447	Metoprolo Metoprolo Oral suspei	Beta-adren 02040000/		%Metoprolol%
Y		20093	Metoprolo Metoprolo Modified-r	Unknown	0	%CHLOROTHIAZ%, %Metoprolol%, %thiazide9
Y	also used f	8068	Metoprolo Metoprolo Modified-r	Beta-adren 02040000/		%Metoprolol%
Y	also used f	55979	Metoprolo Metoprolo Oral suspei	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34890	Metoprolo Metoprolo Tablet	Beta-adren 2040000		%Metoprolol%
Y	also used f	739	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34094	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34430	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	32836	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34584	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34925	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	34407	Metoprolo Metoprolo Tablet	Beta-adren 02040000/		%Metoprolol%
Y	also used f	11793	Metoprolo Metoprolo Oral suspei	Beta-adren 02040000/		%Metoprolol%
Y	also used f	57240	Metoprolo Metoprolo Oral suspei	Beta-adren 02040000/		%Metoprolol%
Y		17876	METOPROLOL FUMAR, Unknown		0	%Metoprolol%
Y		28493	METOPROLOL FUMAR, Unknown		0	%Metoprolol%
Y	also used f	47536	Metoprolo Metoprolo Oral Suspei	Beta-adren 2040000		%Metoprolol%
Y	also used f	45289	Metoprolo Metoprolo Oral Soluti	Beta-adren 2040000		%Metoprolol%
Y		15488	Metoprolo Metoprolo Tablet	Thiazides A 02020100/		%Metoprolol%, %chlortalidone%
Y		29998	Metoprolo Metoros 15 Tablet	Beta-adren 2040000		%METOROS%, %Metoprolol%
Y		27719	Metoprolo Metoros 15 Tablet	Beta-adren 2040000		%METOROS%, %Metoprolol%
Y	also used f	22241	Mibefradil Mibefradil Tablet	Calcium-ch 2060200		%mibefradil%
Y	also used f	15652	Mibefradil Mibefradil Tablet	Calcium-ch 2060200		%mibefradil%
Y	also used f	17686	Telmisartai Micardis 20 Tablet	Angiotensii 2050502		%Micardis%, %Telmisartan%
Y	also used f	13821	Telmisartai Micardis 40 Tablet	Angiotensii 2050502		%Micardis%, %Telmisartan%
Y	also used f	17545	Telmisartai Micardis 80 Tablet	Angiotensii 2050502		%Micardis%, %Telmisartan%
Y		18202	Telmisartai MicardisPlt Tablet	Angiotensii 2050504		%CHLOROTHIAZ%, %Micardis%, %Telmisartan
Y		17689	Telmisartai MicardisPlt Tablet	Angiotensii 2050504		%CHLOROTHIAZ%, %Micardis%, %Telmisartan
Y		38889	Hydrochlor MicardisPlt Tablets	Angiotensii 2050504		%CHLOROTHIAZ%, %Micardis%, %Telmisartan
Y	also used f	13352	Amiloride f Midamor 5 Tablet	Potassium- 2020300		%MIDAMOR%, %amiloride%
Y	also used f	24835	Furosemid Min-i-jet fu Injection	Loop Diure 2020200		%furosemide%
Y		2968	Minoxidil Minoxidil 1 Tablet	Vasodilato 2050100		%minoxidil%
Y		2970	Minoxidil Minoxidil 2 Tablet	Vasodilato 2050100		%minoxidil%
Y		2967	Minoxidil Minoxidil 5 Tablet	Vasodilato 2050100		%minoxidil%
Y		19687	MODUCREN	Unknown	0	%MODUCREN%

Y		4605	Timolol ma Moducren Tablet	Unknown	0	%CHLOROTHIAZ%, %MODUCREN%, %amiloric
Y	also used f	1251	Amiloride f Moduret 2 Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %MODURET%, %amiloride
Y	also used f	20779	MODURETIC	Unknown	0	%MODURET%
Y	also used f	42142	Amiloride f Moduretic Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %MODURET%, %amiloride
Y	also used f	3293	Amiloride f Moduretic Oral Soluti	Thiazides A	02020100/	%MODURET%, %amiloride%
Y	also used f	348	Amiloride f Moduretic Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %MODURET%, %amiloride
Y		17120	Moexipril f Moexipril 1 Tablet	Angiotensii	2050501	%Moexipril%
Y		15121	Moexipril f Moexipril 7 Tablet	Angiotensii	2050501	%Moexipril%
Y	also used f	56486	Bisoprolol f Monocor 1 Tablet	Beta-adren	02040000/	%Bisoprolol%, %MONOCOR%
Y	also used f	5968	Bisoprolol f Monocor 1 Tablet	Beta-adren	02040000/	%Bisoprolol%, %MONOCOR%
Y	also used f	3588	Bisoprolol f Monocor 5 Tablet	Beta-adren	02040000/	%Bisoprolol%, %MONOCOR%
Y		17149	Bisoprolol f Monozide Tablet	Unknown	0	%Bisoprolol%, %CHLOROTHIAZ%, %MONOZID
Y		11966	Lacidipine Motens 2r Tablet	Calcium-ch	2060200	%MOTENS%, %lacidipine%
Y		9670	Lacidipine Motens 4r Tablet	Calcium-ch	2060200	%MOTENS%, %lacidipine%
Y		4993	Moxonidin Moxonidin Tablet	Centrally A	2050200	%moxonidine%
Y		33322	Moxonidin Moxonidin Tablet	Centrally A	2050200	%moxonidine%
Y		40310	Moxonidin Moxonidin Tablet	Centrally A	2050200	%moxonidine%
Y		10253	Moxonidin Moxonidin Tablet	Centrally A	2050200	%moxonidine%
Y		7174	Moxonidin Moxonidin Tablet	Centrally A	2050200	%moxonidine%
Y		43531	Moxonidin Moxonidin Tablet	Centrally A	2050200	%moxonidine%
Y		23134	Nadolol/Be Nadolol 40 Tablet	Unknown	0	%Nadolol%, %thiazide%
Y	also used f	8935	Nadolol Nadolol 40 Tablet	Unknown	0	%Nadolol%
Y		27946	Nadolol/Be Nadolol 80 Tablet	Unknown	0	%Nadolol%, %thiazide%
Y	also used f	2499	Nadolol Nadolol 80 Tablet	Beta-adren	2040000	%Nadolol%
Y		27086	NADOLOL 80MG/BENC	Unknown	0	%Nadolol%
Y	also used f	27957	Indapamid Natramid 2 Tablet	Thiazides A	2020100	%NATRAMID%, %indapamide%
Y		27546	NATRILIX	Unknown	0	%NATRILIX%
Y	also used f	7641	Indapamid Natrilix 2.5 Tablet	Thiazides A	2020100	%NATRILIX%, %indapamide%
Y		15602	NATRILIX 5 MG TAB	Unknown	0	%NATRILIX%
Y		3056	Indapamid Natrilix SR Modified-r	Thiazides A	2020100	%NATRILIX%, %indapamide%
Y	also used f	22242	NAVIDREX	Unknown	0	%NAVIDREX%
Y	also used f	2046	Cyclopenth Navidrex 5 Tablet	Thiazides A	2020100	%NAVIDREX%, %thiazide%
Y	also used f	1125	Potassium Navidrex -k Tablet	Thiazides A	2020100	%NAVIDREX%
Y	also used f	2255	Amiloride f Navispare Tablet	Potassium-	2020400	%NAVISPARE%, %amiloride%, %thiazide%
Y	also used f	7528	Nebivolol f Nebilet 5m Tablet	Beta-adren	2040000	%NEBILET%, %nebivolol%
Y	also used f	59961	Nebivolol f Nebivolol 1 Tablet	Beta-adren	2040000	%nebivolol%
Y	also used f	40761	Nebivolol f Nebivolol 2 Tablet	Beta-adren	2040000	%nebivolol%
Y	also used f	44808	Nebivolol f Nebivolol 2 Tablet	Beta-adren	2040000	%nebivolol%
Y	also used f	47300	Nebivolol f Nebivolol 2 Tablet	Beta-adren	2040000	%nebivolol%
Y	also used f	54487	Nebivolol f Nebivolol 2 Tablet	Beta-adren	2040000	%nebivolol%
Y	also used f	751	Nebivolol f Nebivolol 5 Tablet	Beta-adren	2040000	%nebivolol%
Y	also used f	24189	Bendroflun Neo-bendr Tablet	Thiazides A	2020100	%NEO-BENDROMAX%, %thiazide%
Y	also used f	24190	Bendroflun Neo-bendr Tablet	Thiazides A	2020100	%NEO-BENDROMAX%, %thiazide%
Y	also used f	29044	Felodipine Neofel XL 1 Modified-r	Calcium-ch	2060200	%NEOFEL%, %felodipine%
Y	also used f	55740	Felodipine Neofel XL 2 Modified-r	Calcium-ch	2060200	%NEOFEL%, %felodipine%
Y	also used f	58339	Felodipine Neofel XL 2 Modified-r	Calcium-ch	2060200	%NEOFEL%, %felodipine%
Y	also used f	39357	Felodipine Neofel XL 2 Modified-r	Calcium-ch	2060200	%NEOFEL%, %felodipine%
Y	also used f	28721	Felodipine Neofel XL 5 Modified-r	Calcium-ch	2060200	%NEOFEL%, %felodipine%
Y	also used f	46302	Bendroflun Neo-Nacle) Tablet	Thiazides A	02020100/	%NEO-NACLEX%, %thiazide%
Y	also used f	1209	Bendroflun Neo-Nacle) Tablet	Thiazides A	2020100	%NEO-NACLEX%, %thiazide%
Y	also used f	1213	Bendroflun Neo-Nacle) Modified-r	Thiazides A	2020100	%NEO-NACLEX%, %thiazide%
Y	also used f	37530	Nifedipine Neozipine) Modified-r	Calcium-ch	2060200	%NEOZIPINE%, %nifedipine%
Y	also used f	35646	Nifedipine Neozipine) Modified-r	Calcium-ch	2060200	%NEOZIPINE%, %nifedipine%
Y	also used f	12360	Polythiazid Nephрил 1m Tablet	Thiazides A	2020100	%NEPHRIL%, %thiazide%
Y	also used f	2926	Nicardipine Nicardipine Capsule	Calcium-ch	2060200	%nicardipine%
Y	also used f	8201	Nicardipine Nicardipine Capsule	Calcium-ch	2060200	%nicardipine%
Y	also used f	45292	Nicardipine Nicardipine Capsule	Calcium-ch	2060200	%nicardipine%
Y	also used f	5477	Nicardipine Nicardipine Modified-r	Calcium-ch	2060200	%nicardipine%
Y	also used f	9386	Nicardipine Nicardipine Modified-r	Calcium-ch	2060200	%nicardipine%
Y	also used f	25055	NIFEDIPINE	Unknown	0	%nifedipine%
Y	also used f	37726	Nifedipine Nifedipine Oral suspei	Calcium-ch	2060200	%nifedipine%
Y	also used f	34247	Nifedipine Nifedipine Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	452	Nifedipine Nifedipine Capsule	Calcium-ch	2060200	%nifedipine%

Y	also used f	43511	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	43515	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	55455	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	46445	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	42912	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	2605	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	34187	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	47027	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	410	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	28688	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	49762	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	58990	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	26774	Nifedipine	Nifedipine	Oral Suspe	Calcium-ch	2060200	%nifedipine%
Y	also used f	53357	Nifedipine	Nifedipine	Oral suspe	Calcium-ch	2060200	%nifedipine%
Y	also used f	1262	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	40074	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	737	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	55824	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	37025	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	25919	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	49338	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	59163	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	47529	Nifedipine	Nifedipine	Oral drops	Calcium-ch	2060200	%nifedipine%
Y	also used f	8213	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	1449	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	5162	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	30199	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	47614	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	9269	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	269	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	34522	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	34607	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	34975	Nifedipine	Nifedipine	Capsule	Calcium-ch	2060200	%nifedipine%
Y	also used f	53990	Nifedipine	Nifedipine	Oral suspe	Calcium-ch	2060200	%nifedipine%
Y	also used f	9750	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	34115	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	3930	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	43410	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	34146	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	34101	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	47707	Nifedipine	Nifedipine	Oral Soluti	Calcium-ch	2060200	%nifedipine%
Y	also used f	25026		NIFEDIPINE RETARD	Unknown		0	%nifedipine%
Y	also used f	25044		NIFEDIPINE RETARD	Unknown		0	%nifedipine%
Y	also used f	38107	Nifedipine	Nifedipine	Tablet	Calcium-ch	2060200	%nifedipine%
Y	also used f	7823		NIFEDIPINE TAB 5 mg	Unknown		0	%nifedipine%
Y		15117	Nifedipine	Nifedipine	Capsule	Beta-adren	02040000/	%Atenolol%, %nifedipine%
Y	also used f	47285	Nifedipine	Nifedipine	Modified-r	Calcium-ch	2060200	%nifedipine%
Y	also used f	11512	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	16073	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	21245	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	10135	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	17448	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	21886	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	10136	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	20591	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	20311	Nifedipine	Nifedipress	Modified-r	Calcium-ch	2060200	%NIFEDIPRESS%, %nifedipine%
Y	also used f	17338	Nifedipine	Nifedotard	Modified-r	Calcium-ch	2060200	%NIFEDOTARD %, %nifedipine%
Y	also used f	12606	Nifedipine	Nifelease 2	Modified-r	Calcium-ch	2060200	%NIFELEAS%, %nifedipine%
Y	also used f	1300	Nifedipine	Nifensar xl	Modified-r	Calcium-ch	2060200	%NIFENSAR%, %nifedipine%
Y	also used f	25132	Nifedipine	Nifopress 1	Modified-r	Calcium-ch	2060200	%NIFOPRESS%, %nifedipine%
Y	also used f	7541	Nifedipine	Nifopress F	Modified-r	Calcium-ch	2060200	%NIFOPRESS%, %nifedipine%
Y	also used f	22217	Nifedipine	Nimodrel 1	Modified-r	Calcium-ch	2060200	%NIMODREL%, %nifedipine%
Y	also used f	24228	Nifedipine	Nimodrel 2	Modified-r	Calcium-ch	2060200	%NIMODREL%, %nifedipine%

Y	also used f	33025	Nifedipine Nimodrel X Modified-r	Calcium-ch	2060200	%NIMODREL%, %nifedipine%
Y	also used f	47887	Nifedipine Nimodrel X Modified-r	Calcium-ch	2060200	%NIMODREL%, %nifedipine%
Y	also used f	26275	Indapamid Nindaxa 2.1 Tablet	Thiazides A	2020100	%NINDAXA%, %indapamide%
Y	also used f	23805	Nisoldipine Nisoldipine Modified-r	Calcium-ch	2060200	%nisoldipine%
Y	also used f	18038	Nisoldipine Nisoldipine Modified-r	Calcium-ch	2060200	%nisoldipine%
Y	also used f	23823	Nisoldipine Nisoldipine Modified-r	Calcium-ch	2060200	%nisoldipine%
Y	also used f	17342	Nifedipine Nivaten ret Modified-r	Calcium-ch	2060200	%NIVATEN%, %nifedipine%
Y	also used f	25646	Nifedipine Nivaten ret Modified-r	Calcium-ch	2060200	%NIVATEN%, %nifedipine%
Y	also used f	8058	Amiloride l Normetic T Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %NORMETIC%, %amiloride
Y	also used f	60349	Captopril Noyada 25 Oral solutic	Angiotensii	2050501	%Captopril%
Y	also used f	31810	Trandolapr Odrik 1mg Capsule	Angiotensii	2050501	%ODRIK%, %Trandolapril%
Y	also used f	28902	Trandolapr Odrik 2mg Capsule	Angiotensii	2050501	%ODRIK%, %Trandolapril%
Y	also used f	31307	Trandolapr Odrik 500n Capsule	Angiotensii	2050501	%ODRIK%, %Trandolapril%
Y		6217	Olmesartar Olmesartar Tablet	Angiotensii	2050502	%Olmesartan%
Y		39786	Olmesartar Olmesartar Oral Suspei	Angiotensii	2050502	%Olmesartan%
Y		40316	Olmesartar Olmesartar Tablet	Angiotensii	02050502/	%Olmesartan%, %amlodipine%
Y		18200	Olmesartar Olmesartar Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %thiazide%
Y		18903	Hydrochlor Olmesartar Tablets	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %thiazide%
Y		6285	Olmesartar Olmesartar Tablet	Angiotensii	2050502	%Olmesartan%
Y		40668	Olmesartar Olmesartar Tablet	Angiotensii	02050502/	%Olmesartan%, %amlodipine%
Y		40639	Olmesartar Olmesartar Tablet	Angiotensii	02050502/	%Olmesartan%, %amlodipine%
Y		43322	Hydrochlor Olmesartar Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %thiazide%
Y		6351	Olmesartar Olmesartar Tablet	Angiotensii	2050502	%Olmesartan%
Y		46687	Amlodipine Olmesartar Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %amlodipi
Y		46715	Amlodipine Olmesartar Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %amlodipi
Y		55358	Amlodipine Olmesartar Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %amlodipi
Y		46792	Amlodipine Olmesartar Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %amlodipi
Y		47467	Amlodipine Olmesartar Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %amlodipi
Y		14983	Olmesartar Olmetec 1C Tablet	Angiotensii	2050502	%Olmesartan%, %Olmetec%
Y		18910	Olmesartar Olmetec 2C Tablet	Angiotensii	2050502	%Olmesartan%, %Olmetec%
Y		20117	Olmesartar Olmetec 4C Tablet	Angiotensii	2050502	%Olmesartan%, %Olmetec%
Y		29634	Olmesartar Olmetec Pl Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %Olmetec
Y		27520	Olmesartar Olmetec Pl Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %Olmetec
Y		43915	Hydrochlor Olmetec Pl Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Olmesartan%, %Olmetec
Y	also used f	21918	Diltiazem h Optil 60mg Modified-r	Calcium-ch	2060200	%Optil 60mg%, %diltiazem%
Y	also used f	26267	Diltiazem l Optil sr 12C Modified-r	Calcium-ch	2060200	%Optil sr%, %diltiazem%
Y	also used f	26269	Diltiazem l Optil sr 18C Modified-r	Calcium-ch	2060200	%Optil sr%, %diltiazem%
Y	also used f	23733	Diltiazem h Optil sr 90r Modified-r	Calcium-ch	2060200	%Optil sr%, %diltiazem%
Y	also used f	26309	Diltiazem h Optil xl 24C Modified-r	Calcium-ch	2060200	%Optil xl%, %diltiazem%
Y	also used f	26270	Diltiazem h Optil xl 30C Modified-r	Calcium-ch	2060200	%Optil xl%, %diltiazem%
Y	also used f	26256	Indapamid Opumide 2 Tablet	Thiazides A	2020100	%OPUMIDE%, %indapamide%
Y	also used f	12497	OXPRENOLOL 10 MG T	Unknown	0	%Oxprenolol%
Y	also used f	1334	Oxprenolol Oxprenolol Modified-r	Beta-adren	2040000	%Oxprenolol%
Y	also used f	3748	Oxprenolol Oxprenolol Tablet	Beta-adren	2040000	%Oxprenolol%
Y	also used f	3516	Oxprenolol Oxprenolol Tablet	Beta-adren	2040000	%Oxprenolol%
Y	also used f	27357	Oxprenolol Oxprenolol Tablet	Beta-adren	2040000	%Oxprenolol%
Y	also used f	1333	Oxprenolol Oxprenolol Tablet	Beta-adren	2040000	%Oxprenolol%
Y	also used f	2780	Oxprenolol Oxprenolol Tablet	Beta-adren	2040000	%Oxprenolol%
Y	also used f	33569	Oxprenolol Oxprenolol Modified-r	Beta-adren	2040000	%Oxprenolol%
Y		8673	Oxprenolol Oxprenolol Modified-r	Thiazides A	02020100/	%Oxprenolol%, %thiazide%
Y	also used f	21885	Oxprenolol Oxyphenix l Tablet	Beta-adren	2040000	%Oxprenolol%
Y	also used f	36620	Felodipine Parmid XL l Modified-r	Calcium-ch	2060200	%PARMID%, %felodipine%
Y	also used f	60652	Felodipine Parmid XL l Modified-r	Calcium-ch	2060200	%PARMID%, %felodipine%
Y	also used f	33932	Felodipine Parmid XL l Modified-r	Calcium-ch	2060200	%PARMID%, %felodipine%
Y		28725	Moexipril l Perdix 15m Tablet	Angiotensii	2050501	%Moexipril%, %PERDIX%
Y		28724	Moexipril l Perdix 7.5n Tablet	Angiotensii	2050501	%Moexipril%, %PERDIX%
Y	also used f	50402	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	37971	Perindopril Perindopril Tablets	Angiotensii	2050501	%Perindopril%
Y	also used f	37964	Perindopril Perindopril Tablets	Angiotensii	2050501	%Perindopril%
Y		50607	Perindopril Perindopril arginine 2r	Thiazides A	02020100/	%Perindopril%, %indapamide%
Y		48098	Perindopril Perindopril Tablets	Thiazides A	02020100/	%Perindopril%, %indapamide%
Y		37978	Indapamid Perindopril Tablets	Thiazides A	02020100/	%Perindopril%, %indapamide%
Y	also used f	37930	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%

Y	also used f	593	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	45319	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	43813	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	59972	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	49491	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	48049	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	58843	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	56516	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	56473	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	58874	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	54899	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y		60067	Perindopril Perindopril Tablet	Angiotensii	02050501/	%Perindopril%, %amlodipine%
Y		6794	Indapamid Perindopril Tablet	Thiazides A	02020100/	%Perindopril%, %indapamide%
Y	also used f	97	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	33095	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	48214	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	38510	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	59770	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	56162	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	57801	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	56472	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	48180	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	60065	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	38285	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	11983	Perindopril Perindopril Oral suspei	Angiotensii	2050501	%Perindopril%
Y	also used f	6078	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	35731	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	59790	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	57701	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	54733	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	54942	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	53058	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	45938	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	54986	Perindopril erbumine	Angiotensii	2050501	%Perindopril%
Y	also used f	43012	Perindopril Perindopril Oral Liquid	Angiotensii	2050501	%Perindopril%
Y	also used f	56079	Perindopril tosilate 10	Angiotensii	2050501	%Perindopril%
Y	also used f	57944	Perindopril tosilate 2.5	Angiotensii	2050501	%Perindopril%
Y		56157	Perindopril tosilate 5r	Thiazides A	02020100/	%Perindopril%, %indapamide%
Y	also used f	57333	Perindopril Perindopril Tablet	Angiotensii	2050501	%Perindopril%
Y	also used f	2927	PERINDOPRIL/TERT-BU	Unknown	0	%Perindopril%
Y		11177	Moxonidin Physiotens Tablet	Centrally A	2050200	%PHYSIOTENS%, %moxonidine%
Y		9876	Moxonidin Physiotens Tablet	Centrally A	2050200	%PHYSIOTENS%, %moxonidine%
Y		9749	Moxonidin Physiotens Tablet	Centrally A	2050200	%PHYSIOTENS%, %moxonidine%
Y		14057	Pindolol/Cl Pindolol 10 Tablet	Beta-adren	2040100	%Clopamide%, %Pindolol%
Y		25764	PINDOLOL 10MG/CLOI	Unknown	0	%Clopamide%, %Pindolol%
Y	also used f	55853	Pindolol Pindolol 15 Tablet	Beta-adren	2040000	%Pindolol%
Y	also used f	14673	Pindolol Pindolol 15 Tablet	Beta-adren	2040000	%Pindolol%
Y	also used f	5284	Pindolol Pindolol 5n Tablet	Beta-adren	2040000	%Pindolol%
Y	also used f	43394	Felodipine Pinefeld XL Modified-r	Calcium-ch	2060200	%PINEFELD%, %felodipine%
Y	also used f	12367	Piretanide Piretanide Capsules	Loop Diure	2020200	%Piretanide%
Y	also used f	7280	Felodipine Plendil 10n Modified-r	Calcium-ch	2060200	%PLENDIL%, %felodipine%
Y	also used f	9334	Felodipine Plendil 2.5r Modified-r	Calcium-ch	2060200	%PLENDIL%, %felodipine%
Y	also used f	9437	Felodipine Plendil 5m Modified-r	Calcium-ch	2060200	%PLENDIL%, %felodipine%
Y	also used f	12926	Polythiazid Polythiazid Tablet	Unknown	0	%thiazide%
Y	also used f	3931	Mibefradil Posicor 10r Tablet	Calcium-ch	2060200	%POSICOR%, %mibefradil%
Y	also used f	1529	Mibefradil Posicor 50r Tablet	Calcium-ch	2060200	%POSICOR%, %mibefradil%
Y	also used f	23252	Enalapril m Pralenal 10 Tablet	Angiotensii	2050501	%Enalapril%, %PRALENAL%
Y	also used f	42723	Enalapril m Pralenal 5 t Tablet	Angiotensii	2050501	%Enalapril%, %PRALENAL%
Y	also used f	60316	Prazosin h Prazosin 1r Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	591	Prazosin h Prazosin 1r Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	41721	Prazosin h Prazosin 1r Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	46922	Prazosin h Prazosin 1r Tablet	Alpha-adre	02050400/	%prazosin%
Y	also used f	445	Prazosin 1r Not applica	Unknown	0	%prazosin%

Y	also used f	726	Prazosin h _y Prazosin 2r Tablet	Alpha-adre 02050400/ %prazosin%
Y	also used f	41651	Prazosin h _y Prazosin 5C Tablet	Alpha-adre 02050400/ %prazosin%
Y	also used f	1455	Prazosin h _y Prazosin 5C Tablet	Alpha-adre 02050400/ %prazosin%
Y	also used f	41652	Prazosin h _y Prazosin 5C Tablet	Alpha-adre 02050400/ %prazosin%
Y	also used f	43547	Prazosin h _y Prazosin 5C Tablet	Alpha-adre 02050400/ %prazosin%
Y	also used f	3715	Prazosin h _y Prazosin 5r Tablet	Alpha-adre 02050400/ %prazosin%
Y	also used f	55826	Prazosin h _y Prazosin 5r Tablet	Alpha-adre 02050400/ %prazosin%
Y		8257	Isradipine Prescal 2.5 Tablet	Calcium-ch 2060200 %PRESCAL%, %isradipine%
Y		21025	Timolol M _a Prestim for Tablet	Thiazides A 02020100/ %PRESTIM%
Y		8623	Timolol m _a Prestim Tal Tablet	Thiazides A 02020100/ %PRESTIM%, %thiazide%
Y		25363	Timolol m _a Prestim tak Tablet	Beta-adren 2040100 %PRESTIM%, %thiazide%
Y	also used f	33376	Propranolol Probeta LA Modified-r _i	Beta-adren 02040000/ %PROBETA%, %Propranolol%
Y	also used f	14552	Propranolol Propanix 1l Tablet	Supraventr 02030202/ %PROPANIX%, %Propranolol%
Y	also used f	8978	Propranolol Propanix 1l Modified-r _i	Beta-adren 02040000/ %PROPANIX%, %Propranolol%
Y	also used f	29763	Propranolol Propanix 1l Tablet	Supraventr 02030202/ %PROPANIX%, %Propranolol%
Y	also used f	3827	Propranolol Propanix 4l Tablet	Supraventr 02030202/ %PROPANIX%, %Propranolol%
Y	also used f	21838	Propranolol Propanix 8l Tablet	Supraventr 02030202/ %PROPANIX%, %Propranolol%
Y	also used f	26228	Propranolol Propanix L Modified-r _i	Beta-adren 02040000/ %PROPANIX%, %Propranolol%
Y	also used f	32470	PROPRANOLOL 1 MG l Unknown	0 %Propranolol%
Y	also used f	22634	PROPRANOLOL 10 MG Unknown	0 %Propranolol%
Y	also used f	297	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	34378	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	34783	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	45494	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	36576	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	43525	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	58297	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	34804	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	5478	Propranolol Propranolol Oral solutic	Beta-adren 02040000/ %Propranolol%
Y	also used f	57567	Propranolol Propranolol Oral suspei	Beta-adren 02040000/ %Propranolol%
Y	also used f	46493	PROPRANOLOL 15 MG Unknown	0 %Propranolol%
Y		8987	Propranolol Propranolol Modified-r _i	Unknown 0 %Propranolol%, %thiazide%
Y	also used f	34949	Propranolol Propranolol Modified-r _i	Beta-adren 02040000/ %Propranolol%
Y	also used f	34945	Propranolol Propranolol Modified-r _i	Beta-adren 02040000/ %Propranolol%
Y	also used f	34884	Propranolol Propranolol Modified-r _i	Beta-adren 02040000/ %Propranolol%
Y	also used f	1448	Propranolol Propranolol Modified-r _i	Beta-adren 02040000/ %Propranolol%
Y	also used f	59597	Propranolol Propranolol Modified-r _i	Beta-adren 02040000/ %Propranolol%
Y	also used f	3167	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	34214	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	55849	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	26788	PROPRANOLOL 2.5 MG Unknown	0 %Propranolol%
Y	also used f	4021	PROPRANOLOL 20 MG Unknown	0 %Propranolol%
Y	also used f	29803	PROPRANOLOL 3 MG f Unknown	0 %Propranolol%
Y	also used f	25818	PROPRANOLOL 30 MG Unknown	0 %Propranolol%
Y	also used f	707	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	41555	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	59415	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	27700	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	58491	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	55416	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	55228	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	31776	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	45297	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	52777	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	57342	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	60565	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	34868	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	56764	Propranolol Propranolol Tablet	Beta-adren 02040000/ %Propranolol%
Y	also used f	55949	Propranolol Propranolol Oral solutic	Beta-adren 02040000/ %Propranolol%
Y	also used f	3087	Propranolol Propranolol Oral solutic	Beta-adren 02040000/ %Propranolol%
Y	also used f	11711	Propranolol Propranolol Oral Solutic	Supraventr 02030202/ %Propranolol%
Y	also used f	54297	Propranolol Propranolol Oral solutic	Beta-adren 02040000/ %Propranolol%
Y	also used f	38433	Propranolol Propranolol Oral Solutic	Supraventr 02030202/ %Propranolol%

Y	also used f	48682	Propranolo Propranolo Oral solutic	Beta-adren	02040000/	%Propranolol%
Y	also used f	220	Propranolo Propranolo Oral Solutic	Supraventr	02030202/	%Propranolol%
Y	also used f	49863	Propranolo Propranolo Oral solutic	Beta-adren	02040000/	%Propranolol%
Y		12054	Propranolo Propranolo Capsule	Unknown	0	%Propranolol%, %thiazide%
Y	also used f	34867	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	28128	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	32162	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	769	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	35938	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	39233	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	940	Propranolo Propranolo Tablet	Beta-adren	02040000/	%Propranolol%
Y	also used f	33644	Propranolo Propranolo Tablet	Beta-adren	02040000/	%Propranolol%
Y	also used f	31214	Propranolo Propranolo Tablet	Beta-adren	02040000/	%Propranolol%
Y	also used f	58407	Propranolo Propranolo Tablet	Beta-adren	02040000/	%Propranolol%
Y	also used f	9185	Propranolo Propranolo Oral Solutic	Supraventr	02030202/	%Propranolol%
Y	also used f	40241	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	34185	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	53177	Propranolo Propranolol oral soluti	Supraventr	02030202/	%Propranolol%
Y	also used f	26105	PROPRANOLOL paed 4	Unknown	0	%Propranolol%
Y	also used f	27036	PROPRANOLOL POWD	Unknown	0	%Propranolol%
Y	also used f	23604	PROPRANOLOL S/R	Unknown	0	%Propranolol%
Y	also used f	34208	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	36603	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y	also used f	45343	Propranolo Propranolo Modified-r	Beta-adren	02040000/	%Propranolol%
Y		15108	Hydrochlor Quinapril 1 Tablet	Angiotensii	2050501	%CHLOROTHIAZ%, %Quinapril%, %thiazide%
Y	also used f	3929	Quinapril h Quinapril 1 Tablet	Angiotensii	2050501	%Quinapril%
Y	also used f	5159	Quinapril h Quinapril 2 Tablet	Angiotensii	2050501	%Quinapril%
Y	also used f	38854	Quinapril H Quinapril 2 Oral Suspe	Angiotensii	2050501	%Quinapril%
Y	also used f	9731	Quinapril h Quinapril 4 Tablet	Angiotensii	2050501	%Quinapril%
Y	also used f	6765	Quinapril h Quinapril 5 Tablet	Angiotensii	2050501	%Quinapril%
Y	also used f	38899	Quinapril h Quinil 10m Tablet	Angiotensii	2050501	%QUINIL%, %Quinapril%
Y	also used f	46365	Quinapril h Quinil 20m Tablet	Angiotensii	2050501	%QUINIL%, %Quinapril%
Y	also used f	42285	Quinapril h Quinil 40m Tablet	Angiotensii	2050501	%QUINIL%, %Quinapril%
Y	also used f	40355	Quinapril h Quinil 5mg Tablet	Angiotensii	2050501	%QUINIL%, %Quinapril%
Y	also used f	22882	RAMIPRIL	Unknown	0	%Ramipril%
Y	also used f	147	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	55299	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	45264	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	56704	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	52399	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	32857	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	57073	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34698	Ramipril Ramipril 1. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	761	Ramipril Ramipril 1. Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	57658	Ramipril Ramipril 1. Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	56148	Ramipril Ramipril 1. Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	57235	Ramipril Ramipril 1. Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	45340	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34583	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34893	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34877	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	82	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34943	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	49164	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	56356	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	56169	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	59788	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34651	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34357	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	52407	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	56763	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34710	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	56855	Ramipril Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%

Y	also used f	33894	Ramipril	Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	57346	Ramipril	Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34657	Ramipril	Ramipril 1C Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	756	Ramipril	Ramipril 1C Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	40384	Ramipril	Ramipril 1C Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	53612	Ramipril	Ramipril 1C Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	56038	Ramipril	Ramipril 1C Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	50509	Ramipril	Ramipril 1C Oral solutic	Angiotensii	2050501	%Ramipril%
Y	also used f	35007	Ramipril	Ramipril 1C Oral suspei	Angiotensii	2050501	%Ramipril%
Y	also used f	654	Ramipril	Ramipril 2. Capsules	Angiotensii	2050501	%Ramipril%
Y	also used f	38308	Ramipril	Ramipril 2. Tablets	Angiotensii	2050501	%Ramipril%
Y	also used f	34732	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	709	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34528	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	47998	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	51714	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	48053	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	54298	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	53621	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34567	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34432	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	59557	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	59603	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	33811	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34505	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	54620	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34490	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	56013	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34431	Ramipril	Ramipril 2. Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	6314	Ramipril	Ramipril 2. Tablet	Angiotensii	2050501	%Ramipril%
Y		11965	Felodipine	Ramipril 2. Modified R	Angiotensii	02050501/	%Ramipril%, %felodipine%
Y	also used f	47021	Ramipril	Ramipril 2. Oral solutic	Angiotensii	2050501	%Ramipril%
Y	also used f	11937	Ramipril	Ramipril 2. Oral suspei	Angiotensii	2050501	%Ramipril%
Y	also used f	34589	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34652	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	80	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34540	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	48008	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	54941	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	51701	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34429	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34390	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	56129	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34539	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	52197	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34412	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	55798	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	34382	Ramipril	Ramipril 5r Capsule	Angiotensii	2050501	%Ramipril%
Y	also used f	6288	Ramipril	Ramipril 5r Tablet	Angiotensii	2050501	%Ramipril%
Y	also used f	57864	Ramipril	Ramipril 5r Tablet	Angiotensii	2050501	%Ramipril%
Y		11567	Felodipine	Ramipril 5r Modified R	Angiotensii	02050501/	%Ramipril%, %felodipine%
Y	also used f	45554	Ramipril	Ramipril 5r Oral solutic	Angiotensii	2050501	%Ramipril%
Y	also used f	46890	Ramipril	Ramipril 5r Oral suspei	Angiotensii	2050501	%Ramipril%
Y	also used f	19457	Verapamil	Ranvera M Modified-r	Calcium-ch	2060200	%RANVERA%, %verapamil%
Y	also used f	46526	Doxazosin	Raporsin XI Modified-r	Alpha-adre	02050400/	%RAPORSIN%, %doxazosin%
Y	also used f	25359	Propranolol	Rapranol S Modified-r	Beta-adren	02040000/	%Propranolol%, %RAPRANOL%
Y	also used f	25367	Propranolol	Rapranol S Modified-r	Beta-adren	02040000/	%Propranolol%, %RAPRANOL%
Y		2104	Alseroxylor	Rauwiloid ; Tablet	Centrally A	2050200	%alseroxylon%
Y	also used f	59616	Indapamid	Rawel XL 1 Modified-r	Thiazides A	2020100	%indapamide%
Y	also used f	22853	Reserpine	Reserpine ; Tablets	Centrally A	2050200	%reserpine%
Y	also used f	20690	Reserpine	Reserpine ; Tablets	Centrally A	2050200	%reserpine%
Y		15493	Reserpine	Reserpine ; Tablets	Centrally A	2050200	%CHLOROTHIAZ%, %reserpine%, %thiazide%
Y		41894		RESERPINE/BENDROFL	Unknown	0	%reserpine%

Y	also used f	21795	Diltiazem h Retalzem 6 Modified-r	Calcium-ch	2060200	%RETALZEM%, %diltiazem%
Y	also used f	17720	Chlorothia: Saluric 500 Tablet	Thiazides A	2020100	%CHLOROTHIAZ%, %SALURIC%, %thiazide%
Y		8189	Acebutolol Secadrex 2 Tablet	Unknown	0	%Acebutolol%, %CHLOROTHIAZ%, %SECADRE
Y	also used f	12296	Acebutolol Sectral 100 Capsule	Beta-adren	2040000	%Acebutolol%, %SECTRAL%
Y	also used f	8555	Acebutolol Sectral 200 Capsule	Beta-adren	2040000	%Acebutolol%, %SECTRAL%
Y	also used f	8023	Acebutolol Sectral 400 Tablet	Beta-adren	2040000	%Acebutolol%, %SECTRAL%
Y	also used f	18690	SECURON (CALENDAR	Unknown	0	%SECURON%
Y	also used f	3057	Verapamil Securon 12 Tablet	Calcium-ch	2060200	%SECURON%, %verapamil%
Y	also used f	22826	Verapamil Securon 16 Tablet	Supraventr	02030202/	%SECURON%, %verapamil%
Y	also used f	8524	Verapamil Securon 40 Tablet	Supraventr	02030202/	%SECURON%, %verapamil%
Y	also used f	10832	Verapamil Securon 80 Tablet	Supraventr	02030202/	%SECURON%, %verapamil%
Y	also used f	3342	Verapamil Securon SR Modified-r	Calcium-ch	2060200	%SECURON%, %verapamil%
Y	also used f	59264	Verapamil Securon SR Modified-r	Calcium-ch	2060200	%SECURON%, %verapamil%
Y	also used f	51461	Verapamil Securon SR Modified-r	Calcium-ch	2060200	%SECURON%, %verapamil%
Y		25645	Theobromi Seominal T Tablet	Centrally A	2050200	%SEOMINAL%, %reserpine%
Y		22466	SERPASIL	Unknown	0	%SERPASIL%
Y		27602	SERPASIL	Unknown	0	%SERPASIL%
Y	also used f	21502	Reserpine Serpasil 10 Tablet	Centrally A	2050200	%SERPASIL%, %reserpine%
Y	also used f	20656	Reserpine Serpasil 25 Tablet	Centrally A	2050200	%SERPASIL%, %reserpine%
Y		19892	Reserpine Serpasil -es Tablet	Centrally A	2050200	%ESIDREX%, %SERPASIL%, %reserpine%
Y		39984	Olmesartar Sevikar 20r Tablet	Angiotensii	02050502/	%Olmesartan%, %SEVIKAR%, %amlodipine%
Y		41203	Olmesartar Sevikar 40r Tablet	Angiotensii	02050502/	%Olmesartan%, %SEVIKAR%, %amlodipine%
Y		41205	Olmesartar Sevikar 40r Tablet	Angiotensii	02050502/	%Olmesartan%, %SEVIKAR%, %amlodipine%
Y		46355	Hydrochlor Sevikar HC Tablet	Angiotensii	2050502	%CHLOROTHIAZ%, %Olmesartan%, %SEVIKAR
Y		47616	Hydrochlor Sevikar HC Tablets	Angiotensii	2050502	%CHLOROTHIAZ%, %Olmesartan%, %SEVIKAR
Y		53220	Hydrochlor Sevikar HC Tablet	Angiotensii	2050502	%CHLOROTHIAZ%, %Olmesartan%, %SEVIKAR
Y		47573	Amlodipine Sevikar HC Tablet	Angiotensii	2050502	%CHLOROTHIAZ%, %Olmesartan%, %SEVIKAR
Y		47727	Hydrochlor Sevikar HC Tablets	Angiotensii	2050502	%CHLOROTHIAZ%, %Olmesartan%, %SEVIKAR
Y	also used f	36740	Doxazosin Slocinx XL Modified-r	Alpha-adre	02050400/	%SLOCINX%, %doxazosin%
Y	also used f	36684	SLOFEDIPINE 20 MG T	Unknown	0	%SLOFEDIPINE%
Y	also used f	22696	Nifedipine Slofedipine Modified-r	Calcium-ch	2060200	%SLOFEDIPINE%, %nifedipine%
Y	also used f	9573	Nifedipine Slofedipine Modified-r	Calcium-ch	2060200	%SLOFEDIPINE%, %nifedipine%
Y	also used f	9553	Nifedipine Slofedipine Modified-r	Calcium-ch	2060200	%SLOFEDIPINE%, %nifedipine%
Y	also used f	33602	Propranolol Slo-Pro 16 Modified-r	Beta-adren	02040000/	%Propranolol%, %SLO-PRO%
Y	also used f	23587	Propranolol Sloprolol 1 Modified-r	Beta-adren	02040000/	%Propranolol%, %SLOPROLOL%
Y	also used f	29230	Oxprenolol Slow-pren Modified-r	Beta-adren	2040000	%Oxprenolol%, %SLOW-PREN%
Y	also used f	4025	Oxprenolol Slow-Trasic Modified-r	Beta-adren	2040000	%Oxprenolol%, %SLOW TRASICOR%, %TRASIC
Y	also used f	2528	Diltiazem h Slozem 12 Modified-r	Calcium-ch	2060200	%SLOZEM%, %diltiazem%
Y	also used f	5234	Diltiazem h Slozem 18 Modified-r	Calcium-ch	2060200	%SLOZEM%, %diltiazem%
Y	also used f	4408	Diltiazem h Slozem 24 Modified-r	Calcium-ch	2060200	%SLOZEM%, %diltiazem%
Y	also used f	17586	Diltiazem h Slozem 30 Modified-r	Calcium-ch	2060200	%SLOZEM%, %diltiazem%
Y	also used f	36612	Sodium nit Sodium nit Powder for Vasodilato		2050100	%nitroprusside%
Y		3691	Sotalol Hyc Sotalol 160 Tablets	Beta-adren	2040000	%CHLOROTHIAZ%, %Sotalol%, %thiazide%
Y		8061	Sotalol Hyc Sotalol 80n Tablets	Beta-adren	2040000	%CHLOROTHIAZ%, %Sotalol%, %thiazide%
Y		29976	SOTAZIDE	Unknown	0	%SOTAZIDE%
Y		12456	Sotalol Hyc Sotazide Te Tablet	Beta-adren	2040000	%SOTAZIDE%, %Sotalol%
Y	also used f	29397	Spironolact Spiretic 10 Tablet	Potassium-	2020300	%SPIRETIC%, %spironolactone%
Y	also used f	47687	Spironolact Spiretic 25 Tablet	Potassium-	2020300	%SPIRETIC%, %spironolactone%
Y	also used f	31131	Spironolact Spiro-co 25 Tablet	Thiazides A	02020100/	%spironolactone%, %thiazide%
Y	also used f	25505	Spironolact Spiro-co 5C Tablet	Thiazides A	02020100/	%spironolactone%, %thiazide%
Y	also used f	7991	Spironolact Spiroctan 1 Capsule	Potassium-	2020300	%SPIROCTAN%, %spironolactone%
Y	also used f	4161	Spironolact Spiroctan 2 Tablet	Potassium-	2020300	%SPIROCTAN%, %spironolactone%
Y	also used f	15052	Spironolact Spiroctan 5 Tablet	Potassium-	2020300	%SPIROCTAN%, %spironolactone%
Y	also used f	17902	Spironolact Spirolone 1 Tablet	Potassium-	2020300	%SPIROLONE%, %spironolactone%
Y	also used f	11156	Spironolact Spirolone 2 Tablet	Potassium-	2020300	%SPIROLONE%, %spironolactone%
Y	also used f	17950	Spironolact Spirolone 5 Tablet	Potassium-	2020300	%SPIROLONE%, %spironolactone%
Y	also used f	25086	SPIRONOLACTONE	Unknown	0	%spironolactone%
Y	also used f	15053	SPIRONOLACTONE 10	Unknown	0	%spironolactone%
Y	also used f	787	Spironolact Spironolact Capsules	Potassium-	2020300	%spironolactone%
Y	also used f	2142	Spironolact Spironolact Tablet	Potassium-	2020300	%spironolactone%
Y	also used f	31219	Spironolact Spironolact Tablet	Potassium-	2020300	%spironolactone%
Y	also used f	41592	Spironolact Spironolact Tablet	Potassium-	2020300	%spironolactone%
Y	also used f	41660	Spironolact Spironolact Tablet	Potassium-	2020300	%spironolactone%

Y	also used f	56536	Spironolactone 100mg Potassium-	2020300	%spironolactone%
Y	also used f	14109	Spironolact Spironolact Suspensior Potassium-	2020300	%spironolactone%
Y	also used f	49388	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	52970	Spironolact Spironolact Oral solutic Potassium-	2020300	%spironolactone%
Y	also used f	50079	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	12946	Spironolact Spironolact Suspensior Potassium-	2020300	%spironolactone%
Y	also used f	57556	Spironolact Spironolact Oral solutic Potassium-	2020300	%spironolactone%
Y	also used f	13264	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	58225	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	57104	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	58757	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	35789	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	692	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	34296	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	34347	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	41074	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	51652	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	34908	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	60343	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	31529	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	8521	Spironolact Spironolact Tablets Thiazides A 02020100/	%spironolactone%, %thiazide%	
Y	also used f	51720	Spironolact Spironolact Oral solutic Potassium-	2020300	%spironolactone%
Y	also used f	45078	Spironolact Spironolact Oral Solutic Potassium-	2020300	%spironolactone%
Y	also used f	47018	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	11519	Spironolact Spironolact Suspensior Potassium-	2020300	%spironolactone%
Y	also used f	60660	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	56274	Spironolactone 4.5mg/ Potassium-	2020300	%spironolactone%
Y	also used f	57933	Spironolactone 40mg/ Potassium-	2020300	%spironolactone%
Y	also used f	56067	Spironolactone 4mg/5 Potassium-	2020300	%spironolactone%
Y	also used f	54120	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	4661	Spironolact Spironolact Capsule Potassium-	2020400	%furosemide%, %spironolactone%
Y	also used f	19195	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	708	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	43514	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	41706	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	32837	Spironolact Spironolact Tablet Potassium-	2020300	%spironolactone%
Y	also used f	7961	Spironolact Spironolact Tablets Thiazides A 02020100/	%spironolactone%, %thiazide%	
Y	also used f	51933	Spironolactone 50mg/ Potassium-	2020300	%spironolactone%
Y	also used f	46990	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	53253	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	6815	Spironolact Spironolact Suspensior Potassium-	2020300	%spironolactone%
Y	also used f	46674	Spironolact Spironolact Oral Suspei Potassium-	2020300	%spironolactone%
Y	also used f	53508	Chlorothia: Spironolact Oral suspei Potassium-	2020400	%CHLOROTHIAZ%, %spironolactone%, %thiazid
Y	also used f	52366	Spironolactone 5mg/5 Potassium-	2020300	%spironolactone%
Y	also used f	50370	Spironolact Spironolact Oral suspei Potassium-	2020300	%spironolactone%
Y	also used f	10214	Spironolact Spironolact Suspensior Potassium-	2020300	%spironolactone%
Y	also used f	58077	Spironolactone 8mg/5 Potassium-	2020300	%spironolactone%
Y		19003	SPIRONOLACTONE/PR Unknown	0	%Propranolol%, %spironolactone%
Y		17783	Propranolol Spiroprop 1 Tablet Beta-adren	2040000	%Propranolol%, %SPIROPROP%
Y	also used f	23091	Spironolact Spirospare Tablet Potassium-	2020300	%spironolactone%
Y	also used f	21911	Spironolact Spirospare Tablet Potassium-	2020300	%spironolactone%
Y	also used f	4571	Fosinopril : Staril 10mg Tablet Angiotensii	2050501	%Fosinopril%, %STARIL%
Y	also used f	13589	Fosinopril : Staril 20mg Tablet Angiotensii	2050501	%Fosinopril%, %STARIL%
Y	also used f	26895	Propranolol Syprol 10m Oral solutic Beta-adren	02040000/	%Propranolol%, %SYPROL%
Y	also used f	45765	Propranolol Syprol 40m Oral solutic Beta-adren	02040000/	%Propranolol%, %SYPROL%
Y	also used f	42152	Propranolol Syprol 50m Oral solutic Beta-adren	02040000/	%Propranolol%, %SYPROL%
Y	also used f	17082	Propranolol Syprol 5mg Oral solutic Beta-adren	02040000/	%Propranolol%, %SYPROL%
Y	also used f	19129	Nisoldipine Syscor MR Modified-r1 Calcium-ch	2060200	%SYSCOR MR%, %nisoldipine%
Y	also used f	31337	Nisoldipine Syscor MR Modified-r1 Calcium-ch	2060200	%SYSCOR MR%, %nisoldipine%
Y	also used f	31336	Nisoldipine Syscor MR Modified-r1 Calcium-ch	2060200	%SYSCOR MR%, %nisoldipine%
Y		12815	Imidapril h Tanatril 10 Tablet Angiotensii	2050501	%Imidapril%, %TANATRIL%
Y		32560	Imidapril h Tanatril 20 Tablet Angiotensii	2050501	%Imidapril%, %TANATRIL%
Y		6408	Imidapril h Tanatril 5m Tablet Angiotensii	2050501	%Imidapril%, %TANATRIL%

Y		20579 Verapamil Tarka modi Modified-r	Angiotensii	02050501/	%TARKA%, %Trandolapril%, %verapamil%
Y	also used f	6243 Telmisarta	Telmisarta	Tablet	Angiotensii 2050502 %Telmisartan%
Y		14870 Telmisarta	Telmisarta	Tablet	Angiotensii 2050504 %CHLOROTHIAZ%, %Telmisartan%, %thiazide%
Y	also used f	5988 Telmisarta	Telmisarta	Tablet	Angiotensii 2050502 %Telmisartan%
Y		16161 Telmisarta	Telmisarta	Tablet	Angiotensii 2050504 %CHLOROTHIAZ%, %Telmisartan%, %thiazide%
Y		38459 Hydrochlor	Telmisarta	Tablets	Angiotensii 2050504 %CHLOROTHIAZ%, %Telmisartan%, %thiazide%
Y	also used f	12874 Telmisarta	Telmisarta	Tablet	Angiotensii 2050502 %Telmisartan%
Y		8303 Meprobam	Tenavoid	T Tablet	Thiazides A 02020100/ %TENAVOID%
Y		18743 Atenolol/B	Tenben	25r Capsule	Unknown 0 %Atenolol%, %TENBEN%, %thiazide%
Y		26248 Atenolol/C	Tenchlor	1r Tablet	Thiazides A 02020100/ %Atenolol%, %TENCHLOR%, %chlortalidone%
Y		31470 Atenolol/C	Tenchlor	5r Tablet	Thiazides A 02020100/ %Atenolol%, %TENCHLOR%, %chlortalidone%
Y		8642 Atenolol/N	Tenif	50mg Modified-r	Beta-adren 2040000 %Atenolol%, %TENIF%, %nifedipine%
Y		1288 Atenolol/C	Tenoret	50 Tablet	Thiazides A 02020100/ %Atenolol%, %TENORET%, %chlortalidone%
Y		26807	TENORETIC		Unknown 0 %TENORET%, %TENORETIC%
Y		1124 Atenolol/C	Tenoretic	1 Tablet	Thiazides A 02020100/ %Atenolol%, %TENORET%, %TENORETIC%, %c
Y	also used f	2587 Atenolol	Tenormin	1 Tablet	Beta-adren 2040000 %Atenolol%, %TENORMIN%
Y	also used f	2590 Atenolol	Tenormin	2 Tablet	Beta-adren 2040000 %Atenolol%, %TENORMIN%
Y	also used f	13394 Atenolol	Tenormin	2 Oral solutic	Beta-adren 2040000 %Atenolol%, %TENORMIN%
Y	also used f	2432 Atenolol	Tenormin	1 Tablet	Beta-adren 2040000 %Atenolol%, %TENORMIN%
Y	also used f	41861 Indapamid	Tensaid	XL Modified-r	Thiazides A 2020100 %TENSAID%, %indapamide%
Y	also used f	19170 Nifedipine	Tensipine	1 Modified-r	Calcium-ch 2060200 %TENSIPINE%, %nifedipine%
Y	also used f	5806 Nifedipine	Tensipine	1 Modified-r	Calcium-ch 2060200 %TENSIPINE%, %nifedipine%
Y	also used f	20849 Captopril	Tensopril	1 Tablet	Angiotensii 2050501 %Captopril%, %TENSOPRIL%
Y	also used f	30039 Captopril	Tensopril	2 Tablet	Angiotensii 2050501 %Captopril%, %TENSOPRIL%
Y	also used f	23478 Captopril	Tensopril	5 Tablet	Angiotensii 2050501 %Captopril%, %TENSOPRIL%
Y	also used f	4875 Terazosin	Terazosin	1 Tablet	Alpha-adre 02050400/ %Terazosin%
Y	also used f	3470 Terazosine	Terazosin	1 Tablets	Alpha-adre 02050400/ %Terazosin%
Y	also used f	4637 Terazosin	Terazosin	2 Tablet	Alpha-adre 02050400/ %Terazosin%
Y	also used f	57145 Terazosin	Terazosin	2 Tablet	Alpha-adre 02050400/ %Terazosin%
Y	also used f	4694	Terazosin	2 Not applica	Alpha-adre 02050400/ %Terazosin%
Y	also used f	3924 Terazosin	Terazosin	5 Tablet	Alpha-adre 02050400/ %Terazosin%
Y		9745 Eprosartan	Teveten	30 Tablet	Angiotensii 2050502 %Eprosartan%, %Teveten%
Y		16285 Eprosartan	Teveten	40 Tablet	Angiotensii 2050502 %Eprosartan%, %Teveten%
Y		16371 Eprosartan	Teveten	60 Tablet	Angiotensii 2050502 %Eprosartan%, %Teveten%
Y	also used f	56467 Diltiazem	h Tildiem	60r Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	2888 Diltiazem	h Tildiem	60r Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	57594 Diltiazem	h Tildiem	60r Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	52701 Diltiazem	h Tildiem	LA Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	38545 Diltiazem	h Tildiem	LA Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	536 Diltiazem	h Tildiem	la 2 Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	54799 Diltiazem	h Tildiem	LA Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	38876 Diltiazem	h Tildiem	LA Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	5296 Diltiazem	h Tildiem	la 3 Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	51261 Diltiazem	h Tildiem	Ret Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	1289 Diltiazem	h Tildiem	Ret Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y	also used f	939 Diltiazem	h Tildiem	Ret Modified-r	Calcium-ch 2060200 %TILDIEM%, %diltiazem%
Y		48745	Timolol	10mg / Amilor	Beta-adren 2040100 %CHLOROTHIAZ%, %Timolol% & %tab%, %am
Y		12651 Timolol	ma Timolol	10r Tablet	Beta-adren 2040100 %Timolol% & %tab%, %thiazide%
Y	also used f	7853 Timolol	ma Timolol	10r Tablet	Beta-adren 02040000/ %Timolol% & %tab%
Y		8788	TIMOLOL	10MG/BEND	Unknown 0 %Timolol% & %tab%
Y		25730 Timolol	Ma Timolol	ma Tablet	Thiazides A 02020100/ %CHLOROTHIAZ%, %Timolol% & %tab%, %am
Y		12517 Timolol	Ma Timolol	ma Tablet	Thiazides A 02020100/ %Timolol% & %tab%, %thiazide%
Y		15042 Sotalol	Hyc Tolerzide	T Tablet	Beta-adren 2040000 %Sotalol%, %TOLERZIDE%
Y	also used f	18096 Torasemid	Torasemid	r Tablet	Loop Diure 2020200 %torasemide%
Y	also used f	11487 Torasemid	Torasemid	r Tablet	Loop Diure 2020200 %torasemide%
Y	also used f	8052 Torasemid	Torasemid	r Tablet	Loop Diure 2020200 %torasemide%
Y	also used f	40898 Torasemid	Torasemid	r Tablet	Loop Diure 2020200 %torasemide%
Y	also used f	46525 Torasemid	Torasemid	r Tablet	Loop Diure 2020200 %torasemide%
Y	also used f	40190 Torasemid	Torasemid	r Intravenou	Loop Diure 2020200 %torasemide%
Y	also used f	22658 Torasemid	Torem	10r Tablet	Loop Diure 2020200 %TOREM%, %torasemide%
Y	also used f	11268 Torasemid	Torem	2.5r Tablet	Loop Diure 2020200 %TOREM%, %torasemide%
Y	also used f	10066 Torasemid	Torem	5mg Tablet	Loop Diure 2020200 %TOREM%, %torasemide%
Y	also used f	40738 Torasemid	Torem	iv 1r Intravenou	Loop Diure 2020200 %TOREM%, %torasemide%

Y	also used f	15730	Atenolol Totamol 1C Tablet	Beta-adren	2040000	%Atenolol%, %TOTAMOL%
Y	also used f	18950	Atenolol Totamol 25 Tablet	Beta-adren	2040000	%Atenolol%, %TOTAMOL%
Y	also used f	15176	Atenolol Totamol 5C Tablet	Beta-adren	2040000	%Atenolol%, %TOTAMOL%
Y		25787	TOTARETIC 100 TAB	Unknown	0	%TOTARETIC%
Y		24280	Atenolol/C Totaretic 1 Tablet	Thiazides A	02020100/	%Atenolol%, %TOTARETIC%, %chlortalidone%
Y		26731	TOTARETIC 50 TAB	Unknown	0	%TOTARETIC%
Y		26741	Atenolol/C Totaretic 5 Tablet	Thiazides A	02020100/	%Atenolol%, %TOTARETIC%, %chlortalidone%
Y		9016	Labetalol h Trandate 1 Tablet	Beta-adren	2040000	%TRANDATE%, %labetalol%
Y	also used f	19998	Labetalol h Trandate 1 Solution fo	Beta-adren	2040000	%TRANDATE%, %labetalol%
Y		8707	Labetalol h Trandate 2 Tablet	Beta-adren	2040000	%TRANDATE%, %labetalol%
Y		8807	Labetalol h Trandate 4 Tablet	Beta-adren	2040000	%TRANDATE%, %labetalol%
Y		9273	Labetalol h Trandate 5 Tablet	Beta-adren	2040000	%TRANDATE%, %labetalol%
Y	also used f	4103	Trandolapr Trandolapr Capsule	Angiotensii	2050501	%Trandolapril%
Y	also used f	5047	Trandolapr Trandolapr Capsule	Angiotensii	2050501	%Trandolapril%
Y	also used f	9948	Trandolapr Trandolapr Capsule	Angiotensii	2050501	%Trandolapril%
Y	also used f	54345	Trandolapr Trandolapr Capsule	Angiotensii	2050501	%Trandolapril%
Y	also used f	7419	Trandolapr Trandolapr Capsule	Angiotensii	2050501	%Trandolapril%
Y		18223	Verapamil Trandolapr Modified-r	Angiotensii	02050501/	%Trandolapril%, %verapamil%
Y	also used f	10777	Oxprenolol Trasicor 16 Tablet	Beta-adren	2040000	%Oxprenolol%, %TRASICOR%
Y	also used f	13309	TRASICOR 2 MG INJ	Unknown	0	%TRASICOR%
Y	also used f	7474	Oxprenolol Trasicor 20 Tablet	Beta-adren	2040000	%Oxprenolol%, %TRASICOR%
Y	also used f	35062	Oxprenolol Trasicor 20 Tablet	Beta-adren	2040000	%Oxprenolol%, %TRASICOR%
Y	also used f	8290	Oxprenolol Trasicor 40 Tablet	Beta-adren	2040000	%Oxprenolol%, %TRASICOR%
Y	also used f	24094	Oxprenolol Trasicor 40 Tablet	Beta-adren	2040000	%Oxprenolol%, %TRASICOR%
Y	also used f	2361	Oxprenolol Trasicor 80 Tablet	Beta-adren	2040000	%Oxprenolol%, %TRASICOR%
Y	also used f	29180	Oxprenolol Trasicor 80 Tablet	Beta-adren	2040000	%Oxprenolol%, %TRASICOR%
Y		4429	Oxprenolol Trasidrex n Modified-r	Beta-adren	2040000	%Oxprenolol%, %TRASIDREX%, %thiazide%
Y	also used f	18726	Triamteren Triamaxco Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %TRIAMAXCO%, %thiazide%
Y	also used f	8897	Triamteren Triam-Co 5 Tablet	Potassium-	2020400	%CHLOROTHIAZ%, %TRIAM-CO%, %thiazide%
Y	also used f	7740	Triamteren Triamteren Capsule	Unknown	0	%thiazide%, %triamterene%
Y	also used f	12547	Chlortalido Triamteren Tablet	Potassium-	2020400	%chlortalidone%, %triamterene%
Y	also used f	11265	Triamteren Triamteren Tablet	Potassium-	2020400	%furosemide%, %triamterene%
Y	also used f	2179	Triamteren Triamteren Capsule	Potassium-	2020300	%triamterene%
Y	also used f	41889	TRIAMTERENE 50MG f	Unknown	0	%CHLOROTHIAZ%, %thiazide%, %triamterene%
Y	also used f	3962	TRIAMTERENE 50MG f	Unknown	0	%CHLOROTHIAZ%, %thiazide%, %triamterene%
Y	also used f	37294	Triamteren Triamteren Tablet	Thiazides A	02020100/	%chlortalidone%, %triamterene%
Y	also used f	9223	Triamteren Triamteren Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %thiazide%, %triamterene%
Y		28438	Felodipine, Triapin 2.5i Modified-r	Drugs Affe	2050500	%Ramipril%, %TRIAPIN%, %felodipine%
Y		17006	Felodipine, Triapin 5m Modified-r	Drugs Affe	2050500	%Ramipril%, %TRIAPIN%, %felodipine%
Y	also used f	31288	TRITACE	Unknown	0	%TRITACE%
Y	also used f	24214	TRITACE 1.25 MG TAB	Unknown	0	%TRITACE%
Y	also used f	9646	Ramipril Tritace 1.2i Capsule	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	42081	Ramipril Tritace 1.2i Tablet	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	6261	Ramipril Tritace 1.2i Tablet	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	9693	Ramipril Tritace 10n Capsule	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	39355	Ramipril Tritace 10n Tablet	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	9915	Ramipril Tritace 10n Tablet	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	29964	TRITACE 2.5 MG TAB	Unknown	0	%TRITACE%
Y	also used f	5275	Ramipril Tritace 2.5i Capsule	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	6364	Ramipril Tritace 2.5i Tablet	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	5735	Ramipril Tritace 5m Capsule	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	6362	Ramipril Tritace 5m Tablet	Angiotensii	2050501	%Ramipril%, %TRITACE%
Y	also used f	6200	Tritace titr: Not applica	Unknown	0	%TRITACE%
Y	also used f	39421	Tritace titr: Not applica	Angiotensii	2050501	%TRITACE%
Y	also used f	59585	Diltiazem h Uard 120XI Modified-r	Calcium-ch	2060200	%diltiazem%
Y	also used f	12613	Nifedipine Unipine xl : Modified-r	Calcium-ch	2060200	%UNIPINE%, %nifedipine%
Y	also used f	6510	Verapamil Univer 120 Modified-r	Calcium-ch	2060200	%Univer 120mg%, %verapamil%
Y	also used f	12392	Verapamil Univer 180 Modified-r	Calcium-ch	2060200	%Univer 180mg%, %verapamil%
Y	also used f	8945	Verapamil Univer 240 Modified-r	Calcium-ch	2060200	%Univer 240mg%, %verapamil%
Y	also used f	43222	Nifedipine Valni 20 Re Modified-r	Calcium-ch	2060200	%VALNI%, %nifedipine%
Y	also used f	37184	Nifedipine Valni XL 30 Modified-r	Calcium-ch	2060200	%VALNI%, %nifedipine%
Y	also used f	39800	Nifedipine Valni XL 60 Modified-r	Calcium-ch	2060200	%VALNI%, %nifedipine%
Y		11864	Valsartan/l Valsartan 1 Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Valsartan%, %thiazide%

Y		14283	Valsartan/	Valsartan 1 Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Valsartan%, %thiazide%
Y	also used f	4645	Valsartan	Valsartan 1 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	55187	Valsartan	Valsartan 1 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	53833	Valsartan	Valsartan 1 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	55821	Valsartan	Valsartan 1 Capsule	Unknown	0	%Valsartan%
Y	also used f	60076	Valsartan	Valsartan 1 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	44778	Valsartan	Valsartan 1 Tablet	Angiotensii	2050502	%Valsartan%
Y		35304	Amlodipine	Valsartan 1 Tablets	Angiotensii	02050502/	%Valsartan%, %amlodipine%
Y		35173	Amlodipine	Valsartan 1 Tablets	Angiotensii	02050502/	%Valsartan%, %amlodipine%
Y	also used f	37573	Valsartan	Valsartan 3 Tablet	Angiotensii	2050502	%Valsartan%
Y	also used f	59029	Valsartan	Valsartan 3 Oral solutio	Angiotensii	2050502	%Valsartan%
Y	also used f	575	Valsartan	Valsartan 4 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	54726	Valsartan	Valsartan 4 Capsule	Unknown	0	%Valsartan%
Y	also used f	58669	Valsartan	Valsartan 4 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	14943	Valsartan	Valsartan 4 Tablet	Angiotensii	2050502	%Valsartan%
Y		16060	Hydrochlor	Valsartan 8 Tablet	Angiotensii	2050504	%CHLOROTHIAZ%, %Valsartan%, %thiazide%
Y	also used f	3222	Valsartan	Valsartan 8 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	59448	Valsartan	Valsartan 8 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	58910	Valsartan	Valsartan 8 Capsule	Angiotensii	2050502	%Valsartan%
Y	also used f	38395	Valsartan	Valsartan 8 Tablet	Angiotensii	2050502	%Valsartan%
Y		35174	Amlodipine	Valsartan 8 Tablets	Angiotensii	02050502/	%Valsartan%, %amlodipine%
Y	also used f	39447	Indapamide	Varbim XL Modified-r	Thiazides A	2020100	%ARBIM%, %indapamide%
Y	also used f	30636	Atenolol	Vasaten 50 Tablet	Beta-adren	2040000	%Atenolol%, %VASATEN%
Y	also used f	23642	Cilazapril	Vascace 0.7 Tablet	Angiotensii	2050501	%Cilazapril%, %VASCACE%
Y	also used f	16212	Cilazapril	n Vascace 1n Tablet	Angiotensii	2050501	%Cilazapril%, %VASCACE%
Y	also used f	16197	Cilazapril	n Vascace 2. Tablet	Angiotensii	2050501	%Cilazapril%, %VASCACE%
Y	also used f	21053	Cilazapril	n Vascace 50 Tablet	Angiotensii	2050501	%Cilazapril%, %VASCACE%
Y	also used f	16196	Cilazapril	n Vascace 5n Tablet	Angiotensii	2050501	%Cilazapril%, %VASCACE%
Y		14305	Felodipine	Vascalpha : Modified-r	Calcium-ch	2060200	%VASCALPHA%, %felodipine%
Y		43790	Felodipine	Vascalpha : Modified-r	Calcium-ch	2060200	%VASCALPHA%, %felodipine%
Y		35084	Felodipine	Vascalpha : Modified-r	Calcium-ch	2060200	%VASCALPHA%, %felodipine%
Y		40633	Felodipine	Vascalpha : Modified-r	Calcium-ch	2060200	%VASCALPHA%, %felodipine%
Y	also used f	24008	Amiloride	Vasetic Tak Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %VASETIC%, %amiloride%,
Y	also used f	23730		VERAPAMIL 100 MG T,	Unknown	0	%verapamil%
Y	also used f	1574	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	9569	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	47222	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	1747	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	41693	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	46009	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	40405	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	10688	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y		19690	Verapamil	Verapamil Modified-r	Angiotensii	02050501/	%Trandolapril%, %verapamil%
Y	also used f	8975	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	3943	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	1298	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	19459	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	45308	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	47230	Verapamil	Verapamil Modified-r	Calcium-ch	2060200	%verapamil%
Y	also used f	1118	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	34959	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	33471	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	32590	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	19175	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	39009	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	11777	Verapamil	Verapamil Oral solutio	Calcium-ch	2060200	%verapamil%
Y	also used f	1120	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	31711	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	41586	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	46955	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	41679	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	35729	Verapamil	Verapamil Tablet	Calcium-ch	2060200	%verapamil%
Y	also used f	45051	Verapamil	Verapamil Modified-r	Supraventr	02030202/	%verapamil%

Y	also used f	46884	Verapamil	Verapamil Modified-r	Supraventr	02030202/	%verapamil%
Y	also used f	28843	Verapamil	Verapamil Tablet	Supraventr	02030202/	%verapamil%
Y	also used f	8759	Verapamil	Verapamil Modified R	Supraventr	02030202/	%verapamil%
Y	also used f	18631		VERAPAMIL HCL MR	Unknown	0	%verapamil%
Y	also used f	10897		VERAPAMIL S/F 40 MG	Unknown	0	%verapamil%
Y	also used f	23458		VERAPAMIL SR	Unknown	0	%verapamil%
Y	also used f	13856	Verapamil	Verapress I Modified-r	Calcium-ch	2060200	%VERAPRESS%, %verapamil%
Y	also used f	16328	Verapamil	Verapress I Modified-r	Calcium-ch	2060200	%VERAPRESS%, %verapamil%
Y	also used f	17599	Verapamil	Verapress I Modified-r	Calcium-ch	2060200	%VERAPRESS%, %verapamil%
Y	also used f	29637	Verapamil	Verapress I Modified-r	Calcium-ch	2060200	%VERAPRESS%, %verapamil%
Y	also used f	42625	Verapamil	Vera-Til SR Modified-r	Calcium-ch	2060200	%VERA-TIL%, %verapamil%
Y	also used f	700	Verapamil	Vera-Til SR Modified-r	Calcium-ch	2060200	%VERA-TIL%, %verapamil%
Y	also used f	43879	Verapamil	Vera-Til SR Modified-r	Calcium-ch	2060200	%VERA-TIL%, %verapamil%
Y	also used f	13251	Verapamil	Vera-Til SR Modified-r	Calcium-ch	2060200	%VERA-TIL%, %verapamil%
Y	also used f	11972	Verapamil	Vertab SR Modified-r	Calcium-ch	2060200	%VERTAB%, %verapamil%
Y	also used f	2592	Diltiazem h	Viazem XL Modified-r	Calcium-ch	2060200	%VIAZEM%, %diltiazem%
Y	also used f	17666	Diltiazem h	Viazem XL Modified-r	Calcium-ch	2060200	%VIAZEM%, %diltiazem%
Y	also used f	13027	Diltiazem h	Viazem XL Modified-r	Calcium-ch	2060200	%VIAZEM%, %diltiazem%
Y	also used f	1130	Diltiazem h	Viazem XL Modified-r	Calcium-ch	2060200	%VIAZEM%, %diltiazem%
Y	also used f	7398	Diltiazem h	Viazem XL Modified-r	Calcium-ch	2060200	%VIAZEM%, %diltiazem%
Y		9143	Pindolol/Cl	Viskaldix ta Tablet	Beta-adren	2040100	%Clopamide%, %Pindolol%, %VISKALDIX%
Y	also used f	20012	Pindolol	Visken 15n Tablet	Beta-adren	2040000	%Pindolol%, %VISKEN%
Y	also used f	32787	Pindolol	Visken 15n Tablet	Beta-adren	2040000	%Pindolol%, %VISKEN%
Y	also used f	4588	Pindolol	Visken 5m Tablet	Beta-adren	2040000	%Pindolol%, %VISKEN%
Y	also used f	35695	Pindolol	Visken 5m Tablet	Beta-adren	2040000	%Pindolol%, %VISKEN%
Y	also used f	32630	Bisoprolol	Vivacor 10i Tablet	Beta-adren	02040000/	%Bisoprolol%, %VIVACOR%
Y	also used f	39846	Bisoprolol	Vivacor 5m Tablet	Beta-adren	02040000/	%Bisoprolol%, %VIVACOR%
Y	also used f	26675		XIPAMIDE	Unknown	0	%Xipamide%
Y	also used f	7618	Xipamide	Xipamide 2 Tablet	Thiazides A	2020100	%Xipamide%
Y	also used f	19352	Metolazon	Xuret 0.5m Tablet	Thiazides A	2020100	%XURET%, %metolazone%
Y		5570	Lercanidipi	Zanidip 10i Tablet	Calcium-ch	2060200	%ZANIDIP%, %lercanidipine%
Y		14300	Lercanidipi	Zanidip 20i Tablet	Calcium-ch	2060200	%ZANIDIP%, %lercanidipine%
Y	also used f	47732	Diltiazem h	Zemret 18C Modified-r	Calcium-ch	2060200	%ZEMRET%, %diltiazem%
Y	also used f	44192	Diltiazem h	Zemret 24C Modified-r	Calcium-ch	2060200	%ZEMRET%, %diltiazem%
Y	also used f	47608	Diltiazem h	Zemret 30C Modified-r	Calcium-ch	2060200	%ZEMRET%, %diltiazem%
Y	also used f	36583	Diltiazem h	Zemret xl 1 Capsule	Calcium-ch	2060200	%ZEMRET%, %diltiazem%
Y	also used f	26463	Diltiazem h	Zemret xl 2 Modified-r	Calcium-ch	2060200	%ZEMRET%, %diltiazem%
Y	also used f	36664	Diltiazem h	Zemret xl 3 Modified-r	Calcium-ch	2060200	%ZEMRET%, %diltiazem%
Y	also used f	17425	Diltiazem h	Zemtard 12 Modified-r	Calcium-ch	2060200	%ZEMTARD%, %diltiazem%
Y	also used f	17406	Diltiazem h	Zemtard 18 Modified-r	Calcium-ch	2060200	%ZEMTARD%, %diltiazem%
Y	also used f	20890	Diltiazem h	Zemtard 24 Modified-r	Calcium-ch	2060200	%ZEMTARD%, %diltiazem%
Y	also used f	17492	Diltiazem h	Zemtard 3C Modified-r	Calcium-ch	2060200	%ZEMTARD%, %diltiazem%
Y		6359	Lisinopril/f	Zestoretic : Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Lisinopril%, %ZESTORETI%
Y		39137	Lisinopril/f	Zestoretic : Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Lisinopril%, %ZESTORETI%
Y		57539	Lisinopril/f	Zestoretic : Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Lisinopril%, %ZESTORETI%
Y		2982	Lisinopril/f	Zestoretic : Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Lisinopril%, %ZESTORETI%
Y		38995	Lisinopril/f	Zestoretic : Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %Lisinopril%, %ZESTORETI%
Y	also used f	6806	Lisinopril	Zestril 10m Tablet	Angiotensii	2050501	%Lisinopril%, %ZESTRIL%
Y	also used f	3720	Lisinopril	Zestril 2.5n Tablet	Angiotensii	2050501	%Lisinopril%, %ZESTRIL%
Y	also used f	57588	Lisinopril	Zestril 2.5n Tablet	Angiotensii	2050501	%Lisinopril%, %ZESTRIL%
Y	also used f	8268	Lisinopril	Zestril 20m Tablet	Angiotensii	2050501	%Lisinopril%, %ZESTRIL%
Y	also used f	56510	Lisinopril	Zestril 20m Tablet	Angiotensii	2050501	%Lisinopril%, %ZESTRIL%
Y	also used f	6807	Lisinopril	Zestril 5mg Tablet	Angiotensii	2050501	%Lisinopril%, %ZESTRIL%
Y	also used f	56505	Lisinopril	Zestril 5mg Tablet	Angiotensii	2050501	%Lisinopril%, %ZESTRIL%
Y	also used f	26219	Amiloride h	Zida-co 5m Tablet	Thiazides A	02020100/	%CHLOROTHIAZ%, %ZIDA-CO%, %amiloride%
Y	also used f	31737	Diltiazem h	Zildil SR 12 Modified-r	Calcium-ch	2060200	%ZILDIL%, %diltiazem%
Y	also used f	26759	Diltiazem h	Zildil SR 60 Modified-r	Calcium-ch	2060200	%ZILDIL%, %diltiazem%
Y	also used f	31490	Verapamil	Zolvera 40i Oral solutic	Calcium-ch	2060200	%ZOLVERA%, %verapamil%
N		14892	Diltiazem h	Anoheal 29 Cream	Manageme	1070400	%diltiazem%
N		51489	Diltiazem h	Anoheal 29 Cream	Local Prep:	01070000/	%diltiazem%
N		35276	Apraclonid	Apraclonid Eye drops	Ocular Peri	11080251	%clonidine%
N		3420	Apraclonid	Apraclonid Eye drops	Ocular Peri	11080251	%clonidine%
N		6915	Apraclonid	Apraclonid Ophthalmic	Ocular Peri	11080251	%clonidine%

N	59984	Aptamil Comfort milk (Nutritional 09040251/ %AMIL-CO%		
N	197	Atenolol Atenolol 5r Solution fo	Beta-adren	2040000 %Atenolol%
N	13487	Sotalol hyd Beta-Cardo Tablet	Drugs For / 02030200/ %BETA-CARDONE%, %Sotalol%	
N	5858	Sotalol hyd Beta-Cardo Tablet	Drugs For / 02030200/ %BETA-CARDONE%, %Sotalol%	
N	6751	Sotalol hyd Beta-Cardo Tablet	Drugs For / 02030200/ %BETA-CARDONE%, %Sotalol%	
N	24461	Metoprolol Betaloc I.V. Solution fo	Beta-adren	2040000 %BETALOC%, %Metoprolol%
N	39646	Bisoprolol Bisoprolol (Oral Liquid	Beta-adren	2040000 %Bisoprolol%
N	50403	Bisoprolol Bisoprolol Tablet	Beta-adren	2040000 %Bisoprolol%
N	599	Bisoprolol Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
N	53885	Bisoprolol Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
N	51528	Bisoprolol Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
N	54479	Bisoprolol Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
N	52548	Bisoprolol Bisoprolol Tablet	Unknown	0 %Bisoprolol%
N	43251	Bisoprolol Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
N	58511	Bisoprolol Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
N	59495	Bisoprolol Bisoprolol Tablet	Beta-adren 02040000/	%Bisoprolol%
N	57626	Bisoprolol Bisoprolol Oral solutio	Beta-adren 02040000/	%Bisoprolol%
N	58109	Bisoprolol Bisoprolol Oral suspei	Beta-adren 02040000/	%Bisoprolol%
N	822	Bisoprolol Bisoprolol Oral Suspei	Beta-adren	2040000 %Bisoprolol%
N	37837	Bisoprolol Bisoprolol :Tablet	Beta-adren	2040000 %Bisoprolol%
N	594	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	37118	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	56459	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	58974	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	53916	Bisoprolol Bisoprolol :Tablet	Unknown	0 %Bisoprolol%
N	57023	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	50514	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	47041	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	58498	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	56768	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	53664	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	58763	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	59148	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	52686	Bisoprolol Bisoprolol :Oral solutio	Beta-adren 02040000/	%Bisoprolol%
N	44000	Bisoprolol Bisoprolol :Oral suspei	Beta-adren 02040000/	%Bisoprolol%
N	7091	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	55791	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	60502	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	56240	Bisoprolol Bisoprolol :Tablet	Beta-adren 02040000/	%Bisoprolol%
N	32135	Esmolol hy Brevibloc C Solution fo	Unknown	0 %BREVIBLOC%, %Esmolol%
N	26922	Esmolol hy Brevibloc P Solution fo	Beta-adren	2040000 %BREVIBLOC%, %Esmolol%
N	22004	CARACE (SPECIAL COM	Unknown	0 %CARACE%
N	23382	CARACE (SPECIAL COM	Unknown	0 %CARACE%
N	24693	CARACE (SPECIAL COM	Unknown	0 %CARACE%
N	14058	Bisoprolol Cardicor 1. Tablet	Beta-adren 02040000/	%Bisoprolol%, %CARDICOR%
N	14030	Bisoprolol Cardicor 2. Tablet	Beta-adren 02040000/	%Bisoprolol%, %CARDICOR%
N	57578	Bisoprolol Cardicor 2. Tablet	Beta-adren 02040000/	%Bisoprolol%, %CARDICOR%
N	19853	Bisoprolol Cardicor 3. Tablet	Beta-adren 02040000/	%Bisoprolol%, %CARDICOR%
N	3085	Carteolol h Carteolol 1 Eye drops	Beta-block	11065000 %Carteolol%
N	4532	Carteolol h Carteolol 2 Eye drops	Beta-block	11065000 %Carteolol%
N	21638	CARTEOLOL HYDROCH	Unknown	0 %Carteolol%
N	25641	CARTEOLOL HYDROCH	Unknown	0 %Carteolol%
N	54106	Carvedilol Carvedilol : Oral suspei	Beta-adren	2040000 %carvedilol%
N	22796	CARVEDILOL 3.125 MG	Unknown	0 %carvedilol%
N	817	Carvedilol Carvedilol : Tablet	Beta-adren	2040000 %carvedilol%
N	46936	Carvedilol Carvedilol : Tablet	Beta-adren	2040000 %carvedilol%
N	46935	Carvedilol Carvedilol : Tablet	Beta-adren	2040000 %carvedilol%
N	34741	Carvedilol Carvedilol : Tablet	Beta-adren	2040000 %carvedilol%
N	49142	Carvedilol Carvedilol : Oral suspei	Beta-adren	2040000 %carvedilol%
N	19013	Lidoflazine Clinium 12i Tablet	Calcium-ch	2060200 %CLINIUM%, %lidoflazine%
N	338	Clonidine h Clonidine 2 Tablet	Centrally A 02050200/	%clonidine%
N	45578	Clonidine h Clonidine 2 Tablet	Centrally A 02050200/	%clonidine%
N	33093	Clonidine h Clonidine 2 Tablet	Centrally A 02050200/	%clonidine%

N	60089	Clonidine h Clonidine 2 Tablet	Centrally A 02050200/ %clonidine%
N	55797	Clonidine h Clonidine 2 Oral solutic	Centrally A 02050200/ %clonidine%
N	50300	Bisoprolol h Congescor Tablet	Beta-adren 02040000/ %Bisoprolol%, %CONGESCOR%
N	33909	Bisoprolol h Congescor Tablet	Beta-adren 02040000/ %Bisoprolol%, %CONGESCOR%
N	50224	Bisoprolol h Congescor Tablet	Beta-adren 02040000/ %Bisoprolol%, %CONGESCOR%
N	32552	Bisoprolol h Congescor Tablet	Beta-adren 02040000/ %Bisoprolol%, %CONGESCOR%
N	19325	Verapamil Cordilox 2. Solution fo	Supraventr 02030202/ %CORDILOX%, %verapamil%
N	43878	Degarelix a Degarelix 1 Powder an	Gonadoreli 8030402 %Arelix%
N	42338	Degarelix A Degarelix 8 Powder Fo	Gonadoreli 8030402 %Arelix%
N	22454	Metirosine Demser 25 Capsule	Alpha-adre 2050400 %DEMSEr%, %metirosine%
N	54340	Diazoxide Diazoxide 1 Oral solutic	Treatment 6010400 %diazoxide%
N	42677	Diazoxide Diazoxide 2 Oral solutic	Treatment 6010400 %diazoxide%
N	39956	Diazoxide Diazoxide 2 Oral suspei	Treatment 6010400 %diazoxide%
N	55989	Diazoxide Diazoxide 2 Oral solutic	Treatment 6010400 %diazoxide%
N	6265	Diazoxide Diazoxide 5 Tablet	Treatment 6010400 %diazoxide%
N	51018	Diazoxide Diazoxide 5 Oral solutic	Treatment 6010400 %diazoxide%
N	35960	Diazoxide Diazoxide 5 Oral suspei	Treatment 6010400 %diazoxide%
N	31417	Diazoxide Diazoxide 5 Oral Solutic	Treatment 6010400 %diazoxide%
N	49237	Diltiazem 0.2% cream	Local Prep: 01070000/ %diltiazem%
N	56271	Diltiazem 0.2% cream	Local Prep: 01070000/ %diltiazem%
N	9919	Diltiazem h Diltiazem 2 Cream	Local Prep: 01070000/ %diltiazem%
N	47996	Diltiazem h Diltiazem 2 Gel	Local Prep: 01070000/ %diltiazem%
N	45564	Diltiazem h Diltiazem 2 Ointment	Local Prep: 01070000/ %diltiazem%
N	49500	Diltiazem h Diltiazem 2 Ointment	Local Prep: 01070000/ %diltiazem%
N	2630	Clonidine h Dixarit 25n Tablet	Prophylaxi: 04070402/ %clonidine%
N	2117	Indoramin Doralese Ti Tablet	Alpha-adre 02050400/ %DORALESE%, %indoramin%
N	18650	Etacrynic A Edecrin 50r Tablet	Loop Diure 2020200 %EDECRIN%, %etacryn%
N	39819	Esmolol Hy Esmolol 2.5 Solution Fc	Beta-adren 2040000 %Esmolol%
N	30541	Esmolol Hy Esmolol HC Concentrat	Beta-adren 2040000 %Esmolol%
N	12354	Etacrynic A Etacrynic 5 Tablets	Loop Diure 2020200 %etacryn%
N	32002	Etacrynic A Etacrynic 5 Injection	Loop Diure 2020200 %etacryn%
N	14117	Carvedilol Eucardic 3. Tablet	Beta-adren 2040000 %EUCARDIC%, %carvedilol%
N	25887	Diazoxide Eudemine ! Tablet	Treatment 6010400 %EUDEMINE%, %diazoxide%
N	10931	Adrenaline Ganda 1 + l Eye drops	Unknown 0 %guanethidine%
N	12046	Adrenaline Ganda 3 + l Eye drops	Unknown 0 %guanethidine%
N	60645	Generic Aptamil Comfr Nutritional	09040251/ %AMIL-CO%
N	3495	Metipranolol Glauine 0. Eye Drops	Beta-block 11065000 %metipranolol%
N	8140	Metipranolol Glauine 0. Eye Drops	Beta-block 11065000 %metipranolol%
N	12191	Metipranolol Glauine 0. Eye Drops	Beta-block 11065000 %metipranolol%
N	18270	Adrenaline Guanethidi Eye drops	Unknown 0 %guanethidine%
N	27984	GUANETHIDINE 1% AD	Unknown 0 %guanethidine%
N	22631	Adrenaline Guanethidi Eye drops	Unknown 0 %guanethidine%
N	22289	GUANETHIDINE 3%/AI	Unknown 0 %guanethidine%
N	12321	GUANETHIDINE 5% AD	Unknown 0 %guanethidine%
N	17826	Guanethidi Guanethidi Eye Drops	Sympathor 11065200 %guanethidine%
N	31297	GUANETHIDINE DROP!	Unknown 0 %guanethidine%
N	22648	GUANETHIDINE DROP!	Unknown 0 %guanethidine%
N	30207	Calendula (Hypercal cr Cream	Homeopat 51010000 %HYPERCAL%
N	8863	Prazosin hy Hypovase k Tablet	Alpha-adre 02050400/ %HYPOVASE%, %prazosin%
N	23459	Prazosin hy Hypovase k Tablet	Alpha-adre 02050400/ %HYPOVASE%, %prazosin%
N	25047	Prazosin hy Hypovase k Tablet	Alpha-adre 02050400/ %HYPOVASE%, %prazosin%
N	26693	Hypovase k Not applica	Alpha-adre 02050400/ %HYPOVASE%
N	2348	Terazosin f Hytrin bph Tablet	Alpha-adre 02050400/ %Hytrin%, %Terazosin%
N	16201	Terazosin f Hytrin bph Tablet	Alpha-adre 02050400/ %Hytrin%, %Terazosin%
N	5337	Terazosin f Hytrin bph Tablet	Alpha-adre 02050400/ %Hytrin%, %Terazosin%
N	2345	Hytrin BPH Not applica	Alpha-bloc 7040150 %Hytrin%
N	10294	Propranolol Inderal 1m; Solution fo	Drugs For / 02030200/ %INDERAL%, %Propranolol%
N	2816	Indoramin Indoramin Tablet	Alpha-adre 02050400/ %indoramin%
N	17543	Apraclonid lopidine 1% Eye Drops	Ocular Peri 11080251 %clonidine%
N	35134	Apraclonid lopidine 1% Eye drops	Ocular Peri 11080251 %clonidine%
N	6709	Apraclonid lopidine 5n Eye drops	Ocular Peri 11080251 %clonidine%
N	59633	Guanethidi Ismelin 5% Eye Drops	Sympathor 11065200 %SMELIN%, %guanethidine%
N	27777	Dicobalt ec Kelocyanor Solution fo	Therapy Of 54010000 %KELOC%

N	30758	Lidoflazine Lidoflazine Tablet	Calcium-ch	2060200	%lidoflazine%
N	8464	Meprobam Meprobam Tablet	Thiazides	02020100/	%thiazide%
N	31013	Mersalyl Mersalyl 5l Injection	Mercurial I	2020600	%Mersalyl%
N	17759	Metipranol Metipranol Eye Drops	Beta-block	11065000	%metipranolol%
N	12749	Metipranol Metipranol Eye drops	Beta-block	11065000	%metipranolol%
N	8142	Metipranol Metipranol Eye Drops	Beta-block	11065000	%metipranolol%
N	18114	Metipranol Metipranol Eye drops	Unknown	0	%metipranolol%
N	23190	METIPRANOLOL EYE	Unknown	0	%metipranolol%
N	23462	METIPRANOLOL EYE	Unknown	0	%metipranolol%
N	23498	METIPRANOLOL EYE	Unknown	0	%metipranolol%
N	10496	METIPRANOLOL EYE .6	Unknown	0	%metipranolol%
N	33788	Metirosine Metirosine Capsule	Alpha-adre	2050400	%metirosine%
N	14502	Metoprolo Metoprolo Solution fo	Beta-adren	2040000	%Metoprolol%
N	14211	Metipranol Minims me Eye drops	Beta-block	11065000	%metipranolol%
N	20015	Metipranol Minims me Eye drops	Unknown	0	%metipranolol%
N	18956	Metipranol Minims me Eye Drops	Beta-block	11065000	%metipranolol%
N	7790	MINOXIDIL 1 % LOT	Unknown	0	%minoxidil%
N	18938	MINOXIDIL 1 % TAB	Unknown	0	%minoxidil%
N	35116	Minoxidil Minoxidil 2 Gel	Vasodilato	02050100/	%minoxidil%
N	7333	Minoxidil Minoxidil 2 Liquid	Vasodilato	02050100/	%minoxidil%
N	45179	Minoxidil Minoxidil 5 Foam	Vasodilato	02050100/	%minoxidil%
N	11000	Minoxidil Minoxidil 5 Liquid	Vasodilato	02050100/	%minoxidil%
N	23683	MINOXIDIL LIQUID	Unknown	0	%minoxidil%
N	11547	Nimodipine Nimodipine Tablet	Calcium-ch	2060200	%nimodipine%
N	10595	Nimodipine Nimotop 3l Tablet	Calcium-ch	2060200	%NIMOTOP%, %nimodipine%
N	21496	PERHEXILINE MALEATE	Unknown	0	%perhexiline%
N	29116	Perhexiline Perhexiline Tablets	Other Anti-	2060300	%perhexiline%
N	20169	Practolol Practolol 2 Injection	Beta-adren	2040000	%Practolol%
N	8442	PRENYLAMINE LACTAT	Unknown	0	%Prenylamine%
N	27486	Propranolol Propranolol Solution fo	Drugs For /	02030200/	%Propranolol%
N	11304	Minoxidil Regaine ex Liquid	Androgene	13090300	%minoxidil%
N	35693	Minoxidil Regaine fo Gel	Vasodilato	02050100/	%minoxidil%
N	46055	Minoxidil Regaine fo Foam	Vasodilato	02050100/	%minoxidil%
N	18199	Minoxidil Regaine fo Liquid	Vasodilato	02050100/	%minoxidil%
N	24797	Minoxidil Regaine fo Liquid	Vasodilato	02050100/	%minoxidil%
N	11806	Minoxidil Regaine fo Liquid	Vasodilato	02050100/	%minoxidil%
N	4089	Minoxidil Regaine re Liquid	Androgene	13090300	%minoxidil%
N	19051	Minoxidil Regaine re Liquid	Androgene	13090300	%minoxidil%
N	46471	Tolvaptan Samsca 15l Tablet	Posterior P	6050200	%SAMSCA%, %tolvaptan%
N	27295	Verapamil Securon IV Solution fo	Calcium-ch	2060200	%SECURON%, %verapamil%
N	24635	Sotalol Hyc Sotalol 10 Injection	Supraventr	02030201/	%SOTACOR%, %Sotalol%
N	11380	Sotalol hyd Sotalol 16l Tablet	Drugs For /	02030200/	%SOTACOR%, %Sotalol%
N	26290	SOTALOL 40 MG INJ	Unknown	0	%SOTACOR%
N	33578	Sotalol hyd Sotalol 40 Solution fo	Unknown	0	%SOTACOR%, %Sotalol%
N	4004	Sotalol hyd Sotalol 80 Tablet	Drugs For /	02030200/	%SOTACOR%, %Sotalol%
N	17679	Sotalol Hyc Sotalol 10n Injection	Supraventr	02030201/	%Sotalol%
N	9292	Sotalol hyd Sotalol 160 Tablet	Drugs For /	02030200/	%Sotalol%
N	13051	Sotalol hyd Sotalol 200 Tablet	Drugs For /	02030200/	%Sotalol%
N	51492	Sotalol hyd Sotalol 25n Oral solutic	Drugs For /	02030200/	%Sotalol%
N	35710	Sotalol hyd Sotalol 25n Oral suspei	Drugs For /	02030200/	%Sotalol%
N	27727	Sotalol Hyc Sotalol 2m Injection	Supraventr	02030201/	%Sotalol%
N	34640	Sotalol hyd Sotalol 40n Tablet	Supraventr	02030201/	%Sotalol%
N	786	Sotalol hyd Sotalol 40n Tablet	Drugs For /	02030200/	%Sotalol%
N	34371	Sotalol hyd Sotalol 40n Tablet	Drugs For /	02030200/	%Sotalol%
N	43549	Sotalol hyd Sotalol 40n Tablet	Drugs For /	02030200/	%Sotalol%
N	34600	Sotalol hyd Sotalol 40n Tablet	Drugs For /	02030200/	%Sotalol%
N	38498	Sotalol hyd Sotalol 40n Solution fo	Unknown	0	%Sotalol%
N	1572	Sotalol hyd Sotalol 80n Tablet	Drugs For /	02030200/	%Sotalol%
N	39423	Sotalol hyd Sotalol 80n Tablet	Drugs For /	02030200/	%Sotalol%
N	34520	Sotalol hyd Sotalol 80n Tablet	Drugs For /	02030200/	%Sotalol%
N	34690	Sotalol hyd Sotalol 80n Tablet	Drugs For /	02030200/	%Sotalol%
N	3041	SOTALOL HCl 40 MG IN	Unknown	0	%Sotalol%
N	12119	SOTALOL HCl S/R 80 IN	Unknown	0	%Sotalol%

N	23598	SOTALOL HYDROCHLO Unknown	0 %Sotalol%
N	7681	Prenylamir Synadrin 6(Tablet Calcium-ch	2060200 %Prenylamine%, %Synadrin%
N	7429	Atenolol Tenormin E Solution fo Beta-adren	2040000 %Atenolol%, %TENORMIN%
N	3112	Carteolol h Teoptic 1% Eye drops Beta-block	11065000 %Carteolol%
N	3971	Carteolol h Teoptic 2% Eye drops Beta-block	11065000 %Carteolol%
N	3923	Terazosine Terazosin E Starter Pac Alpha-adre	02050400/ %Terazosin%
N	44029	Tolvaptan Tolvaptan :Tablet Posterior P	6050200 %tolvaptan%
N	2547	Toremifenε Toremifenε Tablet Breast Can	8030401 %TOREM%
N	26674	Verapamil Verapamil Solution fo Calcium-ch	2060200 %verapamil%
N	23328	Homoeopa Veratrum a Tablets Homeopati	51000000 %veratrum%
N	45428	Homoeopa Veratrum v Tablets Homeopati	51000000 %veratrum%

Reviewed by PPD for medications used to treat hypertension

review	classify	medcode	read_code	clinical_pat desc	matching_t
Y	DM unspecified type	22967	2BBF.00	1681 Retinal abnormality - diabetes related	% 2BB%
Y	DM unspecified type	47328	2BBk.00	177 O/E - right eye stable treated prolif diabetic retinopathy	% 2BB%
Y	DM unspecified type	52041	2BBl.00	127 O/E - left eye stable treated prolif diabetic retinopathy	% 2BB%
Y	DM unspecified type	9835	2BBL.00	3331 O/E - diabetic maculopathy present both eyes	% 2BB%
Y	DM unspecified type	52630	2BBo.00	49 O/E - sight threatening diabetic retinopathy	% 2BB%
Y	DM unspecified type	11433	2BBP.00	61538 O/E - right eye background diabetic retinopathy	% 2BB%
Y	DM unspecified type	11129	2BBQ.00	60335 O/E - left eye background diabetic retinopathy	% 2BB%
Y	DM unspecified type	101881	2BBr.00	5 Impaired vision due to diabetic retinopathy	% 2BB%
Y	DM unspecified type	13099	2BBR.00	3971 O/E - right eye preproliferative diabetic retinopathy	% 2BB%
Y	DM unspecified type	13103	2BBS.00	3793 O/E - left eye preproliferative diabetic retinopathy	% 2BB%
Y	DM unspecified type	13097	2BBT.00	2437 O/E - right eye proliferative diabetic retinopathy	% 2BB%
Y	DM unspecified type	13101	2BBV.00	2283 O/E - left eye proliferative diabetic retinopathy	% 2BB%
Y	DM unspecified type	13102	2BBW.00	9061 O/E - right eye diabetic maculopathy	% 2BB%
Y	DM unspecified type	13108	2BBX.00	9213 O/E - left eye diabetic maculopathy	% 2BB%
Y	DM unspecified type	27921	2G51000	428 Foot abnormality - diabetes related	% 2G510%
Y	DM unspecified type	18056	2G5C.00	740 Foot abnormality - diabetes related	% 2G5C%
Y	DM unspecified type	35316	2G5H.00	3671 O/E - Right diabetic foot - ulcerated	% 2G5H%
Y	DM unspecified type	35116	2G5L.00	3529 O/E - Left diabetic foot - ulcerated	% 2G5L%
Y	DM unspecified type	62384	2G5V.00	40 O/E - right chronic diabetic foot ulcer	% 2G5V%
Y	DM unspecified type	49640	2G5W.00	64 O/E - left chronic diabetic foot ulcer	% 2G5W%
Y	DM unspecified type	29218	42W2.00	1154 Hb. A1C 7-10% - borderline	% 42W%
Y	DM unspecified type	13604	42W3.00	1680 Hb. A1C > 10% - bad control	% 42W%
Y	DM unspecified type	1684	66A4.00	197145 Diabetic on oral treatment	% 66A4%
Y	DM unspecified type	8842	66A5.00	63533 Diabetic on insulin	% 66A5%
Y	DM unspecified type	2378	66AJ.00	126414 Diabetic - poor control	% 66AJ%
Y	DM unspecified type	9013	66AJ.11	875 Unstable diabetes	% 66AJ%
Y	DM unspecified type	2478	66AJ100	1038 Brittle diabetes	% 66AJ%
Y	DM unspecified type	22023	66AJz00	1279 Diabetic - poor control NOS	% 66AJ%
Y	DM unspecified type	28769	66AV.00	13039 Diabetic on insulin and oral treatment	% 66AV%
Y	DM unspecified type	711	C10..00	776981 Diabetes mellitus	% C10%
Y	DM unspecified type	38986	C100.00	2316 Diabetes mellitus with no mention of complication	% C10%
Y	DM Type 1	24490	C100000	1291 Diabetes mellitus, juvenile type, no mention of complication	% C10%
Y	DM type 1	1038	C100011	34139 Insulin dependent diabetes mellitus	% C10%
Y	DM type 2	14803	C100100	13104 Diabetes mellitus, adult onset, no mention of complication	% C10%
Y	DM unspecified type	14889	C100111	20590 Maturity onset diabetes	% C10%
Y	DM type 2	506	C100112	93196 Non-insulin dependent diabetes mellitus	% C10%
Y	DM unspecified type	50972	C100z00	575 Diabetes mellitus NOS with no mention of complication	% C10%
Y	DM unspecified type	1682	C101.00	11857 Diabetes mellitus with ketoacidosis	% C10%
Y	DM Type 1	53200	C101000	82 Diabetes mellitus, juvenile type, with ketoacidosis	% C10%
Y	DM type 2	54856	C101100	35 Diabetes mellitus, adult onset, with ketoacidosis	% C10%
Y	DM unspecified type	38617	C101y00	24 Other specified diabetes mellitus with ketoacidosis	% C10%
Y	DM unspecified type	42505	C101z00	315 Diabetes mellitus NOS with ketoacidosis	% C10%
Y	DM unspecified type	21482	C102.00	214 Diabetes mellitus with hyperosmolar coma	% C10%
Y	DM Type 1	40023	C102000	8 Diabetes mellitus, juvenile type, with hyperosmolar coma	% C10%
Y	DM type 2	43139	C102100	29 Diabetes mellitus, adult onset, with hyperosmolar coma	% C10%
Y	DM unspecified type	72345	C102z00	7 Diabetes mellitus NOS with hyperosmolar coma	% C10%
Y	DM unspecified type	15690	C103.00	344 Diabetes mellitus with ketoacidotic coma	% C10%
Y	DM Type 1	42567	C103000	6 Diabetes mellitus, juvenile type, with ketoacidotic coma	% C10%
Y	DM type 2	68843	C103100	4 Diabetes mellitus, adult onset, with ketoacidotic coma	% C10%
Y	DM unspecified type	59288	C103y00	3 Other specified diabetes mellitus with coma	% C10%
Y	DM unspecified type	65062	C103z00	7 Diabetes mellitus NOS with ketoacidotic coma	% C10%
Y	DM unspecified type	16502	C104.00	1355 Diabetes mellitus with renal manifestation	% C10%
Y	DM unspecified type	2475	C104.11	2986 Diabetic nephropathy	% C10%
Y	DM Type 1	93922	C104000	2 Diabetes mellitus, juvenile type, with renal manifestation	% C10%
Y	DM type 2	35105	C104100	44 Diabetes mellitus, adult onset, with renal manifestation	% C10%
Y	DM unspecified type	13279	C104y00	13 Other specified diabetes mellitus with renal complications	% C10%
Y	DM unspecified type	35107	C104z00	277 Diabetes mellitus with nephropathy NOS	% C10%
Y	DM unspecified type	33254	C105.00	1569 Diabetes mellitus with ophthalmic manifestation	% C10%
Y	DM Type 1	69748	C105000	6 Diabetes mellitus, juvenile type, + ophthalmic manifestation	% C10%
Y	DM type 2	41389	C105100	85 Diabetes mellitus, adult onset, + ophthalmic manifestation	% C10%
Y	DM unspecified type	47377	C105y00	6 Other specified diabetes mellitus with ophthalmic complicatn	% C10%
Y	DM unspecified type	34283	C105z00	164 Diabetes mellitus NOS with ophthalmic manifestation	% C10%
Y	DM unspecified type	16230	C106.00	10992 Diabetes mellitus with neurological manifestation	% C10%
Y	DM unspecified type	59903	C106.11	22 Diabetic amyotrophy	% C10%
Y	DM unspecified type	7795	C106.12	8536 Diabetes mellitus with neuropathy	% C10%
Y	DM unspecified type	16491	C106.13	64 Diabetes mellitus with polyneuropathy	% C10%

Y	DM Type 1	67853 C106000	74 Diabetes mellitus, juvenile, + neurological manifestation	% C10%
Y	DM type 2	39317 C106100	185 Diabetes mellitus, adult onset, + neurological manifestation	% C10%
Y	DM unspecified type	61523 C106y00	57 Other specified diabetes mellitus with neurological comps	% C10%
Y	DM unspecified type	22573 C106z00	244 Diabetes mellitus NOS with neurological manifestation	% C10%
Y	DM unspecified type	35399 C107.00	2677 Diabetes mellitus with peripheral circulatory disorder	% C10%
Y	DM unspecified type	32403 C107.11	258 Diabetes mellitus with gangrene	% C10%
Y	DM unspecified type	32556 C107.12	108 Diabetes with gangrene	% C10%
Y	DM Type 1	70448 C107000	2 Diabetes mellitus, juvenile +peripheral circulatory disorder	% C10%
Y	DM type 2	63357 C107100	52 Diabetes mellitus, adult, + peripheral circulatory disorder	% C10%
Y	DM type 2	33807 C107200	41 Diabetes mellitus, adult with gangrene	% C10%
Y	DM Type 1	69124 C107300	11 IDDM with peripheral circulatory disorder	% C10%
Y	DM type 2	56803 C107400	28 NIDDM with peripheral circulatory disorder	% C10%
Y	DM unspecified type	65025 C107z00	74 Diabetes mellitus NOS with peripheral circulatory disorder	% C10%
Y	DM type 1	1647 C108.00	22358 Insulin dependent diabetes mellitus	% C10%
Y	DM type 1	18505 C108.11	7852 IDDM-Insulin dependent diabetes mellitus	% C10%
Y	DM type 1	17858 C108.12	6028 Type 1 diabetes mellitus	% C10%
Y	DM type 1	24423 C108.13	775 Type I diabetes mellitus	% C10%
Y	DM type 1	46963 C108000	29 Insulin-dependent diabetes mellitus with renal complications	% C10%
Y	DM type 1	61344 C108011	5 Type I diabetes mellitus with renal complications	% C10%
Y	DM type 1	21983 C108012	5 Type 1 diabetes mellitus with renal complications	% C10%
Y	DM type 1	49276 C108100	16 Insulin-dependent diabetes mellitus with ophthalmic comps	% C10%
Y	DM type 1	102740 C108112	1 Type 1 diabetes mellitus with ophthalmic complications	% C10%
Y	DM type 1	52283 C108200	8 Insulin-dependent diabetes mellitus with neurological comps	% C10%
Y	DM type 1	49146 C108211	1 Type I diabetes mellitus with neurological complications	% C10%
Y	DM type 1	61829 C108212	6 Type 1 diabetes mellitus with neurological complications	% C10%
Y	DM type 1	52104 C108300	11 Insulin dependent diabetes mellitus with multiple complicatn	% C10%
Y	DM type 1	108007 C108311	1 Type I diabetes mellitus with multiple complications	% C10%
Y	DM type 1	26855 C108400	64 Unstable insulin dependent diabetes mellitus	% C10%
Y	DM type 1	60107 C108411	3 Unstable type I diabetes mellitus	% C10%
Y	DM type 1	97474 C108412	2 Unstable type 1 diabetes mellitus	% C10%
Y	DM type 1	44443 C108500	207 Insulin dependent diabetes mellitus with ulcer	% C10%
Y	DM type 1	51957 C108511	10 Type I diabetes mellitus with ulcer	% C10%
Y	DM type 1	68390 C108512	15 Type 1 diabetes mellitus with ulcer	% C10%
Y	DM type 1	60499 C108600	10 Insulin dependent diabetes mellitus with gangrene	% C10%
Y	DM type 1	6509 C108700	240 Insulin dependent diabetes mellitus with retinopathy	% C10%
Y	DM type 1	38161 C108711	14 Type I diabetes mellitus with retinopathy	% C10%
Y	DM type 1	41049 C108712	9 Type 1 diabetes mellitus with retinopathy	% C10%
Y	DM type 1	6791 C108800	423 Insulin dependent diabetes mellitus - poor control	% C10%
Y	DM type 1	46850 C108811	18 Type I diabetes mellitus - poor control	% C10%
Y	DM type 1	45914 C108812	2 Type 1 diabetes mellitus - poor control	% C10%
Y	DM type 1	31310 C108900	549 Insulin dependent diabetes maturity onset	% C10%
Y	DM type 1	63017 C108911	1 Type I diabetes mellitus maturity onset	% C10%
Y	DM type 1	97446 C108912	2 Type 1 diabetes mellitus maturity onset	% C10%
Y	DM type 1	56448 C108A00	18 Insulin-dependent diabetes without complication	% C10%
Y	DM type 1	95992 C108A11	1 Type I diabetes mellitus without complication	% C10%
Y	DM type 1	24694 C108B00	1 Insulin dependent diabetes mellitus with mononeuropathy	% C10%
Y	DM type 1	99231 C108B11	1 Type I diabetes mellitus with mononeuropathy	% C10%
Y	DM type 1	41716 C108C00	11 Insulin dependent diabetes mellitus with polyneuropathy	% C10%
Y	DM type 1	57621 C108D00	18 Insulin dependent diabetes mellitus with nephropathy	% C10%
Y	DM type 1	66872 C108D11	7 Type I diabetes mellitus with nephropathy	% C10%
Y	DM type 1	44440 C108E00	49 Insulin dependent diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 1	42729 C108E11	14 Type I diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 1	70766 C108E12	2 Type 1 diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 1	44260 C108F00	7 Insulin dependent diabetes mellitus with diabetic cataract	% C10%
Y	DM type 1	17545 C108F11	4 Type I diabetes mellitus with diabetic cataract	% C10%
Y	DM type 1	64446 C108G00	3 Insulin dependent diab mell with peripheral angiopathy	% C10%
Y	DM type 1	65616 C108H00	4 Insulin dependent diabetes mellitus with arthropathy	% C10%
Y	DM type 1	62352 C108H11	1 Type I diabetes mellitus with arthropathy	% C10%
Y	DM type 1	39809 C108J00	27 Insulin dependent diab mell with neuropathic arthropathy	% C10%
Y	DM type 1	60208 C108J11	3 Type I diabetes mellitus with neuropathic arthropathy	% C10%
Y	DM type 1	18230 C108J12	3 Type 1 diabetes mellitus with neuropathic arthropathy	% C10%
Y	DM unspecified type	46290 C108y00	10 Other specified diabetes mellitus with multiple comps	% C10%
Y	DM unspecified type	64449 C108z00	3 Unspecified diabetes mellitus with multiple complications	% C10%
Y	DM type 2	4513 C109.00	82849 Non-insulin dependent diabetes mellitus	% C10%
Y	DM type 2	5884 C109.11	5689 NIDDM - Non-insulin dependent diabetes mellitus	% C10%
Y	DM type 2	17859 C109.12	44200 Type 2 diabetes mellitus	% C10%
Y	DM type 2	18219 C109.13	4676 Type II diabetes mellitus	% C10%

Y	DM type 2	52303 C109000	16 Non-insulin-dependent diabetes mellitus with renal comps	% C10%
Y	DM type 2	50225 C109011	9 Type II diabetes mellitus with renal complications	% C10%
Y	DM type 2	18209 C109012	20 Type 2 diabetes mellitus with renal complications	% C10%
Y	DM type 2	50429 C109100	17 Non-insulin-dependent diabetes mellitus with ophthalm comp	% C10%
Y	DM type 2	59725 C109111	2 Type II diabetes mellitus with ophthalmic complications	% C10%
Y	DM type 2	70316 C109112	36 Type 2 diabetes mellitus with ophthalmic complications	% C10%
Y	DM type 2	55842 C109200	14 Non-insulin-dependent diabetes mellitus with neuro comps	% C10%
Y	DM type 2	67905 C109211	3 Type II diabetes mellitus with neurological complications	% C10%
Y	DM type 2	45919 C109212	15 Type 2 diabetes mellitus with neurological complications	% C10%
Y	DM type 2	62146 C109300	9 Non-insulin-dependent diabetes mellitus with multiple comps	% C10%
Y	DM type 2	108005 C109312	55 Type 2 diabetes mellitus with multiple complications	% C10%
Y	DM type 2	34912 C109400	225 Non-insulin dependent diabetes mellitus with ulcer	% C10%
Y	DM type 2	55075 C109411	18 Type II diabetes mellitus with ulcer	% C10%
Y	DM type 2	65704 C109412	13 Type 2 diabetes mellitus with ulcer	% C10%
Y	DM type 2	40401 C109500	11 Non-insulin dependent diabetes mellitus with gangrene	% C10%
Y	DM type 2	62107 C109511	7 Type II diabetes mellitus with gangrene	% C10%
Y	DM type 2	46150 C109512	5 Type 2 diabetes mellitus with gangrene	% C10%
Y	DM type 2	17262 C109600	108 Non-insulin-dependent diabetes mellitus with retinopathy	% C10%
Y	DM type 2	58604 C109611	21 Type II diabetes mellitus with retinopathy	% C10%
Y	DM type 2	42762 C109612	15 Type 2 diabetes mellitus with retinopathy	% C10%
Y	DM type 2	8403 C109700	1612 Non-insulin dependent diabetes mellitus - poor control	% C10%
Y	DM type 2	24458 C109711	37 Type II diabetes mellitus - poor control	% C10%
Y	DM type 2	45913 C109712	32 Type 2 diabetes mellitus - poor control	% C10%
Y	DM type 2	29979 C109900	241 Non-insulin-dependent diabetes mellitus without complicatio	% C10%
Y	DM type 2	109103 C109911	2 Type II diabetes mellitus without complication	% C10%
Y	DM type 2	105784 C109912	1 Type 2 diabetes mellitus without complication	% C10%
Y	DM type 2	72320 C109A00	2 Non-insulin dependent diabetes mellitus with mononeuropath	% C10%
Y	DM type 2	50813 C109A11	1 Type II diabetes mellitus with mononeuropathy	% C10%
Y	DM type 2	45467 C109B00	10 Non-insulin dependent diabetes mellitus with polyneuropathy	% C10%
Y	DM type 2	47409 C109B11	3 Type II diabetes mellitus with polyneuropathy	% C10%
Y	DM type 2	59365 C109C00	55 Non-insulin dependent diabetes mellitus with nephropathy	% C10%
Y	DM type 2	64571 C109C11	5 Type II diabetes mellitus with nephropathy	% C10%
Y	DM type 2	24836 C109C12	10 Type 2 diabetes mellitus with nephropathy	% C10%
Y	DM type 2	43785 C109D00	9 Non-insulin dependent diabetes mellitus with hypoglyca coma	% C10%
Y	DM type 2	56268 C109D11	2 Type II diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 2	61071 C109D12	7 Type 2 diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 2	69278 C109E00	13 Non-insulin depend diabetes mellitus with diabetic cataract	% C10%
Y	DM type 2	48192 C109E11	10 Type II diabetes mellitus with diabetic cataract	% C10%
Y	DM type 2	44779 C109E12	7 Type 2 diabetes mellitus with diabetic cataract	% C10%
Y	DM type 2	54212 C109F00	6 Non-insulin-dependent d m with peripheral angiopath	% C10%
Y	DM type 2	54899 C109F11	4 Type II diabetes mellitus with peripheral angiopathy	% C10%
Y	DM type 2	60699 C109F12	2 Type 2 diabetes mellitus with peripheral angiopathy	% C10%
Y	DM type 2	24693 C109G00	5 Non-insulin dependent diabetes mellitus with arthropathy	% C10%
Y	DM type 2	18143 C109G11	1 Type II diabetes mellitus with arthropathy	% C10%
Y	DM type 2	49869 C109G12	1 Type 2 diabetes mellitus with arthropathy	% C10%
Y	DM type 2	40962 C109H00	9 Non-insulin dependent d m with neuropathic arthropathy	% C10%
Y	DM type 2	47816 C109H11	7 Type II diabetes mellitus with neuropathic arthropathy	% C10%
Y	DM type 2	66965 C109H12	9 Type 2 diabetes mellitus with neuropathic arthropathy	% C10%
Y	DM type 2	18278 C109J00	3838 Insulin treated Type 2 diabetes mellitus	% C10%
Y	DM type 2	37648 C109J11	22 Insulin treated non-insulin dependent diabetes mellitus	% C10%
Y	DM type 2	18264 C109J12	45 Insulin treated Type II diabetes mellitus	% C10%
Y	DM type 2	36633 C109K00	37 Hyperosmolar non-ketotic state in type 2 diabetes mellitus	% C10%
Y	Secondary DM	52236 C10A.00	46 Malnutrition-related diabetes mellitus	% C10%
Y	Secondary DM	66675 C10A000	3 Malnutrition-related diabetes mellitus with coma	% C10%
Y	Secondary DM	33969 C10A100	90 Malnutrition-related diabetes mellitus with ketoacidosis	% C10%
Y	Secondary DM	100347 C10A500	1 Malnutritn-relat diabetes melitus wth periph circul complctn	% C10%
Y	Secondary DM	11551 C10B.00	1183 Diabetes mellitus induced by steroids	% C10%
Y	Secondary DM	26108 C10B000	110 Steroid induced diabetes mellitus without complication	% C10%
Y	DM unspecified type	43453 C10C.00	28 Diabetes mellitus autosomal dominant	% C10%
Y	DM unspecified type	46624 C10C.11	173 Maturity onset diabetes in youth	% C10%
Y	DM type 1	98392 C10C.12	6 Maturity onset diabetes in youth type 1	% C10%
Y	DM type 2	36695 C10D.00	315 Diabetes mellitus autosomal dominant type 2	% C10%
Y	DM type 2	59991 C10D.11	26 Maturity onset diabetes in youth type 2	% C10%
Y	DM type 1	1549 C10E.00	79340 Type 1 diabetes mellitus	% C10%
Y	DM type 1	12455 C10E.11	352 Type I diabetes mellitus	% C10%
Y	DM type 1	51261 C10E.12	821 Insulin dependent diabetes mellitus	% C10%
Y	DM type 1	47582 C10E000	38 Type 1 diabetes mellitus with renal complications	% C10%

Y	DM type 1	102946	C10E012	3	Insulin-dependent diabetes mellitus with renal complications	% C10%
Y	DM type 1	47649	C10E100	16	Type 1 diabetes mellitus with ophthalmic complications	% C10%
Y	DM type 1	99311	C10E111	1	Type I diabetes mellitus with ophthalmic complications	% C10%
Y	DM type 1	98071	C10E112	2	Insulin-dependent diabetes mellitus with ophthalmic comps	% C10%
Y	DM type 1	42831	C10E200	21	Type 1 diabetes mellitus with neurological complications	% C10%
Y	DM type 1	101735	C10E212	1	Insulin-dependent diabetes mellitus with neurological comps	% C10%
Y	DM type 1	47650	C10E300	29	Type 1 diabetes mellitus with multiple complications	% C10%
Y	DM type 1	91942	C10E311	4	Type I diabetes mellitus with multiple complications	% C10%
Y	DM type 1	45276	C10E312	13	Insulin dependent diabetes mellitus with multiple complicat	% C10%
Y	DM type 1	43921	C10E400	41	Unstable type 1 diabetes mellitus	% C10%
Y	DM type 1	49949	C10E411	5	Unstable type I diabetes mellitus	% C10%
Y	DM type 1	54600	C10E412	5	Unstable insulin dependent diabetes mellitus	% C10%
Y	DM type 1	18683	C10E500	43	Type 1 diabetes mellitus with ulcer	% C10%
Y	DM type 1	93878	C10E511	6	Type I diabetes mellitus with ulcer	% C10%
Y	DM type 1	98704	C10E512	1	Insulin dependent diabetes mellitus with ulcer	% C10%
Y	DM type 1	69993	C10E600	11	Type 1 diabetes mellitus with gangrene	% C10%
Y	DM type 1	102112	C10E611	6	Type I diabetes mellitus with gangrene	% C10%
Y	DM type 1	109051	C10E612	1	Insulin dependent diabetes mellitus with gangrene	% C10%
Y	DM type 1	18387	C10E700	472	Type 1 diabetes mellitus with retinopathy	% C10%
Y	DM type 1	95343	C10E711	11	Type I diabetes mellitus with retinopathy	% C10%
Y	DM type 1	93875	C10E712	6	Insulin dependent diabetes mellitus with retinopathy	% C10%
Y	DM type 1	35288	C10E800	300	Type 1 diabetes mellitus - poor control	% C10%
Y	DM type 1	105337	C10E811	5	Type I diabetes mellitus - poor control	% C10%
Y	DM type 1	72702	C10E812	10	Insulin dependent diabetes mellitus - poor control	% C10%
Y	DM type 1	40682	C10E900	63	Type 1 diabetes mellitus maturity onset	% C10%
Y	DM type 1	96235	C10E911	12	Type I diabetes mellitus maturity onset	% C10%
Y	DM type 1	97849	C10E912	6	Insulin dependent diabetes maturity onset	% C10%
Y	DM type 1	69676	C10EA00	53	Type 1 diabetes mellitus without complication	% C10%
Y	DM type 1	62613	C10EA11	2	Type I diabetes mellitus without complication	% C10%
Y	DM type 1	99719	C10EA12	2	Insulin-dependent diabetes without complication	% C10%
Y	DM type 1	68105	C10EB00	9	Type 1 diabetes mellitus with mononeuropathy	% C10%
Y	DM type 1	46301	C10EC00	27	Type 1 diabetes mellitus with polyneuropathy	% C10%
Y	DM type 1	91943	C10EC11	1	Type I diabetes mellitus with polyneuropathy	% C10%
Y	DM type 1	101311	C10EC12	2	Insulin dependent diabetes mellitus with polyneuropathy	% C10%
Y	DM type 1	10418	C10ED00	450	Type 1 diabetes mellitus with nephropathy	% C10%
Y	DM type 1	102163	C10ED12	1	Insulin dependent diabetes mellitus with nephropathy	% C10%
Y	DM type 1	39070	C10EE00	80	Type 1 diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 1	99716	C10EE12	2	Insulin dependent diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 1	49554	C10EF00	19	Type 1 diabetes mellitus with diabetic cataract	% C10%
Y	DM type 1	100770	C10EF12	1	Insulin dependent diabetes mellitus with diabetic cataract	% C10%
Y	DM type 1	93468	C10EG00	3	Type 1 diabetes mellitus with peripheral angiopathy	% C10%
Y	DM type 1	18642	C10EH00	10	Type 1 diabetes mellitus with arthropathy	% C10%
Y	DM type 1	54008	C10EJ00	53	Type 1 diabetes mellitus with neuropathic arthropathy	% C10%
Y	DM type 1	30323	C10EK00	492	Type 1 diabetes mellitus with persistent proteinuria	% C10%
Y	DM type 1	30294	C10EL00	426	Type 1 diabetes mellitus with persistent microalbuminuria	% C10%
Y	DM type 1	102620	C10EL11	1	Type I diabetes mellitus with persistent microalbuminuria	% C10%
Y	DM type 1	10692	C10EM00	5067	Type 1 diabetes mellitus with ketoacidosis	% C10%
Y	DM type 1	62209	C10EM11	31	Type I diabetes mellitus with ketoacidosis	% C10%
Y	DM type 1	40837	C10EN00	209	Type 1 diabetes mellitus with ketoacidotic coma	% C10%
Y	DM type 1	66145	C10EN11	1	Type I diabetes mellitus with ketoacidotic coma	% C10%
Y	DM type 1	22871	C10EP00	59	Type 1 diabetes mellitus with exudative maculopathy	% C10%
Y	DM type 1	97894	C10EP11	1	Type I diabetes mellitus with exudative maculopathy	% C10%
Y	DM type 1	55239	C10EQ00	215	Type 1 diabetes mellitus with gastroparesis	% C10%
Y	DM type 1	108724	C10EQ11	1	Type I diabetes mellitus with gastroparesis	% C10%
Y	DM type 1	95636	C10ER00	97	Latent autoimmune diabetes mellitus in adult	% C10%
Y	DM type 2	758	C10F.00	766628	Type 2 diabetes mellitus	% C10%
Y	DM type 2	22884	C10F.11	3724	Type II diabetes mellitus	% C10%
Y	DM type 2	18777	C10F000	197	Type 2 diabetes mellitus with renal complications	% C10%
Y	DM type 2	57278	C10F011	4	Type II diabetes mellitus with renal complications	% C10%
Y	DM type 2	47321	C10F100	70	Type 2 diabetes mellitus with ophthalmic complications	% C10%
Y	DM type 2	100964	C10F111	3	Type II diabetes mellitus with ophthalmic complications	% C10%
Y	DM type 2	34268	C10F200	157	Type 2 diabetes mellitus with neurological complications	% C10%
Y	DM type 2	98616	C10F211	2	Type II diabetes mellitus with neurological complications	% C10%
Y	DM type 2	65267	C10F300	29	Type 2 diabetes mellitus with multiple complications	% C10%
Y	DM type 2	43227	C10F311	10	Type II diabetes mellitus with multiple complications	% C10%
Y	DM type 2	49074	C10F400	104	Type 2 diabetes mellitus with ulcer	% C10%
Y	DM type 2	91646	C10F411	5	Type II diabetes mellitus with ulcer	% C10%

Y	DM type 2	12736	C10F500	48	Type 2 diabetes mellitus with gangrene	% C10%
Y	DM type 2	104323	C10F511	1	Type II diabetes mellitus with gangrene	% C10%
Y	DM type 2	18496	C10F600	1687	Type 2 diabetes mellitus with retinopathy	% C10%
Y	DM type 2	49655	C10F611	28	Type II diabetes mellitus with retinopathy	% C10%
Y	DM type 2	25627	C10F700	1162	Type 2 diabetes mellitus - poor control	% C10%
Y	DM type 2	47315	C10F711	75	Type II diabetes mellitus - poor control	% C10%
Y	DM type 2	47954	C10F900	805	Type 2 diabetes mellitus without complication	% C10%
Y	DM type 2	53392	C10F911	173	Type II diabetes mellitus without complication	% C10%
Y	DM type 2	62674	C10FA00	65	Type 2 diabetes mellitus with mononeuropathy	% C10%
Y	DM type 2	95351	C10FA11	10	Type II diabetes mellitus with mononeuropathy	% C10%
Y	DM type 2	18425	C10FB00	210	Type 2 diabetes mellitus with polyneuropathy	% C10%
Y	DM type 2	50527	C10FB11	6	Type II diabetes mellitus with polyneuropathy	% C10%
Y	DM type 2	12640	C10FC00	1907	Type 2 diabetes mellitus with nephropathy	% C10%
Y	DM type 2	102201	C10FC11	18	Type II diabetes mellitus with nephropathy	% C10%
Y	DM type 2	46917	C10FD00	94	Type 2 diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 2	98723	C10FD11	19	Type II diabetes mellitus with hypoglycaemic coma	% C10%
Y	DM type 2	44982	C10FE00	132	Type 2 diabetes mellitus with diabetic cataract	% C10%
Y	DM type 2	93727	C10FE11	29	Type II diabetes mellitus with diabetic cataract	% C10%
Y	DM type 2	37806	C10FF00	52	Type 2 diabetes mellitus with peripheral angiopathy	% C10%
Y	DM type 2	104639	C10FF11	19	Type II diabetes mellitus with peripheral angiopathy	% C10%
Y	DM type 2	59253	C10FG00	46	Type 2 diabetes mellitus with arthropathy	% C10%
Y	DM type 2	103902	C10FG11	13	Type II diabetes mellitus with arthropathy	% C10%
Y	DM type 2	35385	C10FH00	176	Type 2 diabetes mellitus with neuropathic arthropathy	% C10%
Y	DM type 2	109197	C10FH11	1	Type II diabetes mellitus with neuropathic arthropathy	% C10%
Y	DM type 2	1407	C10FJ00	11821	Insulin treated Type 2 diabetes mellitus	% C10%
Y	DM type 2	64668	C10FJ11	89	Insulin treated Type II diabetes mellitus	% C10%
Y	DM type 2	34450	C10FK00	467	Hyperosmolar non-ketotic state in type 2 diabetes mellitus	% C10%
Y	DM type 2	107701	C10FK11	1	Hyperosmolar non-ketotic state in type II diabetes mellitus	% C10%
Y	DM type 2	26054	C10FL00	4239	Type 2 diabetes mellitus with persistent proteinuria	% C10%
Y	DM type 2	60796	C10FL11	59	Type II diabetes mellitus with persistent proteinuria	% C10%
Y	DM type 2	18390	C10FM00	7597	Type 2 diabetes mellitus with persistent microalbuminuria	% C10%
Y	DM type 2	85991	C10FM11	4	Type II diabetes mellitus with persistent microalbuminuria	% C10%
Y	DM type 2	32627	C10FN00	736	Type 2 diabetes mellitus with ketoacidosis	% C10%
Y	DM type 2	106528	C10FN11	1	Type II diabetes mellitus with ketoacidosis	% C10%
Y	DM type 2	51756	C10FP00	27	Type 2 diabetes mellitus with ketoacidotic coma	% C10%
Y	DM type 2	106061	C10FP11	1	Type II diabetes mellitus with ketoacidotic coma	% C10%
Y	DM type 2	25591	C10FQ00	175	Type 2 diabetes mellitus with exudative maculopathy	% C10%
Y	DM type 2	63690	C10FR00	138	Type 2 diabetes mellitus with gastroparesis	% C10%
Y	DM type 2	95539	C10FS00	5	Maternally inherited diabetes mellitus	% C10%
Y	Secondary DM	51697	C10G.00	243	Secondary pancreatic diabetes mellitus	% C10%
Y	Secondary DM	96506	C10G000	2	Secondary pancreatic diabetes mellitus without complication	% C10%
Y	Secondary DM	61122	C10H.00	31	Diabetes mellitus induced by non-steroid drugs	% C10%
Y	Secondary DM	67212	C10H000	2	DM induced by non-steroid drugs without complication	% C10%
Y	Secondary DM	43857	C10M.00	27	Lipoatrophic diabetes mellitus	% C10%
Y	Secondary DM	22487	C10N.00	105	Secondary diabetes mellitus	% C10%
Y	Secondary DM	94383	C10N000	7	Secondary diabetes mellitus without complication	% C10%
Y	Secondary DM	93380	C10N100	80	Cystic fibrosis related diabetes mellitus	% C10%
Y	DM unspecified type	107603	C10P.00	53	Diabetes mellitus in remission	% C10%
Y	DM Type 1	108360	C10P000	2	Type I diabetes mellitus in remission	% C10%
Y	DM type 2	107824	C10P100	5	Type II diabetes mellitus in remission	% C10%
Y	DM unspecified type	33343	C10y.00	65	Diabetes mellitus with other specified manifestation	% C10%
Y	DM type 2	63371	C10y100	7	Diabetes mellitus, adult, + other specified manifestation	% C10%
Y	DM unspecified type	10098	C10yy00	8	Other specified diabetes mellitus with other spec comps	% C10%
Y	DM unspecified type	70821	C10yz00	14	Diabetes mellitus NOS with other specified manifestation	% C10%
Y	DM unspecified type	45491	C10z.00	73	Diabetes mellitus with unspecified complication	% C10%
Y	DM Type 1	68792	C10z000	7	Diabetes mellitus, juvenile type, + unspecified complication	% C10%
Y	DM type 2	63762	C10z100	49	Diabetes mellitus, adult onset, + unspecified complication	% C10%
Y	DM unspecified type	64283	C10zy00	10	Other specified diabetes mellitus with unspecified comps	% C10%
Y	DM unspecified type	64357	C10zz00	112	Diabetes mellitus NOS with unspecified complication	% C10%
Y	Secondary DM	32193	C11y000	290	Steroid induced diabetes	% C11y0%
Y	Secondary DM	14980	C314.00	1909	Renal glycosuria	% C314%
Y	Secondary DM	11848	C314.11	29	Renal diabetes	% C314%
Y	DM unspecified type	52212	Cyu2.00	91	[X]Diabetes mellitus	% Cyu2%
Y	DM unspecified type	41686	Cyu2000	4	[X]Other specified diabetes mellitus	% Cyu2%
Y	DM unspecified type	100292	Cyu2300	2	[X]Unspecified diabetes mellitus with renal complications	% Cyu2%
Y	DM unspecified type	17067	F171100	2226	Autonomic neuropathy due to diabetes	% F1711%
Y	DM unspecified type	44033	F345000	43	Diabetic mononeuritis multiplex	% F3450%

Y	DM unspecified type	17247 F35z000	197 Diabetic mononeuritis NOS	% F35z0%
Y	DM unspecified type	31790 F372.00	1302 Polyneuropathy in diabetes	% F372%
Y	DM unspecified type	5002 F372.11	362 Diabetic polyneuropathy	% F372%
Y	DM unspecified type	2342 F372.12	8193 Diabetic neuropathy	% F372%
Y	DM unspecified type	48078 F372000	129 Acute painful diabetic neuropathy	% F372%
Y	DM unspecified type	35785 F372100	368 Chronic painful diabetic neuropathy	% F372%
Y	DM unspecified type	24571 F372200	186 Asymptomatic diabetic neuropathy	% F372%
Y	DM unspecified type	39420 F381300	34 Myasthenic syndrome due to diabetic amyotrophy	% F3813%
Y	DM unspecified type	2340 F381311	581 Diabetic amyotrophy	% F3813%
Y	DM unspecified type	37315 F3y0.00	294 Diabetic mononeuropathy	% F3y0%
Y	DM unspecified type	1323 F420.00	86521 Diabetic retinopathy	% F420%
Y	DM unspecified type	7069 F420000	71825 Background diabetic retinopathy	% F420%
Y	DM unspecified type	3286 F420100	7895 Proliferative diabetic retinopathy	% F420%
Y	DM unspecified type	2986 F420200	4048 Proliferative diabetic retinopathy	% F420%
Y	DM unspecified type	10099 F420300	761 Advanced diabetic maculopathy	% F420%
Y	DM unspecified type	3837 F420400	20884 Diabetic maculopathy	% F420%
Y	DM unspecified type	47584 F420500	115 Advanced diabetic retinal disease	% F420%
Y	DM unspecified type	10755 F420600	11753 Non proliferative diabetic retinopathy	% F420%
Y	DM unspecified type	30477 F420700	67 High risk proliferative diabetic retinopathy	% F420%
Y	DM unspecified type	65463 F420800	35 High risk non proliferative diabetic retinopathy	% F420%
Y	DM unspecified type	11626 F420z00	1869 Diabetic retinopathy NOS	% F420%
Y	DM unspecified type	17313 F440700	53 Diabetic iritis	% F4407%
Y	DM unspecified type	10659 F464000	1514 Diabetic cataract	% F4640%
Y	DM unspecified type	34152 G73y000	215 Diabetic peripheral angiopathy	% G73y0%
Y	DM unspecified type	2471 K01x100	267 Nephrotic syndrome in diabetes mellitus	% K01x1%
Y	DM unspecified type	45499 K01x111	8 Kimmelstiel - Wilson disease	% K01x1%
Y	DM unspecified type	105302 K08yA00	169 Proteinuric diabetic nephropathy	% K08yA%
Y	DM unspecified type	107881 K08yA11	1 Clinical diabetic nephropathy	% K08yA%
Y	DM unspecified type	99628 Kyu0300	2 [X]Glomerular disorders in diabetes mellitus	% Kyu03%
Y	Gestational DM	11359 L180.00	920 Diabetes mellitus during pregnancy/childbirth/puerperium	% L180%
Y	Gestational DM	67635 L180000	9 Diabetes mellitus - unspec whether in pregnancy/puerperium	% L180%
Y	Gestational DM	34639 L180100	48 Diabetes mellitus during pregnancy - baby delivered	% L180%
Y	Gestational DM	49559 L180300	37 Diabetes mellitus during pregnancy - baby not yet delivered	% L180%
Y	Gestational DM	96823 L180400	2 Diabetes mellitus in puerperium - baby previously delivered	% L180%
Y	DM type 1	50960 L180500	214 Pre-existing diabetes mellitus, insulin-dependent	% L180%
Y	DM type 2	50609 L180600	44 Pre-existing diabetes mellitus, non-insulin-dependent	% L180%
Y	Secondary DM	109133 L180700	1 Pre-existing malnutrition-related diabetes mellitus	% L180%
Y	Gestational DM	10278 L180800	425 Diabetes mellitus arising in pregnancy	% L180%
Y	Gestational DM	8446 L180811	21101 Gestational diabetes mellitus	% L180%
Y	Gestational DM	2664 L180900	3300 Gestational diabetes mellitus	% L180%
Y	DM unspecified type	55431 L180X00	42 Pre-existing diabetes mellitus, unspecified	% L180%
Y	Gestational DM	64384 L180z00	40 Diabetes mellitus in pregnancy/childbirth/puerperium NOS	% L180%
Y	DM unspecified type	7328 M037200	627 Cellulitis in diabetic foot	% M0372%
Y	DM unspecified type	24327 M271000	2114 Ischaemic ulcer diabetic foot	% M271%
Y	DM unspecified type	11663 M271100	1740 Neuropathic diabetic ulcer - foot	% M271%
Y	DM unspecified type	9881 M271200	2420 Mixed diabetic ulcer - foot	% M271%
Y	DM unspecified type	18142 N030000	250 Diabetic cheiroarthropathy	% N030%
Y	DM unspecified type	57333 N030011	27 Diabetic cheiropathy	% N030%
Y	DM unspecified type	27891 N030100	793 Diabetic Charcot arthropathy	% N030%
Y	DM type 1	106927 PKyP.00	2 Diab insipidus, diab mell, optic atrophy and deafness	% PKyP%
Y	DM type 1	106926 PKyP.11	5 Wolfram syndrome	% PKyP%
Y	DM unspecified type	53634 R054200	82 [D]Gangrene of toe in diabetic	% R0542%
Y	DM unspecified type	31053 R054300	46 [D]Widespread diabetic foot gangrene	% R0543%
N		33681 2BB..00	10443 O/E - retinal inspection	% 2BB%
N		17198 2BB..11	925 O/E - retina	% 2BB%
N		24080 2BB1.00	16052 O/E - retina normal	% 2BB%
N		45145 2BB2.00	147 O/E - retinal vessel narrowing	% 2BB%
N		48751 2BB3.00	296 O/E - retinal A-V nipping	% 2BB%
N		19532 2BB4.00	986 O/E - retinal microaneurysms	% 2BB%
N		8742 2BB5.00	6011 O/E - retinal haemorrhages	% 2BB%
N		13106 2BB6.00	715 O/E - retinal exudates	% 2BB%
N		35659 2BB7.00	95 O/E - retinal vascular prolif.	% 2BB%
N		3822 2BB8.00	7203 O/E - vitreous haemorrhages	% 2BB%
N		3914 2BB9.00	2782 O/E - retinal pigmentation	% 2BB%
N		19535 2BBA.00	16176 Examination of retina	% 2BB%
N		36867 2BBa.00	119 O/E - non-referable retinopathy	% 2BB%
N		18438 2BBb.00	173 O/E - fundus not adequately seen	% 2BB%

N	60146 2BBB.00	1406 O/E - Right retina not seen	% 2BB%
N	39156 2BBC.00	1476 O/E - Left retina not seen	% 2BB%
N	50656 2BBc.00	2036 O/E - No retinal laser photocoagulation scars	% 2BB%
N	31088 2BBd.00	9227 O/E - Right retina normal	% 2BB%
N	34480 2BBd.00	231 O/E - Red reflex absent	% 2BB%
N	31089 2BBE.00	8873 O/E - Left retina normal	% 2BB%
N	70163 2BBe.00	55 O/E - right retina partially assessable	% 2BB%
N	92317 2BBf.00	70 O/E - left retina partially assessable	% 2BB%
N	36855 2BBG.00	240 Retinal abnormality - non-diabetes	% 2BB%
N	66273 2BBg.00	52 O/E - right retina fully assessable	% 2BB%
N	8518 2BBH.00	3689 Retinal drusen	% 2BB%
N	95916 2BBh.00	53 O/E - left retina fully assessable	% 2BB%
N	19149 2BBi.00	45554 O/E - no retinopathy	% 2BB%
N	26538 2BBi.00	31017 O/E - right eye no maculopathy	% 2BB%
N	13100 2BBj.00	143927 O/E - no right diabetic retinopathy	% 2BB%
N	43501 2BBj.00	30848 O/E - left eye no maculopathy	% 2BB%
N	13104 2BBk.00	144190 O/E - no left diabetic retinopathy	% 2BB%
N	25888 2BBm.00	881 O/E - right eye clinically significant macular oedema	% 2BB%
N	47144 2BBM.00	29043 O/E - diabetic maculopathy absent both eyes	% 2BB%
N	13107 2BBn.00	730 O/E - left eye clinically significant macular oedema	% 2BB%
N	22968 2BBN.00	389 Myelinated retinal nerve fibres	% 2BB%
N	18775 2BBO.00	193 O/E - Laser photocoagulation scars	% 2BB%
N	95946 2BBp.00	3207 On examination right red reflex present	% 2BB%
N	95947 2BBq.00	3050 On examination left red reflex present	% 2BB%
N	102242 2BBs.00	12 Retinal arteries silverwire	% 2BB%
N	19533 2BBY.00	473 O/E - referable retinopathy	% 2BB%
N	25116 2BBZ.00	357 O/E - retinal inspection NOS	% 2BB%
N	58179 2G5c.00	28 O/E - Left foot colour abnormal	% 2G5C%
N	9958 42W..00	24013 Hb. A1C - diabetic control	% 42W%
N	5717 42W..11	7354 Glycosylated Hb	% 42W%
N	14052 42W..12	941 Glycated haemoglobin	% 42W%
N	13597 42W1.00	2103 Hb. A1C < 7% - good control	% 42W%
N	14053 42W4.00	107 HbA1c level (DCCT aligned)	% 42W%
N	96968 42W5.00	985 Haemoglobin A1c level - IFCC standardised	% 42W%
N	14049 42WZ.00	81 Hb. A1C - diabetic control NOS	% 42W%
N	36644 66a3.00	46 Osteoporosis treatment stopped	% 66A3%
N	7563 66A3.00	93004 Diabetic on diet only	% 66A3%
N	34129 66a4.00	201 Osteoporosis treatment changed	% 66A4%
N	48962 66a5.00	80 Osteoporosis - no treatment	% 66A5%
N	69152 66Aj.00	41 Insulin needles changed less than once a day	% 66AJ%
N	22959 66AJ000	860 Chronic hyperglycaemia	% 66AJ%
N	21420 66AJ200	428 Loss of hypoglycaemic warning	% 66AJ%
N	37625 66AJ300	260 Recurrent severe hypos	% 66AJ%
N	108218 66AJ400	1	% 66AJ%
N	102490 66Av.00	35791 Diabetic assessment of erectile dysfunction	% 66AV%
N	12213 8BL2.00	67314 Patient on maximal tolerated therapy for diabetes	% 8BL2%
N	39406 C109800	16 Reaven's syndrome	% C10%
N	54773 C10F800	26 Reaven's syndrome	% C10%
N	39481 C10F811	150 Metabolic syndrome X	% C10%
N	68517 C10J.00	3 Insulin autoimmune syndrome	% C10%
N	37957 C10K.00	81 Type A insulin resistance	% C10%
N	56885 C10K000	1 Type A insulin resistance without complication	% C10%
N	75579 L1801G		% L180%
N	82025 L1801NM		% L180%
N	77675 L1801T		% L180%
N	3928 M271.00	12196 Non-pressure ulcer lower limb	% M271%
N	5057 M271.11	26845 Foot ulcer	% M271%
N	6308 M271.12	2329 Ischaemic leg ulcer	% M271%
N	1216 M271.13	392671 Leg ulcer NOS	% M271%
N	32006 M271.14	64 Neurogenic leg ulcer	% M271%
N	14838 M271.15	428 Trophic leg ulcer	% M271%
N	11624 M271300	6182 Arterial leg ulcer	% M271%
N	8801 M271400	13392 Mixed venous and arterial leg ulcer	% M271%
N	5855 M271500	32858 Venous ulcer of leg	% M271%
N	5790 M271600	4166 Traumatic leg ulcer	% M271%
N	99855 M271700	327 Neuropathic foot ulcer	% M271%
N	62290 N030.00	5 Arthropathy associated with endocrine and metabolic disorder	% N030%

N

94141 N030200

4 Arthropathy in amyloidosis

% N030%

Reviewed by PPD for Diabetes diagnosis (include DM type 1 & 2, unspecified type, secondary and gestational diabetes)

erms

Y	42395	Insulin lispro/Insulin lispro protamine	Humalog Mix25 100units/ml suspensio Suspension Intermedia	6010102	%HUMALOG%
Y	10243	Insulin lispro/Insulin lispro protamine	Humalog Mix25 100units/ml suspensio Suspension Intermedia	6010102	%HUMALOG%
Y	39006	Insulin lispro/Insulin lispro protamine	Humalog Mix25 KwikPen 100units/ml s Suspension Intermedia	6010102	%HUMALOG%
Y	14270	Insulin lispro/Insulin lispro protamine	Humalog Mix25 Pen 100units/ml suspe Suspension Intermedia	6010102	%HUMALOG%
Y	18593	Insulin lispro protamine/Insulin lispro	Humalog Mix50 100units/ml suspensio Suspension Intermedia	6010102	%HUMALOG%
Y	52522	Insulin lispro/Insulin lispro protamine	Humalog Mix50 KwikPen 100units/ml s Suspension Intermedia	6010102	%HUMALOG%
Y	39086	Insulin lispro/Insulin lispro protamine	Humalog Mix50 KwikPen 100units/ml s Suspension Intermedia	6010102	%HUMALOG%
Y	57622	Insulin lispro/Insulin lispro protamine	Humalog Mix50 KwikPen 100units/ml s Suspension Intermedia	6010102	%HUMALOG%
Y	10001	Insulin lispro/Insulin lispro protamine	Humalog Mix50 Pen 100units/ml suspe Suspension Intermedia	6010102	%HUMALOG%
Y	10264	Insulin lispro	Humalog Pen 100units/ml solution for Solution fo Short-actin	6010101	%HUMALOG%
Y	1649	Insulin Soluble Human	Human actraphane 100iu/ml Injection Injection Intermedia	6010102	%ACTRAPHANE%
Y	56115	Insulin soluble human	Human Actrapid Penfill 100units/ml so Solution fo Unknown	0	%ACTRAPID%
Y	34097	Insulin Soluble Human	Human initar 50/50 100unit/ml Inject Injection Intermedia	6010102	%INITARD%
Y	50691	Insulin soluble human/Insulin isophane human	Human Mixtard 20 Penfill 100units/ml Suspension Unknown	0	%MIXTARD%
Y	52722	Insulin soluble human/Insulin isophane human	Human Mixtard 30 Penfill 100units/ml Suspension Unknown	0	%MIXTARD%
Y	12818	Insulin soluble human/Insulin isophane human	Human Mixtard 50 100units/ml suspen Suspension Unknown	0	%MIXTARD%
Y	7772	Insulin isophane human	Human protaphane 100unit/ml Injectic Suspension Intermedia	6010102	%PROTAPHANE%
Y	7771	Insulin isophane human	Human protaphane penfill 100 100unit Suspension Intermedia	6010102	%PROTAPHANE%
Y	4760	Insulin isophane Human	Humulin l 100unit/ml Injection (Eli Lilly Injection Intermedia	6010102	%HUMULIN%
Y	14918	Insulin isophane human	Humulin l 100units/ml suspension for i Suspension Intermedia	6010102	%HUMULIN%
Y	14357	Insulin isophane human	Humulin l 100units/ml suspension for i Suspension Intermedia	6010102	%HUMULIN%
Y	43950	Insulin isophane human	Humulin l KwikPen 100units/ml suspen Suspension Intermedia	6010102	%HUMULIN%
Y	10229	Insulin isophane human	Humulin l Pen 100units/ml suspension Suspension Intermedia	6010102	%HUMULIN%
Y	10547	Insulin zinc suspension mixed human	Humulin Lente 100units/ml suspension Suspension Unknown	0	%HUMULIN%
Y	4199	Insulin Soluble Human	Humulin m1 100unit/ml M1 injection (l M1 Injectic Intermedia	6010102	%HUMULIN%
Y	4093	Insulin soluble human/Insulin isophane human	Humulin M2 100units/ml suspension fc Suspension Unknown	0	%HUMULIN%
Y	4198	Insulin Soluble Human	Humulin m3 100unit/ml M3 injection (l M3 Injectic Intermedia	6010102	%HUMULIN%
Y	19513	Insulin soluble human/Insulin isophane human	Humulin M3 100units/ml suspension fc Suspension Biphasic In:	6010151	%HUMULIN%
Y	57620	Insulin soluble human/Insulin isophane human	Humulin M3 100units/ml suspension fc Suspension Unknown	0	%HUMULIN%
Y	60933	Insulin soluble human/Insulin isophane human	Humulin M3 100units/ml suspension fc Suspension Biphasic In:	6010151	%HUMULIN%
Y	10277	Insulin soluble human/Insulin isophane human	Humulin M3 100units/ml suspension fc Suspension Biphasic In:	6010151	%HUMULIN%
Y	43991	Insulin soluble human/Insulin isophane human	Humulin M3 KwikPen 100units/ml susç Suspension Biphasic In:	6010151	%HUMULIN%
Y	16160	Insulin soluble human/Insulin isophane human	Humulin M3 Pen 100units/ml suspensi Suspension Unknown	0	%HUMULIN%
Y	11107	Insulin Soluble Human	Humulin m4 100unit/ml M4 injection (l M4 Injectic Intermedia	6010102	%HUMULIN%
Y	8841	Insulin soluble human/Insulin isophane human	Humulin M5 100units/ml suspension fc Suspension Unknown	0	%HUMULIN%
Y	62276	Insulin human	Humulin R 500units/ml solution for injc Solution fo Insulins	6010100	%HUMULIN%
Y	1840	Insulin Soluble Human	Humulin s 100unit/ml Injection (Eli Lilly Injection Short-actin	06010101/	%HUMULIN%
Y	21235	Insulin soluble human	Humulin S 100units/ml solution for injc Solution fo Short-actin	6010101	%HUMULIN%
Y	14944	Insulin soluble human	Humulin S 100units/ml solution for injc Solution fo Short-actin	6010101	%HUMULIN%
Y	7537	Insulin zinc suspension crystalline human	Humulin Zn 100units/ml suspension fo Suspension Unknown	0	%HUMULIN%
Y	13516	Insulin isophane bovine	Hypurin bovine isophane 100unit/ml In Suspension Intermedia	6010102	%HYPURIN%, %ISOPHANE%
Y	14340	Insulin isophane bovine	Hypurin Bovine Isophane 100units/ml s Suspension Intermedia	6010102	%HYPURIN%, %ISOPHANE%
Y	28588	Insulin isophane bovine	Hypurin Bovine Isophane 100units/ml s Suspension Intermedia	6010102	%HYPURIN%, %ISOPHANE%
Y	17712	Insulin zinc suspension mixed bovine	Hypurin Bovine Lente 100units/ml susç Suspension Intermedia	6010102	%HYPURIN%
Y	12297	Insulin Soluble Bovine	Hypurin bovine neutral 100unit/ml Inje Injection Short-actin	06010101/	%HYPURIN%
Y	14339	Insulin soluble bovine	Hypurin Bovine Neutral 100units/ml so Solution fo Short-actin	6010101	%HYPURIN%
Y	23231	Insulin soluble bovine	Hypurin Bovine Neutral 100units/ml so Solution fo Short-actin	6010101	%HYPURIN%
Y	9503	Insulin protamine zinc bovine	Hypurin Bovine Protamine Zinc 100unit Suspension Intermedia	6010102	%HYPURIN%
Y	9618	Insulin soluble porcine/Insulin isophane porcine	Hypurin Porcine 30/70 Mix 100units/m Suspension Unknown	0	%HYPURIN%
Y	24800	Insulin soluble porcine/Insulin isophane porcine	Hypurin Porcine 30/70 Mix 100units/m Suspension Biphasic In:	6010151	%HYPURIN%
Y	20995	Insulin isophane porcine/Insulin soluble porcine	Hypurin Porcine 30/70 Mix 100units/m Suspension Biphasic In:	6010151	%HYPURIN%
Y	13819	Insulin isophane porcine	Hypurin Porcine Isophane 100units/ml Suspension Unknown	0	%HYPURIN%, %ISOPHANE%
Y	28183	Insulin isophane porcine	Hypurin Porcine Isophane 100units/ml Suspension Intermedia	6010102	%HYPURIN%, %ISOPHANE%
Y	14933	Insulin isophane porcine	Hypurin Porcine Isophane 100units/ml Suspension Intermedia	6010102	%HYPURIN%, %ISOPHANE%
Y	13622	Insulin soluble porcine	Hypurin porcine neutral 100unit/ml Inj Solution fo Short-actin	06010101/	%HYPURIN%
Y	26098	Insulin soluble porcine	Hypurin Porcine Neutral 100units/ml si Solution fo Short-actin	6010101	%HYPURIN%
Y	14930	Insulin soluble porcine	Hypurin Porcine Neutral 100units/ml si Solution fo Short-actin	6010101	%HYPURIN%
Y	8895	Insulin Isophane Porcine	Initar 50/50 100unit/ml Injection (Nov Injection Intermedia	6010102	%INITARD%
Y	1886	Insulin isophane human	Insulatard 100iu/ml GE injection (Novo Suspension Intermedia	6010102	%INSULATARD%
Y	33966	Insulin Isophane Human	Insulatard 100unit/ml Injection (Novo l Injection Intermedia	6010102	%INSULATARD%
Y	14928	Insulin isophane human	Insulatard 100units/ml suspension for i Suspension Intermedia	6010102	%INSULATARD%
Y	5891	Insulin isophane human	Insulatard FlexPen 100units/ml suspen Suspension Intermedia	6010102	%INSULATARD%
Y	9737	Insulin isophane human	Insulatard innolet 100iu/ml Injection (l Suspension Intermedia	6010102	%INSULATARD%
Y	10208	Insulin isophane human	Insulatard InnoLet 100units/ml suspen: Suspension Intermedia	6010102	%INSULATARD%
Y	1595	Insulin isophane human	Insulatard NovoLet 100units/ml susper Suspension Intermedia	6010102	%INSULATARD%
Y	1593	Insulin isophane human	Insulatard penfill 100 100iu/ml Penfill (Suspension Intermedia	6010102	%INSULATARD%
Y	14290	Insulin isophane human	Insulatard Penfill 100units/ml suspensi Suspension Intermedia	6010102	%INSULATARD%
Y	52748	Insulin isophane human	Insulatard Penfill 100units/ml suspensi Suspension Intermedia	6010102	%INSULATARD%
Y	62180	Insulin aspart	Insulin aspart 100units/ml solution for injection 1.ç Short-actin	6010101	%Insulin% & %aspart%
Y	29567	Insulin aspart	Insulin aspart 100units/ml solution for Solution fo Short-actin	6010101	%Insulin% & %aspart%
Y	16142	Insulin aspart	Insulin aspart 100units/ml solution for Solution fo Short-actin	6010101	%Insulin% & %aspart%
Y	19877	Insulin aspart	Insulin aspart 100units/ml solution for Solution fo Short-actin	6010101	%Insulin% & %aspart%
Y	24795	Insulin aspart/Insulin aspart protamine	Insulin aspart biphasic 30/70 100units/ Suspension Biphasic In:	6010151	%Insulin% & %aspart%, %Insulin% i
Y	23099	Insulin aspart/Insulin aspart protamine	Insulin aspart biphasic 30/70 100units/ Suspension Biphasic In:	6010151	%Insulin% & %aspart%, %Insulin% i
Y	6447	Insulin Aspart	Insulin aspart human pyr 100 iu/ml Inje Injection Short-actin	6010101	%Insulin% & %aspart%, %Insulin% i
Y	13416	Insulin	Insulin biphasic 100 units/ml Injection Injection Intermedia	6010102	%Insulin% & %biphasic%
Y	10067	Insulin Aspart	Insulin biphasic aspart human pyr 30:7l Injection Intermedia	6010102	%Insulin% & %aspart%, %Insulin% i
Y	33167	Insulin Soluble Human	Insulin biphasic isophane human crb 2ç Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	54462	Insulin Soluble Human	Insulin biphasic isophane human emp 2 Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	13837	Insulin Soluble Human	Insulin biphasic isophane human prb 1l Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	14644	Insulin Soluble Human	Insulin biphasic isophane human prb 2l Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	29837	Insulin Soluble Human	Insulin biphasic isophane human prb 2l Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	9341	Insulin Soluble Human	Insulin biphasic isophane human prb 3l Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	21374	Insulin Soluble Human	Insulin biphasic isophane human prb 4l Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	21110	Insulin Soluble Human	Insulin biphasic isophane human prb 5l Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	14649	Insulin Soluble Human	Insulin biphasic isophane human pyr 1ç Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	11055	Insulin Soluble Human	Insulin biphasic isophane human pyr 2ç Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph
Y	11056	Insulin Soluble Human	Insulin biphasic isophane human pyr 3ç Injection Intermedia	6010102	%SOPHANE%, %Insulin% & %biph

Y	21395	Insulin Soluble Human	Insulin biphasic isophane human pyr 4I Injection	Intermedia	6010102	%ISOPHANE%, %Insulin% & %biph
Y	5250	Insulin Lispro	Insulin biphasic lispro human prb 25:75 Injection	Intermedia	6010102	%Insulin% & %biphasic%, %Insulin%
Y	27177	Insulin Lispro	Insulin biphasic lispro human prb 50:5C Injection	Intermedia	6010102	%Insulin% & %biphasic%, %Insulin%
Y	14506		INSULIN BOVINE PROTAMINE ZINC 100 I/U INJ	Unknown	0	%Insulin% & %bovine%, %Insulin%
Y	20195		INSULIN BOVINE PROTAMINE ZINC 40 I/U INJ	Unknown	0	%Insulin% & %bovine%, %Insulin%
Y	13550		INSULIN BP 100 I/U	Unknown	0	%Insulin bp%
Y	55907	Insulin degludec	Insulin degludec 100units/ml solution f Solution fo	Intermedia	6010102	%Insulin% & %degludec%
Y	55687		Insulin degludec 100units/ml solution for injection	Intermedia	6010102	%Insulin% & %degludec%
Y	56691		Insulin degludec 200units/ml solution for injection	Intermedia	6010102	%Insulin% & %degludec%
Y	10184	Insulin Detemir	Insulin detemir 100 iu/ml Solution for i Solution Fo	Intermedia	6010102	%Insulin% & %detemir%
Y	14301	Insulin detemir	Insulin detemir 100units/ml solution fo Solution fo	Intermedia	6010102	%Insulin% & %detemir%
Y	14330	Insulin detemir	Insulin detemir 100units/ml solution fo Solution fo	Intermedia	6010102	%Insulin% & %detemir%
Y	5953	Insulin Glargine	Insulin glargine 100iu/ml Injection Injection	Intermedia	6010102	%Insulin% & %glargine%
Y	10259	Insulin glargine	Insulin glargine 100units/ml solution fc Solution fo	Intermedia	6010102	%Insulin% & %glargine%
Y	7393	Insulin glargine	Insulin glargine 100units/ml solution fc Solution fo	Intermedia	6010102	%Insulin% & %glargine%
Y	7400	Insulin glargine	Insulin glargine 100units/ml solution fo Solution fo	Intermedia	6010102	%Insulin% & %glargine%
Y	28442	Insulin Glulisine	Insulin glulisine 100unit/ml Solution fo Solution Fo	Short-actin	6010101	%Insulin% & %glulisine%
Y	28101	Insulin glulisine	Insulin glulisine 100units/ml solution fc Solution fo	Short-actin	6010101	%Insulin% & %glulisine%
Y	14299	Insulin glulisine	Insulin glulisine 100units/ml solution fc Solution fo	Short-actin	6010101	%Insulin% & %glulisine%
Y	21590	Insulin glulisine	Insulin glulisine 100units/ml solution fc Solution fo	Short-actin	6010101	%Insulin% & %glulisine%
Y	20671		INSULIN HUM/ACTRAPHANE	Unknown	0	%ACTRAPHANE%
Y	20672		INSULIN HUM/ACTRAPID	Unknown	0	%ACTRAPID%
Y	32053		INSULIN HUMALOG MIX 25	Unknown	0	%HUMALOG%
Y	60951		Insulin human 100units/ml solution for injection 1I	Insulins	6010100	%Insulin% & %human%
Y	36355	Insulin Human	Insulin human 1mg inhalation powder Powder Fo	Unknown	0	%Insulin% & %human%, %Insulin%
Y	36356	Insulin human	Insulin human 3mg inhalation powder Inhalation	Unknown	0	%Insulin% & %human%, %Insulin%
Y	53710	Insulin human	Insulin human 500units/ml solution for Solution fo	Insulins	6010100	%Insulin% & %human%
Y	25006		INSULIN HUMAN ACTRAPID (NEUTRAL)	Unknown	0	%ACTRAPID%, %Insulin% & %NEUT
Y	321		INSULIN HUMAN ACTRAPID (NEUTRAL) 40 I/U INJ	Unknown	0	%ACTRAPID%, %Insulin% & %NEUT
Y	27911		INSULIN HUMAN ACTRAPID PENFILL	Unknown	0	%ACTRAPID%, %Insulin% & %huma
Y	2373		INSULIN HUMAN VELOSULIN 100 I/U INJ	Unknown	0	%Insulin% & %human%, %VELOSUI
Y	1839		INSULIN HUMULIN I (ISOPHANE) 100 I/U INJ	Unknown	0	%HUMULIN%, %ISOPHANE%
Y	10566		INSULIN HUMULIN M CARTRIDGE 100 I/U	Unknown	0	%HUMULIN%
Y	22161		INSULIN HUMULIN M1 VIAL	Unknown	0	%HUMULIN%
Y	22094		INSULIN HUMULIN M2 VIAL	Unknown	0	%HUMULIN%
Y	10546		INSULIN HUMULIN M4 100 I/U INJ	Unknown	0	%HUMULIN%
Y	10545		INSULIN HUMULIN M4 CARTRIDGE 100 I/U	Unknown	0	%HUMULIN%
Y	19707		INSULIN HUMULIN S (NEUTRAL SOLUBLE)	Unknown	0	%HUMULIN%, %Insulin% & %NEUT
Y	7861		INSULIN HUMULIN S (NEUTRAL) CARTRIDGE 100 I/	Unknown	0	%HUMULIN%, %Insulin% & %NEUT
Y	14504		INSULIN HYPURIN PROTAMINE ZINC 100 I/U INJ	Unknown	0	%HYPURIN%, %Insulin% & %zinc%
Y	16209		INSULIN HYPURIN SOLUBLE 100 I/U INJ	Unknown	0	%HYPURIN%, %Insulin% & %SOLUE
Y	24866		INSULIN INSULATARD (LEO RETARD) 40 I/U INJ	Unknown	0	%INSULATARD%
Y	15624		INSULIN ISOPHANE (HIGHLY PURIFIED) 100 I/U INJ	Unknown	0	%ISOPHANE%
Y	7783		INSULIN ISOPHANE (HUMAN) 100 I/U INJ	Unknown	0	%ISOPHANE%, %Insulin% & %hum:
Y	10691		INSULIN ISOPHANE (NPH) 100 I/U INJ	Unknown	0	%ISOPHANE%
Y	23003		INSULIN ISOPHANE (NPH) 40 I/U	Unknown	0	%ISOPHANE%
Y	22823		INSULIN ISOPHANE (PURIFIED) 100 I/U INJ	Unknown	0	%ISOPHANE%
Y	8376		INSULIN ISOPHANE 100 I/U	Unknown	0	%ISOPHANE%
Y	24722		INSULIN ISOPHANE 50%/NEUTRAL 50% 100 I/U INJ	Unknown	0	%ISOPHANE%, %Insulin% & %NEUT
Y	8354		INSULIN ISOPHANE 70%/NEUTRAL 30% 100 I/U INJ	Unknown	0	%ISOPHANE%, %Insulin% & %NEUT
Y	25736	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 10/90 Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %biph:
Y	56857	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 15/85 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	25735	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 20/80 Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %biph:
Y	36194	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 25/75 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	44378	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 25/75 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	42954	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 25/75 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	21232	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 30/70 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	16152	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 30/70 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	19878	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 30/70 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	21422	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 40/60 Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %biph:
Y	22697	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 50/50 Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %biph:
Y	28096	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 50/50 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	41120	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 50/50 Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	33232	Insulin soluble human/Insulin isophane human	Insulin isophane biphasic human 50/50 Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %biph:
Y	14619	Insulin soluble porcine/Insulin isophane porcine	Insulin isophane biphasic porcine 30/7I Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %biph:
Y	27280	Insulin soluble porcine/Insulin isophane porcine	Insulin isophane biphasic porcine 30/7I Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	36031	Insulin isophane porcine/Insulin soluble porcine	Insulin isophane biphasic porcine 30/7I Suspension	Biphasic In	6010151	%ISOPHANE%, %Insulin% & %biph:
Y	15484	Insulin isophane bovine	Insulin isophane bovine 100units/ml su Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %bovir
Y	18590	Insulin isophane bovine	Insulin isophane bovine 100units/ml su Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %bovir
Y	36066	Insulin isophane bovine	Insulin isophane bovine 100units/ml su Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %bovir
Y	10175	Insulin isophane human	Insulin isophane human 100units/ml sl Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %hum:
Y	55517	Insulin isophane human	Insulin isophane human 100units/ml sl Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	10207	Insulin isophane human	Insulin isophane human 100units/ml sl Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	25812	Insulin isophane human	Insulin isophane human 100units/ml sl Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	59500	Insulin isophane human	Insulin isophane human 100units/ml sl Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	15961	Insulin Isophane Human	Insulin isophane human crb 100iu/ml li Injection	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	13729	Insulin Isophane Human	Insulin isophane human emp 100unit/r Injection	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	11080	Insulin Isophane Human	Insulin isophane human prb 100iu/ml I Injection	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	14925	Insulin Isophane Human	Insulin isophane human vial 100unit/m Sterile Susj	Intermedia	6010102	%ISOPHANE%, %Insulin% & %hum:
Y	4247	Insulin isophane porcine	Insulin isophane porcine 100units/ml s Suspension	Unknown	0	%ISOPHANE%, %Insulin% & %porci
Y	7350	Insulin isophane porcine	Insulin isophane porcine 100units/ml s Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %porci
Y	30686	Insulin isophane porcine	Insulin isophane porcine 100units/ml s Suspension	Intermedia	6010102	%ISOPHANE%, %Insulin% & %porci
Y	2808		INSULIN LENTARD INJ	Unknown	0	%LENTARD%
Y	5214	Insulin lispro	Insulin lispro 100units/ml solution for li Solution fo	Unknown	0	%Insulin% & %lispro%
Y	26060	Insulin lispro	Insulin lispro 100units/ml solution for li Solution fo	Short-actin	6010101	%Insulin% & %lispro%
Y	14313	Insulin lispro	Insulin lispro 100units/ml solution for li Solution fo	Short-actin	6010101	%Insulin% & %lispro%
Y	14362	Insulin lispro	Insulin lispro 100units/ml solution for li Solution fo	Short-actin	6010101	%Insulin% & %lispro%
Y	43953	Insulin lispro/Insulin lispro protamine	Insulin lispro biphasic 25/75 100units/r Suspension	Intermedia	6010102	%Insulin% & %biphasic%, %Insulin%

Y	28185	Insulin lispro/Insulin lispro protamine	Insulin lispro biphasic 25/75 100units/r Suspension Intermedia	6010102	%Insulin% & %biphasic%, %Insulin%
Y	31258	Insulin lispro/Insulin lispro protamine	Insulin lispro biphasic 25/75 100units/r Suspension Intermedia	6010102	%Insulin% & %biphasic%, %Insulin%
Y	36146	Insulin lispro protamine/Insulin lispro	Insulin lispro biphasic 50/50 100units/r Suspension Intermedia	6010102	%Insulin% & %biphasic%, %Insulin%
Y	35701	Insulin lispro/Insulin lispro protamine	Insulin lispro biphasic 50/50 100units/r Suspension Intermedia	6010102	%Insulin% & %biphasic%, %Insulin%
Y	7959		INSULIN MIXTARD 30/70 40 I/U INJ Unknown	0	%MIXTARD%
Y	15040		INSULIN MONOPHANE (ISOPHANE) 100 I/U INJ Unknown	0	%SOPHANE%
Y	7757		INSULIN NEULENTE (ZINC SUSP)(PURIFIED) 100 I/U Unknown	0	%NEULENTE%, %insulin% & %zinc%
Y	7763		INSULIN NEUPHANE (ISOPHANE)(PURIFIED) 100 I/U Unknown	0	%SOPHANE%, %NEUPHANE%
Y	7764		INSULIN NEUSULIN (NEUTRAL)(PURIFIED) 100 I/U I Unknown	0	%Insulin% & %NEUTRAL%, %NEUSULIN%
Y	7765		INSULIN NEUTRAL (HUMAN) 100 I/U INJ Unknown	0	%Insulin% & %NEUTRAL%, %Insulin%
Y	18645		INSULIN NEUTRAL (PURIFIED) 100 I/U INJ Unknown	0	%Insulin% & %NEUTRAL%
Y	1645		INSULIN NOVO ACTRAPID MC 100 I/U INJ Unknown	0	%ACTRAPID%
Y	19829		INSULIN NOVO MONOTARD MC Unknown	0	%MONOTARD%
Y	1643		INSULIN NOVO MONOTARD MC 100 I/U INJ Unknown	0	%MONOTARD%
Y	4248		INSULIN NOVO ULTRATARD MC 100 I/U INJ Unknown	0	%ULTRATARD%
Y	22806		INSULIN PORK ACTRAPID Unknown	0	%ACTRAPID%
Y	21945		INSULIN PORK INSULATARD Unknown	0	%INSULATARD%
Y	14505	Insulin protamine zinc bovine	Insulin protamine zinc bovine 100units, Suspension Intermedia	6010102	%Insulin% & %bovine%, %insulin%
Y	24845		INSULIN PUR-IN ISOPHANE 100 I/U INJ Unknown	0	%SOPHANE%, %PUR-IN%
Y	28978		INSULIN PUR-IN MIX 15/85 100 I/U INJ Unknown	0	%PUR-IN%
Y	31267		INSULIN PUR-IN MIX 50/50 100 I/U INJ Unknown	0	%PUR-IN%
Y	12060		INSULIN QUICKSOL (SOLUBLE NEUTRAL) 100 I/U IN Unknown	0	%Insulin% & %NEUTRAL%, %Insulin%
Y	8839		INSULIN SEMITARD 100 I/U INJ Unknown	0	%SEMITARD%
Y	8838		INSULIN SEMITARD 40 I/U INJ Unknown	0	%SEMITARD%
Y	9079		INSULIN SOLUBLE 100 I/U INJ Unknown	0	%Insulin% & %SOLUBLE%
Y	20196		INSULIN SOLUBLE 40 I/U INJ Unknown	0	%Insulin% & %SOLUBLE%
Y	10572	Insulin Soluble Bovine	Insulin soluble bovine 100unit/ml Injec Injection Short-actin	06010101/	%Insulin% & %SOLUBLE%, %Insulin%
Y	18592	Insulin soluble bovine	Insulin soluble bovine 100units/ml solu Solution fo Short-actin	6010101	%Insulin% & %SOLUBLE%, %Insulin%
Y	14938	Insulin Soluble Bovine	Insulin soluble bovine cartridge 100uni Solution Fo Short-actin	06010101/	%Insulin% & %SOLUBLE%, %Insulin%
Y	27402	Insulin soluble human	Insulin soluble human 100units/ml sol. Solution fo Short-actin	6010101	%Insulin% & %SOLUBLE%, %Insulin%
Y	16129	Insulin soluble human	Insulin soluble human 100units/ml sol. Solution fo Short-actin	6010101	%Insulin% & %SOLUBLE%, %Insulin%
Y	36430	Insulin soluble human	Insulin soluble human 100units/ml sol. Solution fo Short-actin	6010101	%Insulin% & %SOLUBLE%, %Insulin%
Y	26621	Insulin Soluble Human	Insulin soluble human crb 100iu/ml Inj Injection Short-actin	06010101/	%Insulin% & %SOLUBLE%, %Insulin%
Y	15710	Insulin Soluble Human	Insulin soluble human emp 100unit/ml Injection Short-actin	06010101/	%Insulin% & %SOLUBLE%, %Insulin%
Y	12654	Insulin Soluble Human	Insulin soluble human prb 100unit/ml I Injection Short-actin	06010101/	%Insulin% & %SOLUBLE%, %Insulin%
Y	12638	Insulin Soluble Human	Insulin soluble human pyr 100unit/ml I Injection Short-actin	06010101/	%Insulin% & %SOLUBLE%, %Insulin%
Y	18301		INSULIN SOLUBLE INJ I/U*2 Unknown	0	%Insulin% & %SOLUBLE%
Y	4129	Insulin soluble porcine	Insulin soluble porcine 100units/ml soli Solution fo Unknown	0	%Insulin% & %SOLUBLE%, %Insulin%
Y	27396	Insulin soluble porcine	Insulin soluble porcine 100units/ml soli Solution fo Short-actin	6010101	%Insulin% & %SOLUBLE%, %Insulin%
Y	25479	Insulin soluble porcine	Insulin soluble porcine 100units/ml soli Solution fo Short-actin	6010101	%Insulin% & %SOLUBLE%, %Insulin%
Y	24485		INSULIN ZINC ANIMAL SUSPENSION Unknown	0	%Insulin% & %ANIMAL%, %Insulin%
Y	12244		INSULIN ZINC BOVINE susp 100 I/U INJ Unknown	0	%Insulin% & %bovine%, %Insulin%
Y	28723		INSULIN ZINC BOVINE SUSPENSION Unknown	0	%Insulin% & %bovine%, %Insulin%
Y	18931	Insulin zinc suspension crystalline human	Insulin zinc crystalline human 100units, Suspension Unknown	0	%Insulin% & %human%, %Insulin%
Y	8646		INSULIN ZINC CRYSTALLINE susp 100 I/U INJ Unknown	0	%Insulin% & %zinc%
Y	30861		INSULIN ZINC HUMAN SUSPENSION Unknown	0	%Insulin% & %human%, %Insulin%
Y	22496		INSULIN ZINC LENTE PURIFIED SUSPENSION Unknown	0	%Insulin% & %zinc%
Y	12035	Insulin zinc suspension mixed bovine	Insulin zinc mixed bovine 100units/ml : Suspension Intermedia	6010102	%Insulin% & %bovine%, %Insulin%
Y	16700	Insulin Zinc Suspension Mixed Bovine	Insulin zinc mixed bovine vial 100unit/ Sterile Susj Intermedia	6010102	%Insulin% & %bovine%, %Insulin%
Y	18461	Insulin zinc suspension mixed human	Insulin zinc mixed human 100units/ml Suspension Unknown	0	%Insulin% & %human%, %Insulin%
Y	26784		INSULIN ZINC SEMILENTE SUSP BP 100 I/U INJ Unknown	0	%Insulin% & %zinc%
Y	9376	Insulin Zinc Suspension Crystalline Human	Insulin zinc suspension crystalline hum Injection Intermedia	6010102	%Insulin% & %human%, %Insulin%
Y	41834	Insulin zinc suspension mixed bovine	Insulin zinc suspension lente 100iu/ml Suspension Intermedia	6010102	%Insulin% & %zinc%
Y	26498	Pork Insulin	Insulin zinc suspension mixed bovine a Injection Intermedia	6010102	%Insulin% & %bovine%, %Insulin%
Y	8322	Insulin Zinc Suspension Crystalline Human	Insulin zinc suspension mixed human p Injection Intermedia	6010102	%Insulin% & %human%, %Insulin%
Y	44251	Pork Insulin	Insulin zinc suspension mixed porcine J Injection Intermedia	6010102	%Insulin% & %porcine%, %Insulin%
Y	5501	Insulin Isophane Human	Insuman basal 100iu/ml Injection (Aver Injection Intermedia	6010102	%INSUMAN%
Y	27461	Insulin isophane human	Insuman Basal 100units/ml suspension Suspension Intermedia	6010102	%INSUMAN%
Y	23992	Insulin isophane human	Insuman Basal 100units/ml suspension Suspension Intermedia	6010102	%INSUMAN%
Y	46001	Insulin isophane human	Insuman Basal 100units/ml suspension Suspension Intermedia	6010102	%INSUMAN%
Y	35468	Insulin isophane human	Insuman Basal 100units/ml suspension Suspension Intermedia	6010102	%INSUMAN%
Y	20422	Insulin isophane human/Insulin soluble human	Insuman comb 15 100iu/ml Injection (Suspension Intermedia	6010102	%INSUMAN%
Y	45158	Insulin soluble human/Insulin isophane human	Insuman Comb 15 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	30819	Insulin soluble human/Insulin isophane human	Insuman Comb 15 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	15199	Insulin Soluble Human	Insuman comb 25 100iu/ml Injection (Injection Intermedia	6010102	%INSUMAN%
Y	24993	Insulin soluble human/Insulin isophane human	Insuman Comb 25 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	25133	Insulin soluble human/Insulin isophane human	Insuman Comb 25 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	44480	Insulin soluble human/Insulin isophane human	Insuman Comb 25 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	24002	Insulin soluble human/Insulin isophane human	Insuman Comb 25 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	21554	Insulin soluble human/Insulin isophane human	Insuman comb 50 100iu/ml Injection (Suspension Intermedia	6010102	%INSUMAN%
Y	35253	Insulin soluble human/Insulin isophane human	Insuman Comb 50 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	31205	Insulin soluble human/Insulin isophane human	Insuman Comb 50 100units/ml suspen: Suspension Biphasic In	6010151	%INSUMAN%
Y	22945	Insulin Soluble Human	Insuman rapid 100iu/ml Injection (Aver Injection Short-actin	06010101/	%INSUMAN%
Y	22983	Insulin soluble human	Insuman Rapid 100units/ml solution fo Solution fo Short-actin	6010101	%INSUMAN%
Y	23993	Insulin soluble human	Insuman Rapid 100units/ml solution fo Solution fo Short-actin	6010101	%INSUMAN%
Y	60066		Invokana 100mg tablets (Janssen-Cilag Tablet Other Antic	6010203	%Invokana%
Y	60430	Canagliflozin hemihydrate	Invokana 100mg tablets (Janssen-Cilag Tablet Other Antic	6010203	%Invokana%, %canagliflozin%
Y	60379		Invokana 300mg tablets (Janssen-Cilag Ltd) Other Antic	6010203	%Invokana%
Y	38422	Insulin isophane bovine	Isophane 100iu/ml Injection (Celltech F Suspension Intermedia	6010102	%SOPHANE%
Y	30236	Insulin Isophane Bovine	Isophane insulin 100iu/ml Injection Injection Intermedia	6010102	%SOPHANE%
Y	43684	Sitagliptin phosphate/Metformin hydrochloride	Janumet 50mg/1000mg tablets (Merck Tablet Other Antic	6010203	%Janumet%, %METFORMIN %, %N
Y	35462	Sitagliptin phosphate	Januvia 100mg tablets (Merck Sharp & Tablet Other Antic	6010203	%JANUVIA%, %SITAGLIPTIN%
Y	50124	Sitagliptin phosphate	Januvia 25mg tablets (Merck Sharp & C Tablet Other Antic	6010203	%JANUVIA%, %SITAGLIPTIN%
Y	50087	Sitagliptin phosphate	Januvia 50mg tablets (Merck Sharp & C Tablet Other Antic	6010203	%JANUVIA%, %SITAGLIPTIN%
Y	50682		Jentaduetto 2.5mg/1000mg tablets (Boehringer Ing Biguanides, 06010202/	%Jentaduetto%	
Y	54150	Linagliptin/Metformin hydrochloride	Jentaduetto 2.5mg/850mg tablets (Boel Tablet Biguanides, 06010202/	%Jentaduetto%, %METFORMIN %, %	
Y	56965	Metformin hydrochloride/Saxagliptin hydrochloride	Komboglyze 2.5mg/1000mg tablets (A: Tablet Other Antic	6010203	%Komboglyze%, %METFORMIN %, %
Y	58865		Komboglyze 2.5mg/850mg tablets (AstraZeneca UI Other Antic	6010203	%Komboglyze%

Y	62034	Gliclazide	Laaglyda MR 60mg tablets (Consilient Modified-r Sulphonylu	6010201	%GLICLAZIDE%
Y	6057	Insulin Glargine	Lantus 100iu/ml Injection (Aventis Phai Injection Intermedia	6010102	%LANTUS%
Y	7402	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Intermedia	6010102	%LANTUS%
Y	50633	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Intermedia	6010102	%LANTUS%
Y	7266	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Intermedia	6010102	%LANTUS%
Y	10225	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Intermedia	6010102	%LANTUS%
Y	7237	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Intermedia	6010102	%LANTUS%
Y	56495	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Unknown	0	%LANTUS%
Y	49831	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Intermedia	6010102	%LANTUS%
Y	36853	Insulin glargine	Lantus 100units/ml solution for injectic Solution fo Intermedia	6010102	%LANTUS%
Y	4784	Pork Insulin	LENTARD mc 100unit/ml Injection (Novo Injection Intermedia	6010102	%LENTARD%
Y	6958	Insulin detemir	Levemir FlexPen 100units/ml solution f Solution fo Intermedia	6010102	%LEVEMIR%
Y	55618	Insulin detemir	Levemir FlexPen 100units/ml solution f Solution fo Intermedia	6010102	%LEVEMIR%
Y	35260	Insulin detemir	Levemir InnoLet 100units/ml solution f Solution fo Intermedia	6010102	%LEVEMIR%
Y	6965	Insulin detemir	Levemir Penfill 100units/ml solution fo Solution fo Intermedia	6010102	%LEVEMIR%
Y	25636	Glibenclamide	Libanil 2.5mg Tablet (Approved Prescri Tablet Sulphonylu	6010201	%GLIBENCLAMIDE%, %LIBANIL%
Y	31474	Glibenclamide	Libanil 5mg Tablet (Approved Prescript Tablet Sulphonylu	6010201	%GLIBENCLAMIDE%, %LIBANIL%
Y	52445		Linagliptin 2.5mg / Metformin 1g tablets Biguanides, 06010202/	%METFORMIN %, %METFORMIN%,	
Y	52449		Linagliptin 2.5mg / Metformin 850mg tablets Biguanides, 06010202/	%METFORMIN %, %METFORMIN%,	
Y	46665	Linagliptin	Linagliptin 5mg tablets Tablets Other Antic	6010203	%linagliptin%
Y	40693	Liraglutide	Liraglutide 6mg/ml solution for injectic Solution fo Other Antic	6010203	%liraglutide%
Y	55459		Lixisenatide 10micrograms/0.2ml solution for injec Other Antic	6010203	%Lixisenatide%
Y	55723		Lixisenatide 10micrograms/0.2ml solution for injec Other Antic	6010203	%Lixisenatide%
Y	55413		Lixisenatide 20micrograms/0.2ml solution for injec Other Antic	6010203	%Lixisenatide%
Y	55728		Lyxumia 10micrograms/0.2ml solution for injector Other Antic	6010203	%Lyxumia%
Y	55767		Lyxumia 10micrograms/0.2ml solution for injector Other Antic	6010203	%Lyxumia%
Y	55729		Lyxumia 20micrograms/0.2ml solution for injector Other Antic	6010203	%Lyxumia%
Y	28708	Glibenclamide	Malix 2.5mg Tablet (Lagap) Tablet Sulphonylu	6010201	%GLIBENCLAMIDE%, %MALIX%
Y	30460	Glibenclamide	Malix 5mg Tablet (Lagap) Tablet Sulphonylu	6010201	%GLIBENCLAMIDE%, %MALIX%
Y	51080	Metformin hydrochloride	Metabet SR 1000mg tablets (Actavis UI Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	46989	Metformin hydrochloride	Metabet SR 1000mg tablets (Morningsi Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	53774	Metformin hydrochloride	Metabet SR 500mg tablets (Actavis UK Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	45581	Metformin hydrochloride	Metabet SR 500mg tablets (Morningsic Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	20810		METFORMIN Unknown	0	%METFORMIN %, %METFORMIN%,
Y	54442	Metformin Hydrochloride	Metformin (roi) 1000mg Tablet Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	735	Metformin Hydrochloride	Metformin 100mg/ml Oral solution Oral Solutic Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	43619	Sitagliptin phosphate/Metformin hydrochloride	Metformin 1g / Sitagliptin 50mg tablet: Tablet Other Antic	6010203	%METFORMIN %, %METFORMIN%,
Y	39598	Metformin hydrochloride	Metformin 1g modified-release tablets Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	49738	Metformin hydrochloride	Metformin 1g modified-release tablets Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	60074	Metformin hydrochloride	Metformin 1g modified-release tablets Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	40233	Metformin hydrochloride	Metformin 1g oral powder sachets sug: Powder Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	16213		METFORMIN 250 MG TAB Unknown	0	%METFORMIN %, %METFORMIN%,
Y	7048	Metformin hydrochloride	Metformin 500mg modified-release tal Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	51135	Metformin hydrochloride	Metformin 500mg modified-release tal Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	60968	Metformin hydrochloride	Metformin 500mg modified-release tal Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	62144	Metformin hydrochloride	Metformin 500mg modified-release tal Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	53478	Metformin hydrochloride	Metformin 500mg modified-release tal Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	62265	Metformin hydrochloride	Metformin 500mg modified-release tal Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	39988	Metformin Hydrochloride	Metformin 500mg oral powder sachets Oral Powde Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34135	Metformin hydrochloride	Metformin 500mg Tablet (M & A Pharr Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	23	Metformin hydrochloride	Metformin 500mg tablets Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34323	Metformin hydrochloride	Metformin 500mg tablets (A A H Pharrn Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	33087	Metformin hydrochloride	Metformin 500mg tablets (Actavis UK l Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	55711	Metformin hydrochloride	Metformin 500mg tablets (Alliance He: Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	48149	Metformin hydrochloride	Metformin 500mg tablets (Almus Pharrn Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	57457	Metformin hydrochloride	Metformin 500mg tablets (Aurobindo f Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	51527	Metformin hydrochloride	Metformin 500mg tablets (Boston Heal Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	50970	Metformin hydrochloride	Metformin 500mg tablets (Bristol Labo Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34598	Metformin hydrochloride	Metformin 500mg tablets (Generics (U Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34004	Metformin hydrochloride	Metformin 500mg tablets (IVAX Pharm Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	52442	Metformin hydrochloride	Metformin 500mg tablets (Pfizer Ltd) Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34917	Metformin hydrochloride	Metformin 500mg tablets (Teva UK Ltd Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	55739	Metformin hydrochloride	Metformin 500mg tablets (Tilomed Lal Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34504	Metformin hydrochloride	Metformin 500mg tablets (Wockhardt Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	53867	Metformin hydrochloride	Metformin 500mg tablets (Zentiva) Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	58051	Metformin hydrochloride	Metformin 500mg/5ml oral solution Oral solutic Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	44250	Metformin hydrochloride	Metformin 500mg/5ml Oral solution (f Oral solutic Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	11990	Metformin hydrochloride	Metformin 500mg/5ml oral solution su Oral solutic Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	43270	Metformin hydrochloride	Metformin 500mg/5ml oral solution su Oral solutic Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	58607	Metformin hydrochloride	Metformin 500mg/5ml oral solution su Oral solutic Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	60286	Metformin hydrochloride	Metformin 500mg/5ml oral suspensor Oral susper Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	38355	Metformin hydrochloride	Metformin 750mg modified-release tal Modified-r Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	7815		METFORMIN 800 MG TAB Unknown	0	%METFORMIN %, %METFORMIN%,
Y	93	Metformin hydrochloride	Metformin 850mg tablets Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	33674	Metformin hydrochloride	Metformin 850mg tablets (A A H Pharrn Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34836	Metformin hydrochloride	Metformin 850mg tablets (Actavis UK l Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	54898	Metformin hydrochloride	Metformin 850mg tablets (Almus Pharrn Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34020	Metformin hydrochloride	Metformin 850mg tablets (IVAX Pharm Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	50821	Metformin hydrochloride	Metformin 850mg tablets (Pfizer Ltd) Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34742	Metformin hydrochloride	Metformin 850mg tablets (Teva UK Ltd Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	34697	Metformin hydrochloride	Metformin 850mg tablets (Wockhardt Tablet Biguanides	6010202	%METFORMIN %, %METFORMIN%,
Y	3252		METFORMIN HCl 500 MG TAB Unknown	0	%METFORMIN %, %METFORMIN%,
Y	2928		METFORMIN HCl 850 MG TAB Unknown	0	%METFORMIN %, %METFORMIN%,
Y	30316	Metformin	Metformin with pioglitazone 850mg + : Tablet Biguanides, 06010202/	%METFORMIN %, %METFORMIN%,	
Y	11760	Metformin Hydrochloride	Metformin with rosiglitazone 1000mg · Tablet Biguanides, 06010202/	%METFORMIN %, %METFORMIN%,	
Y	11737	Metformin Hydrochloride	Metformin with rosiglitazone 1000mg · Tablet Biguanides, 06010202/	%METFORMIN %, %METFORMIN%,	
Y	11609	Metformin Hydrochloride	Metformin with rosiglitazone 500mg + Tablet Biguanides, 06010202/	%METFORMIN %, %METFORMIN%,	
Y	11610	Metformin Hydrochloride	Metformin with rosiglitazone 500mg + Tablet Biguanides, 06010202/	%METFORMIN %, %METFORMIN%,	

Y	31146	Metformin hydrochloride	Metsol 500mg/5ml oral solution (Kappi Oral solutic Biguanides	6010202	%METFORMIN % , %METFORMIN%
Y	17706	Glipizide	Minodiab 2.5mg tablets (Pfizer Ltd) Tablet Unknown	0	%GLIPIZIDE% , %MINODIAB%
Y	17698	Glipizide	Minodiab 5mg tablets (Pfizer Ltd) Tablet Sulphonylu	6010201	%GLIPIZIDE% , %MINODIAB%
Y	2456	Insulin soluble human/Insulin isophane human	Mixtard 10 NovoLet 100units/ml suspe Suspension Unknown	0	%MIXTARD%
Y	5255	Insulin Soluble Human	Mixtard 10 penfill 100 100iu/ml Penfill Penfill Intermedia	6010102	%MIXTARD%
Y	10245	Insulin soluble human/Insulin isophane human	Mixtard 10 Penfill 100units/ml suspens Suspension Unknown	0	%MIXTARD%
Y	2455	Insulin soluble human/Insulin isophane human	Mixtard 20 NovoLet 100units/ml suspe Suspension Unknown	0	%MIXTARD%
Y	3551	Insulin Soluble Human	Mixtard 20 penfill 100 100iu/ml Penfill Penfill Intermedia	6010102	%MIXTARD%
Y	7319	Insulin soluble human/Insulin isophane human	Mixtard 20 Penfill 100units/ml suspens Suspension Unknown	0	%MIXTARD%
Y	2929	Insulin Soluble Human	Mixtard 30 100iu/ml GE injection (Nov Ge Injectio Intermedia	6010102	%MIXTARD%
Y	7300	Insulin soluble human/Insulin isophane human	Mixtard 30 100units/ml suspension for Suspension Biphasic In:	6010151	%MIXTARD%
Y	60938	Insulin soluble human/Insulin isophane human	Mixtard 30 100units/ml suspension for Suspension Unknown	0	%MIXTARD%
Y	5845	Insulin soluble human/Insulin isophane human	Mixtard 30 InnoLet 100units/ml susper Suspension Biphasic In:	6010151	%MIXTARD%
Y	2221	Insulin soluble human/Insulin isophane human	Mixtard 30 NovoLet 100units/ml suspe Suspension Unknown	0	%MIXTARD%
Y	2454	Insulin Soluble Human	Mixtard 30 penfill 100 100iu/ml Penfill Penfill Intermedia	6010102	%MIXTARD%
Y	7231	Insulin soluble human/Insulin isophane human	Mixtard 30 Penfill 100units/ml suspens Suspension Biphasic In:	6010151	%MIXTARD%
Y	1805	Insulin Soluble Human	Mixtard 30/70 100unit/ml Injection (Nt Injection Intermedia	6010102	%MIXTARD%
Y	2812	Insulin soluble human/Insulin isophane human	Mixtard 40 NovoLet 100units/ml suspe Suspension Unknown	0	%MIXTARD%
Y	3550	Insulin Soluble Human	Mixtard 40 penfill 100 100iu/ml Penfill Penfill Intermedia	6010102	%MIXTARD%
Y	10244	Insulin soluble human/Insulin isophane human	Mixtard 40 Penfill 100units/ml suspens Suspension Unknown	0	%MIXTARD%
Y	5933	Insulin soluble human/Insulin isophane human	Mixtard 50 NovoLet 100units/ml suspe Suspension Unknown	0	%MIXTARD%
Y	4790	Insulin soluble human/Insulin isophane human	Mixtard 50 penfill 100 100iu/ml Penfill Suspension Intermedia	6010102	%MIXTARD%
Y	13277	Insulin soluble human/Insulin isophane human	Mixtard 50 Penfill 100units/ml suspens Suspension Unknown	0	%MIXTARD%
Y	1587	Insulin zinc suspension mixed human	Monotard 100units/ml suspension for i Suspension Unknown	0	%MONOTARD%
Y	34031	Pork Insulin	Monotard mc 100unit/ml Injection (No Injection Intermedia	6010102	%MONOTARD%
Y	5678	Nateglinide	Nateglinide 120mg tablets Tablet Other Antic	6010203	%NATEGLINIDE%
Y	5989	Nateglinide	Nateglinide 180mg tablets Tablet Other Antic	6010203	%NATEGLINIDE%
Y	11483	Nateglinide	Nateglinide 60mg tablets Tablet Other Antic	6010203	%NATEGLINIDE%
Y	47894	Gliclazide	Nazdol MR 30mg tablets (Consilient He Modified-r Sulphonylu	6010201	%GLICLAZIDE% , %NAZDOL%
Y	40425	Gliclazide	Nazdol MR 30mg tablets (Teva UK Ltd) Modified-r Sulphonylu	6010201	%GLICLAZIDE% , %NAZDOL%
Y	47856	Insulin isophane bovine	Neuphane 100unit/ml Injection (Wellc Suspension Intermedia	6010102	%NEUPHANE%
Y	47360	Insulin Soluble Bovine	Neutral insulin 100unit/ml Injection (Ct Injection Short-actin	06010101/	%INSULIN% & %NEUTRAL%
Y	24593	Insulin Soluble Bovine	Neutral insulin bovine 100unit/ml Injec Injection Short-actin	06010101/	%INSULIN% & %NEUTRAL% , %INSULIR
Y	44738	Glimepiride	Niddaryl 1mg tablets (Dee Pharmaceut Tablet Sulphonylu	6010201	%GLIMEPIRIDE% , %NIDDARYL%
Y	6061	Insulin Aspart	Novomix 30 30/70 100units/ml Injectic Injection Intermedia	6010102	%NOVOMIX%
Y	7228	Insulin aspart/Insulin aspart protamine	NovoMix 30 FlexPen 100units/ml suspe Suspension Biphasic In:	6010151	%NOVOMIX%
Y	7267	Insulin aspart/Insulin aspart protamine	NovoMix 30 Penfill 100units/ml susper Suspension Biphasic In:	6010151	%NOVOMIX%
Y	56489	Insulin aspart/Insulin aspart protamine	NovoMix 30 Penfill 100units/ml susper Suspension Biphasic In:	6010151	%NOVOMIX%
Y	11321	Repaglinide	NovoNorm 1mg tablets (Novo Nordisk Tablet Other Antic	6010203	%NOVONORM% , %REPAGLINIDE%
Y	11366	Repaglinide	NovoNorm 2mg tablets (Novo Nordisk Tablet Other Antic	6010203	%NOVONORM% , %REPAGLINIDE%
Y	11316	Repaglinide	NovoNorm 500microgram tablets (Nov Tablet Other Antic	6010203	%NOVONORM% , %REPAGLINIDE%
Y	61925	Repaglinide	NovoNorm 500microgram tablets (Wa Tablet Other Antic	6010203	%NOVONORM% , %REPAGLINIDE%
Y	17336	Insulin Soluble Human	Novopen 100unit/ml Injection device (I Injection D Short-actin	06010101/	%Novopen% & %100unit%
Y	6209	Insulin aspart	NovoRapid 100units/ml solution for inj Solution fo Short-actin	6010101	%NOVORAPID%
Y	53118	Insulin aspart	NovoRapid FlexPen 100units/ml solutic Solution fo Short-actin	6010101	%NOVORAPID%
Y	5892	Insulin aspart	NovoRapid FlexPen 100units/ml solutic Solution fo Short-actin	6010101	%NOVORAPID%
Y	59533	Insulin aspart	NovoRapid FlexPen 100units/ml solutic Solution fo Short-actin	6010101	%NOVORAPID%
Y	46666	Insulin aspart	NovoRapid FlexTouch 100units/ml solu Solution fo Short-actin	6010101	%NOVORAPID%
Y	11337	Insulin aspart	NovoRapid Novolet 100units/ml solutic Solution fo Unknown	0	%NOVORAPID%
Y	53251	Insulin aspart	NovoRapid Penfill 100units/ml solution Solution fo Short-actin	6010101	%NOVORAPID%
Y	49108	Insulin aspart	NovoRapid Penfill 100units/ml solution Solution fo Short-actin	6010101	%NOVORAPID%
Y	5021	Insulin aspart	NovoRapid Penfill 100units/ml solution Solution fo Short-actin	6010101	%NOVORAPID%
Y	51743	Insulin aspart	NovoRapid Penfill 100units/ml solution Solution fo Short-actin	6010101	%NOVORAPID%
Y	61845		NovoRapid PumpCart 100units/ml solution for inje Short-actin	6010101	%NOVORAPID%
Y	45821	Saxagliptin hydrochloride	Onglyza 2.5mg tablets (AstraZeneca UK Tablet Other Antic	6010203	%ONGLYZA% , %saxagliptin%
Y	41431	Saxagliptin hydrochloride	Onglyza 5mg tablets (AstraZeneca UK L Tablet Other Antic	6010203	%ONGLYZA% , %saxagliptin%
Y	27501	Metformin hydrochloride	Orabet 500mg Tablet (Lagap) Tablet Biguanides	6010202	%METFORMIN % , %METFORMIN%
Y	42161	Metformin hydrochloride	Orabet 500mg Tablet (Sandoz Ltd) Tablet Biguanides	6010202	%METFORMIN % , %METFORMIN%
Y	31868		Penject 100unit/ml Injection device (H) Injection D -	59030200	%PENJECT%
Y	41959	Insulin Soluble Human	Penject 100unit/ml Injection device (H) Injection D Short-actin	06010101/	%PENJECT%
Y	3439	Insulin Soluble Human	Penmix 10/90 Pen (Novo Nordisk Ltd) Pen Intermedia	6010102	%PENMIX%
Y	3396	Insulin Soluble Human	Penmix 10/90 Penfill (Novo Nordisk Ltc Penfill Intermedia	6010102	%PENMIX%
Y	2220	Insulin Soluble Human	Penmix 20/80 Pen (Novo Nordisk Ltd) Pen Intermedia	6010102	%PENMIX%
Y	10484	Insulin Soluble Human	Penmix 20/80 Penfill (Novo Nordisk Ltc Penfill Intermedia	6010102	%PENMIX%
Y	27614	Insulin Soluble Human	Penmix 30/70 100iu/ml Injection (Novc Injection Intermedia	6010102	%PENMIX%
Y	1806	Insulin Soluble Human	Penmix 30/70 100iu/ml Penfill (Novo N Injection Intermedia	6010102	%PENMIX%
Y	21347	Insulin Soluble Human	Penmix 40/60 100iu/ml Injection (Novc Injection Intermedia	6010102	%PENMIX%
Y	10887	Insulin Soluble Human	Penmix 40/60 100iu/ml Penfill (Novo N Injection Intermedia	6010102	%PENMIX%
Y	17731	Insulin soluble human/Insulin isophane human	Penmix 50/50 100iu/ml Injection (Novc Suspension Intermedia	6010102	%PENMIX%
Y	8203	Insulin soluble human/Insulin isophane human	Penmix 50/50 100iu/ml Penfill (Novo N Suspension Intermedia	6010102	%PENMIX%
Y	18220	Metformin hydrochloride/Pioglitazone hydroch	Pioglitazone 15mg / Metformin 850mg Tablet Other Antic	6010203	%METFORMIN % , %METFORMIN%
Y	548	Pioglitazone hydrochloride	Pioglitazone 15mg tablets Tablet Other Antic	6010203	%PIOGLITAZONE%
Y	56208	Pioglitazone hydrochloride	Pioglitazone 15mg tablets (A A H Pharn Tablet Other Antic	6010203	%PIOGLITAZONE%
Y	9699	Pioglitazone hydrochloride	Pioglitazone 30mg tablets Tablet Other Antic	6010203	%PIOGLITAZONE%
Y	48139	Pioglitazone hydrochloride	Pioglitazone 30mg tablets (A A H Pharn Tablet Other Antic	6010203	%PIOGLITAZONE%
Y	57659	Pioglitazone hydrochloride	Pioglitazone 30mg tablets (Actavis UK I Tablet Other Antic	6010203	%PIOGLITAZONE%
Y	10051	Pioglitazone hydrochloride	Pioglitazone 45mg tablets Tablet Other Antic	6010203	%PIOGLITAZONE%
Y	9521	Insulin soluble porcine	Pork Actrapid 100units/ml solution for Solution fo Short-actin	6010101	%ACTRAPID%
Y	1843	Insulin isophane porcine	Pork Insulatard 100units/ml suspensior Suspension Unknown	0	%INSULATARD%
Y	2459	Insulin soluble porcine/Insulin isophane porcine	Pork Mixtard 30 100units/ml suspensic Suspension Unknown	0	%MIXTARD%
Y	1842	Insulin soluble porcine	Pork velosulin 100unit/ml Injection (Nc Solution fo Short-actin	06010101/	%VELOSULIN%
Y	36948	Repaglinide	Prandin 0.5mg tablets (Novo Nordisk Li Tablet Other Antic	6010203	%PRANDIN% , %REPAGLINIDE%
Y	36774	Repaglinide	Prandin 1mg tablets (Novo Nordisk Ltd Tablet Other Antic	6010203	%PRANDIN% , %REPAGLINIDE%
Y	35561	Repaglinide	Prandin 2mg tablets (Novo Nordisk Ltd Tablet Other Antic	6010203	%PRANDIN% , %REPAGLINIDE%
Y	22058	Insulin Soluble Human	Pur-in mix 15/85 Injection (C P Pharma Injection Intermedia	6010102	%PUR-IN%
Y	26403	Insulin Soluble Human	Pur-in mix 25/75 Injection (C P Pharma Injection Intermedia	6010102	%PUR-IN%
Y	24846	Insulin Soluble Human	Pur-in neutral 100unit/ml Injection (C F Injection Short-actin	06010101/	%PUR-IN%
Y	4163	Insulin	Rapitard MC 100unit/ml Injection (Nov Injection Intermedia	6010102	%RAPITARD%

Y	21870	RASTINON	Unknown	0	%RASTINON%		
Y	12455	Tolbutamide	Sulphonyly	6010201	%RASTINON%, %TOLBUTAMIDE%		
Y	9707	Repaglinide	Other Antic	6010203	%REPAGLINIDE%		
Y	9748	Repaglinide	Other Antic	6010203	%REPAGLINIDE%		
Y	9865	Repaglinide	Other Antic	6010203	%REPAGLINIDE%		
Y	13628	Troglitazone	Other Antic	6010203	%ROMOZIN%, %TROGLITAZONE%		
Y	11604	Rosiglitazone maleate/Metformin hydrochlorid	Unknown	0	%METFORMIN %, %METFORMIN%		
Y	11717	Metformin hydrochloride/Rosiglitazone maleate	Unknown	0	%METFORMIN %, %METFORMIN%		
Y	11601	Rosiglitazone maleate/Metformin hydrochlorid	Unknown	0	%METFORMIN %, %METFORMIN%		
Y	37617	Rosiglitazone Maleate	Other Antic	6010203	%ROSIGLITAZONE%		
Y	7375	Metformin hydrochloride/Rosiglitazone maleate	Unknown	0	%METFORMIN %, %METFORMIN%		
Y	469	Rosiglitazone maleate	Unknown	0	%ROSIGLITAZONE%		
Y	56376	Rosiglitazone Maleate	Sulphonyly	06010201/	%GLIMEPIRIDE%, %ROSIGLITAZON		
Y	5227	Rosiglitazone maleate	Unknown	0	%ROSIGLITAZONE%		
Y	54891	Metformin hydrochloride/Saxagliptin hydrochlorid	Other Antic	6010203	%METFORMIN %, %METFORMIN%		
Y	54973	Saxagliptin 2.5mg / Metformin 850mg tablets	Other Antic	6010203	%METFORMIN %, %METFORMIN%		
Y	45775	Saxagliptin hydrochloride	Other Antic	6010203	%saxagliptin%		
Y	41204	Saxagliptin hydrochloride	Other Antic	6010203	%saxagliptin%		
Y	7912	Glibenclamide	Sulphonyly	6010201	%DAONIL%, %GLIBENCLAMIDE%, 9		
Y	12299	Pork Insulin	Semitarad mc 100unit/ml Injection (Nov Injection	Intermedia	6010102	%SEMITARAD%	
Y	35022	Sitagliptin phosphate	Tablet	6010203	%SITAGLIPTIN%		
Y	48533	Sitagliptin phosphate	Tablet	6010203	%SITAGLIPTIN%		
Y	48401	Sitagliptin phosphate	Tablet	6010203	%SITAGLIPTIN%		
Y	15955	Nateglinide	Starlix 120mg tablets (Novartis Pharma Tablet	Other Antic	6010203	%NATEGLINIDE%, %STARLIX%	
Y	27125	Nateglinide	Starlix 180mg tablets (Novartis Pharma Tablet	Other Antic	6010203	%NATEGLINIDE%, %STARLIX%	
Y	23945	Nateglinide	Starlix 60mg tablets (Novartis Pharmac Tablet	Other Antic	6010203	%NATEGLINIDE%, %STARLIX%	
Y	61043	Metformin hydrochloride	Sukkarto SR 1000mg tablets (Mornings Modified-r	Biguanides	6010202	%METFORMIN %, %METFORMIN%	
Y	61559	Metformin hydrochloride	Sukkarto SR 500mg tablets (Morningsic Modified-r	Biguanides	6010202	%METFORMIN %, %METFORMIN%	
Y	16682	Insulin zinc suspension mixed bovine	Tempulin 100unit/ml Injection (Knoll LI Suspension	Intermedia	6010102	%TEMPULIN%	
Y	22145	Tolazamide	Tolanase 100mg Tablet (Pharmacia Ltd Tablet	Sulphonyly	6010201	%TOLANASE%, %TOLAZAMIDE%	
Y	21489	Tolazamide	Tolanase 250mg Tablet (Pharmacia Ltd Tablet	Sulphonyly	6010201	%TOLANASE%, %TOLAZAMIDE%	
Y	19336	Tolazamide	Tolazamide 100mg Tablet	Sulphonyly	6010201	%TOLAZAMIDE%	
Y	10427	Tolazamide	Tolazamide 250mg Tablet	Sulphonyly	6010201	%TOLAZAMIDE%	
Y	22636	TOLBUTAMIDE 1 GM TAB	Unknown	0	%TOLBUTAMIDE%		
Y	16211	TOLBUTAMIDE 100 MG TAB	Unknown	0	%TOLBUTAMIDE%		
Y	9108	TOLBUTAMIDE 250 MG TAB	Unknown	0	%TOLBUTAMIDE%		
Y	1965	Tolbutamide	Tolbutamide 500mg tablets	Sulphonyly	6010201	%TOLBUTAMIDE%	
Y	34957	Tolbutamide	Tolbutamide 500mg tablets (A A H Pha Tablet	Sulphonyly	6010201	%TOLBUTAMIDE%	
Y	33673	Tolbutamide	Tolbutamide 500mg tablets (Actavis Uf Tablet	Sulphonyly	6010201	%TOLBUTAMIDE%	
Y	46927	Tolbutamide	Tolbutamide 500mg tablets (Teva UK L Tablet	Sulphonyly	6010201	%TOLBUTAMIDE%	
Y	11946	Tolbutamide	Tolbutamide 50mg/ml Injection	Injection	Sulphonyly	6010201	%TOLBUTAMIDE%
Y	46716	Linagliptin	Trajenta 5mg tablets (Boehringer Ingell Tablet	Other Antic	6010203	%Trajenta%, %linagliptin%	
Y	55462	Insulin degludec	Tresiba FlexTouch 100units/ml solution Solution fo	Intermedia	6010102	%Tresiba% & %inj%	
Y	55234	Insulin degludec	Tresiba FlexTouch 200units/ml solution Solution fo	Intermedia	6010102	%Tresiba% & %inj%	
Y	55910	Insulin degludec	Tresiba Penfill 100units/ml solution for Solution fo	Intermedia	6010102	%Tresiba% & %inj%	
Y	56831	Troglitazone 200mg Tablet	Tablet	Other Antic	6010203	%TROGLITAZONE%	
Y	1844	Insulin zinc suspension crystalline human	Ultratard 100units/ml suspension for ir Suspension	Unknown	0	%ULTRATARD%	
Y	4706	Insulin soluble human	Velosulin 100units/ml solution for injec Solution fo	Unknown	0	%VELOSULIN%	
Y	36513	Insulin soluble porcine	Velosulin cartridge 100unit/ml Injectio Solution fo	Short-actin	06010101/	%VELOSULIN%	
Y	40642	Liraglutide	Victoza 6mg/ml solution for injection 3 Solution fo	Other Antic	6010203	%VICTOZA%, %liraglutide%	
Y	37902	Metformin hydrochloride/Vildagliptin	Vildagliptin 50mg / Metformin 1g table Tablet	Other Antic	6010203	%METFORMIN %, %METFORMIN%	
Y	37874	Metformin Hydrochloride/vildagliptin	Vildagliptin 50mg / Metformin 850mg 1 Tablets	Other Antic	6010203	%METFORMIN %, %METFORMIN%	
Y	37875	Vildagliptin	Vildagliptin 50mg tablets	Tablet	Antidiabeti	6010200	%VILDAGLIPTIN%
Y	59385	Vipdomet 12.5mg/1000mg tablets (Takeda UK Ltd)	Antidiabeti	6010200	%Vipdomet%		
Y	60681	Vipidia 12.5mg tablets (Takeda UK Ltd)	Antidiabeti	6010200	%Vipidia%		
Y	60682	Vipidia 25mg tablets (Takeda UK Ltd)	Antidiabeti	6010200	%Vipidia%		
Y	60643	Metformin hydrochloride/Dapagliflozin	Xigduo 5mg/1000mg tablets (AstraZen Tablet	Biguanides	6010202	%METFORMIN %, %METFORMIN%	
Y	43465	Gliclazide	Zicron 40mg tablets (Bristol Laborator Tablet	Sulphonyly	6010201	%GLICLAZIDE%, %ZICRON%	

Reviewed by PPD for hypoglycemic agents used for diabetes treatment

review	classify	comments	medcode	read_code	clinical_pat desc	matching_terms
Y	cancer		10335	100..00	8101 Cancer con %	100..%
Y	cancer		52946	4C53.00	1 Bone marr %	4C53%
Y	cancer		65172	4C54.00	1 Bone marr %	4C54%
Y	cancer		49341	4D56.00	3 Pleural fluid %	4D56%
Y	cancer		59076	4E33.00	2 Sputum: m %	4E33%
Y	cancer		13575	4F32.00	29 Ascitic fluid %	4F32%
Y	cancer		7728	4K24.00	73252 Cerv.smear %	4K2%
Y	cancer		223	4K24.11	34058 CIN III - sev %	4K2%
Y	cancer		5276	4K25.00	5647 Cerv.smear %	4K2%
Y	cancer		107264	4K2L.00	598 Cervical sm %	4K2%
Y	cancer		107456	4K2M.00	31 Crv smr - hi %	4K2%
Y	cancer		23224	4M...00	105 Tumour sta %	4M%
Y	cancer		10178	4M0..00	558 Gleason gr: %	4M%
Y	cancer		18503	4M00.00	172 Gleason pr: %	4M%
Y	cancer		18612	4M01.00	382 Gleason pr: %	4M%
Y	cancer		26081	4M02.00	154 Gleason pr: %	4M%
Y	cancer		12033	4M1..00	109 Dukes stag %	4M%
Y	cancer		40986	4M10.00	62 Dukes stag %	4M%
Y	cancer		19092	4M11.00	166 Dukes stag %	4M%
Y	cancer		35458	4M12.00	118 Dukes stag %	4M%
Y	cancer		42361	4M13.00	15 Dukes stag %	4M%
Y	cancer		64727	4M14.00	4 Dukes stag %	4M%
Y	cancer		40991	4M2..00	41 Lymphoma %	4M%
Y	cancer		60918	4M20.00	1 Lymphoma %	4M%
Y	cancer		94935	4M21.00	2 Lymphoma %	4M%
Y	cancer		32240	4M22.00	7 Lymphoma %	4M%
Y	cancer		71672	4M23.00	8 Lymphoma %	4M%
Y	cancer		57294	4M3..00	19 Breslow de %	4M%
Y	cancer		37793	4M4..00	24 FIGO stagir %	4M%
Y	cancer		57122	4M5..00	19 TNM tumo %	4M%
Y	cancer		94688	4M6..00	487 Recurrence %	4M%
Y	cancer		97188	4M7..00	1 Clark stagir %	4M%
Y	cancer		101198	4M70.00	1 Clark melar %	4M%
Y	cancer		104609	4M71.00	3 Clark melar %	4M%
Y	cancer		96280	4M72.00	2 Clark melar %	4M%
Y	cancer		102116	4M73.00	Clark melar %	4M%
Y	cancer		108866	4M74.00	Clark melar %	4M%
Y	cancer		108905	68W2400	2 Bowel scop %	68w24%
Y	cancer		94000	9Ow1.00	101 Bowel canc %	9Ow1%
Y	cancer		67575	A788W00	10 HIV disease %	A788W%
Y	cancer		44617	A789600	13 HIV disease %	A7896%
Y	cancer		66367	A789700	10 HIV dis resl %	A7897%
Y	cancer		105324	A789800	1 HIV disease %	A7898%
Y	cancer		51708	A789X00	6 HIV dis resl %	A789X%
Y	cancer		69767	AyuC600	2 [X]HIV dise %	AyuC6%
Y	cancer		2755	B....11	19197 Cancers %	B....11%
Y	cancer		19415	B0...00	649 Malignant i %	B0%
Y	cancer		24374	B0...11	454 Carcinoma %	B0%
Y	cancer		14712	B00..00	523 Malignant i %	B0%

Y	cancer	9984 B00..11	150 Carcinoma % B0%
Y	cancer	73962 B000.00	4 Malignant i % B0%
Y	cancer	66270 B000000	9 Malignant i % B0%
Y	cancer	50296 B000100	2 Malignant i % B0%
Y	cancer	98740 B000z00	4 Malignant i % B0%
Y	cancer	67446 B001.00	8 Malignant i % B0%
Y	cancer	66384 B001000	23 Malignant i % B0%
Y	cancer	95480 B001100	5 Malignant i % B0%
Y	cancer	101707 B001z00	5 Malignant i % B0%
Y	cancer	99493 B002.00	2 Malignant i % B0%
Y	cancer	99001 B002100	3 Malignant i % B0%
Y	cancer	98500 B002200	3 Malignant i % B0%
Y	cancer	90610 B002300	6 Malignant i % B0%
Y	cancer	100721 B002z00	1 Malignant i % B0%
Y	cancer	71147 B003.00	4 Malignant i % B0%
Y	cancer	67504 B003000	4 Malignant i % B0%
Y	cancer	91843 B003100	8 Malignant i % B0%
Y	cancer	89909 B003200	8 Malignant i % B0%
Y	cancer	94441 B003300	3 Malignant i % B0%
Y	cancer	96782 B003z00	3 Malignant i % B0%
Y	cancer	61692 B004.00	2 Malignant i % B0%
Y	cancer	73614 B004000	8 Malignant i % B0%
Y	cancer	68399 B004200	1 Malignant i % B0%
Y	cancer	100144 B004300	5 Malignant i % B0%
Y	cancer	96783 B005.00	3 Malignant i % B0%
Y	cancer	18882 B006.00	25 Malignant i % B0%
Y	cancer	37553 B007.00	15 Malignant i % B0%
Y	cancer	100906 B00z000	1 Malignant i % B0%
Y	cancer	94251 B00z100	2 Malignant i % B0%
Y	cancer	69761 B00zz00	3 Malignant i % B0%
Y	cancer	10283 B01..00	2910 Malignant i % B0%
Y	cancer	43431 B010.00	207 Malignant i % B0%
Y	cancer	69671 B010.11	1 Malignant i % B0%
Y	cancer	34409 B010000	4 Malignant i % B0%
Y	cancer	91035 B010z00	3 Malignant i % B0%
Y	cancer	43642 B011.00	9 Malignant i % B0%
Y	cancer	107258 B011100	Malignant i % B0%
Y	cancer	43781 B011z00	7 Malignant i % B0%
Y	cancer	36161 B012.00	33 Malignant i % B0%
Y	cancer	62840 B013.00	18 Malignant i % B0%
Y	cancer	102142 B013000	2 Malignant i % B0%
Y	cancer	63979 B013100	5 Malignant i % B0%
Y	cancer	38488 B013z00	3 Malignant i % B0%
Y	cancer	58121 B014.00	5 Malignant i % B0%
Y	cancer	37096 B015.00	6 Malignant i % B0%
Y	cancer	24852 B016.00	86 Malignant i % B0%
Y	cancer	47205 B017.00	16 Malignant i % B0%
Y	cancer	41530 B01y.00	7 Malignant i % B0%
Y	cancer	40557 B01z.00	118 Malignant i % B0%
Y	cancer	20292 B02..00	262 Malignant i % B0%

Y	cancer	4388	B020.00	801	Malignant i % B0%
Y	cancer	51786	B021.00	84	Malignant i % B0%
Y	cancer	70928	B022.00	4	Malignant i % B0%
Y	cancer	70696	B02y.00	2	Malignant i % B0%
Y	cancer	50475	B02z.00	8	Malignant i % B0%
Y	cancer	43400	B03..00	122	Malignant i % B0%
Y	cancer	32024	B030.00	13	Malignant i % B0%
Y	cancer	49360	B031.00	26	Malignant i % B0%
Y	cancer	101753	B03y.00	1	Malignant i % B0%
Y	cancer	93218	B03z.00	2	Malignant i % B0%
Y	cancer	20092	B04..00	521	Malignant i % B0%
Y	cancer	45408	B040.00	28	Malignant i % B0%
Y	cancer	45986	B041.00	12	Malignant i % B0%
Y	cancer	17912	B042.00	23	Malignant i % B0%
Y	cancer	56709	B04y.00	5	Malignant i % B0%
Y	cancer	36716	B04z.00	50	Malignant i % B0%
Y	cancer	14792	B05..00	665	Malignant i % B0%
Y	cancer	31364	B050.00	111	Malignant i % B0%
Y	cancer	30402	B050.11	65	Malignant i % B0%
Y	cancer	103796	B051.00	2	Malignant i % B0%
Y	cancer	95772	B051000	8	Malignant i % B0%
Y	cancer	97530	B051100	7	Malignant i % B0%
Y	cancer	37590	B052.00	78	Malignant i % B0%
Y	cancer	40292	B053.00	166	Malignant i % B0%
Y	cancer	37516	B054.00	26	Malignant i % B0%
Y	cancer	70819	B055.00	19	Malignant i % B0%
Y	cancer	96003	B055000	4	Malignant i % B0%
Y	cancer	69951	B055100	4	Malignant i % B0%
Y	cancer	28559	B055z00	16	Malignant i % B0%
Y	cancer	37724	B056.00	55	Malignant i % B0%
Y	cancer	37916	B05y.00	25	Malignant i % B0%
Y	cancer	55015	B05z.00	113	Malignant i % B0%
Y	cancer	37549	B05z000	7	Kaposi's sar % B0%
Y	cancer	22893	B06..00	418	Malignant i % B0%
Y	cancer	16241	B060.00	1398	Malignant i % B0%
Y	cancer	26448	B060000	3	Malignant i % B0%
Y	cancer	101988	B060100	1	Malignant i % B0%
Y	cancer	102151	B060200	1	Malignant i % B0%
Y	cancer	53884	B060z00	107	Malignant i % B0%
Y	cancer	24397	B061.00	123	Malignant i % B0%
Y	cancer	55066	B062.00	15	Malignant i % B0%
Y	cancer	51926	B062000	33	Malignant i % B0%
Y	cancer	99185	B062100	1	Malignant i % B0%
Y	cancer	61510	B062200	2	Malignant i % B0%
Y	cancer	93842	B062300	1	Malignant i % B0%
Y	cancer	100002	B062z00	4	Malignant i % B0%
Y	cancer	39554	B063.00	18	Malignant i % B0%
Y	cancer	46728	B064.00	35	Malignant i % B0%
Y	cancer	26134	B064000	8	Malignant i % B0%
Y	cancer	91895	B064100	4	Malignant i % B0%

Y	cancer	73439 B064z00	7 Malignant i % B0%
Y	cancer	48519 B065.00	5 Malignant i % B0%
Y	cancer	56355 B066.00	8 Malignant i % B0%
Y	cancer	90124 B067.00	5 Malignant i % B0%
Y	cancer	67323 B06y.00	24 Malignant i % B0%
Y	cancer	91037 B06yz00	6 Malignant i % B0%
Y	cancer	43200 B06z.00	57 Malignant i % B0%
Y	cancer	24675 B07..00	397 Malignant i % B0%
Y	cancer	94390 B070.00	3 Malignant i % B0%
Y	cancer	95429 B071.00	6 Malignant i % B0%
Y	cancer	33388 B071000	12 Malignant i % B0%
Y	cancer	46548 B071100	38 Malignant i % B0%
Y	cancer	96869 B071z00	3 Malignant i % B0%
Y	cancer	59004 B072.00	3 Malignant i % B0%
Y	cancer	37940 B072000	54 Malignant i % B0%
Y	cancer	102205 B072z00	1 Malignant i % B0%
Y	cancer	44139 B073.00	1 Malignant i % B0%
Y	cancer	106915 B073100	1 Malignant i % B0%
Y	cancer	99386 B073200	3 Malignant i % B0%
Y	cancer	100918 B073z00	1 Malignant i % B0%
Y	cancer	66422 B074.00	1 Malignant i % B0%
Y	cancer	55630 B07y.00	7 Malignant i % B0%
Y	cancer	28665 B07z.00	42 Malignant i % B0%
Y	cancer	34012 B08..00	183 Malignant i % B0%
Y	cancer	43548 B080.00	24 Malignant i % B0%
Y	cancer	39897 B081.00	88 Malignant i % B0%
Y	cancer	57248 B082.00	6 Malignant i % B0%
Y	cancer	64462 B083.00	16 Malignant i % B0%
Y	cancer	88362 B08y.00	3 Malignant i % B0%
Y	cancer	28451 B08z.00	22 Malignant i % B0%
Y	cancer	46114 B0z..00	30 Malig neop % B0%
Y	cancer	16297 B0z0.00	642 Malignant i % B0%
Y	cancer	95016 B0z1.00	2 Malignant i % B0%
Y	cancer	39084 B0z2.00	378 Malignant i % B0%
Y	cancer	49758 B0zy.00	21 Malignant i % B0%
Y	cancer	39430 B0zz.00	442 Malignant i % B0%
Y	cancer	15709 B1...00	1564 Malignant i % B1%
Y	cancer	3357 B1...11	1841 Carcinoma % B1%
Y	cancer	1062 B10..00	15040 Malignant i % B1%
Y	cancer	61695 B100.00	19 Malignant i % B1%
Y	cancer	41362 B101.00	31 Malignant i % B1%
Y	cancer	63470 B102.00	28 Malignant i % B1%
Y	cancer	50789 B103.00	60 Malignant i % B1%
Y	cancer	54171 B104.00	66 Malignant i % B1%
Y	cancer	42416 B105.00	512 Malignant i % B1%
Y	cancer	67497 B106.00	5 Malignant i % B1%
Y	cancer	98142 B107.00	22 Siewert typ % B1%
Y	cancer	53591 B10y.00	45 Malignant i % B1%
Y	cancer	30700 B10z.00	2503 Malignant i % B1%
Y	cancer	4865 B10z.11	6941 Oesophage % B1%

Y	cancer	8386 B11..00	9350 Malignant % B1%
Y	cancer	32022 B110.00	319 Malignant % B1%
Y	cancer	100584 B110000	2 Malignant % B1%
Y	cancer	22894 B110100	129 Malignant % B1%
Y	cancer	94278 B110111	14 Malignant % B1%
Y	cancer	37859 B110z00	34 Malignant % B1%
Y	cancer	21620 B111.00	73 Malignant % B1%
Y	cancer	48237 B111000	27 Malignant % B1%
Y	cancer	41215 B111100	110 Malignant % B1%
Y	cancer	59092 B111z00	20 Malignant % B1%
Y	cancer	19318 B112.00	102 Malignant % B1%
Y	cancer	32362 B113.00	69 Malignant % B1%
Y	cancer	43572 B114.00	131 Malignant % B1%
Y	cancer	42193 B115.00	99 Malignant % B1%
Y	cancer	55434 B116.00	41 Malignant % B1%
Y	cancer	51690 B117.00	1 Malignant % B1%
Y	cancer	97499 B118.00	38 Siewert typ % B1%
Y	cancer	96094 B119.00	31 Siewert typ % B1%
Y	cancer	55019 B11y.00	20 Malignant % B1%
Y	cancer	65312 B11y000	1 Malignant % B1%
Y	cancer	96802 B11y100	4 Malignant % B1%
Y	cancer	65372 B11yz00	14 Malignant % B1%
Y	cancer	14800 B11z.00	4954 Malignant % B1%
Y	cancer	6806 B12..00	169 Malignant % B1%
Y	cancer	18613 B120.00	341 Malignant % B1%
Y	cancer	43479 B121.00	39 Malignant % B1%
Y	cancer	33871 B122.00	66 Malignant % B1%
Y	cancer	63995 B123.00	3 Malignant % B1%
Y	cancer	66166 B124.00	3 Malignant % B1%
Y	cancer	99896 B12y.00	3 Malignant % B1%
Y	cancer	43390 B12z.00	152 Malignant % B1%
Y	cancer	1220 B13..00	33916 Malignant % B1%
Y	cancer	9088 B130.00	421 Malignant % B1%
Y	cancer	6935 B131.00	684 Malignant % B1%
Y	cancer	10864 B132.00	496 Malignant % B1%
Y	cancer	2815 B133.00	5499 Malignant % B1%
Y	cancer	3811 B134.00	6153 Malignant % B1%
Y	cancer	22163 B134.11	591 Carcinoma % B1%
Y	cancer	18632 B135.00	254 Malignant % B1%
Y	cancer	10946 B136.00	1151 Malignant % B1%
Y	cancer	18619 B137.00	321 Malignant % B1%
Y	cancer	93478 B138.00	4 Malignant % B1%
Y	cancer	101700 B139.00	46 Hereditary % B1%
Y	cancer	48231 B13y.00	60 Malignant % B1%
Y	cancer	28163 B13z.00	2245 Malignant % B1%
Y	cancer	9118 B13z.11	6021 Colonic car % B1%
Y	cancer	35357 B14..00	886 Malignant % B1%
Y	cancer	27855 B140.00	969 Malignant % B1%
Y	cancer	1800 B141.00	19861 Malignant % B1%
Y	cancer	7219 B141.11	2194 Carcinoma % B1%

Y	cancer	5901 B141.12	8615 Rectal carc % B1%
Y	cancer	24370 B142.00	889 Malignant i % B1%
Y	cancer	9491 B142.11	565 Anal carcin % B1%
Y	cancer	46159 B142000	6 Malignant i % B1%
Y	cancer	27897 B143.00	230 Malignant i % B1%
Y	cancer	55659 B14y.00	24 Malig neop % B1%
Y	cancer	50974 B14z.00	63 Malignant i % B1%
Y	cancer	8918 B15..00	211 Malignant i % B1%
Y	cancer	25535 B150.00	499 Primary mæ % B1%
Y	cancer	16126 B150000	337 Primary cai % B1%
Y	cancer	31210 B150100	121 Hepatoblas % B1%
Y	cancer	68410 B150200	8 Primary an, % B1%
Y	cancer	22187 B150300	1928 Hepatocelli % B1%
Y	cancer	44399 B150z00	47 Primary mæ % B1%
Y	cancer	16915 B151.00	86 Malignant i % B1%
Y	cancer	65124 B151000	5 Malignant i % B1%
Y	cancer	89593 B151200	6 Malignant i % B1%
Y	cancer	58088 B151400	11 Malignant i % B1%
Y	cancer	61643 B151z00	17 Malignant i % B1%
Y	cancer	26393 B152.00	801 Malignant i % B1%
Y	cancer	38978 B15z.00	47 Malignant i % B1%
Y	cancer	54103 B16..00	78 Malignant i % B1%
Y	cancer	16105 B160.00	735 Malignant i % B1%
Y	cancer	31393 B160.11	344 Carcinoma % B1%
Y	cancer	23433 B161.00	95 Malignant i % B1%
Y	cancer	72445 B161000	3 Malignant i % B1%
Y	cancer	52537 B161100	29 Malignant i % B1%
Y	cancer	7982 B161200	192 Malignant i % B1%
Y	cancer	36495 B161211	65 Carcinoma % B1%
Y	cancer	105613 B161300	2 Malignant i % B1%
Y	cancer	74896 B161z00	25 Malignant i % B1%
Y	cancer	10949 B162.00	372 Malignant i % B1%
Y	cancer	35039 B163.00	14 Malignant i % B1%
Y	cancer	60312 B16y.00	9 Malignant i % B1%
Y	cancer	15907 B16z.00	218 Malignant i % B1%
Y	cancer	8166 B17..00	13081 Malignant i % B1%
Y	cancer	8771 B170.00	970 Malignant i % B1%
Y	cancer	40810 B171.00	106 Malignant i % B1%
Y	cancer	39870 B172.00	106 Malignant i % B1%
Y	cancer	35535 B173.00	113 Malignant i % B1%
Y	cancer	35795 B174.00	6 Malignant i % B1%
Y	cancer	97875 B175.00	3 Malignant i % B1%
Y	cancer	48537 B17y.00	8 Malignant i % B1%
Y	cancer	96635 B17y000	2 Malignant i % B1%
Y	cancer	95783 B17yz00	9 Malignant i % B1%
Y	cancer	34388 B17z.00	995 Malignant i % B1%
Y	cancer	44108 B18..00	61 Malignant i % B1%
Y	cancer	21330 B180.00	111 Malignant i % B1%
Y	cancer	65159 B180100	4 Malignant i % B1%
Y	cancer	24048 B180200	9 Malignant i % B1%

Y	cancer	61555 B180z00	11 Malignant i % B1%
Y	cancer	17874 B181.00	166 Mesothelic % B1%
Y	cancer	101907 B182.00	1 Overlappin % B1%
Y	cancer	46613 B18y.00	162 Malignant i % B1%
Y	cancer	59388 B18y100	1 Malignant i % B1%
Y	cancer	30165 B18y200	3 Malignant i % B1%
Y	cancer	50898 B18y300	66 Malignant i % B1%
Y	cancer	64516 B18y400	9 Malignant i % B1%
Y	cancer	39413 B18y500	61 Malignant i % B1%
Y	cancer	69821 B18y600	9 Malignant i % B1%
Y	cancer	90290 B18y700	13 Malignant i % B1%
Y	cancer	64106 B18yz00	41 Malignant i % B1%
Y	cancer	16298 B18z.00	45 Malignant i % B1%
Y	cancer	11009 B1z..00	51 Malig neop % B1%
Y	cancer	17559 B1z0.00	518 Malignant i % B1%
Y	cancer	11628 B1z0.11	4525 Cancer of b % B1%
Y	cancer	65460 B1z1.00	16 Malignant i % B1%
Y	cancer	108667 B1z1000	1 Angiosarco % B1%
Y	cancer	72224 B1z1100	7 Fibrosarcor % B1%
Y	cancer	93778 B1z1z00	1 Malignant i % B1%
Y	cancer	94776 B1z2.00	5 Malignant i % B1%
Y	cancer	56918 B1zy.00	64 Malignant i % B1%
Y	cancer	51255 B1zz.00	48 Malignant i % B1%
Y	cancer	34075 B2...00	737 Malig neop % B2%
Y	cancer	45307 B2...11	47 Carcinoma % B2%
Y	cancer	26652 B20..00	16 Malig neop % B2%
Y	cancer	23389 B200.00	272 Malignant i % B2%
Y	cancer	71204 B200000	4 Malignant i % B2%
Y	cancer	98911 B200100	2 Malignant i % B2%
Y	cancer	62761 B200200	19 Malignant i % B2%
Y	cancer	62182 B200300	11 Malignant i % B2%
Y	cancer	42856 B200z00	23 Malignant i % B2%
Y	cancer	24456 B201.00	10 Malig neop % B2%
Y	cancer	107916 B201000	1 Malignant i % B2%
Y	cancer	98537 B201100	Malignant i % B2%
Y	cancer	54613 B201200	3 Malignant i % B2%
Y	cancer	71946 B201300	2 Malignant i % B2%
Y	cancer	73537 B201z00	5 Malig neop % B2%
Y	cancer	32174 B202.00	72 Malignant i % B2%
Y	cancer	54636 B203.00	48 Malignant i % B2%
Y	cancer	15684 B204.00	31 Malignant i % B2%
Y	cancer	65215 B205.00	15 Malignant i % B2%
Y	cancer	39590 B206.00	2 Malignant i % B2%
Y	cancer	96971 B20y.00	1 Malig neop % B2%
Y	cancer	55246 B20z.00	5 Malignant i % B2%
Y	cancer	319 B21..00	4011 Malignant i % B2%
Y	cancer	318 B210.00	389 Malignant i % B2%
Y	cancer	26165 B211.00	372 Malignant i % B2%
Y	cancer	22441 B212.00	25 Malignant i % B2%
Y	cancer	43111 B213.00	63 Malignant i % B2%

Y	cancer	63460 B213000	5 Malignant % B2%
Y	cancer	37805 B213100	22 Malignant % B2%
Y	cancer	107878 B213200	1 Malignant % B2%
Y	cancer	47862 B213300	83 Malignant % B2%
Y	cancer	97332 B213z00	10 Malignant % B2%
Y	cancer	50579 B214.00	3 Malignant % B2%
Y	cancer	55374 B215.00	76 Malignant % B2%
Y	cancer	26813 B21y.00	69 Malignant % B2%
Y	cancer	9237 B21z.00	545 Malignant % B2%
Y	cancer	13243 B22..00	9371 Malignant % B2%
Y	cancer	15221 B220.00	182 Malignant % B2%
Y	cancer	103946 B220100	2 Malignant % B2%
Y	cancer	37810 B220z00	22 Malignant % B2%
Y	cancer	12870 B221.00	2503 Malignant % B2%
Y	cancer	17391 B221000	133 Malignant % B2%
Y	cancer	33444 B221100	260 Malignant % B2%
Y	cancer	21698 B221z00	581 Malignant % B2%
Y	cancer	10358 B222.00	1616 Malignant % B2%
Y	cancer	20170 B222.11	338 Pancoast's % B2%
Y	cancer	31700 B222000	406 Malignant % B2%
Y	cancer	25886 B222100	2167 Malignant % B2%
Y	cancer	44169 B222z00	187 Malignant % B2%
Y	cancer	31268 B223.00	265 Malignant % B2%
Y	cancer	41523 B223000	63 Malignant % B2%
Y	cancer	39923 B223100	250 Malignant % B2%
Y	cancer	54134 B223z00	36 Malignant % B2%
Y	cancer	31188 B224.00	672 Malignant % B2%
Y	cancer	18678 B224000	200 Malignant % B2%
Y	cancer	12582 B224100	1110 Malignant % B2%
Y	cancer	42566 B224z00	144 Malignant % B2%
Y	cancer	36371 B225.00	82 Malignant % B2%
Y	cancer	7484 B226.00	3757 Mesothelic % B2%
Y	cancer	38961 B22y.00	361 Malignant % B2%
Y	cancer	3903 B22z.00	32838 Malignant % B2%
Y	cancer	2587 B22z.11	33732 Lung cance % B2%
Y	cancer	31573 B23..00	154 Malignant % B2%
Y	cancer	67107 B230.00	4 Malignant % B2%
Y	cancer	106194 B231.00	1 Malignant % B2%
Y	cancer	9600 B232.00	1168 Mesothelic % B2%
Y	cancer	98104 B23y.00	4 Malignant % B2%
Y	cancer	34742 B23z.00	71 Malignant % B2%
Y	cancer	62556 B24..00	13 Malignant % B2%
Y	cancer	27483 B240.00	138 Malignant % B2%
Y	cancer	95644 B241.00	4 Malignant % B2%
Y	cancer	63430 B241000	4 Malignant % B2%
Y	cancer	65605 B241200	2 Malignant % B2%
Y	cancer	94975 B241300	3 Malignant % B2%
Y	cancer	101885 B241400	2 Mesothelic % B2%
Y	cancer	50289 B241z00	2 Malignant % B2%
Y	cancer	27715 B242.00	15 Malignant % B2%

Y	cancer	92720 B243.00	3 Malignant i % B2%
Y	cancer	61064 B24X.00	24 Malignant i % B2%
Y	cancer	100232 B24y.00	1 Malig neop % B2%
Y	cancer	66750 B24z.00	4 Malignant i % B2%
Y	cancer	39531 B25..00	5 Malig neo, % B2%
Y	cancer	66646 B26..00	6 Malignant i % B2%
Y	cancer	44356 B2z..00	10 Malig neop % B2%
Y	cancer	65793 B2z0.00	6 Malig neop % B2%
Y	cancer	29283 B2zy.00	11 Malignant i % B2%
Y	cancer	42569 B2zz.00	163 Malignant i % B2%
Y	cancer	18608 B3...00	1359 Malig neop % B3%
Y	cancer	9902 B3...11	1132 Carcinoma % B3%
Y	cancer	12539 B3...12	981 Sarcoma of % B3%
Y	cancer	18314 B30..00	221 Malignant i % B3%
Y	cancer	59036 B300.00	15 Malignant i % B3%
Y	cancer	53594 B300000	7 Malignant i % B3%
Y	cancer	53599 B300100	7 Malignant i % B3%
Y	cancer	59520 B300200	2 Malignant i % B3%
Y	cancer	95458 B300300	8 Malignant i % B3%
Y	cancer	55953 B300400	4 Malignant i % B3%
Y	cancer	50298 B300500	3 Malignant i % B3%
Y	cancer	54747 B300600	4 Malignant i % B3%
Y	cancer	55595 B300700	7 Malignant i % B3%
Y	cancer	62104 B300800	6 Malignant i % B3%
Y	cancer	50299 B300900	2 Malignant i % B3%
Y	cancer	17475 B300A00	118 Malignant i % B3%
Y	cancer	96445 B300B00	Malignant i % B3%
Y	cancer	44452 B300C00	6 Malignant i % B3%
Y	cancer	69146 B300z00	7 Malignant i % B3%
Y	cancer	33833 B301.00	173 Malignant i % B3%
Y	cancer	16704 B302.00	64 Malignant i % B3%
Y	cancer	46939 B302000	20 Malignant i % B3%
Y	cancer	32372 B302100	38 Malignant i % B3%
Y	cancer	54691 B302200	56 Malignant i % B3%
Y	cancer	49701 B302z00	19 Malignant i % B3%
Y	cancer	27528 B303.00	9 Malignant i % B3%
Y	cancer	37842 B303000	57 Malignant i % B3%
Y	cancer	49491 B303100	30 Malignant i % B3%
Y	cancer	66639 B303200	12 Malignant i % B3%
Y	cancer	60403 B303300	8 Malignant i % B3%
Y	cancer	67763 B303400	2 Malignant i % B3%
Y	cancer	54493 B303500	7 Malignant i % B3%
Y	cancer	51237 B303z00	4 Malignant i % B3%
Y	cancer	71810 B304.00	7 Malignant i % B3%
Y	cancer	49054 B304000	24 Malignant i % B3%
Y	cancer	105797 B304100	1 Malignant i % B3%
Y	cancer	61741 B304200	47 Malignant i % B3%
Y	cancer	92371 B304300	2 Malignant i % B3%
Y	cancer	64848 B304400	3 Malignant i % B3%
Y	cancer	65880 B304z00	2 Malig neop % B3%

Y	cancer	73530 B305.00	6 Malignant % B3%
Y	cancer	106069 B305.11	1 Malignant % B3%
Y	cancer	72464 B305.12	3 Malignant % B3%
Y	cancer	57988 B305000	1 Malignant % B3%
Y	cancer	69104 B305100	5 Malignant % B3%
Y	cancer	108638 B305A00	1 Malignant % B3%
Y	cancer	94427 B305C00	1 Malignant % B3%
Y	cancer	86812 B305D00	11 Malignant % B3%
Y	cancer	73556 B305z00	5 Malignant % B3%
Y	cancer	54631 B306.00	34 Malignant % B3%
Y	cancer	44609 B306000	16 Malignant % B3%
Y	cancer	59223 B306100	5 Malignant % B3%
Y	cancer	51921 B306200	7 Malignant % B3%
Y	cancer	40966 B306300	23 Malignant % B3%
Y	cancer	66908 B306400	5 Malignant % B3%
Y	cancer	50152 B306500	57 Malignant % B3%
Y	cancer	38938 B306z00	27 Malignant % B3%
Y	cancer	68055 B307.00	26 Malignant % B3%
Y	cancer	56513 B307000	99 Malignant % B3%
Y	cancer	50402 B307100	6 Malignant % B3%
Y	cancer	40814 B307200	33 Malignant % B3%
Y	cancer	62630 B307z00	1 Malignant % B3%
Y	cancer	105475 B308.00	1 Malignant % B3%
Y	cancer	95182 B308100	2 Malignant % B3%
Y	cancer	72212 B308200	3 Malignant % B3%
Y	cancer	34878 B308300	1 Malignant % B3%
Y	cancer	69927 B308800	1 Malignant % B3%
Y	cancer	92382 B308B00	1 Malignant % B3%
Y	cancer	58949 B308D00	8 Malignant % B3%
Y	cancer	103354 B308z00	2 Malignant % B3%
Y	cancer	67451 B30W.00	2 Malignant % B3%
Y	cancer	43614 B30X.00	12 Malignant % B3%
Y	cancer	16075 B30z.00	382 Malignant % B3%
Y	cancer	19437 B30z000	418 Osteosarco % B3%
Y	cancer	34451 B31..00	457 Malignant % B3%
Y	cancer	43475 B310.00	27 Malig neop % B3%
Y	cancer	59382 B310000	66 Malignant % B3%
Y	cancer	40014 B310100	99 Malignant % B3%
Y	cancer	48517 B310200	78 Malignant % B3%
Y	cancer	60035 B310300	20 Malignant % B3%
Y	cancer	49463 B310400	12 Malignant % B3%
Y	cancer	108389 B310500	1 Malignant % B3%
Y	cancer	73718 B310z00	19 Malig neop % B3%
Y	cancer	53989 B311.00	11 Malig neop % B3%
Y	cancer	50222 B311000	12 Malignant % B3%
Y	cancer	64345 B311100	18 Malignant % B3%
Y	cancer	57482 B311200	25 Malignant % B3%
Y	cancer	19321 B311300	20 Malignant % B3%
Y	cancer	91586 B311400	7 Malignant % B3%
Y	cancer	63988 B311500	7 Malignant % B3%

Y	cancer	104913	B311z00	5	Malig neop% B3%
Y	cancer	66088	B312.00	21	Malig neop% B3%
Y	cancer	102949	B312000	6	Malignant i% B3%
Y	cancer	44805	B312100	100	Malig neop% B3%
Y	cancer	54965	B312200	4	Malig neop% B3%
Y	cancer	30542	B312300	60	Malig neop% B3%
Y	cancer	54222	B312400	10	Malignant i% B3%
Y	cancer	99572	B312500		Malignant i% B3%
Y	cancer	90546	B312z00	4	Malig neop% B3%
Y	cancer	22290	B313.00	18	Malignant i% B3%
Y	cancer	29160	B313000	28	Malignant i% B3%
Y	cancer	54186	B313100	4	Malignant i% B3%
Y	cancer	72522	B313200	2	Malignant i% B3%
Y	cancer	104139	B313300	1	Malig neop% B3%
Y	cancer	98408	B313z00	7	Malig neop% B3%
Y	cancer	45071	B314.00	39	Malignant i% B3%
Y	cancer	66488	B314000	10	Malig neop% B3%
Y	cancer	94272	B314100	2	Malig neop% B3%
Y	cancer	60247	B314z00	15	Malig neop% B3%
Y	cancer	51965	B315.00	25	Malignant i% B3%
Y	cancer	70463	B315000	13	Malignant i% B3%
Y	cancer	67324	B315100	6	Malig neop% B3%
Y	cancer	59152	B315200	7	Malignant i% B3%
Y	cancer	58836	B315z00	6	Malig neop% B3%
Y	cancer	57471	B316.00	13	Malig neop% B3%
Y	cancer	65233	B31y.00	16	Malig neop% B3%
Y	cancer	15182	B31z.00	402	Malignant i% B3%
Y	cancer	104128	B31z000	2	Kaposi's sar% B3%
Y	cancer	865	B32..00	27057	Malignant i% B3%
Y	cancer	70637	B320.00	9	Malignant i% B3%
Y	cancer	54632	B321.00	25	Malignant i% B3%
Y	cancer	57260	B322.00	30	Malignant i% B3%
Y	cancer	59061	B322000	26	Malignant i% B3%
Y	cancer	102145	B322100	2	Malignant i% B3%
Y	cancer	73744	B322z00	5	Malignant i% B3%
Y	cancer	47252	B323.00	54	Malignant i% B3%
Y	cancer	41278	B323000	92	Malignant i% B3%
Y	cancer	71136	B323100	7	Malignant i% B3%
Y	cancer	47094	B323200	4	Malignant i% B3%
Y	cancer	68133	B323300	18	Malignant i% B3%
Y	cancer	45139	B323400	39	Malignant i% B3%
Y	cancer	58958	B323500	20	Malignant i% B3%
Y	cancer	67806	B323z00	52	Malignant i% B3%
Y	cancer	65625	B324.00	158	Malignant i% B3%
Y	cancer	55881	B324000	73	Malignant i% B3%
Y	cancer	45306	B324100	90	Malignant i% B3%
Y	cancer	99257	B324z00	3	Malignant i% B3%
Y	cancer	38689	B325.00	211	Malignant i% B3%
Y	cancer	49814	B325000	39	Malignant i% B3%
Y	cancer	32768	B325100	482	Malignant i% B3%

Y	cancer	53629 B325200	10 Malignant % B3%
Y	cancer	34259 B325300	54 Malignant % B3%
Y	cancer	109002 B325400	1 Malignant % B3%
Y	cancer	95629 B325500	6 Malignant % B3%
Y	cancer	43715 B325600	6 Malignant % B3%
Y	cancer	43463 B325700	313 Malignant % B3%
Y	cancer	51209 B325800	66 Malignant % B3%
Y	cancer	45760 B325z00	48 Malignant % B3%
Y	cancer	65164 B326.00	144 Malignant % B3%
Y	cancer	50505 B326000	109 Malignant % B3%
Y	cancer	54685 B326100	142 Malignant % B3%
Y	cancer	45755 B326200	143 Malignant % B3%
Y	cancer	62475 B326300	13 Malignant % B3%
Y	cancer	25602 B326400	11 Malignant % B3%
Y	cancer	63997 B326500	14 Malignant % B3%
Y	cancer	55292 B326z00	10 Malignant % B3%
Y	cancer	46255 B327.00	344 Malignant % B3%
Y	cancer	73536 B327000	4 Malignant % B3%
Y	cancer	51873 B327100	157 Malignant % B3%
Y	cancer	54305 B327200	56 Malignant % B3%
Y	cancer	39878 B327300	6 Malignant % B3%
Y	cancer	37872 B327400	325 Malignant % B3%
Y	cancer	42714 B327500	43 Malignant % B3%
Y	cancer	61246 B327600	13 Malignant % B3%
Y	cancer	41490 B327700	62 Malignant % B3%
Y	cancer	36899 B327800	31 Malignant % B3%
Y	cancer	53369 B327900	11 Malignant % B3%
Y	cancer	64327 B327z00	25 Malignant % B3%
Y	cancer	42153 B32y.00	47 Malignant % B3%
Y	cancer	96585 B32y000	1 Overlappin % B3%
Y	cancer	28556 B32z.00	754 Malignant % B3%
Y	cancer	24375 B339.00	661 Dermatofit % B3%
Y	cancer	3968 B34..00	118553 Malignant % B3%
Y	cancer	348 B34..11	52915 Ca female % B3%
Y	cancer	26853 B340.00	302 Malignant % B3%
Y	cancer	23380 B340000	140 Malignant % B3%
Y	cancer	64686 B340100	27 Malignant % B3%
Y	cancer	59831 B340z00	20 Malignant % B3%
Y	cancer	31546 B341.00	171 Malignant % B3%
Y	cancer	29826 B342.00	233 Malignant % B3%
Y	cancer	45222 B343.00	108 Malignant % B3%
Y	cancer	23399 B344.00	800 Malignant % B3%
Y	cancer	42070 B345.00	152 Malignant % B3%
Y	cancer	20685 B346.00	85 Malignant % B3%
Y	cancer	49148 B347.00	18 Malignant % B3%
Y	cancer	56715 B34y.00	67 Malignant % B3%
Y	cancer	95057 B34y000	2 Malignant % B3%
Y	cancer	38475 B34yz00	52 Malignant % B3%
Y	cancer	9470 B34z.00	9645 Malignant % B3%
Y	cancer	19423 B35..00	610 Malignant % B3%

Y	cancer	54494 B350.00	5 Malignant i % B3%
Y	cancer	68480 B350000	7 Malignant i % B3%
Y	cancer	67884 B350100	4 Malignant i % B3%
Y	cancer	54202 B35z.00	6 Malignant i % B3%
Y	cancer	95323 B35z000	1 Malignant i % B3%
Y	cancer	48809 B35zz00	45 Malignant i % B3%
Y	cancer	105488 B36..00	69 Local recur % B3%
Y	cancer	19389 B3y..00	50 Malig neop % B3%
Y	cancer	41011 B3z..00	52 Malig neop % B3%
Y	cancer	13252 B4...00	1486 Malignant i % B4%
Y	cancer	16874 B4...11	602 Carcinoma % B4%
Y	cancer	2744 B40..00	3429 Malignant i % B4%
Y	cancer	2747 B41..00	6622 Malignant i % B4%
Y	cancer	3230 B41..11	3858 Cervical cai % B4%
Y	cancer	48820 B410.00	213 Malignant i % B4%
Y	cancer	57235 B410000	20 Malignant i % B4%
Y	cancer	53103 B410100	6 Malignant i % B4%
Y	cancer	50285 B410z00	56 Malignant i % B4%
Y	cancer	50297 B411.00	52 Malignant i % B4%
Y	cancer	58094 B412.00	20 Malignant i % B4%
Y	cancer	32955 B41y.00	86 Malignant i % B4%
Y	cancer	95505 B41y000	5 Malignant i % B4%
Y	cancer	57719 B41y100	3 Malignant i % B4%
Y	cancer	43435 B41yz00	45 Malignant i % B4%
Y	cancer	28311 B41z.00	1169 Malignant i % B4%
Y	cancer	93762 B42..00	4 Malignant i % B4%
Y	cancer	28003 B420.00	137 Choriocarci % B4%
Y	cancer	7046 B43..00	2679 Malignant i % B4%
Y	cancer	3213 B430.00	286 Malignant i % B4%
Y	cancer	72723 B430000	5 Malignant i % B4%
Y	cancer	68155 B430100	6 Malignant i % B4%
Y	cancer	2890 B430200	6512 Malignant i % B4%
Y	cancer	49400 B430211	159 Malignant i % B4%
Y	cancer	45793 B430300	24 Malignant i % B4%
Y	cancer	45490 B430z00	61 Malignant i % B4%
Y	cancer	43940 B431.00	12 Malignant i % B4%
Y	cancer	59097 B431000	4 Malignant i % B4%
Y	cancer	70729 B431z00	3 Malignant i % B4%
Y	cancer	16967 B432.00	27 Malignant i % B4%
Y	cancer	31608 B43y.00	42 Malignant i % B4%
Y	cancer	33617 B43z.00	387 Malignant i % B4%
Y	cancer	19141 B44..00	406 Malignant i % B4%
Y	cancer	7805 B440.00	8784 Malignant i % B4%
Y	cancer	1986 B440.11	11069 Cancer of c % B4%
Y	cancer	49828 B441.00	131 Malignant i % B4%
Y	cancer	101778 B442.00	3 Malignant i % B4%
Y	cancer	46153 B443.00	6 Malignant i % B4%
Y	cancer	97996 B44y.00	8 Malignant i % B4%
Y	cancer	65106 B44z.00	24 Malignant i % B4%
Y	cancer	4555 B45..00	554 Malig neop % B4%

Y	cancer	37328	B450.00	258	Malignant i % B4%
Y	cancer	10698	B450100	72	Malignant i % B4%
Y	cancer	60772	B450z00	32	Malignant i % B4%
Y	cancer	43761	B451.00	38	Malignant i % B4%
Y	cancer	47899	B451000	16	Malignant i % B4%
Y	cancer	59362	B451z00	13	Malignant i % B4%
Y	cancer	58061	B452.00	12	Malignant i % B4%
Y	cancer	53910	B453.00	21	Malignant i % B4%
Y	cancer	4554	B454.00	1541	Malignant i % B4%
Y	cancer	11991	B454.11	45	Primary vu % B4%
Y	cancer	26454	B45X.00	11	Malignant i % B4%
Y	cancer	95421	B45y.00	6	Malignant i % B4%
Y	cancer	27617	B45y000	6	Malignant i % B4%
Y	cancer	20166	B45z.00	34	Malignant i % B4%
Y	cancer	780	B46..00	114429	Malignant i % B4%
Y	cancer	15148	B47..00	2205	Malignant i % B4%
Y	cancer	64602	B470.00	16	Malignant i % B4%
Y	cancer	7740	B470200	207	Seminoma % B4%
Y	cancer	36325	B470300	70	Teratoma c % B4%
Y	cancer	96429	B470z00	2	Malignant i % B4%
Y	cancer	19475	B471.00	44	Malignant i % B4%
Y	cancer	21786	B471000	1375	Seminoma % B4%
Y	cancer	9476	B471100	679	Teratoma c % B4%
Y	cancer	91509	B471z00	12	Malignant i % B4%
Y	cancer	38510	B47z.00	936	Malignant i % B4%
Y	cancer	2961	B47z.11	1934	Seminoma % B4%
Y	cancer	15989	B47z.12	1132	Teratoma c % B4%
Y	cancer	3541	B48..00	509	Malignant i % B4%
Y	cancer	50681	B480.00	46	Malignant i % B4%
Y	cancer	17841	B481.00	128	Malignant i % B4%
Y	cancer	48743	B482.00	50	Malignant i % B4%
Y	cancer	43392	B483.00	201	Malignant i % B4%
Y	cancer	72127	B484.00	5	Malignant i % B4%
Y	cancer	63331	B485.00	5	Malignant i % B4%
Y	cancer	47767	B486.00	106	Malignant i % B4%
Y	cancer	52570	B487.00	2	Malignant i % B4%
Y	cancer	67949	B48y.00	10	Malignant i % B4%
Y	cancer	68161	B48y000	14	Malignant i % B4%
Y	cancer	47668	B48y100	4	Malignant i % B4%
Y	cancer	68824	B48y200	2	Malignant i % B4%
Y	cancer	92329	B48yz00	11	Malignant i % B4%
Y	cancer	63224	B48z.00	9	Malignant i % B4%
Y	cancer	779	B49..00	33756	Malignant i % B4%
Y	cancer	38862	B490.00	43	Malignant i % B4%
Y	cancer	44996	B491.00	31	Malignant i % B4%
Y	cancer	35963	B492.00	145	Malignant i % B4%
Y	cancer	19162	B493.00	35	Malignant i % B4%
Y	cancer	42012	B494.00	90	Malignant i % B4%
Y	cancer	41571	B495.00	80	Malignant i % B4%
Y	cancer	28241	B496.00	133	Malignant i % B4%

Y	cancer	42023	B497.00	13	Malignant i % B4%
Y	cancer	105388	B498.00	51	Local recur % B4%
Y	cancer	36949	B49y.00	49	Malignant i % B4%
Y	cancer	47801	B49y000	6	Malignant i % B4%
Y	cancer	31102	B49z.00	3915	Malignant i % B4%
Y	cancer	13559	B4A..00	2921	Malig neop % B4%
Y	cancer	18712	B4A..11	1771	Renal maliç % B4%
Y	cancer	1599	B4A0.00	3777	Malignant i % B4%
Y	cancer	7978	B4A0000	587	Hyperneph % B4%
Y	cancer	12389	B4A1.00	465	Malignant i % B4%
Y	cancer	27540	B4A1000	42	Malignant i % B4%
Y	cancer	101608	B4A1100	5	Malignant i % B4%
Y	cancer	54184	B4A1z00	87	Malignant i % B4%
Y	cancer	15223	B4A2.00	578	Malignant i % B4%
Y	cancer	15644	B4A3.00	154	Malignant i % B4%
Y	cancer	72174	B4A4.00	1	Malignant i % B4%
Y	cancer	44884	B4Ay.00	17	Malignant i % B4%
Y	cancer	59286	B4Ay000	6	Malignant i % B4%
Y	cancer	29462	B4Az.00	1510	Malignant i % B4%
Y	cancer	38931	B4y..00	47	Malignant i % B4%
Y	cancer	52594	B4z..00	48	Malignant i % B4%
Y	cancer	10995	B5...00	1847	Malignant i % B5%
Y	cancer	8693	B5...11	689	Carcinoma % B5%
Y	cancer	20160	B50..00	342	Malignant i % B5%
Y	cancer	98813	B500.00	1	Malig neop % B5%
Y	cancer	59041	B500000	30	Malignant i % B5%
Y	cancer	59381	B500100	22	Malignant i % B5%
Y	cancer	106569	B500200	1	Malignant i % B5%
Y	cancer	56718	B500z00	15	Malignant i % B5%
Y	cancer	45667	B501.00	22	Malignant i % B5%
Y	cancer	86996	B501000	3	Malignant i % B5%
Y	cancer	63104	B501z00	6	Malignant i % B5%
Y	cancer	64817	B502.00	7	Malignant i % B5%
Y	cancer	63657	B503.00	33	Malignant i % B5%
Y	cancer	73992	B504.00	4	Malignant i % B5%
Y	cancer	28069	B505.00	39	Malignant i % B5%
Y	cancer	15991	B506.00	390	Malignant i % B5%
Y	cancer	71584	B507.00	4	Malignant i % B5%
Y	cancer	101805	B507000	1	Malignant i % B5%
Y	cancer	65357	B507100	1	Malignant i % B5%
Y	cancer	45922	B508.00	12	Malignant i % B5%
Y	cancer	108363	B509.00	16	Malignant i % B5%
Y	cancer	40437	B50y.00	20	Malignant i % B5%
Y	cancer	54956	B50z.00	23	Malignant i % B5%
Y	cancer	18617	B51..00	3134	Malignant i % B5%
Y	cancer	10851	B51..11	748	Cerebral tu % B5%
Y	cancer	15711	B510.00	132	Malignant i % B5%
Y	cancer	48073	B510000	18	Malignant i % B5%
Y	cancer	61399	B510100	25	Malignant i % B5%
Y	cancer	99913	B510300	1	Malignant i % B5%

Y	cancer	70942 B510400	7 Malignant % B5%
Y	cancer	62126 B510500	17 Malignant % B5%
Y	cancer	54133 B510z00	38 Malignant % B5%
Y	cancer	42426 B511.00	170 Malignant % B5%
Y	cancer	46792 B512.00	87 Malignant % B5%
Y	cancer	67236 B512000	2 Malignant % B5%
Y	cancer	47556 B512z00	22 Malignant % B5%
Y	cancer	19226 B513.00	126 Malignant % B5%
Y	cancer	39088 B514.00	30 Malignant % B5%
Y	cancer	52511 B515.00	6 Malignant % B5%
Y	cancer	46789 B515000	13 Malignant % B5%
Y	cancer	45154 B516.00	100 Malignant % B5%
Y	cancer	44089 B517.00	26 Malignant % B5%
Y	cancer	64557 B517000	3 Malignant % B5%
Y	cancer	49132 B517100	5 Malignant % B5%
Y	cancer	93537 B517200	3 Malignant % B5%
Y	cancer	91240 B517300	15 Malignant % B5%
Y	cancer	68641 B517z00	8 Malignant % B5%
Y	cancer	71139 B51y.00	19 Malignant % B5%
Y	cancer	59170 B51y000	17 Malignant % B5%
Y	cancer	65241 B51y200	3 Malignant % B5%
Y	cancer	100733 B51yz00	2 Malignant % B5%
Y	cancer	41520 B51z.00	372 Malignant % B5%
Y	cancer	65458 B52..00	12 Malig neop% B5%
Y	cancer	99621 B520.00	3 Malignant % B5%
Y	cancer	64971 B520000	2 Malignant % B5%
Y	cancer	70126 B520100	8 Malignant % B5%
Y	cancer	65599 B520200	8 Malignant % B5%
Y	cancer	101086 B520z00	1 Malignant % B5%
Y	cancer	28919 B521.00	41 Malignant % B5%
Y	cancer	70104 B521z00	5 Malignant % B5%
Y	cancer	51115 B522.00	90 Malignant % B5%
Y	cancer	49714 B523.00	8 Malignant % B5%
Y	cancer	67211 B523z00	1 Malignant % B5%
Y	cancer	24235 B524.00	19 Malig neop% B5%
Y	cancer	63568 B524000	7 Malignant % B5%
Y	cancer	61716 B524100	2 Malignant % B5%
Y	cancer	89258 B524200	5 Malignant % B5%
Y	cancer	63695 B524300	3 Malignant % B5%
Y	cancer	86046 B524400	16 Malignant % B5%
Y	cancer	73988 B524500	6 Malignant % B5%
Y	cancer	50777 B524600	1 Malignant % B5%
Y	cancer	106654 B524W00	Mal neopla% B5%
Y	cancer	9622 B525.00	36 Malignant % B5%
Y	cancer	53504 B52W.00	15 Malig neop% B5%
Y	cancer	49875 B52X.00	13 Malignant % B5%
Y	cancer	88144 B52y.00	2 Malignant % B5%
Y	cancer	56490 B52z.00	12 Malignant % B5%
Y	cancer	5637 B53..00	4841 Malignant % B5%
Y	cancer	30511 B54..00	36 Malig neop% B5%

Y	cancer	28148 B540.00	183 Malignant i % B5%
Y	cancer	18231 B540.11	869 Phaeochro i % B5%
Y	cancer	61390 B540000	9 Malignant i % B5%
Y	cancer	94220 B540100	2 Malignant i % B5%
Y	cancer	70824 B540z00	19 Malignant i % B5%
Y	cancer	4218 B541.00	46 Malignant i % B5%
Y	cancer	59823 B542.00	1 Malignant i % B5%
Y	cancer	8550 B542000	89 Malignant i % B5%
Y	cancer	39899 B542100	33 Malignant i % B5%
Y	cancer	59718 B542z00	2 Malig neop % B5%
Y	cancer	42460 B543.00	39 Malignant i % B5%
Y	cancer	57047 B544.00	12 Malignant i % B5%
Y	cancer	50035 B545.00	30 Malignant i % B5%
Y	cancer	51795 B545000	29 Malignant i % B5%
Y	cancer	47840 B545100	4 Malignant i % B5%
Y	cancer	46905 B545200	1 Malignant i % B5%
Y	cancer	103995 B545z00	2 Malignant i % B5%
Y	cancer	100083 B546.00	105 Neuroblast % B5%
Y	cancer	87113 B54X.00	Malignant i % B5%
Y	cancer	90659 B54y.00	11 Malignant i % B5%
Y	cancer	64195 B54z.00	12 Malig neop % B5%
Y	cancer	9030 B55..00	162 Malignant i % B5%
Y	cancer	68236 B550.00	3044 Malignant i % B5%
Y	cancer	55098 B550000	54 Malignant i % B5%
Y	cancer	41931 B550100	69 Malignant i % B5%
Y	cancer	12490 B550200	67 Malignant i % B5%
Y	cancer	51818 B550300	24 Malignant i % B5%
Y	cancer	16280 B550400	140 Malignant i % B5%
Y	cancer	73510 B550500	7 Malignant i % B5%
Y	cancer	58903 B550z00	27 Malignant i % B5%
Y	cancer	47286 B551.00	19 Malignant i % B5%
Y	cancer	37618 B551000	66 Malignant i % B5%
Y	cancer	23861 B551100	53 Malignant i % B5%
Y	cancer	97547 B551200	3 Malignant i % B5%
Y	cancer	64810 B551z00	5 Malignant i % B5%
Y	cancer	15976 B552.00	236 Malignant i % B5%
Y	cancer	52316 B553.00	26 Malignant i % B5%
Y	cancer	57854 B553000	5 Malignant i % B5%
Y	cancer	89916 B553100	1 Malignant i % B5%
Y	cancer	107126 B553200	1 Malignant i % B5%
Y	cancer	55101 B553z00	15 Malignant i % B5%
Y	cancer	27449 B554.00	40 Malignant i % B5%
Y	cancer	31399 B555.00	62 Malignant i % B5%
Y	cancer	42218 B55y.00	56 Malignant i % B5%
Y	cancer	68787 B55y000	18 Malignant i % B5%
Y	cancer	67217 B55y100	7 Malignant i % B5%
Y	cancer	94355 B55y200	2 Malignant i % B5%
Y	cancer	60052 B55yz00	101 Malignant i % B5%
Y	cancer	45267 B55z.00	29 Malignant i % B5%
Y	cancer	47810 B59..00	201 Malignant i % B5%

Y	cancer	13569 B590.00	19727 Disseminat % B5%
Y	cancer	6170 B590.11	10479 Carcinoma % B5%
Y	cancer	26034 B591.00	110 Other mali % B5%
Y	cancer	51352 B592.00	8 Malignant i % B5%
Y	cancer	65466 B592X00	2 Kaposi's sai % B5%
Y	cancer	11035 B593.00	403 Primary m % B5%
Y	cancer	104324 B595.00	66 Malignant i % B5%
Y	cancer	54267 B59z.00	78 Malignant i % B5%
Y	cancer	49525 B59zX00	45 Kaposi's sai % B5%
Y	cancer	38736 B5y..00	67 Malignant i % B5%
Y	cancer	1056 B5z..00	7968 Malignant i % B5%
Y	cancer	12323 B6...00	1261 Malignant i % B6%
Y	cancer	37112 B6...11	6 Malignant i % B6%
Y	cancer	41369 B60..00	4 Lymphosar % B6%
Y	cancer	1481 B600.00	47 Reticulosar % B6%
Y	cancer	60242 B600000	1 Reticulosar % B6%
Y	cancer	71031 B600100	1 Reticulosar % B6%
Y	cancer	70374 B600300	1 Reticulosar % B6%
Y	cancer	95058 B600700	1 Reticulosar % B6%
Y	cancer	99240 B600z00	1 Reticulosar % B6%
Y	cancer	27416 B601.00	190 Lymphosar % B6%
Y	cancer	71625 B601000	1 Lymphosar % B6%
Y	cancer	71238 B601100	5 Lymphosar % B6%
Y	cancer	62380 B601200	2 Lymphosar % B6%
Y	cancer	64670 B601300	1 Lymphosar % B6%
Y	cancer	100352 B601500	2 Lymphosar % B6%
Y	cancer	103245 B601700	1 Lymphosar % B6%
Y	cancer	104790 B601800	1 Lymphosar % B6%
Y	cancer	63723 B601z00	12 Lymphosar % B6%
Y	cancer	21402 B602.00	369 Burkitt's ly % B6%
Y	cancer	59115 B602100	3 Burkitt's ly % B6%
Y	cancer	100006 B602200	3 Burkitt's ly % B6%
Y	cancer	97577 B602300	1 Burkitt's ly % B6%
Y	cancer	92380 B602500	1 Burkitt's ly % B6%
Y	cancer	71304 B602z00	12 Burkitt's ly % B6%
Y	cancer	99887 B60y.00	2 Other spec % B6%
Y	cancer	99951 B60z.00	3 Reticulosar % B6%
Y	cancer	2462 B61..00	9776 Hodgkin's c % B6%
Y	cancer	104291 B61..11	193 Hodgkin ly % B6%
Y	cancer	65489 B610.00	3 Hodgkin's r % B6%
Y	cancer	100423 B610100	1 Hodgkin's r % B6%
Y	cancer	98840 B610300	1 Hodgkin's r % B6%
Y	cancer	44196 B611.00	12 Hodgkin's e % B6%
Y	cancer	98909 B611100	1 Hodgkin's e % B6%
Y	cancer	64036 B612.00	3 Hodgkin's s % B6%
Y	cancer	68039 B612400	Hodgkin's s % B6%
Y	cancer	38939 B613.00	34 Hodgkin's c % B6%
Y	cancer	71142 B613000	2 Hodgkin's, % B6%
Y	cancer	68330 B613100	8 Hodgkin's, % B6%
Y	cancer	92245 B613200	1 Hodgkin's, % B6%

Y	cancer	73532 B613300	1 Hodgkin's, % B6%
Y	cancer	93951 B613500	2 Hodgkin's, % B6%
Y	cancer	95338 B613600	2 Hodgkin's, % B6%
Y	cancer	106911 B613700	1 Hodgkin's, % B6%
Y	cancer	104743 B613800	1 Hodgkin's, % B6%
Y	cancer	29876 B613z00	6 Hodgkin's, % B6%
Y	cancer	29178 B614.00	469 Hodgkin's c % B6%
Y	cancer	57225 B614000	7 Hodgkin's c % B6%
Y	cancer	55303 B614100	22 Hodgkin's r % B6%
Y	cancer	67506 B614200	9 Hodgkin's r % B6%
Y	cancer	61149 B614300	3 Hodgkin's r % B6%
Y	cancer	65483 B614400	3 Hodgkin's r % B6%
Y	cancer	105472 B614700	1 Hodgkin's c % B6%
Y	cancer	19140 B614800	3 Hodgkin's r % B6%
Y	cancer	63054 B614z00	40 Hodgkin's c % B6%
Y	cancer	49605 B615.00	41 Hodgkin's c % B6%
Y	cancer	97863 B615000	2 Hodgkin's c % B6%
Y	cancer	94407 B615100	3 Hodgkin's r % B6%
Y	cancer	58684 B615200	2 Hodgkin's r % B6%
Y	cancer	108886 B615500	1 Hodgkin's r % B6%
Y	cancer	94005 B615z00	37 Hodgkin's c % B6%
Y	cancer	67703 B616.00	7 Hodgkin's c % B6%
Y	cancer	95049 B616000	3 Hodgkin's l % B6%
Y	cancer	63625 B616400	Hodgkin's l % B6%
Y	cancer	101715 B616700	1 Hodgkin's c % B6%
Y	cancer	107032 B616800	1 Hodgkin's l % B6%
Y	cancer	101530 B616z00	1 Hodgkin's c % B6%
Y	cancer	104895 B617.00	12 Nodular lyr % B6%
Y	cancer	105841 B618.00	7 Nodular scl % B6%
Y	cancer	108775 B619.00	1 Mixed cell % B6%
Y	cancer	106597 B61B.00	1 Lymphocyt % B6%
Y	cancer	104484 B61C.00	8 Other class % B6%
Y	cancer	53397 B61z.00	181 Hodgkin's c % B6%
Y	cancer	106349 B61z.11	3 Hodgkin lyr % B6%
Y	cancer	61662 B61z000	11 Hodgkin's c % B6%
Y	cancer	59778 B61z100	24 Hodgkin's c % B6%
Y	cancer	59755 B61z200	18 Hodgkin's c % B6%
Y	cancer	107804 B61z300	1 Hodgkin's c % B6%
Y	cancer	91900 B61z400	5 Hodgkin's c % B6%
Y	cancer	99012 B61z500	1 Hodgkin's c % B6%
Y	cancer	94279 B61z700	1 Hodgkin's c % B6%
Y	cancer	97746 B61z800	8 Hodgkin's c % B6%
Y	cancer	42461 B61zz00	136 Hodgkin's c % B6%
Y	cancer	33333 B62..00	157 Other mali % B6%
Y	cancer	5179 B620.00	228 Nodular lyr % B6%
Y	cancer	66327 B620000	10 Nodular lyr % B6%
Y	cancer	45264 B620100	18 Nodular lyr % B6%
Y	cancer	105203 B620200	1 Nodular lyr % B6%
Y	cancer	92068 B620300	5 Nodular lyr % B6%
Y	cancer	94995 B620500	5 Nodular lyr % B6%

Y	cancer	58082 B620800	5 Nodular lyr % B6%
Y	cancer	65701 B620z00	24 Nodular lyr % B6%
Y	cancer	12006 B621.00	2237 Mycosis fui % B6%
Y	cancer	95949 B621000	15 Mycosis fui % B6%
Y	cancer	91674 B621300	1 Mycosis fui % B6%
Y	cancer	96379 B621400	1 Mycosis fui % B6%
Y	cancer	72714 B621500	4 Mycosis fui % B6%
Y	cancer	95012 B621800	2 Mycosis fui % B6%
Y	cancer	38005 B621z00	31 Mycosis fui % B6%
Y	cancer	35014 B622.00	66 Sezary's dis % B6%
Y	cancer	100532 B622z00	3 Sezary's dis % B6%
Y	cancer	44267 B623.00	65 Malignant l % B6%
Y	cancer	69497 B623000	1 Malignant l % B6%
Y	cancer	94415 B623100	2 Malignant l % B6%
Y	cancer	65642 B623300	2 Malignant l % B6%
Y	cancer	58871 B623z00	8 Malignant l % B6%
Y	cancer	27330 B624.00	48 Leukaemic % B6%
Y	cancer	5137 B624.11	301 Leukaemic % B6%
Y	cancer	87335 B624.12	275 Hairy cell l % B6%
Y	cancer	65122 B624000	2 Leukaemic % B6%
Y	cancer	65123 B624300	1 Leukaemic % B6%
Y	cancer	73777 B624z00	2 Leukaemic % B6%
Y	cancer	34926 B625.00	48 Letterer-Siv % B6%
Y	cancer	4870 B625.11	233 Histiocytos % B6%
Y	cancer	102715 B625000	1 Letterer-Siv % B6%
Y	cancer	102158 B625200	1 Letterer-Siv % B6%
Y	cancer	54083 B625800	1 Letterer-Siv % B6%
Y	cancer	47204 B625z00	5 Letterer-Siv % B6%
Y	cancer	15036 B626.00	49 Malignant i % B6%
Y	cancer	103900 B626000	1 Mast cell r % B6%
Y	cancer	100615 B626500	1 Mast cell r % B6%
Y	cancer	31324 B626800	37 Mast cell r % B6%
Y	cancer	89657 B626z00	1 Malignant i % B6%
Y	cancer	3604 B627.00	13556 Non - Hodg % B6%
Y	cancer	104391 B627.11	80 Non-Hodgk % B6%
Y	cancer	28639 B627000	108 Follicular n % B6%
Y	cancer	70842 B627100	7 Follicular n % B6%
Y	cancer	49262 B627200	46 Follicular n % B6%
Y	cancer	50668 B627300	12 Diffuse nor % B6%
Y	cancer	108182 B627400	1 Diffuse nor % B6%
Y	cancer	50695 B627500	9 Diffuse nor % B6%
Y	cancer	53551 B627600	7 Diffuse nor % B6%
Y	cancer	17460 B627700	87 Diffuse nor % B6%
Y	cancer	65180 B627800	12 Diffuse nor % B6%
Y	cancer	95715 B627900	26 Mucosa-as: % B6%
Y	cancer	95545 B627911	34 Maltoma % B6%
Y	cancer	101114 B627A00	68 Diffuse nor % B6%
Y	cancer	31576 B627B00	66 Other type: % B6%
Y	cancer	21549 B627C00	656 Follicular n % B6%
Y	cancer	17182 B627C11	1293 Follicular ly % B6%

Y	cancer	70509 B627D00	5 Diffuse nor % B6%
Y	cancer	102594 B627E00	367 Diffuse larg % B6%
Y	cancer	105966 B627F00	3 Extranod r % B6%
Y	cancer	105038 B627G00	9 Mediastina % B6%
Y	cancer	31794 B627W00	603 Unspecifier % B6%
Y	cancer	39798 B627X00	110 Diffuse nor % B6%
Y	cancer	104152 B628.00	486 Follicular ly % B6%
Y	cancer	105889 B628000	8 Follicular ly % B6%
Y	cancer	105095 B628100	10 Follicular ly % B6%
Y	cancer	107166 B628200	3 Follicular ly % B6%
Y	cancer	105020 B628300	5 Follicular ly % B6%
Y	cancer	107973 B628400	1 Follicular ly % B6%
Y	cancer	106969 B628500	1 Diffuse folli % B6%
Y	cancer	108719 B628600	2 Cutaneous % B6%
Y	cancer	106063 B628700	1 Other type: % B6%
Y	cancer	105792 B629.00	4 Multifocal i % B6%
Y	cancer	105335 B62A.00	1 Sarcoma of % B6%
Y	cancer	105762 B62C.00	6 Unifocal La % B6%
Y	cancer	105083 B62D.00	11 Histiocytic % B6%
Y	cancer	105085 B62E.00	24 T/NK-cell ly % B6%
Y	cancer	105559 B62E100	15 Anaplastic % B6%
Y	cancer	105955 B62E200	9 Anaplastic % B6%
Y	cancer	104862 B62E300	11 Cutaneous % B6%
Y	cancer	107949 B62E500	2 Hepatosple % B6%
Y	cancer	105709 B62E600	2 Enteropath % B6%
Y	cancer	105925 B62E700	1 Subcutane % B6%
Y	cancer	105375 B62E800	2 Blastic NK-r % B6%
Y	cancer	105636 B62E900	10 Angioimmu % B6%
Y	cancer	105286 B62EA00	6 Primary cu % B6%
Y	cancer	104934 B62Ew00	1 Other mat % B6%
Y	cancer	106884 B62F.00	5 Nonfollicul % B6%
Y	cancer	106867 B62F.11	3 Non-follicu % B6%
Y	cancer	104386 B62F000	73 Small cell B % B6%
Y	cancer	104620 B62F100	157 Mantle cell % B6%
Y	cancer	104412 B62F200	4 Lymphobla % B6%
Y	cancer	17887 B62x.00	851 Malignant l % B6%
Y	cancer	90201 B62x000	6 T-zone lym % B6%
Y	cancer	57737 B62x100	5 Lymphoepi % B6%
Y	cancer	12464 B62x200	126 Peripheral % B6%
Y	cancer	62437 B62x400	7 Malignant i % B6%
Y	cancer	58962 B62x500	4 Malignant i % B6%
Y	cancer	95630 B62x600	1 True histio % B6%
Y	cancer	44318 B62xX00	130 Oth and un % B6%
Y	cancer	12335 B62y.00	6405 Malignant l % B6%
Y	cancer	57427 B62y000	28 Malignant l % B6%
Y	cancer	50696 B62y100	31 Malignant l % B6%
Y	cancer	72725 B62y200	8 Malignant l % B6%
Y	cancer	42579 B62y300	8 Malignant l % B6%
Y	cancer	34089 B62y400	6 Malignant l % B6%
Y	cancer	63105 B62y500	11 Malignant l % B6%

Y	cancer	71262 B62y600	4 Malignant l % B6%
Y	cancer	60092 B62y700	15 Malignant l % B6%
Y	cancer	15504 B62y800	142 Malignant l % B6%
Y	cancer	15027 B62yz00	807 Malignant l % B6%
Y	cancer	65434 B62z.00	7 Malignant l % B6%
Y	cancer	108037 B62z000	1 Unspec ma % B6%
Y	cancer	64427 B62z100	7 Unspec ma % B6%
Y	cancer	93384 B62z200	2 Unspec ma % B6%
Y	cancer	103353 B62z300	1 Unspec ma % B6%
Y	cancer	107638 B62z400	1 Unspec ma % B6%
Y	cancer	71609 B62z500	3 Unspec ma % B6%
Y	cancer	101465 B62z800	4 Unspec ma % B6%
Y	cancer	95792 B62zz00	8 Lymphoid t % B6%
Y	cancer	70716 B62zz11	2 Immunopr % B6%
Y	cancer	37182 B63..00	70 Multiple m % B6%
Y	cancer	4944 B630.00	13603 Multiple m % B6%
Y	cancer	43552 B630.11	31 Kahler's dis % B6%
Y	cancer	15211 B630.12	372 Myelomatc % B6%
Y	cancer	22158 B630000	83 Malignant j % B6%
Y	cancer	19028 B630100	295 Solitary my % B6%
Y	cancer	21329 B630200	597 Plasmacytc % B6%
Y	cancer	46042 B630300	146 Lambda ligl % B6%
Y	cancer	104418 B630400	10 Solitary pla % B6%
Y	cancer	39187 B631.00	98 Plasma cell % B6%
Y	cancer	64567 B63y.00	12 Other imm % B6%
Y	cancer	43450 B63z.00	34 Immunopr % B6%
Y	cancer	19372 B64..00	1207 Lymphoid l % B6%
Y	cancer	4222 B64..11	2119 Lymphatic % B6%
Y	cancer	4251 B640.00	2535 Acute lymp % B6%
Y	cancer	104325 B640000	81 B-cell acute % B6%
Y	cancer	8625 B641.00	14892 Chronic lyn % B6%
Y	cancer	27790 B641.11	773 Chronic lyn % B6%
Y	cancer	104328 B641000	87 B-cell chror % B6%
Y	cancer	107017 B641011	5 Chronic lyn % B6%
Y	cancer	107052 B641100	18 Clinical sta % B6%
Y	cancer	106924 B641200	4 Clinical sta % B6%
Y	cancer	107163 B641300	2 Clinical sta % B6%
Y	cancer	72774 B642.00	2 Subacute ly % B6%
Y	cancer	49725 B64y.00	16 Other lymp % B6%
Y	cancer	31586 B64y100	100 Prolympho % B6%
Y	cancer	37461 B64y200	36 Adult T-cell % B6%
Y	cancer	108656 B64y300	1 B-cell proly % B6%
Y	cancer	107643 B64y400	1 T-cell proly % B6%
Y	cancer	104939 B64y500	9 Adult T-cell % B6%
Y	cancer	38331 B64yz00	20 Other lymp % B6%
Y	cancer	38914 B64z.00	53 Lymphoid l % B6%
Y	cancer	7176 B65..00	2322 Myeloid lei % B6%
Y	cancer	4413 B650.00	5922 Acute myel % B6%
Y	cancer	10726 B651.00	3058 Chronic my % B6%
Y	cancer	31701 B651.11	161 Chronic gra % B6%

Y	cancer	100786 B651000	3 Chronic eo:% B6%
Y	cancer	105957 B651100	3 Chronic my % B6%
Y	cancer	102783 B651200	1 Chronic nei % B6%
Y	cancer	107236 B651300	3 Atypical ch % B6%
Y	cancer	27520 B651z00	60 Chronic my % B6%
Y	cancer	63475 B652.00	4 Subacute n % B6%
Y	cancer	70724 B653.00	7 Myeloid sa % B6%
Y	cancer	52327 B653000	15 Chloroma % B6%
Y	cancer	39629 B653100	16 Granulocyt % B6%
Y	cancer	104788 B654.00	6 Acute myel % B6%
Y	cancer	27664 B65y100	234 Acute pron % B6%
Y	cancer	66089 B65yz00	5 Other myel % B6%
Y	cancer	33344 B65z.00	30 Myeloid lei % B6%
Y	cancer	35875 B66..00	38 Monocytic % B6%
Y	cancer	108715 B66..11	1 Histiocytic % B6%
Y	cancer	67700 B66..12	4 Monoblast % B6%
Y	cancer	19974 B660.00	39 Acute mon % B6%
Y	cancer	27458 B661.00	120 Chronic mc % B6%
Y	cancer	101606 B662.00	1 Subacute n % B6%
Y	cancer	108424 B663.00	1 Acute mon % B6%
Y	cancer	99015 B66y.00	1 Other mon % B6%
Y	cancer	103645 B66yz00	1 Other mon % B6%
Y	cancer	93342 B66z.00	2 Monocytic % B6%
Y	cancer	37272 B67..00	118 Other spec % B6%
Y	cancer	42539 B670.00	52 Acute erytl % B6%
Y	cancer	27340 B670.11	5 Di Guglielr % B6%
Y	cancer	37468 B671.00	34 Chronic ery % B6%
Y	cancer	63653 B671.11	2 Heilmeyer % B6%
Y	cancer	57671 B672.00	7 Megakaryo % B6%
Y	cancer	65777 B672.11	8 Thrombocy % B6%
Y	cancer	65721 B673.00	2 Mast cell le % B6%
Y	cancer	50858 B674.00	11 Acute panr % B6%
Y	cancer	28276 B675.00	327 Acute myel % B6%
Y	cancer	104273 B677.00	155 Myelodysp % B6%
Y	cancer	94174 B67y.00	8 Other and i % B6%
Y	cancer	72197 B67y000	2 Lymphosar % B6%
Y	cancer	99413 B67yz00	5 Other and i % B6%
Y	cancer	30632 B67z.00	39 Other spec % B6%
Y	cancer	25191 B68..00	468 Leukaemia % B6%
Y	cancer	4072 B680.00	525 Acute leuk: % B6%
Y	cancer	16416 B681.00	379 Chronic leu % B6%
Y	cancer	54793 B682.00	3 Subacute le % B6%
Y	cancer	34692 B68y.00	22 Other leuk: % B6%
Y	cancer	4250 B68z.00	3159 Leukaemia % B6%
Y	cancer	20440 B69..00	205 Myelomon % B6%
Y	cancer	61500 B690.00	10 Acute myel % B6%
Y	cancer	22050 B691.00	457 Chronic my % B6%
Y	cancer	104475 B692.00	1 Subacute n % B6%
Y	cancer	105069 B693.00	3 Juvenile my % B6%
Y	cancer	30646 B6y..00	21 Malignant i % B6%

Y	cancer	6115 B6y0.00	3322 Myeloproliferative % B6%
Y	cancer	17056 B6y0.11	809 Myeloproliferative % B6%
Y	cancer	39336 B6y1.00	9 Myelofibrosis % B6%
Y	cancer	49301 B6z..00	388 Malignant melanoma % B6%
Y	cancer	50290 B6z0.00	4 Kaposi's sarcoma % B6%
Y	cancer	7473 B8...00	7184 Carcinoma % B8%
Y	cancer	60511 B80..00	13 Carcinoma % B8%
Y	cancer	33250 B80..11	7 Carcinoma in situ % B8%
Y	cancer	95390 B800.00	3 Carcinoma % B8%
Y	cancer	37505 B800.11	52 Carcinoma % B8%
Y	cancer	42129 B800.12	53 Carcinoma % B8%
Y	cancer	47737 B800000	24 Carcinoma % B8%
Y	cancer	27944 B800100	551 Carcinoma % B8%
Y	cancer	50288 B800200	45 Carcinoma % B8%
Y	cancer	57866 B800300	5 Carcinoma % B8%
Y	cancer	24801 B800400	144 Carcinoma % B8%
Y	cancer	34823 B800500	47 Carcinoma % B8%
Y	cancer	30966 B800600	39 Carcinoma % B8%
Y	cancer	36104 B800700	99 Carcinoma % B8%
Y	cancer	50419 B800800	73 Carcinoma % B8%
Y	cancer	44663 B800900	37 Carcinoma % B8%
Y	cancer	37187 B800z00	6 Carcinoma % B8%
Y	cancer	8244 B801.00	1717 Carcinoma % B8%
Y	cancer	99155 B801000	2 Carcinoma % B8%
Y	cancer	64274 B801100	5 Carcinoma % B8%
Y	cancer	56077 B801200	17 Carcinoma % B8%
Y	cancer	44228 B801z00	69 Carcinoma % B8%
Y	cancer	17093 B802.00	1133 Carcinoma % B8%
Y	cancer	17258 B802000	76 Carcinoma % B8%
Y	cancer	72947 B802100	3 Carcinoma % B8%
Y	cancer	63087 B802200	10 Carcinoma % B8%
Y	cancer	51748 B802300	12 Carcinoma % B8%
Y	cancer	58883 B802400	6 Carcinoma % B8%
Y	cancer	37774 B802z00	57 Carcinoma % B8%
Y	cancer	6903 B803.00	2322 Carcinoma % B8%
Y	cancer	39080 B803000	65 Carcinoma % B8%
Y	cancer	37125 B803100	111 Carcinoma % B8%
Y	cancer	47667 B803200	31 Carcinoma % B8%
Y	cancer	17144 B803300	1125 Carcinoma % B8%
Y	cancer	16916 B803400	887 Carcinoma % B8%
Y	cancer	47656 B803500	75 Carcinoma % B8%
Y	cancer	31893 B803600	84 Carcinoma % B8%
Y	cancer	22699 B803700	56 Carcinoma % B8%
Y	cancer	105228 B803800	26 High grade % B8%
Y	cancer	33561 B803z00	131 Carcinoma % B8%
Y	cancer	60477 B804.00	18 Carcinoma % B8%
Y	cancer	27811 B804000	228 Carcinoma % B8%
Y	cancer	29975 B804100	234 Carcinoma % B8%
Y	cancer	38883 B804z00	14 Carcinoma % B8%
Y	cancer	51054 B805.00	68 Carcinoma % B8%

Y	cancer	34094 B805000	160 Anal intrae % B8%
Y	cancer	12273 B806.00	128 Carcinoma % B8%
Y	cancer	22392 B807.00	10 Carcinoma % B8%
Y	cancer	45070 B807000	68 Carcinoma % B8%
Y	cancer	63804 B807100	11 Carcinoma % B8%
Y	cancer	45217 B807200	8 Carcinoma % B8%
Y	cancer	100183 B807300	1 Carcinoma % B8%
Y	cancer	70728 B807z00	1 Carcinoma % B8%
Y	cancer	66673 B808.00	5 Carcinoma % B8%
Y	cancer	51934 B808.11	23 Carcinoma % B8%
Y	cancer	25310 B808000	356 Carcinoma % B8%
Y	cancer	99580 B808100	4 Carcinoma % B8%
Y	cancer	37501 B808200	6 Carcinoma % B8%
Y	cancer	46594 B808300	81 Carcinoma % B8%
Y	cancer	73164 B808400	3 Carcinoma % B8%
Y	cancer	64089 B808500	5 Carcinoma % B8%
Y	cancer	21792 B808600	69 Carcinoma % B8%
Y	cancer	98540 B808z00	3 Carcinoma % B8%
Y	cancer	44166 B80z.00	2 Carcinoma % B8%
Y	cancer	16931 B80z000	1997 Carcinoma % B8%
Y	cancer	64700 B80z100	5 Carcinoma % B8%
Y	cancer	64050 B81..00	26 Carcinoma % B8%
Y	cancer	11403 B810.00	770 Carcinoma % B8%
Y	cancer	35772 B810000	54 Carcinoma % B8%
Y	cancer	36948 B810100	12 Carcinoma % B8%
Y	cancer	53460 B810200	61 Carcinoma % B8%
Y	cancer	65953 B810300	1 Carcinoma % B8%
Y	cancer	31860 B810600	3 Carcinoma % B8%
Y	cancer	73076 B810700	2 Carcinoma % B8%
Y	cancer	7697 B810800	186 Carcinoma % B8%
Y	cancer	10375 B810811	42 Carcinoma % B8%
Y	cancer	53882 B810z00	37 Carcinoma % B8%
Y	cancer	51714 B811.00	20 Carcinoma % B8%
Y	cancer	9267 B812.00	2937 Carcinoma % B8%
Y	cancer	49159 B812000	64 Carcinoma % B8%
Y	cancer	35058 B812100	126 Carcinoma % B8%
Y	cancer	37579 B812200	58 Carcinoma % B8%
Y	cancer	47897 B812300	7 Carcinoma % B8%
Y	cancer	52373 B812400	25 Carcinoma % B8%
Y	cancer	25372 B812z00	474 Carcinoma % B8%
Y	cancer	97954 B81y.00	1 Carcinoma % B8%
Y	cancer	59426 B81y.11	9 Carcinoma % B8%
Y	cancer	46497 B81y000	9 Carcinoma % B8%
Y	cancer	39717 B81y100	23 Carcinoma % B8%
Y	cancer	97200 B81y400	2 Carcinoma % B8%
Y	cancer	68135 B81y500	3 Carcinoma % B8%
Y	cancer	43380 B81y600	23 Carcinoma % B8%
Y	cancer	26846 B81y700	5 Carcinoma % B8%
Y	cancer	39064 B81y900	14 Carcinoma % B8%
Y	cancer	95559 B81yz00	1 Carcinoma % B8%

Y	cancer	62610 B81z.00	12 Carcinoma % B8%
Y	cancer	19686 B828.00	1499 Melanoma % B8%
Y	cancer	46536 B828000	3 Melanoma % B8%
Y	cancer	37108 B828100	11 Melanoma % B8%
Y	cancer	72032 B828200	6 Melanoma % B8%
Y	cancer	97858 B828300	9 Melanoma % B8%
Y	cancer	59768 B828400	31 Melanoma % B8%
Y	cancer	56694 B828500	27 Melanoma % B8%
Y	cancer	47850 B828600	52 Melanoma % B8%
Y	cancer	49572 B828700	4 Melanoma % B8%
Y	cancer	52332 B828800	1 Melanoma % B8%
Y	cancer	71044 B828900	34 Melanoma % B8%
Y	cancer	54246 B828W00	61 Melanoma % B8%
Y	cancer	61989 B828X00	6 Melanoma % B8%
Y	cancer	45681 B83..00	46 Carcinoma % B8%
Y	cancer	7833 B830.00	8481 Carcinoma % B8%
Y	cancer	10387 B830000	949 Lobular car % B8%
Y	cancer	18694 B830100	1309 Intraductal % B8%
Y	cancer	3279 B831.00	7765 Carcinoma % B8%
Y	cancer	4087 B831.11	7001 CIN III - car % B8%
Y	cancer	5295 B831.12	1329 Cervical int % B8%
Y	cancer	21886 B831.13	4661 Cervical int % B8%
Y	cancer	24228 B831000	133 Carcinoma % B8%
Y	cancer	50126 B831100	20 Carcinoma % B8%
Y	cancer	29898 B832.00	129 Carcinoma % B8%
Y	cancer	61803 B832.11	16 Carcinoma % B8%
Y	cancer	7904 B832000	2028 Carcinoma % B8%
Y	cancer	44915 B833.00	3 Carcinoma % B8%
Y	cancer	17137 B833000	1053 Carcinoma % B8%
Y	cancer	59499 B833100	41 Carcinoma % B8%
Y	cancer	34946 B833200	116 Carcinoma % B8%
Y	cancer	12119 B833300	728 Carcinoma % B8%
Y	cancer	3281 B833311	1841 Vulval intra % B8%
Y	cancer	97096 B833400	74 Vulval intra % B8%
Y	cancer	96999 B833500	47 Vulval intra % B8%
Y	cancer	97107 B833600	158 Vulval intra % B8%
Y	cancer	102476 B833700	32 Vaginal intr % B8%
Y	cancer	101708 B833800	15 Vaginal intr % B8%
Y	cancer	102599 B833900	17 Vaginal intr % B8%
Y	cancer	69208 B833z00	5 Carcinoma % B8%
Y	cancer	6328 B834.00	12953 Carcinoma % B8%
Y	cancer	54599 B834000	105 High grade % B8%
Y	cancer	105236 B834100	47 Prostatic in % B8%
Y	cancer	27311 B835.00	293 Carcinoma % B8%
Y	cancer	107958 B836.00	1 Carcinoma % B8%
Y	cancer	8177 B836000	160 Carcinoma % B8%
Y	cancer	58879 B836300	7 Carcinoma % B8%
Y	cancer	7187 B837.00	5561 Carcinoma % B8%
Y	cancer	68358 B83z.00	11 Carcinoma % B8%
Y	cancer	38611 B8y..00	18 Carcinoma % B8%

Y	cancer	58124 B8y0.00	27 Carcinoma % B8%
Y	cancer	53349 B8yy.00	14 Carcinoma % B8%
Y	cancer	8958 B8yy000	784 Carcinoma % B8%
Y	cancer	46478 B8yy100	77 Carcinoma % B8%
Y	cancer	58016 B8yy200	19 Carcinoma % B8%
Y	cancer	45909 B8yy300	19 Carcinoma % B8%
Y	cancer	56640 B8yyz00	35 Carcinoma % B8%
Y	cancer	35136 B8z..00	234 Carcinoma % B8%
Y	cancer	19657 B911000	152 Malignant l% B9110%
Y	cancer	101813 B911012	1 Invasive m% B9110%
Y	cancer	5136 B911013	80 Choriocarci% B9110%
Y	cancer	2481 B934.00	11675 Polycytha% B934%
Y	cancer	5542 B934.11	1899 Polycytha% B934%
Y	cancer	36790 B934.12	404 Primary po% B934%
Y	cancer	20609 B937.00	146 Neop unce% B937%
Y	cancer	72551 B937.11	1 Neoplasm c% B937%
Y	cancer	31560 B937.12	67 Idiopathic t% B937%
Y	cancer	14927 B937.14	3953 Myelodysp% B937%
Y	cancer	22890 B937000	118 Refractory % B937%
Y	cancer	10817 B937100	118 Refractory % B937%
Y	cancer	23875 B937200	91 Refractory % B937%
Y	cancer	44420 B937300	4 Refractory % B937%
Y	cancer	11950 B937400	1709 Essential (h% B937%
Y	cancer	12265 B937411	645 Primary thr% B937%
Y	cancer	17386 B937500	978 Idiopathic t% B937%
Y	cancer	105985 B937600	2 Refractory % B937%
Y	cancer	106993 B937700	5 Refractory % B937%
Y	cancer	104740 B937800	2 Refractory % B937%
Y	cancer	105915 B937900	3 5Q minus s% B937%
Y	cancer	105390 B937911	2 Myelodysp% B937%
Y	cancer	45285 B937W00	488 Myelodysp% B937%
Y	cancer	4561 B937W11	6474 Myelodysp% B937%
Y	cancer	19130 B937X00	1697 Refractory % B937%
Y	cancer	21868 BB02.00	2352 [M]Neopla:% BB%
Y	cancer	100590 BB03.12	2 [M]Tumoui% BB%
Y	cancer	100112 BB03.13	8 [M]Tumoui% BB%
Y	cancer	22267 BB04.00	201 [M]Neopla:% BB%
Y	cancer	8627 BB07.00	459 [M]Tumoui% BB%
Y	cancer	22156 BB08.00	189 [M]Malign% BB%, % BB08%
Y	cancer	24511 BB09.00	84 [M]Malign% BB%
Y	cancer	32213 BB0A.00	2 [M]Malign% BB%
Y	cancer	20564 BB11.00	754 [M]Carcino% BB%
Y	cancer	21914 BB11.11	242 [M]Intraep% BB%
Y	cancer	8695 BB12.00	6322 [M]Carcino% BB%
Y	cancer	16692 BB14.00	1002 [M]Carcino% BB%
Y	cancer	57336 BB16.00	50 [M]Epitheli% BB%
Y	cancer	25961 BB17.00	159 [M]Large c% BB%
Y	cancer	21609 BB18.00	123 [M]Carcino% BB%
Y	cancer	12609 BB19.00	208 [M]Carcino% BB%
Y	cancer	26413 BB1A.00	84 [M]Pleomo% BB%

Y	cancer	48048 BB1B.00	46 [M]Giant c α % BB%
Y	cancer	35474 BB1C.00	31 [M]Giant c α % BB%
Y	cancer	6966 BB1D.00	245 [M]Spindle % BB%
Y	cancer	54276 BB1E.00	4 [M]Pseudo % BB%
Y	cancer	69300 BB1F.00	5 [M]Polygor % BB%
Y	cancer	61984 BB1G.00	9 [M]Spheroid % BB%
Y	cancer	9291 BB1J.00	2218 [M]Small c α % BB%
Y	cancer	66541 BB1J.12	2 [M]Round c α % BB%
Y	cancer	9156 BB1K.00	196 [M]Oat cell % BB%
Y	cancer	67970 BB1L.00	2 [M]Small c α % BB%
Y	cancer	30988 BB1M.00	99 [M]Small c α % BB%
Y	cancer	21217 BB1N.00	61 [M]Small c α % BB%
Y	cancer	106519 BB1P.00	40 [M]Non-sr α % BB%
Y	cancer	38651 BB21.00	52 [M]Papillar % BB%
Y	cancer	10541 BB22.00	231 [M]Papillar % BB%
Y	cancer	34395 BB24.00	152 [M]Verrucc % BB%
Y	cancer	43717 BB24.11	11 [M]Verrucc % BB%
Y	cancer	20807 BB26.00	179 [M]Papillar % BB%
Y	cancer	67912 BB26.11	3 [M]Papillar % BB%
Y	cancer	10134 BB29.00	1120 [M]Squam α % BB%
Y	cancer	19678 BB29.13	982 [M]Intraep % BB%
Y	cancer	1624 BB2A.00	34131 [M]Squam α % BB%
Y	cancer	24293 BB2B.00	1044 [M]Squam α % BB%
Y	cancer	59143 BB2D.00	6 [M]Squam α % BB%
Y	cancer	41816 BB2E.00	58 [M]Squam α % BB%
Y	cancer	31004 BB2G.00	45 [M]Adenoid % BB%
Y	cancer	61928 BB2H.00	5 [M]Squam α % BB%
Y	cancer	33497 BB2J.00	97 [M]Squam α % BB%
Y	cancer	45510 BB2M.00	29 [M]Lymphc % BB%
Y	cancer	44534 BB2N.00	71 [M]Intraep % BB%
Y	cancer	21652 BB42.00	601 [M]Transiti % BB%
Y	cancer	6436 BB43.00	3298 [M]Transiti % BB%
Y	cancer	12388 BB43.11	214 [M]Urothel % BB%
Y	cancer	100111 BB46.00	1 [M]Schneic % BB%
Y	cancer	58798 BB47.00	2 [M]Transiti % BB%
Y	cancer	38454 BB48.00	185 [M]Basaloid % BB%
Y	cancer	65216 BB49.00	11 [M]Cloaco ξ % BB%
Y	cancer	9712 BB4A.00	766 [M]Papillar % BB%
Y	cancer	101095 BB4B.00	24 [M]Grade 1% BB%
Y	cancer	102244 BB4C.00	27 [M]Grade 2% BB%
Y	cancer	101978 BB4D.00	26 [M]Grade 3% BB%
Y	cancer	33897 BB4z.00	121 [M]Transiti % BB%
Y	cancer	19091 BB5..00	921 [M]Adenor % BB%
Y	cancer	2272 BB5..11	26937 [M]Adenoc % BB%
Y	cancer	27827 BB51.00	1113 [M]Adenoc % BB%
Y	cancer	29170 BB51000	118 [M]Adenoc % BB%
Y	cancer	37137 BB51100	154 [M]Adenoc % BB%
Y	cancer	8930 BB52.00	4162 [M]Adenoc % BB%
Y	cancer	44778 BB52000	81 [M]Adenoc % BB%
Y	cancer	5455 BB53.00	2443 [M]Adenoc % BB%

Y	cancer	48223	BB54.00	27	[M]Scirrhoi % BB%
Y	cancer	27440	BB55.00	268	[M]Linitis p % BB%
Y	cancer	71895	BB56.00	9	[M]Superfi % BB%
Y	cancer	28272	BB57.00	424	[M]Adenoc % BB%
Y	cancer	59240	BB58.00	19	[M]Carcino % BB%
Y	cancer	8101	BB5a.00	2590	[M]Renal a % BB%
Y	cancer	10668	BB5a000	1852	[M]Renal c % BB%
Y	cancer	52266	BB5a011	5	[M]Grawitz % BB%
Y	cancer	15419	BB5a012	642	[M]Hypern % BB%
Y	cancer	34096	BB5b.00	66	[M]Granulæ % BB%
Y	cancer	8032	BB5B.00	1244	[M]Pancreæ % BB%
Y	cancer	11469	BB5B011	12	[M]Nesidio % BB%
Y	cancer	63102	BB5B100	6	[M]Islet cel % BB%
Y	cancer	95609	BB5B300	6	[M]Insulinc % BB%
Y	cancer	32294	BB5B500	1	[M]Glucagc % BB%
Y	cancer	98825	BB5B600	2	[M]Mixed i % BB%
Y	cancer	4217	BB5c.00	692	[M]Parathy % BB%
Y	cancer	26858	BB5C.00	129	[M]Gastrin % BB%
Y	cancer	35718	BB5C000	20	[M]Gastrin % BB%
Y	cancer	49629	BB5C100	7	[M]Gastrin % BB%
Y	cancer	36031	BB5D.00	29	[M]Hepato % BB%
Y	cancer	70516	BB5D.11	9	[M]Biliary t % BB%
Y	cancer	8711	BB5D100	3153	[M]Cholanç % BB%
Y	cancer	40438	BB5D111	39	[M]Bile duc % BB%
Y	cancer	41313	BB5D300	19	[M]Bile duc % BB%
Y	cancer	40240	BB5D500	261	[M]Hepato % BB%
Y	cancer	26814	BB5D512	181	[M]Hepato % BB%
Y	cancer	25641	BB5D513	134	[M]Liver ce % BB%
Y	cancer	107299	BB5D700	1	[M]Combin % BB%
Y	cancer	46771	BB5D800	16	[M]Hepato % BB%
Y	cancer	98781	BB5F.00	1	[M]Trabecu % BB%
Y	cancer	19263	BB5f.00	395	[M]Thyroid % BB%
Y	cancer	21741	BB5f100	54	[M]Follicul % BB%
Y	cancer	21847	BB5f111	322	[M]Follicul % BB%
Y	cancer	59918	BB5f200	5	[M]Follicul % BB%
Y	cancer	61467	BB5f300	1	[M]Follicul % BB%
Y	cancer	46761	BB5f600	49	[M]Papillar % BB%
Y	cancer	68757	BB5f700	2	[M]Nonenc % BB%
Y	cancer	60775	BB5h100	11	[M]Adrena % BB%
Y	cancer	33775	BB5J.00	329	[M]Adenoit % BB%
Y	cancer	8606	BB5j.00	2049	[M]Endom % BB%
Y	cancer	34879	BB5J.11	1	[M]Cylindr % BB%
Y	cancer	35747	BB5j100	2	[M]Endom % BB%
Y	cancer	9447	BB5j200	858	[M]Endom % BB%
Y	cancer	99570	BB5j400		[M]Endom % BB%
Y	cancer	103034	BB5j500	1	[M]Endom % BB%
Y	cancer	50140	BB5K.00	15	[M]Cribrifo % BB%
Y	cancer	18255	BB5L.00	128	[M]Adenor % BB%
Y	cancer	52326	BB5L100	39	[M]Adenoc % BB%
Y	cancer	55741	BB5L200	19	[M]Adenoc % BB%

Y	cancer	73434	BB5L300	6	[M]Adenoc % BB%
Y	cancer	6746	BB5M.00	1750	[M]Tubular % BB%
Y	cancer	60045	BB5M100	28	[M]Tubular % BB%
Y	cancer	41702	BB5N.00	90	[M]Adenor % BB%
Y	cancer	73275	BB5N100	4	[M]Adenoc % BB%
Y	cancer	94083	BB5P.00	1	[M]Solid ca % BB%
Y	cancer	34110	BB5R100	90	[M]Carcino % BB%
Y	cancer	100625	BB5R500	1	[M]Carcino % BB%
Y	cancer	55468	BB5R600	7	[M]Mucocæ % BB%
Y	cancer	69210	BB5R611	23	[M]Goblet % BB%
Y	cancer	56794	BB5R800	52	[M]Adenoc % BB%
Y	cancer	26253	BB5R900	764	[M]Neuroe % BB%
Y	cancer	26848	BB5S.00	17	[M]Respira % BB%
Y	cancer	34015	BB5S200	169	[M]Bronchi % BB%
Y	cancer	36530	BB5S211	81	[M]Alveola % BB%
Y	cancer	16723	BB5S212	635	[M]Bronchi % BB%
Y	cancer	57802	BB5S400	15	[M]Alveola % BB%
Y	cancer	42273	BB5T.00	124	[M]Papillar % BB%
Y	cancer	35348	BB5T100	82	[M]Papillar % BB%
Y	cancer	6920	BB5U.00	604	[M]Villous : % BB%
Y	cancer	67342	BB5U100	7	[M]Adenoc % BB%
Y	cancer	27849	BB5U200	10	[M]Villous : % BB%
Y	cancer	26120	BB5V.00	169	[M]Pituitar % BB%
Y	cancer	68456	BB5V100	19	[M]Chromc % BB%
Y	cancer	36876	BB5V311	1	[M]Eosinoç % BB%
Y	cancer	72277	BB5V700	4	[M]Basoph % BB%
Y	cancer	40622	BB5V711	29	[M]Mucoïd % BB%
Y	cancer	62199	BB5W.00	7	[M]Oxyphil % BB%
Y	cancer	71497	BB5W100	4	[M]Oxyphil % BB%
Y	cancer	29008	BB5W111	48	[M]Hurthle % BB%
Y	cancer	53129	BB5W112	3	[M]Oncytic % BB%
Y	cancer	36882	BB5X.00	120	[M]Clear cæ % BB%
Y	cancer	37354	BB5X100	62	[M]Clear cæ % BB%
Y	cancer	27697	BB5Y.00	14	[M]Hypern % BB%
Y	cancer	29362	BB5y.00	19	[M]Adenor % BB%
Y	cancer	61764	BB5y100	7	[M]Vipoma % BB%
Y	cancer	49900	BB5y200	34	[M]Klatskir % BB%
Y	cancer	28625	BB71.00	67	[M]Mucoeï % BB%
Y	cancer	34984	BB80.00	120	[M]Cystadæ % BB%
Y	cancer	34000	BB80100	93	[M]Cystadæ % BB%
Y	cancer	69978	BB80200	183	[M]Borderl % BB%
Y	cancer	52263	BB81100	15	[M]Serous % BB%
Y	cancer	38442	BB81200	29	[M]Serous % BB%
Y	cancer	98696	BB81400	1	[M]Papillar % BB%
Y	cancer	65051	BB81500	3	[M]Papillar % BB%
Y	cancer	44930	BB81800	11	[M]Papillar % BB%
Y	cancer	95774	BB81A00	1	[M]Serous % BB%
Y	cancer	95150	BB81B00	2	[M]Serous % BB%
Y	cancer	28396	BB81D00	36	[M]Mucino % BB%
Y	cancer	51656	BB81E00	26	[M]Mucino % BB%

Y	cancer	66876	BB81E11	3	[M]Pseudo % BB%
Y	cancer	54749	BB81H00	2	[M]Papillar % BB%
Y	cancer	21131	BB81J00	108	[M]Serous % BB%
Y	cancer	46113	BB81K00	5	[M]Papillar % BB%
Y	cancer	6203	BB81M00	38	[M]Papillar % BB%
Y	cancer	40632	BB82.00	136	[M]Mucino % BB%
Y	cancer	12497	BB82100	126	[M]Mucino % BB%
Y	cancer	30416	BB82111	10	[M]Colloid % BB%
Y	cancer	95008	BB82112	1	[M]Gelatin % BB%
Y	cancer	55429	BB82113	5	[M]Mucoïd % BB%
Y	cancer	59284	BB82114	11	[M]Mucou: % BB%
Y	cancer	44074	BB84.00	26	[M]Mucin-ï % BB%
Y	cancer	39038	BB85.00	74	[M]Signet r % BB%
Y	cancer	61588	BB85000	5	[M]Signet r % BB%
Y	cancer	54874	BB85100	1	[M]Metast: % BB%
Y	cancer	53694	BB85111	53	[M]Krukenl % BB%
Y	cancer	94438	BB85z00	2	[M]Signet r % BB%
Y	cancer	27728	BB90.00	188	[M]Intradu % BB%
Y	cancer	8351	BB91.00	802	[M]Infiltrat % BB%
Y	cancer	21833	BB91.11	775	[M]Duct ca % BB%
Y	cancer	30189	BB91000	74	[M]Intradu % BB%
Y	cancer	39760	BB91100	124	[M]Infiltrat % BB%
Y	cancer	62871	BB92.00	2	[M]Comedi % BB%
Y	cancer	58131	BB93.00	12	[M]Comedi % BB%
Y	cancer	40359	BB94.00	29	[M]Juvenil: % BB%
Y	cancer	67701	BB94.11	28	[M]Secreto % BB%
Y	cancer	102593	BB96.00	1	[M]Noninfi % BB%
Y	cancer	16677	BB9B.00	132	[M]Medull: % BB%
Y	cancer	47920	BB9B.11	15	[M]C cell c: % BB%
Y	cancer	50946	BB9C.00	5	[M]Medull: % BB%
Y	cancer	98883	BB9D.00	4	[M]Medull: % BB%
Y	cancer	21861	BB9E.00	80	[M]Lobular % BB%
Y	cancer	9956	BB9E000	282	[M]Intradu % BB%
Y	cancer	12427	BB9F.00	261	[M]Lobular % BB%
Y	cancer	7319	BB9G.00	211	[M]Infiltrat % BB%
Y	cancer	32472	BB9H.00	44	[M]Inflamn % BB%
Y	cancer	12300	BB9J.00	709	[M]Paget's % BB%
Y	cancer	60803	BB9J.11	37	[M]Paget's % BB%
Y	cancer	42542	BB9K.00	74	[M]Paget's % BB%
Y	cancer	12480	BB9K000	296	[M]Paget's % BB%
Y	cancer	24523	BB9L.00	196	[M]Paget's % BB%
Y	cancer	3969	BB9M.00	20	[M]Intracy: % BB%
Y	cancer	28178	BBa0.00	810	[M]Cranioç % BB%
Y	cancer	99949	BBa0.11	1	[M]Rathke' % BB%
Y	cancer	37688	BBA2.00	22	[M]Acinar ç % BB%
Y	cancer	50151	BBa3.00	16	[M]Pineobl % BB%
Y	cancer	12309	BBb..00	475	[M]Glioma: % BB%
Y	cancer	31574	BBb0.00	201	[M]Glioma, % BB%
Y	cancer	12580	BBB0.00	162	[M]Adenos % BB%
Y	cancer	8523	BBb0.11	3686	[M]Glioma % BB%

Y	cancer	34252	BBb0.12	52	[M]Gliosar % BB%
Y	cancer	38551	BBb1.00	30	[M]Glioma % BB%
Y	cancer	68808	BBb2.00	9	[M]Mixed ξ % BB%
Y	cancer	16146	BBB2.00	38	[M]Adenoc % BB%
Y	cancer	39386	BBb2.11	8	[M]Mixed ξ % BB%
Y	cancer	94267	BBb3.00	13	[M]Subepe % BB%
Y	cancer	42553	BBB3.00	17	[M]Adenoc % BB%
Y	cancer	90487	BBb3.11	5	[M]Subepe % BB%
Y	cancer	28344	BBb3.12	58	[M]Subepe % BB%
Y	cancer	50834	BBb3.13	37	[M]Subepe % BB%
Y	cancer	49168	BBb4.00	14	[M]Subepe % BB%
Y	cancer	94810	BBB4.00	1	[M]Adenoc % BB%
Y	cancer	66000	BBB5.00	6	[M]Adenoc % BB%
Y	cancer	59415	BBB6100	24	[M]Thymoi % BB%
Y	cancer	20084	BBb7.00	598	[M]Ependy % BB%
Y	cancer	38770	BBB7.00	4	[M]Epitheli % BB%
Y	cancer	52751	BBb8.00	32	[M]Ependy % BB%
Y	cancer	46769	BBb8.11	11	[M]Ependy % BB%
Y	cancer	70151	BBb9.00	4	[M]Papillar % BB%
Y	cancer	43114	BBbA.00	55	[M]Myxop % BB%
Y	cancer	107884	BBba000	1	[M]Periphe % BB%
Y	cancer	8547	BBbB.00	2949	[M]Astrocy % BB%
Y	cancer	27748	BBbB.11	121	[M]Astrocy % BB%
Y	cancer	8328	BBbC.00	304	[M]Astrocy % BB%
Y	cancer	45531	BBbE.00	32	[M]Gemist % BB%
Y	cancer	27846	BBbF.00	44	[M]Fibrillar % BB%
Y	cancer	30273	BBbG.00	319	[M]Pilocyti % BB%
Y	cancer	61783	BBbG.11	19	[M]Juvenil % BB%
Y	cancer	98800	BBbG.12	2	[M]Piloid a % BB%
Y	cancer	103047	BBbH.00	1	[M]Spongic % BB%
Y	cancer	50235	BBbK.00	4	[M]Astrobl % BB%
Y	cancer	23083	BBbL.00	770	[M]Gliobla % BB%
Y	cancer	9575	BBbL.11	3103	[M]Gliobla % BB%
Y	cancer	66064	BBbM.00	12	[M]Giant c % BB%
Y	cancer	27744	BBbQ.00	900	[M]Oligode % BB%
Y	cancer	49186	BBbR.00	105	[M]Oligode % BB%
Y	cancer	46404	BBbS.00	20	[M]Oligode % BB%
Y	cancer	34763	BBbT.00	449	[M]Medull % BB%
Y	cancer	65952	BBbU.00	9	[M]Desmo % BB%
Y	cancer	31767	BBbV.00	16	[M]Medull % BB%
Y	cancer	37473	BBbW.00	26	[M]Cerebel % BB%
Y	cancer	27653	BBbz.00	125	[M]Glioma % BB%
Y	cancer	67587	BBbZ.00	18	[M]Pleomo % BB%
Y	cancer	107681	BBc3.00	1	[M]Teratoi % BB%
Y	cancer	31609	BBC4.00	19	[M]Granul % BB%
Y	cancer	68479	BBc7.11	3	[M]Neuroa % BB%
Y	cancer	28836	BBc9.00	484	[M]Retinot % BB%
Y	cancer	103883	BBc9100	1	[M]Retinot % BB%
Y	cancer	48952	BBc9z00	78	[M]Retinot % BB%
Y	cancer	29580	BBCA.00	16	[M]Sertoli % BB%

Y	cancer	51878 BBcC.00	7 [M]Aesthe: % BB%
Y	cancer	39388 BBcC.11	42 [M]Olfacto % BB%
Y	cancer	95373 BBCC100	2 [M]Leydig c % BB%
Y	cancer	95818 BBD1.00	4 [M]Paragar % BB%
Y	cancer	27363 BBd2.00	18 [M]Mening % BB%
Y	cancer	60347 BBd2.11	6 [M]Leptom % BB%
Y	cancer	96798 BBd2.12	1 [M]Mening % BB%
Y	cancer	65047 BBDA.00	9 [M]Phaeoc % BB%
Y	cancer	106134 BBdB.00	1 [M]Mening % BB%
Y	cancer	50605 BBDB.00	3 [M]Glomar % BB%
Y	cancer	105166 BBDB.11	1 [M]Glomoi % BB%
Y	cancer	7693 BBE..00	2838 [M]Naevi a % BB%
Y	cancer	579 BBE1.00	8606 [M]Malign: % BB%
Y	cancer	24551 BBE1.11	48 [M]Melanc % BB%
Y	cancer	7483 BBE1.12	6745 [M]Melanc % BB%
Y	cancer	44157 BBE1.13	5 [M]Melanc % BB%
Y	cancer	67966 BBE1.14	3 [M]Naevoc % BB%
Y	cancer	51353 BBE1000	7 [M]Malign: % BB%
Y	cancer	58835 BBE1100	25 [M]Desmoj % BB%
Y	cancer	20982 BBE2.00	249 [M]Nodula % BB%
Y	cancer	62941 BBe2.00	10 [M]Neurofi % BB%
Y	cancer	68889 BBE4.00	[M]Balloon % BB%
Y	cancer	69981 BBe7.00	10 [M]Neurile % BB%
Y	cancer	37477 BBe7.11	46 [M]Schwan % BB%
Y	cancer	17292 BBE8.11	106 [M]Melanc % BB%
Y	cancer	40492 BBe9.00	13 [M]Triton t % BB%
Y	cancer	17232 BBEA.00	147 [M]Amelan % BB%
Y	cancer	63574 BBEC.00	10 [M]Malign: % BB%
Y	cancer	43189 BBED.00	29 [M]Precanc % BB%
Y	cancer	20709 BBEF.00	401 [M]Hutchir % BB%
Y	cancer	2705 BBEF.11	4754 [M]Lentigo % BB%
Y	cancer	62088 BBEG.00	34 [M]Malign: % BB%
Y	cancer	11922 BBEG.11	772 [M]Lentigo % BB%
Y	cancer	22692 BBEG000	110 [M]Acral le % BB%
Y	cancer	24208 BBEH.00	692 [M]Superfi: % BB%
Y	cancer	73251 BBEM.00	[M]Malign: % BB%
Y	cancer	23085 BBEP.00	2 [M]Epitheli % BB%
Y	cancer	44061 BBEQ.00	35 [M]Spindle % BB%
Y	cancer	92293 BBES.00	1 [M]Spindle % BB%
Y	cancer	40303 BBET.00	2 [M]Mixed e % BB%
Y	cancer	68447 BBEV.00	6 [M]Blue na % BB%
Y	cancer	39059 BBEX.00	83 [M]Melanc % BB%
Y	cancer	41803 BBf..00	47 [M]Granul: % BB%
Y	cancer	17366 BBF..00	279 [M]Soft tis: % BB%
Y	cancer	8085 BBF1.00	2759 [M]Sarcom % BB%
Y	cancer	34891 BBF2.00	29 [M]Sarcom % BB%
Y	cancer	71869 BBf2.00	11 [M]Alveola % BB%
Y	cancer	31026 BBF3.00	169 [M]Spindle % BB%
Y	cancer	97463 BBF4.00	3 [M]Giant c: % BB%
Y	cancer	46581 BBF4.11	121 [M]Pleomo % BB%

Y	cancer	58837	BBF5.00	13	[M]Small c α % BB%
Y	cancer	69844	BBF5.11	11	[M]Round r α % BB%
Y	cancer	62396	BBF6.00	24	[M]Epitheli α % BB%
Y	cancer	55116	BBFz.00	41	[M]Soft tisc α % BB%
Y	cancer	17178	BBg..00	484	[M]Lymphc α % BB%
Y	cancer	36114	BBg1.00	546	[M]Malign α % BB%
Y	cancer	31323	BBG1.00	154	[M]Fibrosa α % BB%
Y	cancer	1483	BBg1.11	12158	[M]Lymphc α % BB%
Y	cancer	23711	BBg1000	111	[M]Malign α % BB%
Y	cancer	16460	BBg2.00	480	[M]Malign α % BB%
Y	cancer	3371	BBg2.11	2964	[M]Non Ho α % BB%
Y	cancer	71117	BBg3.00	2	[M]Malign α % BB%
Y	cancer	8088	BBG3.00	16	[M]Fibrom α % BB%
Y	cancer	46931	BBg4.00	3	[M]Malign α % BB%
Y	cancer	69301	BBg5.00	1	[M]Malign α % BB%
Y	cancer	99655	BBg6.00	3	[M]Lymphc α % BB%
Y	cancer	41754	BBg7.00	51	[M]Malign α % BB%
Y	cancer	48253	BBg8.00	7	[M]Malign α % BB%
Y	cancer	95024	BBG8.00	3	[M]Infantil α % BB%
Y	cancer	94286	BBG8.11	3	[M]Congen α % BB%
Y	cancer	68964	BBgA.00	2	[M]Malign α % BB%
Y	cancer	41841	BBgB.00	11	[M]Malign α % BB%
Y	cancer	69980	BBgC.00	22	[M]Malign α % BB%
Y	cancer	21463	BBgC.11	249	[M]Lymphc α % BB%
Y	cancer	60504	BBgC.12	1	[M]Lymphc α % BB%
Y	cancer	51852	BBgD.00	1	[M]Malig ly α % BB%
Y	cancer	39906	BBgE.00	3	[M]Malign α % BB%
Y	cancer	37680	BBGF.00	127	[M]Fibrous α % BB%
Y	cancer	72196	BBgG.00	5	[M]Malign α % BB%
Y	cancer	67203	BBgG.11	7	[M]Lymphc α % BB%
Y	cancer	34352	BBgG.12	106	[M]Lymphc α % BB%
Y	cancer	52591	BBgG.13	12	[M]Lymphc α % BB%
Y	cancer	72241	BBgH.00	1	[M]Prolym α % BB%
Y	cancer	60275	BBgJ.00	8	[M]Malign α % BB%
Y	cancer	96231	BBGJ.00	6	[M]Fibroxa α % BB%
Y	cancer	108682	BBgJ.11	1	[M]Germin α % BB%
Y	cancer	35034	BBGJ.11	81	[M]Fibroxa α % BB%
Y	cancer	66603	BBgK.00	12	[M]Malig ly α % BB%
Y	cancer	46877	BBgL.00	37	[M]Malign α % BB%
Y	cancer	31726	BBgM.00	6	[M]Malign α % BB%
Y	cancer	31772	BBGM.00	142	[M]Dermat α % BB%
Y	cancer	61251	BBgN.00	2	[M]Malign α % BB%
Y	cancer	71652	BBgP.00	2	[M]Malign α % BB%
Y	cancer	31090	BBGP.00	19	[M]Pigmen α % BB%
Y	cancer	58015	BBgQ.00	9	[M]Malign α % BB%
Y	cancer	33869	BBgR.00	107	[M]Malign α % BB%
Y	cancer	63994	BBgS.00	1	[M]Malign α % BB%
Y	cancer	71619	BBgT.00	1	[M]Malign α % BB%
Y	cancer	51680	BBgV.00	8	[M]Malign α % BB%
Y	cancer	51895	BBgz.00	69	[M]Lymphc α % BB%

Y	cancer	106137 BBh..00	1 [M]Reticul% BB%
Y	cancer	72433 BBh0.00	3 [M]Reticul% BB%
Y	cancer	49825 BBh0.11	23 [M]Reticul% BB%
Y	cancer	21732 BBH1.00	36 [M]Myxosa% BB%
Y	cancer	100544 BBh2.00	1 [M]Reticul% BB%
Y	cancer	20710 BBj..00	749 [M]Hodgki% BB%
Y	cancer	61997 BBj0.00	26 [M]Hodgki% BB%
Y	cancer	101429 BBj0.11	1 [M]Lymphc% BB%
Y	cancer	56041 BBj1.00	9 [M]Hodgki% BB%
Y	cancer	28599 BBJ1.00	457 [M]Liposa% BB%
Y	cancer	101923 BBJ1.11	1 [M]Fibrolip% BB%
Y	cancer	65584 BBJ1000	4 [M]Hodgki% BB%
Y	cancer	31537 BBJ1100	9 [M]Hodgki% BB%
Y	cancer	51285 BBJ2.00	11 [M]Hodgki% BB%
Y	cancer	28628 BBJ3.00	68 [M]Liposa% BB%
Y	cancer	96183 BBJ4.00	1 [M]Hodgki% BB%
Y	cancer	56676 BBJ5.00	143 [M]Myxoid% BB%
Y	cancer	60127 BBJ5.12	5 [M]Myxoli% BB%
Y	cancer	42198 BBJ6.00	27 [M]Hodgki% BB%
Y	cancer	103708 BBJ6.00	1 [M]Round c% BB%
Y	cancer	40508 BBJ6000	4 [M]Hodgki% BB%
Y	cancer	64343 BBJ6100	9 [M]Hodgki% BB%
Y	cancer	31741 BBJ6200	2 [M]Hodgki% BB%
Y	cancer	99200 BBJ7.00	1 [M]Hodgki% BB%
Y	cancer	55947 BBJ7.00	28 [M]Pleomo% BB%
Y	cancer	59651 BBJ8.00	3 [M]Mixed t% BB%
Y	cancer	89230 BBJ9.00	1 [M]Hodgki% BB%
Y	cancer	7856 BBJH.00	333 [M]Dediffe% BB%
Y	cancer	42769 BBjz.00	10 [M]Hodgki% BB%
Y	cancer	20437 BBk..00	342 [M]Lymphc% BB%
Y	cancer	63699 BBk0.00	14 [M]Malign% BB%
Y	cancer	64947 BBk0.11	1 [M]Brill - S% BB%
Y	cancer	27562 BBk0.12	5 [M]Follicul% BB%
Y	cancer	49253 BBk0.13	11 [M]Giant fc% BB%
Y	cancer	10588 BBK0200	1551 [M]Leiomy% BB%
Y	cancer	56740 BBK0311	39 [M]Leiomy% BB%
Y	cancer	73916 BBK0400	8 [M]Epitheli% BB%
Y	cancer	64596 BBK0700	13 [M]Myxoid% BB%
Y	cancer	67019 BBK1100	2 [M]Angiom% BB%
Y	cancer	98961 BBk2.00	1 [M]Malign% BB%
Y	cancer	31818 BBK2.00	32 [M]Myoma% BB%
Y	cancer	55268 BBK2100	27 [M]Myosar% BB%
Y	cancer	106970 BBk3.00	2 [M]Malig ly% BB%
Y	cancer	31421 BBK3100	218 [M]Rhabdc% BB%
Y	cancer	57505 BBK3200	12 [M]Pleomo% BB%
Y	cancer	105944 BBK3300	1 [M]Mixed c% BB%
Y	cancer	48275 BBK3600	46 [M]Embryc% BB%
Y	cancer	63247 BBK3611	3 [M]Sarcom% BB%
Y	cancer	42082 BBK3700	33 [M]Alveola% BB%
Y	cancer	39883 BBk5.00	4 [M]Malig ly% BB%

Y	cancer	97852	BBk7.00	3	[M]Malignant % BB%
Y	cancer	58953	BBk8.00	1	[M]Malignant % BB%
Y	cancer	40513	BBkz.00	63	[M]Lymphatic % BB%
Y	cancer	46967	BBl..00	84	[M]Mycosis % BB%
Y	cancer	95464	BBl0.00	1	[M]Mycosis % BB%
Y	cancer	34030	BBL0.00	160	[M]Endometrial % BB%
Y	cancer	97756	BBl1.00	2	[M]Sezary's % BB%
Y	cancer	66607	BBL4.00	6	[M]Mixed tumor % BB%
Y	cancer	71161	BBL7.00	4	[M]Mixed tumor % BB%
Y	cancer	43703	BBL7.11	28	[M]Nephrotic % BB%
Y	cancer	54594	BBL7000	15	[M]Mesothelial % BB%
Y	cancer	21681	BBL7100	105	[M]Nephrotic % BB%
Y	cancer	36870	BBL7111	42	[M]Adenocarcinoma % BB%
Y	cancer	17314	BBL7112	706	[M]Wilms' tumor % BB%
Y	cancer	100371	BBL7200	3	[M]Epithelial % BB%
Y	cancer	105862	BBL7300	1	[M]Mesenchymal % BB%
Y	cancer	57677	BBL8.00	32	[M]Hepatic % BB%
Y	cancer	106889	BBL8.11	1	[M]Embryonal % BB%
Y	cancer	19334	BBL9.00	216	[M]Carcinoma % BB%
Y	cancer	67934	BBLA.00	6	[M]Carcinoma % BB%
Y	cancer	61082	BBLA.11	4	[M]Pneumonia % BB%
Y	cancer	87003	BBLC100	1	[M]Mesenchymal % BB%
Y	cancer	98797	BBLD.00	3	[M]Embryonal % BB%
Y	cancer	63518	BBLE.00	11	[M]Adenocarcinoma % BB%
Y	cancer	37510	BBLG.00	19	[M]Carcinoma % BB%
Y	cancer	17212	BBLH.00	137	[M]Rhabdomyosarcoma % BB%
Y	cancer	18771	BBLJ.00	65	[M]Clear cell % BB%
Y	cancer	48348	BBLM.00	16	[M]Pulmonary % BB%
Y	cancer	99695	BBlz.00	2	[M]Mycosis % BB%
Y	cancer	63973	BBm0.00	1	[M]Microglial % BB%
Y	cancer	71490	BBM0000	3	[M]Brenner % BB%
Y	cancer	70383	BBM0100	2	[M]Brenner % BB%
Y	cancer	63239	BBm1.00	7	[M]Malignant % BB%
Y	cancer	70740	BBm1.11	1	[M]Malignant % BB%
Y	cancer	59593	BBm3.00	13	[M]Letterer % BB%
Y	cancer	45768	BBm3.12	23	[M]Acute promyelocytic % BB%
Y	cancer	57544	BBm4.00	6	[M]True histiocytic % BB%
Y	cancer	40766	BBm5.00	166	[M]Peripheral % BB%
Y	cancer	39312	BBM8.00	25	[M]Cystosarcoma % BB%
Y	cancer	31492	BBm9.00	312	[M]Monoclonal % BB%
Y	cancer	59251	BBM9.00	15	[M]Cystosarcoma % BB%
Y	cancer	56756	BBmA.00	25	[M]Refractile % BB%
Y	cancer	60186	BBmB.00	4	[M]Refractile % BB%
Y	cancer	49530	BBmC.00	63	[M]T-gamma % BB%
Y	cancer	16774	BBmD.00	377	[M]Cutaneous % BB%
Y	cancer	52593	BBmE.00	4	[M]Gamma % BB%
Y	cancer	61146	BBmF.00	4	[M]Angiocarcinoma % BB%
Y	cancer	18383	BBmH.00	556	[M]Large cell % BB%
Y	cancer	68353	BBmJ.00	1	[M]Angioendothelioma % BB%
Y	cancer	9172	BBmK.00	1115	[M]Waldenstrom % BB%

Y	cancer	94921 BBmL.00	4 [M] Refract % BB%
Y	cancer	31671 BBn0.00	457 [M] Plasma % BB%
Y	cancer	18744 BBn0.11	442 [M] Multipl % BB%
Y	cancer	3672 BBn0.12	6647 [M] Myelon % BB%
Y	cancer	53647 BBn0.13	15 [M] Myelon % BB%
Y	cancer	39490 BBn0.14	36 [M] Plasma % BB%
Y	cancer	50379 BBN1.00	41 [M] Synovia % BB%
Y	cancer	105073 BBN2.00	1 [M] Synovia % BB%
Y	cancer	99702 BBn3.00	2 [M] Plasma % BB%
Y	cancer	57796 BBN4.00	5 [M] Synovia % BB%
Y	cancer	63286 BBN5.00	3 [M] Clear cε % BB%
Y	cancer	94239 BBp1.00	1 [M] Mast cε % BB%
Y	cancer	27509 BBP1.00	86 [M] Mesoth % BB%
Y	cancer	67339 BBp2.00	1 [M] Malignε % BB%
Y	cancer	104720 BBP3.11	8 [M] Sarcom % BB%
Y	cancer	47734 BBP5.00	32 [M] Epitheli % BB%
Y	cancer	86820 BBP7.00	5 [M] Mesoth % BB%
Y	cancer	21770 BBPX.00	828 [M] Mesoth % BB%
Y	cancer	7476 BBQ1.00	873 [M] Semino % BB%
Y	cancer	57084 BBQ1000	6 [M] Semino % BB%
Y	cancer	35223 BBQ1100	9 [M] Sperma % BB%
Y	cancer	9859 BBQ1z00	242 [M] Semino % BB%
Y	cancer	28941 BBQ3.00	66 [M] Embryc % BB%
Y	cancer	37621 BBQ4.00	23 [M] Endode % BB%
Y	cancer	104147 BBQ4.11	[M] Infantil % BB%
Y	cancer	55658 BBQ4.12	5 [M] Orchiot % BB%
Y	cancer	20350 BBQ4.14	57 [M] Yolk sac % BB%
Y	cancer	40449 BBQ6.00	12 [M] Gonadc % BB%
Y	cancer	33636 BBQ7200	92 [M] Terator % BB%
Y	cancer	57087 BBQ7211	2 [M] Embryc % BB%
Y	cancer	43865 BBQ7212	10 [M] Immatu % BB%
Y	cancer	52493 BBQ7213	20 [M] Teratot % BB%
Y	cancer	37542 BBQ7300	2 [M] Teratoc % BB%
Y	cancer	61542 BBQ7400	26 [M] Malignε % BB%
Y	cancer	21682 BBQ7500	15 [M] Malignε % BB%
Y	cancer	65861 BBQ9.00	6 [M] Dermoι % BB%
Y	cancer	71301 BBQA100	5 [M] Struma % BB%
Y	cancer	4637 BBr..00	694 [M] Leukaει % BB%
Y	cancer	40420 BBr0.00	5 [M] Leukaει % BB%
Y	cancer	41734 BBr0000	15 [M] Leukaει % BB%
Y	cancer	6316 BBr0100	227 [M] Acute lε % BB%
Y	cancer	22071 BBr0111	8 [M] Blast ce % BB%
Y	cancer	64963 BBr0112	11 [M] Blastic l % BB%
Y	cancer	63570 BBr0113	3 [M] Stem cε % BB%
Y	cancer	72179 BBr0200	1 [M] Subacu % BB%
Y	cancer	31750 BBr0300	100 [M] Chronic % BB%
Y	cancer	72310 BBr0400	1 [M] Aleukaε % BB%
Y	cancer	59929 BBr0z00	3 [M] Leukaει % BB%
Y	cancer	59409 BBR1.00	5 [M] Invasivε % BB%
Y	cancer	56538 BBR1.11	6 [M] Chorioε % BB%

Y	cancer	68211 BBR1.12	1 [M]Chorioœ % BB%
Y	cancer	47339 BBR1.13	10 [M]Invasivε % BB%
Y	cancer	48155 BBr2.00	17 [M]Lymphc % BB%
Y	cancer	67712 BBR2.00	8 [M]Chorioc % BB%
Y	cancer	12146 BBr2000	16 [M]Lymphc % BB%
Y	cancer	20635 BBr2011	28 [M]Lymphε % BB%
Y	cancer	37410 BBr2100	60 [M]Acute lγ % BB%
Y	cancer	41500 BBr2300	53 [M]Chronic % BB%
Y	cancer	46048 BBr2500	5 [M]Prolymγ % BB%
Y	cancer	50928 BBr2600	9 [M]Burkitt' % BB%
Y	cancer	29335 BBr2700	108 [M]Adult T- % BB%
Y	cancer	64618 BBr3.00	4 [M]Plasma % BB%
Y	cancer	54627 BBR3.00	5 [M]Chorioc % BB%
Y	cancer	46444 BBr4.00	17 [M]Erythro % BB%
Y	cancer	29945 BBR4.00	87 [M]Malignε % BB%
Y	cancer	70935 BBr4000	1 [M]Erythro % BB%
Y	cancer	100927 BBr4z00	1 [M]Erythro % BB%
Y	cancer	4873 BBR5.00	462 [M]Partial l % BB%
Y	cancer	35697 BBr6.00	41 [M]Myeloic % BB%
Y	cancer	88593 BBR6.00	9 [M]Placent % BB%
Y	cancer	71850 BBr6000	4 [M]Myeloic % BB%
Y	cancer	37723 BBr6011	47 [M]Granulc % BB%
Y	cancer	54585 BBr6100	48 [M]Acute n % BB%
Y	cancer	106483 BBr6200	1 [M]Subacu % BB%
Y	cancer	52942 BBr6300	19 [M]Chronic % BB%
Y	cancer	66694 BBr6311	1 [M]Naegeli % BB%
Y	cancer	57316 BBr6600	30 [M]Acute p % BB%
Y	cancer	46263 BBr6700	58 [M]Acute n % BB%
Y	cancer	48049 BBr6800	19 [M]Chronic % BB%
Y	cancer	108964 BBr6900	2 [M]Juvenilε % BB%
Y	cancer	62330 BBr6z00	2 [M]Other n % BB%
Y	cancer	28635 BBR7.00	85 [M]Classica % BB%
Y	cancer	106197 BBr7000	1 [M]Basoph % BB%
Y	cancer	57713 BBr8.00	2 [M]Eosinoç % BB%
Y	cancer	47989 BBR8.00	57 [M]Comple % BB%
Y	cancer	71377 BBr8000	1 [M]Eosinoç % BB%
Y	cancer	107773 BBr8z00	1 [M]Eosinoç % BB%
Y	cancer	73088 BBr9000	2 [M]Monocγ % BB%
Y	cancer	73066 BBrA.00	1 [M]Miscell: % BB%
Y	cancer	72222 BBrA100	1 [M]Megakε % BB%
Y	cancer	69299 BBrA111	1 [M]Thromt % BB%
Y	cancer	96893 BBrA300	4 [M]Myeloic % BB%
Y	cancer	93944 BBrA311	1 [M]Chloror % BB%
Y	cancer	98009 BBrA312	[M]Granulc % BB%
Y	cancer	5915 BBrA400	515 [M]Hairy cε % BB%
Y	cancer	49327 BBrA500	8 [M]Acute n % BB%
Y	cancer	102764 BBrA600	1 [M]Acute p % BB%
Y	cancer	37487 BBrA700	6 [M]Acute n % BB%
Y	cancer	108316 BBrAz00	2 [M]Miscell: % BB%
Y	cancer	42297 BBrz.00	93 [M]Leukaei % BB%

Y	cancer	96078 BBRz.00	5 [M]Tropho % BB%
Y	cancer	69462 BBS..00	2 [M]Mesone % BB%
Y	cancer	30139 BBS..00	34 [M]Misc m % BB%
Y	cancer	16922 BBS0.00	586 [M]Polycyt % BB%
Y	cancer	58888 BBS0.11	58 [M]Polycyt % BB%
Y	cancer	101271 BBS1.00	1 [M]Acute p % BB%
Y	cancer	17091 BBS2.00	185 [M]Chronic % BB%
Y	cancer	30043 BBS4.00	159 [M]Idiopat % BB%
Y	cancer	9673 BBS5.00	530 [M]Chronic % BB%
Y	cancer	37692 BBSz.00	47 [M]Misc m % BB%
Y	cancer	62348 BBT1.00	7 [M]Haema % BB%
Y	cancer	22650 BBT1.11	278 [M]Angios % BB%
Y	cancer	98322 BBT7100	1 [M]Haema % BB%
Y	cancer	27439 BBTA.00	323 [M]Kaposi' % BB%
Y	cancer	105296 BBTD200	3 [M]Haema % BB%
Y	cancer	38481 BBTK.00	8 [M]Epitheli % BB%
Y	cancer	57729 BBU1.00	6 [M]Lymph % BB%
Y	cancer	39522 BBV..00	53 [M]Osteor % BB%
Y	cancer	7799 BBv..00	2004 [M]Myelod % BB%
Y	cancer	99665 BBV..11	3 [M]Juxtaco % BB%
Y	cancer	63571 BBV..12	18 [M]Paroste % BB%
Y	cancer	105275 BBV..13	1 [M]Perioste % BB%
Y	cancer	31749 BBv0.00	16 [M]Monoc % BB%
Y	cancer	8660 BBV1.00	138 [M]Osteos % BB%
Y	cancer	49862 BBV1.11	41 [M]Osteob % BB%
Y	cancer	59310 BBV1.12	15 [M]Osteocl % BB%
Y	cancer	5052 BBV1.13	245 [M]Osteogr % BB%
Y	cancer	24539 BBV2.00	51 [M]Chondr % BB%
Y	cancer	27965 BBv2.00	21 [M]Angioc % BB%
Y	cancer	21447 BBV3.00	9 [M]Fibrobl % BB%
Y	cancer	22561 BBV4.00	168 [M]Telangi % BB%
Y	cancer	60631 BBV5.00	13 [M]Osteos % BB%
Y	cancer	4118 BBV9.00	339 [M]Myxoid % BB%
Y	cancer	29337 BBVA.00	76 [M] Small c % BB%
Y	cancer	7941 BBW4.00	151 [M]Chondr % BB%
Y	cancer	68220 BBW4.11	2 [M]Fibroch % BB%
Y	cancer	63659 BBW6.00	1 [M]Juxtaco % BB%
Y	cancer	98559 BBW8.00	1 [M]Chondr % BB%
Y	cancer	52684 BBW9.00	13 [M]Mesenc % BB%
Y	cancer	68956 BBX1.00	8 [M]Giant c % BB%
Y	cancer	50859 BBX1.11	6 [M]Giant c % BB%
Y	cancer	31673 BBX1.12	4 [M]Osteocl % BB%
Y	cancer	99797 BBX3.00	1 [M]Malign % BB%
Y	cancer	4473 BBY0.00	540 [M]Ewing's % BB%
Y	cancer	49023 BBY0.11	10 [M]Endoth % BB%
Y	cancer	72443 BBZ2.00	2 [M]Odonto % BB%
Y	cancer	93175 BBZ2.11	2 [M]Intraos % BB%
Y	cancer	46741 BBZC.00	2 [M]Amelot % BB%
Y	cancer	97593 BBZG.00	6 [M]Amelot % BB%
Y	cancer	100267 BBZG.11	4 [M]Adama % BB%

Y	cancer	68730	BBZN.00	23	[M]Amelot % BB%
Y	cancer	98483	BBZN.11	2	[M]Odonto % BB%
Y	cancer	58973	Byu0.00	36	[X]Maligna % Byu%
Y	cancer	35180	Byu1.00	172	[X]Maligna % Byu%
Y	cancer	43490	Byu1100	34	[X]Other sp % Byu%
Y	cancer	45766	Byu1200	10	[X]Maligna % Byu%
Y	cancer	49292	Byu1300	9	[X]Maligna % Byu%
Y	cancer	35325	Byu2.00	141	[X]Maligna % Byu%
Y	cancer	40595	Byu2000	89	[X]Maligna % Byu%
Y	cancer	66444	Byu2100	2	[X]Maligna % Byu%
Y	cancer	99096	Byu2300	1	[X]Maligna % Byu%
Y	cancer	86997	Byu2400	8	[X]Maligna % Byu%
Y	cancer	50292	Byu2500	4	[X]Maligna % Byu%
Y	cancer	40749	Byu3.00	8	[X]Maligna % Byu%
Y	cancer	73296	Byu3100	4	[X]Maligna % Byu%
Y	cancer	63300	Byu3200	1	[X]Maligna % Byu%
Y	cancer	43151	Byu3300	2	[X]Maligna % Byu%
Y	cancer	56925	Byu4000	31	[X]Maligna % Byu%
Y	cancer	19444	Byu4100	434	[X]Maligna % Byu%
Y	cancer	40592	Byu5.00	11	[X]Maligna % Byu%
Y	cancer	67034	Byu5000	11	[X]Mesothel % Byu%
Y	cancer	21715	Byu5011	274	[X]Mesothel % Byu%
Y	cancer	30526	Byu5100	41	[X]Mesothel % Byu%
Y	cancer	93665	Byu5300	6	[X]Kaposi's % Byu%
Y	cancer	101668	Byu5400	4	[X]Maligna % Byu%
Y	cancer	105072	Byu5500		[X]Mal neo % Byu%
Y	cancer	95671	Byu5700	9	[X]Maligna % Byu%
Y	cancer	91896	Byu5800	5	[X]Mal neo % Byu%
Y	cancer	91457	Byu5900	11	[X]Maligna % Byu%
Y	cancer	98361	Byu5B00	1	[X]Kaposi's % Byu%
Y	cancer	12499	Byu6.00	1021	[X]Maligna % Byu%
Y	cancer	40598	Byu7.00	115	[X]Maligna % Byu%
Y	cancer	64497	Byu7000	6	[X]Maligna % Byu%
Y	cancer	57756	Byu7100	8	[X]Maligna % Byu%
Y	cancer	55588	Byu7300	12	[X]Maligna % Byu%
Y	cancer	40671	Byu8.00	88	[X]Maligna % Byu%
Y	cancer	57191	Byu8000	4	[X]Maligna % Byu%
Y	cancer	45262	Byu8200	7	[X]Maligna % Byu%
Y	cancer	35113	Byu9.00	137	[X]Maligna % Byu%
Y	cancer	45260	Byu9000	8	[X]Maligna % Byu%
Y	cancer	35285	ByuA.00	117	[X]Maligna % Byu%
Y	cancer	68027	ByuA000	4	[X]Maligna % Byu%
Y	cancer	41515	ByuA100	59	[X]Maligna % Byu%
Y	cancer	63925	ByuA200	15	[X]Maligna % Byu%
Y	cancer	47633	ByuA300	38	[X]Maligna % Byu%
Y	cancer	40608	ByuB.00	182	[X]Maligna % Byu%
Y	cancer	64309	ByuB100	13	[X]Maligna % Byu%
Y	cancer	35186	ByuC.00	33	[X]Maligna % Byu%
Y	cancer	39027	ByuC000	89	[X]Maligna % Byu%
Y	cancer	96226	ByuC100	4	[X]Maligna % Byu%

Y	cancer	52029	ByuC800	70	[X]Maligna % Byu%
Y	cancer	40740	ByuD.00	41	[X]Maligna % Byu%
Y	cancer	43415	ByuD000	11	[X]Other H: % Byu%
Y	cancer	67518	ByuD100	4	[X]Other ty % Byu%
Y	cancer	98596	ByuD200	19	[X]Other ty % Byu%
Y	cancer	64336	ByuD300	16	[X]Other sp % Byu%
Y	cancer	102688	ByuD400	3	[X]Other m % Byu%
Y	cancer	67029	ByuD500	11	[X]Other ly % Byu%
Y	cancer	61693	ByuD600	13	[X]Other m % Byu%
Y	cancer	89762	ByuD700	1	[X]Other m % Byu%
Y	cancer	89329	ByuD800	6	[X]Other sp % Byu%
Y	cancer	65165	ByuD900	1	[X]Other le % Byu%
Y	cancer	105025	ByuDA00	3	[X]Oth spcf % Byu%
Y	cancer	72500	ByuDB00	6	[X]Mal neo % Byu%
Y	cancer	64515	ByuDC00	3	[X]Diffuse r % Byu%
Y	cancer	63375	ByuDE00	41	[X]Unspecii % Byu%
Y	cancer	8649	ByuDF00	400	[X]Non-Hor % Byu%
Y	cancer	7940	ByuDF11	383	[X]Non-Hor % Byu%
Y	cancer	63598	ByuE.00	22	[X]Maligna % Byu%
Y	cancer	64897	ByuE000	13	[X]Maligna % Byu%
Y	cancer	101772	ByuF.00	2	[X]In situ n: % Byu%
Y	cancer	102708	ByuF100	1	[X]Carcinor % Byu%
Y	cancer	100781	ByuF300	1	[X]Carcinor % Byu%
Y	cancer	97628	ByuF600	4	[X]Melanor % Byu%
Y	cancer	72695	ByuFA00	11	[X]Carcinor % Byu%
Y	cancer	106003	ByuFC00	2	[X]Carcinor % Byu%
Y	cancer	73261	ByuFF00	6	[X]Melanor % Byu%
Y	cancer	53803	ByuFG00	91	[X]Other ca % Byu%
Y	cancer	45143	ByuHD00	6	[X]Myelody % Byu%
Y	cancer	30537	F373.00	14	Polyneuroç % F373%
Y	cancer	57551	F381100	2	Myasthenic % F3811%
Y	cancer	49482	F396200	3	Myopathy % F3962%
Y	cancer	7593	H51y700	2911	Malignant j % H51y7%
Y	cancer	108591	K01w100	1	Drash synd % K01w1%
Y	cancer	108922	K01w112	1	Wilms' tur % K01w1%
Y	cancer	60433	N330900	17	Osteopor: % N3309%
Y	cerebrovascular diseas	41577	1477	237	H/O: cereb % 1477%
Y	cerebrovascular diseas	31941	A94y600	25	Rupture of % A94y6%
Y	cerebrovascular diseas	25114	E030400	204	Acute confi % E0304%
Y	cerebrovascular diseas	24035	E031400	87	Subacute c % E0314%
Y	cerebrovascular diseas	54744	F11x200	31	Cerebral de % F11x2%
Y	cerebrovascular diseas	1195	F423600	13554	Amaurosis % F4236%
Y	cerebrovascular diseas	50242	F423700	27	Retinal trar % F4237%
Y	cerebrovascular diseas	39309	F481400	60	Other tran: % F4814%
Y	cerebrovascular diseas	63746	Fyu5500	15	[X]Other tr % Fyu55%
Y	cerebrovascular diseas	95347	Fyu5700	3	[X]Other va % Fyu57%
Y	cerebrovascular diseas	2418	G6...00	176976	Cerebrovas % G6%
Y	cerebrovascular diseas	1786	G60..00	24230	Subarachnc % G6%
Y	cerebrovascular diseas	29939	G600.00	321	Ruptured b % G6%
Y	cerebrovascular diseas	56007	G601.00	4	Subarachnc % G6%

Y	cerebrovascular diseas	19412 G602.00	307 Subarachn(% G6%
Y	cerebrovascular diseas	42331 G603.00	121 Subarachn(% G6%
Y	cerebrovascular diseas	9696 G604.00	63 Subarachn(% G6%
Y	cerebrovascular diseas	41910 G605.00	54 Subarachn(% G6%
Y	cerebrovascular diseas	60692 G606.00	8 Subarachn(% G6%
Y	cerebrovascular diseas	17326 G60X.00	174 Subarachn(% G6%
Y	cerebrovascular diseas	23580 G60z.00	700 Subarachn(% G6%
Y	cerebrovascular diseas	5051 G61..00	12806 Intracerebr % G6%
Y	cerebrovascular diseas	6960 G61..11	10213 CVA - ceret % G6%
Y	cerebrovascular diseas	18604 G61..12	1711 Stroke due % G6%
Y	cerebrovascular diseas	31595 G610.00	104 Cortical ha % G6%
Y	cerebrovascular diseas	40338 G611.00	172 Internal ca % G6%
Y	cerebrovascular diseas	46316 G612.00	90 Basal nucle % G6%
Y	cerebrovascular diseas	13564 G613.00	1366 Cerebellar % G6%
Y	cerebrovascular diseas	7912 G614.00	284 Pontine ha % G6%
Y	cerebrovascular diseas	62342 G615.00	11 Bulbar haei % G6%
Y	cerebrovascular diseas	30045 G616.00	25 External ca % G6%
Y	cerebrovascular diseas	30202 G617.00	602 Intracerebr % G6%
Y	cerebrovascular diseas	57315 G618.00	28 Intracerebr % G6%
Y	cerebrovascular diseas	107440 G619.00	27 Lobar cerel % G6%
Y	cerebrovascular diseas	31060 G61X.00	89 Intracerebr % G6%
Y	cerebrovascular diseas	28314 G61X000	189 Left sided i % G6%
Y	cerebrovascular diseas	19201 G61X100	168 Right sided % G6%
Y	cerebrovascular diseas	3535 G61z.00	1757 Intracerebr % G6%
Y	cerebrovascular diseas	31805 G62..00	146 Other and i % G6%
Y	cerebrovascular diseas	36178 G620.00	170 Extradural % G6%
Y	cerebrovascular diseas	4273 G621.00	2089 Subdural h: % G6%
Y	cerebrovascular diseas	17734 G622.00	2676 Subdural h: % G6%
Y	cerebrovascular diseas	18912 G623.00	2725 Subdural h: % G6%
Y	cerebrovascular diseas	20284 G62z.00	567 Intracrania % G6%
Y	cerebrovascular diseas	45781 G63..00	333 Precerebra % G6%
Y	cerebrovascular diseas	57495 G63..11	35 Infarction - % G6%
Y	cerebrovascular diseas	63830 G63..12	6 Stenosis of % G6%
Y	cerebrovascular diseas	32447 G630.00	133 Basilar arte % G6%
Y	cerebrovascular diseas	4240 G631.00	1911 Carotid art: % G6%
Y	cerebrovascular diseas	2156 G631.11	3261 Stenosis, c: % G6%
Y	cerebrovascular diseas	4152 G631.12	159 Thrombosi: % G6%
Y	cerebrovascular diseas	40847 G632.00	174 Vertebral a % G6%
Y	cerebrovascular diseas	98642 G633.00	3 Multiple ar % G6%
Y	cerebrovascular diseas	2652 G634.00	10585 Carotid art: % G6%
Y	cerebrovascular diseas	51326 G63y.00	35 Other prec: % G6%
Y	cerebrovascular diseas	23671 G63y000	1085 Cerebral in % G6%
Y	cerebrovascular diseas	24446 G63y100	268 Cerebral in % G6%
Y	cerebrovascular diseas	71585 G63z.00	38 Precerebra % G6%
Y	cerebrovascular diseas	8837 G64..00	17994 Cerebral ar % G6%
Y	cerebrovascular diseas	5363 G64..11	22594 CVA - ceret % G6%
Y	cerebrovascular diseas	569 G64..12	3749 Infarction - % G6%
Y	cerebrovascular diseas	6155 G64..13	3898 Stroke due % G6%
Y	cerebrovascular diseas	16517 G640.00	3123 Cerebral th % G6%
Y	cerebrovascular diseas	36717 G640000	742 Cerebral in % G6%

Y	cerebrovascular diseas	15019 G641.00	1199 Cerebral er % G6%
Y	cerebrovascular diseas	34758 G641.11	64 Cerebral er % G6%
Y	cerebrovascular diseas	27975 G641000	174 Cerebral in % G6%
Y	cerebrovascular diseas	3149 G64z.00	22419 Cerebral in % G6%
Y	cerebrovascular diseas	15252 G64z.11	366 Brainstem i % G6%
Y	cerebrovascular diseas	5602 G64z.12	5604 Cerebellar % G6%
Y	cerebrovascular diseas	25615 G64z000	636 Brainstem i % G6%
Y	cerebrovascular diseas	47642 G64z100	38 Wallenberg % G6%
Y	cerebrovascular diseas	5185 G64z111	234 Lateral mer % G6%
Y	cerebrovascular diseas	9985 G64z200	1632 Left sided c % G6%
Y	cerebrovascular diseas	10504 G64z300	1657 Right sided % G6%
Y	cerebrovascular diseas	26424 G64z400	889 Infarction c % G6%
Y	cerebrovascular diseas	504 G65..00	164860 Transient c % G6%
Y	cerebrovascular diseas	3132 G65..11	4454 Drop attac % G6%
Y	cerebrovascular diseas	1433 G65..12	136579 Transient is % G6%
Y	cerebrovascular diseas	2417 G65..13	7554 Vertebro-b % G6%
Y	cerebrovascular diseas	23942 G650.00	1015 Basilar arte % G6%
Y	cerebrovascular diseas	5268 G650.11	4812 Insufficienc % G6%
Y	cerebrovascular diseas	33377 G651.00	159 Vertebral a % G6%
Y	cerebrovascular diseas	21118 G651000	1009 Vertebro-b % G6%
Y	cerebrovascular diseas	23465 G652.00	433 Subclavian % G6%
Y	cerebrovascular diseas	44765 G653.00	57 Carotid arti % G6%
Y	cerebrovascular diseas	50594 G654.00	5 Multiple ar % G6%
Y	cerebrovascular diseas	6489 G655.00	1574 Transient g % G6%
Y	cerebrovascular diseas	10794 G656.00	1886 Vertebroba % G6%
Y	cerebrovascular diseas	105738 G657.00	5 Carotid ter % G6%
Y	cerebrovascular diseas	19354 G65y.00	194 Other tran % G6%
Y	cerebrovascular diseas	1895 G65z.00	1743 Transient c % G6%
Y	cerebrovascular diseas	55247 G65z000	15 Impending % G6%
Y	cerebrovascular diseas	16507 G65z100	172 Intermittent % G6%
Y	cerebrovascular diseas	15788 G65z00	5876 Transient c % G6%
Y	cerebrovascular diseas	1469 G66..00	207537 Stroke and % G6%
Y	cerebrovascular diseas	1298 G66..11	102049 CVA unsp % G6%
Y	cerebrovascular diseas	6253 G66..12	4109 Stroke unsp % G6%
Y	cerebrovascular diseas	6116 G66..13	14511 CVA - Cerel % G6%
Y	cerebrovascular diseas	18689 G660.00	458 Middle cer % G6%
Y	cerebrovascular diseas	19280 G661.00	265 Anterior ce % G6%
Y	cerebrovascular diseas	19260 G662.00	308 Posterior c % G6%
Y	cerebrovascular diseas	8443 G663.00	1123 Brain stem % G6%
Y	cerebrovascular diseas	17322 G664.00	1312 Cerebellar % G6%
Y	cerebrovascular diseas	33499 G665.00	341 Pure moto % G6%
Y	cerebrovascular diseas	51767 G666.00	109 Pure senso % G6%
Y	cerebrovascular diseas	7780 G667.00	4327 Left sided C % G6%
Y	cerebrovascular diseas	12833 G668.00	3859 Right sided % G6%
Y	cerebrovascular diseas	16956 G669.00	443 Cerebral p % G6%
Y	cerebrovascular diseas	13577 G67..00	671 Other cerel % G6%
Y	cerebrovascular diseas	11171 G670.00	1717 Cerebral at % G6%
Y	cerebrovascular diseas	5184 G670.11	195 Precerebra % G6%
Y	cerebrovascular diseas	40053 G671.00	186 Generaliser % G6%
Y	cerebrovascular diseas	70536 G671000	11 Acute cerel % G6%

Y	cerebrovascular diseas	24385 G671100	641 Chronic cer % G6%
Y	cerebrovascular diseas	12555 G671z00	142 Generaliser % G6%
Y	cerebrovascular diseas	4635 G673.00	1976 Cerebral ar % G6%
Y	cerebrovascular diseas	22018 G673000	75 Dissection % G6%
Y	cerebrovascular diseas	35059 G673100	88 Carotico-ca % G6%
Y	cerebrovascular diseas	12634 G673200	379 Carotid art % G6%
Y	cerebrovascular diseas	97122 G673300	121 Vertebral a % G6%
Y	cerebrovascular diseas	22400 G674.00	134 Cerebral ar % G6%
Y	cerebrovascular diseas	10189 G674000	208 Cerebral ar % G6%
Y	cerebrovascular diseas	32310 G675.00	201 Moyamoya % G6%
Y	cerebrovascular diseas	37947 G676.00	334 Nonpyoger % G6%
Y	cerebrovascular diseas	39344 G676000	196 Cereb infar % G6%
Y	cerebrovascular diseas	31704 G677.00	29 Occlusion/ % G6%
Y	cerebrovascular diseas	51759 G677000	72 Occlusion æ % G6%
Y	cerebrovascular diseas	57527 G677100	16 Occlusion æ % G6%
Y	cerebrovascular diseas	65770 G677200	9 Occlusion æ % G6%
Y	cerebrovascular diseas	55602 G677300	34 Occlusion æ % G6%
Y	cerebrovascular diseas	71274 G677400	3 Occlusion+ % G6%
Y	cerebrovascular diseas	9943 G678.00	175 Cereb auto % G6%
Y	cerebrovascular diseas	98188 G679.00	3536 Small vesse % G6%
Y	cerebrovascular diseas	101733 G67A.00	91 Cerebral ve % G6%
Y	cerebrovascular diseas	34117 G67y.00	98 Other cerel % G6%
Y	cerebrovascular diseas	37493 G67z.00	410 Other cerel % G6%
Y	cerebrovascular diseas	23361 G68..00	489 Late effect: % G6%
Y	cerebrovascular diseas	44740 G680.00	32 Sequelae o % G6%
Y	cerebrovascular diseas	48149 G681.00	30 Sequelae o % G6%
Y	cerebrovascular diseas	43451 G682.00	127 Sequelae o % G6%
Y	cerebrovascular diseas	39403 G683.00	112 Sequelae o % G6%
Y	cerebrovascular diseas	51138 G68W.00	20 Sequelae/c % G6%
Y	cerebrovascular diseas	6228 G68X.00	358 Sequelae o % G6%
Y	cerebrovascular diseas	40758 G6W..00	288 Cereb infar % G6%
Y	cerebrovascular diseas	33543 G6X..00	1707 Cerebrl inf: % G6%
Y	cerebrovascular diseas	51311 G6y..00	87 Other spec % G6%
Y	cerebrovascular diseas	10062 G6z..00	2546 Cerebrovas % G6%
Y	cerebrovascular diseas	73901 Gyu6.00	31 [X]Cerebro % Gyu6%
Y	cerebrovascular diseas	108668 Gyu6000	1 [X]Subarac l % Gyu6%
Y	cerebrovascular diseas	65745 Gyu6100	7 [X]Other su % Gyu6%
Y	cerebrovascular diseas	53810 Gyu6200	25 [X]Other in % Gyu6%
Y	cerebrovascular diseas	91627 Gyu6300	57 [X]Cerebrl i % Gyu6%
Y	cerebrovascular diseas	53745 Gyu6400	365 [X]Other ce % Gyu6%
Y	cerebrovascular diseas	90572 Gyu6500	14 [X]Occlusio % Gyu6%
Y	cerebrovascular diseas	92036 Gyu6600	28 [X]Occlusio % Gyu6%
Y	cerebrovascular diseas	99367 Gyu6A00	1 [X]Other ce % Gyu6%
Y	cerebrovascular diseas	108630 Gyu6E00	1 [X]Subarac l % Gyu6%
Y	cerebrovascular diseas	96630 Gyu6F00	6 [X]Intracere % Gyu6%
Y	cerebrovascular diseas	94482 Gyu6G00	36 [X]Cereb in % Gyu6%
Y	cerebrovascular diseas	42335 L440.00	21 Cerebrovas % L440%
Y	cerebrovascular diseas	47607 L440.11	73 CVA - ceret % L440%
Y	cerebrovascular diseas	56279 L440.12	9 Stroke in th % L440%
Y	cerebrovascular diseas	67640 L440000	10 Puerperal c % L440%

Y	cerebrovascular diseas	97470 L440100	1 Puerperal c % L440%
Y	cerebrovascular diseas	91272 L440300	Puerperal c % L440%
Y	cerebrovascular diseas	3608 R014.00	748 [D]Transier % R014%
Y	cerebrovascular diseas	29657 R014000	104 [D]Transier % R014%
Y	cerebrovascular diseas	41513 R014z00	20 [D]Transier % R014%
Y	cerebrovascular diseas	19348 ZV12511	528 [V]Persona % ZV125%
Y	cerebrovascular diseas	7138 ZV12512	505 [V]Persona % ZV125%
Y	cerebrovascular diseas	101251 ZV12D00	187 [V]Persona % ZV12D%
Y	Chronic pulmonary dis	5867 173A.00	41362 Exercise inr % 173A.%, %asthma%
Y	Chronic pulmonary dis	22752 173c.00	483 Occupatio %asthma%
Y	Chronic pulmonary dis	73522 173d.00	135 Work aggr %asthma%
Y	Chronic pulmonary dis	11022 178..00	54594 Asthma tri %asthma%
Y	Chronic pulmonary dis	41017 1780	195 Aspirin ind %asthma%
Y	Chronic pulmonary dis	102341 1781	12925 Asthma tri %asthma%
Y	Chronic pulmonary dis	103955 1782	3570 Asthma tri %asthma%
Y	Chronic pulmonary dis	102952 1783	4859 Asthma tri %asthma%
Y	Chronic pulmonary dis	103952 1784	3909 Asthma tri %asthma%
Y	Chronic pulmonary dis	103945 1785	5279 Asthma tri %asthma%
Y	Chronic pulmonary dis	103321 1786	7919 Asthma tri %asthma%
Y	Chronic pulmonary dis	102301 1787	7685 Asthma tri %asthma%
Y	Chronic pulmonary dis	103813 1788	12624 Asthma tri %asthma%
Y	Chronic pulmonary dis	102449 1789	20800 Asthma tri %asthma%
Y	Chronic pulmonary dis	103944 178A.00	8847 Asthma tri %asthma%
Y	Chronic pulmonary dis	102871 178B.00	11486 Asthma tri %asthma%
Y	Chronic pulmonary dis	11370 102..00	9495 Asthma coi % 102.%, %asthma%
Y	Chronic pulmonary dis	24479 663d.00	2696 Emergency %asthma%
Y	Chronic pulmonary dis	25181 663e.00	17662 Asthma res %asthma%
Y	Chronic pulmonary dis	26861 6.63E+02	80881 Asthma sor %asthma%
Y	Chronic pulmonary dis	26506 6.63E+102	5160 Asthma sev %asthma%
Y	Chronic pulmonary dis	26504 663f.00	113917 Asthma ne %asthma%
Y	Chronic pulmonary dis	13066 663h.00	16248 Asthma - ci %asthma%
Y	Chronic pulmonary dis	10487 663j.00	10786 Asthma - ci %asthma%
Y	Chronic pulmonary dis	47337 663m.00	7920 Asthma acc %asthma%
Y	Chronic pulmonary dis	19520 663n.00	177323 Asthma tre %asthma%
Y	Chronic pulmonary dis	7416 663N.00	96182 Asthma dis %asthma%
Y	Chronic pulmonary dis	30815 663N000	23100 Asthma cai %asthma%
Y	Chronic pulmonary dis	38146 663N100	11155 Asthma dis %asthma%
Y	Chronic pulmonary dis	13175 663N200	10612 Asthma dis %asthma%
Y	Chronic pulmonary dis	13173 663O.00	618716 Asthma no %asthma%
Y	Chronic pulmonary dis	38143 663O000	100764 Asthma ne %asthma%
Y	Chronic pulmonary dis	19519 663p.00	28851 Asthma tre %asthma%
Y	Chronic pulmonary dis	7191 663P.00	108475 Asthma lim %asthma%
Y	Chronic pulmonary dis	102713 663P000	1782 Asthma lim %asthma%
Y	Chronic pulmonary dis	102888 663P100	2139 Asthma lim %asthma%
Y	Chronic pulmonary dis	103998 663P200	2311 Asthma lim %asthma%
Y	Chronic pulmonary dis	13174 663Q.00	596742 Asthma no %asthma%
Y	Chronic pulmonary dis	42824 663q.00	430916 Asthma da %asthma%
Y	Chronic pulmonary dis	39570 663r.00	23147 Asthma cai %asthma%
Y	Chronic pulmonary dis	26501 663s.00	235197 Asthma ne %asthma%
Y	Chronic pulmonary dis	31225 663t.00	73310 Asthma cai %asthma%

Y	Chronic pulmonary dis	24884	663u.00	68307	Asthma cat %asthma%
Y	Chronic pulmonary dis	7378	663U.00	512103	Asthma ma %asthma%
Y	Chronic pulmonary dis	13064	663V.00	183308	Asthma sev %asthma%
Y	Chronic pulmonary dis	26503	663v.00	77652	Asthma cat %asthma%
Y	Chronic pulmonary dis	3458	663V000	9548	Occasional %asthma%
Y	Chronic pulmonary dis	3018	663V100	17921	Mild asthm %asthma%
Y	Chronic pulmonary dis	13065	663V200	11620	Moderate i %asthma%
Y	Chronic pulmonary dis	3366	663V300	2338	Severe astf %asthma%
Y	Chronic pulmonary dis	38144	663w.00	21056	Asthma lim %asthma%
Y	Chronic pulmonary dis	7229	663W.00	24287	Asthma prc %asthma%
Y	Chronic pulmonary dis	38145	663x.00	3567	Asthma lim %asthma%
Y	Chronic pulmonary dis	9018	663y.00	44444	Number of %asthma%
Y	Chronic pulmonary dis	9552	66Y5.00	7758	Change in e %asthma%
Y	Chronic pulmonary dis	9663	66Y9.00	20072	Step up ch %asthma%
Y	Chronic pulmonary dis	18223	66YA.00	9764	Step down %asthma%
Y	Chronic pulmonary dis	41020	66YC.00	5054	Absent fro %asthma%
Y	Chronic pulmonary dis	10043	66YJ.00	2287342	Asthma an %asthma%
Y	Chronic pulmonary dis	13176	66YK.00	773267	Asthma fol %asthma%
Y	Chronic pulmonary dis	102170	66Yp.00	9092	Asthma rev %asthma%
Y	Chronic pulmonary dis	31167	66YP.00	23194	Asthma nig %asthma%
Y	Chronic pulmonary dis	102400	66Yq.00	11002	Asthma ca %asthma%
Y	Chronic pulmonary dis	102395	66Yr.00	10325	Asthma ca %asthma%
Y	Chronic pulmonary dis	103612	66Ys.00	5023	Asthma ne % 66YS%, %asthma%
Y	Chronic pulmonary dis	107167	66Yu.00	3	Number da %asthma%
Y	Chronic pulmonary dis	24506	8791	215	Further ast %asthma%
Y	Chronic pulmonary dis	29645	8793	13601	Asthma cor %asthma%
Y	Chronic pulmonary dis	16785	8794	54553	Asthma cor %asthma%
Y	Chronic pulmonary dis	16667	8795	118979	Asthma cor %asthma%
Y	Chronic pulmonary dis	18224	8796	84932	Asthma cor %asthma%
Y	Chronic pulmonary dis	20886	8797	9200	Asthma cor %asthma%
Y	Chronic pulmonary dis	20860	8798	1243	Asthma cor %asthma%
Y	Chronic pulmonary dis	10274	8B3j.00	577570	Asthma me %asthma%
Y	Chronic pulmonary dis	25791	8CR0.00	2736	Asthma clir %asthma%
Y	Chronic pulmonary dis	5515	9N1d.00	192493	Seen in ast %asthma%
Y	Chronic pulmonary dis	6181	H061400	72	Obliteratin % H0614%
Y	Chronic pulmonary dis	26125	H312300	158	Bronchiolit % H3%
Y	Chronic pulmonary dis	70787	H32y100	3	Atrophic (s % H3%
Y	Chronic pulmonary dis	78	H33..00	4064442	Asthma % H3%, %asthma%
Y	Chronic pulmonary dis	1555	H33..11	49071	Bronchial a % H3%, %asthma%
Y	Chronic pulmonary dis	7146	H330.00	19977	Extrinsic (a % H3%, %asthma%
Y	Chronic pulmonary dis	2290	H330.11	13147	Allergic ast % H3%, %asthma%
Y	Chronic pulmonary dis	1208	H330.12	18729	Childhood i % H3%, %asthma%
Y	Chronic pulmonary dis	15248	H330.13	4994	Hay fever v % H3%, %asthma%
Y	Chronic pulmonary dis	7731	H330.14	2849	Pollen asth % H3%, %asthma%
Y	Chronic pulmonary dis	14777	H330000	2443	Extrinsic as % H3%, %asthma%
Y	Chronic pulmonary dis	5627	H330011	5936	Hay fever v % H3%, %asthma%
Y	Chronic pulmonary dis	27926	H330100	219	Extrinsic as % H3%, %asthma%
Y	Chronic pulmonary dis	6707	H330111	2652	Extrinsic as % H3%, %asthma%
Y	Chronic pulmonary dis	45782	H330z00	932	Extrinsic as % H3%, %asthma%
Y	Chronic pulmonary dis	5267	H331.00	9031	Intrinsic asi % H3%, %asthma%

Y	Chronic pulmonary dis	3665 H331.11	4700 Late onset % H3%, %asthma%
Y	Chronic pulmonary dis	29325 H331000	394 Intrinsic ast % H3%, %asthma%
Y	Chronic pulmonary dis	58196 H331100	79 Intrinsic ast % H3%, %asthma%
Y	Chronic pulmonary dis	18323 H331111	134 Intrinsic ast % H3%, %asthma%
Y	Chronic pulmonary dis	45073 H331z00	374 Intrinsic ast % H3%, %asthma%
Y	Chronic pulmonary dis	25796 H332.00	840 Mixed asth % H3%, %asthma%
Y	Chronic pulmonary dis	40823 H334.00	726 Brittle asth % H3%, %asthma%
Y	Chronic pulmonary dis	4442 H33z.00	39657 Asthma un: % H3%, %asthma%
Y	Chronic pulmonary dis	32727 H33z.11	622 Hyperreact % H3%
Y	Chronic pulmonary dis	4892 H33z000	3572 Status asth % H3%, %asthma%
Y	Chronic pulmonary dis	233 H33z011	25060 Severe astf % H3%, %asthma%
Y	Chronic pulmonary dis	232 H33z100	85236 Asthma att % H3%, %asthma%
Y	Chronic pulmonary dis	8335 H33z111	2046 Asthma att % H3%, %asthma%
Y	Chronic pulmonary dis	12987 H33z200	2776 Late-onset % H3%, %asthma%
Y	Chronic pulmonary dis	16070 H33zz00	119714 Asthma NC % H3%, %asthma%
Y	Chronic pulmonary dis	4606 H33zz11	6425 Exercise inc % H3%, %asthma%
Y	Chronic pulmonary dis	21232 H33zz12	152 Allergic ast % H3%, %asthma%
Y	Chronic pulmonary dis	18207 H33zz13	667 Allergic brc % H3%
Y	Chronic pulmonary dis	2195 H34..00	82434 Bronchiect: % H3%
Y	Chronic pulmonary dis	20364 H340.00	389 Recurrent l % H3%
Y	Chronic pulmonary dis	41491 H341.00	88 Post-infect % H3%
Y	Chronic pulmonary dis	32679 H34z.00	1818 Bronchiect: % H3%
Y	Chronic pulmonary dis	93353 H35y600	1 Sequoiosis % H3%, %asthma%
Y	Chronic pulmonary dis	39478 H35y700	5 Wood asth % H3%, %asthma%
Y	Chronic pulmonary dis	25013 H4...11	1078 Pneumoco: % H4..%
Y	Chronic pulmonary dis	21257 H4...12	135 Occupatio: % H4..%
Y	Chronic pulmonary dis	19492 H40..00	194 Coal worke % H40%
Y	Chronic pulmonary dis	8303 H41..00	4998 Asbestosis % H41%
Y	Chronic pulmonary dis	5005 H410.00	2654 Pleural plar % H41%
Y	Chronic pulmonary dis	100994 H410.11	837 Asbestos-ir % H41%
Y	Chronic pulmonary dis	51410 H41z.00	76 Asbestosis % H41%
Y	Chronic pulmonary dis	46460 H42..00	51 Silica and s % H42%
Y	Chronic pulmonary dis	60805 H420.00	4 Talc pneur % H42%
Y	Chronic pulmonary dis	62233 H421.00	33 Simple silic % H42%
Y	Chronic pulmonary dis	71853 H422.00	5 Complicate % H42%
Y	Chronic pulmonary dis	89206 H423.00	4 Massive sil: % H42%
Y	Chronic pulmonary dis	23446 H42z.00	73 Silica pneu: % H42%
Y	Chronic pulmonary dis	65376 H43..00	16 Pneumoco: % H43%
Y	Chronic pulmonary dis	94894 H431.00	1 Bauxite fib: % H43%
Y	Chronic pulmonary dis	49194 H432.00	11 Berylliosis % H43%
Y	Chronic pulmonary dis	94575 H433.00	1 Graphite fil % H43%
Y	Chronic pulmonary dis	30235 H434.00	108 Siderosis % H43%
Y	Chronic pulmonary dis	93577 H435.00	61 Stannosis % H43%
Y	Chronic pulmonary dis	23461 H43z.00	434 Pneumoco: % H43%
Y	Chronic pulmonary dis	60313 H44..00	1 Pneumopa: % H44%
Y	Chronic pulmonary dis	37365 H440.00	297 Byssinosis % H44%
Y	Chronic pulmonary dis	26442 H441.00	158 Cannabino: % H44%
Y	Chronic pulmonary dis	73414 H44z.00	2 Pneumopa: % H44%
Y	Chronic pulmonary dis	31423 H45..00	908 Pneumoco: % H45%
Y	Chronic pulmonary dis	63172 H450.00	4 Pneumoco: % H45%

Y	Chronic pulmonary dis	47142 H464.00	21 Chronic res % H464%
Y	Chronic pulmonary dis	64721 H464000	5 Chronic em % H464%
Y	Chronic pulmonary dis	63216 H464100	3 Obliterativ % H464%
Y	Chronic pulmonary dis	47782 H464200	86 Chronic pul % H464%
Y	Chronic pulmonary dis	70815 H464z00	2 Chronic res % H464%
Y	Chronic pulmonary dis	47684 H47y000	27 Detergent ;%asthma%
Y	Chronic pulmonary dis	69914 H4y1.00	5 Chronic pul % H4y1%
Y	Chronic pulmonary dis	22536 H4y1000	171 Chronic pul % H4y1%
Y	Chronic pulmonary dis	50374 H4y1z00	1 Chronic pul % H4y1%
Y	Chronic pulmonary dis	43417 H4y2100	6 Chronic dru % H4y21%
Y	Chronic pulmonary dis	61119 H560.00	15 Pulmonary % H56%
Y	Chronic pulmonary dis	27348 H561.00	45 Idiopathic ¶ % H56%
Y	Chronic pulmonary dis	68814 H562.00	12 Pulmonary % H56%
Y	Chronic pulmonary dis	6837 H563.00	6442 Idiopathic f % H56%
Y	Chronic pulmonary dis	63174 H563.11	3 Hamman - % H56%
Y	Chronic pulmonary dis	5519 H563.12	2282 Cryptogeni % H56%
Y	Chronic pulmonary dis	103753 H563.13	168 Idiopathic ¶ % H56%
Y	Chronic pulmonary dis	6051 H563100	9126 Diffuse puli % H56%
Y	Chronic pulmonary dis	103472 H563200	2879 Pulmonary % H56%
Y	Chronic pulmonary dis	103559 H563300	196 Usual inter % H56%
Y	Chronic pulmonary dis	28229 H563z00	205 Idiopathic f % H56%
Y	Chronic pulmonary dis	22835 H564.00	185 Bronchiolit % H56%
Y	Chronic pulmonary dis	103475 H564.11	96 Cryptogeni % H56%
Y	Chronic pulmonary dis	61991 H56y000	7 Endogenou % H56%
Y	Chronic pulmonary dis	22905 H581.00	163 Interstitial % H581%
Y	Chronic pulmonary dis	54893 H582.00	10 Compensat % H582%
Y	Chronic pulmonary dis	106650 H583200	9 Eosinophili % H583%
Y	Chronic pulmonary dis	24814 H591.00	87 Chronic res % H59%
Y	Chronic pulmonary dis	94486 H593.00	696 Chronic typ % H59%
Y	Chronic pulmonary dis	67278 Hyu3.00	16 [X]Chronic % Hyu3%
Y	Chronic pulmonary dis	105939 Hyu4000	1 [X]Pneumo % Hyu40%
Y	Chronic pulmonary dis	105628 Hyu4800	1 [X]Chronic % Hyu48%
Y	Chronic pulmonary dis	65060 Hyu5000	42 [X]Other in % Hyu50%
Y	Congestive heart failur	9913 1O1..00	5453 Heart failur % 1O1%
Y	Congestive heart failur	7251 33BA.00	5148 Impaired le % 33BA%
Y	Congestive heart failur	11284 585f.00	5224 Echocardio % 585f%
Y	Congestive heart failur	11351 585g.00	993 Echocardio % 585g%
Y	Congestive heart failur	18853 662f.00	2728 New York F % 662f%
Y	Congestive heart failur	13189 662g.00	4500 New York F % 662g%
Y	Congestive heart failur	19066 662h.00	2529 New York F % 662h%
Y	Congestive heart failur	51214 662i.00	293 New York F % 662i%
Y	Congestive heart failur	83502 662p.00	914 Heart failur % 662p%
Y	Congestive heart failur	12366 662T.00	8673 Congestive % 662T%
Y	Congestive heart failur	30779 662W.00	7394 Heart failur % 662W%
Y	Congestive heart failur	24503 8B29.00	1147 Cardiac fail % 8B29%
Y	Congestive heart failur	32898 8H2S.00	221 Admit hear % 8H2S%
Y	Congestive heart failur	17851 8HBE.00	10012 Heart failur % 8HBE%
Y	Congestive heart failur	12627 9N0k.00	16050 Seen in heε % 9N0K%
Y	Congestive heart failur	19002 9N2p.00	11376 Seen by cor % 9N2p%
Y	Congestive sensitive cc	46294 G41..00	196 Chronic pul % G41..%

Y	Congestive sensitive cc	54113 G41y.00	154 Other chro % G41y.%
Y	Congestive sensitive cc	71046 G41yz00	19 Other chro % G41yz%
Y	Congestive sensitive cc	15782 G41z.00	271 Chronic pul % G41z%
Y	Congestive sensitive cc	5695 G41z.11	6864 Chronic cor % G41z%
Y	Congestive heart failur	2062 G58..00	91831 Heart failur % G58%
Y	Congestive heart failur	1223 G58..11	8416 Cardiac fail % G58%
Y	Congestive heart failur	398 G580.00	192681 Congestive % G58%
Y	Congestive heart failur	2906 G580.11	73506 Congestive % G58%
Y	Congestive heart failur	10079 G580.12	1034 Right heart % G58%
Y	Congestive heart failur	10154 G580.13	497 Right ventr % G58%
Y	Congestive heart failur	9524 G580.14	1008 Biventricul: % G58%
Y	Congestive heart failur	23707 G580000	565 Acute cong % G58%
Y	Congestive heart failur	32671 G580100	1088 Chronic cor % G58%
Y	Congestive heart failur	27884 G580200	599 Decompen % G58%
Y	Congestive heart failur	11424 G580300	170 Compensat % G58%
Y	Congestive heart failur	94870 G580400	62 Congestive % G58%
Y	Congestive heart failur	884 G581.00	162415 Left ventric % G58%
Y	Congestive heart failur	23481 G581.11	425 Asthma - c: % G58%
Y	Congestive heart failur	43618 G581.12	215 Pulmonary % G58%
Y	Congestive heart failur	5942 G581.13	4870 Impaired le % G58%
Y	Congestive heart failur	5255 G581000	1538 Acute left v % G58%
Y	Congestive heart failur	27964 G582.00	492 Acute hear % G58%
Y	Congestive heart failur	101138 G583.00	136 Heart failur % G58%
Y	Congestive heart failur	101137 G583.11	46 HFNEF - he % G58%
Y	Congestive heart failur	106897 G583.12	82 Heart failur % G58%
Y	Congestive heart failur	104275 G584.00	80 Right ventr % G58%
Y	Congestive heart failur	4024 G58z.00	15653 Heart failur % G58%
Y	Congestive heart failur	12590 G58z.11	95 Weak hear % G58%
Y	Congestive heart failur	17278 G58z.12	697 Cardiac fail % G58%
Y	Congestive heart failur	8966 G5yy900	14142 Left ventric % G5yy9%
Y	Congestive heart failur	12550 G5yyA00	1506 Left ventric % G5yyA%
Y	Congestive heart failur	104876 G5yyB00	22 Right ventr % G5yyB%
Y	Congestive heart failur	104333 G5yyC00	365 Diastolic d: % G5yyC%
Y	Congestive heart failur	107397 G5yyD00	313 Left ventric % G5yyD%
Y	Congestive heart failur	24185 R055100	1020 [D]Cardiogr % R0551%
Y	Congestive heart failur	93947 R055111	1 [D]Heart st % R0551%
Y	Congestive heart failur	20324 R2y1000	552 [D]Cardiore % R2y10%
Y	Connective tissue disoi	6639 14G1.00	6508 H/O: rheun % 14G1%
Y	Connective tissue disoi	4502 43F1.00	2383 Rheumatoi % 43F1%
Y	Connective tissue disoi	29339 66H..00	39792 Rheumatol % 66H%
Y	Connective tissue disoi	17412 66H..13	10513 Rheumatoi % 66H%
Y	Connective tissue disoi	15575 66H3.00	220 Rheumat.d % 66H%
Y	Connective tissue disoi	29644 66H4.00	166 Rheumat. s % 66H%
Y	Connective tissue disoi	72098 66H5.00	76 Rheumat. c % 66H%
Y	Connective tissue disoi	53649 66H6.00	673 Rheumat. t % 66H%
Y	Connective tissue disoi	44257 66H6.11	205 Rheumat.d % 66H%
Y	Connective tissue disoi	29646 66H7.00	587 Rheumat.d % 66H%
Y	Connective tissue disoi	36154 66H8.00	371 Rheumat.d % 66H%
Y	Connective tissue disoi	100443 66HB.00	1115 Rheumatol % 66H%
Y	Connective tissue disoi	105507 66HB000	33050 Rheumatoi % 66H%

Y	Connective tissue diso	100820 66HC.00	6455 Rheumatic % 66H%
Y	Connective tissue diso	21911 66HZ.00	2275 Rheumatol % 66H%
Y	Connective tissue diso	3865 AD5..00	26854 Sarcoidosis % AD5%
Y	Connective tissue diso	33980 AD50.00	302 Sarcoidosis % AD5%
Y	Connective tissue diso	49075 AD51.00	62 Sarcoidosis % AD5%
Y	Connective tissue diso	58841 AD52.00	36 Sarcoidosis % AD5%
Y	Connective tissue diso	27769 AD53.00	212 Sarcoidosis % AD5%
Y	Connective tissue diso	28952 AD53000	217 Lupus pern % AD5%
Y	Connective tissue diso	72595 AD54.00	24 Sarcoidosis % AD5%
Y	Connective tissue diso	40613 AD55.00	50 Sarcoid artl % AD5%
Y	Connective tissue diso	20455 C332100	127 Cryoglobuli % C3321%
Y	Connective tissue diso	73284 Cyu0600	8 [X]Sarcoidc % Cyu06%
Y	Connective tissue diso	49454 F013.00	7 Meningitis % F013.%
Y	Connective tissue diso	55612 F326300	26 Multiple cr % F3263%
Y	Connective tissue diso	57313 F371.00	8 Polyneuroç % F371%
Y	Connective tissue diso	44095 F371000	37 Polyneuroç % F371%, % F3710%
Y	Connective tissue diso	47465 F371100	4 Polyneuroç % F371%
Y	Connective tissue diso	62401 F371200	19 Polyneuroç % F371%
Y	Connective tissue diso	71258 F371z00	4 Polyneuroç % F371%
Y	Connective tissue diso	40751 F374900	15 Polyneuroç % F3749%
Y	Connective tissue diso	108072 F396100	1 Myopathy % F396%
Y	Connective tissue diso	57888 F396300	15 Myopathy % F396%
Y	Connective tissue diso	31209 F396400	20 Myopathy % F396%
Y	Connective tissue diso	52519 F396500	11 Myopathy % F396%
Y	Connective tissue diso	55601 F396600	18 Myopathy % F396%
Y	Connective tissue diso	21022 F396700	82 Myopathy % F396%, % F3967%
Y	Connective tissue diso	47037 G558300	52 Sarcoid heç % G5583%
Y	Connective tissue diso	34437 G5y7.00	11 Sarcoid my % G5y7.%
Y	Connective tissue diso	49787 G5y8.00	6 Rheumatoi % G5y8%
Y	Connective tissue diso	43816 G5yA.00	25 Rheumatoi % G5yA%
Y	Connective tissue diso	62323 G75..00	11 Polyarteriti % G75%
Y	Connective tissue diso	1471 G750.00	1634 Polyarteriti % G75%
Y	Connective tissue diso	98769 G750.11	3 Necrotising % G75%
Y	Connective tissue diso	102193 G751.00	2 Acute febril % G75%
Y	Connective tissue diso	6157 G751000	1846 Kawasaki d % G75%
Y	Connective tissue diso	93037 G751z00	3 Acute febril % G75%
Y	Connective tissue diso	20509 G752.00	248 Hypersensi % G75%
Y	Connective tissue diso	62277 G752.11	7 Hypersensi % G75%
Y	Connective tissue diso	26860 G752000	204 Goodpastu % G75%
Y	Connective tissue diso	107564 G752111	2 Antiglomer % G75%
Y	Connective tissue diso	107045 G752112	5 Anti GBM c % G75%
Y	Connective tissue diso	23569 G752z00	134 Hypersensi % G75%
Y	Connective tissue diso	4810 G754.00	3471 Wegener's % G75%
Y	Connective tissue diso	109112 G754.11	4 % G75%
Y	Connective tissue diso	10432 G755.00	4674 Giant cell a % G75%
Y	Connective tissue diso	9843 G755000	2480 Cranial arteç % G75%
Y	Connective tissue diso	3275 G755100	36233 Temporal a % G75%
Y	Connective tissue diso	49149 G755200	9 Horton's di % G75%
Y	Connective tissue diso	68403 G755z00	56 Giant cell a % G75%
Y	Connective tissue diso	37640 G757.00	204 Takayasu's % G75%

Y	Connective tissue diso	19107 G757.11	23 Aortic arch % G75%
Y	Connective tissue diso	33963 G757.12	39 Pulseless d % G75%
Y	Connective tissue diso	21602 G758.00	883 Churg-Strai % G75%
Y	Connective tissue diso	18380 G759.00	106 Juvenile po % G75%
Y	Connective tissue diso	104312 G75A.00	36 Microscopi % G75%
Y	Connective tissue diso	68136 G75z.00	112 Polyarteriti % G75%
Y	Connective tissue diso	4649 G766.00	4449 Arteritis un % G766%
Y	Connective tissue diso	23533 G766.11	74 Aortitis % G766%
Y	Connective tissue diso	1470 G76B.00	18074 Vasculitis % G76B%
Y	Connective tissue diso	9954 H570.00	234 Rheumatoi % H57%
Y	Connective tissue diso	64799 H571.00	8 Rheumatic % H57%
Y	Connective tissue diso	94996 H572.00	1 Lung disea: % H57%
Y	Connective tissue diso	42940 H57y100	72 Lung disea: % H57%
Y	Connective tissue diso	3859 H57y200	2668 Pulmonary % H57%
Y	Connective tissue diso	47364 H57y300	43 Lung disea: % H57%
Y	Connective tissue diso	31564 H57y400	105 Lung disea: % H57%
Y	Connective tissue diso	26405 J63A.00	34 Hepatic gra: % J63A.%
Y	Connective tissue diso	58750 K01x300	7 Nephrotic : % K01x3%
Y	Connective tissue diso	47672 K01x400	49 Nephrotic : % K01x4%
Y	Connective tissue diso	22205 K01x411	617 Lupus neph: % K01x4%
Y	Connective tissue diso	105976 K0H..00	1 Acute scler % K0H%
Y	Connective tissue diso	107382 K0J0.00	1 Renal invol % K0J0%
Y	Connective tissue diso	7871 N000.00	17580 Systemic lu % N000%
Y	Connective tissue diso	20007 N000000	564 Disseminat % N000%
Y	Connective tissue diso	57675 N000100	8 Libman-Sac % N000%
Y	Connective tissue diso	36942 N000200	32 Drug-induc % N000%
Y	Connective tissue diso	29519 N000300	121 Systemic lu % N000%
Y	Connective tissue diso	11920 N000400	33 Systemic lu % N000%
Y	Connective tissue diso	99435 N000500	12 Neonatal lu % N000%
Y	Connective tissue diso	101433 N000600	14 Cerebral lu % N000%
Y	Connective tissue diso	42719 N000z00	316 Systemic lu % N000%
Y	Connective tissue diso	3670 N001.00	5979 Scleroderr % N001%
Y	Connective tissue diso	68277 N001.11	4 Acrosclero: % N001%
Y	Connective tissue diso	28417 N001.12	1489 Systemic sc % N001%
Y	Connective tissue diso	44141 N001000	43 Progressive % N001%
Y	Connective tissue diso	17675 N001100	1140 CREST sync % N001%
Y	Connective tissue diso	2360 N002.00	11532 Sicca (Sjogr % N002%
Y	Connective tissue diso	1928 N002.11	1895 Keratoconj % N002%
Y	Connective tissue diso	15511 N004.00	2956 Polymyositis % N004%
Y	Connective tissue diso	23834 N005.00	598 Adult Still's % N005%
Y	Connective tissue diso	27603 N04..00	1643 Rheumatoi % N04%
Y	Connective tissue diso	844 N040.00	246582 Rheumatoi % N04%
Y	Connective tissue diso	44743 N040000	16 Rheumatoi % N04%
Y	Connective tissue diso	44203 N040100	45 Other rheu % N04%
Y	Connective tissue diso	21358 N040200	35 Rheumatoi % N04%
Y	Connective tissue diso	107963 N040300	1 Rheumatoi % N04%
Y	Connective tissue diso	100914 N040400	4 Rheumatoi % N04%
Y	Connective tissue diso	59738 N040500	25 Rheumatoi % N04%
Y	Connective tissue diso	63365 N040600	2 Rheumatoi % N04%
Y	Connective tissue diso	48832 N040700	98 Rheumatoi % N04%

Y	Connective tissue diso	42299	N040800	65	Rheumatoi % N04%
Y	Connective tissue diso	41941	N040900	41	Rheumatoi % N04%
Y	Connective tissue diso	63198	N040A00	12	Rheumatoi % N04%
Y	Connective tissue diso	49067	N040B00	24	Rheumatoi % N04%
Y	Connective tissue diso	100776	N040C00	2	Rheumatoi % N04%
Y	Connective tissue diso	50863	N040D00	128	Rheumatoi % N04%
Y	Connective tissue diso	107791	N040E00	1	Rheumatoi % N04%
Y	Connective tissue diso	51239	N040F00	53	Rheumatoi % N04%
Y	Connective tissue diso	73619	N040G00	6	Rheumatoi % N04%
Y	Connective tissue diso	70658	N040H00	6	Rheumatoi % N04%
Y	Connective tissue diso	71784	N040J00	4	Rheumatoi % N04%
Y	Connective tissue diso	51238	N040K00	16	Rheumatoi % N04%
Y	Connective tissue diso	99414	N040L00	2	Rheumatoi % N04%
Y	Connective tissue diso	107112	N040M00	4	Rheumatoi % N04%
Y	Connective tissue diso	30548	N040N00	208	Rheumatoi % N04%
Y	Connective tissue diso	6916	N040P00	5855	Seronegati % N04%
Y	Connective tissue diso	18155	N040Q00	52	Rheumatoi % N04%
Y	Connective tissue diso	53621	N040R00	88	Rheumatoi % N04%
Y	Connective tissue diso	31054	N040S00	309	Rheumatoi % N04%
Y	Connective tissue diso	8350	N040T00	4266	Flare of rhe % N04%
Y	Connective tissue diso	23552	N041.00	361	Felty's sync % N04%
Y	Connective tissue diso	49227	N042.00	24	Other rheu % N04%
Y	Connective tissue diso	46436	N042100	27	Rheumatoi % N04%
Y	Connective tissue diso	5723	N042200	1883	Rheumatoi % N04%
Y	Connective tissue diso	37431	N042z00	33	Rheumatoi % N04%
Y	Connective tissue diso	4186	N043.00	4026	Juvenile rhi % N04%
Y	Connective tissue diso	50644	N043000	29	Juvenile rhi % N04%
Y	Connective tissue diso	47831	N043100	43	Acute poly: % N04%
Y	Connective tissue diso	21533	N043200	614	Pauciarticu % N04%
Y	Connective tissue diso	36276	N043300	112	Monarticul % N04%
Y	Connective tissue diso	27557	N043z00	199	Juvenile rhi % N04%
Y	Connective tissue diso	31360	N045500	303	Juvenile rhi % N04%
Y	Connective tissue diso	9707	N047.00	855	Seropositiv % N04%
Y	Connective tissue diso	12019	N04X.00	3366	Seropositiv % N04%
Y	Connective tissue diso	31724	N04y000	101	Rheumatoi % N04%
Y	Connective tissue diso	56838	N04y011	6	Caplan's sy % N04%
Y	Connective tissue diso	28853	N04y012	287	Fibrosing a % N04%
Y	Connective tissue diso	32001	N04y200	134	Adult-onse % N04%
Y	Connective tissue diso	1408	N20..00	275174	Polymyalgi. % N20%
Y	Connective tissue diso	3042	N20..11	13920	Polymyalgi. % N20%
Y	Connective tissue diso	29472	N200.00	446	Giant cell a % N20%
Y	Connective tissue diso	47718	N233200	2	Myositis in % N2332%
Y	Connective tissue diso	106440	Nyu1000	1	[X]Rheuma % Nyu10%
Y	Connective tissue diso	93715	Nyu1100	13	[X]Other se % Nyu11%
Y	Connective tissue diso	70221	Nyu1200	17	[X]Other sp % Nyu12%
Y	Connective tissue diso	56202	Nyu1G00	30	[X]Seropos % Nyu1G%
Y	Connective tissue diso	52860	Nyu4.00	17	[X]Systemic % Nyu4%
Y	Connective tissue diso	53789	Nyu4100	4	[X]Other gi % Nyu4%
Y	Connective tissue diso	58706	Nyu4300	1	[X]Other fo % Nyu4%
Y	Connective tissue diso	71763	Nyu4500	11	[X]Other fo % Nyu4%

Y	Connective tissue diso	67149	Nyu4600	5	[X]Other ov % Nyu4%
Y	Connective tissue diso	68965	Nyu4700	9	[X]Other sy % Nyu4%
Y	Connective tissue diso	92421	Nyu4C00	1	[X]Systemic % Nyu4%
Y	Connective tissue diso	83529	Nyu4F00	429	[X]Mixed cr % Nyu4%
Y	Dementia	5931	1461	13716	H/O: deme % 1461%
Y	Dementia	55023	66h..00	8006	Dementia r % 66h..%
Y	Dementia	12710	6AB..00	190800	Dementia r % 6AB%
Y	Dementia	85853	9Ou..00	818	Dementia r % 9Ou%
Y	Dementia	49674	9Ou1.00	11037	Dementia r % 9Ou%
Y	Dementia	83576	9Ou2.00	2260	Dementia r % 9Ou%
Y	Dementia	89036	9Ou3.00	900	Dementia r % 9Ou%
Y	Dementia	89037	9Ou4.00	277	Dementia r % 9Ou%
Y	Dementia	65235	9Ou5.00	388	Dementia r % 9Ou%
Y	Dementia	38286	A411.00	68	Jakob-Creu % A411%
Y	Dementia	1916	E00..11	24179	Senile dem % E00%
Y	Dementia	1350	E00..12	64141	Senile/pres % E00%
Y	Dementia	7323	E000.00	15351	Uncomplic: % E00%
Y	Dementia	15165	E001.00	1537	Presenile d % E00%
Y	Dementia	42602	E001000	31	Uncomplic: % E00%
Y	Dementia	49513	E001100	50	Presenile d % E00%
Y	Dementia	30032	E001200	143	Presenile d % E00%
Y	Dementia	27677	E001300	85	Presenile d % E00%
Y	Dementia	38438	E001z00	210	Presenile d % E00%
Y	Dementia	44674	E002.00	231	Senile dem % E00%
Y	Dementia	18386	E002000	513	Senile dem % E00%
Y	Dementia	21887	E002100	612	Senile dem % E00%
Y	Dementia	41089	E002z00	31	Senile dem % E00%
Y	Dementia	37015	E003.00	306	Senile dem % E00%
Y	Dementia	19477	E004.00	2530	Arterioscle % E00%
Y	Dementia	8634	E004.11	4087	Multi infarc % E00%
Y	Dementia	43089	E004000	86	Uncomplic: % E00%
Y	Dementia	56912	E004100	16	Arterioscle % E00%
Y	Dementia	55467	E004200	34	Arterioscle % E00%
Y	Dementia	43292	E004300	71	Arterioscle % E00%
Y	Dementia	42279	E004z00	304	Arterioscle % E00%
Y	Dementia	54505	E012.00	99	Other alcof % E012%
Y	Dementia	27342	E012.11	652	Alcoholic d % E012%
Y	Dementia	62132	E02y100	23	Drug-induc % E02y1%
Y	Dementia	25386	E041.00	1294	Dementia i % E041%
Y	Dementia	7664	Eu00.00	16671	[X]Dement % Eu00%
Y	Dementia	49263	Eu00000	263	[X]Dement % Eu00%
Y	Dementia	25704	Eu00011	45	[X]Presenil: % Eu00%
Y	Dementia	60059	Eu00012	13	[X]Primary % Eu00%
Y	Dementia	61528	Eu00013	9	[X]Alzheim: % Eu00%
Y	Dementia	38678	Eu00100	596	[X]Dement % Eu00%
Y	Dementia	46762	Eu00111	38	[X]Alzheim: % Eu00%
Y	Dementia	11379	Eu00112	1152	[X]Senile dr % Eu00%
Y	Dementia	43346	Eu00113	57	[X]Primary % Eu00%
Y	Dementia	30706	Eu00200	1241	[X]Dement % Eu00%
Y	Dementia	29386	Eu00z00	777	[X]Dement % Eu00%

Y	Dementia	8195	Eu00z11	6497	[X]Alzheimer's % Eu00%
Y	Dementia	6578	Eu01.00	38479	[X]Vascular % Eu01%
Y	Dementia	9565	Eu01.11	942	[X]Arteriosclerotic % Eu01%
Y	Dementia	46488	Eu01000	41	[X]Vascular % Eu01%
Y	Dementia	11175	Eu01100	1057	[X]Multi-infarct % Eu01%
Y	Dementia	55838	Eu01111	31	[X]Predominantly cortical % Eu01%
Y	Dementia	8934	Eu01200	179	[X]Subcortical % Eu01%
Y	Dementia	31016	Eu01300	635	[X]Mixed cortical and subcortical % Eu01%
Y	Dementia	55313	Eu01y00	153	[X]Other vascular % Eu01%
Y	Dementia	19393	Eu01z00	704	[X]Vascular % Eu01%
Y	Dementia	12621	Eu02.00	651	[X]Demented % Eu02%
Y	Dementia	28402	Eu02000	146	[X]Demented % Eu02%
Y	Dementia	54106	Eu02100	44	[X]Demented % Eu02%
Y	Dementia	37014	Eu02200	167	[X]Demented % Eu02%
Y	Dementia	9509	Eu02300	1464	[X]Demented % Eu02%
Y	Dementia	41185	Eu02400	16	[X]Demented % Eu02%
Y	Dementia	26270	Eu02500	2383	[X]Lewy body % Eu02%
Y	Dementia	64267	Eu02y00	51	[X]Demented % Eu02%
Y	Dementia	4693	Eu02z00	31042	[X] Unspecified % Eu02%
Y	Dementia	48501	Eu02z11	50	[X] Presenile % Eu02%
Y	Dementia	34944	Eu02z13	82	[X] Primary % Eu02%
Y	Dementia	4357	Eu02z14	11289	[X] Senile dementia % Eu02%
Y	Dementia	27759	Eu02z16	183	[X] Senile dementia % Eu02%
Y	Dementia	53446	Eu04100	53	[X]Delirium % Eu04%
Y	Dementia	26323	Eu10711	496	[X]Alcoholism % Eu10711%
Y	Dementia	101999	Eu84311	1	[X]Demented % Eu84311%
Y	Dementia	1917	F110.00	49331	Alzheimer's % F110%
Y	Dementia	16797	F110000	630	Alzheimer's % F110%
Y	Dementia	32057	F110100	689	Alzheimer's % F110%
Y	Dementia	11136	F111.00	289	Pick's disease % F111%
Y	Dementia	29512	F112.00	551	Senile degeneration % F112%
Y	Dementia	7572	F116.00	1481	Lewy body % F116%
Y	Dementia	59122	Fyu3000	4	[X]Other Alcoholism % Fyu30%
Y	Dementia	55222	ZS7C500	10	Language disorder % ZS7C5%
Y	Diabetes	29218	42W2.00	1154	Hb. A1C 7-7.9 % 42W%
Y	Diabetes	13604	42W3.00	1680	Hb. A1C > 8 % 42W%
Y	Diabetes	1684	66A4.00	197145	Diabetic on insulin % 66A4%
Y	Diabetes	8842	66A5.00	63533	Diabetic on insulin % 66A5%
Y	Diabetes	2378	66AJ.00	126414	Diabetic - not on insulin % 66AJ%
Y	Diabetes	9013	66AJ.11	875	Unstable diabetes % 66AJ%
Y	Diabetes	2478	66AJ100	1038	Brittle diabetes % 66AJ%
Y	Diabetes	22023	66AJz00	1279	Diabetic - not on insulin % 66AJ%
Y	Diabetes	28769	66AV.00	13039	Diabetic on insulin % 66AV%
Y	Diabetes	711	C10..00	776981	Diabetes mellitus % C10%
Y	Diabetes	38986	C100.00	2316	Diabetes mellitus % C10%
Y	Diabetes	24490	C100000	1291	Diabetes mellitus % C10%
Y	Diabetes	1038	C100011	34139	Insulin dependent % C10%
Y	Diabetes	14803	C100100	13104	Diabetes mellitus % C10%
Y	Diabetes	14889	C100111	20590	Maturity onset diabetes of the young % C10%
Y	Diabetes	506	C100112	93196	Non-insulin dependent % C10%

Y	Diabetes	50972 C100z00	575 Diabetes m % C10%
Y	Diabetes	1682 C101.00	11857 Diabetes m % C10%
Y	Diabetes	53200 C101000	82 Diabetes m % C10%
Y	Diabetes	54856 C101100	35 Diabetes m % C10%
Y	Diabetes	38617 C101y00	24 Other spec % C10%
Y	Diabetes	42505 C101z00	315 Diabetes m % C10%
Y	Diabetes	21482 C102.00	214 Diabetes m % C10%
Y	Diabetes	40023 C102000	8 Diabetes m % C10%
Y	Diabetes	43139 C102100	29 Diabetes m % C10%
Y	Diabetes	72345 C102z00	7 Diabetes m % C10%
Y	Diabetes	15690 C103.00	344 Diabetes m % C10%
Y	Diabetes	42567 C103000	6 Diabetes m % C10%
Y	Diabetes	68843 C103100	4 Diabetes m % C10%
Y	Diabetes	59288 C103y00	3 Other spec % C10%
Y	Diabetes	65062 C103z00	7 Diabetes m % C10%
Y	Diabetes	1647 C108.00	22358 Insulin dep % C10%
Y	Diabetes	18505 C108.11	7852 IDDM-Insul % C10%
Y	Diabetes	17858 C108.12	6028 Type 1 diat % C10%
Y	Diabetes	24423 C108.13	775 Type I diab % C10%
Y	Diabetes	26855 C108400	64 Unstable in % C10%
Y	Diabetes	60107 C108411	3 Unstable ty % C10%
Y	Diabetes	97474 C108412	2 Unstable ty % C10%
Y	Diabetes	6791 C108800	423 Insulin dep % C10%
Y	Diabetes	46850 C108811	18 Type I diab % C10%
Y	Diabetes	45914 C108812	2 Type 1 diat % C10%
Y	Diabetes	31310 C108900	549 Insulin dep % C10%
Y	Diabetes	63017 C108911	1 Type I diab % C10%
Y	Diabetes	97446 C108912	2 Type 1 diat % C10%
Y	Diabetes	56448 C108A00	18 Insulin-dep % C10%
Y	Diabetes	95992 C108A11	1 Type I diab % C10%
Y	Diabetes	44440 C108E00	49 Insulin dep % C10%
Y	Diabetes	42729 C108E11	14 Type I diab % C10%
Y	Diabetes	70766 C108E12	2 Type 1 diat % C10%
Y	Diabetes	4513 C109.00	82849 Non-insulir % C10%
Y	Diabetes	5884 C109.11	5689 NIDDM - N % C10%
Y	Diabetes	17859 C109.12	44200 Type 2 diat % C10%
Y	Diabetes	18219 C109.13	4676 Type II diat % C10%
Y	Diabetes	8403 C109700	1612 Non-insulir % C10%
Y	Diabetes	24458 C109711	37 Type II diat % C10%
Y	Diabetes	45913 C109712	32 Type 2 diat % C10%
Y	Diabetes	29979 C109900	241 Non-insulir % C10%
Y	Diabetes	109103 C109911	2 Type II diat % C10%
Y	Diabetes	105784 C109912	1 Type 2 diat % C10%
Y	Diabetes	43785 C109D00	9 Non-insulir % C10%
Y	Diabetes	56268 C109D11	2 Type II diat % C10%
Y	Diabetes	61071 C109D12	7 Type 2 diat % C10%
Y	Diabetes	18278 C109J00	3838 Insulin trea % C10%
Y	Diabetes	37648 C109J11	22 Insulin trea % C10%
Y	Diabetes	18264 C109J12	45 Insulin trea % C10%
Y	Diabetes	36633 C109K00	37 Hyperosmc % C10%

Y	Diabetes	52236 C10A.00	46 Malnutritic % C10%
Y	Diabetes	66675 C10A000	3 Malnutritic % C10%
Y	Diabetes	33969 C10A100	90 Malnutritic % C10%
Y	Diabetes	11551 C10B.00	1183 Diabetes m % C10%
Y	Diabetes	26108 C10B000	110 Steroid ind % C10%
Y	Diabetes	43453 C10C.00	28 Diabetes m % C10%
Y	Diabetes	46624 C10C.11	173 Maturity o1 % C10%
Y	Diabetes	98392 C10C.12	6 Maturity o1 % C10%
Y	Diabetes	36695 C10D.00	315 Diabetes m % C10%
Y	Diabetes	59991 C10D.11	26 Maturity o1 % C10%
Y	Diabetes	1549 C10E.00	79340 Type 1 diat % C10%
Y	Diabetes	12455 C10E.11	352 Type I diab % C10%
Y	Diabetes	51261 C10E.12	821 Insulin dep % C10%
Y	Diabetes	43921 C10E400	41 Unstable ty % C10%
Y	Diabetes	49949 C10E411	5 Unstable ty % C10%
Y	Diabetes	54600 C10E412	5 Unstable in % C10%
Y	Diabetes	35288 C10E800	300 Type 1 diat % C10%
Y	Diabetes	105337 C10E811	5 Type I diab % C10%
Y	Diabetes	72702 C10E812	10 Insulin dep % C10%
Y	Diabetes	40682 C10E900	63 Type 1 diat % C10%
Y	Diabetes	96235 C10E911	12 Type I diab % C10%
Y	Diabetes	97849 C10E912	6 Insulin dep % C10%
Y	Diabetes	69676 C10EA00	53 Type 1 diat % C10%
Y	Diabetes	62613 C10EA11	2 Type I diab % C10%
Y	Diabetes	99719 C10EA12	2 Insulin-dep % C10%
Y	Diabetes	39070 C10EE00	80 Type 1 diat % C10%
Y	Diabetes	99716 C10EE12	2 Insulin dep % C10%
Y	Diabetes	10692 C10EM00	5067 Type 1 diat % C10%
Y	Diabetes	62209 C10EM11	31 Type I diab % C10%
Y	Diabetes	40837 C10EN00	209 Type 1 diat % C10%
Y	Diabetes	66145 C10EN11	1 Type I diab % C10%
Y	Diabetes	95636 C10ER00	97 Latent autc % C10%
Y	Diabetes	758 C10F.00	766628 Type 2 diat % C10%
Y	Diabetes	22884 C10F.11	3724 Type II diat % C10%
Y	Diabetes	25627 C10F700	1162 Type 2 diat % C10%
Y	Diabetes	47315 C10F711	75 Type II diat % C10%
Y	Diabetes	47954 C10F900	805 Type 2 diat % C10%
Y	Diabetes	53392 C10F911	173 Type II diat % C10%
Y	Diabetes	46917 C10FD00	94 Type 2 diat % C10%
Y	Diabetes	98723 C10FD11	19 Type II diat % C10%
Y	Diabetes	1407 C10FJ00	11821 Insulin trea % C10%
Y	Diabetes	64668 C10FJ11	89 Insulin trea % C10%
Y	Diabetes	34450 C10FK00	467 Hyperosmc % C10%
Y	Diabetes	107701 C10FK11	1 Hyperosmc % C10%
Y	Diabetes	32627 C10FN00	736 Type 2 diat % C10%
Y	Diabetes	106528 C10FN11	1 Type II diat % C10%
Y	Diabetes	51756 C10FP00	27 Type 2 diat % C10%
Y	Diabetes	106061 C10FP11	1 Type II diat % C10%
Y	Diabetes	95539 C10FS00	5 Maternally % C10%
Y	Diabetes	51697 C10G.00	243 Secondary % C10%

Y	Diabetes	96506 C10G000	2 Secondary % C10%
Y	Diabetes	61122 C10H.00	31 Diabetes m% C10%
Y	Diabetes	67212 C10H000	2 DM induce % C10%
Y	Diabetes	43857 C10M.00	27 Lipoatroph % C10%
Y	Diabetes	22487 C10N.00	105 Secondary % C10%
Y	Diabetes	94383 C10N000	7 Secondary % C10%
Y	Diabetes	93380 C10N100	80 Cystic fibro% C10%
Y	Diabetes	33343 C10y.00	65 Diabetes m% C10%
Y	Diabetes	63371 C10y100	7 Diabetes m% C10%
Y	Diabetes	10098 C10yy00	8 Other spec % C10%
Y	Diabetes	70821 C10yz00	14 Diabetes m% C10%
Y	Diabetes	45491 C10z.00	73 Diabetes m% C10%
Y	Diabetes	68792 C10z000	7 Diabetes m% C10%
Y	Diabetes	63762 C10z100	49 Diabetes m% C10%
Y	Diabetes	64283 C10zy00	10 Other spec % C10%
Y	Diabetes	64357 C10zz00	112 Diabetes m% C10%
Y	Diabetes	32193 C11y000	290 Steroid ind % C11y0%
Y	Diabetes	14980 C314.00	1909 Renal glycc % C314%
Y	Diabetes	11848 C314.11	29 Renal diabε % C314%
Y	Diabetes	52212 Cyu2.00	91 [X]Diabete: % Cyu2%
Y	Diabetes	41686 Cyu2000	4 [X]Other sç % Cyu2%
Y	Diabetes	30477 F420700	67 High risk pr % F420%
Y	Diabetes	65463 F420800	35 High risk nε % F420%
Y	Diabetes	50960 L180500	214 Pre-existinç % L180%
Y	Diabetes	50609 L180600	44 Pre-existinç % L180%
Y	Diabetes	109133 L180700	1 Pre-existinç % L180%
Y	Diabetes	55431 L180X00	42 Pre-existinç % L180%
Y	Diabetes	106927 PKyP.00	2 Diab insipic % PKyP%
Y	Diabetes	106926 PKyP.11	5 Wolfram sy % PKyP%
Y	Diabetes with complica	22967 2BBF.00	1681 Retinal abn% 2BB%
Y	Diabetes with complica	47328 2BBk.00	177 O/E - right % 2BB%
Y	Diabetes with complica	52041 2BBl.00	127 O/E - left e % 2BB%
Y	Diabetes with complica	9835 2BBL.00	3331 O/E - diabe % 2BB%
Y	Diabetes with complica	52630 2BBo.00	49 O/E - sight % 2BB%
Y	Diabetes with complica	11433 2BBP.00	61538 O/E - right % 2BB%
Y	Diabetes with complica	11129 2BBQ.00	60335 O/E - left e % 2BB%
Y	Diabetes with complica	101881 2BBr.00	5 Impaired vi % 2BB%
Y	Diabetes with complica	13099 2BBR.00	3971 O/E - right % 2BB%
Y	Diabetes with complica	13103 2BBS.00	3793 O/E - left e % 2BB%
Y	Diabetes with complica	13097 2BBT.00	2437 O/E - right % 2BB%
Y	Diabetes with complica	13101 2BBV.00	2283 O/E - left e % 2BB%
Y	Diabetes with complica	13102 2BBW.00	9061 O/E - right % 2BB%
Y	Diabetes with complica	13108 2BBX.00	9213 O/E - left e % 2BB%
Y	Diabetes with complica	27921 2G51000	428 Foot abnor % 2G510%
Y	Diabetes with complica	18056 2G5C.00	740 Foot abnor % 2G5C%
Y	Diabetes with complica	35316 2G5H.00	3671 O/E - Right % 2G5H%
Y	Diabetes with complica	35116 2G5L.00	3529 O/E - Left d % 2G5L%
Y	Diabetes with complica	62384 2G5V.00	40 O/E - right % 2G5V%
Y	Diabetes with complica	49640 2G5W.00	64 O/E - left cl % 2G5W%
Y	Diabetes with complica	16502 C104.00	1355 Diabetes m% C10%

Y	Diabetes with complica	2475 C104.11	2986 Diabetic ne % C10%
Y	Diabetes with complica	93922 C104000	2 Diabetes m % C10%
Y	Diabetes with complica	35105 C104100	44 Diabetes m % C10%
Y	Diabetes with complica	13279 C104y00	13 Other spec % C10%
Y	Diabetes with complica	35107 C104z00	277 Diabetes m % C10%
Y	Diabetes with complica	33254 C105.00	1569 Diabetes m % C10%
Y	Diabetes with complica	69748 C105000	6 Diabetes m % C10%
Y	Diabetes with complica	41389 C105100	85 Diabetes m % C10%
Y	Diabetes with complica	47377 C105y00	6 Other spec % C10%
Y	Diabetes with complica	34283 C105z00	164 Diabetes m % C10%
Y	Diabetes with complica	16230 C106.00	10992 Diabetes m % C10%
Y	Diabetes with complica	59903 C106.11	22 Diabetic an % C10%
Y	Diabetes with complica	7795 C106.12	8536 Diabetes m % C10%
Y	Diabetes with complica	16491 C106.13	64 Diabetes m % C10%
Y	Diabetes with complica	67853 C106000	74 Diabetes m % C10%
Y	Diabetes with complica	39317 C106100	185 Diabetes m % C10%
Y	Diabetes with complica	61523 C106y00	57 Other spec % C10%
Y	Diabetes with complica	22573 C106z00	244 Diabetes m % C10%
Y	Diabetes with complica	35399 C107.00	2677 Diabetes m % C10%
Y	Diabetes with complica	32403 C107.11	258 Diabetes m % C10%
Y	Diabetes with complica	32556 C107.12	108 Diabetes w % C10%
Y	Diabetes with complica	70448 C107000	2 Diabetes m % C10%
Y	Diabetes with complica	63357 C107100	52 Diabetes m % C10%
Y	Diabetes with complica	33807 C107200	41 Diabetes m % C10%
Y	Diabetes with complica	69124 C107300	11 IDDM with % C10%
Y	Diabetes with complica	56803 C107400	28 NIDDM wit % C10%
Y	Diabetes with complica	65025 C107z00	74 Diabetes m % C10%
Y	Diabetes with complica	46963 C108000	29 Insulin-dep % C10%
Y	Diabetes with complica	61344 C108011	5 Type I diab % C10%
Y	Diabetes with complica	21983 C108012	5 Type 1 diat % C10%
Y	Diabetes with complica	49276 C108100	16 Insulin-dep % C10%
Y	Diabetes with complica	102740 C108112	1 Type 1 diat % C10%
Y	Diabetes with complica	52283 C108200	8 Insulin-dep % C10%
Y	Diabetes with complica	49146 C108211	1 Type I diab % C10%
Y	Diabetes with complica	61829 C108212	6 Type 1 diat % C10%
Y	Diabetes with complica	52104 C108300	11 Insulin dep % C10%
Y	Diabetes with complica	108007 C108311	1 Type I diab % C10%
Y	Diabetes with complica	44443 C108500	207 Insulin dep % C10%
Y	Diabetes with complica	51957 C108511	10 Type I diab % C10%
Y	Diabetes with complica	68390 C108512	15 Type 1 diat % C10%
Y	Diabetes with complica	60499 C108600	10 Insulin dep % C10%
Y	Diabetes with complica	6509 C108700	240 Insulin dep % C10%
Y	Diabetes with complica	38161 C108711	14 Type I diab % C10%
Y	Diabetes with complica	41049 C108712	9 Type 1 diat % C10%
Y	Diabetes with complica	24694 C108B00	1 Insulin dep % C10%
Y	Diabetes with complica	99231 C108B11	1 Type I diab % C10%
Y	Diabetes with complica	41716 C108C00	11 Insulin dep % C10%
Y	Diabetes with complica	57621 C108D00	18 Insulin dep % C10%
Y	Diabetes with complica	66872 C108D11	7 Type I diab % C10%
Y	Diabetes with complica	44260 C108F00	7 Insulin dep % C10%

Y	Diabetes with complica	17545 C108F11	4 Type I diab % C10%
Y	Diabetes with complica	64446 C108G00	3 Insulin dep % C10%
Y	Diabetes with complica	65616 C108H00	4 Insulin dep % C10%
Y	Diabetes with complica	62352 C108H11	1 Type I diab % C10%
Y	Diabetes with complica	39809 C108J00	27 Insulin dep % C10%
Y	Diabetes with complica	60208 C108J11	3 Type I diab % C10%
Y	Diabetes with complica	18230 C108J12	3 Type 1 diat % C10%
Y	Diabetes with complica	46290 C108y00	10 Other spec % C10%
Y	Diabetes with complica	64449 C108z00	3 Unspecifier % C10%
Y	Diabetes with complica	52303 C109000	16 Non-insulir % C10%
Y	Diabetes with complica	50225 C109011	9 Type II diat % C10%
Y	Diabetes with complica	18209 C109012	20 Type 2 diat % C10%
Y	Diabetes with complica	50429 C109100	17 Non-insulir % C10%
Y	Diabetes with complica	59725 C109111	2 Type II diat % C10%
Y	Diabetes with complica	70316 C109112	36 Type 2 diat % C10%
Y	Diabetes with complica	55842 C109200	14 Non-insulir % C10%
Y	Diabetes with complica	67905 C109211	3 Type II diat % C10%
Y	Diabetes with complica	45919 C109212	15 Type 2 diat % C10%
Y	Diabetes with complica	62146 C109300	9 Non-insulir % C10%
Y	Diabetes with complica	108005 C109312	55 Type 2 diat % C10%
Y	Diabetes with complica	34912 C109400	225 Non-insulir % C10%
Y	Diabetes with complica	55075 C109411	18 Type II diat % C10%
Y	Diabetes with complica	65704 C109412	13 Type 2 diat % C10%
Y	Diabetes with complica	40401 C109500	11 Non-insulir % C10%
Y	Diabetes with complica	62107 C109511	7 Type II diat % C10%
Y	Diabetes with complica	46150 C109512	5 Type 2 diat % C10%
Y	Diabetes with complica	17262 C109600	108 Non-insulir % C10%
Y	Diabetes with complica	58604 C109611	21 Type II diat % C10%
Y	Diabetes with complica	42762 C109612	15 Type 2 diat % C10%
Y	Diabetes with complica	72320 C109A00	2 Non-insulir % C10%
Y	Diabetes with complica	50813 C109A11	1 Type II diat % C10%
Y	Diabetes with complica	45467 C109B00	10 Non-insulir % C10%
Y	Diabetes with complica	47409 C109B11	3 Type II diat % C10%
Y	Diabetes with complica	59365 C109C00	55 Non-insulir % C10%
Y	Diabetes with complica	64571 C109C11	5 Type II diat % C10%
Y	Diabetes with complica	24836 C109C12	10 Type 2 diat % C10%
Y	Diabetes with complica	69278 C109E00	13 Non-insulir % C10%
Y	Diabetes with complica	48192 C109E11	10 Type II diat % C10%
Y	Diabetes with complica	44779 C109E12	7 Type 2 diat % C10%
Y	Diabetes with complica	54212 C109F00	6 Non-insulir % C10%
Y	Diabetes with complica	54899 C109F11	4 Type II diat % C10%
Y	Diabetes with complica	60699 C109F12	2 Type 2 diat % C10%
Y	Diabetes with complica	24693 C109G00	5 Non-insulir % C10%
Y	Diabetes with complica	18143 C109G11	1 Type II diat % C10%
Y	Diabetes with complica	49869 C109G12	1 Type 2 diat % C10%
Y	Diabetes with complica	40962 C109H00	9 Non-insulir % C10%
Y	Diabetes with complica	47816 C109H11	7 Type II diat % C10%
Y	Diabetes with complica	66965 C109H12	9 Type 2 diat % C10%
Y	Diabetes with complica	100347 C10A500	1 Malnutritn % C10%
Y	Diabetes with complica	47582 C10E000	38 Type 1 diat % C10%

Y	Diabetes with complica	102946	C10E012	3	Insulin-dep % C10%
Y	Diabetes with complica	47649	C10E100	16	Type 1 diat % C10%
Y	Diabetes with complica	99311	C10E111	1	Type I diab % C10%
Y	Diabetes with complica	98071	C10E112	2	Insulin-dep % C10%
Y	Diabetes with complica	42831	C10E200	21	Type 1 diat % C10%
Y	Diabetes with complica	101735	C10E212	1	Insulin-dep % C10%
Y	Diabetes with complica	47650	C10E300	29	Type 1 diat % C10%
Y	Diabetes with complica	91942	C10E311	4	Type I diab % C10%
Y	Diabetes with complica	45276	C10E312	13	Insulin dep % C10%
Y	Diabetes with complica	18683	C10E500	43	Type 1 diat % C10%
Y	Diabetes with complica	93878	C10E511	6	Type I diab % C10%
Y	Diabetes with complica	98704	C10E512	1	Insulin dep % C10%
Y	Diabetes with complica	69993	C10E600	11	Type 1 diat % C10%
Y	Diabetes with complica	102112	C10E611	6	Type I diab % C10%
Y	Diabetes with complica	109051	C10E612	1	Insulin dep % C10%
Y	Diabetes with complica	18387	C10E700	472	Type 1 diat % C10%
Y	Diabetes with complica	95343	C10E711	11	Type I diab % C10%
Y	Diabetes with complica	93875	C10E712	6	Insulin dep % C10%
Y	Diabetes with complica	68105	C10EB00	9	Type 1 diat % C10%
Y	Diabetes with complica	46301	C10EC00	27	Type 1 diat % C10%
Y	Diabetes with complica	91943	C10EC11	1	Type I diab % C10%
Y	Diabetes with complica	101311	C10EC12	2	Insulin dep % C10%
Y	Diabetes with complica	10418	C10ED00	450	Type 1 diat % C10%
Y	Diabetes with complica	102163	C10ED12	1	Insulin dep % C10%
Y	Diabetes with complica	49554	C10EF00	19	Type 1 diat % C10%
Y	Diabetes with complica	100770	C10EF12	1	Insulin dep % C10%
Y	Diabetes with complica	93468	C10EG00	3	Type 1 diat % C10%
Y	Diabetes with complica	18642	C10EH00	10	Type 1 diat % C10%
Y	Diabetes with complica	54008	C10EJ00	53	Type 1 diat % C10%
Y	Diabetes with complica	30323	C10EK00	492	Type 1 diat % C10%
Y	Diabetes with complica	30294	C10EL00	426	Type 1 diat % C10%
Y	Diabetes with complica	102620	C10EL11	1	Type I diab % C10%
Y	Diabetes with complica	22871	C10EP00	59	Type 1 diat % C10%
Y	Diabetes with complica	97894	C10EP11	1	Type I diab % C10%
Y	Diabetes with complica	55239	C10EQ00	215	Type 1 diat % C10%
Y	Diabetes with complica	108724	C10EQ11	1	Type I diab % C10%
Y	Diabetes with complica	18777	C10F000	197	Type 2 diat % C10%
Y	Diabetes with complica	57278	C10F011	4	Type II diat % C10%
Y	Diabetes with complica	47321	C10F100	70	Type 2 diat % C10%
Y	Diabetes with complica	100964	C10F111	3	Type II diat % C10%
Y	Diabetes with complica	34268	C10F200	157	Type 2 diat % C10%
Y	Diabetes with complica	98616	C10F211	2	Type II diat % C10%
Y	Diabetes with complica	65267	C10F300	29	Type 2 diat % C10%
Y	Diabetes with complica	43227	C10F311	10	Type II diat % C10%
Y	Diabetes with complica	49074	C10F400	104	Type 2 diat % C10%
Y	Diabetes with complica	91646	C10F411	5	Type II diat % C10%
Y	Diabetes with complica	12736	C10F500	48	Type 2 diat % C10%
Y	Diabetes with complica	104323	C10F511	1	Type II diat % C10%
Y	Diabetes with complica	18496	C10F600	1687	Type 2 diat % C10%
Y	Diabetes with complica	49655	C10F611	28	Type II diat % C10%

Y	Diabetes with complica	62674 C10FA00	65 Type 2 diat % C10%
Y	Diabetes with complica	95351 C10FA11	10 Type II diat % C10%
Y	Diabetes with complica	18425 C10FB00	210 Type 2 diat % C10%
Y	Diabetes with complica	50527 C10FB11	6 Type II diat % C10%
Y	Diabetes with complica	12640 C10FC00	1907 Type 2 diat % C10%
Y	Diabetes with complica	102201 C10FC11	18 Type II diat % C10%
Y	Diabetes with complica	44982 C10FE00	132 Type 2 diat % C10%
Y	Diabetes with complica	93727 C10FE11	29 Type II diat % C10%
Y	Diabetes with complica	37806 C10FF00	52 Type 2 diat % C10%
Y	Diabetes with complica	104639 C10FF11	19 Type II diat % C10%
Y	Diabetes with complica	59253 C10FG00	46 Type 2 diat % C10%
Y	Diabetes with complica	103902 C10FG11	13 Type II diat % C10%
Y	Diabetes with complica	35385 C10FH00	176 Type 2 diat % C10%
Y	Diabetes with complica	109197 C10FH11	1 Type II diat % C10%
Y	Diabetes with complica	26054 C10FL00	4239 Type 2 diat % C10%
Y	Diabetes with complica	60796 C10FL11	59 Type II diat % C10%
Y	Diabetes with complica	18390 C10FM00	7597 Type 2 diat % C10%
Y	Diabetes with complica	85991 C10FM11	4 Type II diat % C10%
Y	Diabetes with complica	25591 C10FQ00	175 Type 2 diat % C10%
Y	Diabetes with complica	63690 C10FR00	138 Type 2 diat % C10%
Y	Diabetes with complica	100292 Cyu2300	2 [X]Unspeci % Cyu2%
Y	Diabetes with complica	17067 F171100	2226 Autonomic % F1711%
Y	Diabetes with complica	44033 F345000	43 Diabetic m % F3450%
Y	Diabetes with complica	17247 F35z000	197 Diabetic m % F35z0%
Y	Diabetes with complica	31790 F372.00	1302 Polyneuroç % F372%
Y	Diabetes with complica	5002 F372.11	362 Diabetic pc % F372%
Y	Diabetes with complica	2342 F372.12	8193 Diabetic ne % F372%
Y	Diabetes with complica	48078 F372000	129 Acute pain! % F372%
Y	Diabetes with complica	35785 F372100	368 Chronic pai % F372%
Y	Diabetes with complica	24571 F372200	186 Asymptom % F372%
Y	Diabetes with complica	39420 F381300	34 Myasthenic % F3813%
Y	Diabetes with complica	2340 F381311	581 Diabetic an % F3813%
Y	Diabetes with complica	37315 F3y0.00	294 Diabetic m % F3y0%
Y	Diabetes with complica	1323 F420.00	86521 Diabetic re % F420%
Y	Diabetes with complica	7069 F420000	71825 Background % F420%
Y	Diabetes with complica	3286 F420100	7895 Proliferativ % F420%
Y	Diabetes with complica	2986 F420200	4048 Preprolifer: % F420%
Y	Diabetes with complica	10099 F420300	761 Advanced ç % F420%
Y	Diabetes with complica	3837 F420400	20884 Diabetic m: % F420%
Y	Diabetes with complica	47584 F420500	115 Advanced ç % F420%
Y	Diabetes with complica	10755 F420600	11753 Non prolife % F420%
Y	Diabetes with complica	11626 F420z00	1869 Diabetic re % F420%
Y	Diabetes with complica	17313 F440700	53 Diabetic iri! % F4407%
Y	Diabetes with complica	10659 F464000	1514 Diabetic ca % F4640%
Y	Diabetes with complica	34152 G73y000	215 Diabetic pe % G73y0%
Y	Diabetes with complica	2471 K01x100	267 Nephrotic ç % K01x1%
Y	Diabetes with complica	45499 K01x111	8 Kimmelstie % K01x1%
Y	Diabetes with complica	105302 K08yA00	169 Proteinuric % K08yA%
Y	Diabetes with complica	107881 K08yA11	1 Clinical dial % K08yA%
Y	Diabetes with complica	99628 Kyu0300	2 [X]Glomerç % Kyu03%

Y	Diabetes with complica	7328	M037200	627	Cellulitis in % M0372%
Y	Diabetes with complica	24327	M271000	2114	Ischaemic c % M271%
Y	Diabetes with complica	11663	M271100	1740	Neuropath % M271%
Y	Diabetes with complica	9881	M271200	2420	Mixed diab % M271%
Y	Diabetes with complica	18142	N030000	250	Diabetic ch % N030%
Y	Diabetes with complica	57333	N030011	27	Diabetic ch % N030%
Y	Diabetes with complica	27891	N030100	793	Diabetic Ch % N030%
Y	Diabetes with complica	53634	R054200	82	[D]Gangrer % R0542%
Y	Diabetes with complica	31053	R054300	46	[D]Widespr % R0543%
Y	hemiplegia/paraplegia	22135	2833	529	O/E - hemij % 2833%
Y	hemiplegia/paraplegia	36133	2835	80	O/E - paraç % 2835%
Y	hemiplegia/paraplegia	8282	2836	179	O/E - quadri % 2836%
Y	hemiplegia/paraplegia	1749	F22..00	16823	Hemiplegia % F22%
Y	hemiplegia/paraplegia	807	F22..11	14542	Hemiparesi % F22%
Y	hemiplegia/paraplegia	39085	F220.00	85	Flaccid hen % F22%
Y	hemiplegia/paraplegia	20122	F221.00	1264	Spastic hen % F22%
Y	hemiplegia/paraplegia	35106	F221.11	128	Spastic foo % F22%
Y	hemiplegia/paraplegia	8933	F222.00	2024	Left hemipl % F22%
Y	hemiplegia/paraplegia	8862	F222.11	4854	Left sided v % F22%
Y	hemiplegia/paraplegia	3293	F223.00	1877	Right hemij % F22%
Y	hemiplegia/paraplegia	2713	F223.11	3769	Right sided % F22%
Y	hemiplegia/paraplegia	8492	F22z.00	2164	Hemiplegia % F22%
Y	hemiplegia/paraplegia	99040	F230.11	1	Paraplegia % F230%
Y	hemiplegia/paraplegia	37160	F230000	35	Congenital % F230%
Y	hemiplegia/paraplegia	27966	F231.00	422	Congenital % F231%
Y	hemiplegia/paraplegia	21249	F232.00	186	Congenital % F232%
Y	hemiplegia/paraplegia	48126	F232.11	21	Tetraplegia % F232%
Y	hemiplegia/paraplegia	2019	F234.00	224	Infantile he % F234%
Y	hemiplegia/paraplegia	9271	F240.00	2142	Quadripleg % F240%
Y	hemiplegia/paraplegia	16117	F240.11	1218	Tetraplegia % F240%
Y	hemiplegia/paraplegia	46128	F240000	9	Flaccid tetr % F240%
Y	hemiplegia/paraplegia	35540	F240100	412	Spastic tetr % F240%
Y	hemiplegia/paraplegia	3063	F241.00	4457	Paraplegia % F241%
Y	hemiplegia/paraplegia	46175	F241000	55	Flaccid par: % F241%
Y	hemiplegia/paraplegia	9375	F241100	1184	Spastic par % F241%
Y	hemiplegia/paraplegia	12793	F2A..00	2900	Hemiparesi % F2A%
Y	hemiplegia/paraplegia	65275	F2Az.00	106	Hemiparesi % F2A%
Y	hemiplegia/paraplegia	104580	F2B0.00	62	Spastic qua % F2B0%
Y	hemiplegia/paraplegia	105133	F2B1.00	14	Spastic hen % F2B1%
Y	HIV/AIDS	540	43C3.00	1112	HTLV-3 ant % 43C3%
Y	HIV/AIDS	2835	43C3.11	6219	HIV positiv % 43C3%
Y	HIV/AIDS	23770	A788.00	1106	Acquired in % A788%
Y	HIV/AIDS	9130	A788.11	2220	Human imr % A788%
Y	HIV/AIDS	58857	A788000	31	Acute hum % A788%
Y	HIV/AIDS	58859	A788100	109	Asymptom % A788%
Y	HIV/AIDS	69766	A788200	8	HIV infectic % A788%
Y	HIV/AIDS	70869	A788300	3	Human imr % A788%
Y	HIV/AIDS	53636	A788400	3	Human imr % A788%
Y	HIV/AIDS	70528	A788500	5	Human imr % A788%
Y	HIV/AIDS	101836	A788600		Human imr % A788%

Y	HIV/AIDS	47632 A788U00	3 HIV disease % A788%
Y	HIV/AIDS	67575 A788W00	10 HIV disease % A788%
Y	HIV/AIDS	71450 A788X00	2 HIV disease % A788%
Y	HIV/AIDS	62891 A788y00	9 Human imr % A788%
Y	HIV/AIDS	36294 A788z00	138 Acquired h % A788%
Y	HIV/AIDS	44303 A789.00	99 Human imr % A789%
Y	HIV/AIDS	37006 A789000	26 HIV disease % A789%
Y	HIV/AIDS	66368 A789100	4 HIV disease % A789%
Y	HIV/AIDS	23951 A789200	41 HIV disease % A789%
Y	HIV/AIDS	27641 A789300	187 HIV disease % A789%
Y	HIV/AIDS	104717 A789311	HIV disease % A789%
Y	HIV/AIDS	50076 A789400	13 HIV disease % A789%
Y	HIV/AIDS	27853 A789500	42 HIV disease % A789%
Y	HIV/AIDS	108054 A789511	1 HIV disease % A789%
Y	HIV/AIDS	44617 A789600	13 HIV disease % A789%
Y	HIV/AIDS	66367 A789700	10 HIV dis resl % A789%
Y	HIV/AIDS	105324 A789800	1 HIV disease % A789%
Y	HIV/AIDS	65117 A789900	8 HIV disease % A789%
Y	HIV/AIDS	8281 A789A00	11 HIV disease % A789%
Y	HIV/AIDS	51708 A789X00	6 HIV dis resl % A789%
Y	HIV/AIDS	62854 AyuC.00	33 [X]Human i % AyuC%
Y	HIV/AIDS	107807 AyuC100	1 [X]HIV dise % AyuC%
Y	HIV/AIDS	102117 AyuC300	1 [X]HIV dise % AyuC%
Y	HIV/AIDS	104134 AyuC400	1 [X]HIV dise % AyuC%
Y	HIV/AIDS	69767 AyuC600	2 [X]HIV dise % AyuC%
Y	HIV/AIDS	96751 AyuCB00	1 [X]HIV dise % AyuC%
Y	HIV/AIDS	102252 AyuCC00	2 [X]HIV dise % AyuC%
Y	HIV/AIDS	100769 AyuCD00	5 [X]Unspecii % AyuC%
Y	HIV/AIDS	41185 Eu02400	16 [X]Dement % Eu024%
Y	HIV/AIDS	104466 L179.00	3 HIV disease % L179.00%
Y	HIV/AIDS	44288 R109.00	108 [D]Laboratr % R109%
Y	HIV/AIDS	24872 ZV01A00	99 [V]Asympt % ZV01A%
Y	Metastatic cancer	101836 A788600	Human imr % A7886%
Y	Metastatic cancer	36147 B153.00	485 Secondary % B1%
Y	Metastatic cancer	9618 B56..00	732 Secondary % B5%
Y	Metastatic cancer	7830 B56..11	2004 Lymph nod % B5%
Y	Metastatic cancer	49214 B560.00	56 Secondary % B5%
Y	Metastatic cancer	64918 B560000	5 Secondary % B5%
Y	Metastatic cancer	66775 B560100	1 Secondary % B5%
Y	Metastatic cancer	33395 B560200	15 Secondary % B5%
Y	Metastatic cancer	65253 B560300	3 Secondary % B5%
Y	Metastatic cancer	92703 B560400	5 Secondary % B5%
Y	Metastatic cancer	39433 B560500	10 Secondary % B5%
Y	Metastatic cancer	28059 B560600	3 Secondary % B5%
Y	Metastatic cancer	38343 B560700	4 Secondary % B5%
Y	Metastatic cancer	44627 B560800	7 Secondary % B5%
Y	Metastatic cancer	68611 B560900	8 Secondary % B5%
Y	Metastatic cancer	67129 B560z00	16 Secondary % B5%
Y	Metastatic cancer	64116 B561.00	11 Secondary % B5%
Y	Metastatic cancer	37919 B561000	5 Secondary % B5%

Y	Metastatic cancer	105953 B561100	1 Secondary % B5%
Y	Metastatic cancer	95378 B561200	3 Secondary % B5%
Y	Metastatic cancer	25366 B561300	32 Secondary % B5%
Y	Metastatic cancer	55463 B561400	6 Secondary % B5%
Y	Metastatic cancer	58692 B561500	10 Secondary % B5%
Y	Metastatic cancer	67797 B561600	2 Secondary % B5%
Y	Metastatic cancer	69392 B561700	1 Secondary % B5%
Y	Metastatic cancer	62124 B561800	7 Secondary % B5%
Y	Metastatic cancer	52190 B561900	47 Secondary % B5%
Y	Metastatic cancer	93716 B561z00	4 Secondary % B5%
Y	Metastatic cancer	52736 B562.00	29 Secondary % B5%
Y	Metastatic cancer	41691 B562000	6 Secondary % B5%
Y	Metastatic cancer	72713 B562100	4 Secondary % B5%
Y	Metastatic cancer	61677 B562200	3 Secondary % B5%
Y	Metastatic cancer	18658 B562300	3 Secondary % B5%
Y	Metastatic cancer	69132 B562400	4 Secondary % B5%
Y	Metastatic cancer	44931 B562z00	16 Secondary % B5%
Y	Metastatic cancer	50199 B563.00	23 Secondary % B5%
Y	Metastatic cancer	37540 B563000	135 Secondary % B5%
Y	Metastatic cancer	98626 B563100	2 Secondary % B5%
Y	Metastatic cancer	50904 B563200	6 Secondary % B5%
Y	Metastatic cancer	46409 B563300	6 Secondary % B5%
Y	Metastatic cancer	73538 B563z00	6 Secondary % B5%
Y	Metastatic cancer	63915 B564.00	15 Secondary % B5%
Y	Metastatic cancer	54278 B564000	12 Secondary % B5%
Y	Metastatic cancer	61289 B564100	4 Secondary % B5%
Y	Metastatic cancer	70747 B564z00	7 Secondary % B5%
Y	Metastatic cancer	6701 B565.00	21 Secondary % B5%
Y	Metastatic cancer	84368 B565000	5 Secondary % B5%
Y	Metastatic cancer	101662 B565200	1 Secondary % B5%
Y	Metastatic cancer	47366 B565300	3 Secondary % B5%
Y	Metastatic cancer	72803 B565z00	5 Secondary % B5%
Y	Metastatic cancer	20159 B56y.00	24 Secondary % B5%
Y	Metastatic cancer	15507 B56z.00	231 Secondary % B5%
Y	Metastatic cancer	35053 B57..00	184 Secondary % B5%
Y	Metastatic cancer	6471 B57..11	1801 Metastase: % B5%
Y	Metastatic cancer	24301 B57..12	45 Secondary % B5%
Y	Metastatic cancer	4137 B570.00	4698 Secondary % B5%
Y	Metastatic cancer	51551 B571.00	37 Secondary % B5%
Y	Metastatic cancer	16213 B572.00	330 Secondary % B5%
Y	Metastatic cancer	62584 B573.00	27 Secondary % B5%
Y	Metastatic cancer	64680 B574.00	7 Secondary % B5%
Y	Metastatic cancer	55946 B574000	6 Secondary % B5%
Y	Metastatic cancer	99511 B574200	1 Secondary % B5%
Y	Metastatic cancer	70026 B574z00	7 Secondary % B5%
Y	Metastatic cancer	44529 B575.00	38 Secondary % B5%
Y	Metastatic cancer	28727 B575000	129 Secondary % B5%
Y	Metastatic cancer	62909 B575100	21 Secondary % B5%
Y	Metastatic cancer	36200 B575z00	8 Secondary % B5%
Y	Metastatic cancer	67396 B576.00	17 Secondary % B5%

Y	Metastatic cancer	35364 B576000	22 Secondary % B5%
Y	Metastatic cancer	27391 B576100	289 Secondary % B5%
Y	Metastatic cancer	8154 B576200	744 Malignant ; % B5%
Y	Metastatic cancer	97672 B576z00	3 Secondary % B5%
Y	Metastatic cancer	15103 B577.00	4513 Secondary % B5%
Y	Metastatic cancer	4403 B577.11	12523 Liver meta: % B5%
Y	Metastatic cancer	56345 B57y.00	44 Secondary % B5%
Y	Metastatic cancer	66083 B57z.00	23 Secondary % B5%
Y	Metastatic cancer	5842 B58..00	6291 Secondary % B5%
Y	Metastatic cancer	27651 B58..11	161 Secondary % B5%
Y	Metastatic cancer	1952 B580.00	143 Secondary % B5%
Y	Metastatic cancer	73213 B581.00	11 Secondary % B5%
Y	Metastatic cancer	60134 B581000	2 Secondary % B5%
Y	Metastatic cancer	22146 B581100	83 Secondary % B5%
Y	Metastatic cancer	53528 B581200	6 Secondary % B5%
Y	Metastatic cancer	62828 B581z00	10 Secondary % B5%
Y	Metastatic cancer	19945 B582.00	331 Secondary % B5%
Y	Metastatic cancer	43930 B582000	12 Secondary % B5%
Y	Metastatic cancer	100296 B582100	5 Secondary % B5%
Y	Metastatic cancer	35999 B582200	12 Secondary % B5%
Y	Metastatic cancer	41144 B582300	32 Secondary % B5%
Y	Metastatic cancer	63896 B582400	5 Secondary % B5%
Y	Metastatic cancer	48828 B582500	12 Secondary % B5%
Y	Metastatic cancer	9505 B582600	65 Secondary % B5%
Y	Metastatic cancer	55096 B582z00	26 Secondary % B5%
Y	Metastatic cancer	33843 B583.00	334 Secondary % B5%
Y	Metastatic cancer	5198 B583000	2972 Secondary % B5%
Y	Metastatic cancer	38918 B583100	133 Secondary % B5%
Y	Metastatic cancer	5199 B583200	5252 Cerebral m % B5%
Y	Metastatic cancer	59375 B583z00	22 Secondary % B5%
Y	Metastatic cancer	54120 B584.00	5 Secondary % B5%
Y	Metastatic cancer	7654 B585.00	6697 Secondary % B5%
Y	Metastatic cancer	18676 B585000	915 Pathologic: % B5%
Y	Metastatic cancer	44615 B586.00	113 Secondary % B5%
Y	Metastatic cancer	36401 B587.00	141 Secondary % B5%
Y	Metastatic cancer	18616 B58y.00	281 Secondary % B5%
Y	Metastatic cancer	16760 B58y000	335 Secondary % B5%
Y	Metastatic cancer	55090 B58y100	19 Secondary % B5%
Y	Metastatic cancer	73616 B58y200	14 Secondary % B5%
Y	Metastatic cancer	97832 B58y211	4 Secondary % B5%
Y	Metastatic cancer	70736 B58y300	7 Secondary % B5%
Y	Metastatic cancer	60335 B58y400	20 Secondary % B5%
Y	Metastatic cancer	65490 B58y411	2 Secondary % B5%
Y	Metastatic cancer	21590 B58y500	328 Secondary % B5%
Y	Metastatic cancer	34145 B58y600	5 Secondary % B5%
Y	Metastatic cancer	49145 B58y700	8 Secondary % B5%
Y	Metastatic cancer	104480 B58y800	1 Secondary % B5%
Y	Metastatic cancer	45824 B58y900	7 Secondary % B5%
Y	Metastatic cancer	22524 B58yz00	283 Secondary % B5%
Y	Metastatic cancer	16500 B58z.00	765 Secondary % B5%

Y	Metastatic cancer	54679 B594.00	80 Secondary % B5%
Y	Metastatic cancer	3197 BB03.00	21190 [M]Neopla: % BB%
Y	Metastatic cancer	6985 BB03.11	188 [M]Second % BB%
Y	Metastatic cancer	3152 BB13.00	11967 [M]Carcino % BB%
Y	Metastatic cancer	9366 BB13.11	290 [M]Second % BB%
Y	Metastatic cancer	66163 ByuC200	9 [X]2ndry+u % Byu%
Y	Metastatic cancer	57481 ByuC300	38 [X]Seconda % Byu%
Y	Metastatic cancer	88022 ByuC400	25 [X]Seconda % Byu%
Y	Metastatic cancer	97091 ByuC500	6 [X]2ndry m % Byu%
Y	Metastatic cancer	68332 ByuC600	11 [X]2ndry m % Byu%
Y	Metastatic cancer	54253 ByuC700	220 [X]Seconda % Byu%
Y	Mild liver disease	99898 9kR..00	138 Chronic hej % 9kR..%
Y	Mild liver disease	26367 A707.00	149 Chronic vir: % A707%
Y	Mild liver disease	24813 A707000	52 Chronic vir: % A707%
Y	Mild liver disease	41096 A707100	118 Chronic vir: % A707%
Y	Mild liver disease	30586 A707200	2504 Chronic vir: % A707%
Y	Mild liver disease	106642 A707300	55 Chronic vir: % A707%
Y	Mild liver disease	32277 A707X00	44 Chronic vir: % A707%
Y	Mild liver disease	57995 C310200	11 Hepatoren: % C31020%
Y	Mild liver disease	19512 C310400	92 Glycogeno: % C31040%
Y	Mild liver disease	8206 C350012	42 Pigmentary % C350012%
Y	Mild liver disease	102922 C370800	1 Cystic fibro % C3708%
Y	Mild liver disease	6863 J61..00	5898 Cirrhosis ar % J61%
Y	Mild liver disease	4743 J612.00	10048 Alcoholic ci % J61%
Y	Mild liver disease	68376 J612.11	4 Florid cirrh % J61%
Y	Mild liver disease	100474 J612.12	2 Laennec's c % J61%
Y	Mild liver disease	1754 J614.00	4685 Chronic hej % J61%
Y	Mild liver disease	23578 J614000	186 Chronic pei % J61%
Y	Mild liver disease	9029 J614100	2278 Chronic act % J61%
Y	Mild liver disease	7957 J614111	999 Autoimmui % J61%
Y	Mild liver disease	1755 J614200	42 Chronic ag: % J61%
Y	Mild liver disease	53480 J614300	24 Recurrent l % J61%
Y	Mild liver disease	66534 J614400	17 Chronic lo: % J61%
Y	Mild liver disease	53877 J614y00	51 Chronic hej % J61%
Y	Mild liver disease	15489 J614z00	513 Chronic hej % J61%
Y	Mild liver disease	16725 J615.00	850 Cirrhosis - r % J61%
Y	Mild liver disease	47257 J615.11	14 Portal cirrh % J61%
Y	Mild liver disease	69204 J615100	2 Multilobul: % J61%
Y	Mild liver disease	3450 J615300	120 Diffuse noc % J61%
Y	Mild liver disease	44676 J615400	3 Fatty porta % J61%
Y	Mild liver disease	92909 J615500	3 Hypertropt % J61%
Y	Mild liver disease	40567 J615600	9 Capsular pr % J61%
Y	Mild liver disease	27438 J615700	30 Cardiac por % J61%
Y	Mild liver disease	108819 J615711	1 Congestive % J61%
Y	Mild liver disease	96664 J615800	3 Juvenile po % J61%
Y	Mild liver disease	58184 J615812	3 Indian chilc % J61%
Y	Mild liver disease	100253 J615C00	1 Xanthomat % J61%
Y	Mild liver disease	73482 J615D00	1 Bacterial pr % J61%
Y	Mild liver disease	48928 J615H00	12 Infectious c % J61%
Y	Mild liver disease	55454 J615y00	16 Portal cirrh % J61%

Y	Mild liver disease	16455	J615z00	565	Non-alcohc % J61%
Y	Mild liver disease	22841	J615z11	126	Macronodu % J61%
Y	Mild liver disease	18739	J615z12	396	Cryptogeni % J61%
Y	Mild liver disease	1638	J615z13	7230	Cirrhosis of % J61%
Y	Mild liver disease	9494	J616.00	1939	Biliary cirrh % J61%
Y	Mild liver disease	5638	J616000	5462	Primary bil % J61%
Y	Mild liver disease	15424	J616100	39	Secondary % J61%
Y	Mild liver disease	91591	J616200	1	Biliary cirrh % J61%
Y	Mild liver disease	58630	J616z00	40	Biliary cirrh % J61%
Y	Mild liver disease	7602	J617000	123	Chronic alc % J61%
Y	Mild liver disease	17219	J635300	13	Toxic liver (% J635%
Y	Mild liver disease	64750	J635400	7	Toxic liver (% J635%
Y	Mild liver disease	39351	J635500	17	Toxic liver (% J635%
Y	Mild liver disease	44120	J635600	17	Toxic liver (% J635%
Y	Mild liver disease	6015	Jyu7100	247	[X]Other ar % Jyu71%
Y	Mod/severe liver disea	4405	7800	1071	Transplant: % 7800%
Y	Mod/severe liver disea	32025	7800000	136	Orthotopic % 7800%
Y	Mod/severe liver disea	71422	7800100	3	Heterotopi % 7800%
Y	Mod/severe liver disea	89445	7800111	1	Auxillary liv % 7800%
Y	Mod/severe liver disea	100073	7800112	2	Piggy back % 7800%
Y	Mod/severe liver disea	69194	7800200	9	Replaceme % 7800%
Y	Mod/severe liver disea	105506	7800400	1	Orthotopic % 7800%
Y	Mod/severe liver disea	97157	7800500	2	Orthotopic % 7800%
Y	Mod/severe liver disea	99250	7800y00	1	Other spec % 7800%
Y	Mod/severe liver disea	27319	7800z00	194	Transplant: % 7800%
Y	Mod/severe liver disea	24989	G850.00	1565	Oesophage % G850%
Y	Mod/severe liver disea	30655	G851.00	884	Oesophage % G851%
Y	Mod/severe liver disea	44424	G852.00	26	Oesophage % G852%
Y	Mod/severe liver disea	96756	G852000	1	Oesophage % G852%
Y	Mod/severe liver disea	73139	G852100	1	Oesophage % G852%
Y	Mod/severe liver disea	26319	G852200	165	Oesophage % G852%
Y	Mod/severe liver disea	8363	G852300	355	Oesophage % G852%
Y	Mod/severe liver disea	62582	G852z00	20	Oesophage % G852%
Y	Mod/severe liver disea	10797	G858.00	3471	Oesophage % G858%
Y	Mod/severe liver disea	23511	J622.00	148	Hepatic coi % J62%
Y	Mod/severe liver disea	22411	J622.11	1399	Encephalor % J62%
Y	Mod/severe liver disea	5129	J623.00	3571	Portal hype % J62%
Y	Mod/severe liver disea	10636	J624.00	361	Hepatoren: % J62%
Y	Mod/severe liver disea	6692	SP08600	138	Liver trans: % SP086%
Y	Mod/severe liver disea	9026	ZV42700	1247	[V]Liver tra % ZV427%
Y	Mod/Severe Renal dise	20196	14V2.00	1916	H/O: renal % 14V2%
Y	Mod/Severe Renal dise	44422	14V2.11	46	H/O: kidne % 14V2%
Y	Mod/Severe Renal dise	12720	1Z1..00	18706	Chronic rer % 1Z1%
Y	Mod/Severe Renal dise	29013	1Z10.00	20522	Chronic kid % 1Z1%
Y	Mod/Severe Renal dise	12586	1Z11.00	82157	Chronic kid % 1Z1%
Y	Mod/Severe Renal dise	12566	1Z12.00	398835	Chronic kid % 1Z1%
Y	Mod/Severe Renal dise	12479	1Z13.00	43667	Chronic kid % 1Z1%
Y	Mod/Severe Renal dise	12585	1Z14.00	8617	Chronic kid % 1Z1%
Y	Mod/Severe Renal dise	94965	1Z15.00	13255	Chronic kid % 1Z1%
Y	Mod/Severe Renal dise	95179	1Z16.00	5848	Chronic kid % 1Z1%

Y	Mod/Severe Renal dise	94789 1Z17.00	115 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	97980 1Z17.11	4 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95572 1Z18.00	210 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	95146 1Z19.00	411 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	97979 1Z19.11	18 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95121 1Z1A.00	2064 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	97978 1Z1A.11	19 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	94793 1Z1B.00	2520 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	95145 1Z1B.11	38 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95123 1Z1C.00	9854 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	95188 1Z1C.11	84 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95408 1Z1D.00	1320 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	95571 1Z1D.11	18 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95175 1Z1E.00	10602 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	95176 1Z1E.11	36 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95178 1Z1F.00	1061 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	95180 1Z1F.11	12 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95177 1Z1G.00	3934 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	100633 1Z1G.11	8 CKD stage :% 1Z1%
Y	Mod/Severe Renal dise	95122 1Z1H.00	1102 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	99312 1Z1H.11	63 CKD stage % 1Z1%
Y	Mod/Severe Renal dise	95406 1Z1J.00	1367 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	97587 1Z1J.11	14 CKD stage % 1Z1%
Y	Mod/Severe Renal dise	95508 1Z1K.00	313 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	99160 1Z1K.11	13 CKD stage !% 1Z1%
Y	Mod/Severe Renal dise	95405 1Z1L.00	116 Chronic kid% 1Z1%
Y	Mod/Severe Renal dise	97683 1Z1L.11	8 CKD stage !% 1Z1%
Y	Mod/Severe Renal dise	19473 66i..00	55821 Chronic kid% 66i..%
Y	Mod/Severe Renal dise	60302 7A60600	320 Creation of % 7A606%
Y	Mod/Severe Renal dise	96347 7A61900	11 Ligation of % 7A619%
Y	Mod/Severe Renal dise	107719 7A61A00	1 Ligation of % 7A61A%
Y	Mod/Severe Renal dise	2997 7B00.00	5588 Transplant:% 7B00%
Y	Mod/Severe Renal dise	55151 7B00000	18 Autotransp % 7B00%
Y	Mod/Severe Renal dise	11745 7B00100	2094 Transplant:% 7B00%
Y	Mod/Severe Renal dise	66705 7B00111	3 Allotranspl:% 7B00%
Y	Mod/Severe Renal dise	24361 7B00200	526 Transplant:% 7B00%
Y	Mod/Severe Renal dise	98364 7B00211	2 Allotranspl:% 7B00%
Y	Mod/Severe Renal dise	105328 7B00212	41 Cadaveric r % 7B00%
Y	Mod/Severe Renal dise	89924 7B00300	9 Allotranspl:% 7B00%
Y	Mod/Severe Renal dise	96133 7B00400	8 Allotranspl:% 7B00%
Y	Mod/Severe Renal dise	105787 7B00600	3 Xenograft r % 7B00%
Y	Mod/Severe Renal dise	70874 7B00y00	9 Other spec % 7B00%
Y	Mod/Severe Renal dise	5504 7B00z00	1986 Transplant:% 7B00%
Y	Mod/Severe Renal dise	48121 7B01500	193 Transplant % 7B015%
Y	Mod/Severe Renal dise	72004 7B01511	4 Excision of % 7B015%
Y	Mod/Severe Renal dise	93366 7B0F.00	5 Interventio % 7B0F%
Y	Mod/Severe Renal dise	90952 7B0F100	3 Pre-transpl % 7B0F%
Y	Mod/Severe Renal dise	96095 7B0F200	16 Pre-transpl % 7B0F%
Y	Mod/Severe Renal dise	103429 7B0F300	2 Post-transç % 7B0F%
Y	Mod/Severe Renal dise	94964 7B0F400	4 Post-transç % 7B0F%

Y	Mod/Severe Renal dise	104050 7B0Fy00	1 OS interver % 7B0F%
Y	Mod/Severe Renal dise	104049 7B0Fz00	2 Interventio % 7B0F%
Y	Mod/Severe Renal dise	31549 7L1A.00	150 Compensat % 7L1A%
Y	Mod/Severe Renal dise	11773 7L1A.11	2711 Dialysis for % 7L1A%
Y	Mod/Severe Renal dise	20073 7L1A000	1206 Renal dialy: % 7L1A%
Y	Mod/Severe Renal dise	101756 7L1A011	3 Thomas int % 7L1A%
Y	Mod/Severe Renal dise	2994 7L1A100	2666 Peritoneal % 7L1A%
Y	Mod/Severe Renal dise	2996 7L1A200	5482 Haemodial: % 7L1A%
Y	Mod/Severe Renal dise	71124 7L1A300	70 Haemofiltr: % 7L1A%
Y	Mod/Severe Renal dise	88597 7L1A400	21 Automated % 7L1A%
Y	Mod/Severe Renal dise	30756 7L1A500	102 Continuous: % 7L1A%
Y	Mod/Severe Renal dise	64828 7L1A600	136 Peritoneal % 7L1A%
Y	Mod/Severe Renal dise	48022 7L1Ay00	7 Other spec % 7L1A%
Y	Mod/Severe Renal dise	64636 7L1Az00	3 Compensat % 7L1A%
Y	Mod/Severe Renal dise	56760 7L1B.00	19 Placement % 7L1B%
Y	Mod/Severe Renal dise	36442 7L1B.11	33 Placement % 7L1B%
Y	Mod/Severe Renal dise	8037 7L1B000	581 Insertion o % 7L1B%
Y	Mod/Severe Renal dise	23773 7L1B100	276 Removal of % 7L1B%
Y	Mod/Severe Renal dise	104586 7L1B200	1 Flushing of % 7L1B%
Y	Mod/Severe Renal dise	59194 7L1By00	1 Placement % 7L1B%
Y	Mod/Severe Renal dise	83513 7L1C.00	18 Placement % 7L1C%
Y	Mod/Severe Renal dise	30709 7L1C000	184 Insertion o % 7L1C%
Y	Mod/Severe Renal dise	107901 7L1Cy00	1 Placement % 7L1C%
Y	Mod/Severe Renal dise	65089 7L1Cz00	3 Placement % 7L1C%
Y	Mod/Severe Renal dise	71271 9Ot..00	4071 Chronic kid % 9Ot%
Y	Mod/Severe Renal dise	30739 9Ot0.00	84533 Chronic kid % 9Ot%
Y	Mod/Severe Renal dise	72962 9Ot1.00	16110 Chronic kid % 9Ot%
Y	Mod/Severe Renal dise	72964 9Ot2.00	5509 Chronic kid % 9Ot%
Y	Mod/Severe Renal dise	88494 9Ot3.00	1383 Chronic kid % 9Ot%
Y	Mod/Severe Renal dise	69679 9Ot4.00	2548 Chronic kid % 9Ot%
Y	Mod/Severe Renal dise	89332 9Ot5.00	27 Predicted s % 9Ot%
Y	Mod/Severe Renal dise	25394 D215000	634 Anaemia se % D2150%
Y	Mod/Severe Renal dise	19454 F374A00	29 Polyneuroç % F374A%
Y	Mod/Severe Renal dise	40956 G500400	25 Acute peric % G5004%
Y	Mod/Severe Renal dise	105760 G72C.00	Ruptured a % G72C%
Y	Mod/Severe Renal dise	107188 G72D.00	3 Aneurysm (% G72D%
Y	Mod/Severe Renal dise	107220 G72D100	1 Aneurysm (% G72D%
Y	Mod/Severe Renal dise	105742 G72D200	2 Aneurysm (% G72D%
Y	Mod/Severe Renal dise	107746 Gy1..00	2 Stenosis of % Gy1%
Y	Mod/Severe Renal dise	108699 Gy10.00	1 Stenosis of % Gy1%
Y	Mod/Severe Renal dise	106720 Gy21.00	4 Thrombosi: % Gy2%
Y	Mod/Severe Renal dise	108116 Gy3..00	1 Occlusion c % Gy3%
Y	Mod/Severe Renal dise	109135 Gy30.00	1 Occlusion c % Gy3%
Y	Mod/Severe Renal dise	107082 Gy31.00	1 Occlusion c % Gy3%
Y	Mod/Severe Renal dise	108213 Gy40.00	1 Infection o % Gy4%
Y	Mod/Severe Renal dise	107260 Gy41.00	3 Infection o % Gy4%
Y	Mod/Severe Renal dise	108759 Gy5..00	1 Haemorrhæ % Gy5%
Y	Mod/Severe Renal dise	106975 Gy51.00	3 Haemorrhæ % Gy5%
Y	Mod/Severe Renal dise	108423 Gy60.00	1 Rupture of % Gy6%
Y	Mod/Severe Renal dise	7804 K02..00	1755 Chronic glo % K02%

Y	Mod/Severe Renal dise	10647 K02..11	366 Nephritis - % K02%
Y	Mod/Severe Renal dise	11875 K02..12	779 Nephropat % K02%
Y	Mod/Severe Renal dise	34998 K020.00	70 Chronic prc % K02%
Y	Mod/Severe Renal dise	10809 K021.00	288 Chronic me % K02%
Y	Mod/Severe Renal dise	61494 K022.00	24 Chronic me % K02%
Y	Mod/Severe Renal dise	65064 K023.00	4 Chronic raç % K02%
Y	Mod/Severe Renal dise	60960 K02y.00	12 Other chro % K02%
Y	Mod/Severe Renal dise	97758 K02y000	2 Chronic glo % K02%
Y	Mod/Severe Renal dise	4669 K02y200	190 Chronic foc % K02%
Y	Mod/Severe Renal dise	65400 K02y300	4 Chronic dif % K02%
Y	Mod/Severe Renal dise	63615 K02yz00	9 Other chro % K02%
Y	Mod/Severe Renal dise	15097 K02z.00	168 Chronic glo % K02%
Y	Mod/Severe Renal dise	512 K05..00	58754 Chronic rer % K05%
Y	Mod/Severe Renal dise	10081 K05..11	197 Chronic urç % K05%
Y	Mod/Severe Renal dise	53852 K05..12	112 End stage r % K05%
Y	Mod/Severe Renal dise	104981 K05..13	51 Chronic kid % K05%
Y	Mod/Severe Renal dise	6712 K050.00	3459 End stage r % K05%
Y	Mod/Severe Renal dise	105392 K051.00	19 Chronic kid % K05%
Y	Mod/Severe Renal dise	105383 K052.00	298 Chronic kid % K05%
Y	Mod/Severe Renal dise	104619 K053.00	9346 Chronic kid % K05%
Y	Mod/Severe Renal dise	104963 K054.00	826 Chronic kid % K05%
Y	Mod/Severe Renal dise	105151 K055.00	194 Chronic kid % K05%
Y	Mod/Severe Renal dise	350 K06..00	38003 Renal failur % K06%
Y	Mod/Severe Renal dise	4809 K06..11	2262 Uraemia Nr % K06%
Y	Mod/Severe Renal dise	107771 K06..12	4 Kidney failu % K06%
Y	Mod/Severe Renal dise	11787 K060.00	14737 Renal impa % K06%
Y	Mod/Severe Renal dise	6842 K060.11	7741 Impaired rç % K06%
Y	Mod/Severe Renal dise	21297 K0A3.00	74 Chronic nej % K0A3%
Y	Mod/Severe Renal dise	66505 K0A3000	5 Chronic nej % K0A3%
Y	Mod/Severe Renal dise	40413 K0A3100	10 Chronic nej % K0A3%
Y	Mod/Severe Renal dise	57168 K0A3200	11 Chron nept % K0A3%
Y	Mod/Severe Renal dise	56893 K0A3300	9 Chron nept % K0A3%
Y	Mod/Severe Renal dise	73026 K0A3500	3 Chronic nej % K0A3%
Y	Mod/Severe Renal dise	60198 K0A3600	7 Chronic nej % K0A3%
Y	Mod/Severe Renal dise	60857 K0A3700	18 Chronic nej % K0A3%
Y	Mod/Severe Renal dise	48057 K0B5.00	21 Renal tubu % K0B5%
Y	Mod/Severe Renal dise	8330 K0D..00	355 End-stage r % K0D%
Y	Mod/Severe Renal dise	100205 K0E..00	147 Acute-on-c % K0E%
Y	Mod/Severe Renal dise	106060 K105.00	5 Chronic infi % K105%
Y	Mod/Severe Renal dise	105746 K13C000	1 Chronic cyc % K13C0%
Y	Mod/Severe Renal dise	101453 Kyu1000	2 [X]Other ct % Kyu10%
Y	Mod/Severe Renal dise	100693 Kyu1C00	1 [X]Renal tu % Kyu1C%
Y	Mod/Severe Renal dise	61930 Kyu2.00	243 [X]Renal fa % Kyu2%
Y	Mod/Severe Renal dise	53940 Kyu2100	8 [X]Other ct % Kyu2%
Y	Mod/Severe Renal dise	48639 SP01500	38 Mechanica % SP015%
Y	Mod/Severe Renal dise	46438 SP05613	100 [X] Peritonı % SP05613%
Y	Mod/Severe Renal dise	101124 SP06B00	5 Continuous % SP06B%
Y	Mod/Severe Renal dise	59315 SP07G00	59 Stenosis of % SP07G%
Y	Mod/Severe Renal dise	70712 SP08011	5 Det.ren.fur % SP08%
Y	Mod/Severe Renal dise	11553 SP08300	320 Kidney trar % SP08%

Y	Mod/Severe Renal dise	104905 SP08D00	1 Acute-on-c % SP08%
Y	Mod/Severe Renal dise	104960 SP08E00	8 Acute rejec % SP08%
Y	Mod/Severe Renal dise	107000 SP08F00	1 Acute rejec % SP08%
Y	Mod/Severe Renal dise	104630 SP08G00	2 Acute rejec % SP08%
Y	Mod/Severe Renal dise	104201 SP08H00	10 Acute rejec % SP08%
Y	Mod/Severe Renal dise	106620 SP08J00	2 Chronic rej % SP08%
Y	Mod/Severe Renal dise	105724 SP08N00	3 Unexplaine % SP08%
Y	Mod/Severe Renal dise	106301 SP08P00	1 Stenosis of % SP08%
Y	Mod/Severe Renal dise	105811 SP08R00	10 Renal trans % SP08%
Y	Mod/Severe Renal dise	107752 SP08T00	1 Urological r % SP08%
Y	Mod/Severe Renal dise	108437 SP08V00	1 Very mild a % SP08%
Y	Mod/Severe Renal dise	108705 SP08V11	1 Borderline % SP08%
Y	Mod/Severe Renal dise	106866 SP08W00	2 Vascular cc % SP08%
Y	Mod/Severe Renal dise	107900 SP0E.00	2 Disorders a % SP0E%
Y	Mod/Severe Renal dise	108785 SP0F.00	1 Haemodial % SP0F%
Y	Mod/Severe Renal dise	105436 SP0G.00	1 Anaphylact % SP0G%
Y	Mod/Severe Renal dise	96184 TA02000	2 Accid cut,p % TA020%
Y	Mod/Severe Renal dise	69266 TA22000	3 Failure of s % TA220%
Y	Mod/Severe Renal dise	54990 TB00100	47 Kidney trar % TB001%
Y	Mod/Severe Renal dise	18774 TB00111	176 Renal trans % TB001%
Y	Mod/Severe Renal dise	28158 TB11.00	17 Kidney dial % TB11%
Y	Mod/Severe Renal dise	66714 TB11.11	5 Renal dialy % TB11%
Y	Mod/Severe Renal dise	5911 ZV42000	1669 [V]Kidney t % ZV420%
Y	Mod/Severe Renal dise	22252 ZV45100	298 [V]Renal di % ZV451%
Y	Mod/Severe Renal dise	60743 ZV56.00	12 [V]Aftercar % ZV56%
Y	Mod/Severe Renal dise	99692 ZV56000	1 [V]Aftercar % ZV56%
Y	Mod/Severe Renal dise	46145 ZV56011	16 [V]Aftercar % ZV56%
Y	Mod/Severe Renal dise	52088 ZV56100	26 [V]Prepara % ZV56%
Y	Mod/Severe Renal dise	63488 ZV56y00	3 [V]Other sr % ZV56%
Y	Mod/Severe Renal dise	45160 ZV56y11	5 [V]Aftercar % ZV56%
Y	Mod/Severe Renal dise	63038 ZV56z00	2 [V]Unspeci % ZV56%
Y	Myocardial infarction	35674 14A3.00	2373 H/O: myoc: % 14A3%
Y	Myocardial infarction	40399 14A4.00	1596 H/O: myoc: % 14A4%
Y	Myocardial infarction	50372 14AH.00	99 H/O: Myoc % 14AH%
Y	Myocardial infarction	100139 14AT.00	343 History of r % 14AT%
Y	Myocardial infarction	241 G30..00	203381 Acute myo: % G30%
Y	Myocardial infarction	13566 G30..11	408 Attack - he: % G30%
Y	Myocardial infarction	2491 G30..12	3344 Coronary tl % G30%
Y	Myocardial infarction	30421 G30..13	144 Cardiac rup % G30%
Y	Myocardial infarction	1204 G30..14	4453 Heart attac % G30%
Y	Myocardial infarction	1677 G30..15	78490 MI - acute i % G30%
Y	Myocardial infarction	13571 G30..16	396 Thrombosi: % G30%
Y	Myocardial infarction	17689 G30..17	391 Silent myor % G30%
Y	Myocardial infarction	12139 G300.00	1553 Acute ante % G30%
Y	Myocardial infarction	5387 G301.00	1870 Other spec % G30%
Y	Myocardial infarction	40429 G301000	90 Acute ante % G30%
Y	Myocardial infarction	17872 G301100	1007 Acute ante % G30%
Y	Myocardial infarction	14897 G301z00	2711 Anterior m: % G30%
Y	Myocardial infarction	8935 G302.00	1363 Acute infer % G30%
Y	Myocardial infarction	29643 G303.00	430 Acute infer % G30%

Y	Myocardial infarction	23892 G304.00	628 Posterior n % G30%
Y	Myocardial infarction	14898 G305.00	483 Lateral myc % G30%
Y	Myocardial infarction	63467 G306.00	48 True poste % G30%
Y	Myocardial infarction	3704 G307.00	3114 Acute sube % G30%
Y	Myocardial infarction	9507 G307000	828 Acute non- % G30%
Y	Myocardial infarction	10562 G307100	42454 Acute non- % G30%
Y	Myocardial infarction	1678 G308.00	11171 Inferior my % G30%
Y	Myocardial infarction	30330 G309.00	87 Acute Q-w: % G30%
Y	Myocardial infarction	32854 G30B.00	52 Acute post: % G30%
Y	Myocardial infarction	29758 G30X.00	145 Acute tran: % G30%
Y	Myocardial infarction	12229 G30X000	14036 Acute ST se % G30%
Y	Myocardial infarction	34803 G30y.00	193 Other acuti % G30%
Y	Myocardial infarction	28736 G30y000	77 Acute atria % G30%
Y	Myocardial infarction	62626 G30y100	3 Acute papil % G30%
Y	Myocardial infarction	41221 G30y200	150 Acute sept: % G30%
Y	Myocardial infarction	46017 G30yz00	298 Other acuti % G30%
Y	Myocardial infarction	14658 G30z.00	77767 Acute myo: % G30%
Y	Myocardial infarction	23579 G310.00	89 Postmyoca % G310%
Y	Myocardial infarction	15661 G310.11	494 Dressler's s % G310%
Y	Myocardial infarction	68357 G31y100	16 Microinfarc % G31y1%
Y	Myocardial infarction	4017 G32..00	9458 Old myoca: % G32%
Y	Myocardial infarction	16408 G32..11	337 Healed my: % G32%
Y	Myocardial infarction	17464 G32..12	1230 Personal hi % G32%
Y	Myocardial infarction	18842 G35..00	271 Subsequen % G35%
Y	Myocardial infarction	45809 G350.00	53 Subsequen % G35%
Y	Myocardial infarction	38609 G351.00	43 Subsequen % G35%
Y	Myocardial infarction	72562 G353.00	6 Subsequen % G35%
Y	Myocardial infarction	46166 G35X.00	10 Subsequen % G35%
Y	Myocardial infarction	36423 G36..00	29 Certain cur % G36%
Y	Myocardial infarction	24126 G360.00	152 Haemoperi % G36%
Y	Myocardial infarction	23708 G361.00	30 Atrial sept: % G36%
Y	Myocardial infarction	37657 G362.00	49 Ventric sep % G36%
Y	Myocardial infarction	59189 G363.00	6 Ruptur car: % G36%
Y	Myocardial infarction	59940 G364.00	2 Ruptur cho % G36%
Y	Myocardial infarction	69474 G365.00	4 Rupture pa % G36%
Y	Myocardial infarction	29553 G366.00	48 Thrombosi: % G36%
Y	Myocardial infarction	32272 G38..00	194 Postoperat % G38%
Y	Myocardial infarction	46112 G380.00	5 Postoperat % G38%
Y	Myocardial infarction	46276 G381.00	17 Postoperat % G38%
Y	Myocardial infarction	106812 G383.00	1 Postoperat % G38%
Y	Myocardial infarction	41835 G384.00	28 Postoperat % G38%
Y	Myocardial infarction	68748 G38z.00	11 Postoperat % G38%
Y	Myocardial infarction	35119 G501.00	45 Post infarct % G501%
Y	Myocardial infarction	96838 Gyu3400	1 [X]Acute tr. % Gyu34%
Y	Myocardial infarction	109035 Gyu3500	1 [X]Subsequ % Gyu35%
Y	Myocardial infarction	99991 Gyu3600	3 [X]Subsequ % Gyu36%
Y	Peptic ulcer disease	2489 J102.00	4971 Ulcer of oe % J102%
Y	Peptic ulcer disease	24021 J102000	269 Peptic ulce % J102%
Y	Peptic ulcer disease	49926 J102100	29 Fungal ulce % J102%
Y	Peptic ulcer disease	51013 J102200	15 Oesophage % J102%

Y	Peptic ulcer disease	94752 J102300	2 Oesophage % J102%
Y	Peptic ulcer disease	58603 J102400	20 Oesophage % J102%
Y	Peptic ulcer disease	5596 J102500	2436 Barrett's ul % J102%
Y	Peptic ulcer disease	42150 J102z00	242 Ulcer of oe % J102%
Y	Peptic ulcer disease	1262 J11..00	42221 Gastric ulcε % J11%
Y	Peptic ulcer disease	6333 J11..11	1566 Prepyloric ι % J11%
Y	Peptic ulcer disease	3101 J11..12	2551 Pyloric ulcε % J11%
Y	Peptic ulcer disease	24040 J110.00	307 Acute gastr % J11%
Y	Peptic ulcer disease	64165 J110000	30 Acute gastr % J11%
Y	Peptic ulcer disease	30054 J110100	292 Acute gastr % J11%
Y	Peptic ulcer disease	11124 J110111	414 Bleeding ac % J11%
Y	Peptic ulcer disease	14671 J110200	476 Acute gastr % J11%
Y	Peptic ulcer disease	71403 J110300	7 Acute gastr % J11%
Y	Peptic ulcer disease	24342 J110y00	10 Acute gastr % J11%
Y	Peptic ulcer disease	44324 J110z00	107 Acute gastr % J11%
Y	Peptic ulcer disease	18654 J111.00	332 Chronic ga: % J11%
Y	Peptic ulcer disease	48946 J111000	19 Chronic ga: % J11%
Y	Peptic ulcer disease	63582 J111100	58 Chronic ga: % J11%
Y	Peptic ulcer disease	36583 J111111	48 Bleeding ct % J11%
Y	Peptic ulcer disease	53336 J111200	46 Chronic ga: % J11%
Y	Peptic ulcer disease	11104 J111211	317 Perforated % J11%
Y	Peptic ulcer disease	71897 J111300	4 Chronic ga: % J11%
Y	Peptic ulcer disease	67356 J111400	3 Chronic ga: % J11%
Y	Peptic ulcer disease	64556 J111y00	8 Chronic ga: % J11%
Y	Peptic ulcer disease	44309 J111z00	119 Chronic ga: % J11%
Y	Peptic ulcer disease	63001 J112.00	1 Anti-platele % J11%
Y	Peptic ulcer disease	89227 J112z00	1 Anti-platele % J11%
Y	Peptic ulcer disease	89023 J113.00	31 Non steroid % J11%
Y	Peptic ulcer disease	97993 J113z00	0 Non steroid % J11%
Y	Peptic ulcer disease	53081 J11y.00	84 Unspecifier % J11%
Y	Peptic ulcer disease	73338 J11y000	14 Unspecifier % J11%
Y	Peptic ulcer disease	57958 J11y100	23 Unspecifier % J11%
Y	Peptic ulcer disease	36461 J11y200	33 Unspecifier % J11%
Y	Peptic ulcer disease	73697 J11y400	1 Unspecifier % J11%
Y	Peptic ulcer disease	94397 J11yy00	9 Unspec gas % J11%
Y	Peptic ulcer disease	44284 J11yz00	80 Unspecifier % J11%
Y	Peptic ulcer disease	29771 J11z.00	1573 Gastric ulcε % J11%
Y	Peptic ulcer disease	2877 J11z.11	7143 Gastric ero % J11%
Y	Peptic ulcer disease	52323 J11z.12	90 Multiple ga % J11%
Y	Peptic ulcer disease	352 J12..00	121081 Duodenal ι % J12%
Y	Peptic ulcer disease	18027 J120.00	519 Acute duoc % J12%
Y	Peptic ulcer disease	44335 J120000	93 Acute duoc % J12%
Y	Peptic ulcer disease	18001 J120100	583 Acute duoc % J12%
Y	Peptic ulcer disease	18324 J120200	801 Acute duoc % J12%
Y	Peptic ulcer disease	48730 J120300	21 Acute duoc % J12%
Y	Peptic ulcer disease	73417 J120400	3 Acute duoc % J12%
Y	Peptic ulcer disease	53822 J120y00	25 Acute duoc % J12%
Y	Peptic ulcer disease	53797 J120z00	354 Acute duoc % J12%
Y	Peptic ulcer disease	9853 J121.00	1065 Chronic du: % J12%
Y	Peptic ulcer disease	33438 J121000	67 Chronic du: % J12%

Y	Peptic ulcer disease	48951 J121100	181 Chronic du % J12%
Y	Peptic ulcer disease	18625 J121111	443 Bleeding ct % J12%
Y	Peptic ulcer disease	37643 J121200	283 Chronic du % J12%
Y	Peptic ulcer disease	23087 J121211	1582 Perforated % J12%
Y	Peptic ulcer disease	71881 J121300	4 Chronic du % J12%
Y	Peptic ulcer disease	44073 J121400	8 Chronic du % J12%
Y	Peptic ulcer disease	52138 J121y00	50 Chronic du % J12%
Y	Peptic ulcer disease	51406 J121z00	630 Chronic du % J12%
Y	Peptic ulcer disease	22918 J122.00	213 Duodenal t % J12%
Y	Peptic ulcer disease	3462 J123.00	1210 Duodenal e % J12%
Y	Peptic ulcer disease	29317 J124.00	548 Recurrent r % J12%
Y	Peptic ulcer disease	89234 J125.00	3 Anti-platelet % J12%
Y	Peptic ulcer disease	85989 J126.00	15 Non steroid % J12%
Y	Peptic ulcer disease	53669 J12y.00	60 Unspecified % J12%
Y	Peptic ulcer disease	71150 J12y000	14 Unspecified % J12%
Y	Peptic ulcer disease	2814 J12y100	763 Unspecified % J12%
Y	Peptic ulcer disease	657 J12y200	3038 Unspecified % J12%
Y	Peptic ulcer disease	93436 J12y300	1 Unspecified % J12%
Y	Peptic ulcer disease	71904 J12y400	2 Unspecified % J12%
Y	Peptic ulcer disease	28366 J12yy00	5 Unspec dur % J12%
Y	Peptic ulcer disease	65737 J12yz00	49 Unspecified % J12%
Y	Peptic ulcer disease	15175 J12z.00	4396 Duodenal t % J12%
Y	Peptic ulcer disease	670 J13..00	23163 Peptic ulce % J13%
Y	Peptic ulcer disease	15821 J13..11	918 Stress ulcer % J13%
Y	Peptic ulcer disease	32856 J130.00	171 Acute pept % J13%
Y	Peptic ulcer disease	68661 J130000	8 Acute pept % J13%
Y	Peptic ulcer disease	44637 J130100	75 Acute pept % J13%
Y	Peptic ulcer disease	5521 J130200	790 Acute pept % J13%
Y	Peptic ulcer disease	45304 J130300	2 Acute pept % J13%
Y	Peptic ulcer disease	67711 J130y00	11 Acute pept % J13%
Y	Peptic ulcer disease	50048 J130z00	106 Acute pept % J13%
Y	Peptic ulcer disease	40997 J131.00	93 Chronic pept % J13%
Y	Peptic ulcer disease	99430 J131000	4 Chronic pept % J13%
Y	Peptic ulcer disease	53126 J131100	16 Chronic pept % J13%
Y	Peptic ulcer disease	37620 J131200	10 Chronic pept % J13%
Y	Peptic ulcer disease	52313 J131400	1 Chronic pept % J13%
Y	Peptic ulcer disease	70390 J131y00	7 Chronic pept % J13%
Y	Peptic ulcer disease	69663 J131z00	35 Chronic pept % J13%
Y	Peptic ulcer disease	50497 J13y.00	67 Unspecified % J13%
Y	Peptic ulcer disease	67082 J13y000	3 Unspecified % J13%
Y	Peptic ulcer disease	70456 J13y100	7 Unspecified % J13%
Y	Peptic ulcer disease	64111 J13y200	22 Unspecified % J13%
Y	Peptic ulcer disease	96622 J13y300	1 Unspecified % J13%
Y	Peptic ulcer disease	99670 J13y400	1 Unspecified % J13%
Y	Peptic ulcer disease	60249 J13yz00	18 Unspecified % J13%
Y	Peptic ulcer disease	19928 J13z.00	3013 Peptic ulce % J13%
Y	Peripheral vascular dis	16993 14AE.00	1865 H/O: aortic % 14AE%
Y	Peripheral vascular dis	59534 14NB.00	27 H/O: Peripl % 14NB%
Y	Peripheral vascular dis	7975 16l..00	6257 Claudicatio % 16l..00%
Y	Peripheral vascular dis	11680 2I16.00	2199 O/E - gangr % 2I16%

Y	Peripheral vascular dis	18499 662U.00	9474 Peripheral % 662U%
Y	Peripheral vascular dis	103613 66f3.00	105 Aortic aneu % 66f3%
Y	Peripheral vascular dis	52358 7A11.00	33 Replaceme % 7A11%
Y	Peripheral vascular dis	96654 7A11000	1 Emerg repl % 7A11%
Y	Peripheral vascular dis	56495 7A11100	8 Replace an % 7A11%
Y	Peripheral vascular dis	69922 7A11200	6 Emerg repl % 7A11%
Y	Peripheral vascular dis	92925 7A11211	6 Y graft of a % 7A11%
Y	Peripheral vascular dis	56510 7A11300	11 Replace an % 7A11%
Y	Peripheral vascular dis	51166 7A11311	31 Y graft abd % 7A11%
Y	Peripheral vascular dis	62301 7A11y00	1 Replaceme % 7A11%
Y	Peripheral vascular dis	66761 7A11z00	5 Replaceme % 7A11%
Y	Peripheral vascular dis	31613 7A13.00	122 Emergency % 7A13%
Y	Peripheral vascular dis	17220 7A13.11	709 Emergency % 7A13%
Y	Peripheral vascular dis	99722 7A13000	1 Emerg repl % 7A13%
Y	Peripheral vascular dis	93060 7A13100	1 Emerg repl % 7A13%
Y	Peripheral vascular dis	66232 7A13300	8 Emerg repl % 7A13%
Y	Peripheral vascular dis	54192 7A13400	14 Emerg repl % 7A13%
Y	Peripheral vascular dis	63408 7A13411	18 Tube graft % 7A13%
Y	Peripheral vascular dis	45477 7A13y00	7 Emergency % 7A13%
Y	Peripheral vascular dis	45474 7A13z00	12 Emergency % 7A13%
Y	Peripheral vascular dis	43108 7A14.00	393 Other repl % 7A14%
Y	Peripheral vascular dis	1736 7A14.11	6546 Aortic aneu % 7A14%
Y	Peripheral vascular dis	64961 7A14000	16 Replace an % 7A14%
Y	Peripheral vascular dis	42444 7A14100	15 Replace an % 7A14%
Y	Peripheral vascular dis	54379 7A14200	1 Replace an % 7A14%
Y	Peripheral vascular dis	44553 7A14300	37 Replace an % 7A14%
Y	Peripheral vascular dis	19996 7A14400	74 Replace an % 7A14%
Y	Peripheral vascular dis	26232 7A14411	29 Tube graft % 7A14%
Y	Peripheral vascular dis	55445 7A14y00	19 Other repl % 7A14%
Y	Peripheral vascular dis	36651 7A14z00	71 Other repl % 7A14%
Y	Peripheral vascular dis	33430 7A19400	153 Operation % 7A194%
Y	Peripheral vascular dis	93959 7A1B.00	16 Translumin % 7A1B%
Y	Peripheral vascular dis	70446 7A1B000	67 Endovascu % 7A1B%
Y	Peripheral vascular dis	97030 7A1B100	6 Endovascu % 7A1B%
Y	Peripheral vascular dis	51061 7A1B200	21 Endovascu % 7A1B%
Y	Peripheral vascular dis	95976 7A1B500	23 Endovascu % 7A1B%
Y	Peripheral vascular dis	100195 7A1B600	4 Endovascu % 7A1B%
Y	Peripheral vascular dis	97109 7A1B700	1 Endovascu % 7A1B%
Y	Peripheral vascular dis	97217 7A1B800	86 Endovascu % 7A1B%
Y	Peripheral vascular dis	106780 7A1B900	3 Endovascu % 7A1B%
Y	Peripheral vascular dis	98542 7A1BA00	11 Endovascu % 7A1B%
Y	Peripheral vascular dis	99859 7A1BC00	3 Endovas in: % 7A1B%
Y	Peripheral vascular dis	98175 7A1BD00	2 Endovascu % 7A1B%
Y	Peripheral vascular dis	90861 7A1Bz00	10 Translumin % 7A1B%
Y	Peripheral vascular dis	94331 7A1C.00	19 Translum ir % 7A1C%
Y	Peripheral vascular dis	83577 7A1C000	156 Endovas in: % 7A1C%
Y	Peripheral vascular dis	94682 7A1C100	3 Endovas in: % 7A1C%
Y	Peripheral vascular dis	91462 7A1C200	32 Endov inse % 7A1C%
Y	Peripheral vascular dis	103427 7A1C500	5 Endovas in: % 7A1C%
Y	Peripheral vascular dis	98565 7A1Cy00	1 OS translur % 7A1C%

Y	Peripheral vascular dis	93627 7A1Cz00	3 Translum ir % 7A1C%
Y	Peripheral vascular dis	21927 7A41.00	156 Other bypa % 7A41%
Y	Peripheral vascular dis	101910 7A41.11	2 Other bypa % 7A41%
Y	Peripheral vascular dis	44250 7A41000	8 Emerg byp: % 7A41%
Y	Peripheral vascular dis	28616 7A41100	96 Bypass iliac % 7A41%
Y	Peripheral vascular dis	72448 7A41200	5 Emerg byp: % 7A41%
Y	Peripheral vascular dis	43648 7A41211	7 Emergency % 7A41%
Y	Peripheral vascular dis	36443 7A41300	24 Bypass iliac % 7A41%
Y	Peripheral vascular dis	30989 7A41311	28 Femoro-fer % 7A41%
Y	Peripheral vascular dis	68141 7A41400	2 Emerg byp: % 7A41%
Y	Peripheral vascular dis	66917 7A41600	1 Emerg byp: % 7A41%
Y	Peripheral vascular dis	32492 7A41900	7 Bypass con % 7A41%
Y	Peripheral vascular dis	55554 7A41B00	11 Bypass leg % 7A41%
Y	Peripheral vascular dis	66804 7A41C00	6 Bypass leg % 7A41%
Y	Peripheral vascular dis	100036 7A41D00	1 Bypass iliac % 7A41%
Y	Peripheral vascular dis	41768 7A41F00	111 Ilio-femora % 7A41%
Y	Peripheral vascular dis	52357 7A41y00	16 Other spec % 7A41%
Y	Peripheral vascular dis	38921 7A41z00	23 Other bypa % 7A41%
Y	Peripheral vascular dis	9099 7A47.00	81 Other eme % 7A47%
Y	Peripheral vascular dis	72491 7A47.11	4 Other eme % 7A47%
Y	Peripheral vascular dis	100113 7A47.12	1 Other eme % 7A47%
Y	Peripheral vascular dis	63238 7A47.13	1 Other eme % 7A47%
Y	Peripheral vascular dis	39776 7A47.14	76 Other eme % 7A47%
Y	Peripheral vascular dis	97606 7A47.15	1 Other eme % 7A47%
Y	Peripheral vascular dis	11766 7A47.16	171 Other eme % 7A47%
Y	Peripheral vascular dis	43651 7A47000	25 Emerg byp: % 7A47%
Y	Peripheral vascular dis	67818 7A47100	2 Emerg byp: % 7A47%
Y	Peripheral vascular dis	52342 7A47200	16 Emerg byp: % 7A47%
Y	Peripheral vascular dis	60693 7A47300	4 Emerg byp: % 7A47%
Y	Peripheral vascular dis	66820 7A47400	5 Emerg byp: % 7A47%
Y	Peripheral vascular dis	96255 7A47600	1 Emerg byp: % 7A47%
Y	Peripheral vascular dis	66879 7A47700	1 Emerg byp: % 7A47%
Y	Peripheral vascular dis	99676 7A47800	1 Emerg byp: % 7A47%
Y	Peripheral vascular dis	62775 7A47B00	1 Emerg byp: % 7A47%
Y	Peripheral vascular dis	48939 7A47C00	12 Emerg byp: % 7A47%
Y	Peripheral vascular dis	70922 7A47D00	4 Emerg byp: % 7A47%
Y	Peripheral vascular dis	65692 7A47y00	8 Other eme % 7A47%
Y	Peripheral vascular dis	68320 7A47z00	9 Other eme % 7A47%
Y	Peripheral vascular dis	24692 7A48.00	1163 Other bypa % 7A48%
Y	Peripheral vascular dis	61974 7A48.11	15 Other bypa % 7A48%
Y	Peripheral vascular dis	37787 7A48.12	18 Other bypa % 7A48%
Y	Peripheral vascular dis	18060 7A48.14	1703 Other bypa % 7A48%
Y	Peripheral vascular dis	12331 7A48.15	860 Other bypa % 7A48%
Y	Peripheral vascular dis	40732 7A48.16	20 Other bypa % 7A48%
Y	Peripheral vascular dis	27580 7A48000	420 Bypass fem % 7A48%
Y	Peripheral vascular dis	64555 7A48100	5 Bypass pop % 7A48%
Y	Peripheral vascular dis	28030 7A48200	361 Bypass fem % 7A48%
Y	Peripheral vascular dis	24097 7A48300	29 Bypass pop % 7A48%
Y	Peripheral vascular dis	39877 7A48400	22 Bypass fem % 7A48%
Y	Peripheral vascular dis	60465 7A48500	9 Bypass pop % 7A48%

Y	Peripheral vascular dis	41823 7A48600	54 Bypass fem % 7A48%
Y	Peripheral vascular dis	48700 7A48700	17 Bypass pop % 7A48%
Y	Peripheral vascular dis	67982 7A48800	3 Bypass fem % 7A48%
Y	Peripheral vascular dis	107158 7A48900	1 Bypass pop % 7A48%
Y	Peripheral vascular dis	53675 7A48A00	21 Bypass fem % 7A48%
Y	Peripheral vascular dis	68412 7A48B00	3 Bypass pop % 7A48%
Y	Peripheral vascular dis	45428 7A48C00	55 Bypass fem % 7A48%
Y	Peripheral vascular dis	42115 7A48D00	36 Bypass pop % 7A48%
Y	Peripheral vascular dis	22016 7A48E00	636 Femoro-fer % 7A48%
Y	Peripheral vascular dis	42640 7A48y00	121 Other bypa % 7A48%
Y	Peripheral vascular dis	2066 7A48z00	2945 Other bypa % 7A48%
Y	Peripheral vascular dis	106224 9m1..00	1790 Peripheral % 9m1%
Y	Peripheral vascular dis	106260 9m10.00	3807 Peripheral % 9m1%
Y	Peripheral vascular dis	106660 9m11.00	501 Peripheral % 9m1%
Y	Peripheral vascular dis	106855 9m12.00	264 Peripheral % 9m1%
Y	Peripheral vascular dis	51204 A3A0.00	57 Gas gangre % A3A0%
Y	Peripheral vascular dis	99592 A3A0000	1 Gas gangre % A3A0%
Y	Peripheral vascular dis	105609 A3A0100	1 Gas gangre % A3A0%
Y	Peripheral vascular dis	99978 A3A0200	3 Gas gangre % A3A0%
Y	Peripheral vascular dis	27349 A3A0500	27 Gas gangre % A3A0%
Y	Peripheral vascular dis	105581 A3A0B00	1 Gas gangre % A3A0%
Y	Peripheral vascular dis	99616 A3A0E00	2 Gas gangre % A3A0%
Y	Peripheral vascular dis	72632 A3A0F00	3 Gas gangre % A3A0%
Y	Peripheral vascular dis	1735 G71..00	36455 Aortic aneu % G71%
Y	Peripheral vascular dis	16521 G710.00	1396 Dissecting % G71%
Y	Peripheral vascular dis	27563 G711.00	118 Thoracic ac % G71%
Y	Peripheral vascular dis	16800 G711.11	221 Ruptured tl % G71%
Y	Peripheral vascular dis	23532 G712.00	909 Thoracic ac % G71%
Y	Peripheral vascular dis	17767 G713.00	907 Abdominal % G71%
Y	Peripheral vascular dis	13572 G713.11	1271 Ruptured a % G71%
Y	Peripheral vascular dis	63920 G713000	7 Ruptured s % G71%
Y	Peripheral vascular dis	1867 G714.00	7751 Abdominal % G71%
Y	Peripheral vascular dis	17345 G714.11	4692 AAA - Abdc % G71%
Y	Peripheral vascular dis	45521 G714000	66 Juxtarenal % G71%
Y	Peripheral vascular dis	28109 G714100	21 Inflammatc % G71%
Y	Peripheral vascular dis	101379 G714200	243 Infrarenal % G71%
Y	Peripheral vascular dis	101195 G714300	6 Aneurysm % G71%
Y	Peripheral vascular dis	15304 G715.00	921 Ruptured a % G71%
Y	Peripheral vascular dis	11430 G715000	51 Thoracoabr % G71%
Y	Peripheral vascular dis	16034 G716.00	302 Aortic aneu % G71%
Y	Peripheral vascular dis	40787 G716000	92 Thoracoabr % G71%
Y	Peripheral vascular dis	70260 G717.00	2 Aortic aneu % G71%
Y	Peripheral vascular dis	9759 G718.00	238 Leaking abr % G71%
Y	Peripheral vascular dis	6872 G71z.00	1150 Aortic aneu % G71%
Y	Peripheral vascular dis	5943 G73..00	19673 Other periç % G73%
Y	Peripheral vascular dis	5702 G73..11	2863 Peripheral % G73%
Y	Peripheral vascular dis	1826 G73..12	11361 Ischaemia % G73%
Y	Peripheral vascular dis	6827 G73..13	2427 Peripheral % G73%
Y	Peripheral vascular dis	9204 G732.00	909 Peripheral % G73%
Y	Peripheral vascular dis	5414 G732000	1443 Gangrene c % G73%

Y	Peripheral vascular dis	12735 G732100	497 Gangrene c % G73%
Y	Peripheral vascular dis	39949 G732200	55 Gangrene c % G73%
Y	Peripheral vascular dis	51057 G732300	5 Gangrene c % G73%
Y	Peripheral vascular dis	23672 G732400	9 Gangrene c % G73%
Y	Peripheral vascular dis	98174 G733.00	1028 Ischaemic f % G73%
Y	Peripheral vascular dis	105317 G734.00	631 Peripheral % G73%
Y	Peripheral vascular dis	38907 G73y.00	118 Other spec % G73%
Y	Peripheral vascular dis	23871 G73y100	11 Peripheral % G73%
Y	Peripheral vascular dis	4325 G73yz00	9122 Other spec % G73%
Y	Peripheral vascular dis	3530 G73z.00	43797 Peripheral % G73%
Y	Peripheral vascular dis	1517 G73z000	107767 Intermittent % G73%
Y	Peripheral vascular dis	6853 G73z011	11629 Claudicatio % G73%
Y	Peripheral vascular dis	101866 G73z012	18 Vascular cl: % G73%
Y	Peripheral vascular dis	2760 G73zz00	44532 Peripheral % G73%
Y	Peripheral vascular dis	18423 G76A.00	464 Arterial ins % G76A%
Y	Peripheral vascular dis	102725 Gyu7100	1 [X]Aortic ar % Gyu71%
Y	Peripheral vascular dis	102719 Gyu7200	1 [X]Aortic ar % Gyu72%
Y	Peripheral vascular dis	73961 Gyu7400	19 [X]Other sp % Gyu74%
Y	Peripheral vascular dis	105621 Gyu7800	1 [X]Aneurys % Gyu78%
Y	Peripheral vascular dis	4970 R054.00	5569 [D]Gangrer % R054%
Y	Peripheral vascular dis	51634 R054000	11 [D]Gangrer % R054%
Y	Peripheral vascular dis	53634 R054200	82 [D]Gangrer % R054%
Y	Peripheral vascular dis	31053 R054300	46 [D]Widespr % R054%
Y	Peripheral vascular dis	37750 R054z00	119 [D]Gangrer % R054%
N		30919 43c3.00	1 Lupus antic % 43C3%
N		43274 43f1.00	1 Aspergillus % 43F1%
N		64967 66F3.00	4 Blood drug % 66f3%
N		16839 66H..12	15219 Rheumatis % 66H%
N		36302 66H1.00	646 Rheumat. i % 66H%
N		38340 66H2.00	7556 Rheumat. f % 66H%
N		47071 66H9.00	374 Rheumatol % 66H%
N		99802 66HA.00	6730 Rheumatol % 66H%
N		79425 7800C	% 7800%
N		78758 7800TP	% 7800%
N		83527 7A1B300	4 Endovascul % 7A1B%
N		90549 7A1B400	6 Endovascul % 7A1B%
N		99787 7A1BB00	17 Endovascul % 7A1B%
N		89714 7A1C300	14 Endov ins s % 7A1C%
N		94069 7A1C400	6 Endovas in: % 7A1C%
N		103004 9kr..00	135 Subdermal % 9kr..%
N		11489 9M1..00	2531 Informed d % 9m1%
N		44312 9M10.00	33 Informed d % 9m1%
N		19479 A3A0.11	845 Clostridium % A3A0%
N		86049 A3A0011	2 Clostridium % A3A0%
N		66057 A3A0111	4 Clostridium % A3A0%
N		27490 A3A0211	43 Clostridium % A3A0%
N		95475 A3A0311	2 Clostridium % A3A0%
N		25324 F230.00	493 Congenital % F230%
N		5512 F230100	1082 Cerebral pæ % F230%
N		104775 F230111	23 Spastic dipl % F230%

N	45551 F230z00	63 Congenital % F230%
N	63541 F396.00	6 Symptoma: % F396%
N	62297 F396000	8 Myopathy i: % F396%
N	49482 F396200	3 Myopathy i: % F396%
N	57638 F396z00	7 Symptoma: % F396%
N	17133 G30A.00	466 Mural thro % G30%
N	3979 G672.00	453 Hypertensi % G6%
N	31816 G672.11	98 Hypertensi % G6%
N	107725 G67B.00	8 Reversible % G6%
N	107890 G67B.11	2 Call-Flemin % G6%
N	98593 G719.00	5 Abscess of % G71%
N	98277 G71A.00	308 Aortic root % G71%
N	1231 G730.00	84407 Raynaud's : % G73%
N	1002 G730000	16421 Raynaud's i: % G73%
N	5595 G730100	9527 Raynaud's j: % G73%
N	23880 G730111	1483 Vibratory v % G73%
N	39097 G730z00	533 Raynaud's : % G73%
N	34638 G731.00	81 Thromboar % G73%
N	23497 G731000	599 Buerger's d % G73%
N	40068 G731100	6 Presenile g % G73%
N	67401 G731z00	2 Thromboar % G73%
N	107272 G735.00	30 HAVS - Han % G73%
N	107372 G735.11	41 Vibration w % G73%
N	34152 G73y000	215 Diabetic pe % G73%
N	4317 G73y200	1692 Acrocya: % G73%
N	22834 G73y400	36 Acroparaes % G73%
N	25954 G73y500	4 Acroparaes % G73%
N	68698 G73y511	3 Nothnagel' % G73%
N	3715 G73y600	660 Acroparaes % G73%
N	15272 G73y700	323 Erythrocy % G73%
N	10500 G73y800	1103 Erythromel % G73%
N	42611 G73y811	14 Erythralgia % G73%
N	15863 G73z100	540 Spasm of p % G73%
N	52604 G753.00	4 Lethal midl % G75%
N	37747 G756.00	47 Thrombotic % G75%
N	47260 G756000	3 Moschcow % G75%
N	21697 G756100	234 Thrombotic % G75%
N	93424 G756z00	1 Thrombotic % G75%
N	30532 G75X.00	69 Necrotising % G75%
N	49044 H57..00	29 Lung involv % H57%
N	58791 H57y.00	10 Lung disea: % H57%
N	54010 H57y000	32 Pulmonary % H57%
N	96655 H57y500	1 Lung disea: % H57%
N	63912 H57yz00	5 Lung disea: % H57%
N	10691 J610.00	4229 Alcoholic f: % J61%
N	3216 J611.00	3497 Acute alcol % J61%
N	21713 J612000	80 Alcoholic fi % J61%
N	7885 J613.00	9237 Alcoholic li % J61%
N	17330 J613000	375 Alcoholic h % J61%
N	71453 J615z15	15 Hepatic fib % J61%

N	7943 J617.00	2476 Alcoholic h % J61%
N	42843 J61y.00	103 Other non- % J61%
N	10234 J61y100	25829 Non-alcohc % J61%
N	1780 J61y200	1621 Hepatosple % J61%
N	40963 J61y300	25 Portal fibrc % J61%
N	25383 J61y400	366 Hepatic fib % J61%
N	60104 J61y500	24 Hepatic scl % J61%
N	100592 J61y600	3 Hepatic fib % J61%
N	10572 J61y700	1222 Steatosis o % J61%
N	98148 J61y800	634 Nonalcoho % J61%
N	103466 J61y900	3963 Fatty chang % J61%
N	103706 J61y911	414 Fatty liver % J61%
N	33597 J61yz00	55 Other non- % J61%
N	10539 J61z.00	1521 Chronic livr % J61%
N	31897 J62..00	240 Liver absce % J62%
N	46023 J620.00	126 Liver absce % J62%
N	68692 J620000	3 Liver absce % J62%
N	25341 J620100	33 Liver absce % J62%
N	103715 J620200	2 Liver absce % J62%
N	70524 J620300	2 Liver absce % J62%
N	4454 J620z00	768 Liver absce % J62%
N	63404 J621.00	24 Portal pyae % J62%
N	46278 J621.11	8 Phlebitis of % J62%
N	24901 J625.00	311 [X] Hepatic % J62%
N	21769 J625.11	436 [X] Liver fai % J62%
N	48102 J62y.00	59 Other sequ % J62%
N	56070 J62y.11	9 Hepatic fail % J62%
N	23775 J62y.12	205 Liver failure % J62%
N	16062 J62y.13	699 Hepatic fail % J62%
N	108800 J62z.00	1 Liver absce % J62%
N	36727 J635.00	111 Toxic liver (% J635%
N	22766 J635000	357 Toxic liver (% J635%
N	36107 J635100	19 Toxic liver (% J635%
N	41104 J635200	69 Toxic liver (% J635%
N	41386 J635700	37 Acute hepa % J635%
N	41673 J635X00	13 Toxic liver (% J635%
N	81760 L4400DI	% L440%
N	82702 L4400HF	% L440%
N	20615 N04..11	4115 Inflammatic % N04%
N	8583 N042000	352 Rheumatic % N04%
N	3944 N044.00	9091 Chronic po: % N04%
N	40841 N044.11	27 Jaccoud's s % N04%
N	58543 N044.12	6 Nodular fib % N04%
N	7196 N045.00	3031 Other juvei % N04%
N	42405 N045000	107 Juvenile an % N04%
N	31181 N045100	177 Juvenile se % N04%
N	28456 N045200	149 Juvenile art % N04%
N	12575 N045300	45 Juvenile art % N04%
N	71083 N045400	4 Juvenile art % N04%
N	46622 N045600	113 Pauciarticu % N04%

N	36597 N04y.00	90 Other spec % N04%
N	4578 N04y100	10067 Sero negati% N04%
N	10919 N04y111	1749 Sero negati% N04%
N	102873 N04y300	24 Remitting s% N04%
N	23833 N04yz00	50 Other spec % N04%
N	24747 N04z.00	2192 Inflammatc% N04%
N	62652 Nyu4200	2 [X]Other sp% Nyu4%
N	53862 Nyu4400	3 [X]Other de% Nyu4%
N	95437 Nyu4E00	1 [X]Dermatc% Nyu4%
N	47877 R054100	6 [D]Phagedc% R054%
N	27741 ZV12500	349 [V]Persona % ZV125%
N	100141 122C000	4934 No family h%asthma%
N	6973 12D2.00	492383 FH: Asthma%asthma%
N	87521 135 BB	% BB%
N	85042 136 BB	% BB%
N	43770 13Y4.00	124 Asthma soc%asthma%
N	719 14B4.00	243374 H/O: asthr%asthma%
N	101843 173a.00	1 Borg Breatl% 173A.%
N	10318 1J70.00	67740 Suspected %asthma%
N	10996 2126200	110059 Asthma res%asthma%
N	11839 212G.00	42594 Asthma res%asthma%
N	COPD 38887 222I.00	36 Blue bloate% 222I.%
N	33681 2BB..00	10443 O/E - retin% 2BB%
N	17198 2BB..11	925 O/E - retin% 2BB%
N	24080 2BB1.00	16052 O/E - retin% 2BB%
N	45145 2BB2.00	147 O/E - retin% 2BB%
N	48751 2BB3.00	296 O/E - retin% 2BB%
N	19532 2BB4.00	986 O/E - retin% 2BB%
N	8742 2BB5.00	6011 O/E - retin% 2BB%
N	13106 2BB6.00	715 O/E - retin% 2BB%
N	35659 2BB7.00	95 O/E - retin% 2BB%
N	3822 2BB8.00	7203 O/E - vitrec% 2BB%
N	3914 2BB9.00	2782 O/E - retin% 2BB%
N	19535 2BBA.00	16176 Examinatio% 2BB%
N	36867 2BBa.00	119 O/E- non-r% 2BB%
N	18438 2BBb.00	173 O/E - fundu% 2BB%
N	60146 2BBB.00	1406 O/E - Right % 2BB%
N	39156 2BBC.00	1476 O/E - Left r% 2BB%
N	50656 2BBc.00	2036 O/E - No re% 2BB%
N	31088 2BBD.00	9227 O/E - Right % 2BB%
N	34480 2BBd.00	231 O/E - Red r% 2BB%
N	31089 2BBE.00	8873 O/E - Left r% 2BB%
N	70163 2BBe.00	55 O/E - right % 2BB%
N	92317 2BBf.00	70 O/E - left r% 2BB%
N	36855 2BBG.00	240 Retinal abn% 2BB%
N	66273 2BBg.00	52 O/E - right % 2BB%
N	8518 2BBH.00	3689 Retinal dru% 2BB%
N	95916 2BBh.00	53 O/E - left r% 2BB%
N	19149 2BBI.00	45554 O/E - no re% 2BB%
N	26538 2BBI.00	31017 O/E - right % 2BB%

N	13100 2BBJ.00	143927 O/E - no rig % 2BB%
N	43501 2BBj.00	30848 O/E - left e % 2BB%
N	13104 2BBK.00	144190 O/E - no let % 2BB%
N	25888 2BBm.00	881 O/E - right % 2BB%
N	47144 2BBM.00	29043 O/E - diabe % 2BB%
N	13107 2BBn.00	730 O/E - left e % 2BB%
N	22968 2BBN.00	389 Myelinatec % 2BB%
N	18775 2BBO.00	193 O/E - Laser % 2BB%
N	95946 2BBp.00	3207 On examin: % 2BB%
N	95947 2BBq.00	3050 On examin: % 2BB%
N	102242 2BBs.00	12 Retinal arte % 2BB%
N	19533 2BBY.00	473 O/E - refer: % 2BB%
N	25116 2BBZ.00	357 O/E - retin: % 2BB%
N	58179 2G5c.00	28 O/E - Left fi % 2G5C%
N	92007 322 BB	% BB%
N	75101 351 BB	% BB%
N	93736 388t.00	10005 Royal Colle %asthma%
N	103631 388t000	5400 Royal Colle %asthma%
N	98185 38DL.00	18540 Asthma cor %asthma%
N	100397 38DT.00	2065 Asthma cor %asthma%
N	102209 38DV.00	12 Mini asthm %asthma%
N	92637 420 BB	% BB%
N	88015 426 BB	% BB%
N	83023 429 BB	% BB%
N	9958 42W..00	24013 Hb. A1C - d % 42W%
N	5717 42W..11	7354 Glycosylate % 42W%
N	14052 42W..12	941 Glycated h: % 42W%
N	13597 42W1.00	2103 Hb. A1C < 7 % 42W%
N	14053 42W4.00	107 HbA1c leve % 42W%
N	96968 42W5.00	985 Haemoglot % 42W%
N	14049 42WZ.00	81 Hb. A1C - d % 42W%
N	75752 455 BB	% BB%
N	8578 4K2..00	688508 Cervical sm % 4K2%
N	7610 4K2..11	17734 Dyskaryosi: % 4K2%
N	20403 4K2..12	2377 Dysplasia (r % 4K2%
N	3644 4K21.00	744998 Cervical sm % 4K2%
N	11 4K22.00	11207181 Cervical sm % 4K2%
N	12931 4K22.11	52444 Smear NAC % 4K2%
N	5190 4K23.00	292454 Cerv.smear % 4K2%
N	1341 4K23.11	73798 CIN I - mild % 4K2%
N	4288 4K26.00	4987 Cervical sm % 4K2%
N	17712 4K27.00	5197 Cervical sm % 4K2%
N	12927 4K27.11	1918 Atrophic cf % 4K2%
N	12896 4K28.00	82964 Cerv.smear % 4K2%
N	692 4K28.11	36582 CIN II - mox % 4K2%
N	4823 4K29.00	465372 Cerv.smear % 4K2%
N	107261 4K29000	1889 Cervical sm % 4K2%
N	107344 4K29100	141 Cervical sm % 4K2%
N	12934 4K2A.00	25424 Cervical sm % 4K2%
N	12932 4K2B.00	8068 Cervical sm % 4K2%

N		26468 4K2C.00	9387 Smear NAC % 4K2%
N		26469 4K2D.00	13639 Cervical sm % 4K2%
N		32971 4K2E.00	3548 Cervical sm % 4K2%
N		104617 4K2F.00	15 Cervical sm % 4K2%
N		104665 4K2G.00	40 Cervical sm % 4K2%
N		105903 4K2H.00	2 Cervical sm % 4K2%
N		107295 4K2J.00	2216 Cervical sm % 4K2%
N		107363 4K2K.00	443 Cervical sm % 4K2%
N		107497 4K2N.00	29 Cervical sm % 4K2%
N		107348 4K2P.00	13 Cervical sm % 4K2%
N		107412 4K2Q.00	496 Cervical sm % 4K2%
N		107312 4K2R.00	419 Cervical sm % 4K2%
N		12917 4K2Z.00	44234 Cervical sm % 4K2%
N		12933 4K2Z.11	6128 Nuclear abi % 4K2%
N		91021 575 BB	% BB%
N		11611 585F.00	2154 Endoscopic % 585f%
N		2611 585G.00	1570 Ultrasound % 585g%
N		79387 610 BB	% BB%
N		78314 657 BB	% BB%
N		105674 661M100	531 Asthma sel %asthma%
N		105420 661N100	42 Asthma sel %asthma%
N		21826 662F.00	5385 Hypertensi % 662f%
N		13188 662G.00	23421 Hypertensi % 662g%
N		12948 662H.00	2388 Hypertensi % 662h%
N		31744 662I.00	5433 No record (% 662i%
N		13186 662P.00	930493 Hypertensi % 662p%
N		102406 662P000	3012 Hypertensi % 662p%
N		81 663..11	2292779 Asthma mc %asthma%
N		22041 663k.00	2652 Reversibilit % 663K.%
N	COPD	4084 663K.00	1414 Airways ob % 663K.%
N		36644 66a3.00	46 Osteoporos % 66A3%
N		7563 66A3.00	93004 Diabetic or % 66A3%
N		34129 66a4.00	201 Osteoporos % 66A4%
N		48962 66a5.00	80 Osteoporos % 66A5%
N		69152 66Aj.00	41 Insulin nee % 66AJ%
N		22959 66AJ000	860 Chronic hyp % 66AJ%
N		21420 66AJ200	428 Loss of hyp % 66AJ%
N		37625 66AJ300	260 Recurrent % 66AJ%
N		108218 66AJ400	1 % 66AJ%
N		102490 66Av.00	35791 Diabetic as % 66AV%
N		8111 66H..11	14192 Arthritis m % 66h..%
N		11868 66I..00	24799 Skin disord % 66i..%
N		38077 66Yb.00	437 Reversibilit % 66YB%
N	COPD	9520 66YB.00	184105 Chronic ob % 66YB%
N	COPD	102685 66YB000	3459 Chronic ob % 66YB%
N	COPD	103007 66YB100	3589 Chronic ob % 66YB%
N	COPD	19106 66Yd.00	8560 COPD accic % 66YD%
N	COPD	37371 66YD.00	2971 Chronic ob % 66YD%
N		18141 66YE.00	24505 Asthma mc % 66Ye%, %asthma%
N	COPD	19003 66Ye.00	8276 Emergency % 66Ye%

N		46899 66YF.00	63 Nebulizer t % 66Yf%
N	COPD	28743 66Yf.00	122100 Number of % 66Yf%
N		25163 66YG.00	6 Nebulizer t % 66Yg%
N	COPD	45770 66Yg.00	329 Chronic ob:% 66Yg%
N		46550 66YH.00	15 Attends res:% 66Yh%
N	COPD	45771 66Yh.00	936 Chronic ob:% 66Yh%
N	COPD - Hig	18501 66YI.00	99953 COPD self-r % 66Yi%
N	COPD	46036 66Yi.00	1001 Multiple CC % 66Yi%
N		61127 66YI.00	29 Home oxyg % 66YL%
N	COPD	18621 66YL.00	51453 Chronic ob:% 66YL%
N	COPD	18476 66YL.11	32570 COPD follo:% 66YL%
N	COPD - Hig	42624 66YL.12	410 COAD follo % 66YL%
N		93393 66Ym.00	1783 Inhaler dev % 66YM.%
N	COPD	11287 66YM.00	493884 Chronic ob:% 66YM.%
N		19167 66YQ.00	57497 Asthma mc %asthma%
N		30458 66YR.00	18921 Asthma mc %asthma%
N	COPD	26018 66YS.00	3047 Chronic ob:% 66YS%
N		103593 66Yt.00	1518 Spirometric % 66YT%
N	COPD	45998 66YT.00	449 Chronic ob:% 66YT%
N		47993 66YZ.00	548 Does not h. %asthma%
N		26496 679J.00	65957 Health edu %asthma%
N		100107 679J000	3029 Health edu %asthma%
N		100740 679J100	1832 Health edu %asthma%
N		103318 679J200	7362 Health edu %asthma%
N		5609 68C3.00	33495 Asthma scr %asthma%
N		81698 735 BB	% BB%
N		80626 738 BB	% BB%
N		84394 7B0F000	56 Live kidney % 7B0F%
N		47588 7L1a.00	2869 Cognitive b % 7L1A%
N		107523 7L1a000	1 Cognitive b % 7L1A%
N		102640 7L1a100	4 Cognitive b % 7L1A%
N		93663 7L1ay00	8 Other spec % 7L1A%
N		47578 7L1az00	48 Cognitive b % 7L1A%
N		89452 7L1b.00	4 Procureme % 7L1B%
N		12213 8BL2.00	67314 Patient on % 8BL2%
N		35927 8CE2.00	5302 Asthma lea %asthma%
N		99793 8CMA000	4172 Patient has %asthma%
N	COPD	45777 8CR1.00	8050 Chronic ob:% 8CR1%
N		7058 8H2P.00	26561 Emergency %asthma%
N	COPD Exac	11019 8H2R.00	13886 Admit COP % 8H2R%
N		18763 8HTT.00	1383 Referral to %asthma%
N		18692 9hA..00	5273 Exception r %asthma%
N		11673 9hA1.00	54548 Excepted fr %asthma%
N		11695 9hA2.00	207505 Excepted fr %asthma%
N		11971 9N0K.00	4355 Seen in ort % 9N0K%
N		9282 9N2P.00	46916 Seen by chi % 9N2p%
N		56717 9N2P.11	12980 Seen by po % 9N2p%
N		30308 9N4Q.00	104249 DNA - Did r %asthma%
N		92109 9NI8.00	21 Asthma ou %asthma%
N		100509 9NNX.00	54 Under care %asthma%

N		5215 90I..00	105184 Hypertensi % 90i%
N	COPD	18792 90i..00	10827 Chronic ob:% 90i%
N		27525 90I..11	6660 Hypertensi % 90i%
N	COPD	28755 90i0.00	182110 Chronic ob:% 90i%
N		45149 90I1.00	33377 Attends hy % 90i%
N	COPD	34202 90i1.00	54936 Chronic ob:% 90i%
N		43220 90I2.00	267 Refuses hy % 90i%
N	COPD	34215 90i2.00	26060 Chronic ob:% 90i%
N		28828 90I3.00	7532 Hyperten.n % 90i%
N	COPD	42258 90i3.00	5193 Chronic ob:% 90i%
N		31117 90I4.00	639932 Hypertens. % 90i%
N	COPD	38074 90i4.00	9761 Chronic ob:% 90i%
N		31127 90I5.00	158514 Hypertens. % 90i%
N		31175 90I6.00	69395 Hypertens. % 90i%
N		41634 90I7.00	17845 Hypertens. % 90i%
N		28874 90I8.00	20933 Hypertens. % 90i%
N		66645 90I9.00	255 Hypertens. % 90i%
N		36305 90IA.00	48894 Hypertensi % 90i%
N		24127 90IA.11	6899 Hypertensi % 90i%
N		34192 90IZ.00	4142 Hypertens. % 90i%
N		16655 90J..00	43828 Asthma mc %asthma%
N		20422 90J..11	9967 Asthma clir %asthma%
N		46529 90J1.00	12320 Attends ast %asthma%
N		11387 90J2.00	52393 Refuses ast %asthma%
N		41554 90J3.00	10559 Asthma mc %asthma%
N		25707 90J4.00	888932 Asthma mc %asthma%
N		25706 90J5.00	397001 Asthma mc %asthma%
N		25705 90J6.00	240366 Asthma mc %asthma%
N		37943 90J7.00	29243 Asthma mc %asthma%
N		31135 90J8.00	27931 Asthma mc %asthma%
N		54946 90J9.00	1733 Asthma mc %asthma%
N		19539 90JA.00	161895 Asthma mc %asthma%
N		8355 90JA.11	7854 Asthma mc %asthma%
N		30382 90JZ.00	16343 Asthma mc %asthma%
N		49065 90T..00	3830 Clinic 'B' m % 90t%
N		59234 90T1.00	93 Attends clir % 90t%
N		59252 90T2.00	2 Refuses clir % 90t%
N		51917 90T3.00	362 Clinic B mo % 90t%
N		42637 90T4.00	11493 Clinic B mo % 90t%
N		42641 90T5.00	3072 Clinic B mo % 90t%
N		42644 90T6.00	1773 Clinic B mo % 90t%
N		66587 90T7.00	71 Clinic B mo % 90t%
N		66586 90T8.00	108 Clinic B mo % 90t%
N		59245 90T9.00	37 Clinic B mo % 90t%
N		51904 90TA.00	4495 Clinic B mo % 90t%
N		66588 90TZ.00	9721 Clinic B mo % 90t%
N		35089 90U..00	2303 Clinic 'C' m % 90u%
N		35099 90U1.00	16017 Attends clir % 90u%
N		51188 90U2.00	49 Refuses clir % 90u%
N		51953 90U3.00	61 Clinic C mo % 90u%

N		42646 90U4.00	17558 Clinic C mo % 90u%
N		42650 90U5.00	5747 Clinic C mo % 90u%
N		42651 90U6.00	2995 Clinic C mo % 90u%
N		55465 90U7.00	32 Clinic C mo % 90u%
N		60443 90U8.00	51 Clinic C mo % 90u%
N		59248 90U9.00	48 Clinic C mo % 90u%
N		46313 90UA.00	1776 Clinic C mo % 90u%
N		64287 90UZ.00	4585 Clinic C mo % 90u%
N		106 90W1.00	946605 Attended n % 90w1%
N		5138 9Q21.00	6384 Patient in a % asthma%
N		10314 B057.00	248 Overlappin % B0%
N		10368 B11..11	865 Gastric nec % B1%
N		5062 B30..11	282 Chondrom: % B3%
N		29735 B30..12	91 Osteoma % B3%
N	Other skin	4632 B33..00	12348 Other maliq % B3%
N	Basal cell c	876 B33..11	261113 Basal cell c: % B3%
N		5034 B33..12	2358 Epitheliom: % B3%
N	Other skin	1940 B33..13	20439 Rodent ulc: % B3%
N	Other skin	37016 B33..14	42 Malignant i % B3%
N	Other skin	40443 B33..15	17 Malignant i % B3%
N	Basal cell c	3445 B33..16	25484 Epitheliom: % B3%
N	Other skin	18245 B330.00	139 Malignant i % B3%
N	Other skin	43087 B331.00	187 Malignant i % B3%
N	Other skin	36731 B331000	121 Malignant i % B3%
N	Other skin	55550 B331100	32 Malignant i % B3%
N	Other skin	41958 B331200	136 Malignant i % B3%
N	Other skin	53515 B332.00	97 Malignant i % B3%
N	Other skin	33997 B332000	104 Malignant i % B3%
N	Other skin	62080 B332100	10 Malignant i % B3%
N	Other skin	33271 B332200	260 Malignant i % B3%
N	Other skin	62399 B332z00	51 Malig neop % B3%
N	Other skin	27370 B333.00	145 Malignant i % B3%
N	Other skin	30645 B333000	402 Malignant i % B3%
N	Other skin	49403 B333100	54 Malignant i % B3%
N	Other skin	55670 B333200	60 Malignant i % B3%
N	Other skin	30576 B333300	377 Malignant i % B3%
N	Other skin	16202 B333400	619 Malignant i % B3%
N	Other skin	21327 B333500	296 Malignant i % B3%
N	Other skin	46008 B333z00	86 Malignant i % B3%
N	Other skin	54234 B334.00	31 Malignant i % B3%
N	Other skin	37165 B334000	306 Malignant i % B3%
N	Other skin	43619 B334100	149 Malignant i % B3%
N	Other skin	73760 B334z00	9 Malignant i % B3%
N	Other skin	57446 B335.00	341 Malignant i % B3%
N	Other skin	70380 B335000	5 Malignant i % B3%
N	Other skin	37969 B335100	114 Malignant i % B3%
N	Other skin	30543 B335200	112 Malignant i % B3%
N	Other skin	18618 B335300	31 Malignant i % B3%
N	Other skin	67748 B335400	2 Malignant i % B3%
N	Other skin	66319 B335500	4 Malignant i % B3%

N	Other skin	46458	B335600	8	Malignant i % B3%
N	Other skin	45077	B335700	218	Malignant i % B3%
N	Other skin	62305	B335800	5	Malignant i % B3%
N	Other skin	23480	B335900	142	Malignant i % B3%
N	Other skin	66447	B335A00	12	Malignant i % B3%
N	Other skin	15868	B335z00	95	Malignant i % B3%
N	Other skin	30747	B336.00	216	Malignant i % B3%
N	Other skin	43122	B336000	105	Malignant i % B3%
N	Other skin	42707	B336100	48	Malignant i % B3%
N	Other skin	30577	B336200	76	Malignant i % B3%
N	Other skin	54352	B336300	82	Malignant i % B3%
N	Other skin	25245	B336400	13	Malignant i % B3%
N	Other skin	64406	B336500	5	Malignant i % B3%
N	Other skin	60526	B336z00	10	Malignant i % B3%
N	Other skin	57442	B337.00	473	Malignant i % B3%
N	Other skin	70988	B337000	4	Malignant i % B3%
N	Other skin	58601	B337100	47	Malignant i % B3%
N	Other skin	56954	B337200	13	Malignant i % B3%
N	Other skin	68197	B337300	4	Malignant i % B3%
N	Other skin	33682	B337400	223	Malignant i % B3%
N	Other skin	64270	B337500	13	Malignant i % B3%
N	Other skin	104025	B337600	1	Malignant i % B3%
N	Other skin	70587	B337700	8	Malignant i % B3%
N	Other skin	65782	B337800	4	Malignant i % B3%
N	Other skin	67914	B337900	3	Malignant i % B3%
N	Other skin	61194	B337z00	12	Malignant i % B3%
N	Squamous	93352	B338.00	12507	Squamous % B3%
N	Other skin	42429	B33X.00	9	Malignant i % B3%
N	Other skin	18354	B33y.00	79	Malignant i % B3%
N	Other skin	2492	B33z.00	9546	Malignant i % B3%
N	Squamous	93490	B33z.11	2255	Squamous % B3%
N	Other skin	27931	B33z000	60	Kaposi's sar % B3%
N	Basal cell c	54182	B33z100	37	Naevoid ba % B3%
N	Basal cell c	21156	B33z111	180	Basal cell n % B3%
N	Squamous	2467	B8...11	35562	Bowen's di: % B8%
N	Squamous	34088	B8...12	63	Erythroplas % B8%
N	Squamous	51899	B8...13	17	Queyrats's % B8%
N	Other skin	12084	B82..00	421	Carcinoma % B8%
N	Other skin	63957	B820.00	14	Carcinoma % B8%
N	Other skin	57550	B821.00	17	Carcinoma % B8%
N	Other skin	50189	B822.00	9	Carcinoma % B8%
N	Other skin	32249	B822.11	45	Carcinoma % B8%
N	Other skin	59614	B822000	9	Carcinoma % B8%
N	Other skin	70295	B822z00	5	Carcinoma % B8%
N	Other skin	49254	B823.00	22	Carcinoma % B8%
N	Other skin	47789	B823000	47	Carcinoma % B8%
N	Other skin	69720	B823100	12	Carcinoma % B8%
N	Other skin	61103	B823300	50	Carcinoma % B8%
N	Other skin	3135	B823400	56	Carcinoma % B8%
N	Other skin	31511	B823500	54	Carcinoma % B8%

N	Other skin	65222 B823600	6 Carcinoma % B8%
N	Other skin	69345 B824.00	6 Carcinoma % B8%
N	Other skin	19665 B824000	112 Carcinoma % B8%
N	Other skin	54140 B824100	39 Carcinoma % B8%
N	Other skin	52328 B825.00	3 Carcinoma % B8%
N	Other skin	8647 B825000	636 Carcinoma % B8%
N	Other skin	62939 B825100	13 Carcinoma % B8%
N	Other skin	39390 B825200	15 Carcinoma % B8%
N	Other skin	38032 B825300	21 Carcinoma % B8%
N	Other skin	42212 B825400	13 Carcinoma % B8%
N	Other skin	57358 B825500	9 Carcinoma % B8%
N	Other skin	38777 B825600	5 Carcinoma % B8%
N	Other skin	61321 B825700	2 Carcinoma % B8%
N	Other skin	56374 B825800	14 Carcinoma % B8%
N	Other skin	60563 B825z00	2 Carcinoma % B8%
N	Other skin	46568 B826.00	6 Carcinoma % B8%
N	Other skin	56554 B826000	11 Carcinoma % B8%
N	Other skin	57284 B826100	6 Carcinoma % B8%
N	Other skin	54790 B826200	15 Carcinoma % B8%
N	Other skin	49358 B826300	36 Carcinoma % B8%
N	Other skin	90339 B826z00	3 Carcinoma % B8%
N	Other skin	14815 B827.00	3093 Carcinoma % B8%
N	Other skin	708 B827.11	2310 Carcinoma % B8%
N	Other skin	71655 B827000	2 Carcinoma % B8%
N	Other skin	46469 B827100	11 Carcinoma % B8%
N	Other skin	69601 B827200	8 Carcinoma % B8%
N	Other skin	27542 B827300	136 Carcinoma % B8%
N	Other skin	67755 B827400	5 Carcinoma % B8%
N	Other skin	64630 B827z00	7 Carcinoma % B8%
N	Other skin	108227 B829.00	4 Bowenoid % B8%
N	Other skin	57450 B82y.00	6 Carcinoma % B8%
N	Other skin	63142 B82z.00	27 Carcinoma % B8%
N		35532 BB...00	633 [M]Morphc % BB%
N		21207 BB...11	94 [M]Tumoui % BB%
N		10258 BB0..00	310 [M]Neopla: % BB%
N		12629 BB00.00	220 [M]Neopla: % BB%
N		15543 BB01.00	102 [M]Neopla: % BB%
N		6895 BB05.00	534 [M]Tumoui % BB%
N		5932 BB06.00	475 [M]Tumoui % BB%
N		33508 BB0z.00	145 [M]Unspec % BB%
N		20653 BB1..00	163 [M]Epitheli % BB%
N		10805 BB10.00	132 [M]Epitheli % BB%
N		6457 BB15.00	275 [M]Epitheli % BB%
N		68679 BB1H.00	8 [M]Tumoui % BB%
N		60082 BB1z.00	18 [M]Unspec % BB%
N		40494 BB2..00	616 [M]Papillar % BB%
N		11782 BB2..11	276 [M]Papillar % BB%
N		7967 BB2..12	10194 [M]Squamc % BB%
N		222 BB20.00	28083 [M]Papillor % BB%
N		46432 BB23.00	168 [M]Verrucc % BB%

N	Squamous	4852	BB24.12	623	[M]Verrucc % BB%
N		155	BB25.00	3353	[M]Squamc % BB%
N		48321	BB25.11	26	[M]Dysker % BB%
N		7386	BB25.12	1242	[M]Hyperk % BB%
N		8909	BB25.13	925	[M]Keratot % BB%
N		29892	BB25.14	25	[M]Paraker % BB%
N		9675	BB27.00	197	[M]Inverte % BB%
N		8196	BB28.00	1832	[M]Papillor % BB%
N	Squamous	48182	BB29.11	30	[M]Epidern % BB%
N	Squamous	19041	BB29.12	903	[M]Intraep % BB%
N	Squamous	56600	BB2A.11	96	[M]Epidern % BB%
N	Squamous	57680	BB2A.12	2	[M]Spinous % BB%
N	Squamous	94873	BB2A.13	18	[M]Squamc % BB%
N	Squamous	29787	BB2C.00	222	[M]Squamc % BB%
N	Squamous	57513	BB2C.11	6	[M]Epidern % BB%
N	Squamous	45458	BB2F.00	29	[M]Squamc % BB%
N	Squamous	41481	BB2K.00	83	[M]Queyra % BB%
N	Squamous	8917	BB2L.00	3015	[M]Bowen' % BB%
N		49399	BB2z.00	53	[M]Papillar % BB%
N		3516	BB3..00	4267	[M]Basal cε % BB%
N		29282	BB30.00	308	[M]Basal cε % BB%
N	Basal cell c	3028	BB31.00	18850	[M]Basal cε % BB%
N	Basal cell c	59919	BB32.00	45	[M]Multice % BB%
N	Basal cell c	9885	BB33.00	4685	[M]Basal cε % BB%
N	Basal cell c	29524	BB34.00	204	[M]Basal cε % BB%
N	Basal cell c	35457	BB35.00	219	[M]Basosqi % BB%
N	Basal cell c	13574	BB36.00	8	[M]Metaty % BB%
N		49835	BB37.00	26	[M]Intraep % BB%
N		20869	BB38.00	583	[M]Trichoe % BB%
N		49765	BB38.12	12	[M]Epitheli % BB%
N		22060	BB39.00	168	[M]Trichofr % BB%
N		24711	BB3A.00	192	[M]Tricholε % BB%
N		6280	BB3B.00	2619	[M]Pilomat % BB%
N		28812	BB3B.11	260	[M]Malher % BB%
N	Basal cell c	102417	BB3C.00	227	[M]Superfir % BB%
N	Basal cell c	102547	BB3D.00	356	[M]Basal cε % BB%
N	Basal cell c	103440	BB3E.00	11	[M]Basal cε % BB%
N	Basal cell c	103178	BB3F.00	44	[M]Basal cε % BB%
N	Basal cell c	103066	BB3G.00	11	[M]Pigmen % BB%
N		104854	BB3H.00	9	[M]Trichob % BB%
N	Basal cell c	30853	BB3z.00	259	[M]Basal cε % BB%
N	Basal cell c	1950	BB4..00	8464	[M]Transiti % BB%
N		41726	BB40.00	206	[M]Transiti % BB%
N		50294	BB41.00	75	[M]Urothel % BB%
N		1904	BB41.11	1163	[M]Urinary % BB%
N		42001	BB44.00	33	[M]Schneic % BB%
N		61490	BB45.00	10	[M]Transiti % BB%
N		1799	BB5..12	6314	[M]Adenor % BB%
N		4903	BB50.00	1303	[M]Adenor % BB%
N		47721	BB50000	55	[M]Microcy % BB%

N	30125	BB59.00	25 [M]Monorr % BB%
N	34291	BB5A.00	328 [M]Basal cε % BB%
N	35467	BB5az00	127 [M]Renal a % BB%
N	65658	BB5B000	7 [M]Islet cel % BB%
N	9224	BB5B200	237 [M]Insulinc % BB%
N	58022	BB5B400	12 [M]Glucagc % BB%
N	21659	BB5Bz00	253 [M]Pancrez % BB%
N	55380	BB5c000	14 [M]Chief cε % BB%
N	45814	BB5C011	7 [M]G cell tı % BB%
N	85969	BB5c100	4 [M]Water-t % BB%
N	42169	BB5cz00	376 [M]Parathy % BB%
N	43594	BB5Cz00	12 [M]Gastrin % BB%
N	72198	BB5D000	4 [M]Bile dur % BB%
N	17979	BB5D011	25 [M]Cholanę % BB%
N	30596	BB5D200	22 [M]Bile dur % BB%
N	29792	BB5D400	65 [M]Liver ce % BB%
N	52492	BB5D411	23 [M]Hepato % BB%
N	37483	BB5D412	36 [M]Hepato % BB%
N	20234	BB5D511	432 [M]Hepato % BB%
N	53987	BB5Dz00	7 [M]Hepato % BB%
N	40371	BB5e.00	45 [M]Lipoade % BB%
N	67399	BB5E.00	7 [M]Trabect % BB%
N	21424	BB5f000	577 [M]Folliculı % BB%
N	35428	BB5f400	13 [M]Microfc % BB%
N	26296	BB5f500	24 [M]Macrof % BB%
N	31061	BB5f511	132 [M]Colloid % BB%
N	38685	BB5fz00	110 [M]Thyroid % BB%
N	40266	BB5g.00	91 [M]Multipl % BB%
N	72292	BB5G.00	2 [M]Embryc % BB%
N	36124	BB5H.00	97 [M]Eccrine % BB%
N	40883	BB5h.00	141 [M]Adrena % BB%
N	50753	BB5H.11	9 [M]Turban % BB%
N	53968	BB5h000	81 [M]Adrena % BB%
N	97740	BB5h400	2 [M]Adrena % BB%
N	96181	BB5h600	2 [M]Adrena % BB%
N	62256	BB5hz00	11 [M]Adrena % BB%
N	60756	BB5J.12	4 [M]Cylindrı % BB%
N	5265	BB5J.13	406 [M]Cylindrı % BB%
N	35012	BB5j000	53 [M]Endomı % BB%
N	37728	BB5j011	119 [M]Endomı % BB%
N	107097	BB5j300	1 [M]Endomı % BB%
N	28388	BB5jz00	176 [M]Endomı % BB%
N	18114	BB5L000	1656 [M]Adenor % BB%
N	452	BB5L011	10905 [M]Polypoi % BB%
N	36286	BB5Lz00	7 [M]Adenor % BB%
N	10689	BB5M000	4192 [M]Tubular % BB%
N	39148	BB5Mz00	14 [M]Tubular % BB%
N	19731	BB5N.11	26 [M]Adenor % BB%
N	33904	BB5N000	89 [M]Adenor % BB%
N	54883	BB5N011	44 [M]Adenor % BB%

N		12494 BB5N012	366 [M]Familial % BB%
N		11398 BB5N200	65 [M]Multipl % BB%
N		2721 BB5N211	776 [M]Multipl % BB%
N		39875 BB5Nz00	42 [M]Adenor % BB%
N		3923 BB5R.00	2723 [M]Carcino % BB%
N		38444 BB5R000	259 [M]Carcino % BB%
N		23081 BB5R111	175 [M]Carcino % BB%
N		39130 BB5R200	9 [M]Carcino % BB%
N		49797 BB5R211	2 [M]Argent % BB%
N		99296 BB5R400	2 [M]Carcino % BB%
N	Merkel cell	32641 BB5RA00	476 [M]Merkel % BB%
N		45573 BB5Rz00	75 [M]Carcino % BB%
N		91889 BB5S000	5 [M]Pulmon % BB%
N		41260 BB5S100	79 [M]Bronchi % BB%
N		72290 BB5S300	9 [M]Alveola % BB%
N		36221 BB5Sz00	44 [M]Respira % BB%
N		67004 BB5T000	17 [M]Papillar % BB%
N		96494 BB5Tz00	8 [M]Papillar % BB%
N		3935 BB5U000	1457 [M]Villous % BB%
N		29449 BB5U011	134 [M]Villous % BB%
N		10624 BB5U300	5907 [M]Tubulo % BB%
N		68367 BB5U311	5 [M]Papillot % BB%
N		35891 BB5U312	62 [M]Villogla % BB%
N		50108 BB5Uz00	9 [M]Villous % BB%
N		39727 BB5V000	69 [M]Chromc % BB%
N		56907 BB5V200	3 [M]Acidopt % BB%
N		68218 BB5V211	1 [M]Eosinoç % BB%
N		72185 BB5V600	7 [M]Basoph % BB%
N		40965 BB5V611	56 [M]Mucoïd % BB%
N		57422 BB5Vz00	70 [M]Pituitar % BB%
N		71518 BB5W000	13 [M]Oxyphil % BB%
N		44903 BB5W011	90 [M]Hurthle % BB%
N		41934 BB5W012	18 [M]Oncocy % BB%
N		28806 BB5W013	252 [M]Oncocy % BB%
N		73662 BB5Wz00	1 [M]Oxyphil % BB%
N		37673 BB5X000	4 [M]Clear cç % BB%
N		72192 BB5Xz00	12 [M]Clear cç % BB%
N	Basal cell c	16902 BB5y000	1229 [M]Basal cç % BB%
N		55663 BB5y300	4 [M]Apudor % BB%
N		5707 BB5y400	3973 [M]Prolacti % BB%
N		35975 BB5z.00	125 [M]Adenor % BB%
N		73568 BB5Z.00	5 [M]Clear cç % BB%
N		29563 BB6..00	153 [M]Adnexa % BB%
N	Other skin	95046 BB60.00	3 [M]Skin apı % BB%
N		100117 BB60000	3 [M]Skin apı % BB%
N	Other skin	68783 BB60100	2 [M]Skin apı % BB%
N	Other skin	52496 BB61.00	15 [M]Sweat ç % BB%
N		38506 BB61000	19 [M]Sweat ç % BB%
N		11182 BB61011	268 [M]Hidrade % BB%
N		33819 BB61012	36 [M]Nodula % BB%

N		17164	BB61013	41	[M]Syringa % BB%
N		67354	BB61100	12	[M]Sweat ξ % BB%
N	Other skin	71627	BB61200	2	[M]Sweat ξ % BB%
N	Other skin	24312	BB62.00	25	[M]Apocrir % BB%
N		60901	BB62000	20	[M]Apocrin % BB%
N	Other skin	38575	BB62100	6	[M]Apocrin % BB%
N		104973	BB62z00	1	[M]Apocrin % BB%
N		44066	BB63.00	39	[M]Eccrine % BB%
N		60071	BB63.11	20	[M]Clear cε % BB%
N		6753	BB63.12	232	[M]Eccrine % BB%
N		17501	BB64.00	212	[M]Eccrine % BB%
N		30293	BB64.11	43	[M]Spirade % BB%
N		28563	BB65.00	334	[M]Hidrocy % BB%
N		12254	BB66.00	171	[M]Papillar % BB%
N		49416	BB67.00	14	[M]Papillar % BB%
N		17676	BB68.00	59	[M]Syringo % BB%
N	Other skin	28291	BB69.00	148	[M]Sebacer % BB%
N		29361	BB69000	1393	[M]Sebacer % BB%
N	Other skin	34269	BB69100	13	[M]Sebacer % BB%
N		91842	BB69z00	3	[M]Sebacer % BB%
N	Other skin	67913	BB6A.00	7	[M]Cerumi % BB%
N		105776	BB6A000	2	[M]Cerumi % BB%
N		55430	BB6B.00	24	[M]Eccrine % BB%
N		10315	BB6z.00	28	[M]Adnexa % BB%
N		34627	BB7..00	84	[M]Mucoej % BB%
N		59100	BB70.00	9	[M]Mucoej % BB%
N		70918	BB7z.00	1	[M]Mucoej % BB%
N		21651	BB8..00	268	[M]Cystic, ι % BB%
N		18633	BB80000	447	[M]Cystade % BB%
N		35377	BB80011	46	[M]Cystom % BB%
N		65207	BB80z00	6	[M]Cystade % BB%
N		2979	BB81.00	675	[M]Ovariar % BB%
N		17151	BB81.11	1133	[M]Ovariar % BB%
N		18638	BB81.12	203	[M]Ovariar % BB%
N		39007	BB81.13	27	[M]Ovariar % BB%
N		30541	BB81.14	110	[M]Ovariar % BB%
N		28939	BB81000	169	[M]Serous % BB%
N		51394	BB81300	9	[M]Papillar % BB%
N		60406	BB81600	13	[M]Papillar % BB%
N		62246	BB81900	2	[M]Serous % BB%
N		20210	BB81C00	235	[M]Mucino % BB%
N		38808	BB81C11	42	[M]Pseudo % BB%
N		65645	BB81F00	1	[M]Papillar % BB%
N		72684	BB81L00	7	[M]Papillar % BB%
N		40033	BB81z00	51	[M]Ovariar % BB%
N		41911	BB82000	56	[M]Mucino % BB%
N		64796	BB82z00	15	[M]Mucino % BB%
N		17098	BB83.00	445	[M]Pseudo % BB%
N		44231	BB8z.00	23	[M]Cystic, ι % BB%
N		18029	BB9..00	347	[M]Ductal, % BB%

N	18417 BB95.00	664 [M]Intradu % BB%
N	93987 BB95.11	7 [M]Duct ad % BB%
N	31740 BB95.12	213 [M]Ductal p % BB%
N	39394 BB97.00	18 [M]Intracy: % BB%
N	67932 BB99.00	17 [M]Intradu % BB%
N	39145 BB9A.00	33 [M]Subare: % BB%
N	36488 BB9A.11	90 [M]Adenor % BB%
N	52269 BB9A.12	5 [M]Erosive % BB%
N	60683 BB9z.00	75 [M]Ductal, % BB%
N	64314 BBa..00	21 [M]Miscell: % BB%
N	90320 BBA..00	11 [M]Acinar c % BB%
N	70631 BBA0.00	3 [M]Acinar c % BB%
N	48477 BBa1.00	25 [M]Pinealo % BB%
N	72440 BBA1.00	7 [M]Acinar c % BB%
N	33951 BBa2.00	15 [M]Pineocy % BB%
N	64874 BBa4.00	21 [M]Melano % BB%
N	57864 BBa4.11	1 [M]Melano % BB%
N	67715 BBa4.12	2 [M]Melano % BB%
N	73023 BBa4.13	2 [M]Retinal % BB%
N	21758 BBa5.00	179 [M]Chordo % BB%
N	28950 BBaz.00	77 [M]Miscell: % BB%
N	96870 BBAz.00	1 [M]Acinar c % BB%
N	68810 BBB..00	2 [M]Comple % BB%
N	3710 BBB1.00	395 [M]Adenol % BB%
N	27594 BBB1.11	44 [M]Warthir % BB%
N	8524 BBB2.11	19 [M]Adenoa % BB%
N	26157 BBb5.00	106 [M]Choroic % BB%
N	31793 BBB6.00	529 [M]Thymor % BB%
N	31343 BBB6000	30 [M]Thymor % BB%
N	67767 BBB6z00	18 [M]Thymor % BB%
N	41695 BBba.00	70 [M]Primitiv % BB%
N	102030 BBBz.00	3 [M]Comple % BB%
N	39294 BBC..00	17 [M]Speciali % BB%
N	54284 BBc..00	17 [M]Neuroe % BB%
N	32357 BBc0.00	129 [M]Ganglio % BB%
N	54654 BBC0.00	32 [M]Sex cor % BB%
N	92275 BBC0.11	2 [M]Gonada % BB%
N	21435 BBC0.12	260 [M]Ovariar % BB%
N	21319 BBC0.13	329 [M]Testicul % BB%
N	34713 BBc0000	77 [M]Ganglio % BB%
N	61115 BBC0000	2 [M]Sex cor % BB%
N	41953 BBc0011	37 [M]Ganglio % BB%
N	39121 BBc0100	13 [M]Ganglio % BB%
N	62567 BBc0200	4 [M]Ganglio % BB%
N	2123 BBc1.00	925 [M]Neurob % BB%
N	64491 BBC1.00	2 [M]Thecal c % BB%
N	60530 BBC1000	30 [M]Thecor % BB%
N	40742 BBC1200	20 [M]Thecor % BB%
N	107109 BBC2.00	1 [M]Luteom % BB%
N	67288 BBc2.00	5 [M]Medull % BB%

N	6751 BBC3.00	288 [M]Granulc % BB%
N	52963 BBC3000	14 [M]Juvenilc % BB%
N	97961 BBc4.00	2 [M]Neuroe % BB%
N	48957 BBC5.00	4 [M]Granulc % BB%
N	31629 BBc6.00	175 [M]Ganglio % BB%
N	89457 BBC6.00	5 [M]Androb % BB%
N	93097 BBc6.11	6 [M]Glione % BB%
N	107253 BBC6000	2 [M]Androb % BB%
N	48560 BBC6011	4 [M]Arrhenc % BB%
N	94614 BBC6z11	2 [M]Arrhenc % BB%
N	18065 BBC7.00	36 [M]Sertoli- % BB%
N	51920 BBc7.00	56 [M]Neuroc % BB%
N	104977 BBc8.00	1 [M]Paciniar % BB%
N	59787 BBC9.00	22 [M]Tubular % BB%
N	62056 BBC9.11	9 [M]Pick's ti % BB%
N	87331 BBC9.12	4 [M]Sertoli c % BB%
N	38979 BBC9.13	16 [M]Sertoli c % BB%
N	40954 BBC9.14	42 [M]Testicul % BB%
N	58902 BBcA.00	2 [M]Olfacto % BB%
N	72912 BBCB.00	1 [M]Tubular % BB%
N	31170 BBCC.00	113 [M]Leydig c % BB%
N	62944 BBCC000	3 [M]Leydig c % BB%
N	49286 BBCC011	2 [M]Intersti % BB%
N	73623 BBCCz00	2 [M]Leydig c % BB%
N	99219 BBCCz11	1 [M]Intersti % BB%
N	39734 BBcD.00	91 [M]Hilar ce % BB%
N	106131 BBcD.11	1 [M]Olfacto % BB%
N	59995 BBCE.00	13 [M]Lipid ce % BB%
N	50519 BBcF.00	19 [M]Adrena % BB%
N	11754 BBcG.00	53 [M]Sclerosi % BB%
N	99491 BBcz.00	2 [M]Neuroe % BB%
N	24924 BBd..00	52 [M]Paragar % BB%
N	2843 BBd..00	3030 [M]Mening % BB%
N	10913 BBd0.00	56 [M]Paragar % BB%
N	12096 BBd0.00	538 [M]Mening % BB%
N	98677 BBd1.00	2 [M]Mening % BB%
N	95108 BBd1.11	1 [M]Diffuse % BB%
N	54710 BBd1.12	5 [M]Multipl % BB%
N	101342 BBd3.00	1 [M]Parasyr % BB%
N	65426 BBd3.00	5 [M]Mening % BB%
N	96487 BBd3.11	1 [M]Endoth % BB%
N	38295 BBd4.00	19 [M]Fibrous % BB%
N	45953 BBd4.00	71 [M]Glomus % BB%
N	70320 BBd4.11	7 [M]Jugular % BB%
N	38870 BBd5.00	40 [M]Psamm % BB%
N	67018 BBd5.00	3 [M]Aortic t % BB%
N	36209 BBd6.00	173 [M]Carotid % BB%
N	46251 BBd6.00	14 [M]Angiom % BB%
N	21598 BBd7.00	187 [M]Haemar % BB%
N	93717 BBd7.00	2 [M]Extra-ar % BB%

N	46490 BBd7.11	4 [M]Angiobl % BB%
N	48326 BBD7.11	21 [M]Chemoi % BB%
N	50822 BBd8.00	53 [M]Haema % BB%
N	44435 BBD9.00	31 [M]Phaeoc % BB%
N	67929 BBd9.00	11 [M]Transiti % BB%
N	109110 BBD9.11	1 [M]Chromε % BB%
N	70176 BBdA.00	1 [M]Papillar % BB%
N	106613 BBDA.11	1 [M]Phaeoc % BB%
N	45969 BBDC.00	71 [M]Glomus % BB%
N	4916 BBDD.00	114 [M]Glomar % BB%
N	52070 BBDE.00	17 [M]Ganglio % BB%
N	34712 BBDF.00	109 [M]Glomar % BB%
N	47848 BBdz.00	280 [M]Mening % BB%
N	69421 BBDz.00	3 [M]Paragar % BB%
N	18690 BBe..00	359 [M]Nerve s % BB%
N	3023 BBe..11	4425 [M]Neurofi % BB%
N	26309 BBe0.00	713 [M]Neurofi % BB%
N	3659 BBE0.00	9959 [M]Pigmen % BB%
N	12574 BBE0.11	2110 [M]Hairi n: % BB%
N	832 BBE0.12	81259 [M]Naevus % BB%
N	765 BBe1.00	3109 [M]Neurofi % BB%
N	36785 BBe1.11	192 [M]Multipl % BB%
N	23455 BBe1.12	72 [M]Von Rei % BB%
N	59749 BBe3.00	9 [M]Melanc % BB%
N	99595 BBE3.00	1 [M]Balloon % BB%
N	12016 BBe4.00	94 [M]Plexifor % BB%
N	22843 BBe5.00	502 [M]Neurile % BB%
N	4776 BBE5.00	5898 [M]Halo na % BB%
N	21247 BBe5.11	94 [M]Acousti % BB%
N	46753 BBe5.12	36 [M]Neurinc % BB%
N	8527 BBe5.13	2643 [M]Schwan % BB%
N	60590 BBe6.00	9 [M]Neurinc % BB%
N	9431 BBE6.00	554 [M]Fibrous % BB%
N	20853 BBE6.11	6 [M]Involuti % BB%
N	53522 BBE7.00	5 [M]Neuron % BB%
N	11496 BBE8.00	21 [M]Magnor % BB%
N	2296 BBe8.00	8579 [M]Neuron % BB%
N	4209 BBE9.00	320 [M]Nonpig % BB%
N	68621 BBE9.11	12 [M]Achrorr % BB%
N	28592 BBeA.00	25 [M]Neurotl % BB%
N	34237 BBEa.00	200 [M]Spindle % BB%
N	3564 BBEB.00	3519 [M]Junctioi % BB%
N	48152 BBEB.00	97 [M] Epithel % BB%
N	55556 BBEB.11	81 [M]Intraep % BB%
N	931 BBEJ.00	36532 [M]Intrade % BB%
N	9568 BBEJ.11	1113 [M]Dermal % BB%
N	1732 BB EK.00	21085 [M]Compo % BB%
N	42340 BBEL.00	87 [M]Giant p % BB%
N	1261 BBEN.00	637 [M]Epitheli % BB%
N	4871 BBEN.11	269 [M]Juvenilε % BB%

N	38842	BBEN.12	31	[M]Juvenilc % BB%
N	6937	BBEN.13	1596	[M] Spitz n: % BB%
N	4716	BBEU.00	909	[M]Blue na % BB%
N	21383	BBEU.11	30	[M]Jadasso % BB%
N	7264	BBEW.00	492	[M]Cellular % BB%
N	105954	BBEW.11	1	[M]Giant b % BB%
N	3376	BBEY.00	5033	[M]Dysplas % BB%
N	33734	BBEz.00	505	[M]Naevi o % BB%
N	35284	BBez.00	17	[M]Nerve s % BB%
N	18266	BBf0.00	117	[M]Granulc % BB%
N	29359	BBF0.00	33	[M]Soft tis: % BB%
N	38869	BBG..00	173	[M]Fibrom: % BB%
N	2507	BBG0.00	6496	[M]Fibrom: % BB%
N	49131	BBg0.00	14	[M]Lymphc % BB%
N	10465	BBG0.11	1163	[M]Fibrom: % BB%
N	61822	BBG2.00	8	[M]Fibrom: % BB%
N	50574	BBG2.11	35	[M]Myxofil % BB%
N	23919	BBG4.00	71	[M]Periost: % BB%
N	12242	BBG6.00	18	[M]Fascial : % BB%
N	50423	BBG9.00	58	[M]Elastofi % BB%
N	55886	BBGA.00	21	[M]Aggress % BB%
N	2776	BBGA.11	156	[M]Desmoi % BB%
N	60177	BBGA.12	39	[M]Extra-al % BB%
N	44277	BBGA.13	11	[M]Invasivc % BB%
N	53333	BBGB.00	33	[M]Abdom % BB%
N	18566	BBGB.11	72	[M]Abdom % BB%
N	46243	BBGC.00	85	[M]Desmoi % BB%
N	15323	BBGD.00	6819	[M]Fibrous % BB%
N	27674	BBGE.00	329	[M]Atypica % BB%
N	41839	BBGG.00	79	[M]Fibroxa % BB%
N	24682	BBGG.11	24	[M]Xantho: % BB%
N	34276	BBGH.00	180	[M]Atypica % BB%
N	18699	BBGK.00	3542	[M]Dermat % BB%
N	43169	BBGK.11	8	[M]Dermat % BB%
N	3348	BBGK.12	8838	[M]Histiocy % BB%
N	22655	BBGK.13	152	[M]Sclerosi % BB%
N	27905	BBGK.14	53	[M]Subepic % BB%
N	26881	BBGL.00	42	[M]Dermat % BB%
N	30314	BBGN.00	27	[M]Myofibi: % BB%
N	40525	BBGz.00	11	[M]Fibrom: % BB%
N	64642	BBH..00	17	[M]Myxom % BB%
N	8985	BBH0.00	616	[M]Myxom % BB%
N	26171	BBHZ.00	90	[M]Angiom % BB%
N	63050	BBHz.00	7	[M]Myxom % BB%
N	12268	BBJ..00	202	[M]Lipoma % BB%
N	45882	BBJ0.00	292	[M]Lipoma % BB%
N	10472	BBJ2.00	866	[M]Fibrolip % BB%
N	42422	BBJ2.11	23	[M]Fibrom: % BB%
N	6720	BBJ2.12	3008	[M]Soft fib: % BB%
N	23904	BBJ4.00	14	[M]Fibrom: % BB%

N	57685	BBJ4.11	7 [M]Myxoliğ % BB%
N	39431	BBJ9.00	124 [M]Intramı % BB%
N	60747	BBJ9.11	6 [M]Infiltrat % BB%
N	12058	BBJA.00	82 [M]Spindle % BB%
N	18521	BBJB.00	436 [M]Angioliğ % BB%
N	37857	BBJB000	286 [M]Angiom % BB%
N	27596	BBJB200	546 [M]Angioliğ % BB%
N	94454	BBJBz00	4 [M]Angioliğ % BB%
N	69326	BBJC.00	35 [M]Myeloli % BB%
N	42528	BBJD.00	78 [M]Hibernc % BB%
N	57601	BBJD.11	4 [M]Brown i % BB%
N	100947	BBJE.00	5 [M]Lipobla: % BB%
N	96523	BBJF.00	10 [M]Pleomo % BB%
N	57628	BBJz.00	37 [M]Lipoma % BB%
N	21064	BBK..00	17 [M]Myoma % BB%
N	33691	BBK0.00	253 [M]Leiomy % BB%
N	28324	BBK0000	1604 [M]Leiomy % BB%
N	8655	BBK0011	15726 [M]Fibroid % BB%
N	22195	BBK0012	143 [M]Fibrom % BB%
N	24308	BBK0013	79 [M]Leiomy % BB%
N	39743	BBK0014	50 [M]Myofibi % BB%
N	70473	BBK0100	7 [M]Intrava: % BB%
N	61404	BBK0300	9 [M]Epitheli % BB%
N	61105	BBK0500	6 [M]Cellular % BB%
N	72251	BBK0600	2 [M]Bizarre % BB%
N	67322	BBK0z00	11 [M]Leiomy % BB%
N	42526	BBK1.00	152 [M]Angiom % BB%
N	47811	BBK1000	107 [M]Angiom % BB%
N	17530	BBK1011	422 [M]Angiole % BB%
N	31094	BBK1012	254 [M]Vascula % BB%
N	62662	BBK1z00	16 [M]Angiom % BB%
N	54486	BBK2000	37 [M]Myoma % BB%
N	68999	BBK2z00	1 [M]Myoma % BB%
N	28382	BBK3.00	114 [M]Rhabdc % BB%
N	43773	BBK3000	57 [M]Rhabdc % BB%
N	101225	BBK3400	3 [M]Fetal rh % BB%
N	108495	BBK3500	1 [M]Adult rı % BB%
N	37081	BBK3800	243 [M]Smooth % BB%
N	70807	BBK3z00	1 [M]Rhabdc % BB%
N	97974	BBKz.00	2 [M]Myoma % BB%
N	47874	BBL..00	44 [M]Comple % BB%
N	72319	BBL1.00	1 [M]Endolyr % BB%
N	56751	BBL1.11	5 [M]Stroma % BB%
N	9114	BBL2.00	169 [M]Adenor % BB%
N	7802	BBL3.00	3835 [M]Pleomo % BB%
N	21419	BBL3.11	143 [M]Chondr % BB%
N	44217	BBL3.12	19 [M]Mixed t % BB%
N	21173	BBL5.00	202 [M]Mulleri: % BB%
N	49811	BBL6.00	35 [M]Mesodı % BB%
N	45668	BBLB.00	72 [M]Myoepi % BB%

N	44060	BBLC.00	20	[M]Mesenc % BB%
N	71746	BBLC000	10	[M]Mesenc % BB%
N	50344	BBLCz00	3	[M]Mesenc % BB%
N	43975	BBLF.00	36	[M]Endom % BB%
N	61933	BBLz.00	15	[M]Comple % BB%
N	5694	BBM..00	1610	[M]Fibroep % BB%
N	66267	BBm..00	4	[M]Miscell % BB%
N	25810	BBM0.00	97	[M]Brenne % BB%
N	44793	BBM0z00	25	[M]Brenne % BB%
N	1722	BBM1.00	8105	[M]Fibroad % BB%
N	47330	BBm2.00	2	[M]Histioc % BB%
N	48254	BBM2.00	25	[M]Intracal % BB%
N	54692	BBM3.00	17	[M]Perican % BB%
N	9066	BBM4.00	112	[M]Adenof % BB%
N	17446	BBM4.11	284	[M]Cystad % BB%
N	37507	BBM5.00	46	[M]Serous % BB%
N	26135	BBm6.00	8	[M] Alpha t % BB%
N	40514	BBM6.00	23	[M]Mucino % BB%
N	10395	BBm7.00	3135	[M] Monoc % BB%
N	62431	BBM7.00	22	[M]Cellular % BB%
N	36242	BBM7.11	68	[M]Cystosa % BB%
N	10595	BBM7.12	164	[M]Fibroad % BB%
N	36701	BBM7.13	13	[M]Giant fi % BB%
N	54190	BBm8.00	35	[M] Angioir % BB%
N	50905	BBMA.00	15	[M]Juvenil % BB%
N	49755	BBMB.00	26	[M]Giant fi % BB%
N	7966	BBMz.00	512	[M]Fibroep % BB%
N	35883	BBN..00	19	[M]Synovia % BB%
N	43459	BBn..00	30	[M]Plasma % BB%
N	34332	BBN0.00	47	[M]Synovic % BB%
N	44207	BBn1.00	4	[M]Plasma % BB%
N	17409	BBN1.11	223	[M]Synovic % BB%
N	58075	BBn1.11	3	[M]Plasma % BB%
N	63864	BBn2.00	11	[M]Plasma % BB%
N	102164	BBn2.11	1	[M]Monost % BB%
N	73135	BBn2.12	2	[M]Solitary % BB%
N	64068	BBnz.00	5	[M]Plasma % BB%
N	96780	BBnz.00	4	[M]Synovia % BB%
N	16474	BBP..00	867	[M]Mesoth % BB%
N	37128	BBp..00	9	[M]Mast ce % BB%
N	70951	BBP0.00	3	[M]Mesoth % BB%
N	94750	BBp0.00	11	[M]Mastoc % BB%
N	96515	BBP2.00	1	[M]Fibrous % BB%
N	100375	BBP4.00	2	[M]Epitheli % BB%
N	21882	BBP8.00	169	[M]Adenor % BB%
N	38756	BBP9.00	5	[M]Cystic n % BB%
N	69755	BBPz.00	6	[M]Mesoth % BB%
N	92385	BBpz.00	1	[M]Mast ce % BB%
N	17468	BBQ..00	259	[M]Germ c % BB%
N	32191	BBQ0.00	90	[M]Dysgerr % BB%

N	27971	BBQ2.00	88	[M]Germin % BB%
N	102356	BBQ5.00	1	[M]Polyem % BB%
N	17435	BBQ7.00	881	[M]Terator % BB%
N	50432	BBQ7000	36	[M]Terator % BB%
N	73155	BBQ7011	14	[M]Adult c % BB%
N	56251	BBQ7012	36	[M]Mature % BB%
N	19180	BBQ7100	68	[M]Terator % BB%
N	42300	BBQ7z00	80	[M]Terator % BB%
N	847	BBQ8.00	11649	[M]Dermoi % BB%
N	11051	BBQ8.11	871	[M]Dermoi % BB%
N	103259	BBQA.00	1	[M]Struma % BB%
N	52306	BBQA000	12	[M]Struma % BB%
N	99800	BBQA200	3	[M]Struma % BB%
N	35071	BBQB.00	115	[M]Mixed ξ % BB%
N	43582	BBQz.00	38	[M]Germ c % BB%
N	5135	BBR..00	23	[M]Tropho % BB%
N	11404	BBR0.00	731	[M]Hydatic % BB%
N	10875	BBR0.11	313	[M]Hydatic % BB%
N	24317	BBr6012	4	[M]Myelos % BB%
N	52062	BBS3.00	9	[M]Endosa % BB%
N	58976	BBT..00	19	[M]Blood v % BB%
N	36646	BBT..11	64	[M]Haemai % BB%
N	45686	BBT0.00	296	[M]Haemai % BB%
N	5989	BBT0.11	1438	[M]Angiom % BB%
N	60191	BBT0.12	15	[M]Chorioε % BB%
N	4392	BBT2.00	3346	[M]Cavernι % BB%
N	17738	BBT3.00	353	[M]Venous % BB%
N	101256	BBT4.00	7	[M]Racemι % BB%
N	11719	BBT4.11	102	[M]Arterioι % BB%
N	67106	BBT7.00	5	[M]Haemai % BB%
N	94042	BBT7000	3	[M]Haemai % BB%
N	72247	BBT7z00	2	[M]Haemai % BB%
N	40853	BBT7z11	16	[M]Angioer % BB%
N	7363	BBT8.00	5512	[M]Capillar % BB%
N	50658	BBT8.12	119	[M]Infantili % BB%
N	65852	BBT8.13	5	[M]Juveniliε % BB%
N	62001	BBT8.14	4	[M]Plexifor % BB%
N	43321	BBT9.00	24	[M]Intramι % BB%
N	11993	BBTB.00	1136	[M]Angiokε % BB%
N	37117	BBTC.00	17	[M]Verrucc % BB%
N	99715	BBTD000	4	[M]Haemai % BB%
N	34324	BBTD100	7	[M]Haemai % BB%
N	96072	BBTDz00	2	[M]Haemai % BB%
N	5430	BBTE.00	322	[M]Angiofil % BB%
N	34385	BBTE.11	14	[M]Juveniliε % BB%
N	1969	BBTF.00	152	[M]Haemai % BB%
N	41349	BBTF.11	10	[M]Angiobl % BB%
N	53774	BBTG.00	29	[M]Epitheli % BB%
N	59746	BBTH.00	6	[M]Histiocy % BB%
N	22712	BBTJ.00	59	[M]Epitheli % BB%

N	52178	BBTL.00	14	[M]Intrava:	%	BB%
N	62881	BBTz.00	2	[M]Blood v	%	BB%
N	71481	BBU..00	4	[M]Lymphæ	%	BB%
N	40415	BBU..11	37	[M]Lymphæ	%	BB%
N	53735	BBU0.00	14	[M]Lymphæ	%	BB%
N	57337	BBU2.00	10	[M]Capillar	%	BB%
N	38417	BBU3.00	26	[M]Cavernæ	%	BB%
N	7834	BBU4.00	69	[M]Cystic l	%	BB%
N	1325	BBU4.11	886	[M]Cystic h	%	BB%
N	44191	BBU4.12	132	[M]Hygrorr	%	BB%
N	93852	BBU5.00	1	[M]Lymphæ	%	BB%
N	72439	BBU6.00	12	[M]Lymphæ	%	BB%
N	43845	BBU7.00	21	[M]Haemo	%	BB%
N	96713	BBUz.00	1	[M]Lymphæ	%	BB%
N	44556	BBV0.00	101	[M]Osteor	%	BB%
N	33993	BBV7.00	273	[M]Osteoic	%	BB%
N	62492	BBV8.00	40	[M]Osteob	%	BB%
N	21224	BBV8.11	169	[M]Giant o	%	BB%
N	48271	BBVz.00	15	[M]Osteor	%	BB%
N	36503	BBW..00	29	[M]Chondr	%	BB%
N	3166	BBW0.00	4148	[M]Osteocl	%	BB%
N	19660	BBW0.11	285	[M]Cartilag	%	BB%
N	40469	BBW0.12	48	[M]Ecchon	%	BB%
N	5773	BBW0.13	1502	[M]Osteoc:	%	BB%
N	16204	BBW1.00	220	[M]Osteocl	%	BB%
N	58904	BBW1.11	6	[M]Ecchon	%	BB%
N	50796	BBW2.00	69	[M]Chondr	%	BB%
N	4781	BBW2.11	1341	[M]Enchon	%	BB%
N	33589	BBW3.00	47	[M]Chondr	%	BB%
N	49667	BBW5.00	5	[M]Juxtaco	%	BB%
N	33504	BBW5.11	13	[M]Periost:	%	BB%
N	68524	BBW7.00	27	[M]Chondr	%	BB%
N	32442	BBW7.11	14	[M]Chondr	%	BB%
N	49568	BBWA.00	43	[M]Chondr	%	BB%
N	33973	BBWz.00	5	[M]Chondr	%	BB%
N	22330	BBX..00	808	[M]Giant c:	%	BB%
N	38477	BBX0.00	78	[M]Giant c:	%	BB%
N	29385	BBX0.11	123	[M]Osteocl	%	BB%
N	45364	BBX2.00	34	[M]Giant c:	%	BB%
N	37830	BBXz.00	182	[M]Giant c:	%	BB%
N	49872	BBy..00	18	[M]No mic:	%	BB%
N	9102	BBY..00	121	[M]Miscell:	%	BB%
N	69172	BBy0.00	1	[M]No mic:	%	BB%
N	38593	BBY1.00	25	[M]Adama:	%	BB%
N	67430	BBY1.11	4	[M]Tibial a:	%	BB%
N	104699	BBy2.00	1	[M]No mic:	%	BB%
N	6080	BBY2.00	144	[M]Ossifyir	%	BB%
N	65643	BBY2.11	1	[M]Ossifyir	%	BB%
N	53489	BBY2.12	9	[M]Osteofi	%	BB%
N	66502	BBYz.00	20	[M]Miscell:	%	BB%

N		72791 BByz.00	1 [M]No micr % BB%
N		41274 BBZ..00	35 [M]Odonto % BB%
N		50635 BBz..00	8 [M]Neopla: % BB%
N		107281 BBz0.00	49 [M]Neuroe % BB%
N		95603 BBZ0.00	7 [M]Odonto % BB%
N		55833 BBZ1.00	8 [M]Odonto % BB%
N		94828 BBZ3.00	1 [M]Dentinc % BB%
N		45961 BBZ4.00	20 [M]Cement % BB%
N		65086 BBZ5.00	6 [M]Cement % BB%
N		55474 BBZ6.00	3 [M]Cement % BB%
N		69443 BBZ7.00	1 [M]Giganti: % BB%
N		44210 BBZ8.00	15 [M]Odonto % BB%
N		101590 BBZ9.00	1 [M]Compo % BB%
N		62007 BBZA.00	8 [M]Comple % BB%
N		22057 BBZB.00	34 [M]Amelot % BB%
N		98019 BBZD.00	3 [M]Adenor % BB%
N		58550 BBZD.11	1 [M]Adenoa % BB%
N		57799 BBZE.00	8 [M]Calcifyii % BB%
N		40467 BBZF.00	170 [M]Amelot % BB%
N		63171 BBZF.11	15 [M]Adama: % BB%
N		98861 BBZH.00	1 [M]Odonto % BB%
N		45189 BBZJ.00	9 [M]Squamc % BB%
N		67837 BBZK.00	11 [M]Odonto % BB%
N		97546 BBZK.11	4 [M]Odonto % BB%
N		36576 BBZL.00	13 [M]Odonto % BB%
N		59010 BBZM.00	11 [M]Amelot % BB%
N		59274 BBZP.00	16 [M]Calcifyii % BB%
N		101568 BBZz.00	2 [M]Odonto % BB%
N		60053 Byu..00	16 [X]Addition % Byu%
N	Other skin	19144 Byu4.00	203 [X]Melanor % Byu%
N	Other skin	57184 Byu4200	4 [X]Oth mal % Byu%
N	Other skin	56121 Byu4300	73 [X]Maligna % Byu%
N	Other skin	60162 Byu5A00	15 [X]Maligna % Byu%
N	Other skin	101561 ByuF900	3 [X]Carcinor % Byu%
N		55929 ByuG.00	10 [X]Benign r % Byu%
N		97575 ByuG000	1 [X]Benign r % Byu%
N		50810 ByuG100	1 [X]Benign r % Byu%
N		97876 ByuG600	2 [X]Ben lipo % Byu%
N		95147 ByuG700	15 [X]Benign li % Byu%
N		73950 ByuG900	4 [X]Melanoc % Byu%
N		98193 ByuGA00	2 [X]Benign r % Byu%
N		33859 ByuGB00	1 [X]Benign r % Byu%
N		71428 ByuGC00	4 [X]Benign r % Byu%
N		59038 ByuGD00	4 [X]Benign r % Byu%
N		56872 ByuGH00	35 [X]Benign r % Byu%
N		17589 ByuGH11	285 [X]Benign c % Byu%
N		98684 ByuGJ00	1 [X]Benign r % Byu%
N		53816 ByuGN00	50 [X]Melanoc % Byu%
N		60270 ByuH.00	5 [X]Neoplas % Byu%
N		96489 ByuH000	1 [X]Neoplas % Byu%

N		108882	ByuH900	1 [X]Neoplas % Byu%
N		39406	C109800	16 Reaven's sy % C10%
N		54773	C10F800	26 Reaven's sy % C10%
N		39481	C10F811	150 Metabolic : % C10%
N		68517	C10J.00	3 Insulin aut % C10%
N		37957	C10K.00	81 Type A ins % C10%
N		56885	C10K000	1 Type A ins % C10%
N	DM in remi	107603	C10P.00	53 Diabetes m % C10%
N	DM in remi	108360	C10P000	2 Type I diab % C10%
N	DM in remi	107824	C10P100	5 Type II diat % C10%
N		33707	E00..00	3705 Senile and % E00%
N		15249	E00y.00	2086 Other senil % E00%
N		51494	E00y.11	2 Presbyophi % E00%
N		2882	E00z.00	12881 Senile or p % E00%
N		37946	E012000	34 Chronic alc % E012%
N		47619	Eu02z12	45 [X] Presenil % Eu02%
N		27935	Eu02z15	283 [X] Senile p % Eu02%
N		25066	Eu04.00	225 [X]Delirium % Eu04%
N		39337	Eu04.11	44 [X]Acute / : % Eu04%
N		7389	Eu04.12	5816 [X]Acute / : % Eu04%
N		24387	Eu04.13	141 [X]Acute / : % Eu04%
N		21933	Eu04.14	52 [X]Acute / : % Eu04%
N		22065	Eu04.15	34 [X]Acute / : % Eu04%
N		68125	Eu04000	13 [X]Delirium % Eu04%
N		52394	Eu04y00	90 [X]Other d % Eu04%
N		53924	Eu04z00	312 [X]Delirium % Eu04%
N		89580	F1110A	% F111%
N		85114	F3730T	% F373%
N		23481	G581.11	425 Asthma - c % asthma%
N	COPD	1001	H3...00	362799 Chronic ob: % H3%
N	COPD	998	H3...11	207230 Chronic ob: % H3%
N		148	H30..00	433411 Bronchitis % H3%
N		17359	H30..11	3060 Chest infec % H3%
N	COPD - Hig	7092	H30..12	3422 Recurrent % H3%
N		3163	H300.00	11944 Tracheobrc % H3%
N		1934	H301.00	4028 Laryngotra % H3%
N	COPD - Hig	152	H302.00	68983 Wheezy br % H3%
N	COPD - Hig	3480	H30z.00	14304 Bronchitis I % H3%
N	COPD - Hig	3243	H31..00	24546 Chronic brc % H3%
N	COPD - Hig	25603	H310.00	622 Simple chr % H3%
N	COPD - Hig	15626	H310000	1676 Chronic cat % H3%
N		16717	H310100	2298 Smokers' c % H3%
N	COPD - Hig	61118	H310z00	35 Simple chr % H3%
N	COPD - Hig	11150	H311.00	317 Mucopurul % H3%
N	COPD - Hig	40159	H311000	48 Purulent ct % H3%
N	COPD - Hig	37959	H311100	2 Fetid chron % H3%
N	COPD - Hig	61513	H311z00	22 Mucopurul % H3%
N	COPD	27819	H312.00	1083 Obstructive % H3%
N	COPD - Hig	5798	H312000	1675 Chronic ast % H3%, %asthma%
N	COPD - Hig	5909	H312011	470 Chronic wh % H3%

N	COPD	14798	H312100	1177	Emphysem % H3%
N	COPD Exac	1446	H312200	175526	Acute exac % H3%
N	COPD	44525	H312z00	68	Obstructive % H3%
N	COPD - Hig	24248	H313.00	28	Mixed sim % H3%
N	COPD - Hig	66043	H31y.00	22	Other chro % H3%
N		23618	H31y000	799	Chronic tra % H3%
N	COPD - Hig	45089	H31y100	58	Chronic tra % H3%
N	COPD - Hig	68066	H31yz00	18	Other chro % H3%
N	COPD - Hig	15157	H31z.00	3502	Chronic br % H3%
N	COPD	794	H32..00	47236	Emphysem % H3%
N	COPD	26306	H320.00	449	Chronic bul % H3%
N	COPD - Hig	56860	H320000	11	Segmental % H3%
N	COPD - Hig	68662	H320100	10	Zonal bullo % H3%
N	COPD - Hig	60188	H320200	16	Giant bullo % H3%
N	COPD - Hig	99536	H320300	9	Bullous em % H3%
N		103733	H320311	4	Tension pn % H3%
N	COPD	23492	H320z00	79	Chronic bul % H3%
N	COPD - Hig	46578	H321.00	24	Panlobular % H3%
N	COPD	10980	H322.00	196	Centrilobul % H3%
N	COPD - Hig	40788	H32y.00	52	Other emp % H3%
N		92955	H32y000	2	Acute vesic % H3%
N		59263	H32y111	3	Acute inter % H3%
N	COPD - Hig	63479	H32y200	25	MacLeod's % H3%
N	COPD - Hig	16410	H32yz00	57	Other emp % H3%
N	COPD	33450	H32z.00	915	Emphysem % H3%
N		185	H333.00	354458	Acute exac % H3%, %asthma%
N	COPD - Hig	106805	H335.00	102	Chronic ast % H3%, %asthma%
N		11312	H35..00	1917	Extrinsic all % H3%
N		103637	H35..11	210	Hypersensi % H3%
N		15588	H350.00	618	Farmers' lu % H3%
N		62200	H351.00	1	Bagassosis % H3%
N		27345	H352.00	355	Bird-fancie % H3%
N		54822	H352000	20	Budgerigar % H3%
N		31447	H352100	395	Pigeon-fan % H3%
N		36240	H352z00	13	Bird-fancie % H3%
N		93206	H353.00	2	Suberosis (% H3%
N		67709	H354.00	5	Malt worke % H3%
N		41694	H355.00	7	Mushroom % H3%
N		56652	H356.00	5	Maple bark % H3%
N		26278	H357.00	175	'Ventilator % H3%
N		51858	H35y.00	36	Other aller % H3%
N		91989	H35y000	11	Cheese-wa % H3%
N		53943	H35y100	2	Coffee-wor % H3%
N		70286	H35y200	3	Fish-meal v % H3%
N		45427	H35y500	2	Pituitary sn % H3%
N		69452	H35y800	6	Air-conditic % H3%
N		55552	H35yz00	24	Other aller % H3%
N		46977	H35z.00	28	Allergic alv % H3%
N		62442	H35z000	17	Allergic ext % H3%
N		11833	H35z100	170	Hypersensi % H3%

N		53095 H35zz00	9 Allergic alv % H3%
N	COPD	10863 H36..00	58566 Mild chron % H3%
N	COPD	10802 H37..00	54521 Moderate c % H3%
N	COPD	9876 H38..00	24628 Severe chr % H3%
N	COPD	93568 H39..00	1797 Very sever % H3%
N	COPD	104608 H3A..00	63 End stage c % H3%
N	COPD	12166 H3y..00	1145 Other spec % H3%
N	COPD - Hig	67040 H3y..11	8 Other spec % H3%
N	COPD Exac	21061 H3y0.00	4350 Chronic ob % H3%
N	COPD Exac	7884 H3y1.00	55398 Chron obst % H3%
N	COPD	5710 H3z..00	56244 Chronic ob % H3%
N	COPD	37247 H3z..11	883 Chronic ob % H3%
N		21973 H4...00	675 Lung disea % H4..%
N		31806 H56..00	78 Other alve % H56%
N		94136 H563000	1 Alveolar ca % H56%
N		54308 H56y.00	8 Other alve % H56%
N		4910 H56y100	1096 Interstitial % H56%
N		33830 H56yz00	12 Other alve % H56%
N		15815 H56z.00	18 Alveolar an % H56%
N		35432 H581.11	187 Pneumome % H581%
N		22915 H583.00	653 Pulmonary % H583%
N		31319 H583000	29 Loeffler's s % H583%
N		16439 H583100	26 Tropical eo % H583%
N		20269 H583z00	54 Pulmonary % H583%
N		8317 H58y300	3780 Interstitial % H58y3%
N		103785 H58y500	50 Respiratory % H58y5%
N		104915 H58y700	18 Interstitial % H58y7%
N		25249 H59..00	2112 Respiratory % H59%
N		37961 H590.00	336 Acute respi % H59%
N		94946 H592.00	139 Chronic ty % H59%
N	COPD - Hig	66058 Hyu3000	7 [X]Other er % Hyu3%
N	COPD - Hig	65733 Hyu3100	47 [X]Other s % Hyu3%
N		91912 Hyu5100	5 [X]Other s % Hyu51%
N		82577 K020	% K02%
N		58394 K020 L	% K02%
N		85590 K0201	% K02%
N		87429 K0202	% K02%
N		88097 K0202C	% K02%
N		90750 K021	% K02%
N		90627 K0211	% K02%
N		77656 K022	% K02%
N		77655 K022 F	% K02%
N		85767 K022 G	% K02%
N		85616 K022 LS	% K02%
N		92704 K0222	% K02%
N		84809 K0231	% K02%
N		87760 K0231A	% K02%
N		75785 K0231AA	% K02%
N		74523 K0231D	% K02%
N		58449 K0231DA	% K02%

N	90056 K0231FH	% K02%
N	85730 K0231L	% K02%
N	101387 K024.00	38 Thin baser % K02%
N	82659 K025	% K02%
N	85370 K026	% K02%
N	82515 K027	% K02%
N	81211 K027 AA	% K02%
N	82338 K027 C	% K02%
N	83667 K027 CM	% K02%
N	80162 K027 H	% K02%
N	80670 K028	% K02%
N	75782 K0281	% K02%
N	95212 K0282	% K02%
N	76252 K0282CI	% K02%
N	92760 K0282FH	% K02%
N	58319 K0282N	% K02%
N	88710 K0282NT	% K02%
N	58221 K029	% K02%
N	79605 K029 H	% K02%
N	88800 K0291	% K02%
N	90139 K0295	% K02%
N	89906 K0296	% K02%
N	95281 K052 AA	% K05%
N	92482 K0523	% K05%
N	82224 K0531H	% K05%
N	87684 K0532H	% K05%
N	81989 K0533	% K05%
N	79683 K0533H	% K05%
N	88443 K0541	% K05%
N	87478 K055 A	% K05%
N	87415 K055 BT	% K05%
N	90725 K055 C	% K05%
N	87314 K055 G	% K05%
N	80757 K055 L	% K05%
N	81843 K0553A	% K05%
N	85638 K057	% K05%
N	82028 K0591	% K05%
N	75353 K061 H	% K06%
N	86534 K061 P	% K06%
N	82054 K063 AA	% K06%
N	89957 K063 B	% K06%
N	87383 K0633	% K06%
N	86253 K0633AA	% K06%
N	88191 K065	% K06%
N	85423 K066	% K06%
N	86316 K067	% K06%
N	93112 K068	% K06%
N	85566 K795 BB	% BB%
N	53945 Kyu2000	9 [X]Other ac % Kyu2%
N	75579 L1801G	% L180%

N	82025 L1801NM	% L180%
N	77675 L1801T	% L180%
N	3928 M271.00	12196 Non-pressu % M271%
N	5057 M271.11	26845 Foot ulcer % M271%
N	6308 M271.12	2329 Ischaemic l % M271%
N	1216 M271.13	392671 Leg ulcer N % M271%
N	32006 M271.14	64 Neurogenic % M271%
N	14838 M271.15	428 Trophic leg % M271%
N	11624 M271300	6182 Arterial leg % M271%
N	8801 M271400	13392 Mixed ven % M271%
N	5855 M271500	32858 Venous ulc % M271%
N	5790 M271600	4166 Traumatic l % M271%
N	99855 M271700	327 Neuropath % M271%
N	62290 N030.00	5 Arthropath % N030%
N	94141 N030200	4 Arthropath % N030%
N	73408 SLF7z00	2 Antiasthma % asthma%
N	44893 SP08.00	48 Transplant % SP08%
N	29831 SP08000	60 Transplant % SP08%
N	11113 SP08100	404 Transplant % SP08%
N	52943 SP08200	19 Bone-marr % SP08%
N	47484 SP08400	12 Heart trans % SP08%
N	27679 SP08500	10 Heart-lung % SP08%
N	6692 SP08600	138 Liver trans % SP08%
N	22728 SP08700	154 Acute graft % SP08%
N	25695 SP08800	161 Chronic gra % SP08%
N	108330 SP08900	1 Complicati % SP08%
N	99847 SP08A00	29 Post-trans % SP08%
N	25896 SP08z00	28 Transplant % SP08%
N	55816 TJF7.00	27 Adverse re: % asthma%
N	48591 TJF7300	106 Adverse re: % asthma%
N	63233 TJF7z00	66 Adverse re: % asthma%
N	51116 U60F600	17 [X]Antiasth % asthma%
N	104235 U60F611	3 [X] Adverse % asthma%
N	40864 U60F615	3 [X] Adverse % asthma%
N	101133 U60F61A	1 [X] Adverse % asthma%
N	91055 Y060 BB	% BB%
N	89683 Y10 B1	% B1%
N	88838 Y43 BB	% BB%
N	18176 ZV17500	2317 [V]Family h % asthma%
N	53812 ZVu6700	11 [X]Family h % asthma%

Reviewed
by PP
D for
Charlson
score (not
including
COPD)

Summary of findings from a pilot study to assess utility of capturing Parkinson's disease related outcome data by GP questionnaire

In support of the Post marketing study of ropinirole prolonged release tablets: Evaluation of the short term drug utilisation patterns and long term use of ropinirole PR using the CPRD

Overview:

In 2008, GSK was granted approval for the prolonged release formulation of ropinirole (ropinirole PR) for the treatment of Parkinson's disease (PD) by the MHRA.

As part of its post-marketing commitment to the MHRA, GSK proposed to conduct an observational study using the Clinical Practice Datalink (CPRD). The primary aim of this study will be to evaluate long term outcomes amongst individuals prescribed ropinirole-PR as compared to those prescribed immediate release dopamine agonists.

A pilot study was conducted together with the University of Bath, to determine whether it was feasible or necessary to supplement information routinely captured on the CPRD relating to outcomes of interest and PD disease stage (early or advanced) and duration by use of a GP questionnaire.

Methods:

Parkinson's disease patients were identified on the CPRD using READ and OXMIS medical codes. All patients were required to have at least 12 months of registration prior to PD index date.

Algorithms were developed together with the University of Bath for each potential outcome of interest. Potential outcomes of interest included dyskinesias, sudden onset of sleep, end-of dose wearing off, on-off phenomenon and impulse control disorders. GSK and the University of Bath independently identified READ and OXMIS codes for each outcome of interest. Codes underwent clinical review at both sites and lists were compared to ensure completeness. For each outcome of interest, clinicians at GSK and at the University of Bath independently assigned the level of certainty associated with each code as 'no', 'possible', 'probable' based on the READ and OXMIS codes.

Questionnaires were sent (via the MHRA) to the GP's of 60 Parkinson's patients identified on the CPRD; 50 of whom had at least one of the potential outcomes of interest recorded on the CPRD and 10 without an outcome recorded on the CPRD. The following baseline and outcome information was requested on the GP questionnaire:

- Baseline data: Confirmation of PD diagnosis, year PD diagnosed, year dopaminergic therapy initiated, motor fluctuations experienced on or prior to initiation of dopamine agonist therapy.
- Outcomes (including date of onset):

- Dyskinesia
- Proportion of waking day with dyskinesia
- End of dose wearing off ¹
- On-off phenomena
- Proportion of waking day off
- Sudden onset of sleep (during day)
- Impulse control disorders (pathological gambling, hypersexuality, compulsive shopping, compulsive eating, other impulse control disorders)

Data recorded on the CPRD were compared with the GP responses. On-off phenomena could not be defined using codes available on the CPRD, therefore identification of this outcome was made by GP response alone.

Findings

Responses were received for 41 questionnaires (response rate of 68%).

Confirmation of PD diagnosis: PD diagnosis was recorded correctly on the CPRD in 40 of the 41 responses. It was therefore deemed that data captured on the CPRD was sufficient and that further validation from the GP questionnaire would not be necessary for the main study.

Year of PD diagnosis: The year of PD diagnosis matched in 28 of the 40 responses. Of the remaining 12 responses, the GP response was always earlier than the CPRD date. Based on these results, and following a review of patient medical records, an algorithm was defined. By using the earliest of the PD diagnosis code, dopaminergic therapy or PD symptomatology allows estimation of PD diagnosis date to within 4 months in approximately 90% of cases compared to using date of PD READ coding date alone. It is proposed to use this algorithm to derive PD diagnosis date (and hence PD duration) using data captured within the CPRD. Supplementary information from GP questionnaire are not required.

Motor fluctuations prior to index date: This question aimed help classify patients into PD disease stage (early vs. advanced) at index date. The response to this question was reported as not known in 35% of GP responses, yes in 37.5% and no in 27.5%. It is proposed to retain this question in the GP questionnaire however if there are significant numbers of responses that are not known in the main study, this variable may be omitted.

Medication use: Medication use was well captured on the CPRD. Supplementary information from GP questionnaire will not be required in the main study.

Outcomes:

¹ Individuals with end of dose wearing off were identified on the CPRD based on evidence of clinical manifestations of wearing off (READ codes for motor fluctuations, or evaluation of prescriptions suggesting increasing dose of levodopa /carbidopa, addition of a dopamine agonist, COMT inhibitor, apomorphine or MAO-B inhibitor, or deep brain stimulation) amongst individuals with PD that were treated with levodopa . In the GP questionnaire, the GP was required to tick a box to indicate the presence or absence of end of dose wearing off, together with a date of onset.

Dyskinesia:

Of the 12 cases that were identified as having probable dyskinesia on the CPRD, 7 were also confirmed by the GP questionnaire, 3 GPs responded no to the question and 2 did not know. 3 of the 9 cases that were identified as possible dyskinesia on the CPRD were also confirmed by the GP. 4 cases of dyskinesia were reported by the GP that were not identified using data from the CPRD. Data from the CPRD alone cannot be used to identify all dyskinesia cases. It is proposed that dyskinesia be identified based on data captured from the CPRD and from GP questionnaire. Individuals with dyskinesia reported from the GP questionnaire or with probable dyskinesia (defined using CPRD codes) will be used to identify individuals with dyskinesia. A clinical review of patient records with possible dyskinesia will be conducted to determine whether additional cases of dyskinesia exist.

Proportion of waking day with dyskinesia:

In the pilot study, we requested that GPs provided an estimate of the proportion of the waking day with dyskinesias. This information was poorly completed, and it is therefore proposed to omit this from the questionnaire for the main study.

End of dose wearing off:

Of the 9 patients identified on the CPRD as having end of dose wearing off, 1 of the GPs agreed but had the diagnosis 13 months earlier. 2 the GPs responded Not known and 6 stated No.

The GP identified 3 patients with end of off dose wearing off that had not been identified on the GPRD

Due to the inconsistency between the two sources of data, it is proposed to omit this outcome from the main study. Data captured within the CPRD are insufficient to define end of dose wearing off using READ, CPRD medical codes, or prescription data based on findings from the pilot study. There are concerns about the reliability and validity of this outcome if obtained from GP questionnaire alone, it is therefore proposed to omit this outcome from the main study.

On-off phenomena:

On-off phenomena was identified from the GP questionnaire alone since no relevant CPRD codes exist. Three patients were reported as having on-off phenomena from GP questionnaire. Since the accuracy and validity of this outcome is not known, all analyses evaluating this outcome must be interpreted with caution. In addition, should GP response rates substantially differ between exposure groups in the main study, then consideration to omit this outcome from the main study should be given.

Proportion of waking day off:

Although requested, no responses to the question “what proportion of the waking day is off” were received. It is therefore proposed to omit this question from the GP questionnaire.

Sudden onset of sleep (SOS):

Results from the CPRD and GP questionnaire were conflicting. Of the five individuals identified with READ codes suggestive of SOS (codes included narcolepsy, cataplexy, hypersomnia/excessive sleepiness and drowsiness) on the CPRD, only one was confirmed by the GP questionnaire. A code for hypersomnia was recorded in the GP record for the patient which was identified as possibly having SOS. The remaining four were reported not to have sudden onset of sleep from the GP questionnaire.

In total, four individuals were reported to have SOS based on GP questionnaire responses (including the one patient that was identified using READ codes). None of the GPs reported date of onset of SOS. It is therefore proposed to omit this outcome from the study due to concerns about the reliability or validity of the outcome.

Impulse control disorders:

It is proposed to retain this question in the GP questionnaire.

Pathological gambling: All three of the individuals identified as having pathological gambling on the CPRD were confirmed on the GP questionnaire.

Hypersexuality: No cases were identified on the CPRD, however three were identified by GP questionnaire.

Compulsive shopping, eating or other compulsive disorders: No cases were identified on the CPRD or by GP questionnaire.

Summary

It is not feasible to reliably identify patients with sudden onset of sleep or end of dose wearing off using data captured on the CPRD or by GP questionnaire. It is proposed to include questions on dyskinesias, on-off phenomena and impulse control disorders on the GP questionnaire for the main study. An evaluation of the GP questionnaire response rate between exposure groups must be taken into consideration prior to analysis of data.

TITLE PAGE

Division: Worldwide Development

Information Type: Worldwide Epidemiology Study Protocol

Title:	Post-marketing study of ropinirole prolonged release tablets in Parkinson's disease: Evaluation outcomes associated with long term use of Ropinirole-PR using the clinical practice research datalink (CPRD)
---------------	--

Compound Number: SKF101468

Development Phase IV

Effective Date: 30-NOV-2015

Subject: Pharmacoepidemiology post marketing study, Parkinson's disease

Author(s):

PPD

A large rectangular area of the document is redacted with a solid light blue color, covering the names of the authors.

PASS information

Title	Post-marketing study of ropinirole prolonged release tablets: Evaluation of the short term drug utilisation patterns and long term use of Ropinirole-PR using the clinical practice research database (CPRD)
Protocol version identifier	1
Date of last version of protocol	29 September 2015
EU PAS register number	Study not registered.
Active substance	Ropinirole
Medicinal product	Trade names Adartrel; Requip; Requip XL; Spiroco XL; Ralnea XL
Product reference	Ropinirole [2mg] Prolonged-release tablet (PL 10592/0293) Ropinirole [3mg] Prolonged-release tablet (10592/0294) Ropinirole [4mg] Prolonged-release tablet (PL 10592/0295) Ropinirole [8mg] Prolonged-release tablet (PL 10592/0296)
Procedure number	MHRA Ref No: PL 10592/0293 – 0001

Marketing authorisation holder(s)	Adartrel: GlaxoWellcome UK Ltd. Requip and Requip XL – SmithKline Beecham Ltd
Joint PASS	No
Research question and objectives	The primary objective of this study is to estimate the risk of dyskinesias amongst individuals prescribed the prolonged release ropinirole as monotherapy, compared to individuals initiating immediate release dopamine agonist monotherapy. Additional outcomes of interest are impulse control disorders, on-off phenomena and time to levodopa initiation. Secondary objectives include evaluating adherence to medication and off label use of medication
Country(-ies) of study	England and Wales.
Author	PPD Manager Epidemiology Worldwide Epidemiology R&D Projects, Clinical Platforms & Sciences GSK Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex, UB11 1BT, United Kingdom Email PPD

MARKETING AUTHORISATION HOLDER(S)

Marketing authorisation holder(s)	SmithKline Beecham Limited Great West Road, Brentford, Middlesex TW8 9GS Trading as: GlaxoSmithKline UK Stockley Park West, Uxbridge, Middlesex UB11 1BT
MAH contact person	PPD [REDACTED] Regulatory Project Manager UK Pharma Regulatory Direct Tel: PPD [REDACTED] e-mail: PPD [REDACTED]

TABLE OF CONTENTS

	PAGE
1. LIST OF ABBREVIATIONS	8
2. RESPONSIBLE PARTIES	9
3. ABSTRACT	12
4. AMENDMENTS AND UPDATES	14
5. MILESTONES	14
6. RATIONALE AND BACKGROUND	14
6.1. Background	14
6.1.1. Parkinson's disease	14
6.1.2. Treatment of Parkinson's disease	15
6.1.2.1. Dopamine agonists	15
6.1.2.2. Levodopa	16
6.1.2.2.1. Levodopa add-on therapies	17
6.1.3. Motor complications associated with long-term treatment of PD	17
6.1.3.1. End-of-dose wearing off	17
6.1.3.2. On-off phenomena	17
6.1.3.3. Dyskinesias	18
6.1.4. Impulse control disorders (ICDs)	18
7. RATIONALE	19
8. RESEARCH QUESTION AND OBJECTIVE(S)	19
8.1. Primary objectives:	19
8.2. Secondary objectives:	19
9. RESEARCH METHODS	19
9.1. Design	20
9.2. Setting	22
9.2.1. Clinical Practice Research Datalink	23
9.2.2. Populations of interest	23
9.2.2.1. PD patients initiating ropinirole-PR	24
9.2.2.2. Ropinirole-PR monotherapy (<u>ropinirole-PR cohort</u>)	24
9.2.2.3. PD patients initiating immediate release dopamine agonists	24
9.2.2.4. Immediate release dopamine agonist monotherapy	25
9.2.2.5. Ropinirole-PR off-label population	25
9.2.3. Matching Criteria	25
9.3. Variables	26
9.3.1. Outcome definitions	26
9.3.1.1. Dyskinesia	26
9.3.1.2. On-off phenomena	27
9.3.1.3. Impulse control disorders	27

9.3.1.4.	Additional outcomes of interest.....	28
9.3.2.	Exposure definitions	30
9.3.2.1.	Parkinson's disease population (PD).....	30
9.3.2.2.	Ropinirole-PR.....	30
9.3.2.3.	Oral immediate release dopamine agonists.....	30
9.3.2.4.	Dopamine agonist monotherapy definition.....	30
9.3.2.5.	Adjunctive use of dopamine agonist definition	30
9.3.3.	Confounders and effect modifiers	30
9.3.3.1.	Baseline covariates	31
9.3.3.2.	Time varying covariates.....	33
9.4.	Data sources	34
9.4.1.	Validity of using READ codes to identify individuals with Parkinson's disease.....	34
9.4.2.	Capture of PD medication use in the primary care setting.....	34
9.4.3.	Validity and justification for choice of outcomes of interest.....	34
9.5.	Study size	35
9.6.	Data management.....	36
9.6.1.	Data handling conventions.....	36
9.6.2.	Resourcing needs.....	36
9.6.3.	Timings of Assessment during follow-up.....	36
9.7.	Data analysis	36
9.7.1.	Overview of statistical techniques	36
9.7.1.1.	Descriptive and univariate analyses	36
9.7.1.2.	Incidence estimation.....	37
9.7.1.3.	Multiple regression analyses - Cox proportional hazards regression.....	37
9.7.1.4.	Censoring.....	37
9.7.2.	Essential analysis	38
9.7.3.	Exploratory analysis.....	41
9.7.4.	General considerations for data analyses	41
9.8.	Quality control.....	42
9.9.	Strengths of data source.....	42
9.10.	Limitations of the research methods	42
9.10.1.	Study closure/uninterpretability of results.....	43
9.11.	Other aspects	43
10.	PROTECTION OF HUMAN SUBJECTS	43
10.1.	Ethical approval and subject consent.....	43
10.2.	Subject confidentiality	43
11.	MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS	43
12.	PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS	44
12.1.	Target Audience	44
12.2.	Study reporting and publications.....	44
13.	REFERENCES.....	45
14.	ANNEX 1. LIST OF STAND-ALONE DOCUMENTS.....	47

15. ANNEX 2.ENCEPP CHECKLIST FOR STUDY PROTOCOLS	49
16. ANNEX 3.ADDITIONAL INFORMATION	58
16.1. Dyskinesia	58
16.2. Impulse control disorders	58
16.3. Parkinson's disease medications	58
16.4. Off-label indications	59
16.5. Parkinson's disease population (PD)	59
16.6. Date of PD diagnosis	60
16.7. Charlson comorbidity score.....	60
16.8. Hypertension	61
16.9. Hypercholesteraemia.....	61
16.10. Type 2 diabetes	61
16.11. Psychiatric disease	61
16.12. Respiratory disease	61

1. LIST OF ABBREVIATIONS

AE	Adverse Event
CPRD	Clinical Practice Research Database (UK)
GSK	GlaxoSmithKline
MHRA	UK Medicines and Healthcare products Regulatory Agency
Ropinirole-IR	Ropinirole immediate release formulation
Ropinirole-PR	Ropinirole prolonged release formulation

Trademark Information

Trademarks of the GlaxoSmithKline group of companies
Adartrel
Ralnea XL
Requip
Requip XL
Spiroco

Trademarks not owned by the GlaxoSmithKline group of companies
SAS

2. RESPONSIBLE PARTIES

PPD

Manager Epidemiology

Worldwide Epidemiology
R&D Projects, Clinical Platforms & Sciences
GSK
Stockley Park West,
1-3 Ironbridge Road,
Uxbridge,
Middlesex,
UB11 1BT, United Kingdom
Email PPD

PPD

Regulatory Project Manager
UK Pharma Regulatory
GlaxoSmithKline UK Limited
Stockley Park West,
1-3 Ironbridge Road,
Uxbridge,
Middlesex,
UB11 1BT, United Kingdom
Email PPD

SPONSOR SIGNATORY:

PPD


Usha Gungabissoon
Primary Author/ Project officer

30/11/2015

Date

PPD


Monika Stender
Therapy Area Leader

30/11/2015

Date

SPONSOR INFORMATION PAGE

WWEpi Project Identifier: WEUKSTV2488

DNG number: 2015N258148_00

Sponsor Legal Registered Address:

GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK

Sponsor Contact Address

PPD

GlaxoSmithKline Research & Development Limited
Iron Bridge Road
Stockley Park West, Uxbridge, Middlesex, UB11 1BU, UK
Telephone: PPD

In some countries, the clinical trial sponsor may be the local GlaxoSmithKline affiliate company (or designee). Where applicable, the details of the Sponsor and contact person will be provided to the relevant regulatory authority as part of the clinical trial submission.

Regulatory Agency Identifying Number(s):

3. ABSTRACT

Title

Post-marketing study of ropinirole prolonged release tablets: Evaluation of the short term drug utilisation patterns and long term use of Ropinirole-PR using the clinical practice research database (CPRD)

Rationale and background

The proposed study is required as part of a post marketing commitment to the MHRA to evaluate the long term safety of ropinirole-PR. Specifically, it is proposed to estimate the incidence of dyskinesias, on-off phenomena and impulse control disorders, in Parkinson's patients initiating ropinirole-PR monotherapy as compared to those initiating immediate release dopamine agonists as monotherapy up to a maximum of 5 years of treatment. The study will use data recorded on the Clinical Practice Research Datalink (CPRD) a primary care based observational data source, supplemented with data to be obtained by GP questionnaire. As part of these activities, treatment persistence and adherence will be evaluated as well as off-label use of ropinirole-PR.

Research question and Objective(s)

Primary objectives:

1: To estimate, amongst individuals with Parkinson's disease, the incidence rate ratio of dyskinesia in individuals initiating ropinirole-PR monotherapy compared to those initiating immediate release dopamine agonist monotherapy. Incidence rate ratios will also be estimated for other outcomes of interest, notably on-off phenomena and impulse control disorders. The exposure groups will be propensity score matched.

Secondary objectives:

2: To describe and compare the baseline characteristics of individuals initiating ropinirole-PR with those initiating immediate release dopamine agonist monotherapy for PD.

3: To describe treatment persistence and adherence amongst patients initiating therapy on ropinirole-PR versus a matched cohort initiating immediate release dopamine agonists.

4: To describe the extent of off-label use amongst ropinirole-PR initiators.

Study Design

Propensity matched cohort design with adjustments for time varying covariates

Population, including the setting and study population

Parkinson's disease patients initiating an oral dopamine agonist therapy between 2004 and 2012 will be eligible for inclusion in the study. Follow-up will commence at date of initiation of treatment +30days (index date). Individuals with an outcome of interest on or prior to index date will be excluded. Follow-up will continue to the earliest of development of an outcome of interest, treatment discontinuation+30days, end of follow-up, up to a maximum of 5 years of treatment. The treatment exposure groups of interest are PD patients initiating ropinirole-PR monotherapy or immediate release dopamine agonist monotherapy. Propensity score matching will be used to reduce the risk of confounding by indication, and aims to ensure that the exposure groups are similar with regards to baseline characteristics.

Variables

Outcomes: Incident dyskinesia and impulse control disorders will be identified using READ codes and be supplemented with information to be obtained by GP questionnaire. On-off phenomena will be identified based on GP responses alone. Time to levodopa initiation will be estimated to determine whether differences exist between the exposure groups, this will be determined based on prescription patterns on the CPRD

Covariates: Demographics, PD disease duration, PD treatment history and duration, Charlson comorbidity score and morbidity burden at baseline.

Time varying covariates: Initiation of levodopa, COMT inhibitor, MAOB-I, or decarboxylase inhibitor during follow-up

Data sources:

The study will be conducted using the Clinical Practice Research Datalink (CPRD), a primary care database. In the UK ongoing treatment of PD is managed in the primary care setting. This database provides longitudinal follow-up on a representative sample of the U.K. general population.

Study size

A recent feasibility assessment identified 577 individuals initiating ropinirole-PR as monotherapy and 1660 initiating an immediate release dopamine agonist monotherapy on the CPRD. Up to three comparators will be matched to each ropinirole-PR monotherapy patient. The anticipated GP response rate is 68%, which is response rate achieved in the pilot study.

A Cox regression of the log hazard ratio on a covariate with a standard deviation of 0.5000 based on a sample of 1000 observations, based on independent sampling of the exposure groups (i.e. no matching) achieves 82% power at a 0.05 significance level to detect a regression coefficient equal to 0.4055. The sample size was adjusted for an anticipated event rate of 0.2000. It is hoped that in the present study the use of matched samples will give some additional power.

Data analysis

A Cox proportional hazards regression model will be used to evaluate time to dyskinesias in individuals prescribed ropinirole-PR with those prescribed other dopamine agonists of interest. Patients will be followed up from index date (initiation of treatment) up to a censoring event (earliest of the outcome of interest, discontinuation of therapy+30days or end of CPRD follow-up).

Crude and adjusted hazard ratios and 95% CI will be estimated amongst individuals who are free from the outcome of interest at baseline and meeting all inclusion criteria in the two groups of interest (**ropinirole PR cohort** and the **IR-DA matched cohort**) accounting for time varying covariates.

Milestones

ISAC approval will be sought in October 2015. Analysis will commence once approval by ISAC has been granted.

4. AMENDMENTS AND UPDATES

Amendment or update no	Date	Section of study protocol	Amendment or update	Reason

5. MILESTONES

Milestone	Planned date
Submission to ISAC for approval	October-November 2015
Registration in the EU PAS register	<i>Following ISAC approval</i>
Identification of study populations	November 2015
Start of data collection (GP questionnaire)	January 2016
Interim review of response rate	March 2016
End of data collection	May 2016
Review of achieved response rate	May 2016
Analysis of data	June 2016
Final report of study results	September 2016

6. RATIONALE AND BACKGROUND

6.1. Background

6.1.1. Parkinson's disease

Parkinson's disease (PD) is an age-related progressive neurodegenerative condition, the underlying pathology of PD involves progressive loss of nigrostriatal neurones which

results in deficiency of the neurotransmitter dopamine. The mean age of onset is about 65 years, however an early onset form of the condition exists affecting individuals aged less than 40 years. Similar frequencies are observed in males and females. The overall age-adjusted prevalence is approximately 0.3% overall and 1% of individuals aged >60 years. (Samii et al, 2004)

6.1.2. Treatment of Parkinson's disease

Currently available therapies aim to replace or compensate for the lost dopamine in order to improve motor function. There are no disease modifying therapies available.

Choice of initial therapy depends on a patient's age and specific symptoms. If motor symptoms are mild but require therapy, patients may initiate a monoamine oxidase B inhibitor before moving to more potent dopaminergic therapies such as levodopa or a dopamine agonist.

There is a higher incidence of levodopa-related dyskinesia in younger-onset PD, as such dopamine agonists are usually introduced as initial treatment for patients younger than 60 years. (Connolly & Lang, 2014) With time, individuals controlled initially with dopamine agonist monotherapy will eventually require the addition of levodopa to adequately control their symptoms.

In patients aged ≥ 60 years, the levodopa is often favoured as the first line treatment. (Connolly & Lang, 2014)

6.1.2.1. Dopamine agonists

Two subclasses of dopamine agonist exist: ergot (bromocriptine, pergolide, lisuride, α -dihydroergocryptine and cabergoline) and non-ergot (apomorphine, rotigotine, pramipexole, pramipexole and ropinirole).

Whereas the aim of levodopa treatment is to replace dopamine, dopamine agonists exert their anti-parkinsonian effects by acting directly on dopamine receptors and mimicking the endogenous neurotransmitter. (Brooks, 2000) (Bonuccelli & Ceravolo, 2008)

Dopamine agonists can be used as monotherapy or as an adjunct to levodopa. When used as monotherapy, the intention is to delay the need to initiate levodopa therapy and hence deferring the onset of levodopa associated complications. Since younger age-of-onset of Parkinson disease is a risk factor for motor fluctuations and dyskinesia, dopamine agonists are usually introduced as initial treatment for patients younger than 60 to 65 years. (Brooks, 2000)

Most patients that initiate dopamine agonist therapy will eventually need the addition of levodopa to their treatment regimen. (Connolly & Lang, 2014) Conversely, individuals initiating their treatment as levodopa monotherapy may be prescribed a dopamine agonist as adjunctive therapy in patients exhibiting fluctuating motor responses and dyskinesias associated with its chronic use. (Connolly & Lang, 2014; Giroux, 2007) Addition of dopamine agonists allows a reduction in dose of levodopa and leads to improvement in the disabling complications.

Known side effects of dopamine agonists include hallucinations, excessive daytime sleepiness, hypotension and nausea. (Bonuccelli & Ceravolo, 2008) Ergot derived dopamine agonists are also associated with an increased risk of cardiac valve regurgitation and as a result are not generally prescribed. (Schade et al, 2007) Other potential complications of PD medications include impulse control behaviours. (Bonuccelli & Ceravolo, 2008) (British National Formulary, 2015)

Ropinirole for the treatment of Parkinson's disease (prolonged and immediate release)

Ropinirole is a potent and highly selective non-ergot dopamine receptor agonist that is active both peripherally and centrally. It is indicated for Parkinson's disease and the symptomatic treatment of moderate to severe idiopathic restless legs syndrome (RLS). Ropinirole has been approved and marketed in the UK for the treatment of PD for over fifteen years and has been shown to be well tolerated and effective.(Adler et al., 1997; Pahwa et al, 2004)

Immediate release formulation:

Ropinirole is available as an immediate release (IR) formulation (REQUIP™) and is administered three times daily for the treatment of PD. The initial daily dose is 0.75mg titrating upwards to a maximum dose of 24mg daily.

Prolonged release formulation:

A prolonged release formulation of ropinirole (ropinirole-PR) has been more recently developed for the treatment of PD and has the advantage of being taken only once a day providing a simplified dosing regimen and reduced pill-burden. Ropinirole-PR is available in 2, 3, 4 and 8 mg tablet strengths. The initial dose of treatment is 2mg once daily, to a maximum daily dose of 24mg based on the patient's response. For patients switching from ropinirole-IR, patients should be switched to the equivalent daily dose of ropinirole-PR. Ropinirole-PR was licensed in 2008.

The once daily dosing has the potential to improve compliance, which may lead to improved efficacy. The prolonged release formulation reduces plasma-level fluctuations in the concentration of ropinirole over a 24 hour period, producing a smoother pharmacokinetic profile which may result in a reduced potential to cause side-effects.(Pahwa R et al., 2007)

6.1.2.2. Levodopa

Levodopa is the first line treatment of choice amongst PD patients aged over 60 years. Levodopa is the amino acid precursor of dopamine and remains the most potent and widely used antiparkinson drug throughout much of the disease course. In combination with a peripheral decarboxylase inhibitor, it is the most effective symptomatic treatment. Levodopa enters dopaminergic neurons where it is metabolised to dopamine, replacing the depleted endogenous neurotransmitter.

Known side-effects of levodopa include dyskinesias and on-off fluctuations. ([British National Formulary](#), 2015)

6.1.2.2.1. Levodopa add-on therapies

Decarboxylase inhibitors, Catechol O-methyltransferase (COMT) inhibitors and MAO-B inhibitors are often prescribed together with levodopa to prolong its action. Monoamine oxidase type B (MAO-B) inhibitors prevent the breakdown of dopamine in the brain. Whereas decarboxylase and COMT inhibitors are generally only prescribed with levodopa, MAO-B inhibitors can be used on its own in the early stages of the condition or in conjunction with levodopa. In this situation, it reduces the required dosage of levodopa and prolongs its action.

6.1.3. Motor complications associated with long-term treatment of PD

A complication of long-term dopaminergic treatment for PD, are the development of motor fluctuations (such as end-of-dose wearing-off, on-off phenomena) and dyskinesias. ([Samii et al.](#), 2004). Motor complications can impair quality of life and cause significant disability for patients. ([Connolly & Lang](#), 2014)

6.1.3.1. End-of-dose wearing off

End-of-dose wearing off develops as the disease progresses and is often one of the first signs of motor complication associated with therapy. ([Santens & de Noordhout](#), 2006)

With continued loss of substantia nigra, the treatment benefit of each dose of levodopa progressively shortens. Patients notice a re-emergence of their Parkinsonian signs within 4 hours or less after administration of a single dose of levodopa. Symptom control can be regained by taking the next levodopa dose.

End of dose wearing off is a relatively predictable variation of motor fluctuations that is temporally associated with the timing of levodopa ingestion. A study of 60 incident PD patients by [Thomas et al](#) found that 30% on dopamine agonist mono therapy experienced “wearing-off” 15–21 months after beginning treatment. ([Thomas et al.](#), 2006)

6.1.3.2. On-off phenomena

“On-off” phenomenon refers to a switch between mobility and immobility in levodopa-treated patients, which occurs as sudden and unpredictable motor fluctuations. Periods of improved mobility are known as “on” periods during which the patient responds to levodopa and where medication is providing symptomatic benefit and periods of impaired motor function or “off” responses in when symptomatic benefit has been lost over the preceding minutes or hours. ([Samii et al.](#), 2004)

Strategies for reducing the time that medication is not optimally effective (“off” time) include increasing the dosage of dopaminergic medication, adding another dopaminergic medication, dividing the levodopa dosage into smaller but more frequent doses (levodopa dose fractionation), or adding a COMT inhibitor or MAO-B inhibitor to inhibit the breakdown of levodopa and dopamine and prolong their effects. ([Pahwa et al.](#), 2006)

6.1.3.3. Dyskinesias

Dyskinesias are drug-induced involuntary movements including chorea and dystonia and describes a group of abnormal involuntary (non-tremor) movements that appear to be a fragmentation of the normal smoothly controlled limb and facial movements. They are a central side effect of dopaminergic therapy and represent a major clinical problem in the management of patients with PD. Dopaminergic reduction strategies will reduce dyskinesias but worsen PD symptoms. Amantadine may be used to reduce dyskinesia severity. (Connolly & Lang, 2014)

Dyskinesias are reported to occur in up to 45% of patients after 5 years of therapy with levodopa and 20% amongst those prescribed a dopamine agonist. (Gomez, et al., 1997; Rascol et al., 2000; Samii et al., 2004)

6.1.4. Impulse control disorders (ICDs)

ICDs are defined as behaviours that are performed repetitively, excessively, and compulsively to an extent that interferes in major areas of life functioning. In recent years, there has been increasing evidence and awareness that PD patients are at increased risk of developing one or more of four major ICDs, which are compulsive or pathological gambling, buying, sexual, and eating behaviours. (Weintraub et al., 2014)

Amongst patients prescribed levodopa, motor complications can occur as early as 2 years into therapy, although it is generally assumed that motor fluctuations occur in about 50 percent of patients after 5 years of levodopa treatment, increasing to 70 percent among patients treated for 15 years or more. (Giroux, 2007) (Santens & de Noordhout, 2006)

Dopamine agonists are less likely than levodopa to cause dopaminergic motor complications, particularly dyskinesia. The reason for this is not known, however it may be related to the longer half life of dopamine agonists and differences in receptor selectivity. (Brooks, 2000) Evidence suggests that the abnormal pulsatile stimulation of dopamine receptors by the intermittent administration of agents with short half-lives such as levodopa is an important factor in the development of motor fluctuations. (Olanow & Obeso, 2000) (Santens, et al., 2003) (Brooks, 2000; Samii et al., 2004)

Initiating therapy with a long-acting dopamine agonist has been shown to delay the onset and reduce the severity of motor complications in MPTP monkeys and PD patients. Administering levodopa with a COMT inhibitor to block its peripheral metabolism increases its plasma half-life and might have a similar effect. (Olanow & Obeso, 2000)

At the time of submission, the MHRA expressed concerns about the long-term consequences of continuous dopamine agonism in PD patients prescribed ropinirole-PR. GSK have therefore proposed to conduct a post-marketing observational study using the Clinical Practice Research Datalink (CPRD) in order to address these concerns. A post-marketing study will be conducted incidence of known consequences of dopamine agonism over a five-year period in Parkinson's patients initiating ropinirole PR as monotherapy compared to those initiating immediate release dopamine agonist monotherapy.

Additional questions that GSK will address include evaluating adherence and persistence to medication off label use of ropinirole PR.

7. RATIONALE

GSK has committed to conducting a post-marketing observational study to evaluate the long-term consequences of continuous dopamine agonism in PD patients initiating ropinirole-PR monotherapy compared to those initiating an immediate release dopamine agonist monotherapy. GSK have proposed to conduct this post-marketing observational study using data from the CPRD, a UK primary care dataset.

8. RESEARCH QUESTION AND OBJECTIVE(S)

The aim of this study is to estimate the incidence of dyskinesias, on-off phenomena and impulse control disorders amongst PD patients initiating prolonged release ropinirole (ropinirole-PR) monotherapy compared to those initiating immediate release dopamine agonist monotherapy using data from the CPRD.

8.1. Primary objectives:

1: To estimate, amongst individuals with Parkinson's disease, the incidence rate ratio of dyskinesia in individuals initiating ropinirole-PR monotherapy compared to those initiating immediate release dopamine agonist monotherapy. Incidence rate ratios will also be estimated for other outcomes of interest, notably on-off phenomena and impulse control disorders. The exposure groups will be propensity score matched.

8.2. Secondary objectives:

2: To describe and compare the baseline characteristics of individuals initiating ropinirole-PR with those initiating immediate release dopamine agonist monotherapy for PD.

3: To estimate time to levodopa use amongst PD patients initiating ropinirole-PR monotherapy and those initiating immediate release dopamine agonist monotherapy.

4: To describe treatment persistence and adherence amongst patients initiating therapy on ropinirole-PR versus a matched cohort initiating immediate release dopamine agonists.

5: To describe the extent of off-label use amongst ropinirole-PR initiators.

9. RESEARCH METHODS


This observational study will involve retrospective analysis of longitudinal electronic medical records (EMR) from the CPRD. This will be supplemented with data to be obtained by GP questionnaire.

9.1. Design

This study will use a propensity matched cohort design with adjustments for time varying covariates. Parkinson's disease patients initiating an oral dopamine agonist therapy between 2004 and 2012 will be eligible for inclusion in the study.

Comparisons will initially be made between individuals initiating ropinirole-PR and those initiating immediate release dopamine agonists for their Parkinson's disease. Patient demographics and medical history up to the time of initiation of therapy will be described and compared between the two groups. Treatment histories will also be evaluated in order to determine whether patients initiated their therapy as an adjunct to levodopa or as dopamine agonist monotherapy. [Figure 1](#) provides an overview of the eligible population.


Figure 1 Overview of populations of interest



The longitudinal analysis will be restricted to individuals prescribed their dopamine agonist as a monotherapy (i.e. without concomitant use of or a history of levodopa use). The reason for this is because of the complexity of the PD treatment pathway and because patients already established on levodopa may be prescribed a dopamine agonist as an adjunct to help alleviate existing motor fluctuations associated with levodopa use.

Individuals initiating immediate release dopamine agonists as monotherapy will be propensity score matched to individuals initiating ropinirole-PR monotherapy to ensure comparability between groups and to minimise confounding (**ropinirole-PR cohort**). Individuals initially in the IR-DA cohort that switch to ropinirole-PR will enter the ropinirole-PR cohort at the time of switch. See [Figure 2](#).


Figure 2 Populations of interest for longitudinal evaluation (DA monotherapy; ropinirole-PR and propensity score matched immediate release DA)



Factors to be considered in generating the propensity score will include demographics, PD disease duration, morbidity burden and treatment histories up to index date (refer to Section 9.3.3.1). Initiation of levodopa, COMT, decarboxylase inhibitors or MAOB during the observation period will also be accounted for since they are known to prolong the effects of levodopa and hence may modify the risk of some of the outcomes of interest. Compliance and adherence to medication may be greater in individuals prescribed ropinirole-PR compared to immediate release dopamine agonists due to its once a day formulation. Therefore adherence to medication will also be described.

The longitudinal analysis will be conducted amongst those patients initiating ropinirole-PR monotherapy and the IR-DA matched cohort. See [Figure 3](#) below.

Figure 3 Schematic of study design: Longitudinal evaluation of DA monotherapy (ropinirole-PR vs. IR-DA matched cohort)



The observation period will commence from date of initiation of therapy + 30days (index date) and continue up to a censoring event (earliest of discontinuation of therapy +30 days, development of an outcome of interest (dyskinesia, on-off phenomena or impulse control disorder), or end of follow-up on the CPRD) up to a maximum of 5 years of treatment. Follow-up commences 30 days after initiating therapy to allow sufficient exposure to the drug, and to account for instances whereby a patient might be switching from another therapy because of developing an outcome of interest. Similarly this is the justification for censoring patients 30 days after treatment discontinuation.

9.2. Setting

The study population for this study will be comprised of individuals with a recorded Parkinson's disease diagnosis initiating a dopamine agonist therapy between January 1st 2004 and December 31st 2012. Patients will be identified from the CPRD, a UK primary care based electronic health record database. Within the United Kingdom, ongoing

Parkinson's disease treatment is managed in the primary care setting by general practitioners.

9.2.1. Clinical Practice Research Datalink

The CPRD is an observational database of anonymised longitudinal records collected from computerised primary care practices throughout the UK containing all records deemed relevant to patient care. Details of demographics, primary care diagnoses and prescription treatment are routinely recorded by date in individual patient records. Due to the structure of the UK National Health Service, details of referrals, secondary care diagnoses and deaths are also captured. Major events from before computerisation are added retrospectively so that the GP has complete patient records. Data on preventive medicine can also be recorded with laboratory results electronically transferred to many practices. Medical events are automatically coded at entry using the READ coding system.(NIH, 2015). Prescriptions issued by the GP are coded using BNF coding. Each patient within the CPRD is assigned an 'up to standard' date (UTS) when the recording of their details is considered to be of research standard.

Data quality of the CPRD is monitored continuously by MHRA and practices that fail to maintain the required standards are removed from the database. The data is collected from over 400 contributing clinical practices throughout the UK and currently contains around 4 million active patients. The CPRD has been found to be highly representative of the UK general population. Several studies have demonstrated nearly identical age and sex distributions when stratified by geographic region between the CPRD population and the entire UK population. (Walley & Mantgani, 1997) On average, individual patients are followed for more than 6 years.

The latest version of the CRPD available at the time of data analysis will be used.

9.2.2. Populations of interest

To be considered eligible for this study, individuals must first meet the criteria for Parkinson's disease which will be defined using READ codes (Section 9.3.2.1). From this population, individuals initiating a dopamine agonist therapy of interest between 2004 and 2012 will be identified.

From this, the following populations of interest will be derived:

- All individuals initiating ropinirole-PR
 - Individuals initiating ropinirole-PR as monotherapy

- All individuals initiating an oral immediate release DA
 - Individuals initiating an oral immediate release DA as monotherapy.

In addition, a separate population will be identified to evaluate off-label use of ropinirole-PR.

9.2.2.1. PD patients initiating ropinirole-PR

PD patients prescribed ropinirole-PR by their GP will be identified from the CPRD. All individuals that meet the case definition for PD and have least 1 prescription for ropinirole-PR on or after their PD diagnosis date will be considered for inclusion.

Inclusion criteria

- i. Patients must meet the case definition of PD.
- ii. Individuals must have at least one script for ropinirole-PR between 2004 and 2012 (on or after PD diagnosis date).
- iii. Patients must have at least 12 months registration prior to index date in order to collect information on comorbidity, medical and prescription history.

Exclusion criteria

The study population will be redefined for analysis of each outcome of interest to ensure that the population under study is free from that outcome at baseline.

- Exclude patients that belong to practices that are not considered up to research standard on index date.
-
- Exclude individuals with any outcomes of interest (dyskinesia, impulse control, on-off phenomena) on or prior to index date. The study population will be redefined for the analysis of each outcome of interest to ensure that the population under study is free from that outcome at baseline.

9.2.2.2. Ropinirole-PR monotherapy (ropinirole-PR cohort)

A subset of the population above initiating ropinirole-PR as monotherapy. Refer to Section 9.3.2.4 for monotherapy definition.

9.2.2.3. PD patients initiating immediate release dopamine agonists

This group will comprise of Parkinson's disease patients initiating an oral immediate release dopamine agonist between 2004 and 2012. This may include individuals initiating the immediate release formulation of ropinirole. Individuals must not have been prescribed prolonged release formulations of ropinirole or pramipexole prior to index date.

Individuals that subsequently switch to ropinirole-PR during follow-up will enter the ropinirole-PR cohort at the time of switch.

Inclusion

- Individuals meeting the PD case definition and initiating an immediate release formulation of a dopamine agonist of interest (between 2004 and 2012) will be included.
- The index date will be defined as the date the dopamine agonist of interest was initiated.

- Patients must belong to practices that are considered up to research standard on index date.
- Patients must have at least 12 months of registration prior to the index date in order to collect information on disease, comorbidity, medical and prescription history.

Exclusion

- Exclude individuals with exposure to prolonged release dopamine agonists (pramipexole or ropinirole) prior to index date.
- Exclude individuals with any outcomes of interest (dyskinesia, impulse control, on-off phenomena) on or prior to index date. The study population will be redefined for analysis of each outcome of interest to ensure that the population under study is free from that outcome at baseline.
- See Section 9.2.3 relating to matching criteria.

9.2.2.4. Immediate release dopamine agonist monotherapy

A subset of the population above initiating their treatment as monotherapy. Refer to Section 9.3.2.4 for monotherapy definition.

9.2.2.5. Ropinirole-PR off-label population

All individuals on the CPRD with at least one ropinirole-PR prescription (irrespective of age) will be identified. Patients are required to have at least 12 months of medical history prior to the index date in order to determine likely indication for prescription for the off-label evaluation. The off-label population will comprise of those without a prior history of PD. The proportion of the off-label population with restless leg syndrome (RLS), fibromyalgia, sexual dysfunction, periodic limb movement disorder (without mention of RLS) will be estimated. In addition the proportion of the off-label population at are aged <18years at index date will be estimated (paediatric population)

9.2.3. Matching Criteria

Up to 3 individuals from the comparator cohort (**IR-DA cohort**) will be matched to each individual in the **ropinirole-PR cohort** using the propensity scores. The matching technique (greedy vs. optimal) is yet to be determined.

Propensity score matching aims to improve comparability between the ropinirole-PR and immediate release DA monotherapy groups at baseline. The propensity score is defined as the conditional probability of being treated given the baseline covariates. The propensity score will be used as a matching variable in order to balance the baseline covariates in the two groups. (D'Agostino, 1998) Trimming of propensity scores may be used to provide additional equipoise between treatment groups as this will exclude those with more extreme propensity score values.

To estimate propensity scores, the distribution of the treatment indicator variable is modelled, given the observed covariates at baseline. SAS unconditional logistic regression models will be used; ropinirole-PR use will be the outcome variable. Each

individual is assigned a probability for receiving ropinirole-PR (propensity score) given factors known at baseline. Propensity scores are then used to match individuals with the same propensity score for ropinirole-PR, however, one will have received ropinirole-PR and the other treated with another dopamine agonist of interest.

Factors (at baseline) to be considered in the propensity score generation are listed in Section 9.3.3.1 and include age at PD diagnosis, PD disease duration, PD medication history and morbidity burden at index date.

When missing values occur on covariates to be used in the propensity score, subjects will be excluded.

The distribution of the propensity scores for each exposure will be plotted, before and after matching. The variation within each group (e.g. the SD) will be compared with the separation between the exposed and unexposed groups (e.g. difference between means) to determine whether an adequate degree of matching has been achieved.

A comparison between baseline factors (including those used to generate the propensity score) between the ropinirole-PR cohort and IR-DA cohort will be made to ensure that the matching was successful in balancing the groups.

All longitudinal analyses will be conducted amongst the **ropinirole-PR monotherapy cohort** and the propensity matched immediate release monotherapy group (**IR-DA matched cohort**).

9.3. Variables

9.3.1. Outcome definitions

Refer to [ANNEX 1](#) for a copy of the GP questionnaire

9.3.1.1. Dyskinesia

Dyskinesia will be identified using data captured on the CPRD using READ codes, as well as by GP questionnaire.

Individuals will be classified as having dyskinesia if:

Dyskinesia = YES on GP questionnaire

or

Where Dyskinesia is not known/blank on the GP questionnaire AND CPRD algorithm = [probable] or [possible + initiation of amantadine+clinical review]

For patients where there are conflicting information (i.e. no on GP questionnaire and probable on the CPRD), a review of the patients electronic medical record will be made by the clinical consultant and independently by the safety physician to determine outcome status.

Date of dyskinesia is the earliest of the dates cited from either source. In the instance where date of dyskinesia is absent (i.e. if from GP questionnaire only), then patient should be excluded from analysis of that outcome.

READ codes can be found in [ANNEX 3](#).

9.3.1.2. On-off phenomena

READ codes are not specific enough to define on-off phenomena, therefore it will be identified using responses from GP questionnaire alone ([ANNEX 1](#)).

Month and year of diagnosis will be obtained via GP questionnaire. If date is absent, then the patient should be excluded from analysis of that outcome.

Should the GP questionnaire response rate substantially differ between exposure groups, this outcome will not be included.

9.3.1.3. Impulse control disorders

The following impulse control behaviours will be defined using data from the CPRD and from GP questionnaire:

- i. Compulsive eating
- ii. Compulsive shopping
- iii. Pathological gambling
- iv. Hypersexuality
- v. Other impulse control disorder

Individuals will be classified as having an impulse control disorder if:

Response to any ICD question = YES on GP questionnaire

or

ICD response = not known or blank on GP questionnaire AND CPRD algorithm = probable

For patients where there are conflicting information (i.e. no on GP questionnaire and probable on the CPRD, a review of the patients electronic medical record will be made by the clinical consultant and independently by the safety physician to determine outcome status.

Date of onset of ICD is the earliest of the dates cited from either source. In the instance where date of impulse control disorder is absent (i.e. if from GP questionnaire only), then patient should be excluded from analysis of that outcome.

It is proposed to evaluate the risk of ICD overall. A description of the specific behaviours that have been reported will be described.

READ codes can be found in [ANNEX 3](#).

9.3.1.4. Additional outcomes of interest**Time to levodopa initiation**

Time to levodopa use amongst individuals without a history of use of levodopa at baseline will be evaluated in both cohorts. As levodopa is associated with dyskinesias, delay in its use may further reduce the risk of the development of motor complications, or reflect better control of PD symptoms by current therapy.

BNF codes will be used to identify levodopa containing medications. ([ANNEX 3](#))

Duration of treatment persistence

Persistence is defined as time from initiation to discontinuation of therapy (a gap in treatment of at least 60 consecutive days). This will be monitored based on prescriptions issued within the CPRD.

The duration of treatment will be derived from either days supply, or pack size divided by the indicated number of tablets to be taken per day. Some patients may have overlapping prescriptions as prescriptions may be issued prior to the previous prescription ending, in these instances, prescriptions can be assumed immediately follow the previous one.

Adherence

The medication possession ratio (MPR) will be used to describe adherence to medication.

This will be calculated by summing the days supply from the first to the last prescription (inclusive) divided by time between the last prescription date plus days supply and the first prescription date.

The following categories of MPR will be created:

- <30%
- 30-50%
- 51-80%
- \geq 80%

Off-label use of ropinirole-PR

Amongst individuals prescribed ropinirole-PR, diagnoses (defined by READ codes) any time prior to index date will be evaluated to determine likely indication for treatment. The proportion of individuals with any of the following conditions on or prior to index date will be evaluated:

- Parkinson's disease

Then, amongst those without a history of PD:

- Restless legs syndrome (RLS)
- Fibromyalgia
- Periodic limb movement disorder (PLMD) without mention of RLS
- Sexual dysfunction
- Individuals initiating therapy without any history of the mentioned conditions, will be coded as "other".

READ codes have been reviewed by a clinician at GSK can be found in [ANNEX 3](#)

Ropinirole daily dose amongst switchers from ropinirole-IR to ropinirole-PR

Individuals that have switched from the immediate release to the prolonged release formulation of ropinirole will be identified. Switchers will be defined as the subset of the ropinirole-PR population that have at least one script for ropinirole-IR formulation in the one month period prior to index date. The difference between the average daily dose of the last ropinirole-IR script and first ropinirole-PR will be calculated.

The average prescribed daily dose will be calculated based on tablet strength, prescription duration and number of daily tablets per prescription.

- Days' supply: if not stated, then divide total quantity by the quantity prescribed per day.
- Daily dose: multiply the quantity prescribed per day by the dose of the tablets
- Where two scripts are given on the same day (different strengths), assume that the doses are additive (i.e. 2mg and 4mg on same day = 6mg). For instances where the patients have two scripts for the same dose on the same day (i.e. separate

entries for 2 sets of 2mg), these should be flagged. Additional review will be required to determine whether these are additive or not based on data captured on the CPRD.

The number of patients missing dose information will be described.

9.3.2. Exposure definitions

9.3.2.1. Parkinson's disease population (PD)

Parkinson's disease will be defined using READ codes captured on the CPRD. READ codes for Primary/idiopathic Parkinson's disease patients can be found in [ANNEX 3](#).

The date of PD diagnosis will be derived using an algorithm based approach ([ANNEX 3](#))

9.3.2.2. Ropinirole-PR

BNF codes will be used to identify ropinirole-PR prescriptions. These codes have undergone review by a clinician at GSK. These codes will be reviewed prior to starting the study to ensure that the list of codes is complete. ([ANNEX 3](#))

The index date will be defined as date of initiation of the ropinirole-PR therapy + 30 days.

9.3.2.3. Oral immediate release dopamine agonists

BNF codes will be used to identify prescriptions for dopamine agonists that are oral and immediate release formulations. These include both ergot and non-ergot dopamine agonists, and will also include individuals prescribed immediate release formulation of ropinirole. Initiators of therapy will be included.

BNF codes have undergone review by a clinician at GSK. ([ANNEX 3](#)).

Index date will be date of initiation of the dopamine agonist therapy + 30 days.

9.3.2.4. Dopamine agonist monotherapy definition

Monotherapy is defined dopamine agonist use without concurrent levodopa use, or dopamine agonist use without a history of levodopa use prior to dopamine agonist initiation.

9.3.2.5. Adjunctive use of dopamine agonist definition

Adjunctive therapy is defined as concurrent use (overlapping prescriptions/exposures) of a dopamine agonist with levodopa at the time of dopamine agonist initiation.

9.3.3. Confounders and effect modifiers

Potential confounders include age, sex, duration of PD, year of first dopaminergic prescription

Additionally, as the risk of motor fluctuations such as dyskinesias increases with advancing disease state, PD duration at index date will also be determined using data on the CPRD.

The table below outlines the covariates of interest.

9.3.3.1. Baseline covariates

The following covariates are based on data captured on the CPRD up to and including index date.

Covariate	From GP questionnaire	Comments
Demographics and baseline health state		
Age at index date		Age at initiation of medication of interest. Consider using age at index date or PD duration at index date. (age \pm 5yrs)
Age at PD diagnosis		(age \pm 5yrs)
Gender		
Disease state (early or advanced) at baseline	X	To be obtained from GP questionnaire and will be based on whether a patient experienced motor fluctuations at index date.
Socioeconomic status (practice level)		
Mean number of GP consultations in 12 months to index date		
Charlson comorbidity score		Charlson comorbidity score at baseline – based on full available medical history at index date. Scoring: Comorbidity Component (Apply 1 point to each unless otherwise noted). <ol style="list-style-type: none"> 1. Myocardial infarction 2. Congestive heart disease 3. Peripheral vascular disease 4. Cerebrovascular disease 5. Dementia 6. COPD 7. Connective tissue disease 8. Peptic ulcer disease 9. Diabetes mellitus (1 point uncomplicated, 2 points if end-organ damage)

Covariate	From GP questionnaire	Comments
		<p>10. Moderate to severe chronic kidney disease (2 points)</p> <p>11. Hemiplegia (2 points)</p> <p>12. Leukemia (2 points)</p> <p>13. Malignant lymphoma (2 points)</p> <p>14. Solid tumor (2 points, 6 points if metastatic)</p> <p>15. Liver disease (1 point mild, 3 points if moderate to severe)</p> <p>16. Aids (6 points)</p> <p>See ANNEX 3 – READ codes to be defined.</p>
Hypertension		READ diagnosis code or receiving treatment for hypertension – ANNEX 3
Type 2 diabetes		READ diagnosis code or receiving treatment for T2D – ANNEX 3
Hypercholesterolemia		READ diagnosis code or receiving a statin – ANNEX 3
Respiratory illness		COPD, asthma
History of psychiatric disease		ANNEX 3
Index year		
Duration of PD at index date		Time from PD diagnosis date to index date
PD medication history up to and including index date		
Duration of PD treatment		Time in years from first ever dopaminergic therapy to index date.
MAOB-I use		<p>Any history of MAOB-I use up to index date (see ANNEX 3 for code)</p> <p>MAOB-I inhibits an enzyme that breaks down dopamine in the brain. It can be used on its own in the early stages of the condition or in conjunction with levodopa. In this situation, it reduces the required dosage and prolongs the action of the levodopa.</p>
Type of first line therapy used		<p>Dopamine agonist or levodopa</p> <p>**not applicable to longitudinal evaluation**</p>
Number of distinct dopaminergic therapies used up		<p>Based on generic name.</p> <p>To identify frequent switchers of PD treatment.</p>

Covariate	From GP questionnaire	Comments
to index date		Also use to identify whether specific treatment is first line therapy or not.
History of levodopa use up to index date		Ever use – Y/N and total duration of levodopa use up to index date (months). **not applicable to longitudinal evaluation**
Amantadine use		Any history of amantadine use up to index date Amantadine can be prescribed as a monotherapy to provide relief of symptoms of mild, early-stage PD. It may also be prescribed concomitantly with dopaminergic therapies during the later stages of Parkinson’s disease to control involuntary movements (dyskinesias). (see ANNEX 3 for code)
COMT or Decarboxylase inhibitor ever used on or prior to index date		(see ANNEX 3 for code)
Apomorphine use on or prior to index date		(see ANNEX 3 for code)

9.3.3.2. Time varying covariates

Since long-term levodopa use is associated with an increased risk of dyskinesias, initiation of levodopa during follow-up will be captured.

Use of medications such as COMT inhibitors, decarboxylase inhibitors or use of an MAO-B inhibitor prolong the action of levodopa and dopamine respectively, and it is therefore proposed that use of these medications during the period of follow-up will also be accounted for in the analysis

An estimate of duration of exposure to levodopa, or to a levodopa add-on therapy at the time of censoring will be obtained. This estimate will ideally be based on dates and durations of prescriptions issued during follow-up. Should this prove computationally too complex, it will be based on date first prescription and censoring date, otherwise exposure to these may be coded as a binary variable (ever exposed or not exposed during follow-up) to simplify this further.

Time varying covariates include:

- Initiation of a levodopa containing therapy during follow-up
- Initiation of a COMT inhibitor or decarboxylase inhibitor during follow-up
- Initiation of an MAOB-I during follow-up

BNF codes can be found in [ANNEX 3](#)

9.4. Data sources

This study will be conducted using data recorded on the CPRD and supplemented by information to be obtained by GP questionnaire. A pilot study conducted in 2010 confirmed that this was a suitable data source to collect data on exposures and outcomes of interest. Refer to [ANNEX 1](#) for a description of the pilot study findings.

9.4.1. Validity of using READ codes to identify individuals with Parkinson's disease

In the UK, patients with suspected Parkinson's disease are referred by their GP to a specialist (neurologist or a geriatrician with a special interest in Parkinson's disease) where a diagnosis is made and treatment initiated. Patients usually have follow-up visits with the specialist every 6-12 months, however ongoing patient management (including repeat prescriptions) occurs in the primary care setting in coordination with a PD nurse specialist.

The pilot study conducted by GSK found that use of READ codes to identify patients was good; 40 out of the 41 cases included in the pilot study were correctly identified as PD using READ codes.

PD diagnosis date will be derived based on the earliest of PD READ code, PD medication or PD symptomatology to determine PD diagnosis date. In the pilot study, this provided a more accurate estimate of PD diagnosis date than PD READ code alone.

9.4.2. Capture of PD medication use in the primary care setting

Although PD treatment is initiated by a specialist, ongoing treatment (including repeat prescriptions) is managed in the primary care setting; therefore it is believed that the CPRD will adequately capture ongoing treatment of PD patients.

It is important to note that although prescriptions may be issued by a GP, this does not mean that a patient filled their prescription or took their medications as instructed.

9.4.3. Validity and justification for choice of outcomes of interest

A pilot study was conducted to evaluate outcomes based on data captured on the CPRD with those reported via a GP questionnaire. Individuals in the pilot study included individuals with Parkinson's disease, some of whom had an outcome of interest as defined by the presence of READ codes.

Questions were included on the GP questionnaire which required the GP to note the presence or absence of the outcomes and the date of onset of the outcome. The outcomes of interest that were evaluated as part of the pilot study were dyskinesia, end of dose wearing off, sudden onset of sleep and impulse control disorders. Comparisons were made between data captured on the CPRD with GP responses.

Based on findings from the pilot study, it was deemed that it would not be feasible to include end of dose wearing off or sudden onset of sleep as outcomes in the study. Reasons for this include, a poor response to the question by GPs questionnaire, a lack of appropriate medical codes available on the CPRD and substantial conflicting results between CPRD and GP questionnaire, meaning that the validity of the outcome would be questionable.

Refer to [ANNEX 1](#) for details of the pilot study.

9.5. Study size

A Cox regression of the log hazard ratio on a covariate with a standard deviation of 0.5000 based on a sample of 1000 observations, based on independent sampling of the exposure groups (i.e. no matching) achieves 82% power at a 0.05 significance level to detect a regression coefficient equal to 0.4055. The sample size was adjusted for an anticipated event rate of 0.2000. It is hoped that in the present study the use of matched samples will give some additional power.

Cox Regression Power Analysis

Numeric Results

	Sample Size (N)	Reg. Coef. (B)	S.D. of X1 (SD)	Event Rate (P)	R-Squared X1 vs Other X's (R2)	Two- Sided Alpha	Beta
Power	1000	0.4055	0.5000	0.2000	0.0000	0.05000	0.18211
	1500	0.4055	0.5000	0.2000	0.0000	0.05000	0.06036

A recent feasibility assessment identified 577 individuals initiating ropinirole-PR as monotherapy and 1660 initiating an immediate release dopamine agonist monotherapy on the CPRD. Up to three comparators will be matched to each ropinirole-PR monotherapy patient. An anticipated GP response rate is 68%, this estimate is based on the response rate achieved in the pilot study.

Report Definitions

Power is the probability of rejecting a false null hypothesis. It should be close to one.

N is the size of the sample drawn from the population.

B is the size of the regression coefficient to be detected

SD is the standard deviation of X1.

P is the event rate.

R2 is the R-squared achieved when X1 is regressed on the other covariates.

Alpha is the probability of rejecting a true null hypothesis.

Beta is the probability of accepting a false null hypothesis.

9.6. Data management

The study will be performed by the Worldwide Epidemiology department of GlaxoSmithKline using in-house full-featured CPRD data. The analysis will be conducted and quality checked in-house by a named programmer and QC analyst who will be dedicated to this study. This project will be managed by the neurosciences epidemiology team. The data derived from the CPRD database will be held in-house on a secure network server with restricted access.

GP questionnaires will be managed and collated by the MHRA and sent to GSK with the patient identifiers removed. Data from GP questionnaire will be linked to CPRD records, and will remain anonymised.

All data will be stored on secure servers.

9.6.1. Data handling conventions

All data handling and data analysis will be performed by a trained analyst from the Observational Data Analytics group within the Worldwide Epidemiology Department. The data will be extracted from the CPRD and maintained as a SAS dataset in the WWEpi UNIX project area. The MHRA will manage data collection from the GP questionnaire; these will be anonymised and provided to GSK.

9.6.2. Resourcing needs

- A principal programmer will be assigned to this project together with a QC analyst who will independently programme the study.
- A named statistical consultant will provide support as needed.
- Input from the safety physician will be required when reviewing discordant outcomes between the CPRD and GP questionnaire. The physician will not be informed of the exposure status of the individuals to minimise bias.

9.6.3. Timings of Assessment during follow-up

Described elsewhere

9.7. Data analysis

All analyses will be conducted in SAS version 9.3.

9.7.1. Overview of statistical techniques

9.7.1.1. Descriptive and univariate analyses

Normally distributed continuous variables will be presented as mean \pm standard deviation (SD) and skewed data as median (inter quartile range). Comparisons of continuous

variables between the exposure groups will be evaluated using the Student's t-test and categorical data are to be evaluated using a chi-squared test with Yate's correction or by Fisher's exact test depending on the sample sizes. For the univariable analyses a two-sided p-value of 0.05 will be considered to be statistically significant.

A paired sample t-test will be used to assess whether patients prescribed ropinirole-IR who switch to ropinirole-PR, switch to an equivalent daily dose.

9.7.1.2. Incidence estimation

The incidence of newly diagnosed dyskinesia (and other outcomes of interest) events after the index date will be calculated as the number of events per total number of person-years (PY) of follow-up (per 1000 person-years) in individuals in the ropinirole-PR cohort compared to those in the IR-DA matched cohort. In these cohorts, patients will be followed for events until the earliest of an outcome of interest, discontinuation of therapy+30days, end of a patient record or end of the study period. Crude incident rates per 1000 PY with exact Poisson 95%CI for each type of outcome will be calculated.

Incidence rates will be stratified by age group (at index date) and PD duration,. Incidence rate ratios (IRR) will be estimated between the exposure groups and adjusted for risk factors using multivariable Poisson regression

In addition, incidence rates amongst switchers to ropinirole-PR and those initiating ropinirole-PR *de novo* (as a first line therapy) will be estimated. Should the 95% CI of the IRR not include 1, then consideration will need to be given with regards to differential underlying risk of the outcome amongst these two groups.

9.7.1.3. Multiple regression analyses - Cox proportional hazards regression

A Cox proportional hazards regression model will be used to evaluate time to dyskinesias in individuals prescribed ropinirole-PR with those prescribed other dopamine agonists of interest. Patients will be followed up from index date (initiation of treatment) up to a censoring event (see Section 9.7.1.4). A diagnostic test will be done of the proportional hazards assumption, by adding an exposure x time interaction term to the model.

Crude hazard ratios and 95% CI will be estimated amongst individuals who are free from the outcome of interest at baseline and meeting all inclusion criteria in the two groups of interest (**ropinirole PR cohort** and the **IR-DA matched cohort**). Adjusted hazards ratios will be estimated, accounting for potential confounders and time varying covariates.

Matching will be defined as a stratum variable using a STRATA statement in the SAS procedure, PROC PHREG. The follow-up time for a matched set will continue as long as there is at least one case and one matched control in the analysis.

9.7.1.4. Censoring

- Follow-up will continue to the earliest of: the recording of the outcome of interest, discontinuation of therapy+30days, end of a patient record or end of CPRD follow-up up to a maximum of 5 years of treatment.

- For the estimation of incident rate ratios for those continuing therapy for up to 1, 3 and 5 years, censoring will occur at the end of each of those time points.

9.7.2. Essential analysis

Please refer to standalone document in [ANNEX 1](#) for table shells.

Objective: To describe and compare the baseline characteristics of individuals with Parkinson’s disease initiating ropinirole-PR with those initiating immediate release formulation dopamine agonists.

OUTPUT 1: Figure 1 - Derivation of initial study population

Schematic showing derivation of initial study population following application of inclusion and exclusion criteria.

OUTPUT 2: Figure 2 - Derivation of study population for longitudinal analysis

Schematic showing derivation of the two populations of interest for the longitudinal analysis; ropinirole-PR cohort, IR-DA (unmatched) and the matched IR-DA cohort)

OUTPUT 3: Propensity score

- Description of factors used to generate the score
- Distributions of scores for both groups, and matched group (distribution plot, plus quintiles)
- A description of the number of ropinirole-PR patients that were unmatched (no suitable comparator)
- In addition, a count and descriptive analysis of individuals that were not able to be matched that were prescribed ropinirole-PR.

OUTPUT 4: Table 1 - Baseline characteristics of populations of interest before matching

A descriptive analysis of the patient characteristics at index date amongst:

- Ropinirole-PR cohort
- IR-DA (unmatched)

Covariates to include those listed in Section [9.3.3.1](#). and include patient demographics, disease duration, PD treatment history and comorbidity burden.

OUTPUT 5: Table 2 - Baseline characteristics of populations of interest after matching

As per output 4, but instead comparing the following populations:

- Ropinirole-PR cohort
- IR-DA matched cohort

In addition a count of the number of individuals that was not possible to match.

OUTPUT 6: Table 3 - Average daily dose of ropinirole amongst individuals switching from IR to PR formulation

Amongst individuals that switched from the IR to the PR formulation of ropinirole-PR, the difference between average daily dose pre and post switch.

Population: PD patients initiating ropinirole-PR that switched from ropinirole-IR

Exposure categories:

- Parkinson's disease patients initiating ropinirole-PR as monotherapy
- Parkinson's disease patients initiating ropinirole-PR adjunctive to levodopa
- Parkinson's disease patients initiating ropinirole-PR (monotherapy or adjunctive use)

Outputs:

- Average daily dose at last prescription of ropinirole-IR (prior to switch to ropinirole-PR)
- Average daily dose of ropinirole-PR at time of switch

Objective: To estimate the incidence of dyskinesia and other outcomes of interest amongst individuals with Parkinson's disease initiating ropinirole-PR compared to a propensity score matched cohort of individuals initiating immediate release formulations of dopamine agonists as monotherapy

Populations of interest (exposure groups) for the longitudinal analysis are:

- Ropinirole-PR cohort
- IR-DA matched cohort

Outcomes of interest: Dyskinesia, on-off phenomena, impulse control disorders, initiation of levodopa.

The following outputs will be required for **each** outcome of interest

OUTPUT 7: Table 4: Incidence of outcome of interest

- Incidence (per 1,000 person-years) stratified by age group (at index date), gender, PD duration.
- Crude and adjusted incidence rate ratios
- Crude incidence for those continuing therapy for 1, 3 and 5 years respectively (i.e. for this estimation only, censor at year 1, 3 and 5 respectively)

Separate tables required for each outcome of interest.

OUTPUT 8: Table 5 Median time to outcome.

- Median time (days) from initiation of therapy to onset of outcome amongst the ropinirole-PR cohort and IR-DA matched cohort

OUTPUT 9: Cox proportional hazards model

- Crude and adjusted hazards ratio for exposure groups of interest, accounting for initiation of levodopa or levodopa add-on therapies during follow-up (Section 9.3.3.2) when evaluating dyskinesia, impulse control disorders and on-off phenomena.
- Kaplan-Meier survival curves for patients in the ropinirole-PR and matched immediate release DA cohorts.

Refer to Section 9.3.3.1 for list of potential covariates to consider for adjustment. When evaluating time to levodopa use as an outcome, there is no need to account for time varying-covariates.

Objective: To describe treatment persistence and adherence amongst patients initiating therapy on ropinirole-PR versus a matched cohort initiating immediate release dopamine agonists

Populations of interest (exposure groups):

- Ropinirole-PR cohort
- IR-DA matched cohort

OUTPUT 10: Table 6 - Duration of treatment persistence and medication possession ratio amongst the ropinirole-PR and IR-DA matched cohorts.

OUTPUT 11: Kaplan-Meier plot – medication persistence between exposure groups (ropinirole-PR and IR-DA matched cohorts).

Objective 4: Evaluation of off-label use of ropinirole-PR

OUTPUT 12: Figure 3 – extent of off label use of ropinirole-PR

Population of interest – Ropinirole-PR off-label population

Schematic showing derivation of off-label population, and probable indication of ropinirole-PR treatment

9.7.3. Exploratory analysis

- **OUTPUT 13: Table 7 - incidence of [dyskinesia etc] per 1,000 person-years for patients initiating ropinirole-PR as a first line monotherapy and those prescribed ropinirole-pr switching from another dopamine agonist**

Patients may switch therapies due to inadequate control of PD symptoms, onset of motor complications or due to poor tolerability of medication. It is possible that these reasons may be not be recorded by the GP. In this study, patients may have switched from another dopamine agonist therapy prior to switching to ropinirole-PR, it is therefore proposed to estimate the risk of the outcomes of interest amongst the subset of the population that are initiating their ropinirole-PR as first line therapy as compared to those switching from other dopamine agonist therapies.

- **OUTPUT 14 and OUTPUT 15: Table 8, and Table 9 – sensitivity analysis – evaluation of risk of dyskinesias amongst individuals with at least two consecutive prescriptions.**

It is possible that a single script being issued may not represent a medicine having been taken by a patient. Therefore a sensitivity analysis including individuals with at least two consecutive scripts will be conducted when evaluating dyskinesia as an outcome.

- Dose of treatment has not been accounted for in the analyses. A stratified analysis by dose of treatment may be considered for each main outcome; this is dependent upon the extent of missing dose data on the CPRD.

9.7.4. General considerations for data analyses

Two approaches will be used to adjust for potential confounders: propensity score matching and covariate adjustment. These have been discussed in the statistical analysis section.

Colinearity: There are a number of factors that may be highly correlated, for example PD disease duration and duration of PD treatment up to index date. Following inspection of

the intermediate results, it is proposed that one or the other may be dropped from multiple regression models.

9.8. Quality control

The study protocol has undergone internal GSK review by epidemiology, statistics, clinical and observational database experts at the epidemiology Protocol Review Forum (PRF).

All analyses will be conducted according to internal quality control procedures.

9.9. Strengths of data source

The CPRD is an electronic source of medical records and prescriptions that has been designed for epidemiologic research. The average duration of follow-up of patients is sufficiently long allowing the long-term evaluation of patients prescribed dopamine agonist therapy for treatment of their Parkinson's disease. The CPRD population closely matches the age and gender distribution of the UK population and represents clinical practice as it occurs in the real-world; our findings are therefore generalisable to ropinirole PR use as it occurs in the UK primary care population. As the CPRD contains medical diagnoses deemed relevant to patient care, we are able to take into account a number of baseline factors in our analysis, as well as being able to evaluate off-label use of the drug.

9.10. Limitations of the research methods

The use of administrative data of this type carries some limitations. A primary limitation is our limited ability to control for confounding. Matching by use of propensity scores will help ensure that the exposure groups are comparable at baseline, however, we are only able to control for potential confounders that are contained within the CPRD data. GP's choice of therapy may be influenced by a number of factors such as the severity of PD symptoms at baseline, which is not measurable using data from the CPRD.

The CPRD is representative of patient care as provided by GPs in the primary care setting. In the UK, PD patients are initially assessed and prescribed therapy by Neurologists or PD Nurse Specialists, however, it is believed that ongoing therapy is managed in primary care. The CPRD will not therefore capture prescriptions issued by specialists, however subsequent prescriptions will be

There is the possibility of enhanced GP ascertainment/ patient reporting of compulsive behaviours among dopamine agonist users because of media attention related to this class of drug. However, this should not affect our ropinirole-PR vs. other dopamine agonists comparison.

Our study will only follow patients as far back as they were registered with an up-to-standard CPRD practice to obtain information on prior dopamine agonist prescriptions and medical diagnoses. We may be missing some events in the study groups that had occurred further back in time, but their effect on the baseline risk of dyskinesias or other adverse outcomes is likely to be minimal. Dose of treatment has not been accounted for;

if it is feasible to evaluate this (based on the extent of missing dose data), then this may be conducted as part of the exploratory analyses. Finally, we are using prescriptions received as a proxy for treatment compliance. This merely represents prescriptions given to the patient and does not represent dispensed prescriptions. It is therefore possible that some patients are not taking their medications, but are still receiving prescriptions. Again, this occurrence should be non-differential across our treatment groups, however may vary by age of patient.

GP response rate of around 68% is anticipated based on findings from the pilot study. Presence of on-off phenomena will be determined based on GP questionnaire response alone. Should any significant differences in GP response rate between exposure groups be observed, then it may not be feasible or appropriate to include this as an outcome of interest.

Due to the age of PD patients and course of disease, loss-to-follow up due to death or move to secondary care facilities will need to be monitored as this will impact sample size.

9.10.1. Study closure/uninterpretability of results

As mentioned elsewhere, should there be an imbalance of GP questionnaire response rate between exposure groups or a poor GP response rate, then outcomes such as on-off phenomena may be omitted from this study. GSK will communicate such findings to the MHRA.

9.11. Other aspects

Not applicable

10. PROTECTION OF HUMAN SUBJECTS

10.1. Ethical approval and subject consent

Independent Scientific Advisory Committee (ISAC) approval will be sought prior to finalising the protocol. The data analyses can start only after ISAC approval is granted.

10.2. Subject confidentiality

The CPRD has removed all patient identifiers ensuring patient confidentiality. The MHRA will be responsible for contacting GPs via a questionnaire, and collating the responses, GSK will not have access to potentially patient identifiable information.

11. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS

If, during the study, an adverse event (serious or non serious) is identified as explicitly attributed to any GSK product (including products not covered in the specific study objective), this will be reported. The study epidemiologist must forward the report to

GSK central safety department within 24 hours of first becoming aware of the event as per SOP 52214 (Reporting and Disclosing Information from Observational Safety Studies and Analyses of Epidemiology Data).

When conducted by a third party, the adverse event must be faxed to GSK Global Clinical Safety and Pharmacovigilance at ^{PPD} [REDACTED] within 24 hours of receiving the information.

In addition, GSK will evaluate the feasibility of investigating the association of newly reported potential adverse events using the CPRD dopamine agonist cohorts described should they arise or be identified from spontaneous reporting or elsewhere.

12. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS

12.1. Target Audience

Findings from this study will be shared internally to GSK stakeholders (including but not limited to the ropinirole Safety Review Team, Project Team and Regulatory Team). The results will be disseminated externally via regulatory submission to the MHRA as well as, manuscript.

12.2. Study reporting and publications

The results of the study will be disseminated through abstract submissions, publishing in a peer reviewed journal and posting on publically accessible GSK website.

13. REFERENCES

- Adler, C. H., Sethi, K. D., Hauser, R. A., Davis, T. L., Hammerstad, J. P., Bertoni, J. et al. (1997). Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. *Neurology*, *49*, 393-399.
- Bonuccelli, U. & Ceravolo, R. (2008). The safety of dopamine agonists in the treatment of Parkinson's disease. *Expert.Opin.Drug Saf*, *7*, 111-127.
- British National Formulary. (2015). Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Ref Type: Online Source
- Brooks, D. J. (2000). Dopamine agonists: their role in the treatment of Parkinson's disease. *J Neurol Neurosurg.Psychiatry*, *68*, 685-689.
- Connolly, B. S. & Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: a review. *JAMA*, *311*, 1670-1683.
- D'Agostino, R. B. (1998). Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Statistics in Medicine*, *17*, 2265-2281.
- Giroux, M. L. (2007). Parkinson disease: managing a complex, progressive disease at all stages. *Cleve.Clin.J Med.*, *74*, 313-8, 320.
- Gomez, A. G., Jorge, R., Garcia, S., Scipioni, O., & Gershanik, O. (1997). Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. *Mov Disord.*, *12*, 277-284.
- NIH. (2015). Clinical Terms Version 3 (CTV3) (Read Codes) Source Information. 28-9-2015. Ref Type: Online Source
- Olanow, C. W. & Obeso, J. A. (2000). Preventing levodopa-induced dyskinesias. *Ann.Neurol*, *47*, S167-S176.
- Pahwa R, Stacy M A, Factor S A, Lyonsa K E, Stocchi F, Hersh B P et al. (2007). Ropinirole 24-hour prolonged release. *Neurology*, *68*, 1108-1115.
- Pahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H. et al. (2006). Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, *66*, 983-995.
- Pahwa, R., Lyons, K. E., & Hauser, R. A. (2004). Ropinirole therapy for Parkinson's disease. *Expert.Rev.Neurother.*, *4*, 581-588.
- Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000). A five-year study of the incidence of dyskinesia in patients with early Parkinson's

disease who were treated with ropinirole or levodopa. 056 Study Group. *N.Engl.J.Med.*, 342, 1484-1491.

Samii, A., Nutt, J. G., & Ransom, B. R. (2004). Parkinson's disease. *Lancet*, 363, 1783-1793.

Santens, P. & de Noordhout, A. M. (2006). Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey. *Acta Neurol Belg.*, 106, 137-141.

Santens, P., Boon, P., Van, R. D., & Caemaert, J. (2003). The pathophysiology of motor symptoms in Parkinson's disease. *Acta Neurol. Belg.*, 103, 129-134.

Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. *N.Engl.J.Med.*, 356, 29-38.

Thomas, A., Bonanni, L., Di, I. A., Varanese, S., Anzellotti, F., D'Andreagiovanni, A. et al. (2006). End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. *J Neurol*, 253, 1633-1639.

Walley, T. & Mantgani, A. (1997). The UK General Practice Research Database. *Lancet*, 350, 1097-1099.

Weintraub, D., David, A. S., Evans, A. H., Grant, J. E., & Stacy, M. (2014). Clinical spectrum of impulse control disorders in Parkinson's disease. *Mov Disord.*

14. ANNEX 1. LIST OF STAND-ALONE DOCUMENTS

No	Document Reference No	Date	Title
1.	2015N258160_00	29 September 2015	PROPOSED GP QUESTIONNAIRE Questionnaire design_Sept2015.pdf
2.	2015N258149_00		TABLE SHELLS AND FIGURES FOR PROPOSED ANALYSIS TableShells.pdf
3	2015N258161_00		SUMMARY OF FINDINGS FROM THE PILOT STUDY FindingsFromPilotStudy.pdf
4	2015N258154_00		DYSKINESIA READ CODES MCL1802_Dyskinesia_CPRD_jul14.pdf ALSO SEE ANNEX 3
5	2015N258156_00		IMPULSE CONTROL DISORDER READ CODES MCL1803_impulse_control_CPRD_jul14.pdf ALSO SEE ANNEX 3
6	2015N258153_00		PARKINSON'S DISEASE MEDICATION CODES (BNF) MCL1730_antiParkinson_CPRD_may14.pdf ALSO SEE ANNEX 3

No	Document Reference No	Date	Title
7	2015N258157_00		OFF-LABEL INDICATIONS – READ CODES MCL1805_Ropinirol_offlabel_CPRD_jul14.pdf ALSO SEE ANNEX 3
8	2015N258151_00		PARKINSON’S DISEASE READ CODES MCL1690_PD_CPRD.pdf ALSO SEE ANNEX 3
9	2015N258158_00 2015N258159_00		SECONDARY PARKINSONISM EXCLUSION CODES (READ AND BNF) MCL1806_drug_parkinsonism_GPRD_jul14.pdf MCL1806_PD_2nd_CPRD_jul14.pdf ALSO SEE ANNEX 3
10	2015N258152_00		READ CODES – PD SYMPTOMATOLOGY MCL1728_PDSymptom_CPRD_jul14.pdf ALSO SEE ANNEX 3

15. ANNEX 2.ENCEPP CHECKLIST FOR STUDY PROTOCOLS

<u>Section 1: Research question</u>	Yes	No	N/A	Page Number(s)
1.1 Does the formulation of the research question clearly explain:				
1.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	19
1.1.2 The objectives of the study?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	19
1.2 Does the formulation of the research question specify:				
1.2.1 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	20
1.2.2 Which formal hypothesis(-es) is (are) to be tested?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	19
1.2.3 if applicable, that there is no <i>a priori</i> hypothesis?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

--

<u>Section 2: Source and study populations</u>	Yes	No	N/A	Page Number(s)
2.1 Is the source population described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	20
2.2 Is the planned study population defined in terms of:				
2.2.1 Study time period?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	20

<u>Section 2: Source and study populations</u>	Yes	No	N/A	Page Number(s)
2.2.2 Age and sex?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	22
2.2.3 Country of origin?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	22
2.2.4 Disease/indication?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	20
2.2.5 Co-morbidity?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
2.2.6 Seasonality?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
2.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	23

Comments:

--

<u>Section 3: Study design</u>	Yes	No	N/A	Page Number(s)
3.1 Does the protocol specify the primary and secondary (if applicable) endpoint(s) to be investigated?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	26
3.2 Is the study design described? (e.g. cohort, case-control, randomised controlled trial, new or alternative design)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	20
3.3 Does the protocol describe the measure(s) of effect? (e.g. relative risk, odds ratio, deaths per 1000 person-years, absolute risk, excess risk, incidence rate ratio, hazard ratio, number needed to harm (NNH) per year)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
3.4 Is sample size considered?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	35
3.5 Is statistical power calculated?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	35

Comments:

--

<u>Section 4: Data sources</u>	Yes	No	N/A	Page Number(s)
4.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	30
4.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview, etc)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	26
4.1.2 Endpoints? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics, etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	31
4.1.3 Covariates?				
4.2 Does the protocol describe the information available from the data source(s) on:				

<u>Section 4: Data sources</u>	Yes	No	N/A	Page Number(s)
4.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	30
4.2.2 Endpoints? (e.g. date of occurrence, multiple event, severity measures related to event)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	26
4.2.3 Covariates? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, life style, etc.)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	31
4.3 Is the coding system described for:				
4.3.1 Diseases? (e.g. International Classification of Diseases (ICD)-10)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	23
4.3.2 Endpoints? (e.g. Medical Dictionary for Regulatory Activities(MedDRA) for adverse events)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	23
4.3.3 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC)Classification System)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	23
4.4 Is the linkage method between data sources described? (e.g. based on a unique identifier or other)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

--

<u>Section 5: Exposure definition and measurement</u>	Yes	No	N/A	Page Number(s)
5.1 Does the protocol describe how exposure is defined and measured? (e.g. operational details for defining and categorising exposure)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	24
5.2 Does the protocol discuss the validity of exposure measurement? (e.g. precision, accuracy, prospective ascertainment, exposure information recorded before the outcome occurred, use of validation sub-study)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	34
5.3 Is exposure classified according to time windows? (e.g. current user, former user, non-use)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	22
5.4 Is exposure classified based on biological mechanism of action?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
5.5 Does the protocol specify whether a dose-dependent or duration-dependent response is measured?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	41

Comments:

--

<u>Section 6: Endpoint definition and measurement</u>	Yes	No	N/A	Page Number(s)
6.1 Does the protocol describe how the endpoints are defined and measured?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	26
6.2 Does the protocol discuss the validity of endpoint measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, prospective or retrospective ascertainment, use of validation sub-study)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	34

Comments:

<u>Section 7: Biases and Effect modifiers</u>	Yes	No	N/A	Page Number(s)
7.1 Does the protocol address:				
7.1.1 Selection biases?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	42
7.1.2 Information biases? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	42
7.2 Does the protocol address known confounders? (e.g. collection of data on known confounders, methods of controlling for known confounders)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	31
7.3 Does the protocol address known effect modifiers? (e.g. collection of data on known effect modifiers, anticipated direction of effect)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	31
7.4 Does the protocol address other limitations?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	25

Comments:

--

<u>Section 8: Analysis plan</u>	Yes	No	N/A	Page Number(s)
8.1 Does the plan include measurement of absolute effects?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
8.2 Is the choice of statistical techniques described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
8.3 Are descriptive analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
8.4 Are stratified analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
8.5 Does the plan describe the methods for identifying:	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
8.5.1 Confounders?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
8.5.2 Effect modifiers?				
8.6 Does the plan describe how the analysis will address:	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	37
8.6.1 Confounding?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
8.6.2 Effect modification?				

Comments:

--

<u>Section 9: Quality assurance, feasibility and reporting</u>	Yes	No	N/A	Page Number(s)
9.1 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	36
9.2 Are methods of quality assurance described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	42
9.3 Does the protocol describe quality issues related to the data source(s)?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	23

<u>Section 9: Quality assurance, feasibility and reporting</u>	Yes	No	N/A	Page Number(s)
9.4 Does the protocol discuss study feasibility? (e.g. sample size, anticipated exposure, duration of follow-up in a cohort study, patient recruitment)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	35
9.5 Does the protocol specify timelines for				
9.5.1 Start of data collection?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
9.5.2 Any progress report?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
9.5.3 End of data collection?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
9.5.4 Reporting? (i.e. interim reports, final study report)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
9.6 Does the protocol include a section to document future amendments and deviations?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
9.7 Are communication methods to disseminate results described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	44
9.8 Is there a system in place for independent review of study results?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	

Comments:

--

<u>Section 10: Ethical issues</u>	Yes	No	N/A	Page Number(s)
10.1 Have requirements of Ethics Committee/Institutional Review Board approval been described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	43
10.2 Has any outcome of an ethical review procedure been addressed?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
10.3 Have data protection requirements been	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	43

<u>Section 10: Ethical issues</u>	Yes	No	N/A	Page Number(s)
described?				

Comments:

Name of main author of study protocol: PPD

Date: 29/09/2015

Signature: _____

16. ANNEX 3.ADDITIONAL INFORMATION**16.1. Dyskinesia**

GSK coding library identifier: MCL1802

16.2. Impulse control disorders

GSK coding library identifier: MCL1803

16.3. Parkinson's disease medications

GSK coding library identifier: MCL1730

Drug	GSK Coding library identifier	classify	Composition	Release_time
levodopa	MCL1730	<i>Contains</i> levodopa *		
Oral, immediate release dopamine agonists	MCL1730	Dopamine agonist*		<i>Does not =</i> <i>'modified release'</i> (note retain those where release_time is null or immediate release)
Ropinirole-PR Prolonged release formulation of ropinirole	MCL1730	Dopamine agonist*	*ropinirole*	= 'modified release'

Drug	GSK Coding library identifier	classify	Composition	Release_time
Pramipexole-PR Prolonged release formulation of pramipexole	MCL1730	Dopamine agonist*	*pramipexole*	= 'modified release'
COMT	MCL1730	Classify contains *COMT*		
decarboxylase inhibitor	MCL1730	Classify contains *decarboxylase *		
MAO-B inhibitor (time varying medication)	MCL1730	Classify contain "MAO B inhibitor"		
Apomorphine	MCL1730		*apomorphine *	
Amantadine	MCL1730		*amantadine*	

16.4. Off-label indications

GSK coding library identifier: **MCL1805**

16.5. Parkinson's disease population (PD)

Inclusion criteria

1. Primary/idiopathic Parkinson's disease patients will be identified using READ codes outlined below. [GSK coding library identifier: **MCL1690**]

CPRD Medical code	READ Code	Description
9509	Eu02300	[X]Dementia in Parkinson's disease
96860	F11x900	Cerebral degeneration in Parkinson's disease
4321	F12..00	Parkinson's disease
1691	F120.00	Paralysis agitans
14912	F12z.00	Parkinson's disease NOS

2. All individuals in the analyses require at least 12 months of registration prior to the **PD diagnosis date** (see below for algorithm to derive) to allow time for the recording of prevalent events
3. Patients must be aged at least 40 years at the time of PD diagnosis (see algorithm to determine date of PD diagnosis below)

Exclusion criteria

- Patients aged less than 40 years at the time of PD diagnosis.
- Drug induced Parkinsonism (code for drug induced PD or exposure to any prescription for drugs known to induce Parkinsonism in the 3 month period before the Parkinson's disease diagnosis date) [GSK coding library request identifier **MCL1806**]

Other secondary parkinsonism. (including Malignant Neuroleptic syndrome, Postencephalytic Parkinsonism, Vascular and Syphilitic Parkinsonisms) prior to index date [GSK identifier **MCL1806**]

16.6. Date of PD diagnosis

For individuals fulfilling the PD definition (above) use the earliest of:

- Date of Parkinson's READ or CPRD medical code [GSK identifier: **MCL1690**]
- Dopaminergic therapy (dopamine agonist or levodopa therapy) [GSK identifier: **MCL1730** where classify = dopamine agonist* or levodopa*]
- PD symptomatology (based on READ or CPRD code) were reviewed by a GSK clinical consultant. GSK identifier **MCL1728** – where review = yes.

16.7. Charlson comorbidity score

Codes yet to be defined

16.8. Hypertension

Codes yet to be defined

16.9. Hypercholesteraemia

Codes yet to be defined

16.10. Type 2 diabetes

Codes yet to be defined

16.11. Psychiatric disease

Codes yet to be defined

16.12. Respiratory disease

Codes yet to be defined

CPRD/MHRA Identifiers

Practice ID _____

Patient Identifier _____

This questionnaire is part of a prospective study that is evaluating Parkinson's disease outcomes amongst individuals that have been prescribed a dopamine agonist therapy

In particular we wish you to:

- **Confirm that your patient has previously been diagnosed with Parkinson's disease**
- **Document whether they had evidence of specific conditions of interest, and when.**

If this patient is no longer registered at your practice then please complete Section A only

It is anticipated that the information you provide will be used to verify data already present on the CPRD, as well as providing supplementary information.

Section A: Patient registration

1. Is this patient currently registered at your practice
Yes (if Yes, please continue to section B)
No (if No, please complete questions 2 and 3)
2. If this patient no longer registered at this practice, please state reason
Died **Transferred practice** **Not known**
3. Year patient ceased being registered at your practice _____

Section B: Patient Baseline Characteristics

4. Please confirm the year the patient was first diagnosed with Parkinson's disease _____
5. Before **[INDEX DATE]** did the patient experience motor fluctuations?* (please tick one):
Yes **No** **Not known**

* **Motor fluctuations** include, reduced duration of anti-parkinsonian action (wearing off phenomenon, end of dose wearing off), sudden shifts between under-treated and over-treated states (on-off phenomenon), freezing and involuntary movements such as dyskinesias

Section C: Follow-up Questions

6. Has this patient experienced symptoms compatible with or receive a diagnosis for any of the following between INDEX YEAR and CENSOR DATE

	Yes	No	NK	Month + Year of diagnosis/presentation [†] (i.e. Feb 2010)
a. Dyskinesias [‡]	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____
b. On-off phenomena [§]	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____
c. Impulse Control Disorders ^{**}				
<i>Pathological Gambling</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____
<i>Hypersexuality</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____
<i>Compulsive Shopping</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____
<i>Compulsive Eating</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____
<i>Other impulse control disorder</i>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	_____

If other impulse control disorder, please specify _____

[†] If month not available, please enter the year only


[‡] **Dyskinesia** describes a group of involuntary (non-tremor) movements that appear to be a fragmentation of the normal smoothly controlled limb and facial movements.

[§] **On-off phenomena** (unpredictable on-off) is defined as unpredictable fluctuations between periods of relatively good function and good mobility –'on,' and periods of poor function and poor mobility, immobility or freezing–'off'

^{**} **Impulse control disorders** are a class of psychiatric disorders characterised by impulsivity; a failure to resist a temptation, urge or impulse that may harm oneself or others.


OUTPUT 1: FIGURE 1 - DERIVATION OF STUDY POPULATION

Derivation of initial study population following application of inclusion and exclusion criteria.



Provide a breakdown of the following: Dyskinesia N= , impulse control disorder N= , on-off phenomena N=

OUTPUT 2: FIGURE 2 - DERIVATION OF STUDY POPULATION FOR LONGITUDINAL ANALYSIS



* Comprises of individuals switching from an immediate release dopamine agonist monotherapy as well as those whose first prescription between 2004 and 2012 is ropinirole-PR

OUTPUT 3: PROPENSITY SCORE METRICS

- Plot of distributions of propensity scores for ropinirole-PR, IR-DA (unmatched) and IR-DA (matched).
- Description of factors used to generate the propensity score
- Describe number of ropinirole-PR that were unmatched (no suitable comparator)
- In addition, a descriptive analysis of individuals that were not able to be matched that were prescribed ropinirole-PR (use table shell in output 4).

OUTPUT 4: TABLE 1 - BASELINE CHARACTERISTICS OF POPULATIONS OF INTEREST BEFORE MATCHING

	Ropinirole-PR	Immediate release dopamine agonists	
	Ropinirole-PR cohort	IR-DA unmatched	p-value
	N=	N=	
Mean age at index date			
Age at PD diagnosis			
Age at index date			
Gender			
% male			
% female			
PD duration (years)			
Index year			
Disease stage at baseline (early, advanced)			
% early			
% late			
% not specified			
First line dopaminergic treatment at time of PD diagnosis (dopamine agonist or Levodopa)			
MAOB-I ever used prior to index date			
COMT ever used prior to index date			
Decarboxylase inhibitor ever used prior to index date			
Amantadine ever used prior to index date			
Number of distinct dopamine agonists used up to index date			
Mean number of GP consultations in 12months to index date			
Charlson comorbidity score at baseline			

OUTPUT 5: TABLE 2 - BASELINE CHARACTERISTICS OF POPULATIONS OF INTEREST AFTER MATCHING

	Ropinirole-PR	Immediate release dopamine agonists	
	Ropinirole-PR cohort	IR-DA <u>matched</u>	p-value
	N=	N=	
Mean age at index date			
Age at PD diagnosis			
Age at index date			
Gender			
% male			
% female			
PD duration (years)			
Index year			
Disease stage at baseline (early, advanced)			
% early			
% late			
% not specified			
First line dopaminergic treatment at time of PD diagnosis (dopamine agonist or Levodopa)			
MAOB-I ever used prior to index date			
COMT ever used prior to index date			
Decarboxylase inhibitor ever used prior to index date			
Amantadine ever used prior to index date			
Number of distinct dopamine agonists used up to index date			
Mean number of GP consultations in 12months to index date			
Charlson comorbidity score at baseline			

OUTPUT 6: TABLE 3 - AVERAGE DAILY DOSE OF ROPINIROLE AMONGST INDIVIDUALS SWITCHING FROM IR TO PR FORMULATION

	Number of individuals	Average daily dose of IR pre-switch (milligrams)	Average daily dose at switch (milligrams)	p-value
Parkinson's disease patients initiating ropinirole-PR (ropinirole-PR cohort)		-	-	-
Parkinson's disease patients switching from ropinirole-IR to PR amongst:		-	-	-
Parkinson's disease patients initiating ropinirole-PR as monotherapy				
Parkinson's disease patients initiating ropinirole-PR adjunctive to Levodopa				
Parkinson's disease patients initiating ropinirole-PR (all)				

Number of subjects in which dose was missing: N=

OUTPUT 7: TABLE 4 - INCIDENCE OF [DYSKINESIA] PER 1,000 PERSON-YEARS FOR PATIENTS PRESCRIBED ROPINIROLE-PR MONOTHERAPY (ROPINIROLE-PR COHORT) AND THOSE INITIATING AN IMMEDIATE RELEASE DOPAMINE AGONISTS (IR-DA MATCHED COHORT) ON THE CPRD

Cohort	Ropinirole-PR				Immediate release dopamine agonist (matched)				Incident rate ratio - crude	Incident rate ratio - adjusted
	Person-time	Number with incident [dyskinesia]	Rate per 1,000 person years	95% confidence intervals	Person-time	Number with incident [dyskinesia]	Rate per 1,000 person years	95% confidence intervals	RR (95% CI)	RR (95% CI)
Overall										
Age										
<60 yrs										
60-69 yrs										
70-79 yrs										
80 yrs +										
Gender										
Female										
Male										
PD duration (quartiles)										
1 st quartile										
2 nd quartile										
3 rd quartile										
4 th quartile										
Patients continuing treatment										

for:										
1yr										
3yrs										
5yrs										

Repeat for ICD, on-off phenomena and levodopa use as outcomes.

OUTPUT 8: TABLE 5 - MEDIAN TIME TO DYSKINESIA (DAYS)

	Ropinirole-PR	IR-DA matched	p-value
Median Time (days) to [dyskinesia]			
Then stratify by			
Age group			
<60y			
60-60y			
70-79y			
80+			
Male			
Female			
PD duration (quartiles)			
1st			
2nd			
3rd			
4th			

Repeat for ICD, on-off phenomena and levodopa use as outcomes.

OUTPUT 9: COX PROPORTIONAL HAZARDS MODEL


- Crude and adjusted hazards ratio for exposure groups of interest, accounting for initiation of levodopa or levodopa add-on therapies during follow-up (section 8.3.3.2) when evaluating dyskinesia, impulse control disorders and on-off phenomena.
- Kaplan-Meier survival curves for patients in the ropinirole-PR and matched immediate release DA cohorts.

OUTPUT 10: TABLE 6 DURATION OF TREATMENT PERSISTENCE AND MEDICATION POSSESSION RATIO AMONGST THE ROPINIROLE-PR AND IR-DA MATCHED COHORTS.

	Ropinirole-PR	IR-DA matched	p-value
Time from initiation to treatment discontinuation (days)			
Mean (95% CI)			
Median (interquartile range)			
Medication Possession Ratio	N (%)	N (%)	
<30%			
30-50%			
51-79%			
>=80%			

OUTPUT 11: KAPLAN-MEIER PLOTS – PERSISTENCE TO TREATMENT (ROPINIROLE-PR VS, IR-DA MATCHED COHORT).

OUTPUT 12: FIGURE 3 - OFF LABEL EVALUATION OF ROPINIROLE-PR



Note: Paediatric defined as aged,18yrs at index prescription.

OUTPUT 13: TABLE 7 - INCIDENCE OF [DYSKINESIA] PER 1,000 PERSON-YEARS FOR PATIENTS INITIATING ROPINIROLE-PR AS A FIRST LINE MONOTHERAPY AND THOSE PRESCRIBED ROPINIROLE-PR SWITCHING FROM ANOTHER DOPAMINE AGONIST

Cohort	Ropinirole-PR (FIRST LINE)				Ropinirole-PR (SWITCHED)				Incident rate ratio - crude
	Person-time	Number with incident [dyskinesia]	Rate per 1,000 person years	95% confidence intervals	Person-time	Number with incident [dyskinesia]	Rate per 1,000 person years	95% confidence intervals	
Overall									
Age									
<60 yrs									
60-69 yrs									
70-79 yrs									
80 yrs +									
Gender									
Female									
Male									
PD duration (quartiles)									
1 st quartile									
2 nd quartile									
3 rd quartile									
4 th quartile									
Patients continuing treatment for:									
1yr									
3yrs									
5yrs									

OUTPUT 14: TABLE 8 - SENSITIVITY ANALYSIS - EVALUATION OF RISK OF DYSKINESIAS AMONGST INDIVIDUALS WITH AT LEAST TWO CONSECUTIVE PRESCRIPTIONS.

Cohort	Ropinirole-PR (WITH >= 2 SCRIPTS)				Immediate release dopamine agonist (matched) (WITH >= 2 SCRIPTS)				Incident rate ratio - crude	Incident rate ratio - adjusted
	Person-time	Number with incident [dyskinesia]	Rate per 1,000 person years	95% confidence intervals	Person-time	Number with incident [dyskinesia]	Rate per 1,000 person years	95% confidence intervals	RR (95% CI)	RR (95% CI)
Overall										
Age										
<60 yrs										
60-69 yrs										
70-79 yrs										
80 yrs +										
Gender										
Female										
Male										
PD duration (quartiles)										
1 st quartile										
2 nd quartile										
3 rd quartile										
4 th quartile										
Patients continuing treatment for:										
1yr										
3yrs										
5yrs										

OUTPUT 15: TABLE 9 - MEDIAN TIME TO DYSKINESIA (DAYS)

	Ropinirole-PR (WITH >= 2 SCRIPTS)	IR-DA matched cohort (WITH >= 2 SCRIPTS)	p-value
Median Time (days) to [dyskinesia]			
Then stratify by			
Age group			
<60y			
60-60y			
70-79y			
80+			
Male			
Female			
PD duration (quartiles)			
1st			
2nd			
3rd			
4th			

Summary of findings from a pilot study to assess utility of capturing Parkinson's disease related outcome data by GP questionnaire

In support of the Post marketing study of ropinirole prolonged release tablets: Evaluation of the short term drug utilisation patterns and long term use of ropinirole PR using the CPRD

Overview:

In 2008, GSK was granted approval for the prolonged release formulation of ropinirole (ropinirole PR) for the treatment of Parkinson's disease (PD) by the MHRA.

As part of its post-marketing commitment to the MHRA, GSK proposed to conduct an observational study using the Clinical Practice Datalink (CPRD). The primary aim of this study will be to evaluate long term outcomes amongst individuals prescribed ropinirole-PR as compared to those prescribed immediate release dopamine agonists.

A pilot study was conducted together with the University of Bath, to determine whether it was feasible or necessary to supplement information routinely captured on the CPRD relating to outcomes of interest and PD disease stage (early or advanced) and duration by use of a GP questionnaire.

Methods:

Parkinson's disease patients were identified on the CPRD using READ and OXMIS medical codes. All patients were required to have at least 12 months of registration prior to PD index date.

Algorithms were developed together with the University of Bath for each potential outcome of interest. Potential outcomes of interest included dyskinesias, sudden onset of sleep, end-of dose wearing off, on-off phenomenon and impulse control disorders. GSK and the University of Bath independently identified READ and OXMIS codes for each outcome of interest. Codes underwent clinical review at both sites and lists were compared to ensure completeness. For each outcome of interest, clinicians at GSK and at the University of Bath independently assigned the level of certainty associated with each code as 'no', 'possible', 'probable' based on the READ and OXMIS codes.

Questionnaires were sent (via the MHRA) to the GP's of 60 Parkinson's patients identified on the CPRD; 50 of whom had at least one of the potential outcomes of interest recorded on the CPRD and 10 without an outcome recorded on the CPRD. The following baseline and outcome information was requested on the GP questionnaire:

- Baseline data: Confirmation of PD diagnosis, year PD diagnosed, year dopaminergic therapy initiated, motor fluctuations experienced on or prior to initiation of dopamine agonist therapy.
- Outcomes (including date of onset):

- Dyskinesia
- Proportion of waking day with dyskinesia
- End of dose wearing off ¹
- On-off phenomena
- Proportion of waking day off
- Sudden onset of sleep (during day)
- Impulse control disorders (pathological gambling, hypersexuality, compulsive shopping, compulsive eating, other impulse control disorders)

Data recorded on the CPRD were compared with the GP responses. On-off phenomena could not be defined using codes available on the CPRD, therefore identification of this outcome was made by GP response alone.

Findings

Responses were received for 41 questionnaires (response rate of 68%).

Confirmation of PD diagnosis: PD diagnosis was recorded correctly on the CPRD in 40 of the 41 responses. It was therefore deemed that data captured on the CPRD was sufficient and that further validation from the GP questionnaire would not be necessary for the main study.

Year of PD diagnosis: The year of PD diagnosis matched in 28 of the 40 responses. Of the remaining 12 responses, the GP response was always earlier than the CPRD date. Based on these results, and following a review of patient medical records, an algorithm was defined. By using the earliest of the PD diagnosis code, dopaminergic therapy or PD symptomatology allows estimation of PD diagnosis date to within 4 months in approximately 90% of cases compared to using date of PD READ coding date alone. It is proposed to use this algorithm to derive PD diagnosis date (and hence PD duration) using data captured within the CPRD. Supplementary information from GP questionnaire are not required.

Motor fluctuations prior to index date: This question aimed help classify patients into PD disease stage (early vs. advanced) at index date. The response to this question was reported as not known in 35% of GP responses, yes in 37.5% and no in 27.5%. It is proposed to retain this question in the GP questionnaire however if there are significant numbers of responses that are not known in the main study, this variable may be omitted.

Medication use: Medication use was well captured on the CPRD. Supplementary information from GP questionnaire will not be required in the main study.

Outcomes:

¹ Individuals with end of dose wearing off were identified on the CPRD based on evidence of clinical manifestations of wearing off (READ codes for motor fluctuations, or evaluation of prescriptions suggesting increasing dose of levodopa /carbidopa, addition of a dopamine agonist, COMT inhibitor, apomorphine or MAO-B inhibitor, or deep brain stimulation) amongst individuals with PD that were treated with levodopa . In the GP questionnaire, the GP was required to tick a box to indicate the presence or absence of end of dose wearing off, together with a date of onset.

Dyskinesia:

Of the 12 cases that were identified as having probable dyskinesia on the CPRD, 7 were also confirmed by the GP questionnaire, 3 GPs responded no to the question and 2 did not know. 3 of the 9 cases that were identified as possible dyskinesia on the CPRD were also confirmed by the GP. 4 cases of dyskinesia were reported by the GP that were not identified using data from the CPRD. Data from the CPRD alone cannot be used to identify all dyskinesia cases. It is proposed that dyskinesia be identified based on data captured from the CPRD and from GP questionnaire. Individuals with dyskinesia reported from the GP questionnaire or with probable dyskinesia (defined using CPRD codes) will be used to identify individuals with dyskinesia. A clinical review of patient records with possible dyskinesia will be conducted to determine whether additional cases of dyskinesia exist.

Proportion of waking day with dyskinesia:

In the pilot study, we requested that GPs provided an estimate of the proportion of the waking day with dyskinesias. This information was poorly completed, and it is therefore proposed to omit this from the questionnaire for the main study.

End of dose wearing off:

Of the 9 patients identified on the CPRD as having end of dose wearing off, 1 of the GPs agreed but had the diagnosis 13 months earlier. 2 the GPs responded Not known and 6 stated No.

The GP identified 3 patients with end of off dose wearing off that had not been identified on the GPRD

Due to the inconsistency between the two sources of data, it is proposed to omit this outcome from the main study. Data captured within the CPRD are insufficient to define end of dose wearing off using READ, CPRD medical codes, or prescription data based on findings from the pilot study. There are concerns about the reliability and validity of this outcome if obtained from GP questionnaire alone, it is therefore proposed to omit this outcome from the main study.

On-off phenomena:

On-off phenomena was identified from the GP questionnaire alone since no relevant CPRD codes exist. Three patients were reported as having on-off phenomena from GP questionnaire. Since the accuracy and validity of this outcome is not known, all analyses evaluating this outcome must be interpreted with caution. In addition, should GP response rates substantially differ between exposure groups in the main study, then consideration to omit this outcome from the main study should be given.

Proportion of waking day off:

Although requested, no responses to the question “what proportion of the waking day is off” were received. It is therefore proposed to omit this question from the GP questionnaire.

Sudden onset of sleep (SOS):

Results from the CPRD and GP questionnaire were conflicting. Of the five individuals identified with READ codes suggestive of SOS (codes included narcolepsy, cataplexy, hypersomnia/excessive sleepiness and drowsiness) on the CPRD, only one was confirmed by the GP questionnaire. A code for hypersomnia was recorded in the GP record for the patient which was identified as possibly having SOS. The remaining four were reported not to have sudden onset of sleep from the GP questionnaire.

In total, four individuals were reported to have SOS based on GP questionnaire responses (including the one patient that was identified using READ codes). None of the GPs reported date of onset of SOS. It is therefore proposed to omit this outcome from the study due to concerns about the reliability or validity of the outcome.

Impulse control disorders:

It is proposed to retain this question in the GP questionnaire.

Pathological gambling: All three of the individuals identified as having pathological gambling on the CPRD were confirmed on the GP questionnaire.

Hypersexuality: No cases were identified on the CPRD, however three were identified by GP questionnaire.

Compulsive shopping, eating or other compulsive disorders: No cases were identified on the CPRD or by GP questionnaire.

Summary

It is not feasible to reliably identify patients with sudden onset of sleep or end of dose wearing off using data captured on the CPRD or by GP questionnaire. It is proposed to include questions on dyskinesias, on-off phenomena and impulse control disorders on the GP questionnaire for the main study. An evaluation of the GP questionnaire response rate between exposure groups must be taken into consideration prior to analysis of data.

review	comments	medcode	read_code	clinical_pat	desc
Probable		16179	2972.00	335	O/E - choreiform movement
Probable		6889	F135.00	602	Other choreas
Probable		4108	F135000	165	Hemiballismus
Probable		34327	F135200	13	Drug-induced chorea
Probable		27450	F135z00	140	Other choreas NOS
Probable		27655	F137200	69	Drug-induced dystonia
Probable		50078	F138.00	9	Fragments of torsion dystonia
Probable		23356	F138100	481	Orofacial dyskinesia
Probable		5094	F138111	1587	Tardive dyskinesia
Probable		2005	F138200	27453	Spasmodic torticollis
Probable		71249	F138z00	4	Fragments of torsion dystonia NOS
Probable		63182	F139.00	72	Paroxysmal dyskinesia
Probable		107057	F139000	1	Paroxysmal non-kinesigenic dyskinesia
Probable		67242	F139100	11	Paroxysmal kinesigenic dyskinesia
Probable		51777	F13A.00	111	Paroxysmal dystonia
Probable		94690	F13B.00	104	Myoclonic dystonia
Probable		2006	F13X.00	4000	Dystonia, unspecified
Probable		65734	Fyu2400	39	[X]Other dystonia
Probable		94540	Fyu2600	13	[X]Other chorea
Probable		52917	Fyu2A00	27	[X]Dystonia, unspecified
Probable		2003	R013.11	1887	[D]Dyskinesia
Possible		36027	1B2..00	180	Involuntary movement symptom
Possible		31658	1B2Z.00	119	Involuntary movemnt.symptom NOS
Possible		17533	297..00	1255	O/E - involuntary movements
Possible		39341	2973.00	111	O/E - athetosis
Possible		43079	297Z.00	59	O/E - involuntary movement NOS
Possible		19491	E273.00	221	Stereotyped repetitive movements
Possible		64158	E273z00	10	Stereotyped repetitive movements NOS
Possible		19740	Eu9y400	295	[X]Stereotyped movement disorders
Possible		35006	F13..00	119	Other extrapyramidal disease and abnormal movem
Possible		5545	F132.00	2361	Myoclonus
Possible		19015	F132300	2504	Myoclonic jerks
Possible		28281	F132y00	84	Other specified myoclonus
Possible		97376	F132y11	1	Paramyoclonus multiplex
Possible		37897	F132z00	189	Myoclonus NOS
Possible		27967	F137.00	111	Symptomatic torsion dystonia
Possible		92598	F137100	2	Double athetosis
Possible		25777	F137y00	3	Other specified symptomatic torsion dystonia
Possible		62081	F137z00	6	Symptomatic torsion dystonia NOS
Possible		2829	F138000	6179	Blepharospasm
Possible		21268	F138300	312	Organic writers' cramp
Possible		6787	F13z.00	82	Other/unspecified extrapyramidal/abnormal moveme
Possible		36319	F13zz00	1743	Extrapyramidal disease and abnormal movement dis

Possible		100790	Fyu2.00	1	[X]Extrapyramidal and movement disorders
Possible		100612	Fyu2700	1	[X]Other specified extrapyramidal and movement dis
Possible		5412	R010.00	4077	[D]Abnormal involuntary movements
Possible		18925	R010000	182	[D]Head movements abnormal
Possible		20323	R010400	180	[D]Athetosis, acquired, NOS
Possible		15845	R010z00	337	[D]Abnormal involuntary movement NOS
Possible		67936	Ryu3000	5	[X]Other and unspecified abnormal involuntary move
Possible		34864	2979.00	189	O/E - myoclonus
N		106461	1b2..00	42	
N		106321	1b2..11	8	
N		107633	1b2Z.00	1	
N		80481	2979	0	
N		80763	2979P	0	
N		82940	2979PA	0	
N		77525	2979PH	0	
N		80482	2979PI	0	
N		79461	2979PR	0	
N		61547	E273000	9	Body-rocking
N		15196	E273100	1085	Head-banging
N		21560	E273200	91	Spasmus nutans - nodding spasm
N		28170	F13..11	256	Extrapyramidal disease excluding Parkinson's diseas
N		52420	F132000	14	Familial essential myoclonus
N		37644	F132100	77	Progressive myoclonic epilepsy
N		63826	F132111	2	Unverricht - Lundborg disease
N		45602	F132200	62	Myoclonic encephalopathy
N		8487	F132z12	1319	Myoclonic seizure
N		2685	F135100	296	Paroxysmal choreo-athetosis
N		73943	F137.11	10	Athetoid cerebral palsy
N		42406	F137.12	20	Athetosis - congenital
N		16977	F137000	488	Athetoid cerebral palsy
N		64561	F137011	4	Vogt's disease
N		66314	F137111	9	Congenital athetosis
N		33868	F13z000	47	Unspecified extrapyramidal disease
N		25880	F13z100	71	Stiff-man syndrome
N		104967	F13z111	5	Stiff person syndrome
N		6275	F13z200	50398	Restless legs syndrome
N		50476	F13z300	179	Akinetic rigid syndrome
N		62421	F13z400	22	Hyperekplexia
N		30742	F13z500	205	Benign neonatal sleep myoclonus
N		21024	R013.00	1126	[D]Lack of coordination

Reviewed by PPD for Dyskinesia as an outcome

matching_terms
% 2972%
% F135%
% F135%
% F135%
% F135%
% F137%
% F138%
% F138%
% F138%
% F138%
% F138%
% F139%
% F139%
% F139%
% F13A%
% F13B%
% F13X%
% Fyu24%
% Fyu26%
% Fyu2A%
% R013.%
% 1B2..%
% 1B2Z%
% 297..%
% 2973%
% 297Z%
% E273%
% E273%
% Eu9y4%
% F13..%
% F132%
% F132%
% F132%
% F132%
% F132%
% F137%
% F137%
% F137%
% F137%
% F137%
% F138%
% F138%
% F13z%
% F13z%

% Fyu2.%
% Fyu27%
% R010.%
% R0100%
% R0104%
% R010z%
% Ryu30%
% 2979%
% 1B2..%
% 1B2..%
% 1B2Z%
% 2979%
% 2979%
% 2979%
% 2979%
% 2979%
% 2979%
% 2979%
% 2979%
% 2979%
% E273%
% E273%
% E273%
% F13..%
% F132%
% F132%
% F132%
% F132%
% F132%
% F132%
% F135%
% F137%
% F137%
% F137%
% F137%
% F137%
% F137%
% F137%
% F137%
% F13z%
% F13z%
% F13z%
% F13z%
% F13z%
% F13z%
% F13z%
% F13z%
% F13z%
% F13z%
% R013.%

review	Classify	medcode	read_code	clinical_pat	desc
Probable	compulsive eating	35490	1614.00	163	Excessive eating - polyphagia
Probable	compulsive eating	60373	1614.11	6	Hyperalimentation - symptom
Probable	compulsive eating	31227	1614.12	204	Polyphagia symptom
Probable	compulsive eating	3477	C38y.00	450	Other hyperalimentation
Probable	compulsive eating	4377	E275100	6518	Bulimia (non-organic overeating)
Probable	compulsive eating	11608	E275111	432	Compulsive eating disorder
Probable	compulsive eating	9581	Eu50200	6883	[X]Bulimia nervosa
Probable	compulsive eating	6583	Eu50211	3275	[X]Bulimia NOS
Probable	compulsive eating	96475	Eu50212	3	[X]Hyperorexia nervosa
Probable	compulsive eating	33863	Eu50300	185	[X]Atypical bulimia nervosa
Probable	compulsive eating	39383	Eu50400	144	[X]Overeating associated with other psycholog
Probable	compulsive eating	17439	Eu50411	92	[X]Psychogenic overeating
Probable	compulsive eating	15235	R036.00	259	[D]Polyphagia
Probable	compulsive eating	17642	R036000	1667	[D]Excessive eating
Probable	compulsive eating	605	R036011	6070	[D]Bulimia NOS
Probable	compulsive eating	98900	R036100	4	[D]Hyperalimentation
Probable	compulsive eating	72870	R036z00	2	[D]Polyphagia NOS
Possible	Compulsive pulling out hair	20286	E27z000	572	Hair plucking
Probable	Compulsive pulling out hair	3165	Eu63300	1706	[X]Trichotillomania
Probable	Compulsive water drinking	26395	E275700	378	Psychogenic polydipsia
Probable	Compulsive water drinking	45362	E275711	74	Compulsive water drinking
Probable	hypersexuality	52941	E22y500	11	Nymphomania
Probable	hypersexuality	68750	E22y600	5	Satyriasis
Possible	hypersexuality	20882	E27z300	360	Masturbation
Possible	hypersexuality	29001	E2C1.11	190	Promiscuity
Probable	hypersexuality	26411	Eu52700	128	[X]Excessive sexual drive
Probable	hypersexuality	50326	Eu52800	20	[X]Erotomania
Probable	other impulse control disorders	22654	1P3..00	1241	Compulsive behaviour
Possible	other impulse control disorders	51769	1P30.00	11	Compulsive uncontrollable drug taking
Possible	other impulse control disorders	66615	1P31.00	44	Compulsive drug taking
Probable	other impulse control disorders	26155	28L..00	243	O/E - impulsive behaviour
Probable	other impulse control disorders	23597	E213.00	975	Explosive personality disorder
Probable	other impulse control disorders	25468	E2C3.00	206	Impulse control disorder NEC
Probable	other impulse control disorders	22539	E2C3000	20	Impulse control disorder, unspecified
Probable	other impulse control disorders	53590	E2C3400	26	Intermittent explosive disorder
Probable	other impulse control disorders	94096	E2C3500	1	Isolated explosive disorder
Probable	other impulse control disorders	58054	E2C3z00	16	Impulse control disorder NOS
Probable	other impulse control disorders	58693	Eu60313	16	[X]Explosive personality disorder
Probable	other impulse control disorders	20973	Eu63.00	315	[X]Habit and impulse disorders
Probable	other impulse control disorders	25152	Eu63y00	22	[X]Other habit and impulse disorders
Probable	other impulse control disorders	58897	Eu63z00	26	[X]Habit and impulse disorder, unspecified
Probable	Pathological fire-setting	20473	E2C3300	51	Pyromania
Probable	Pathological fire-setting	32142	Eu63100	45	[X]Pathological fire-setting

Probable	pathological gambling	20255	E2C3100	1468	Pathological gambling
Probable	pathological gambling	45543	Eu63000	98	[X]Pathological gambling
Probable	pathological gambling	8863	Eu63011	924	[X]Compulsive gambling
Possible	pathological gambling	25367	ZV4K500	561	[V]Gambling and betting
Possible	Pathological stealing	16631	13HN000	806	Theft
Possible	Pathological stealing	22911	13HN100	641	Shoplifting
Possible	Pathological stealing	9769	E2C1100	221	Solitary stealing
Possible	Pathological stealing	31719	E2C1111	175	Shop lifting
Probable	Pathological stealing	20032	E2C3200	204	Kleptomania
Probable	Pathological stealing	11731	Eu63200	121	[X]Pathological stealing
N		106559	13Hn000	12	
N		106685	13Hn100	8	
N		6339	E213.11	5291	Aggressive personality
N		36043	E213.12	8	Quarrelsome personality
N		20881	E214.00	281	Compulsive personality disorders
N		40057	E214.11	13	Anancastic personality
N		30395	E214000	104	Anankastic personality
N		1293	E214100	3671	Obsessional personality
N		34456	E214z00	66	Compulsive personality disorder NOS
N		46452	E2C1.00	20	Nonaggressive unsocial conduct disorder
N		23973	E2C1000	316	Unsocial childhood truancy
N		4885	E2C1011	6322	School refusal
N		1329	E2C1200	7969	Tantrums
N		20182	E2C1z00	230	Nonaggressive unsocial conduct disorder NOS
N		7745	Eu60300	1796	[X]Emotionally unstable personality disorder
N		20839	Eu60311	294	[X]Aggressive personality disorder
N		31789	Eu60312	196	[X]Borderline personality disorder

Reviewed by PPD [redacted] for impulse control disorders

matching_terms
% 1614%
% 1614%
% 1614%
% C38y.00%
% E2751%
% E2751%
% Eu502%
% Eu502%
% Eu502%
% Eu503%
% Eu504%
% Eu504%
% R036%
% R036%
% R036%
% R036%
% R036%
% E27z0%
% Eu63%
% E2757%
% E2757%
% E22y5%
% E22y6%
% E27z3%
% E2C1%
% Eu527%
% Eu528%
% 1P3%
% 1P3%
% 1P3%
% 28L..00%
% E213%
% E2C3%
% E2C3%
% E2C3%
% E2C3%
% E2C3%
% E2C3%
% Eu603%
% Eu63%
% Eu63%
% Eu63%
% E2C3%
% Eu63%

% E2C3%
% Eu63%
% Eu63%
% ZV4K5%
% 13HN0%
% 13HN1%
% E2C1%
% E2C1%
% E2C3%
% Eu63%
% 13HN0%
% 13HN1%
% E213%
% E213%
% E214%
% E214%
% E214%
% E214%
% E214%
% E214%
% E2C1%
% E2C1%
% E2C1%
% E2C1%
% E2C1%
% Eu603%
% Eu603%
% Eu603%

revi	classify	release_time	Composition	prodcode
Y	Amantadine		Amantadine	5339
Y	Amantadine		Amantadine	6035
Y	Amantadine		Amantadine	25890
Y	Amantadine		Amantadine	7428
Y	Amantadine		Amantadine	21745
Y	Antimuscarinic drugs used in parkinsonism		Benzatropine	3260
Y	Antimuscarinic drugs used in parkinsonism		Benzatropine	29425
Y	Antimuscarinic drugs used in parkinsonism		Benzatropine	19380
Y	Antimuscarinic drugs used in parkinsonism		Benzatropine	3259
Y	Antimuscarinic drugs used in parkinsonism		Benzatropine	40377
Y	Antimuscarinic drugs used in parkinsonism		Biperiden	20073
Y	Antimuscarinic drugs used in parkinsonism		Biperiden	30474
Y	Antimuscarinic drugs used in parkinsonism		Biperiden	12922
Y	Antimuscarinic drugs used in parkinsonism		Biperiden	41888
Y	Antimuscarinic drugs used in parkinsonism		Methixene	7630
Y	Antimuscarinic drugs used in parkinsonism		Methixene	7631
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	29836
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	27718
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	16685
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	4530
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	45258
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	18688
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	2274
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	43551
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	2278
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	15067
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	30068
Y	Antimuscarinic drugs used in parkinsonism		Orphenadrine	14473
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	19646
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	13565
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	17528
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	2095
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	44230
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	8638
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	26239
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	4681
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	1315
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	4151
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	45848
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	1220
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	34569
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	42084
Y	Antimuscarinic drugs used in parkinsonism		Procyclidine	34933

Y	Antimuscarinic drugs used in parkinsonism	Procyclidine	31936
Y	Antimuscarinic drugs used in parkinsonism	Procyclidine	1250
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	7878
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	7623
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	21971
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	12089
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	36516
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	7215
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	57408
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	26954
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	29947
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	552
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	33680
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	30262
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	55927
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	55909
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	41829
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	43419
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	8547
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	42735
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	6551
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	57031
Y	Antimuscarinic drugs used in parkinsonism	Trihexyphenidyl	6550
Y	Apomorphine	Apomorphine	19267
Y	Apomorphine	Apomorphine	38199
Y	Apomorphine	Apomorphine	35939
Y	Apomorphine	Apomorphine	36038
Y	Apomorphine	Apomorphine	18566
Y	Apomorphine	Apomorphine	9701
Y	Apomorphine	Apomorphine	33781
Y	Apomorphine	Apomorphine	35255
Y	Apomorphine	Apomorphine	14935
Y	Apomorphine	Apomorphine	33133
Y	Apomorphine	Apomorphine	20211
Y	COMT inhibitor	Entacapone	20651
Y	COMT inhibitor	Entacapone	758
Y	COMT inhibitor	Tolcapone	26041
Y	COMT inhibitor	Tolcapone	21118
Y	COMT inhibitor	Tolcapone	31356
Y	COMT inhibitor	Tolcapone	9327
Y	COMT inhibitor	Tolcapone	31162
Y	COMT inhibitor	Tolcapone	22675
Y	Decarboxylase inhibitor	Benserazide	10406
Y	Decarboxylase inhibitor	Benserazide	27730

Y	Decarboxylase inhibitor		Carbidopa	10770
Y	dopamine agonist (ergot)		Bromocriptine	12057
Y	dopamine agonist (ergot)		Bromocriptine	4975
Y	dopamine agonist (ergot)		Bromocriptine	34219
Y	dopamine agonist (ergot)		Bromocriptine	32067
Y	dopamine agonist (ergot)		Bromocriptine	2279
Y	dopamine agonist (ergot)		Bromocriptine	34132
Y	dopamine agonist (ergot)		Bromocriptine	56442
Y	dopamine agonist (ergot)		Bromocriptine	4300
Y	dopamine agonist (ergot)		Bromocriptine	21361
Y	dopamine agonist (ergot)		Bromocriptine	13403
Y	dopamine agonist (ergot)		Bromocriptine	41804
Y	dopamine agonist (ergot)		Bromocriptine	9333
Y	dopamine agonist (ergot)		Bromocriptine	40039
Y	dopamine agonist (ergot)		Bromocriptine	13515
Y	dopamine agonist (ergot)		Bromocriptine	40947
Y	dopamine agonist (ergot)		Cabergoline	11541
Y	dopamine agonist (ergot)		Cabergoline	17443
Y	dopamine agonist (ergot)		Cabergoline	14140
Y	dopamine agonist (ergot)		Cabergoline	5389
Y	dopamine agonist (ergot)		Cabergoline	5406
Y	dopamine agonist (ergot)		Cabergoline	6016
Y	dopamine agonist (ergot)		Cabergoline	514
Y	dopamine agonist (ergot)		Cabergoline	4581
Y	dopamine agonist (ergot)		Lisuride	17262
Y	dopamine agonist (ergot)		Lisuride	17147
Y	dopamine agonist (ergot)		Pergolide	13793
Y	dopamine agonist (ergot)		Pergolide	13736
Y	dopamine agonist (ergot)		Pergolide	20023
Y	dopamine agonist (ergot)		Pergolide	11192
Y	dopamine agonist (ergot)		Pergolide	27204
Y	dopamine agonist (ergot)		Pergolide	4941
Y	dopamine agonist (ergot)		Pergolide	2464
Y	dopamine agonist (ergot)		Pergolide	16963
Y	dopamine agonist (ergot)		Pergolide	4146
Y	dopamine agonist (ergot)		Pergolide	55876
Y	dopamine agonist (ergot)		Pergolide	11277
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	16617
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	50289
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	7339
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	37984
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	16933
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	46660
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	5766

Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	37635
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	5909
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	811
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	47730
Y	dopamine agonist (non-ergot)	immediate release	Pramipexole	54469
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41359
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41358
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41360
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	44566
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41350
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	44750
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41484
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41243
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	44486
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41272
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	44649
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41219
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41242
Y	dopamine agonist (non-ergot)	modified release	Pramipexole	41265
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	17058
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	18891
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	17066
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	14934
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	12762
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	17619
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	17622
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	19478
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	12988
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	772
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	53837
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	57652
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	5674
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	41464
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	6012
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	9799
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	45303
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	14342
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	6143
Y	dopamine agonist (non-ergot)	immediate release	Ropinirole	6122
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	52376
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	52579
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	57511
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	38251
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	38250

Y	dopamine agonist (non-ergot)	modified release	Ropinirole	57512
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	38256
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	38245
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	38249
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	38151
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	47762
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	48075
Y	dopamine agonist (non-ergot)	modified release	Ropinirole	47763
Y	dopamine agonist (non-ergot)		Rotigotine	41147
Y	dopamine agonist (non-ergot)		Rotigotine	19492
Y	dopamine agonist (non-ergot)		Rotigotine	42649
Y	dopamine agonist (non-ergot)		Rotigotine	19498
Y	dopamine agonist (non-ergot)		Rotigotine	19505
Y	dopamine agonist (non-ergot)		Rotigotine	57518
Y	dopamine agonist (non-ergot)		Rotigotine	23293
Y	dopamine agonist (non-ergot)		Rotigotine	31647
Y	dopamine agonist (non-ergot)		Rotigotine	40866
Y	dopamine agonist (non-ergot)		Rotigotine	14914
Y	dopamine agonist (non-ergot)		Rotigotine	22602
Y	dopamine agonist (non-ergot)		Rotigotine	41309
Y	dopamine agonist (non-ergot)		Rotigotine	17053
Y	dopamine agonist (non-ergot)		Rotigotine	14915
Y	dopamine agonist (non-ergot)		Rotigotine	22604
Y	Levodopa		Levodopa	18715
Y	Levodopa		Levodopa	27302
Y	Levodopa		Levodopa	24528
Y	Levodopa		Levodopa	19592
Y	Levodopa		Levodopa	4335
Y	Levodopa		Levodopa	12481
Y	Levodopa		Levodopa	18346
Y	Levodopa		Levodopa	10299
Y	Levodopa		Levodopa	25932
Y	Levodopa		Levodopa	25844
Y	Levodopa		Levodopa	16780
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	27649
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	31682
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	35407
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	32003
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	37489
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	16817
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	5464
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	57635
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	11235
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	3642

Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	5673
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	5248
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	9512
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	10507
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	3641
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	16861
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	16970
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	7879
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	8407
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	8408
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	8409
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	25949
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	19787
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	2466
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	5869
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	20726
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	7256
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	26074
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	3562
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	3910
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	20725
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	26078
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Benserazide	2465
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	40452
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	39348
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	32244
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	17578
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	27506
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	5724
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	28416
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	16777
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	36347
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	9283
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	57082
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	25288
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	4866
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	5675
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	6156
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	42215
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	41370
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	41091
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	5310
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	31268
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	7246

Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	43631
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	33541
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	55508
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	45761
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	53526
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	42172
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	1853
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	43718
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	43855
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	22223
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	25050
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	22497
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	7742
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	20250
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	3038
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	4531
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	8191
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	16808
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	51023
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	42293
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	56507
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	546
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	42041
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	57586
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	53299
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	42262
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	2074
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	2739
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	42255
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	2829
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	52694
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	42147
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	49481
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	2534
Y	Levodopa-Decarboxylase inhibitor		Levodopa/Carbidopa	43033
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	10197
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	40605
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	11753
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	38382
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	18076
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	40751
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	56261
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	10142
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor		Levodopa/Carbidopa/Entacapone	40568

Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor	Levodopa/Carbidopa/Entacapone	7386
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor	Levodopa/Carbidopa/Entacapone	47248
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor	Levodopa/Carbidopa/Entacapone	56031
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor	Levodopa/Carbidopa/Entacapone	38357
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor	Levodopa/Carbidopa/Entacapone	14916
Y	Levodopa-Decarboxylase inhibitor-COMT inhibitor	Levodopa/Carbidopa/Entacapone	40306
Y	MAO B inhibitor	Rasagiline	21793
Y	MAO B inhibitor	Rasagiline	7040
Y	MAO B inhibitor	Selegiline	26257
Y	MAO B inhibitor	Selegiline	16224
Y	MAO B inhibitor	Selegiline	25298
Y	MAO B inhibitor	Selegiline	8426
Y	MAO B inhibitor	Selegiline	7051
Y	MAO B inhibitor	Selegiline	3640
Y	MAO B inhibitor	Selegiline	34250
Y	MAO B inhibitor	Selegiline	42808
Y	MAO B inhibitor	Selegiline	41707
Y	MAO B inhibitor	Selegiline	5233
Y	MAO B inhibitor	Selegiline	2467
Y	MAO B inhibitor	Selegiline	34123
Y	MAO B inhibitor	Selegiline	40235
Y	MAO B inhibitor	Selegiline	27738
Y	MAO B inhibitor	Selegiline	40418
Y	MAO B inhibitor	Selegiline	29846
Y	MAO B inhibitor	Selegiline	28590
Y	MAO B inhibitor	Selegiline	11586
N			5487
N			5535
N			12363
N			26868
N			28729
N			8410
N			10399
N			5575
N			5665

Reviewed by PPD for medications used for PD: levodopa, dopamine agonist (ergot), dopamine

drugsubstance	productname	formulation
Amantadine hydrochloride	Amantadine 100mg capsules	Capsule
Amantadine hydrochloride	Amantadine 50mg/5ml oral solution sugar free	Oral solution
Amantadine hydrochloride	Lysovir 100mg capsules (Alliance Pharmaceuticals Ltd)	Capsule
Amantadine hydrochloride	Symmetrel 100mg capsules (Alliance Pharmaceuticals Ltd)	Capsule
Amantadine hydrochloride	Symmetrel 50mg/5ml syrup (Alliance Pharmaceuticals Ltd)	Oral solution
Benzatropine mesilate	Benzatropine 2mg tablets	Tablet
Benzatropine mesilate	Benzatropine 2mg/2ml solution for injection ampoules	Solution for in
Benzatropine mesilate	Cogentin 1mg/ml Injection (Merck Sharp & Dohme Ltd)	Solution for in
Benzatropine mesilate	Cogentin 2mg tablets (Merck Sharp & Dohme Ltd)	Tablet
Benzatropine mesilate	Cogentin 2mg/2ml solution for injection ampoules (Lundbeck Pharmaceutica	Solution for in
Biperiden hydrochloride	Akineton 2mg tablets (Abbott Laboratories Ltd)	Tablet
Biperiden Hydrochloride	Akineton 5mg/ml Injection (Abbott Laboratories Ltd)	Injection
Biperiden hydrochloride	Biperiden 2mg tablets	Tablet
Biperiden Hydrochloride	Biperiden 5mg/ml lactate injection	Injection
Pimethixene	Methixene 5mg Tablet	Tablet
Pimethixene	Tremonil 5mg Tablet (Novartis Pharmaceuticals UK Ltd)	Tablet
Orphenadrine hydrochloride	Biorphen 25mg/5ml oral solution (Rosemont Pharmaceuticals Ltd)	Oral solution
Orphenadrine hydrochloride	DISIPAL	
Orphenadrine hydrochloride	DISIPAL 40 MG INJ	
Orphenadrine hydrochloride	Disipal 50mg tablets (Amdipharm Plc)	Tablet
Orphenadrine Hydrochloride	Orphenadrine 25mg/5ml oral solution	Oral Liquid
Orphenadrine hydrochloride	Orphenadrine 25mg/5ml oral solution sugar free	Oral solution
Orphenadrine hydrochloride	Orphenadrine 50mg tablets	Tablet
Orphenadrine hydrochloride	Orphenadrine 50mg tablets (Teva UK Ltd)	Tablet
Orphenadrine hydrochloride	Orphenadrine 50mg/5ml oral solution sugar free	Oral solution
Orphenadrine hydrochloride	ORPHENADRINE HCl 100 MG TAB	
Orphenadrine hydrochloride	ORPHENADRINE HCl 20 MG INJ	
Orphenadrine hydrochloride	ORPHENADRINE HCl SYR	
Procyclidine hydrochloride	Arpicolin 2.5mg/5ml syrup (Rosemont Pharmaceuticals Ltd)	Oral solution
Procyclidine hydrochloride	Arpicolin 5mg/5ml syrup (Rosemont Pharmaceuticals Ltd)	Oral solution
Procyclidine hydrochloride	Kemadrin 10mg/2ml solution for injection ampoules (Auden McKenzie (Pharr	Solution for in
Procyclidine hydrochloride	Kemadrin 5mg Tablet (Wellcome Medical Division)	Tablet
Procyclidine hydrochloride	Kemadrin 5mg tablets (Aspen Pharma Trading Ltd)	Tablet
Procyclidine hydrochloride	Kemadrin 5mg/ml Injection (Wellcome Medical Division)	Solution for in
Procyclidine hydrochloride	Musciniil 5mg tablets (Opus Pharmaceuticals Ltd)	Tablet
Procyclidine hydrochloride	Procyclidine 10mg/2ml solution for injection ampoules	Solution for in
Procyclidine hydrochloride	PROCYCLIDINE 2.5 MG TAB	
Procyclidine hydrochloride	Procyclidine 2.5mg/5ml oral solution sugar free	Oral solution
Procyclidine hydrochloride	Procyclidine 5mg Tablet (Berk Pharmaceuticals Ltd)	Tablet
Procyclidine hydrochloride	Procyclidine 5mg tablets	Tablet
Procyclidine hydrochloride	Procyclidine 5mg tablets (A A H Pharmaceuticals Ltd)	Tablet
Procyclidine hydrochloride	Procyclidine 5mg tablets (Actavis UK Ltd)	Tablet
Procyclidine hydrochloride	Procyclidine 5mg tablets (IVAX Pharmaceuticals UK Ltd)	Tablet

Procyclidine hydrochloride	Procyclidine 5mg tablets (Teva UK Ltd)	Tablet
Procyclidine hydrochloride	Procyclidine 5mg/5ml oral solution sugar free	Oral solution
Trihexyphenidyl hydrochloride	Artane 2mg Tablet (Wyeth Pharmaceuticals)	Tablet
Trihexyphenidyl hydrochloride	Artane 5mg Tablet (Wyeth Pharmaceuticals)	Tablet
Trihexyphenidyl hydrochloride	ARTANE SUSTETS	
Trihexyphenidyl hydrochloride	ARTANE SUSTETS 5 MG TAB	
Trihexyphenidyl Hydrochloride	Artane sustets 5mg Sustets (Bio-Diagnostics Ltd)	Sustets
Trihexyphenidyl hydrochloride	Broflex 5mg/5ml syrup (Rosemont Pharmaceuticals Ltd)	Oral solution
Trihexyphenidyl hydrochloride	Trihexyphenidyl 1mg/5ml oral solution	
Trihexyphenidyl hydrochloride	Trihexyphenidyl 2mg Tablet (DDSA Pharmaceuticals Ltd)	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 2mg Tablet (Genus Pharmaceuticals Ltd)	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 2mg tablets	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 2mg tablets (A A H Pharmaceuticals Ltd)	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 2mg tablets (Teva UK Ltd)	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 2mg/5ml oral solution	Oral solution
Trihexyphenidyl hydrochloride	Trihexyphenidyl 2mg/5ml oral suspension	Oral suspension
Trihexyphenidyl hydrochloride	Trihexyphenidyl 5mg Tablet (DDSA Pharmaceuticals Ltd)	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 5mg Tablet (Genus Pharmaceuticals Ltd)	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 5mg tablets	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 5mg tablets (Teva UK Ltd)	Tablet
Trihexyphenidyl hydrochloride	Trihexyphenidyl 5mg/5ml oral solution	Oral solution
Trihexyphenidyl hydrochloride	Trihexyphenidyl 5mg/5ml oral suspension	Oral suspension
Trihexyphenidyl Hydrochloride	Trihexyphenidyl hc 2mg/5ml sugar free Oral solution	Oral Solution
Apomorphine Hydrochloride	Apo-go 10mg/ml Injection (Britannia Pharmaceuticals Ltd)	Injection
Apomorphine hydrochloride	APO-go 20mg/2ml solution for injection ampoules (Genus Pharmaceuticals Ltd)	Solution for injection
Apomorphine hydrochloride	APO-go 50mg/5ml solution for injection ampoules (Genus Pharmaceuticals Ltd)	Solution for injection
Apomorphine hydrochloride	APO-go PEN 30mg/3ml solution for injection (Genus Pharmaceuticals Ltd)	Solution for injection
Apomorphine hydrochloride	APO-go PFS 50mg/10ml solution for infusion pre-filled syringes (Genus Pharmaceuticals Ltd)	Solution for injection
Apomorphine Hydrochloride	Apomorphine 10mg/ml injection	Injection
Apomorphine hydrochloride	Apomorphine 20mg/2ml solution for injection ampoules	Solution for injection
Apomorphine hydrochloride	Apomorphine 30mg/3ml solution for injection pre-filled disposable devices	Solution for injection
Apomorphine hydrochloride	Apomorphine 50mg/10ml solution for infusion pre-filled syringes	Solution for injection
Apomorphine hydrochloride	Apomorphine 50mg/5ml solution for injection ampoules	Solution for injection
Apomorphine Hydrochloride	Britaject 10mg/ml Subcutaneous injection (Britannia Pharmaceuticals Ltd)	Subcutaneous injection
Entacapone	Comtess 200mg tablets (Orion Pharma (UK) Ltd)	Tablet
Entacapone	Entacapone 200mg tablets	Tablet
Tolcapone	Tasmar 100mg tablets (Meda Pharmaceuticals Ltd)	Tablet
Tolcapone	Tasmar fc 100mg Tablet (Roche Products Ltd)	Tablet
Tolcapone	Tasmar fc 200mg Tablet (Roche Products Ltd)	Tablet
Tolcapone	Tolcapone 100mg tablets	Tablet
Tolcapone	TOLCAPONE FC	
Tolcapone	Tolcapone fc 200mg Tablet	Tablet
Benserazide hydrochloride	BENSERAZIDE 10 MG CAP	
Benserazide hydrochloride	BENSERAZIDE 10 MG TAB	

Carbidopa	CARBIDOPA 25 MG TAB	
Bromocriptine mesilate	Bromocriptine 10mg capsules	Capsule
Bromocriptine mesilate	Bromocriptine 1mg tablets	Tablet
Bromocriptine mesilate	Bromocriptine 2.5mg Tablet (Berk Pharmaceuticals Ltd)	Tablet
Bromocriptine mesilate	Bromocriptine 2.5mg Tablet (Generics (UK) Ltd)	Tablet
Bromocriptine mesilate	Bromocriptine 2.5mg tablets	Tablet
Bromocriptine mesilate	Bromocriptine 2.5mg tablets (A A H Pharmaceuticals Ltd)	Tablet
Bromocriptine mesilate	Bromocriptine 2.5mg tablets (Kent Pharmaceuticals Ltd)	Tablet
Bromocriptine mesilate	Bromocriptine 5mg capsules	Capsule
Bromocriptine mesilate	Parlodel 10mg Capsule (Novartis Pharmaceuticals UK Ltd)	Capsule
Bromocriptine mesilate	Parlodel 1mg Tablet (Novartis Pharmaceuticals UK Ltd)	Tablet
Bromocriptine mesilate	Parlodel 1mg tablets (Meda Pharmaceuticals Ltd)	Tablet
Bromocriptine mesilate	Parlodel 2.5mg Tablet (Novartis Pharmaceuticals UK Ltd)	Tablet
Bromocriptine mesilate	Parlodel 2.5mg tablets (Meda Pharmaceuticals Ltd)	Tablet
Bromocriptine mesilate	Parlodel 5mg Capsule (Novartis Pharmaceuticals UK Ltd)	Capsule
Bromocriptine mesilate	Parlodel 5mg capsules (Meda Pharmaceuticals Ltd)	Capsule
Cabergoline	Cabaser 1mg tablets (Pfizer Ltd)	Tablet
Cabergoline	Cabaser 2mg tablets (Pfizer Ltd)	Tablet
Cabergoline	Cabaser 4mg tablets (Pfizer Ltd)	Tablet
Cabergoline	Cabergoline 1mg tablets	Tablet
Cabergoline	Cabergoline 2mg tablets	Tablet
Cabergoline	Cabergoline 4mg tablets	Tablet
Cabergoline	Cabergoline 500microgram tablets	Tablet
Cabergoline	Dostinex 500microgram tablets (Pfizer Ltd)	Tablet
Lisuride maleate	Lisuride 200microgram tablets	Tablet
Lisuride maleate	Revanil 200microgram Tablet (Cambridge Laboratories Ltd)	Tablet
Pergolide mesilate	Celance 1mg tablets (Eli Lilly and Company Ltd)	Tablet
Pergolide mesilate	Celance 250microgram tablets (Eli Lilly and Company Ltd)	Tablet
Pergolide mesilate	Celance 50microgram tablets (Eli Lilly and Company Ltd)	Tablet
Pergolide mesilate	Celance tablets 14 day starter pack (Eli Lilly and Company Ltd)	Not applicable
Pergolide mesilate	Celance tablets 30 day starter pack (Eli Lilly and Company Ltd)	Not applicable
Pergolide mesilate	Pergolide 1mg tablets	Tablet
Pergolide mesilate	Pergolide 250microgram tablets	Tablet
Pergolide mesilate	Pergolide 250microgram tablets and Pergolide 50microgram tablets	Not applicable
Pergolide mesilate	Pergolide 50microgram tablets	Tablet
Pergolide mesilate	Pergolide 50microgram tablets (A A H Pharmaceuticals Ltd)	Tablet
Pergolide Mesilate	Pergolide Starter Pack (Pergolide 50 micrograms tablet with Pergolide 250 m	Starter Pack
Pramipexole dihydrochloride monohydrate	Mirapexin 0.088mg tablets (Boehringer Ingelheim Ltd)	Tablet
Pramipexole dihydrochloride monohydrate	Mirapexin 0.088mg tablets (Waymade Healthcare Plc)	Tablet
Pramipexole dihydrochloride monohydrate	Mirapexin 0.18mg tablets (Boehringer Ingelheim Ltd)	Tablet
Pramipexole Dihydrochloride Monohydrate	Mirapexin 0.35mg tablets (Boehringer Ingelheim Ltd)	Tablets
Pramipexole dihydrochloride monohydrate	Mirapexin 0.7mg tablets (Boehringer Ingelheim Ltd)	Tablet
Pramipexole Dihydrochloride Monohydrate	Neliprax 0.35mg tablets (Aspire Pharma Ltd)	Tablets
Pramipexole dihydrochloride monohydrate	Pramipexole 180microgram tablets	Tablet

Pramipexole Dihydrochloride Monohydrate	Pramipexole 350microgram tablets	Tablets
Pramipexole dihydrochloride monohydrate	Pramipexole 700microgram tablets	Tablet
Pramipexole dihydrochloride monohydrate	Pramipexole 88microgram tablets	Tablet
Pramipexole dihydrochloride monohydrate	Pramipexole 88microgram tablets (Actavis UK Ltd)	Tablet
Pramipexole dihydrochloride monohydrate	Pramipexole 88microgram tablets (Sigma Pharmaceuticals Plc)	Tablet
Pramipexole dihydrochloride monohydrate	Mirapexin 0.26mg modified-release tablets (Boehringer Ingelheim Ltd)	Modified-relea
Pramipexole dihydrochloride monohydrate	Mirapexin 0.52mg modified-release tablets (Boehringer Ingelheim Ltd)	Modified-relea
Pramipexole Dihydrochloride Monohydrate	Mirapexin 1.05mg modified-release tablets (Boehringer Ingelheim Ltd)	Prolonged Re
Pramipexole Dihydrochloride Monohydrate	Mirapexin 1.57mg modified-release tablets (Boehringer Ingelheim Ltd)	Prolonged Re
Pramipexole dihydrochloride monohydrate	Mirapexin 2.1mg modified-release tablets (Boehringer Ingelheim Ltd)	Modified-relea
Pramipexole Dihydrochloride Monohydrate	Mirapexin 2.62mg modified-release tablets (Boehringer Ingelheim Ltd)	Prolonged Re
Pramipexole dihydrochloride monohydrate	Mirapexin 3.15mg modified-release tablets (Boehringer Ingelheim Ltd)	Modified-relea
Pramipexole Dihydrochloride Monohydrate	Pramipexole 1.05mg modified-release tablets	Prolonged Re
Pramipexole Dihydrochloride Monohydrate	Pramipexole 1.57mg modified-release tablets	Prolonged Re
Pramipexole dihydrochloride monohydrate	Pramipexole 2.1mg modified-release tablets	Modified-relea
Pramipexole Dihydrochloride Monohydrate	Pramipexole 2.62mg modified-release tablets	Prolonged Re
Pramipexole dihydrochloride monohydrate	Pramipexole 260microgram modified-release tablets	Modified-relea
Pramipexole Dihydrochloride Monohydrate	Pramipexole 3.15mg modified-release tablets	Prolonged Re
Pramipexole dihydrochloride monohydrate	Pramipexole 520microgram modified-release tablets	Modified-relea
Ropinirole hydrochloride	Adartrel 250microgram tablets (GlaxoSmithKline UK Ltd)	Tablet
Ropinirole hydrochloride	Adartrel 2mg tablets (GlaxoSmithKline UK Ltd)	Tablet
Ropinirole hydrochloride	Adartrel 500microgram tablets (GlaxoSmithKline UK Ltd)	Tablet
Ropinirole hydrochloride	ReQuip 1mg tablets (GlaxoSmithKline UK Ltd)	Tablet
Ropinirole hydrochloride	ReQuip 250microgram tablets (GlaxoSmithKline UK Ltd)	Tablet
Ropinirole hydrochloride	ReQuip 2mg tablets (GlaxoSmithKline UK Ltd)	Tablet
Ropinirole hydrochloride	ReQuip 5mg tablets (GlaxoSmithKline UK Ltd)	Tablet
Ropinirole hydrochloride	ReQuip tablets follow on pack (GlaxoSmithKline UK Ltd)	Not applicabl
Ropinirole hydrochloride	ReQuip tablets starter pack (GlaxoSmithKline UK Ltd)	Not applicabl
Ropinirole hydrochloride	Ropinirole 1mg tablets	Tablet
Ropinirole hydrochloride	Ropinirole 1mg tablets (A A H Pharmaceuticals Ltd)	Tablet
Ropinirole hydrochloride	Ropinirole 1mg tablets (Waymade Healthcare Plc)	Tablet
Ropinirole hydrochloride	Ropinirole 250microgram tablets	Tablet
Ropinirole hydrochloride	Ropinirole 250microgram tablets (Zentiva)	Tablet
Ropinirole Hydrochloride	Ropinirole 250micrograms with 500micrograms with 1mg tablet	Tablets
Ropinirole hydrochloride	Ropinirole 2mg tablets	Tablet
Ropinirole hydrochloride	Ropinirole 2mg tablets (Generics (UK) Ltd)	Tablet
Ropinirole hydrochloride	Ropinirole 500microgram tablets	Tablet
Ropinirole Hydrochloride	Ropinirole 500micrograms with 1mg with 2mg tablet	Tablets
Ropinirole hydrochloride	Ropinirole 5mg tablets	Tablet
Ropinirole hydrochloride	Ralnea XL 2mg tablets (Consilient Health Ltd)	Modified-relea
Ropinirole hydrochloride	Ralnea XL 4mg tablets (Consilient Health Ltd)	
Ropinirole hydrochloride	ReQuip XL 2mg tablets (Doncaster Pharmaceuticals Ltd)	Modified-relea
Ropinirole hydrochloride	ReQuip XL 2mg tablets (GlaxoSmithKline UK Ltd)	Modified-relea
Ropinirole hydrochloride	ReQuip XL 4mg tablets (GlaxoSmithKline UK Ltd)	Modified-relea

Ropinirole hydrochloride	ReQuip XL 4mg tablets (Waymade Healthcare Plc)	
Ropinirole hydrochloride	ReQuip XL 8mg tablets (GlaxoSmithKline UK Ltd)	Modified-release
Ropinirole hydrochloride	Ropinirole 2mg modified-release tablets	Modified-release
Ropinirole Hydrochloride	Ropinirole 4mg modified-release tablets	Modified Release
Ropinirole hydrochloride	Ropinirole 8mg modified-release tablets	Modified-release
Ropinirole hydrochloride	Spiroco XL 2mg tablets (Teva UK Ltd)	Modified-release
Ropinirole Hydrochloride	Spiroco XL 4mg tablets (Teva UK Ltd)	Modified Release
Ropinirole hydrochloride	Spiroco XL 8mg tablets (Teva UK Ltd)	Modified-release
Rotigotine	Neupro 1mg/24hours transdermal patches (UCB Pharma Ltd)	Patch
Rotigotine	Neupro 2mg/24hours transdermal patches (UCB Pharma Ltd)	Transdermal patch
Rotigotine	Neupro 3mg/24hours transdermal patches (UCB Pharma Ltd)	Transdermal patch
Rotigotine	Neupro 4mg/24hours transdermal patches (UCB Pharma Ltd)	Transdermal patch
Rotigotine	Neupro 6mg/24hours transdermal patches (UCB Pharma Ltd)	Transdermal patch
Rotigotine	Neupro 8mg/24hours transdermal patches (Mawdsley-Brooks & Company Ltd)	Transdermal patch
Rotigotine	Neupro 8mg/24hours transdermal patches (UCB Pharma Ltd)	Transdermal patch
Rotigotine	Neupro transdermal patches treatment initiation pack (UCB Pharma Ltd)	Not applicable
Rotigotine	Rotigotine 1mg/24hours transdermal patches	Patch
Rotigotine	Rotigotine 2mg/24hours transdermal patches	Transdermal patch
Rotigotine	Rotigotine 2mg/24hr with 4mg/24hr with 6mg/24hr with 8mg/24hr patch	Patch
Rotigotine	Rotigotine 3mg/24hours transdermal patches	Transdermal patch
Rotigotine	Rotigotine 4mg/24hours transdermal patches	Transdermal patch
Rotigotine	Rotigotine 6mg/24hours transdermal patches	Transdermal patch
Rotigotine	Rotigotine 8mg/24hours transdermal patches	Transdermal patch
Levodopa	Brocadopa 125mg Capsule (Yamanouchi Pharma Ltd)	Capsule
Levodopa	Brocadopa 250mg Capsule (Yamanouchi Pharma Ltd)	Capsule
Levodopa	Brocadopa 500mg Capsule (Yamanouchi Pharma Ltd)	Capsule
Levodopa	Larodopa 500mg Tablet (Cambridge Laboratories Ltd)	Tablet
Levodopa	LEVODOPA 125 MG TAB	
Levodopa	Levodopa 125mg Capsule	Capsule
Levodopa	Levodopa 250mg Capsule	Capsule
Levodopa	LEVODOPA 40 MG CAP	
Levodopa	LEVODOPA 40 MG TAB	
Levodopa	Levodopa 500mg Capsule	Capsule
Levodopa	Levodopa 500mg tablets	Tablet
Levodopa	Benserazide 12.5mg with levodopa 50mg capsules	Capsules
Levodopa	Benserazide 12.5mg with Levodopa 50mg dispersible tablets	Dispersible Tablets
Levodopa	Benserazide 25mg with levodopa 100mg capsules	Capsules
Levodopa	Benserazide 25mg with Levodopa 100mg dispersible tablet	Dispersible Tablets
Levodopa	Benserazide 25mg with Levodopa 100mg modified-release capsules	Modified Release
Levodopa	Benserazide 50mg with Levodopa 200mg capsules	Capsules
Benserazide hydrochloride/Levodopa	Co-beneldopa 12.5mg/50mg capsules	Capsule
Benserazide hydrochloride/Levodopa	Co-beneldopa 12.5mg/50mg capsules (Teva UK Ltd)	Capsule
Benserazide hydrochloride/Levodopa	Co-beneldopa 12.5mg/50mg dispersible tablets sugar free	Dispersible tablets
Benserazide hydrochloride/Levodopa	Co-beneldopa 25mg/100mg capsules	Capsule

Levodopa/Benserazide hydrochloride	Co-beneldopa 25mg/100mg dispersible tablets sugar free	Dispersible ta
Benserazide hydrochloride/Levodopa	Co-beneldopa 25mg/100mg modified-release capsules	Modified-relea
Benserazide hydrochloride/Levodopa	Co-beneldopa 50mg/200mg capsules	Capsule
Benserazide hydrochloride/Levodopa	CO-BENELDOPA 62.5 MG CAP	
Levodopa	Levodopa with benserazide 100mg + 25mg Capsule	Capsule
Levodopa	Levodopa with benserazide 100mg + 25mg Dispersible tablet	Dispersible Ta
Levodopa	Levodopa with benserazide 100mg + 25mg Modified-release capsule	Modified-relea
Levodopa	Levodopa with benserazide 200mg + 50mg Capsule	Capsule
Levodopa	Levodopa with benserazide 50mg + 12.5mg Capsule	Capsule
Levodopa	Levodopa with benserazide 50mg + 12.5mg Dispersible tablet	Dispersible Ta
Benserazide hydrochloride/Levodopa	LEVODOPA/BENSERAZIDE 100 MG TAB	
Benserazide hydrochloride/Levodopa	LEVODOPA/BENSERAZIDE 40 MG CAP	
Benserazide hydrochloride/Levodopa	MADOPAR 62.5	
Benserazide hydrochloride/Levodopa	Madopar 100mg/25mg capsules (Roche Products Ltd)	Capsule
Levodopa/Benserazide hydrochloride	Madopar 100mg/25mg dispersible tablets (Roche Products Ltd)	Dispersible ta
Benserazide hydrochloride/Levodopa	MADOPAR 125 DISPERSIBLE	
Benserazide hydrochloride/Levodopa	Madopar 200mg/50mg capsules (Roche Products Ltd)	Capsule
Benserazide hydrochloride/Levodopa	MADOPAR 250	
Benserazide hydrochloride/Levodopa	Madopar 50mg/12.5mg capsules (Roche Products Ltd)	Capsule
Benserazide hydrochloride/Levodopa	Madopar 50mg/12.5mg dispersible tablets (Roche Products Ltd)	Dispersible ta
Benserazide hydrochloride/Levodopa	MADOPAR 62.5 DISPERSIBLE	
Benserazide hydrochloride/Levodopa	MADOPAR CR	
Benserazide hydrochloride/Levodopa	Madopar CR capsules (Roche Products Ltd)	Modified-relea
Carbidopa monohydrate/Levodopa	Caramet 25mg/100mg CR tablets (Teva UK Ltd)	Modified-relea
Carbidopa monohydrate/Levodopa	Caramet 50mg/200mg CR tablets (Teva UK Ltd)	Modified-relea
Carbidopa	Carbidopa 10mg with levodopa 100mg tablets	Tablets
Carbidopa	Carbidopa 12.5mg with levodopa 50mg tablets	Tablets
Carbidopa	Carbidopa 25mg with levodopa 100mg modified-release tablets	Modified Rele
Carbidopa	Carbidopa 25mg with Levodopa 100mg tablets	Tablets
Carbidopa	Carbidopa 25mg with Levodopa 250mg tablets	Tablets
Carbidopa	Carbidopa 50mg with levodopa 200mg modified-release tablets	Modified Rele
Carbidopa	Carbidopa 5mg with levodopa 20mg/ml intestinal gel	Intestinal Gel
Carbidopa monohydrate/Levodopa	Co-careldopa 10mg/100mg tablets	Tablet
Carbidopa monohydrate/Levodopa	Co-careldopa 10mg/100mg tablets (A A H Pharmaceuticals Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Co-careldopa 10mg/100mg tablets (Teva UK Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Co-careldopa 12.5mg/50mg tablets	Tablet
Carbidopa monohydrate/Levodopa	Co-careldopa 25mg/100mg modified-release tablets	Modified-relea
Carbidopa monohydrate/Levodopa	Co-careldopa 25mg/100mg tablets	Tablet
Carbidopa monohydrate/Levodopa	Co-careldopa 25mg/100mg tablets (Teva UK Ltd)	Tablet
Carbidopa/levodopa	Co-careldopa 25mg/100mg/5ml oral solution	Oral Solution
Carbidopa monohydrate/Levodopa	Co-careldopa 25mg/100mg/5ml oral suspension	Oral suspensi
Levodopa/Carbidopa monohydrate	Co-careldopa 25mg/250mg tablets	Tablet
Levodopa/Carbidopa monohydrate	Co-careldopa 25mg/250mg tablets (Teva UK Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Co-careldopa 50mg/200mg modified-release tablets	Modified-relea

Carbidopa monohydrate/Levodopa	Co-careldopa 50mg/200mg modified-release tablets (A A H Pharmaceuticals)	Modified-release
Carbidopa/levodopa	Co-careldopa 5mg/20mg/1ml intestinal gel 100ml cassette	Intestinal Gel
Carbidopa monohydrate/Levodopa	Co-careldopa 6.25mg/25mg/5ml oral suspension	Oral suspension
Carbidopa/levodopa	Duodopa intestinal gel 100ml cassette (AbbVie Ltd)	Intestinal Gel
Carbidopa monohydrate/Levodopa	Half Sinemet CR 25mg/100mg tablets (Doncaster Pharmaceuticals Ltd)	Modified-release
Carbidopa monohydrate/Levodopa	Half Sinemet CR 25mg/100mg tablets (Merck Sharp & Dohme Ltd)	Modified-release
Carbidopa monohydrate/Levodopa	Half sinemet cr 25mg+100mg Tablet (Bristol-Myers Squibb Pharmaceuticals)	Modified-release
Carbidopa monohydrate/Levodopa	Lecado 25mg+100mg Modified-release tablet (Sandoz Ltd)	Modified-release
Carbidopa monohydrate/Levodopa	Lecado 50mg+200mg Modified-release tablet (Sandoz Ltd)	Modified-release
Carbidopa/levodopa	LEVODOPA 100mg/10mg CARBIDOPA	
Carbidopa/levodopa	LEVODOPA 100mg/25mg CARBIDOPA	
Carbidopa/levodopa	LEVODOPA 250mg/25mg CARBIDOPA	
Carbidopa	Levodopa with carbidopa 100mg + 10mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa 100mg + 25mg Modified-release tablet	Modified-release
Carbidopa	Levodopa with carbidopa 100mg + 25mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa 200mg + 50mg Modified-release tablet	Modified-release
Carbidopa	Levodopa with carbidopa 250mg + 25mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa 50mg + 12.5mg Tablet	Tablet
Carbidopa monohydrate/Levodopa	Sinemet 10mg/100mg tablets (Lexon (UK) Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet 10mg/100mg tablets (Merck Sharp & Dohme Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet 10mg/100mg tablets (Sigma Pharmaceuticals Plc)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet 110 Tablet (Bristol-Myers Squibb Pharmaceuticals Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet 12.5mg/50mg tablets (Merck Sharp & Dohme Ltd)	Tablet
Levodopa/Carbidopa monohydrate	Sinemet 25mg/250mg tablets (Dowelhurst Ltd)	Tablet
Levodopa/Carbidopa monohydrate	Sinemet 25mg/250mg tablets (Mawdsley-Brooks & Company Ltd)	Tablet
Levodopa/Carbidopa monohydrate	Sinemet 25mg/250mg tablets (Merck Sharp & Dohme Ltd)	Tablet
Levodopa/Carbidopa monohydrate	Sinemet 275 Tablet (Bristol-Myers Squibb Pharmaceuticals Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet 62.5 Tablet (Bristol-Myers Squibb Pharmaceuticals Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet CR 50mg/200mg tablets (Merck Sharp & Dohme Ltd)	Modified-release
Carbidopa monohydrate/Levodopa	Sinemet CR 50mg+200mg Tablet (Bristol-Myers Squibb Pharmaceuticals Ltd)	Modified-release
Carbidopa monohydrate/Levodopa	Sinemet Plus 25mg/100mg tablets (Doncaster Pharmaceuticals Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet Plus 25mg/100mg tablets (Merck Sharp & Dohme Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet Plus 25mg/100mg tablets (Waymade Healthcare Plc)	Tablet
Carbidopa monohydrate/Levodopa	Sinemet plus Tablet (Bristol-Myers Squibb Pharmaceuticals Ltd)	Tablet
Carbidopa monohydrate/Levodopa	Tilolec 200mg/50mg modified-release tablets (Tillomed Laboratories Ltd)	Modified-release
Carbidopa	Levodopa with carbidopa and entacapone 100mg + 25mg + 200mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa and entacapone 125mg + 31.25mg + 200mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa and entacapone 150mg + 37.5mg + 200mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa and entacapone 200mg + 50mg + 200mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa and entacapone 50mg + 12.5mg + 200mg Tablet	Tablet
Carbidopa	Levodopa with carbidopa and entacapone 75mg + 18.75mg + 200mg Tablet	Tablet
Levodopa/Carbidopa/Entacapone	Stalevo 100mg/25mg/200mg tablets (Lexon (UK) Ltd)	Tablet
Levodopa/Carbidopa/Entacapone	Stalevo 100mg/25mg/200mg tablets (Orion Pharma (UK) Ltd)	Tablet
Carbidopa/levodopa/entacapone	Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd)	Film Coated Tablet

Entacapone/Carbidopa/Levodopa	Stalevo 150mg/37.5mg/200mg tablets (Orion Pharma (UK) Ltd)	Tablet
Carbidopa/levodopa/entacapone	Stalevo 175mg/43.75mg/200mg tablets (Orion Pharma (UK) Ltd)	Film Coated T
Carbidopa/levodopa/entacapone	Stalevo 175mg/43.75mg/200mg tablets (Orion Pharma (UK) Ltd)	
Carbidopa/levodopa/entacapone	Stalevo 200mg/50mg/200mg tablets (Orion Pharma (UK) Ltd)	Film Coated T
Carbidopa/Entacapone/Levodopa	Stalevo 50mg/12.5mg/200mg tablets (Orion Pharma (UK) Ltd)	Tablet
Carbidopa/levodopa/entacapone	Stalevo 75mg/18.75mg/200mg tablets (Orion Pharma (UK) Ltd)	Film Coated T
Rasagiline mesilate	Azilect 1mg tablets (Teva UK Ltd)	Tablet
Rasagiline mesilate	Rasagiline 1mg tablets	Tablet
Selegiline hydrochloride	Centrapryl 5mg Tablet (Opus Pharmaceuticals Ltd)	Tablet
Selegiline hydrochloride	Eldepryl 10mg tablets (Orion Pharma (UK) Ltd)	Tablet
Selegiline hydrochloride	Eldepryl 10mg/5ml syrup (Orion Pharma (UK) Ltd)	Oral solution
Selegiline hydrochloride	Eldepryl 5mg tablets (Orion Pharma (UK) Ltd)	Tablet
Selegiline hydrochloride	Selegiline 1.25mg oral lyophilisates sugar free	Oral lyophilisa
Selegiline hydrochloride	Selegiline 10mg tablets	Tablet
Selegiline hydrochloride	Selegiline 10mg tablets (IVAX Pharmaceuticals UK Ltd)	Tablet
Selegiline hydrochloride	Selegiline 10mg tablets (Niche Generics Ltd)	Tablet
Selegiline hydrochloride	Selegiline 10mg tablets (Teva UK Ltd)	Tablet
Selegiline hydrochloride	Selegiline 10mg/5ml oral solution	Oral solution
Selegiline hydrochloride	Selegiline 5mg tablets	Tablet
Selegiline hydrochloride	Selegiline 5mg tablets (IVAX Pharmaceuticals UK Ltd)	Tablet
Selegiline hydrochloride	Selegiline 5mg tablets (Niche Generics Ltd)	Tablet
Selegiline hydrochloride	Stilline 10mg Tablet (Berk Pharmaceuticals Ltd)	Tablet
Selegiline hydrochloride	Stilline 5mg Tablet (Berk Pharmaceuticals Ltd)	Tablet
Selegiline hydrochloride	Vivapryl 10mg Tablet (Viatris Pharmaceuticals Ltd)	Tablet
Selegiline hydrochloride	Vivapryl 5mg Tablet (Viatris Pharmaceuticals Ltd)	Tablet
Selegiline hydrochloride	Zelapar 1.25mg oral lyophilisates (Teva UK Ltd)	Oral lyophilisa
Apomorphine hydrochloride	Apomorphine 2mg sublingual tablets sugar free	Sublingual tab
Apomorphine hydrochloride	Apomorphine 3mg sublingual tablets sugar free	Sublingual tab
Orphenadrine Hydrochloride	Norflex 100mg Tablet (3M Health Care Ltd)	Tablet
Orphenadrine Hydrochloride	Norflex 30mg/ml Injection (3M Health Care Ltd)	Injection
Orphenadrine Hydrochloride	Orphenadrine citrate 30mg/ml Injection	Injection
Orphenadrine Hydrochloride	ORPHENADRINE CITRATE S/R 100 MG TAB	
Orphenadrine Hydrochloride	PARACETAMOL/ORPHENADRINE CITRATE TAB	
Apomorphine hydrochloride	Uprima 2mg sublingual tablets (Abbott Laboratories Ltd)	Sublingual tab
Apomorphine hydrochloride	Uprima 3mg sublingual tablets (Abbott Laboratories Ltd)	Sublingual tab

agonist (non-ergot), COMT inhibitor, decarboxylase inhibitor, MAO B inhibitor, Amantadine, Apomorphine,

bnfchapter	br	matching_terms
Dopaminergic Drugs Used	04	%Amantadine%, %MANTADINE%
Dopaminergic Drugs Used	04	%Amantadine%, %MANTADINE%
Influenza	05	%Amantadine%, %LYSOVIR%
Dopaminergic Drugs Used	04	%Amantadine%, %SYMMETREL%
Dopaminergic Drugs Used	04	%Amantadine%, %SYMMETREL%
Drugs Used In Parkinsonis	04	%Benzatropine%
Antimuscarinic Drugs Used	04	%Benzatropine%
Antimuscarinic Drugs Used	04	%Benzatropine%, %COGENTIN%
Drugs Used In Parkinsonis	04	%Benzatropine%, %COGENTIN%
Antimuscarinic Drugs Used	04	%Benzatropine%, %COGENTIN%
Unknown	00	%AKINETON%, %Biperiden%
Antimuscarinic Drugs Used	04	%AKINETON%, %Biperiden%
Antimuscarinic Drugs Used	04	%Biperiden%
Antimuscarinic Drugs Used	04	%Biperiden%
Antimuscarinic Drugs Used	04	%methixene%
Antimuscarinic Drugs Used	04	%TREMONIL%, %methixene%
Antimuscarinic Drugs Used	04	%BIORPHEN%, %Orphenadrine%
Unknown	00	%DISIPAL%
Unknown	00	%DISIPAL%
Antimuscarinic Drugs Used	04	%DISIPAL%, %Orphenadrine%
Antimuscarinic Drugs Used	04	%Orphenadrine%
Antimuscarinic Drugs Used	04	%Orphenadrine%
Antimuscarinic Drugs Used	04	%Orphenadrine%
Antimuscarinic Drugs Used	04	%Orphenadrine%
Antimuscarinic Drugs Used	04	%Orphenadrine%
Unknown	00	%Orphenadrine%
Unknown	00	%Orphenadrine%
Unknown	00	%Orphenadrine%
Antimuscarinic Drugs Used	04	%ARPICOLIN%, %Procyclidin%
Antimuscarinic Drugs Used	04	%ARPICOLIN%, %Procyclidin%
Antimuscarinic Drugs Used	04	%KEMADRIN%, %Procyclidin%
Antimuscarinic Drugs Used	04	%KEMADRIN%, %Procyclidin%
Antimuscarinic Drugs Used	04	%KEMADRIN%, %Procyclidin%
Antimuscarinic Drugs Used	04	%KEMADRIN%, %Procyclidin%
Antimuscarinic Drugs Used	04	%KEMADRIN%, %Procyclidin%
Antimuscarinic Drugs Used	04	%MUSCINIL%, %Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%
Unknown	00	%Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%

Antimuscarinic Drugs Used	04	%Procyclidin%
Antimuscarinic Drugs Used	04	%Procyclidin%
Antimuscarinic Drugs Used	04	%ARTANE%, %trihexyphenidyl%
Antimuscarinic Drugs Used	04	%ARTANE%, %trihexyphenidyl%
Unknown	00	%ARTANE%
Unknown	00	%ARTANE%
Antimuscarinic Drugs Used	04	%ARTANE%, %trihexyphenidyl%
Antimuscarinic Drugs Used	04	%BROFLEX%, %trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Antimuscarinic Drugs Used	04	%trihexyphenidyl%
Other Dopaminergic Drugs	04	%APO-GO%, %Apomorphine%
Dopaminergic Drugs Used	04	%APO-GO%, %Apomorphine%
Dopaminergic Drugs Used	04	%APO-GO%, %Apomorphine%
Dopaminergic Drugs Used	04	%APO-GO%, %Apomorphine%
Dopaminergic Drugs Used	04	%APO-GO%, %Apomorphine%
Dopaminergic Drugs Used	04	%APO-GO%, %Apomorphine%
Other Dopaminergic Drugs	04	%Apomorphine%
Dopaminergic Drugs Used	04	%Apomorphine%
Dopaminergic Drugs Used	04	%Apomorphine%
Dopaminergic Drugs Used	04	%Apomorphine%
Dopaminergic Drugs Used	04	%Apomorphine%
Dopaminergic Drugs Used	04	%Apomorphine%
Other Dopaminergic Drugs	04	%Apomorphine%, %BRITAJECT%
Dopaminergic Drugs Used	04	%COMTESS%, %Entacapone%
Dopaminergic Drugs Used	04	%Entacapone%
Dopaminergic Drugs Used	04	%TASMAR%, %Tolcapone%
Other Dopaminergic Drugs	04	%TASMAR%, %Tolcapone%
Other Dopaminergic Drugs	04	%TASMAR%, %Tolcapone%
Dopaminergic Drugs Used	04	%Tolcapone%
Unknown	00	%Tolcapone%
Other Dopaminergic Drugs	04	%Tolcapone%
Unknown	00	%benserazide%
Unknown	00	%benserazide%

Unknown	00	%carbidopa%
Dopaminergic Drugs Used	04	%Bromocriptine%
Dopaminergic Drugs Used	04	%Bromocriptine%
Other Dopaminergic Drugs	04	%Bromocriptine%
Other Dopaminergic Drugs	04	%Bromocriptine%
Dopaminergic Drugs Used	04	%Bromocriptine%
Dopaminergic Drugs Used	04	%Bromocriptine%
Dopaminergic Drugs Used	04	%Bromocriptine%
Dopaminergic Drugs Used	04	%Bromocriptine%
Dopaminergic Drugs Used	04	%Bromocriptine%
Other Dopaminergic Drugs	04	%Bromocriptine%, %PARLODEL%
Other Dopaminergic Drugs	04	%Bromocriptine%, %PARLODEL%
Bromocriptine And Other D	06	%Bromocriptine%, %PARLODEL%
Other Dopaminergic Drugs	04	%Bromocriptine%, %PARLODEL%
Bromocriptine And Other D	06	%Bromocriptine%, %PARLODEL%
Other Dopaminergic Drugs	04	%Bromocriptine%, %PARLODEL%
Dopaminergic Drugs Used	04	%Bromocriptine%, %PARLODEL%
Dopaminergic Drugs Used	04	%CABASER%, %Cabergoline%
Dopaminergic Drugs Used	04	%CABASER%, %Cabergoline%
Dopaminergic Drugs Used	04	%CABASER%, %Cabergoline%
Dopaminergic Drugs Used	04	%Cabergoline%
Dopaminergic Drugs Used	04	%Cabergoline%
Dopaminergic Drugs Used	04	%Cabergoline%
Bromocriptine And Other D	06	%Cabergoline%
Bromocriptine And Other D	06	%Cabergoline%, %DOSTINEX%
Unknown	00	%Lisuride%
Other Dopaminergic Drugs	04	%Lisuride%, %REVANIL%
Dopaminergic Drugs Used	04	%CELANCE%, %Pergolide%
Dopaminergic Drugs Used	04	%CELANCE%, %Pergolide%
Dopaminergic Drugs Used	04	%CELANCE%, %Pergolide%
Unknown	00	%CELANCE%
Unknown	00	%CELANCE%
Dopaminergic Drugs Used	04	%Pergolide%
Dopaminergic Drugs Used	04	%Pergolide%
Unknown	00	%Pergolide%
Dopaminergic Drugs Used	04	%Pergolide%
Dopaminergic Drugs Used	04	%Pergolide%
Other Dopaminergic Drugs	04	%Pergolide%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%NELIPRAX%, %Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%

Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%MIRAPEXIN%, %Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%Pramipexole%
Dopaminergic Drugs Used	04	%ADARTREL%, %Ropinirole%
Dopaminergic Drugs Used	04	%ADARTREL%, %Ropinirole%
Dopaminergic Drugs Used	04	%ADARTREL%, %Ropinirole%
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%
Dopaminergic Drugs Used	04	%REQUIP%
Dopaminergic Drugs Used	04	%REQUIP%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Other Dopaminergic Drugs	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Other Dopaminergic Drugs	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ralnea XL %, %Ropinirole%
Dopaminergic Drugs Used	04	%Ralnea XL %
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%

Dopaminergic Drugs Used	04	%REQUIP%
Dopaminergic Drugs Used	04	%REQUIP%, %Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%Ropinirole%
Dopaminergic Drugs Used	04	%NEUPRO%, %Rotigotine%
Dopaminergic Drugs Used	04	%NEUPRO%, %Rotigotine%
Dopaminergic Drugs Used	04	%NEUPRO%, %Rotigotine%
Dopaminergic Drugs Used	04	%NEUPRO%, %Rotigotine%
Dopaminergic Drugs Used	04	%NEUPRO%, %Rotigotine%
Dopaminergic Drugs Used	04	%NEUPRO%, %Rotigotine%
Dopaminergic Drugs Used	04	%NEUPRO%
Dopaminergic Drugs Used	04	%Rotigotine%
Dopaminergic Drugs Used	04	%Rotigotine%
Other Dopaminergic Drugs	04	%Rotigotine%
Dopaminergic Drugs Used	04	%Rotigotine%
Dopaminergic Drugs Used	04	%Rotigotine%
Dopaminergic Drugs Used	04	%Rotigotine%
Dopaminergic Drugs Used	04	%Rotigotine%
Dopaminergic Drugs Used	04	%BROCADOPA%, %levodopa%
Dopaminergic Drugs Used	04	%BROCADOPA%, %levodopa%
Dopaminergic Drugs Used	04	%BROCADOPA%, %levodopa%
Dopaminergic Drugs Used	04	%LARODOPA%, %levodopa%
Unknown	00	%levodopa%
Dopaminergic Drugs Used	04	%levodopa%
Dopaminergic Drugs Used	04	%levodopa%
Unknown	00	%levodopa%
Unknown	00	%levodopa%
Dopaminergic Drugs Used	04	%levodopa%
Unknown	00	%levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%CO-BENELDOPA%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%CO-BENELDOPA%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%CO-BENELDOPA%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%CO-BENELDOPA%, %benserazide%, %levodopa%

Dopaminergic Drugs Used	04	%CO-BENELDOPA%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%CO-BENELDOPA%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%CO-BENELDOPA%, %benserazide%, %levodopa%
Unknown	00	%CO-BENELDOPA%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%benserazide%, %levodopa%
Unknown	00	%benserazide%, %levodopa%
Unknown	00	%benserazide%, %levodopa%
Unknown	00	%MADOPAR%
Dopaminergic Drugs Used	04	%MADOPAR%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%MADOPAR%, %benserazide%, %levodopa%
Unknown	00	%MADOPAR%
Dopaminergic Drugs Used	04	%MADOPAR%, %benserazide%, %levodopa%
Unknown	00	%MADOPAR%
Dopaminergic Drugs Used	04	%MADOPAR%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%MADOPAR%, %benserazide%, %levodopa%
Unknown	00	%MADOPAR%
Unknown	00	%MADOPAR%
Dopaminergic Drugs Used	04	%MADOPAR%, %benserazide%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%CO-CARELDOPA%, %carbidopa%, %levodopa%

Dopaminergic Drugs Used	04	%Entacapone%, %STALEVO%, %carbidopa%, %levodopa%
Unknown	00	%Entacapone%, %STALEVO%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%STALEVO%
Dopaminergic Drugs Used	04	%Entacapone%, %STALEVO%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%Entacapone%, %STALEVO%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%Entacapone%, %STALEVO%, %carbidopa%, %levodopa%
Dopaminergic Drugs Used	04	%AZILECT%, %rasagiline%
Dopaminergic Drugs Used	04	%rasagiline%
Other Dopaminergic Drugs	04	%CENTRAPRYL%, %selegiline%
Dopaminergic Drugs Used	04	%ELDEPRYL%, %selegiline%
Dopaminergic Drugs Used	04	%ELDEPRYL%, %selegiline%
Dopaminergic Drugs Used	04	%ELDEPRYL%, %selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Dopaminergic Drugs Used	04	%selegiline%
Other Dopaminergic Drugs	04	%STILLINE%, %selegiline%
Other Dopaminergic Drugs	04	%STILLINE%, %selegiline%
Other Dopaminergic Drugs	04	%VIVAPRYL%, %selegiline%
Other Dopaminergic Drugs	04	%VIVAPRYL%, %selegiline%
Dopaminergic Drugs Used	04	%ZELAPAR%, %selegiline%
Dopaminergic Drugs Used	04	%Apomorphine%
Dopaminergic Drugs Used	04	%Apomorphine%
Skeletal Muscle Relaxants	10	%NORFLEX%, %Orphenadrine%
Skeletal Muscle Relaxants	10	%NORFLEX%, %Orphenadrine%
Skeletal Muscle Relaxants	10	%Orphenadrine%
Unknown	00	%Orphenadrine%
Unknown	00	%Orphenadrine%
Dopaminergic Drugs Used	04	%Apomorphine%, %UPRIMA%
Dopaminergic Drugs Used	04	%Apomorphine%, %UPRIMA%

. antimuscarinic

review	classify	comments	medcode	read_code	clinical_pat
Y	Fibromyalgia		4657	N239.00	8957
Y	Fibromyalgia		717	N248.00	29085
Y	Periodic limb movement disorder	unspecific	5545	F132.00	2361
Y	Periodic limb movement disorder	unspecific	19015	F132300	2504
Y	Periodic limb movement disorder	unspecific	28281	F132y00	84
Y	Periodic limb movement disorder	unspecific	37897	F132z00	189
Y	Restless legs syndrome		6275	F13z200	50398
Y	Sexual dysfunction		94821	1ABB.00	1138
Y	Sexual dysfunction		94343	1ABC.00	970
Y	Sexual dysfunction		94316	1ABG.00	505
Y	Sexual dysfunction		102274	1D1B.00	28480
Y	Sexual dysfunction		15649	E227.00	7142
Y	Sexual dysfunction		6362	E227.11	31223
Y	Sexual dysfunction		23534	E227000	310
Y	Sexual dysfunction		2259	E227100	9952
Y	Sexual dysfunction		809	E227200	275
Y	Sexual dysfunction		710	E227300	101805
Y	Sexual dysfunction		3838	E227311	199020
Y	Sexual dysfunction		19082	E227400	267
Y	Sexual dysfunction		27816	E227500	569
Y	Sexual dysfunction		20133	E227z00	578
Y	Sexual dysfunction		9485	Eu52.00	1808
Y	Sexual dysfunction		28283	Eu52000	1040
Y	Sexual dysfunction		48175	Eu52011	8
Y	Sexual dysfunction		56603	Eu52012	20
Y	Sexual dysfunction		21122	Eu52013	1598
Y	Sexual dysfunction		42056	Eu52100	24
Y	Sexual dysfunction		24483	Eu52111	125
Y	Sexual dysfunction		33494	Eu52200	165
Y	Sexual dysfunction		60716	Eu52211	29
Y	Sexual dysfunction		12066	Eu52212	3563
Y	Sexual dysfunction		17639	Eu52213	867
Y	Sexual dysfunction		18332	Eu52300	451
Y	Sexual dysfunction		34336	Eu52311	35
Y	Sexual dysfunction		10550	Eu52312	334
Y	Sexual dysfunction		44683	Eu52y00	15
Y	Sexual dysfunction		48953	Eu52z00	18
Y	Sexual dysfunction		17894	K27y100	1206
Y	Sexual dysfunction		16060	ZV41700	1364
N			365	15D..00	93138
N			17714	1AB..00	7006
N			22377	1AB1.00	1405
N			19498	1AB1.11	902

N			30239	1AB2.00	953
N			85653	1AB3.00	11
N			52618	1AB4.00	31
N			67589	1AB5.00	29
N			94064	1AB6.00	5
N			69910	1AB7.00	12
N			29962	1AB8.00	678
N			71243	1AB9.00	60
N			89467	1ABA.00	49
N			94815	1ABD.00	150
N			94961	1ABE.00	57
N			98122	1ABF.00	9
N			102869	1ABH.00	15
N			105452	1ABH.11	4
N			102325	1ABJ.00	41560
N			103659	1ABK.00	191
N			105754	1ABL.00	11
N			25196	1ABZ.00	1990
N			27406	1ABZ.11	99
N			4485	E227600	11196
N			21253	E227700	204
N			24448	E227z11	340
N			22599	Eu52400	372
N			19745	Eu52500	33
N			30442	Eu52511	95
N			21089	Eu52600	47
N			37089	Eu52611	56
N			26411	Eu52700	128
N			50326	Eu52800	20
N			52420	F132000	14
N			37644	F132100	77
N			63826	F132111	2
N			45602	F132200	62
N			97376	F132y11	1
N			8487	F132z12	1319
N			18374	N239.11	898

Reviewed by PPD for RLS, PLMD, sexual dysfunction, fibromyalgia as the co

desc	matching_terms
Fibromyalgia	% N239.%
Fibromyalgia	% N248.%
Myoclonus	% F132%, % F132.00%
Myoclonic jerks	% F132%, % F1323%
Other specified myoclonus	% F132%, % F132y%
Myoclonus NOS	% F132%, % F132z%
Restless legs syndrome	% F13z2%
Cannot get an erection	% 1AB%
Cannot sustain an erection	% 1AB%
Sexual intercourse difficult	% 1AB%
C/O erectile dysfunction	% 1D1B%
Psychosexual dysfunction	% E227%
Lack of libido	% E227%
Unspecified psychosexual dysfunction	% E227%
Inhibited sexual desire	% E227%
Frigidity	% E227%
Impotence	% E227%
Erectile dysfunction	% E227%
Inhibited female orgasm	% E227%
Inhibited male orgasm	% E227%
Psychosexual dysfunction NOS	% E227%
[X]Sex dysfunction not caused by organic disorder or	% Eu52%
[X]Lack or loss of sexual desire	% Eu52%
[X]Frigidity	% Eu52%
[X]Hypoactive sexual desire disorder	% Eu52%
[X] Lack of libido	% Eu52%
[X]Sexual aversion and lack of sexual enjoyment	% Eu52%
[X]Anhedonia sexual	% Eu52%
[X]Failure of genital response	% Eu52%
[X]Female sexual arousal disorder	% Eu52%
[X]Male erectile disorder	% Eu52%
[X]Psychogenic impotence	% Eu52%
[X]Orgasmic dysfunction	% Eu52%
[X]Inhibited orgasm	% Eu52%
[X]Psychogenic anorgasmy	% Eu52%
[X]Oth sex dysfunction, not caused by organic disorder	% Eu52%
[X]Unspec sex dysfunction not caused by organic disorder	% Eu52%
Impotence of organic origin	% K27y1%
[V]Problem with sexual function	% ZV417%
Dyspareunia	% 15D%
Sexual activity	% 1AB%
Never been sexually active	% 1AB%
Virgin	% 1AB%

Currently not sexually active	% 1AB%
Sexual activity - daily	% 1AB%
Sexual activity - 2-3x / week	% 1AB%
Sexual activity - weekly	% 1AB%
Sexual activity - 2-3x / month	% 1AB%
Sexual activity - monthly	% 1AB%
Improved sex life	% 1AB%
Sexual activity - oral sex	% 1AB%
Sexual activity - anal sex	% 1AB%
Painful erection	% 1AB%
Abnormal angle of erection	% 1AB%
Penetration impossible	% 1AB%
Vaginal penetrative sexual intercourse	% 1AB%
Vaginal penetration	% 1AB%
Does not complain of erectile dysfunction	% 1AB%
Sexually active	% 1AB%
Homosexual activity	% 1AB%
Sexual activity NOS	% 1AB%
Wet dreams	% 1AB%
Premature ejaculation	% E227%
Psychogenic dyspareunia	% E227%
Fear of ejaculation	% E227%
[X]Premature ejaculation	% Eu52%
[X]Nonorganic vaginismus	% Eu52%
[X]Psychogenic vaginismus	% Eu52%
[X]Nonorganic dyspareunia	% Eu52%
[X]Psychogenic dyspareunia	% Eu52%
[X]Excessive sexual drive	% Eu52%
[X]Erotomania	% Eu52%
Familial essential myoclonus	% F132%
Progressive myoclonic epilepsy	% F132%
Unverricht - Lundborg disease	% F132%
Myoclonic encephalopathy	% F132%
Paramyoclonus multiplex	% F132%, % F132y%
Myoclonic seizure	% F132%, % F132z%
Myofascial pain syndrome	% N239.%

nditions for off-label use of the prolonged release formulation of ropinirole

review	comments	medcode	read_code	clinical_pats	desc
Y		9509	Eu02300	1124	[X]Dementia in Parkinson's disease
Y		96860	F11x900	20	Cerebral degeneration in Parkinson's disea
Y		4321	F12..00	35126	Parkinson's disease
Y		1691	F120.00	15273	Paralysis agitans
Y		14912	F12z.00	2740	Parkinson's disease NOS

Reviewed by PPD [redacted] for Primary Parkinson's Disease

matching_terms
% Eu023%
% F11x9%
% F12..%
% F120%
% F12z%

review	omment	prodcode	drugsubstance	productname
Y		3490	Amitriptyline hydrochloride/Pe	Amitriptyline 10mg / Perphenazine 2mg tablets
Y		595	Amitriptyline hydrochloride/Pe	Amitriptyline 25mg / Perphenazine 2mg tablets
Y		21744	Benperidol	Anquil 250microgram Tablet (Concord Pharmaceuticals Ltd)
Y		47365	Benperidol	Anquil 250microgram tablets (Archimedes Pharma UK Ltd)
Y		35442	Cinnarizine/Dimenhydrinate	Arlevert tablets (Hampton Pharmaceuticals Ltd)
Y		12976	Metoclopramide hydrochloride	Aspirin 900mg / Metoclopramide 10mg oral powder sachets
Y		2540	Benperidol	Benperidol 250microgram tablets
Y		31796	Benperidol	Benquil 250microgram tablets (Concord Pharmaceuticals L
Y		500	Prochlorperazine maleate	Buccastem 3mg Tablet (Reckitt Benckiser Healthcare (UK)
Y		42882	Prochlorperazine maleate	Buccastem 3mg tablets (Alliance Pharmaceuticals Ltd)
Y		5971	Prochlorperazine maleate	Buccastem M 3mg tablets (Alliance Pharmaceuticals Ltd)
Y		28862	Chlorpromazine hydrochloride	Chloractil 100mg Tablet (DDSA Pharmaceuticals Ltd)
Y		17227	Chlorpromazine hydrochloride	Chloractil 25mg Tablet (DDSA Pharmaceuticals Ltd)
Y		25653	Chlorpromazine hydrochloride	Chloractil 50mg Tablet (DDSA Pharmaceuticals Ltd)
Y		8506	Chlorpromazine Hydrochlorid	Chlorpromazine 100mg suppository
Y		2154	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets
Y		46960	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets (IVAX Pharmaceuticals UK I
Y		34736	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets (Teva UK Ltd)
Y		58492	Chlorpromazine hydrochloride	Chlorpromazine 100mg tablets (Waymade Healthcare Plc)
Y		8519	Chlorpromazine hydrochloride	Chlorpromazine 100mg/5ml oral solution
Y		45281	Chlorpromazine hydrochloride	Chlorpromazine 100mg/5ml oral solution (Rosemont Pharm
Y		9965	Chlorpromazine embonate	Chlorpromazine 100mg/5ml oral suspension sugar free
Y		37705	Chlorpromazine Hydrochlorid	Chlorpromazine 100mg/5ml suspension
Y		2474	Chlorpromazine hydrochloride	Chlorpromazine 10mg tablets
Y		8045		CHLORPROMAZINE 200 MG TAB
Y		13479		CHLORPROMAZINE 25 MG SUP
Y		588	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets
Y		31175	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (A A H Pharmaceuticals Ltd)
Y		34693	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (Genus Pharmaceuticals Ltd)
Y		31184	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (IVAX Pharmaceuticals UK Lt
Y		34668	Chlorpromazine hydrochloride	Chlorpromazine 25mg tablets (Teva UK Ltd)
Y		22606	Chlorpromazine hydrochloride	Chlorpromazine 25mg/1ml solution for injection ampoules
Y		3952	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml oral solution
Y		44186	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml oral solution (A A H Pharmaceut
Y		37871	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml Oral solution (Rosemont Pharm
Y		9190	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml oral solution sugar free
Y		56862	Chlorpromazine hydrochloride	Chlorpromazine 25mg/5ml syrup (Rosemont Pharmaceutica
Y		8311	Chlorpromazine Hydrochlorid	Chlorpromazine 25mg/ml injection
Y		41645	Chlorpromazine Hydrochlorid	Chlorpromazine 25mg/ml Injection (Antigen Pharmaceutica
Y		247		CHLORPROMAZINE 50 MG INJ
Y		3348	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets
Y		31171	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets (A A H Pharmaceuticals Ltd)
Y		34630	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets (Genus Pharmaceuticals Ltd)

Y		31172	Chlorpromazine hydrochloride	Chlorpromazine 50mg tablets (Teva UK Ltd)
Y		35929	Chlorpromazine hydrochloride	Chlorpromazine 50mg/2ml solution for injection ampoules
Y		4434	Chlorpromazine hydrochloride	Chlorpromazine 50mg/5ml oral solution
Y		17221		CHLORPROMAZINE HCl 10 MG INJ
Y		12544		CHLORPROMAZINE HCl 100 MG MIX
Y		30346		CHLORPROMAZINE HCl 100 MG TAB
Y		12137		CHLORPROMAZINE HCl 25 MG TAB
Y		19033		CHLORPROMAZINE HCl 50 MG INJ
Y		10446		CHLORPROMAZINE HCl 50 MG TAB
Y		31747		CHLORPROMAZINE HYDROCHLORIDE
Y		30111	Chlorprothixene	Chlorprothixene 50mg tablets
Y		7768	Cinnarizine	Cinaziere 15mg tablets (Ashbourne Pharmaceuticals Ltd)
Y		2937		CINNARIZINE 10 MG TAB
Y		845	Cinnarizine	Cinnarizine 15mg tablets
Y		34484	Cinnarizine	Cinnarizine 15mg tablets (A A H Pharmaceuticals Ltd)
Y		34839	Cinnarizine	Cinnarizine 15mg tablets (Actavis UK Ltd)
Y		48215	Cinnarizine	Cinnarizine 15mg tablets (Generics (UK) Ltd)
Y		23974	Cinnarizine	Cinnarizine 15mg tablets (IVAX Pharmaceuticals UK Ltd)
Y		35351	Cinnarizine/Dimenhydrinate	Cinnarizine 20mg / Dimenhydrinate 40mg tablets
Y		55657	Cinnarizine	Cinnarizine 25mg tablets
Y		2098	Cinnarizine	Cinnarizine 75mg capsules
Y		1319	Zuclopenthixol dihydrochloride	Clopixol 10mg tablets (Lundbeck Ltd)
Y		22049	Zuclopenthixol decanoate	Clopixol 200mg/1ml solution for injection ampoules (Lundbeck Ltd)
Y		3774	Zuclopenthixol Decanoate	Clopixol 200mg/ml Oily injection (Lundbeck Ltd)
Y		9347	Zuclopenthixol dihydrochloride	Clopixol 25mg tablets (Lundbeck Ltd)
Y		13368	Zuclopenthixol dihydrochloride	Clopixol 2mg tablets (Lundbeck Ltd)
Y		31538	Zuclopenthixol acetate	Clopixol Acuphase 100mg/2ml solution for injection ampoules (Lundbeck Ltd)
Y		36101	Zuclopenthixol acetate	Clopixol Acuphase 50mg/1ml solution for injection ampoules (Lundbeck Ltd)
Y		5762	Zuclopenthixol Acetate	Clopixol acuphase 50mg/ml Oily injection (Lundbeck Ltd)
Y		12073	Zuclopenthixol decanoate	Clopixol Conc 500mg/1ml solution for injection ampoules (Lundbeck Ltd)
Y		19752		DEPIXOL (10ML VIAL)
Y		19283	Flupentixol decanoate	Depixol 20mg/1ml solution for injection ampoules (Lundbeck Ltd)
Y		2136	Flupentixol Decanoate	Depixol 20mg/ml Injection (Lundbeck Ltd)
Y		5712	Flupentixol dihydrochloride	Depixol 3mg tablets (Lundbeck Ltd)
Y		2156	Flupentixol decanoate	Depixol 40mg/2ml solution for injection ampoules (Lundbeck Ltd)
Y		14889	Flupentixol decanoate	Depixol Conc 100mg/1ml solution for injection ampoules (Lundbeck Ltd)
Y		2155	Flupentixol Decanoate	Depixol -conc 100mg/ml Injection (Lundbeck Ltd)
Y		18197	Flupentixol decanoate	Depixol Conc 50mg/0.5ml solution for injection ampoules (Lundbeck Ltd)
Y		14130	Flupentixol decanoate	Depixol Low Volume 200mg/1ml solution for injection ampoules (Lundbeck Ltd)
Y		25015		DEPIXOL-CONC (1ML AMP)
Y		40326	Dimenhydrinate	Dimenhydrinate with cinnarizine 40mg+20mg tablets
Y		28679	Haloperidol	Dozic 2mg/ml Oral solution (Rosemont Pharmaceuticals Ltd)
Y		6134	Haloperidol	Dozic 5mg/5ml oral solution (Rosemont Pharmaceuticals Ltd)
Y		15171	Droperidol	Droleptan 10mg Tablet (Janssen-Cilag Ltd)

Y		13369	Droperidol	Droleptan 1mg/ml Oral solution (Janssen-Cilag Ltd)
Y		21125	Droperidol	Droleptan 5mg/ml Injection (Janssen-Cilag Ltd)
Y		25759		DROPERIDOL
Y		3773	Droperidol	Droperidol 10mg tablets
Y		15128	Droperidol	Droperidol 1mg/ml liquid
Y		40928	Droperidol	Droperidol 2.5mg/1ml solution for injection ampoules
Y		13341		DROPERIDOL 5 MG/5ML ELI
Y		57571		Droperidol 5mg/5ml oral solution
Y		22609	Droperidol	Droperidol 5mg/ml injection
Y		53634	Droperidol	Droperidol capsules
Y		42229	Droperidol	Droperidol oral liquid
Y		24457	Fentanyl Citrate	Fentanyl with droperidol 500microgramwith2.5mg/ml Injecti
Y		840	Perphenazine	Fentazin 2mg tablets (Mercury Pharma Group Ltd)
Y		7919	Perphenazine	Fentazin 4mg tablets (Mercury Pharma Group Ltd)
Y		228	Perphenazine	Fentazin 5mg/ml Injection (Goldshield Pharmaceuticals Ltd)
Y		24282		FENTAZIN 8 MG TAB
Y		27565		FLUANXOL
Y		3951	Flupentixol dihydrochloride	Fluanxol 1mg tablets (Lundbeck Ltd)
Y		50592	Flupentixol dihydrochloride	Fluanxol 1mg tablets (Sigma Pharmaceuticals Plc)
Y		3953	Flupentixol dihydrochloride	Fluanxol 500microgram tablets (Lundbeck Ltd)
Y		18175	Flupentixol decanoate	Flupentixol 100mg/1ml solution for injection ampoules
Y		600	Flupentixol dihydrochloride	Flupentixol 1mg tablets
Y		14839	Flupentixol decanoate	Flupentixol 200mg/1ml solution for injection ampoules
Y		14966	Flupentixol decanoate	Flupentixol 20mg/1ml solution for injection ampoules
Y		5707	Flupentixol dihydrochloride	Flupentixol 3mg tablets
Y		2276	Flupentixol decanoate	Flupentixol 40mg/2ml solution for injection ampoules
Y		2275	Flupentixol dihydrochloride	Flupentixol 500microgram tablets
Y		18155	Flupentixol decanoate	Flupentixol 50mg/0.5ml solution for injection ampoules
Y		8712	Flupentixol Decanoate	Flupentixol decanoate 100mg/ml Injection
Y		1733	Flupentixol Decanoate	Flupentixol decanoate 20mg/ml Injection
Y		55620	Flupentixol Dihydrochloride	Flupentixol Liquid
Y		5212	Fluphenazine hydrochloride	Fluphenazine 1mg tablets
Y		8377	Fluphenazine hydrochloride	Fluphenazine 2.5mg tablets
Y		5298	Fluphenazine hydrochloride	Fluphenazine 5mg tablets
Y		35176	Fluphenazine decanoate	Fluphenazine decanoate 100mg/1ml solution for injection a
Y		10514	Fluphenazine Decanoate	Fluphenazine decanoate 100mg/ml Injection
Y		16229		FLUPHENAZINE DECANOATE 12.5 MG INJ
Y		35530	Fluphenazine decanoate	Fluphenazine decanoate 12.5mg/0.5ml solution for injectior
Y		35065	Fluphenazine decanoate	Fluphenazine decanoate 25mg/1ml solution for injection arr
Y		41970	Fluphenazine decanoate	Fluphenazine decanoate 25mg/1ml solution for injection arr
Y		9022	Fluphenazine Decanoate	Fluphenazine decanoate 25mg/ml Injection
Y		41971	Fluphenazine decanoate	Fluphenazine decanoate 25mg/ml Injection (Antigen Pharm
Y		35391	Fluphenazine decanoate	Fluphenazine decanoate 50mg/0.5ml solution for injection e
Y		35723	Fluphenazine decanoate	Fluphenazine decanoate 50mg/2ml solution for injection arr

Y		17190	Fluphenazine Enantate	Fluphenazine enanthate 25mg/ml Injection
Y		24107		FLUPHENAZINE HCl ELI
Y		20571	Nortriptyline Hydrochloride	Fluphenazine with nortriptyline 500microgramswith10mg Ta
Y		26526		FLUSPIRILENE 2.00mg/ml
Y		10827	Fluspirilene	Fluspirilene 2mg/ml Injection
Y		21863	Metoclopramide hydrochloride	Gastrese la 15mg Modified-release tablet (Manufacturer un
Y		23379		GASTROBID CONTINUS
Y		8273	Metoclopramide hydrochloride	Gastrobid Continus 15mg tablets (Napp Pharmaceuticals Lt
Y		17496	Metoclopramide hydrochloride	Gastroflux 10mg tablets (Ashbourne Pharmaceuticals Ltd)
Y		17946	Metoclopramide Hydrochlorid	Gastromax 30mg Modified-release capsule (Pfizer Ltd)
Y		30351		HALDOL 1.5 MG TAB
Y		23678	Haloperidol	Haldol 10mg tablets (Janssen-Cilag Ltd)
Y		24494	Haloperidol	Haldol 10mg/ml Liquid (Janssen-Cilag Ltd)
Y		15645		HALDOL 20 MG TAB
Y		12921	Haloperidol	Haldol 2mg/ml oral solution (Janssen-Cilag Ltd)
Y		22660	Haloperidol	Haldol 5mg tablets (Janssen-Cilag Ltd)
Y		38540	Haloperidol	Haldol 5mg/1ml solution for injection ampoules (Janssen-Ci
Y		6523	Haloperidol	Haldol 5mg/ml Injection (Janssen-Cilag Ltd)
Y		12386	Haloperidol decanoate	Haldol decanoate 100mg/1ml solution for injection ampoule
Y		2094	Haloperidol decanoate	Haldol decanoate 50mg/1ml solution for injection ampoules
Y		329	Haloperidol	Haloperidol 1.5mg tablets
Y		34339	Haloperidol	Haloperidol 1.5mg tablets (A A H Pharmaceuticals Ltd)
Y		32838	Haloperidol	Haloperidol 1.5mg tablets (IVAX Pharmaceuticals UK Ltd)
Y		43520	Haloperidol	Haloperidol 1.5mg tablets (Teva UK Ltd)
Y		52050		Haloperidol 1.5mg/5ml oral suspension
Y		17379	Haloperidol	Haloperidol 1.5mg/5ml sugar free Oral solution
Y		25063		HALOPERIDOL 100mg/ml
Y		12050		HALOPERIDOL 100MG/ML 100 MG INJ
Y		475	Haloperidol	Haloperidol 10mg tablets
Y		45810	Haloperidol	Haloperidol 10mg/5ml oral solution sugar free
Y		47808	Haloperidol	Haloperidol 10mg/5ml oral solution sugar free (A A H Pharm
Y		10435	Haloperidol	Haloperidol 10mg/ml Oral solution
Y		47149	Haloperidol	Haloperidol 1mg/5ml oral solution
Y		47013	Haloperidol	Haloperidol 1mg/5ml oral suspension
Y		5192	Haloperidol	Haloperidol 1mg/5ml sugar free Oral solution
Y		41546	Haloperidol	Haloperidol 1mg/ml Liquid (Hillcross Pharmaceuticals Ltd)
Y		34039	Haloperidol	Haloperidol 1mg/ml Liquid (Rosemont Pharmaceuticals Ltd)
Y		2620	Haloperidol	Haloperidol 1mg/ml Oral solution
Y		9975	Haloperidol	Haloperidol 1mg/ml sugar free Oral solution
Y		12387	Haloperidol	Haloperidol 20mg tablets
Y		8129	Haloperidol	Haloperidol 20mg/2ml solution for injection ampoules
Y		36771	Haloperidol	Haloperidol 250micrograms/5ml oral suspension
Y		49207	Haloperidol	Haloperidol 2mg/5ml oral solution
Y		53649	Haloperidol	Haloperidol 2mg/5ml oral suspension

Y		11213	Haloperidol	Haloperidol 2mg/5ml sugar free Oral solution
Y		55871	Haloperidol	Haloperidol 2mg/ml Liquid (Hillcross Pharmaceuticals Ltd)
Y		42000	Haloperidol	Haloperidol 2mg/ml Liquid (Rosemont Pharmaceuticals Ltd)
Y		13105	Haloperidol	Haloperidol 2mg/ml Oral solution
Y		3233	Haloperidol	Haloperidol 2mg/ml sugar free Liquid
Y		8136		HALOPERIDOL 5 MG LIQ
Y		2419	Haloperidol	Haloperidol 500microgram capsules
Y		42807	Haloperidol	Haloperidol 500microgram Tablet (Lagap)
Y		3671	Haloperidol	Haloperidol 500microgram tablets
Y		43431	Haloperidol	Haloperidol 500microgram tablets (A A H Pharmaceuticals Ltd)
Y		41420	Haloperidol	Haloperidol 500microgram tablets (Sandoz Ltd)
Y		32051	Haloperidol	Haloperidol 5mg Tablet (Generics (UK) Ltd)
Y		2621	Haloperidol	Haloperidol 5mg tablets
Y		34903	Haloperidol	Haloperidol 5mg tablets (IVAX Pharmaceuticals UK Ltd)
Y		42895	Haloperidol	Haloperidol 5mg tablets (Teva UK Ltd)
Y		38262	Haloperidol	Haloperidol 5mg/1ml solution for injection ampoules
Y		55848	Haloperidol	Haloperidol 5mg/1ml solution for injection ampoules (Merck)
Y		45880	Haloperidol	Haloperidol 5mg/5ml oral solution sugar free
Y		4234	Haloperidol	Haloperidol 5mg/ml Injection
Y		34272	Haloperidol	Haloperidol 5mg/ml Injection (Antigen Pharmaceuticals)
Y		15814	Haloperidol decanoate	Haloperidol decanoate 100mg/1ml solution for injection ampoules
Y		10565	Haloperidol decanoate	Haloperidol decanoate 50mg/1ml solution for injection ampoules
Y		43020	Haloperidol	Haloperidol Oral solution
Y		19002	Chlorpromazine Hydrochloride	Largactil 100mg Suppository (Rhône-Poulenc Rorer Ltd)
Y		7493	Chlorpromazine hydrochloride	Largactil 100mg Tablet (Hawgreen Ltd)
Y		58702	Chlorpromazine hydrochloride	Largactil 100mg tablets (Sanofi)
Y		8771	Chlorpromazine hydrochloride	Largactil 10mg Tablet (Hawgreen Ltd)
Y		55012	Chlorpromazine hydrochloride	Largactil 10mg tablets (Sanofi)
Y		2814	Chlorpromazine hydrochloride	Largactil 25mg Tablet (Hawgreen Ltd)
Y		55011	Chlorpromazine hydrochloride	Largactil 25mg tablets (Sanofi)
Y		10434	Chlorpromazine hydrochloride	Largactil 25mg/5ml Oral solution (Hawgreen Ltd)
Y		57550	Chlorpromazine hydrochloride	Largactil 25mg/5ml syrup (Sanofi)
Y		12356		LARGACTIL 50 MG INJ
Y		3772	Chlorpromazine hydrochloride	Largactil 50mg Tablet (Hawgreen Ltd)
Y		58703	Chlorpromazine hydrochloride	Largactil 50mg tablets (Sanofi)
Y		7514	Chlorpromazine hydrochloride	Largactil 50mg/2ml solution for injection ampoules (Sanofi)
Y		15418	Chlorpromazine embonate	Largactil forte 100mg/5ml Oral suspension (Hawgreen Ltd)
Y		10689		LARGACTIL FORTE SYR
Y		28231	Levomepromazine maleate	Levinan 6mg Tablet (Link Pharmaceuticals Ltd)
Y		49606	Levomepromazine maleate	Levinan 6mg tablets (Archimedes Pharma UK Ltd)
Y		5014	Levomepromazine maleate	Levomepromazine 25mg tablets
Y		6064	Levomepromazine hydrochloride	Levomepromazine 25mg/1ml solution for injection ampoules
Y		53951	Levomepromazine maleate	Levomepromazine 6.25mg/5ml oral solution
Y		40782	Levomepromazine Maleate	Levomepromazine 6mg Tablet

Y		7390	Levomepromazine maleate	Levomepromazine 6mg tablets
Y		20174	Loxapine succinate	Loxapac 10mg capsules (Wyeth Pharmaceuticals)
Y		12619	Loxapine succinate	Loxapac 25mg capsules (Wyeth Pharmaceuticals)
Y		26800	Loxapine succinate	Loxapac 50mg capsules (Wyeth Pharmaceuticals)
Y		12616	Loxapine succinate	Loxapine 10mg capsules
Y		12615	Loxapine succinate	Loxapine 25mg capsules
Y		12630	Loxapine succinate	Loxapine 50mg capsules
Y		27581		MAXOLON
Y		511	Metoclopramide hydrochloride	Maxolon 10mg Tablet (Shire Pharmaceuticals Ltd)
Y		39621	Metoclopramide hydrochloride	Maxolon 10mg tablets (Amdipharm Plc)
Y		179	Metoclopramide hydrochloride	Maxolon 10mg/2ml Injection (Shire Pharmaceuticals Ltd)
Y		39653	Metoclopramide hydrochloride	Maxolon 10mg/2ml solution for injection ampoules (Amdipharm Plc)
Y		15093		MAXOLON 500 MG INJ
Y		304	Metoclopramide hydrochloride	Maxolon 5mg tablets (Shire Pharmaceuticals Ltd)
Y		1724	Metoclopramide hydrochloride	Maxolon 5mg/5ml Oral solution (Shire Pharmaceuticals Ltd)
Y		39710	Metoclopramide hydrochloride	Maxolon 5mg/5ml syrup (Amdipharm Plc)
Y		14844	Metoclopramide hydrochloride	Maxolon High Dose 100mg/20ml solution for injection ampoules (Shire Pharmaceuticals Ltd)
Y		8386	Metoclopramide hydrochloride	Maxolon Paediatric 5mg/5ml liquid (Amdipharm Plc)
Y		15601	Metoclopramide hydrochloride	Maxolon SR 15mg capsules (Amdipharm Plc)
Y		8774	Thioridazine hydrochloride	Melleril 100mg tablets (Novartis Pharmaceuticals UK Ltd)
Y		26661		MELLERIL 100mg/5ml
Y		15157	Thioridazine	Melleril 100mg/5ml oral suspension (Novartis Pharmaceuticals UK Ltd)
Y		284	Thioridazine hydrochloride	Melleril 10mg tablets (Novartis Pharmaceuticals UK Ltd)
Y		1162	Thioridazine hydrochloride	Melleril 25mg tablets (Novartis Pharmaceuticals UK Ltd)
Y		19606		MELLERIL 25mg/5ml
Y		23201		MELLERIL 25mg/5ml
Y		3579	Thioridazine	Melleril 25mg/5ml oral suspension (Novartis Pharmaceuticals UK Ltd)
Y		4673	Thioridazine hydrochloride	Melleril 25mg/5ml syrup (Novartis Pharmaceuticals UK Ltd)
Y		2502	Thioridazine hydrochloride	Melleril 50mg tablets (Novartis Pharmaceuticals UK Ltd)
Y		11576	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Actavis UK Ltd)
Y		16567	Metoclopramide hydrochloride	Metoclopramide 100mg/20ml solution for injection ampoules (Actavis UK Ltd)
Y		34887	Metoclopramide hydrochloride	Metoclopramide 10mg Tablet (C P Pharmaceuticals Ltd)
Y		455	Metoclopramide hydrochloride	Metoclopramide 10mg tablets
Y		34325	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (A A H Pharmaceuticals Ltd)
Y		26363	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Actavis UK Ltd)
Y		53162	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Alliance Healthcare (Distribution) Ltd)
Y		33229	Metoclopramide hydrochloride	Metoclopramide 10mg tablets (Teva UK Ltd)
Y		299	Metoclopramide Hydrochloride	Metoclopramide 10mg/2ml Injection
Y		35046	Metoclopramide hydrochloride	Metoclopramide 10mg/2ml solution for injection ampoules (Actavis UK Ltd)
Y		48445	Metoclopramide hydrochloride	Metoclopramide 10mg/2ml solution for injection ampoules (Actavis UK Ltd)
Y		34084	Metoclopramide hydrochloride	Metoclopramide 10mg/2ml solution for injection ampoules (Actavis UK Ltd)
Y		43448	Metoclopramide hydrochloride	Metoclopramide 12.5mg/5ml oral solution
Y		405	Metoclopramide hydrochloride	Metoclopramide 15mg modified-release capsules
Y		3716	Metoclopramide hydrochloride	Metoclopramide 15mg modified-release tablets

Y		6521	Metoclopramide Hydrochlorid	Metoclopramide 1mg/ml sugar free Oral solution
Y		17832	Metoclopramide Hydrochlorid	Metoclopramide 30mg Modified-release capsule
Y		1759		METOCLOPRAMIDE 5 MG TAB
Y		4892	Metoclopramide hydrochloride	Metoclopramide 5mg tablets
Y		4142	Metoclopramide Hydrochlorid	Metoclopramide 5mg/5ml Oral solution
Y		5081	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free
Y		47547	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (A A H Ph
Y		52677	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (Alliance I
Y		25994	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (Rosemor
Y		25992	Metoclopramide hydrochloride	Metoclopramide 5mg/5ml oral solution sugar free (Sandoz L
Y		13034	Metoclopramide Hydrochlorid	Metoclopramide 5mg/ml Injection (Phoenix Healthcare Distr
Y		3323		METOCLOPRAMIDE HCl 10 MG TAB
Y		20806		METOCLOPRAMIDE SR
Y		3726	Metoclopramide Hydrochlorid	Metoclopramide with aspirin 5mg + 325mg Effervescent tab
Y		17180	Metoclopramide Hydrochlorid	Metoclopramide with aspirin 5mg + 450mg Effervescent tab
Y		17456	Metoclopramide Hydrochlorid	Metoclopramide with lysine acetylsalicylate 10mg + 900mg
Y		12869	Metoclopramide Hydrochlorid	Metoclopramide with paracetamol 5mg + 500mg Sachets
Y		12778	Metoclopramide Hydrochlorid	Metoclopramide with paracetamol 5mg + 500mg Tablet
Y		8784	Metoclopramide hydrochloride	Metox 10mg Tablet (M A Steinhard Ltd)
Y		5288	Metoclopramide hydrochloride	MigraMax oral powder sachets (Zentiva)
Y		3155	Metoclopramide Hydrochlorid	Migravess 5mg+325mg Effervescent tablet (Bayer Plc)
Y		3386	Metoclopramide Hydrochlorid	Migravess forte 5mg+450mg Effervescent tablet (Bayer Plc)
Y		22174		MODECATE
Y		8043		MODECATE 12.5 MG INJ
Y		35122	Fluphenazine decanoate	Modecate 12.5mg/0.5ml solution for injection ampoules (Sa
Y		33780	Fluphenazine decanoate	Modecate 25mg/1ml solution for injection ampoules (Sanofi
Y		3926	Fluphenazine Decanoate	Modecate 25mg/ml Injection (Sanofi-Synthelabo Ltd)
Y		35445	Fluphenazine decanoate	Modecate 50mg/2ml solution for injection ampoules (Sanofi
Y		23340		MODECATE CONC
Y		35455	Fluphenazine decanoate	Modecate Concentrate 100mg/1ml solution for injection am
Y		12128	Fluphenazine Decanoate	Modecate concentrate 100mg/ml Injection (Sanofi-Synthela
Y		35487	Fluphenazine decanoate	Modecate Concentrate 50mg/0.5ml solution for injection arr
Y		26684		MODECATE DISPOSABLE SYRINGE
Y		26692		MODECATE DISPOSABLE SYRINGE
Y		5597	Fluphenazine hydrochloride	Moditen 1mg tablets (Sanofi)
Y		7918	Fluphenazine hydrochloride	Moditen 2.5mg tablets (Sanofi)
Y		20703	Fluphenazine hydrochloride	Moditen 5mg tablets (Sanofi-Synthelabo Ltd)
Y		25835	Fluphenazine Enantate	Moditen enanthate 25mg/ml Injection (Sanofi-Synthelabo Lt
Y		19738		MORPHINE,COCAINE & CHLORPROMAZINE MIX
Y		8493	Nortriptyline hydrochloride/Flu	Motipress tablets (Sanofi-Synthelabo Ltd)
Y		2936	Fluphenazine hydrochloride/N	Motival 10mg/500microgram tablets (Sanofi)
Y		8031	Pericyazine	Neulactil 10mg Tablet (JHC Healthcare Ltd)
Y		40881	Pericyazine	Neulactil 10mg tablets (Sanofi)
Y		7833	Pericyazine	Neulactil 2.5mg Tablet (JHC Healthcare Ltd)

Y		39830	Pericyazine	Neulactil 2.5mg tablets (Sanofi)
Y		21064	Pericyazine	Neulactil 25mg Tablet (JHC Healthcare Ltd)
Y		29967		NEULACTIL FORTE
Y		13902	Pericyazine	Neulactil Forte syrup (Sanofi)
Y		7780	Fluphenazine hydrochloride/N	Nortriptyline 10mg / Fluphenazine 500microgram tablets
Y		14578	Nortriptyline hydrochloride/Flu	Nortriptyline 30mg / Fluphenazine 1.5mg tablets
Y		4232	Levomepromazine maleate	Nozinan 25mg tablets (Sanofi)
Y		52846	Levomepromazine hydrochlor	Nozinan 25mg/1ml solution for injection ampoules (Lexon (L
Y		4442	Levomepromazine hydrochlor	Nozinan 25mg/1ml solution for injection ampoules (Sanofi)
Y		27148	Pimozide	Orap 10mg Tablet (Janssen-Cilag Ltd)
Y		4524	Pimozide	Orap 2mg tablets (Janssen-Cilag Ltd)
Y		15047	Pimozide	Orap 4mg tablets (Janssen-Cilag Ltd)
Y		3514	Paracetamol/Metoclopramide	Paracetamol 500mg / Metoclopramide 5mg effervescent po
Y		2306	Paracetamol/Metoclopramide	Paracetamol 500mg / Metoclopramide 5mg tablets
Y		890	Paracetamol/Metoclopramide	Paramax sachets (Zentiva)
Y		892	Paracetamol/Metoclopramide	Paramax tablets (Zentiva)
Y		3356	Trifluoperazine Hydrochloride	Parstelin Tablet (GlaxoSmithKline Consumer Healthcare)
Y		29972		PERICYAZINE
Y		8032	Pericyazine	Pericyazine 10mg tablets
Y		12195	Pericyazine	Pericyazine 10mg/5ml oral solution
Y		22655		PERICYAZINE 2.5 MG ELI
Y		7834	Pericyazine	Pericyazine 2.5mg tablets
Y		15472	Pericyazine	Pericyazine 25mg tablet
Y		609	Perphenazine	Perphenazine 2mg tablets
Y		16323	Amitriptyline Hydrochloride	Perphenazine 2mg with Amitriptyline 10mg tablet
Y		6894	Amitriptyline Hydrochloride	Perphenazine 2mg with Amitriptyline 25mg tablet
Y		14987	Perphenazine	Perphenazine 2mg/5ml oral solution sugar free
Y		2157	Perphenazine	Perphenazine 4mg tablets
Y		25909	Perphenazine	Perphenazine 4mg/5ml Oral solution sugar free
Y		17087	Perphenazine	Perphenazine 5mg/ml injection
Y		20061		PERPHENAZINE 8 MG TAB
Y		8637	Pimozide	Pimozide 10mg tablet
Y		2489	Pimozide	Pimozide 2mg tablets
Y		5821	Pimozide	Pimozide 4mg tablets
Y		12340	Pipotiazine Palmitate	Piportil 50mg/ml Depot injection (JHC Healthcare Ltd)
Y		35488	Pipotiazine palmitate	Piportil Depot 100mg/2ml solution for injection ampoules (S
Y		35235	Pipotiazine palmitate	Piportil Depot 50mg/1ml solution for injection ampoules (Sa
Y		36394	Pipotiazine palmitate	Pipotiazine 100mg/2ml solution for injection ampoules
Y		35684	Pipotiazine palmitate	Pipotiazine 50mg/1ml solution for injection ampoules
Y		10944	Pipotiazine Palmitate	Pipotiazine palmitate 50mg/ml depot injection
Y		8525	Metoclopramide hydrochloride	Primperan 10mg Tablet (Berk Pharmaceuticals Ltd)
Y		9118	Metoclopramide hydrochloride	Primperan 5mg/5ml Oral solution sugar free (Berk Pharmaco
Y		23753	Metoclopramide Hydrochlorid	Primperan 5mg/ml Injection (Berk Pharmaceuticals Ltd)
Y		14364	Prochlorperazine mesilate	Prochlorperazine 12.5mg/1ml solution for injection ampoule

Y		32122	Prochlorperazine mesilate	Prochlorperazine 12.5mg/1ml solution for injection ampoule
Y		1990	Prochlorperazine maleate	Prochlorperazine 25mg suppositories
Y		3932	Prochlorperazine maleate	Prochlorperazine 25mg tablets
Y		4769	Prochlorperazine maleate	Prochlorperazine 3mg buccal tablets
Y		237		PROCHLORPERAZINE 5 MG ELI
Y		9590	Prochlorperazine mesilate	Prochlorperazine 5mg effervescent granules sachets sugar
Y		1434	Prochlorperazine maleate	Prochlorperazine 5mg suppositories
Y		54458	Prochlorperazine maleate	Prochlorperazine 5mg Tablet (Teva UK Ltd)
Y		85	Prochlorperazine maleate	Prochlorperazine 5mg tablets
Y		34344	Prochlorperazine maleate	Prochlorperazine 5mg tablets (A A H Pharmaceuticals Ltd)
Y		32064	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Actavis UK Ltd)
Y		43420	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Dr Reddy's Laboratories (UK
Y		32772	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Generics (UK) Ltd)
Y		32551	Prochlorperazine maleate	Prochlorperazine 5mg tablets (IVAX Pharmaceuticals UK Lt
Y		55038	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Sigma Pharmaceuticals Plc)
Y		32876	Prochlorperazine maleate	Prochlorperazine 5mg tablets (Teva UK Ltd)
Y		6036	Prochlorperazine mesilate	Prochlorperazine 5mg/5ml oral solution
Y		4401	Prochlorperazine Maleate	Prochlorperazine maleate 10mg modified release capsule
Y		15438	Prochlorperazine Maleate	Prochlorperazine maleate 15mg modified release capsul
Y		3024		PROCHLORPERAZINE MALEATE 3 MG TAB
Y		5510	Prochlorperazine Mesilate	Prochlorperazine mesilate 12.5mg/ml injection
Y		3197	Promazine Hydrochloride	Promazine 100mg tablet
Y		15395	Promazine Hydrochloride	Promazine 12.5mg/5ml oral solution
Y		46945	Promazine hydrochloride	Promazine 25mg Tablet (Biorex Laboratories Ltd)
Y		2972	Promazine hydrochloride	Promazine 25mg tablets
Y		6443	Promazine hydrochloride	Promazine 25mg/5ml oral solution
Y		40390	Promazine hydrochloride	Promazine 25mg/5ml syrup (Rosemont Pharmaceuticals Lt
Y		3228	Promazine hydrochloride	Promazine 50mg tablets
Y		41732	Promazine hydrochloride	Promazine 50mg tablets (Teva UK Ltd)
Y		55890	Promazine Hydrochloride	Promazine 50mg/5ml Liquid (Rosemont Pharmaceuticals L
Y		10780	Promazine Hydrochloride	Promazine 50mg/5ml oral solution
Y		17634	Promazine hydrochloride	Promazine 50mg/5ml oral solution
Y		14610	Promazine Hydrochloride	Promazine 50mg/5ml oral solution sugar free
Y		38089	Promazine hydrochloride	Promazine 50mg/5ml syrup (Rosemont Pharmaceuticals Lt
Y		15161	Promazine Hydrochloride	Promazine 50mg/ml injection
Y		43654	Promazine Hydrochloride	Promazine 50mg/ml injection
Y		41995	Promazine Hydrochloride	Promazine 50mg/ml Injection (Genus Pharmaceuticals Ltd)
Y		8988		PROMAZINE HCl 25 MG TAB
Y		26660		PROMAZINE HYDROCHLORIDE
Y		13607	Prochlorperazine maleate	Proziere 5mg tablets (Ashbourne Pharmaceuticals Ltd)
Y		57170	Flupentixol decanoate	Psytixol 100mg/1ml solution for injection ampoules (Generi
Y		57762	Flupentixol decanoate	Psytixol 40mg/2ml solution for injection ampoules (Generics
Y		8044	Fluspirilene	Redeptin 2mg/ml Injection (Janssen-Cilag Ltd)
Y		8979	Haloperidol	Serenace 1.5mg tablets (Teva UK Ltd)

Y		13484	Haloperidol	Serenace 10mg tablets (Teva UK Ltd)
Y		13391		SERENACE 20 MG INJ
Y		13483	Haloperidol	Serenace 20mg tablets (Teva UK Ltd)
Y		28968	Haloperidol	Serenace 20mg/2ml solution for injection ampoules (IVAX P
Y		8153	Haloperidol	Serenace 2mg/ml liquid (Teva UK Ltd)
Y		5545	Haloperidol	Serenace 500microgram capsules (Teva UK Ltd)
Y		13338	Haloperidol	Serenace 5mg tablets (Teva UK Ltd)
Y		7436	Haloperidol	Serenace 5mg/1ml solution for injection ampoules (IVAX Ph
Y		33493	Promazine Hydrochloride	Sparine 100mg Tablet (Wyeth Pharmaceuticals)
Y		12193	Promazine hydrochloride	Sparine 25mg Tablet (Wyeth Pharmaceuticals)
Y		3226	Promazine hydrochloride	Sparine 50mg Tablet (Wyeth Pharmaceuticals)
Y		3227	Promazine Hydrochloride	Sparine 50mg/5ml Liquid (Wyeth Pharmaceuticals)
Y		13311	Promazine Hydrochloride	Sparine 50mg/ml Injection (Wyeth Pharmaceuticals)
Y		8445	Isopropamide Iodide	Stelabid Tablet (GlaxoSmithKline Consumer Healthcare)
Y		27582		STELAZINE
Y		1735	Trifluoperazine hydrochloride	Stelazine 10mg Spansules (Mercury Pharma Group Ltd)
Y		18289	Trifluoperazine Hydrochloride	Stelazine 10mg/ml Concentrate (Goldshield Pharmaceutica
Y		8042	Trifluoperazine hydrochloride	Stelazine 15mg Spansules (Mercury Pharma Group Ltd)
Y		57605	Trifluoperazine hydrochloride	Stelazine 1mg tablets (Lexon (UK) Ltd)
Y		1318	Trifluoperazine hydrochloride	Stelazine 1mg tablets (Mercury Pharma Group Ltd)
Y		8985	Trifluoperazine hydrochloride	Stelazine 1mg/5ml syrup (Mercury Pharma Group Ltd)
Y		7479	Trifluoperazine Hydrochloride	Stelazine 1mg/ml Injection (Goldshield Pharmaceuticals Ltd
Y		2713	Trifluoperazine hydrochloride	Stelazine 2mg Spansules (Mercury Pharma Group Ltd)
Y		1316	Trifluoperazine hydrochloride	Stelazine 5mg tablets (Mercury Pharma Group Ltd)
Y		29838		STELAZINE CONCENTRATE 10mg/ml
Y		29948	Trifluoperazine hydrochloride	Stelazine Forte 1mg/ml oral solution (Mercury Pharma Grou
Y		8775		STELAZINE TAB
Y		24243		STEMETIL
Y		19824		STEMETIL (1ML)
Y		14356	Prochlorperazine mesilate	Stemetil 12.5mg/1ml solution for injection ampoules (Sanof
Y		3246	Prochlorperazine Mesilate	Stemetil 12.5mg/ml Injection (Castlemead Healthcare Ltd)
Y		7985		STEMETIL 2.5 MG SUP
Y		1234	Prochlorperazine maleate	Stemetil 25mg suppositories (Sanofi)
Y		5497	Prochlorperazine maleate	Stemetil 25mg tablets (Sanofi)
Y		227	Prochlorperazine maleate	Stemetil 5mg suppositories (Sanofi)
Y		512	Prochlorperazine maleate	Stemetil 5mg Tablet (Castlemead Healthcare Ltd)
Y		50462	Prochlorperazine maleate	Stemetil 5mg tablets (Doncaster Pharmaceuticals Ltd)
Y		49170	Prochlorperazine maleate	Stemetil 5mg tablets (Lexon (UK) Ltd)
Y		51551	Prochlorperazine maleate	Stemetil 5mg tablets (Mawdsley-Brooks & Company Ltd)
Y		39887	Prochlorperazine maleate	Stemetil 5mg tablets (Sanofi)
Y		51579	Prochlorperazine maleate	Stemetil 5mg tablets (Sigma Pharmaceuticals Plc)
Y		54429	Prochlorperazine maleate	Stemetil 5mg tablets (Waymade Healthcare Plc)
Y		7593	Prochlorperazine mesilate	Stemetil 5mg/5ml Oral solution (Castlemead Healthcare Ltd
Y		40001	Prochlorperazine mesilate	Stemetil 5mg/5ml syrup (Sanofi)

Y		3738	Prochlorperazine mesilate	Stemetil Eff 5mg sachets (Sanofi)
Y		9215	Cinnarizine	Stugeron 15mg tablets (Janssen-Cilag Ltd)
Y		1355	Cinnarizine	Stugeron 15mg tablets (McNeil Products Ltd)
Y		9304	Cinnarizine	Stugeron Forte 75mg capsules (Janssen-Cilag Ltd)
Y		28147	Chlorprothixene	Taractan 15mg Tablet (Roche Products Ltd)
Y		16667	Thiethylperazine	Thiethylperazine 10mg Tablet
Y		15343	Thiethylperazine	Thiethylperazine 6.5mg/ml injection
Y		7969	Thiethylperazine	Thiethylperazine suppository
Y		23517		THIOPROPAZATE HCl 10 MG TAB
Y		29445		THIOPROPERAZINE MESYLATE 10 MG TAB
Y		21675		THIOPROPERAZINE MESYLATE 25 MG TAB
Y		28979		THIORIDAZINE 100mg/5ml
Y		45860	Thioridazine hydrochloride	Thioridazine 100mg Tablet (IVAX Pharmaceuticals UK Ltd)
Y		3021	Thioridazine hydrochloride	Thioridazine 100mg tablets
Y		10675	Thioridazine	Thioridazine 100mg/5ml oral suspension
Y		15598	Thioridazine Hydrochloride	Thioridazine 100mg/5ml sugar free Oral solution
Y		1192	Thioridazine hydrochloride	Thioridazine 10mg tablets
Y		2801	Thioridazine Hydrochloride	Thioridazine 10mg/5ml Oral solution
Y		47361	Thioridazine Hydrochloride	Thioridazine 10mg/5ml Oral solution (Rosemont Pharmaceu
Y		34905	Thioridazine hydrochloride	Thioridazine 25mg Tablet (IVAX Pharmaceuticals UK Ltd)
Y		1218	Thioridazine hydrochloride	Thioridazine 25mg tablets
Y		43424	Thioridazine hydrochloride	Thioridazine 25mg tablets (A A H Pharmaceuticals Ltd)
Y		20668		THIORIDAZINE 25mg/5ml
Y		26082		THIORIDAZINE 25mg/5ml
Y		3605	Thioridazine hydrochloride	Thioridazine 25mg/5ml oral solution
Y		47881	Thioridazine hydrochloride	Thioridazine 25mg/5ml oral solution (Rosemont Pharmaceu
Y		9387	Thioridazine	Thioridazine 25mg/5ml oral suspension
Y		10405	Thioridazine Hydrochloride	Thioridazine 25mg/5ml sugar free Oral solution
Y		35787	Thioridazine hydrochloride	Thioridazine 50mg Tablet (IVAX Pharmaceuticals UK Ltd)
Y		1314	Thioridazine hydrochloride	Thioridazine 50mg tablets
Y		34902	Thioridazine hydrochloride	Thioridazine 50mg tablets (A A H Pharmaceuticals Ltd)
Y		17399	Thioridazine Hydrochloride	Thioridazine 50mg/5ml Oral solution
Y		42816	Thioridazine Hydrochloride	Thioridazine 50mg/5ml Oral solution (Rosemont Pharmaceu
Y		52143		THIORIDAZINE CONCENTRATE 750MG/5ML 750 MG ELI
Y		10870		THIORIDAZINE S/F 50 MG/5ML SYR
Y		16668	Thiethylperazine	Torecan 10mg Tablet (Novartis Pharmaceuticals UK Ltd)
Y		22053	Thiethylperazine	Torecan 6.5mg/ml Injection (Novartis Pharmaceuticals UK L
Y		7970	Thiethylperazine	Torecan Suppository (Novartis Pharmaceuticals UK Ltd)
Y		3955	Trifluoperazine Hydrochloride	Tranlycypromine with trifluoperazine Tablet
Y		2714	Trifluoperazine hydrochloride	Trifluoperazine 10mg modified-release capsules
Y		22245		TRIFLUOPERAZINE 10mg/ml
Y		18668	Trifluoperazine Hydrochloride	Trifluoperazine 10mg/ml concentrate
Y		3937	Trifluoperazine hydrochloride	Trifluoperazine 15mg modified-release capsules
Y		1857	Trifluoperazine hydrochloride	Trifluoperazine 1mg tablets

Y		40162	Trifluoperazine hydrochloride	Trifluoperazine 1mg tablets (A A H Pharmaceuticals Ltd)
Y		13145	Trifluoperazine hydrochloride	Trifluoperazine 1mg/5ml oral solution sugar free
Y		55382	Trifluoperazine hydrochloride	Trifluoperazine 1mg/5ml oral solution sugar free (Mercury P
Y		8537	Trifluoperazine Hydrochloride	Trifluoperazine 1mg/ml Injection
Y		1159	Trifluoperazine hydrochloride	Trifluoperazine 2mg modified-release capsules
Y		19645		TRIFLUOPERAZINE 5.00mg/ml
Y		10535		TRIFLUOPERAZINE 5.00MG/ML 5 MG SYR
Y		1245	Trifluoperazine hydrochloride	Trifluoperazine 5mg tablets
Y		41663	Trifluoperazine hydrochloride	Trifluoperazine 5mg tablets (A A H Pharmaceuticals Ltd)
Y		11531	Trifluoperazine hydrochloride	Trifluoperazine 5mg/5ml oral solution sugar free
Y		28965		TRIFLUOPERAZINE HCL/ISOPROP.IODIDE FORTE TAB
Y		10356		TRIFLUOPERAZINE TAB
Y		24890	Trifluoperazine Hydrochloride	Trifluoperazine with tranlycypromine 1mg + 10mg Tablet
Y		23659	Trifluperidol	Trifluperidol 0.5mg Tablet
Y		22814	Trifluperidol	Trifluperidol 1mg Tablet
Y		17877		TRIFLUPERIDOL 2 MG TAB
Y		21047	Trifluperidol	Triperidol 0.5mg Tablet (Lagap)
Y		21027	Trifluperidol	Triperidol 1mg Tablet (Lagap)
Y		1453	Amitriptyline hydrochloride/Pe	Triptafen m 2mg+10mg Tablet (Goldshield Pharmaceuticals)
Y		1208	Amitriptyline hydrochloride/Pe	Triptafen tablets (Mercury Pharma Group Ltd)
Y		38827	Amitriptyline hydrochloride/Pe	Triptafen-M tablets (Mercury Pharma Group Ltd)
Y		21339	Levomepromazine maleate	Veractil 25mg Tablet (Rhone-Poulenc Rorer Ltd)
Y		8689	Prochlorperazine Maleate	Vertigon spansule 10 10mg Spansule (GlaxoSmithKline Co
Y		17849	Prochlorperazine Maleate	Vertigon spansule 15 15mg Spansule (GlaxoSmithKline Co
Y		9686	Zuclopenthixol dihydrochlorid	Zuclopenthixol 10mg tablets
Y		13600	Zuclopenthixol dihydrochlorid	Zuclopenthixol 25mg tablets
Y		12707	Zuclopenthixol dihydrochlorid	Zuclopenthixol 2mg tablets
Y		31537	Zuclopenthixol acetate	Zuclopenthixol acetate 100mg/2ml solution for injection amp
Y		24270	Zuclopenthixol acetate	Zuclopenthixol acetate 50mg/1ml solution for injection ampo
Y		14576	Zuclopenthixol Acetate	Zuclopenthixol acetate 50mg/ml oily injection
Y		28355	Zuclopenthixol decanoate	Zuclopenthixol decanoate 200mg/1ml solution for injection a
Y		3775	Zuclopenthixol Decanoate	Zuclopenthixol decanoate 200mg/ml oily injection
Y		12224	Zuclopenthixol decanoate	Zuclopenthixol decanoate 500mg/1ml solution for injection a
Y		25635		ZUCLOPENTHIXOL DIHYDROCHLORIDE
N		37644	Chlorhexidine Gluconate	Chloraprep solution (CareFusion U.K. Ltd)
N		50098		ChloraPrep solution 0.67ml applicators (CareFusion U.K. Lt
N		49473	Isopropyl alcohol/Chlorhexidin	ChloraPrep solution 1.5ml applicators (CareFusion U.K. Ltd
N		53840		ChloraPrep solution 10.5ml applicators (CareFusion U.K. Lt
N		49393	Chlorhexidine gluconate/Isop	ChloraPrep solution 3ml applicators (CareFusion U.K. Ltd)
N		46656	Chlorhexidine Gluconate	Chloraprep with tint solution (CareFusion U.K. Ltd)
N		49359	Chlorhexidine gluconate/Isop	ChloraPrep with Tint solution 3ml applicators (CareFusion U
N		6209	Insulin aspart	NovoRapid 100units/ml solution for injection 10ml vials (Nov
N		53118	Insulin aspart	NovoRapid FlexPen 100units/ml solution for injection 3ml p
N		5892	Insulin aspart	NovoRapid FlexPen 100units/ml solution for injection 3ml p

N		46666	Insulin aspart	NovoRapid FlexTouch 100units/ml solution for injection 3ml
N		11337	Insulin aspart	NovoRapid Novolet 100units/ml solution for injection (Novo
N		53251	Insulin aspart	NovoRapid Penfill 100units/ml solution for injection 3ml cart
N		49108	Insulin aspart	NovoRapid Penfill 100units/ml solution for injection 3ml cart
N		5021	Insulin aspart	NovoRapid Penfill 100units/ml solution for injection 3ml cart
N		51743	Insulin aspart	NovoRapid Penfill 100units/ml solution for injection 3ml cart
N		2277	Piperazine phosphate/Senna	Piperazine 4g / Senna 15.3mg oral powder sachets sugar fr
N		7470	Pipã©razine Dã©rivã©s	Piperazine 500mg tablet
N		2005	Pipã©razine Dã©rivã©s	Piperazine 750mg/5ml oral solution
N		4500		PIPERAZINE CITRATE 12.6 % SYR
N		32248	Medroxyprogesterone Acetate	Piperazine oestrone sulphate 1.5mg with medroxyprogester
N		243	Piperazine phosphate/Senna	Pripsen powder (Thornton & Ross Ltd)
N		23173	Methylphenidate hydrochlorid	Tranquilyn 10mg tablets (Genesis Pharmaceuticals Ltd)
N		23161	Methylphenidate hydrochlorid	Tranquilyn 5mg tablets (Genesis Pharmaceuticals Ltd)

Reviewed by PPD for drugs known to induce Parkinsonism (including "typical" antipsych

formulation	bnfchapter	bnfcode
Tablet	Unknown	00000000
Tablet	Tricyclic And Related Antidepressant Drugs	04030100
Tablet	Antipsychotic Drugs	04020100
Tablet	First-generation Antipsychotic Drugs	04020101
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Powder	Non-opioid And Compound Analgesics	04070100
Tablet	First-generation Antipsychotic Drugs	04020101
Tablet	Antipsychotic Drugs	04020100
Buccal tablet	Antipsychotic Drugs/-	04020100/40120000
Buccal tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Buccal tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs/-	04020100/40120000
Suppository	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral suspension	Unknown	00000000
Suspension	Antipsychotic Drugs/-	04020100/40120000
Tablet	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs/-	04020100/40120000
Oral solution	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs/-	04020100/40120000
Injection	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100

Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
Tablets	Antipsychotic Drugs	04020100
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
	Unknown	00000000
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
	Peripheral Vasodilators And Related Drugs	02060400/03040103
Capsule	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oily Injection	Antipsychotic Drugs/Antipsychotic Depot In	04020100/04020200
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oily Injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
	Unknown	00000000
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
	Unknown	00000000
Tablets	Peripheral Vasodilators And Related Drugs	02060400/03040103
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Oral solution	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401

Oral Solution	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401
Injection	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401
	Unknown	00000000
Tablets	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401
Liquid	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401
Solution for injection	Drug Used In Nausea And Vertigo - Antihis	04065400
	Unknown	00000000
	Drug Used In Nausea And Vertigo - Antihis	04065400
Injection	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401
	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401
Oral Liquid	Antipsychotic Drugs/Benzodiazepines (peri	04020100/15010401
Injection	Benzodiazepines (peri-operative)	15010401
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
	Unknown	00000000
Tablet	Other Antidepressant Drugs	04030400
Tablet	Other Antidepressant Drugs	04030400
Tablet	Other Antidepressant Drugs	04030400
Solution for injection	Antipsychotic Depot Injections	04020200
Tablet	Other Antidepressant Drugs	04030400
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Depot Injections	04020200
Tablet	Other Antidepressant Drugs	04030400
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Liquid	Antipsychotic Drugs/Other Antidepressant	04020100/04030400
Tablet	Antipsychotic Drugs	04020100
Tablet	Unknown	00000000
Tablet	Unknown	00000000
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
	Unknown	00000000
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200

Injection	Antipsychotic Depot Injections	04020200
	Unknown	00000000
Tablet	Tricyclic And Related Antidepressant Drugs	04030100
	Unknown	00000000
Injection	Antipsychotic Depot Injections	04020200
Modified-release tablet	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
	Unknown	00000000
Modified-release tablet	Unknown	00000000
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Modified-release Capsule	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Liquid	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
Oral solution	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs/-	04020100/40120000
Solution for injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
	Antipsychotic Drugs	04020100
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Oral solution	Antipsychotic Drugs	04020100
Oral suspension	Antipsychotic Drugs	04020100
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Liquid	Antipsychotic Drugs/-	04020100/40120000
Liquid	Antipsychotic Drugs/-	04020100/40120000
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Unknown	00000000
Oral Suspension	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral suspension	Antipsychotic Drugs	04020100

Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Liquid	Antipsychotic Drugs/-	04020100/40120000
Liquid	Antipsychotic Drugs/-	04020100/40120000
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Liquid	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
Capsule	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Unknown	00000000
Tablet	Unknown	00000000
Tablet	Unknown	00000000
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs/-	04020100/40120000
Injection	Antipsychotic Drugs/-	04020100/40120000
Solution for injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oral Solution	Antipsychotic Drugs/-	04020100/40120000
Suppository	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Unknown	00000000
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs/-	04020100/40120000
Oral solution	Antipsychotic Drugs	04020100
	Unknown	00000000
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oral suspension	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100

Tablet	Antipsychotic Drugs	04020100
Capsule	Unknown	00000000
Capsule	Unknown	00000000
Capsule	Unknown	00000000
Capsule	Unknown	00000000
Capsule	Unknown	00000000
Capsule	Unknown	00000000
	Unknown	00000000
Tablet	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Solution for injection	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Solution for injection	Drug Used In Nausea And Vertigo - Dompe	04065500
	Unknown	00000000
Tablet	Unknown	00000000
Oral solution	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Solution for injection	Drug Used In Nausea And Vertigo - Dompe	04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Modified-release capsule	Drug Used In Nausea And Vertigo - Dompe	04065500
Tablet	Unknown	00000000
	Unknown	00000000
Oral suspension	Unknown	00000000
Tablet	Unknown	00000000
Tablet	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
Oral suspension	Unknown	00000000
Oral solution	Unknown	00000000
Tablet	Unknown	00000000
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Solution for injection	Drug Used In Nausea And Vertigo - Dompe	04065500
Tablet	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500
Injection	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Solution for injection	Drug Used In Nausea And Vertigo - Dompe	04065500
Solution for injection	Drug Used In Nausea And Vertigo - Dompe	04065500
Solution for injection	Drug Used In Nausea And Vertigo - Dompe	04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Modified-release capsule	Drug Used In Nausea And Vertigo - Dompe	04065500
Modified-release tablet	Unknown	00000000

Oral Solution	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Modified-release Capsule	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
	Unknown	00000000
Tablet	Unknown	00000000
Oral Solution	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Oral solution	Drug Used In Nausea And Vertigo - Dompe	04065500
Injection	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
	Unknown	00000000
	Unknown	00000000
Effervescent Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500/04070401
Effervescent Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500/04070401
Oral Solution	Drug Used In Nausea And Vertigo - Dompe	04065500/04070401
Sachets	Drug Used In Nausea And Vertigo - Dompe	04065500/04070401
Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500/04070401
Tablet	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Powder	Non-opioid And Compound Analgesics	04070100
Effervescent Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500/04070401
Effervescent Tablet	Drug Used In Nausea And Vertigo - Dompe	04065500/04070401
	Unknown	00000000
	Unknown	00000000
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
	Unknown	00000000
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
	Unknown	00000000
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Unknown	00000000
Tablet	Unknown	00000000
Injection	Antipsychotic Depot Injections	04020200
	Unknown	00000000
Tablet	Unknown	00000000
Tablet	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100

Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
	Unknown	00000000
Oral solution	Antipsychotic Drugs	04020100
Tablet	Unknown	00000000
Tablet	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Effervescent powder	Treatment Of Acute Migraine	04070401
Tablet	Treatment Of Acute Migraine	04070401
Effervescent powder	Treatment Of Acute Migraine	04070401
Tablet	Treatment Of Acute Migraine	04070401
Tablet	Antipsychotic Drugs/Monoamine-oxidase In	04020100/04030200
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablets	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablets	Antipsychotic Drugs/Tricyclic And Related A	04020100/04030100
Tablets	Antipsychotic Drugs/Tricyclic And Related A	04020100/04030100
Syrup Sugar-free	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Syrup Sugar-free	Antipsychotic Drugs/-	04020100/40120000
Injection	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
Tablets	Antipsychotic Drugs	04020100
Tablet	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Depot Injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Depot Injection	Antipsychotic Depot Injections	04020200
Tablet	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Oral solution	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Injection	Motility Stimulants/Drug Used In Nausea A	01020300/04065500
Solution for injection	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400

Solution for injection	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Suppository	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Unknown	00000000
Buccal tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
	Unknown	00000000
Effervescent granules	Unknown	00000000
Suppository	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Oral solution	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Modified Release Capsules	Antipsychotic Drugs/-	04020100/40120000
Modified Release Capsules	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
Injection	Antipsychotic Drugs/-	04020100/40120000
Tablets	Antipsychotic Drugs	04020100
Syrup	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Liquid	Antipsychotic Drugs	04020100
Suspension	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Syrup Sugar-free	Antipsychotic Drugs	04020100
Oral solution	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs	04020100
	Unknown	00000000
	Unknown	00000000
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Solution for injection	Antipsychotic Depot Injections	04020200
Solution for injection	Antipsychotic Depot Injections	04020200
Injection	Antipsychotic Depot Injections	04020200
Tablet	Antipsychotic Drugs	04020100

Tablet	Antipsychotic Drugs	04020100
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Unknown	00000000
Oral solution	Antipsychotic Drugs	04020100
Capsule	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Liquid	Antipsychotic Drugs	04020100
Injection	Antipsychotic Drugs	04020100
Tablet	Antimuscarinics/Antipsychotic Drugs	01020100/04020100
	Unknown	00000000
Modified-release capsule	Unknown	00000000
Concentrate	Antipsychotic Drugs/-	04020100/40120000
Modified-release capsule	Unknown	00000000
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Oral solution	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Injection	Antipsychotic Drugs/-	04020100/40120000
Modified-release capsule	Unknown	00000000
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
	Unknown	00000000
Oral solution	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
Solution for injection	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Injection	Antipsychotic Drugs/-	04020100/40120000
	Unknown	00000000
Suppository	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Unknown	00000000
Suppository	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Oral solution	Antipsychotic Drugs/-	04020100/40120000
Oral solution	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400

Effervescent granules	Unknown	00000000
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Tablet	Drug Used In Nausea And Vertigo - Antihis	04065400
Capsule	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antihistamines In Nausea And Vomiting	03040103
Injection	Antihistamines In Nausea And Vomiting	03040103
Suppository	Antihistamines In Nausea And Vomiting	03040103
	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Oral suspension	Unknown	00000000
Oral Solution	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Oral Solution	Antipsychotic Drugs	04020100
Oral Solution	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
Oral solution	Antipsychotic Drugs	04020100
Oral solution	Unknown	00000000
Oral suspension	Unknown	00000000
Oral Solution	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Unknown	00000000
Oral Solution	Antipsychotic Drugs	04020100
Oral Solution	Antipsychotic Drugs	04020100
	Unknown	00000000
	Unknown	00000000
Tablet	Antihistamines In Nausea And Vomiting	03040103
Injection	Antihistamines In Nausea And Vomiting	03040103
Suppository	Antihistamines In Nausea And Vomiting	03040103
Tablet	Antipsychotic Drugs/Monoamine-oxidase In	04020100/04030200
Modified-release capsule	Unknown	00000000
	Unknown	00000000
Concentrate	Antipsychotic Drugs/-	04020100/40120000
Modified-release capsule	Unknown	00000000
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400

Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Oral solution	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Oral solution	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Injection	Antipsychotic Drugs/-	04020100/40120000
Modified-release capsule	Unknown	00000000
	Unknown	00000000
	Unknown	00000000
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Tablet	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
Oral solution	Antipsychotic Drugs/Drug Used In Nausea	04020100/04065400
	Unknown	00000000
	Unknown	00000000
Tablet	Antipsychotic Drugs/Monoamine-oxidase In	04020100/04030200
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs/Tricyclic And Related A	04020100/04030100
Tablet	Tricyclic And Related Antidepressant Drugs	04030100
Tablet	Unknown	00000000
Tablet	Antipsychotic Drugs	04020100
Spansule	Antipsychotic Drugs/-	04020100/40120000
Spansule	Antipsychotic Drugs/-	04020100/40120000
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Tablet	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oily Injection	Antipsychotic Drugs	04020100
Solution for injection	Antipsychotic Drugs	04020100
Oily Injection	Antipsychotic Drugs/Antipsychotic Depot In	04020100/04020200
Solution for injection	Antipsychotic Drugs	04020100
	Unknown	00000000
Oral Solution	Antibacterial Preparations Only Used Topic	13100101/13110200
	Chlorhexidine Salts	13110200
Liquid	Chlorhexidine Salts	13110200
	Chlorhexidine Salts	13110200
Liquid	Chlorhexidine Salts	13110200
Oral Solution	Antibacterial Preparations Only Used Topic	13100101/13110200
Liquid	Chlorhexidine Salts	13110200
Solution for injection	Short-acting Insulins	06010101
Solution for injection	Short-acting Insulins	06010101
Solution for injection	Short-acting Insulins	06010101

Solution for injection	Short-acting Insulins	06010101
Solution for injection	Unknown	00000000
Solution for injection	Short-acting Insulins	06010101
Solution for injection	Short-acting Insulins	06010101
Solution for injection	Short-acting Insulins	06010101
Solution for injection	Short-acting Insulins	06010101
Powder	Drugs For Threadworms	05050100
Tablets	Drugs For Threadworms/Ascaricides	05050100/05050200
Elixir	Drugs For Threadworms/Ascaricides	05050100/05050200
	Unknown	00000000
Tablets	Oestrogens And Hrt	06040101
Powder	Drugs For Threadworms	05050100
Tablet	Cns Stimulants And Drugs Used For Attent	04040000
Tablet	Cns Stimulants And Drugs Used For Attent	04040000

hotic drugs, metoclopramide, or cinnarizine)

%DROLEPTAN%, %droperidol%
%DROLEPTAN%, %droperidol%
%droperidol%
%droperidol%
%droperidol%
%droperidol%
%droperidol%
%droperidol%
%droperidol%
%droperidol%
%droperidol%
%droperidol%
%FENTAZIN%, %perphenazine%
%FENTAZIN%, %perphenazine%
%FENTAZIN%, %perphenazine%
%FENTAZIN%
%Fluanxol%
%Fluanxol%, %flupentixol%
%Fluanxol%, %flupentixol%
%Fluanxol%, %flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%flupentixol%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%
%fluphenazine%

%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%haloperidol%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%, %chlorpromazine%, %promazine%
%LARGACTIL%
%LEVINAN%, %levomepromazine%, %promazine%
%LEVINAN%, %levomepromazine%, %promazine%
%levomepromazine%, %promazine%
%levomepromazine%, %promazine%
%levomepromazine%, %promazine%
%levomepromazine%, %promazine%

%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%, %Metox%
%Metoclopramide%, %MigraMax%
%Metoclopramide%, %Migravess%
%Metoclopramide%, %Migravess%
%Modecate%
%Modecate%
%Modecate%, %fluphenazine%
%Modecate%, %fluphenazine%
%Modecate%, %fluphenazine%
%Modecate%, %fluphenazine%
%Modecate%
%Modecate%, %fluphenazine%
%Modecate%, %fluphenazine%
%Modecate%, %fluphenazine%
%Modecate%
%Modecate%
%MODITEN%, %fluphenazine%
%MODITEN%, %fluphenazine%
%MODITEN%, %fluphenazine%
%MODITEN%, %fluphenazine%
%chlorpromazine%, %promazine%
%Motipress%, %fluphenazine%
%Motival%, %fluphenazine%
%Neulactil%, %pericyazine%
%Neulactil%, %pericyazine%
%Neulactil%, %pericyazine%

%Neulactil%, %pericyazine%
%Neulactil%, %pericyazine%
%Neulactil%
%Neulactil%, %pericyazine%
%fluphenazine%
%fluphenazine%
%NOZINAN%, %levomepromazine%, %promazine%
%NOZINAN%, %levomepromazine%, %promazine%
%NOZINAN%, %levomepromazine%, %promazine%
%ORAP%, %pimozid%
%ORAP%, %pimozid%
%ORAP%, %pimozid%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%Metoclopramide%
%PARSTELIN%, %Perazine%, %trifluoperazine%
%pericyazine%
%pericyazine%
%pericyazine%
%pericyazine%
%pericyazine%
%pericyazine%
%perphenazine%
%perphenazine%
%perphenazine%
%perphenazine%
%perphenazine%
%perphenazine%
%perphenazine%
%perphenazine%
%perphenazine%
%perphenazine%
%pimozid%
%pimozid%
%pimozid%
%PIPORTIL%, %pipotiazine%
%PIPORTIL%, %pipotiazine%
%PIPORTIL%, %pipotiazine%
%pipotiazine%
%pipotiazine%
%pipotiazine%
%Metoclopramide%, %Primperan%
%Metoclopramide%, %Primperan%
%Metoclopramide%, %Primperan%
%Perazine%, %prochlorperazine%

%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%Perazine%, %prochlorperazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%promazine%
%PROZIERE%, %Perazine%, %prochlorperazine%
%Pxytixol%, %flupentixol%
%Pxytixol%, %flupentixol%
%Fluspirilen%, %REDEPTIN%
%SERENACE%, %haloperidol%

%SERENACE%, %haloperidol%
%SERENACE%
%SERENACE%, %haloperidol%
%SERENACE%, %haloperidol%
%SERENACE%, %haloperidol%
%SERENACE%, %haloperidol%
%SERENACE%, %haloperidol%
%SERENACE%, %haloperidol%
%SPARINE%, %promazine%
%SPARINE%, %promazine%
%SPARINE%, %promazine%
%SPARINE%, %promazine%
%SPARINE%, %promazine%
%STELABID%
%STELAZINE%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%Perazine%, %STELAZINE%, %trifluoperazine%
%STELAZINE%
%Perazine%, %STELAZINE%, %trifluoperazine%
%STELAZINE%
%STEMETIL%
%STEMETIL%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%STEMETIL%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%
%Perazine%, %STEMETIL%, %prochlorperazine%

%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%Perazine%, %trifluoperazine%
%trifluperidol%
%trifluperidol%
%trifluperidol%
%TRIPERIDOL%, %trifluperidol%
%TRIPERIDOL%, %trifluperidol%
%TRIPTAFEN%, %perphenazine%
%TRIPTAFEN%, %perphenazine%
%TRIPTAFEN%, %perphenazine%
%VERACTIL%, %levomepromazine%, %promazine%
%Perazine%, %VERTIGON%, %prochlorperazine%
%Perazine%, %VERTIGON%, %prochlorperazine%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%zuclopenthixol%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%

%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%ORAP%
%Perazine%
%Perazine%
%Perazine%
%Perazine%
%Perazine%
%Perazine%
%ANQUIL%
%ANQUIL%

review	comments	medcode	read_code	clinical_pats	desc
Y	secondary PD	52589	A94y100	15	Syphilitic parkinsonism
Y	secondary PD	51105	F123.00	10	Postencephalitic parkinsonism
Y	secondary PD	100128	F124.00	360	Vascular parkinsonism
Y	secondary PD	24001	F12W.00	28	Secondary parkinsonism due to other external agents
Y	secondary PD	26181	F12X.00	349	Secondary parkinsonism, unspecified
Y	secondary PD	97170	Fyu2100	6	[X]Other secondary parkinsonism
Y	secondary PD	86062	Fyu2200	8	[X]Parkinsonism in diseases classified elsewhere
Y	secondary PD	72879	Fyu2900	7	[X]Secondary parkinsonism, unspecified
Y	drug-induced PD	33544	F121.00	276	Parkinsonism secondary to drugs
Y	drug-induced PD	19478	F121.11	1917	Drug induced parkinsonism
Y	drug-induced PD	5443	F122.00	236	Malignant neuroleptic syndrome
Y	drug-induced PD	105947	Fyu2000	1	[X]Other drug-induced secondary parkinsonism
N		4321	F12..00	36061	Parkinson's disease
N		1691	F120.00	15293	Paralysis agitans
N		14912	F12z.00	2776	Parkinson's disease NOS

Reviewed by PPD [redacted] for Drug-induced parkinsonism or secondary Parkinsonism

matching_terms
% A94y1%
% F12%
% F12%
% F12%
% F12%
% Fyu21%
% Fyu22%
% Fyu29%
% F12%
% F12%
% F12%
% Fyu20%
% F12%
% F12%
% F12%

review	comments	medcode	read_code	clinical_p
Y	Tremor	10718	297A.00	3216
Y		20242	2944.00	781
Y		18660	2944.11	551
Y		53655	2987.00	56
Y		17004	2987.11	540
Y		59824	2994.00	100
Y		16860	2994.11	522
Y		10795	2994.12	191
Y		7572	F116.00	1130
N		10653	2975.00	2065
N		20102	2977.00	2128
N		31695	1B22.00	3981
N		5912	1B22.11	39385
N		2778	1B22.12	28032
N		53212	297B.00	148
N		6948	F131.00	2260
N		3051	F131000	15756
N		2512	F131100	999
N		52748	F131200	52
N		34349	F131z00	324
N		59082	Fyu2500	13
N		2508	R010300	46132
N		7557	13CD.00	13698
N		2539	13CE.00	49521
N		13133	13CP.00	387
N		1512	1B52.00	6724
N		7417	1B52.11	23823
N		2042	29L8.00	10407
N		2555	29L8.11	2118
N		18963	29LB.00	684
N		93421	29LD.00	1659
N		103567	29LF.00	193
N		6375	N097.00	13317
N		28112	N097z00	151
N		39784	R00A.00	611
N		405	R012.00	25983
N		14714	R012z00	22461
N		21024	R013.00	1126
N		2003	R013.11	1887
N		95777	Ryu3100	6
N		95802	Ryu3200	12
N		94162	Ryu3300	8
N		9638	ZO51.00	912

N		9458	ZV4L000	3884
N		9305	ZV4L011	1356
N		54339	297C.00	10
N		2928	1D12.00	21277
N		74741	2944	0
N		13125	13C..00	87219
N		8490	13c..00	8537
N		44966	13cD.00	75
N		25925	13cE.00	1297
N		97148	13cP.00	692
N		67936	Ryu3000	5
N		45237	Ryu3400	4

Reviewed by PPD Parkinson's disease sympto

desc	matching_terms
O/E - Parkinsonian tremor	% 297A%
O/E - muscle rigid - cogwheel	% 2944%
O/E - cog wheel rigidity	% 2944%
O/E -Parkinson flexion posture	% 2987%
O/E - Parkinson posture	% 2987%
O/E-festination-Parkinson gait	% 2994%
O/E - Parkinson gait	% 2994%
O/E - festination	% 2994%
Lewy body disease	% F116%
O/E - fine tremor	% 2975%
O/E - intention tremor	% 2977%
Has a tremor	% 1B22%
Tremor symptom	% 1B22%
Shaking	% 1B22%
O/E - tremor outstretched hands	% 297B%
Essential and other specified forms of tremor	% F131%
Benign essential tremor	% F131%
Familial tremor	% F131%
Drug-induced tremor	% F131%
Essential and other specified forms of tremor NOS	% F131%
[X]Other specified forms of tremor	% Fyu25%
[D]Tremor NOS	% R0103%
Mobility very poor	% 13CD%
Mobility poor	% 13CE%
Impaired mobility	% 13CP%
Unsteadiness present	% 1B52%
Feels off balance	% 1B52%
O/E - generally unsteady	% 29L8%
O/E - generally off balance	% 29L8%
Unable to balance	% 29LB%
Disorder of gait and/or balance present	% 29LD%
Worsening balance	% 29LF%
Difficulty in walking	% N097.00%
Difficulty in walking NOS	% N097z%
[D] Poor mobility	% R00A%
[D]Gait abnormality	% R012.00%
[D]Gait abnormality NOS	% R012z%
[D]Lack of coordination	% R013.%
[D]Dyskinesia	% R013.%
[X]Difficulty in walking, not elsewhere classified	% Ryu3%
[X]Other and unspecified abnormalities of gait and mobility	% Ryu3%
[X]Other and unspecified lack of coordination	% Ryu3%
Impaired mobility	% ZO51%

[V]Reduced mobility	% ZV4L0%
[V] Poor mobility	% ZV4L0%
O/E - tremor of tongue	% 297C%
C/O: stiffness	% 1D12%
	% 2944%
Mobility - social functioning	% 13C..00%
Drug user	% 13C..00%
Episodic use of drugs	% 13CD%
Prolonged high dose use of cannabis	% 13CE%
Does not misuse drugs	% 13CP%
[X]Other and unspecified abnormal involuntary movements	% Ryu3%
[X]Oth/unspecif sympt & signs involv nerv/musculosk systems	% Ryu3%

ims (to determine year of PD diagnosis)